,id,ticker,title,category,content,date,provider,url,article_id
147242,368758,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 01 ,news,"Investing com   Canada stocks were lower after the close on Monday  as losses in the Materials  Consumer Discretionary and Clean Technology sectors led shares lower 
At the close in Toronto  the S P TSX Composite fell 0 01  
The best performers of the session on the S P TSX Composite were Bausch Health Companies Inc  TO BHC   which rose 9 16  or 2 88 points to trade at 34 31 at the close  Meanwhile  Eldorado Gold Corp  TO ELD  added 5 91  or 0 27 points to end at 4 84 and  Air Canada   TO AC  was up 4 94  or 1 660 points to 35 280 in late trade 
The worst performers of the session were Great Canadian Gaming Corporation  TO GC   which fell 7 84  or 3 83 points to trade at 45 01 at the close   Turquoise Hill Resources  Ltd   TO TRQ  declined 6 37  or 0 130 points to end at 1 910 and  NexGen Energy Ltd    TO NXE  was down 4 57  or 0 100 points to 2 090 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 546 to 456 and 149 ended unchanged 
Shares in Turquoise Hill Resources Ltd   TO TRQ  fell to 5 year lows  down 6 37  or 0 130 to 1 910  Shares in Air Canada  TO AC  rose to all time highs  rising 4 94  or 1 660 to 35 280  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 4 53  to 12 01 
Gold Futures for June delivery was up 0 07  or 0 95 to  1282 25 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in June rose 0 94  or 0 58 to hit  62 52 a barrel  while the July Brent oil contract fell 0 64  or 0 46 to trade at  70 90 a barrel 
CAD USD was down 0 05  to 0 7431  while CAD EUR fell 0 06  to 0 6634 
The US Dollar Index Futures was up 0 03  at 97 292 ",2019-05-06,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade-sptsx-composite-down-001-1858137,1858137
147243,368759,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 30 ,news,"Investing com   Canada stocks were lower after the close on Tuesday  as losses in the Real Estate  REITs and Healthcare sectors led shares lower 
At the close in Toronto  the S P TSX Composite fell 0 30  
The best performers of the session on the S P TSX Composite were  New Gold Inc   TSX NGD   which rose 9 30  or 0 080 points to trade at 0 940 at the close  Meanwhile  Eldorado Gold Corp  TSX ELD  added 4 70  or 0 22 points to end at 4 90 and NFI Group Inc  TSX NFI  was up 3 52  or 1 15 points to 33 82 in late trade 
The worst performers of the session were  Enerflex Ltd    TSX EFX   which fell 6 29  or 1 10 points to trade at 16 40 at the close   MEG Energy Corp   TSX MEG  declined 5 77  or 0 27 points to end at 4 41 and Bausch Health Companies Inc  TSX BHC  was down 5 70  or 1 84 points to 30 43 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 626 to 415 and 143 ended unchanged 
Shares in MEG Energy Corp  TSX MEG  fell to 52 week lows  falling 5 77  or 0 27 to 4 41  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 4 23  to 12 31 
Gold Futures for June delivery was down 0 39  or 4 95 to  1278 65 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in July rose 0 72  or 0 42 to hit  59 05 a barrel  while the August Brent oil contract rose 0 06  or 0 04 to trade at  68 68 a barrel 
CAD USD was up 0 00  to 0 7411  while CAD EUR rose 0 02  to 0 6641 
The US Dollar Index Futures was up 0 39  at 97 855 ",2019-05-28,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade-sptsx-composite-down-030-1880897,1880897
147245,368761,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 30 ,news,"Investing com   Canada stocks were lower after the close on Tuesday  as losses in the Real Estate  REITs and Healthcare sectors led shares lower 
At the close in Toronto  the S P TSX Composite declined 0 30  
The best performers of the session on the S P TSX Composite were  New Gold Inc   TSX NGD   which rose 9 30  or 0 080 points to trade at 0 940 at the close  Meanwhile  Eldorado Gold Corp  TSX ELD  added 4 70  or 0 22 points to end at 4 90 and NFI Group Inc  TSX NFI  was up 3 52  or 1 15 points to 33 82 in late trade 
The worst performers of the session were  Enerflex Ltd    TSX EFX   which fell 6 29  or 1 10 points to trade at 16 40 at the close   MEG Energy Corp   TSX MEG  declined 5 77  or 0 27 points to end at 4 41 and Bausch Health Companies Inc  TSX BHC  was down 5 70  or 1 84 points to 30 43 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 626 to 415 and 143 ended unchanged 
Shares in MEG Energy Corp  TSX MEG  fell to 52 week lows  losing 5 77  or 0 27 to 4 41  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 4 23  to 12 31 
Gold Futures for June delivery was down 0 39  or 4 95 to  1278 65 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in July rose 0 72  or 0 42 to hit  59 05 a barrel  while the August Brent oil contract rose 0 06  or 0 04 to trade at  68 68 a barrel 
CAD USD was up 0 00  to 0 7411  while CAD EUR rose 0 02  to 0 6641 
The US Dollar Index Futures was up 0 39  at 97 855 ",2019-05-28,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade-sptsx-composite-down-030-1880898,1880898
147246,368762,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 21 ,news,"Investing com   Canada stocks were lower after the close on Thursday  as losses in the Healthcare  Real Estate and Materials sectors led shares lower 
At the close in Toronto  the S P TSX Composite lost 0 21  
The best performers of the session on the S P TSX Composite were Cogeco Communications Inc  TSX CCA   which rose 5 48  or 5 14 points to trade at 98 99 at the close  Meanwhile   Gran Tierra Energy Inc   TSX GTE  added 3 90  or 0 080 points to end at 2 130 and Cargojet Inc  TSX CJT  was up 3 51  or 3 08 points to 90 86 in late trade 
The worst performers of the session were Bausch Health Companies Inc  TSX BHC   which fell 4 29  or 1 40 points to trade at 31 21 at the close  Canopy Growth Corp  TSX WEED  declined 4 17  or 2 110 points to end at 48 450 and  TORC Oil   Gas  Ltd   TSX TOG  was down 3 71  or 0 16 points to 4 15 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 589 to 453 and 119 ended unchanged 
Shares in Cogeco Communications Inc  TSX CCA  rose to all time highs  up 5 48  or 5 14 to 98 99  Shares in Cargojet Inc  TSX CJT  rose to all time highs  rising 3 51  or 3 08 to 90 86  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 0 09  to 10 77 
Gold Futures for August delivery was down 0 49  or 6 90 to  1405 60 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in August rose 0 02  or 0 01 to hit  60 44 a barrel  while the September Brent oil contract rose 0 01  or 0 01 to trade at  66 78 a barrel 
CAD USD was up 0 12  to 0 7656  while CAD EUR rose 0 10  to 0 6801 
The US Dollar Index Futures was down 0 00  at 96 700 ",2019-07-11,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade-sptsx-composite-down-021-1921564,1921564
147247,368763,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 59 ,news,"Investing com   Canada stocks were higher after the close on Wednesday  as gains in the IT  Healthcare and Energy sectors led shares higher 
At the close in Toronto  the S P TSX Composite rose 0 59  
The best performers of the session on the S P TSX Composite were  Turquoise Hill Resources  Ltd   TSX TRQ   which rose 14 04  or 0 080 points to trade at 0 650 at the close  Meanwhile  Bausch Health Companies Inc  TSX BHC  added 5 37  or 1 52 points to end at 29 83 and  Aphria Inc   TSX APHA  was up 4 93  or 0 410 points to 8 720 in late trade 
The worst performers of the session were  Precision Drilling  Corporation  TSX PD   which fell 4 97  or 0 08 points to trade at 1 53 at the close   CannTrust  Holdings Inc  TSX TRST  declined 4 62  or 0 1200 points to end at 2 4800 and  B2Gold Corp   TSX BTO  was down 3 31  or 0 160 points to 4 670 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 535 to 517 and 126 ended unchanged 
Shares in CannTrust Holdings Inc  TSX TRST  fell to 52 week lows  falling 4 62  or 0 1200 to 2 4800  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 5 15  to 12 88 
Gold Futures for December delivery was down 0 20  or 3 05 to  1512 65 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in October fell 0 48  or 0 27 to hit  55 86 a barrel  while the October Brent oil contract rose 0 05  or 0 03 to trade at  60 42 a barrel 
CAD USD was up 0 05  to 0 7527  while CAD EUR rose 0 06  to 0 6789 
The US Dollar Index Futures was up 0 13  at 98 190 ",2019-08-21,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade-sptsx-composite-up-059-1960698,1960698
147248,368764,BHC,Bausch Health agrees to pay  1 21 billion to settle share price lawsuit,news, Reuters    Bausch Health Cos Inc  TO BHC  said on Monday it settled a class action lawsuit for  1 21 billion related to a drop in the drugmaker s shares during 2013 2015  The company  previously known as Valeant Pharmaceuticals  NYSE BHC   did not admit to any liability and denied all allegations of wrongdoing as part of the settlement for the litigation originally filed in October 2015   Bausch Health said it intends to use a combination of sources to fund the settlement  which may include cash on hand  its revolving credit facility and potentially accessing capital markets  The settlement  subject to court approval  does not impact the company s 2019 financial forecast and will not diminish its ability to continue to invest in its businesses  Bausch Health said  The drugmaker has sought to get past a series of scandals and accounting issues under previous management  Valeant had faced multiple probes into business practices  including its ties to the now defunct specialty pharmacy Philidor  which began drawing scrutiny in October 2015  This lead to a steep fall in share price that was compounded by concerns about the company s heavy debt load  which stood at  23 84 billion as of Sept  30  The company s U S  listed shares fell over 4  to  29 60 in trading before the bell  The stock has fallen nearly 90  from its record high of  347 84 in 2015  but has risen nearly 62  this year ,2019-12-16,Reuters,https://www.investing.com/news/stock-market-news/bausch-health-agrees-to-pay-121-billion-to-settle-share-price-lawsuit-2041949,2041949
147249,368765,BHC,Implied Volatility Surging For Bausch Health  BHC  Stock Options,opinion,Investors in Bausch Health Companies Inc    NYSE BHC   need to pay close attention to the stock based on moves in the options market lately  That is because the Oct 18  2019  18 00 Call had some of the highest implied volatility of all equity options today What is Implied Volatility Implied volatility shows how much movement the market is expecting in the future  Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other  It could also mean there is an event coming up soon that may cause a big rally or a huge sell off  However  implied volatility is only one piece of the puzzle when putting together an options trading strategy What do the Analysts Think Clearly  options traders are pricing in a big move for Bausch Health shares  but what is the fundamental picture for the company  Currently  Bausch Health is a Zacks Rank  3  Hold  in the Medical   Generic Drugs industry that ranks in the Top 38  of our Zacks Industry Rank  Over the last 60 days  one analyst has increased the earnings estimate for the current quarter  while one has dropped the estimate  The net effect has taken our Zacks Consensus Estimate for the current quarter from  1 08 per share to  1 05 in that period Given the way analysts feel about Bausch Health right now  this huge implied volatility could mean there s a trade developing  Oftentimes  options traders look for options with high levels of implied volatility to sell premium  This is a strategy many seasoned traders use because it captures decay  At expiration  the hope for these traders is that the underlying stock does not move as much as originally expected Looking to Trade Options Check out the simple yet high powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple digit winners  In addition to impressive profit potential  these trades can actually reduce your risk ,2019-10-16,Zacks Investment Research,https://www.investing.com/analysis/implied-volatility-surging-for-bausch-health-bhc-stock-options-200473890,200473890
147250,368766,BHC,Left s Citron hedge fund posts 43  gain in first year,news,"By Svea Herbst Bayliss
BOSTON  Reuters    Andrew Left  who has long targeted companies that he thinks are over valued through his work at Citron Research  told investors on Monday that his new hedge fund returned 43  after fees in 2019  its first year in business 
Left also made a prediction that home furnishing company RH  one of his winners last year  may make a tempting takeover target for someone 
 In 2019  our first full year of operation  Citron Capital  LP   Fund   generated a gross return of 56 4  and net return of 43 3    Left wrote in the letter seen by Reuters 
While the fund bet that certain stocks would climb  Left also bet that certain ones would drop  writing  the Fund s average exposure during 2019 was 75 8  long and 80 3  short  
Left said that winners on the long side included Bausch Health  TO BHC   RH  N RH   and Snap  N SNAP  and on the short side included  Ligand Pharmaceuticals   O LGND   Jumia Technologies   and Grand Canyon Education  O LOPE  
After investing only his own wealth for roughly two decades Left in 2018 began laying the groundwork for Citron Capital  his hedge fund  By raising outside capital  Left has more firepower to go after some of the biggest U S  companies 
Citron has not disclosed the size of its hedge fund 
For this year  Left said RH  whose stock price closed at  212 77 on Monday  may be bought   We believe the company has matured to a point that we might see it acquired in 2020  
He also said he is sticking by his bet that shares in Peloton  NASDAQ PTON  Interactive  whose stock closed at  29 75 on Monday  will fall   Citron put a one year price target of  5 and we stand by it as  5 makes this still a  1 5 billion company  
Neither RH nor Peloton responded immediately to emails seeking comment 
Left also gave investors lessons that he learned last year  reminding himself and others to stay away from what he calls  big story  cult stock   companies and sticking with what he does best  exposing fraud 
He also said that this year will be a year of growth and that he is looking to expand beyond his home base in Los Angeles ",2020-01-06,Reuters,https://www.investing.com/news/stock-market-news/lefts-citron-hedge-fund-posts-43-gain-in-first-year-2053568,2053568
147251,368767,BHC,Will Bausch Health Continue To Surge Higher ,opinion,As of late  it has definitely been a great time to be an investor Bausch Health Companies Inc    NYSE BHC    The stock has moved higher by 4 1  in the past month  while it is also above its 20 Day SMA too  This combination of strong price performance and favorable technical  could suggest that the stock may be on the right path We certainly think that this might be the case  particularly if you consider BHC s recent earnings estimate revision activity  From this look  the company s future is quite favorable  as BHC has earned itself a Zacks Rank  2  Buy   meaning that its recent run may continue for a bit longer  and that this isn t the top for the in focus company  You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-11-12,Zacks Investment Research,https://www.investing.com/analysis/will-bausch-health-continue-to-surge-higher-200484496,200484496
147252,368768,BHC,Generic Drugmakers Gain As Price Fixing Probe Nears An End,opinion,A Bloomberg  on a potential settlement of the long running antitrust probe related to price fixing allegations against generic drugmakers drove shares of major players in the generic industry on Nov 25  The report stated that over the past six months  companies like Teva Pharmaceutical   NYSE TEVA   and India s drugmaker Sun Pharmaceutical have been engaged in private negotiations with the U S  Justice Department on price fixing litigations against them A settlement related to price fixing allegation will be a boon to the generic drugmakers as these cases are an overhang  increasing uncertainty among investors and legal expenses for companies  The news led to a rise in share prices of Teva Pharmaceutical as well as other generic players namely Mylan  NASDAQ MYL   Mallinckrodt  NYSE MNK  and Endo International It was alleged previously that generic drugmakers conspired among themselves to keep the prices of major generic drugs high to boost their margins  costing the federal government s health programs billions of dollars  These allegations have been made over the past several years and there have been hints about possible charges to be framed against the companies soon  Apart from federal inquiry  separate similar cases have been filed in the majority of U S  states Although there is no clarity on the future course of the price fixing allegation settlement  a deferred prosecution agreement is a possible solution as discussed with the authorities  A deferred prosecution agreement will allow companies to admit to certain allegations but will shield them from indictment  However  generic drugmakers have to co operate with investigations and have to pay fines  A similar agreement was used to resolve allegations against the privately held  manufacturer of generic pharmaceuticals  Heritage Pharmaceuticals  in 2016 Meanwhile  the federal government has been trying to broaden patients  access to a wide range of medicines by making these affordable  In this scenario  a deferred prosecution agreement can be attractive to both government and the companies  as indicting a company may put certain restrictions on its marketed drugs  which can lead to higher prices of drugs due to lower competition  The companies will benefit from such an agreement and continue to do business as usual However  the Justice Department is yet to comment on the probe  The timeline for a possible solution remains uncertain  Meanwhile  the department may decide to indict any related company Separately  the ongoing multidistrict litigation in a U S  District Court in Ohio  related to the abuse of opioid based drugs  against some of the generic drugmakers is also nearing an outcome  The verdict in the Ohio litigation should pave the way for pending opioid litigations in other states  Although several companies have settled before the litigation  a positive verdict will be a major relief for the accused companies Investors can take a look at these three generic drug companies  which carry a Zacks Rank  1  Strong Buy  or 2  Buy  and have been witnessing rising share prices and positive estimate revisions  despite these uncertainties in the generic industry Bausch Health Cos Inc    NYSE BHC   This Canadian drugmaker has seen a 50  increase in its share price so far this year  The Zacks Consensus Estimate for the company s 2019 and 2020 earnings have been revised 5 1  and 3 2  upward  respectively  over the past 30 days  The company carries a Zacks Rank  2 Zynerba Pharmaceuticals  Inc    NASDAQ ZYNE   The Zacks Consensus Estimate for this Devon  PA baseddrugmaker s loss per share for 2019 and 2020 has narrowed 15 4  and 5 9   respectively  over the past 60 days  Zynerba has a Zacks Rank  1  The stock has surged 120 5  so far this year Akorn  Inc    NASDAQ AKRX   Shares of this Lare Forest  IL baseddrugmaker has gained 18 3  so far this year  The Zacks Consensus Estimate for the company s loss per share for 2019 has narrowed 35 3  and earnings per share has moved up 11 5  for 2020  over the past 30 days  It carries a Zacks Rank  2 5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-11-25,Zacks Investment Research,https://www.investing.com/analysis/generic-drugmakers-gain-as-pricefixing-probe-nears-an-end-200488172,200488172
147253,368769,BHC,Moving Average Crossover Alert  Bausch Health Companies,opinion,Bausch Health Companies Inc    NYSE BHC   is looking like an interesting pick from a technical perspective  as the company is seeing favorable trends on the moving average crossover front  Recently  the 50 Day Moving Average for BHC broke out above the 200 Day Simple Moving Average  suggesting a short term bullish trend This has already started to take place  as the stock has moved higher by 5 1  in the past four weeks  Plus  the company currently has a Zacks Rank  2  Buy  suggesting that now could definitely be the time for this breakout candidate More bullishness may especially be the case when investors consider what has been happening for OSMT on the earnings estimate revision front lately  No estimate has gone lower in the past two months  compared to 7 higher  while the consensus estimate has also moved higher too So  given this move in estimates  and the positive technical factors  investors may want to watch this breakout candidate closely for more gains in the near future  You can see  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ,2019-11-28,Zacks Investment Research,https://www.investing.com/analysis/moving-average-crossover-alert-bausch-health-companies-200488916,200488916
147254,368770,BHC,Luckin Coffee share price may nearly double to  60 on U S  exchanges  hedge fund Citron Capital,news,"By Saqib Iqbal Ahmed
NEW YORK  Reuters    China based  Luckin Coffee  Inc s  O LK  shares could double in price after it overcomes the negative impact of the coronavirus outbreak and a widely publicized bearish bet against its stock  according to Andrew Left  managing partner at hedge fund Citron Capital 
Better known for his short bets  Left  who is also editor of the online investment newsletter Citron Research  has come out in defense of Luckin s stock  which his fund owns  The stock will probably eventually trade at  60 per share on U S  exchanges once uncertainty over the coronavirus clears  he told Reuters 
Luckin was forced to temporarily close an estimated 200 coffee shops in Wuhan  capital of the Hubei province in China and epicenter of the deadly virus outbreak 
Its stock slumped as much as 27  on Friday after hedge fund Muddy Waters said it had sold short the shares of the Chinese challenger to Starbucks  O SBUX   citing an anonymous report that questioned the coffee chain s financials 
Short sellers aim to profit by selling borrowed shares  hoping to buy them back later at a lower price 
Luckin has denied all allegations in the anonymous report 
Left said he decided to take a position in the stock after conducting an analysis of Luckin s business  including speaking with stakeholders and competitors and reviewing payments data 
 I don t think that report is correct   Left told Reuters 
Luckin shares staged a partial recovery on Friday when Left mounted a defense of its fundamentals via Twitter and said his fund had bought the stock 
Shares were up 14  to  35 64 in afternoon trading on Tuesday 
About 30  of Luckin s available shares have been sold short  with the dollar value of these bearish bets at  951 million  according to financial analytics firm S3 Partners  Left  dubbed  The Bounty Hunter of Wall Street  by New York Times Magazine  is known for successful bets against Valeant Pharmaceuticals  NYSE BHC  and for publishing critical reports on Chinese companies and profiting when their shares fell 
Carson Block  founder of Muddy Waters  has made his mark in the hedge fund industry by betting against the stocks of a number of Chinese companies that trade on North American stock exchanges after challenging their accounting practices 
Muddy Waters declined to comment 
The shop closures and movement restrictions due to the spreading coronavirus are putting a damper on Luckin s first quarter results  brokerage Needham said in a note on Tuesday 






Nevertheless  the firm boosted its target price on the company s shares by 48  to  40  pointing to Luckin s new unmanned retail and tea partnership store initiatives ",2020-02-04,Reuters,https://www.investing.com/news/stock-market-news/luckin-coffee-share-price-may-nearly-double-to-60-on-us-exchanges-hedge-fund-citron-capital-2075769,2075769
147255,368771,BHC,Should Value Investors Pick Bausch Health  BHC  Stock Now ,opinion,"Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put  Bausch Health Companies Inc    NYSE BHC   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Bausch Health has a trailing twelve months PE ratio of 6 92  as you can see in the chart below  This level actually compares pretty favorably with the market at large  as the PE for the S P 500 compares in at about 20 57  If we focus on the stock s long term PE trend  the current level Bausch Health puts current PE ratio above its midpoint  which is 5 42  over the past five years  Also  the stock s PE compares favorably with the Zacks Medical sector s trailing twelve months PE ratio  which stands at 23 48  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers  We should also point out that Bausch Health has a forward PE ratio  price relative to this year s earnings  of 6 47  so it is fair to say that a slightly more value oriented path may be ahead for the stock in the near term too P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  Bausch Health has a P S ratio of about 1 25  This is somewhat lower than the S P 500 average  which comes in at 3 56  right now  Also  as we can see in the chart below  this is below the highs for this stock in particular over the past few years  If anything  this suggests some level of undervalued trading at least compared to historical norms    Broad Value OutlookIn aggregate  Bausch Health currently has a Value Style Score of A  putting it into the top 20  of all stocks we cover from this look  This makes BHC a solid choice for value investors and some of its other metrics make it clear too For example  the PEG ratio for Bausch Health is just 0 60  a level that is considerably lower than the industry average of 1 02  The PEG ratio is a modified PE ratio that takes into account the stock s earnings growth rate  Additionally  its P CF ratio  another great indicator of value  comes in at 2 36  which is noticeably better than the industry average of 4 68  Clearly  BHC is a solid choice on the value front from multiple angles What About the Stock Overall 
Though Bausch Health might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth grade of C and a Momentum score of D  This gives BHC a VGM score or its overarching fundamental grade of B   You can read more about the Zacks Style Scores   Meanwhile  the company s recent earnings estimates have been mixed  The current quarter has seen two estimates go lower in the past sixty days compared to one higher  while current year estimate has seen two upward and one downward revision in the same time period This has had a noticeable impact on the consensus estimate as the current quarter consensus estimate has shown no earnings movement in the past two months  while current year estimate has inched up 0 5  in the same time period  You can see the consensus estimate trend and recent price action for the stock in the chart below Bausch Health Cos Inc  Price and Consensus   This somewhat mixed trend is why the stock has just a Zacks Rank  3  Hold  and why we are looking for in line performance from the company in the near term Bottom LineBausch Health is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  Moreover  a strong industry rank  Top 44  out of more than 250 industries  further supports the growth potential of the stock  In fact  over the past one year  the sector has clearly underperformed the broader market  as you can see below  So  value investors might want to wait for estimates and analyst sentiment to turn favorable in this name first  but once that happen  this stock could be a compelling pick Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops   Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ",2020-01-16,Zacks Investment Research,https://www.investing.com/analysis/should-value-investors-pick-bausch-health-bhc-stock-now-200499612,200499612
147277,368793,BHC,What s In The Cards For Bausch Health  BHC  In Q2 Earnings ,opinion,"Bausch Health Companies Inc    NYSE BHC   is scheduled to report second quarter 2019 results on Aug 6  before market open In the last reported quarter  the company s earnings beat estimates by 15 73   Bausch s earnings track record has been excellent so far  The company beat earnings expectations in the last four quarters  the average surprise being 20 51  Bausch s stock has gained 29 1  in the year so far against a 4 1  decline for the    Factors Likely to Impact ResultsBausch conducts business in four operating segments   the Bausch   Lomb International segment  the Salix segment  the Ortho Dermatologics segment and the Diversified Products segment The company generally earns more than 75  of its total revenues from the Bausch   Lomb International and the Salix segments  Hence  the focus will be on these two segments in the second quarter Revenues marginally missed estimates in the first quarter but new launches are expected to boost performance this time Higher volumes boosted the performance of the Bausch   Lomb International segment in the first quarter and the momentum is likely to continue in the second quarter  The company announced the U S  launch of Bausch   Lomb ULTRA Multifocal for Astigmatism contact lenses for patients with both astigmatism and presbyopia  In February 2019  it announced that the FDA has approved Lotemax SM  loteprednol etabonate ophthalmic gel  0 38   a new gel formulation for the treatment of postoperative inflammation and pain following ocular surgery The Salix business should continue to drive growth in the second quarter  In particular  increased sales of Xifaxan  Apriso and Relistonare must have driven revenues in the second quarter despite the loss of exclusivity of Uceris  Recently launched Bryhali is also a key catalyst for the company In June 2019  Bausch launched psoriasis lotion  Duobrii  in the United States  In April  the FDA approved Duobrii Lotion for the topical treatment of plaque psoriasis in adults  The company recently settled the Xifaxan IP litigation  which should preserve market exclusivity until 2028  The addition of Trulance from the Synergy acquisition has also bolstered the franchise Meanwhile  investors are expected to focus on pipeline development  apart from the regular top and bottom line numbers in the upcoming quarterly results  Bausch has narrowed its focus on seven recently launched or expected to be launched products pending completion of testing and receipt of FDA approval  The products include Vyzulta  Siliq  Bryhali  psoriasis   Lumify  Duobrii  Relistor and SiHy Daily  The company earlier acquired the U S  rights to Eton Pharmaceuticals    NASDAQ ETON   EM 100  an investigational eye drop  which  if approved  will be the first over the counter preservative free formulation eye drop for the treatment of ocular itching associated with allergic conjunctivitis The focus will also be on the company s efforts to pay debt  as it had been closely monitored for its huge debt level  Bausch announced clearing an additional  100 million of its senior secured term loans in June 2019  using the cash generated from operations  This led the company to eliminate all mandatory amortization for the first quarter of 2020 Earnings WhispersOur proven model does not conclusively predict that Bausch will beat on earnings in the quarter to be reported  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  Unfortunately  that is not the case here  as you will see below Earnings ESP  Earnings ESP for Bausch is  4 79   This is because the Zacks Consensus Estimate stands at  1 07 and the Most Accurate Estimate at  1 02  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Bausch carries a Zacks Rank  3  which is favorable  However  the negative ESP makes surprise prediction difficult We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
Bausch Health Cos Inc  Price  Consensus and EPS Surprise
 
   
Stocks to ConsiderHere are some companies you may consider  as our model shows that these have the right combination of elements to deliver an earnings beat this reporting cycle Rigel Pharmaceuticals  Inc    NASDAQ RIGL   has an Earnings ESP of  8 77  and a Zacks Rank of 3 at present  The company is scheduled to release second quarter results on Aug 6  You can see  Jazz Pharmaceuticals  Inc    NASDAQ JAZZ   currently has an Earnings ESP of  1 77  and a Zacks Rank  3  The company is scheduled to release second quarter 2019 results on Aug 6 Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-08-01,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-cards-for-bausch-health-bhc-in-q2-earnings-200450182,200450182
147278,368794,BHC,Bausch  BHC  Misses On Q2 Earnings   Sales  Raises View,opinion,"Bausch Health Companies Inc  s   NYSE BHC   earnings and sales missed estimates in the second quarter of 2019  Nevertheless  the company raised its annual sales guidance for the second consecutive time The company s adjusted earnings per share of  1 03 missed the Zacks Consensus Estimate of  1 06 but increased from 93 cents reported in the year ago quarter Total revenues of  2 152 billion marginally missed the Zacks Consensus Estimate of  2 167 billion but increased 1  year over year Quarter in DetailRevenues in the Bausch   Lomb International segment were  1 2 billion  almost flat year over year  Excluding the impact of discontinuations and divestitures  the segment organically improved approximately 4   driven by growth in Global Consumer and Global Vision Care sales Despite the loss of exclusivity of Uceris  the Salix segment revenues rose 15 4  year over year to  509 million  The uptick was primarily driven by 21  growth in Xifaxan  The company earlier acquired certain assets of Synergy Pharmaceuticals Inc   including Trulance  which is a treatment for adults with chronic idiopathic constipation and irritable bowel syndrome with constipation  IBS C   Revenues from Trulance came in at  17 million The Ortho Dermatologics segment revenues were  122 million  down 13  year over year due to lower volumes resulting from the loss of exclusivity of Elidel  Zovirax and Solodyn  This was partially offset by revenue growth in the Global Solta business Diversified Products segment revenues were  313 million  down 7  from the year ago quarter primarily due to the loss of exclusivity of certain products The company reduced debt by approximately  100 million in the second quarter of 2019   Year to date  the company reduced debt by  350 million Pipeline UpdateThe company announced the U S  launch of Bausch   Lomb ULTRA Multifocal for Astigmatism contact lenses for patients with both astigmatism and presbyopia  During the first quarter  the FDA approved Lotemax Sm  loteprednol etabonate ophthalmic gel  0 38   a new gel formulation for the treatment of postoperative inflammation and pain following ocular surgery  Lotemax was launched in April In June 2019  Bausch launched psoriasis lotion  Duobrii  in the United States  In April  the FDA approved Duobrii Lotion for the topical treatment of plaque psoriasis in adults Earlier  Bausch had acquired the U S  rights to Eton Pharmaceuticals    NASDAQ ETON   EM 100  an investigational eye drop for the treatment of ocular itching associated with allergic conjunctivitis  However  the FDA issued a complete response letter   CRL   to a regulatory application seeking approval for the candidate 2019 Guidance UpdatedFor 2019  revenues are now expected between  8 40 billion and  8 60 billion  previous guidance was  8 35  8 55 billion   The Zacks Consensus Estimate is  8 51 billion  up from the mid point of  8 50 billion Our TakeWhile Bausch missed earnings and sales estimates in the second quarter  we are pretty encouraged by the increase in its guidance  The top 10 products grew 13  organically in the quarter  Growth in Xifaxan sales  the launch of Bryhali and Duobrii  and the successful acquisition of Trulance boosted the company s performance Bausch s stock has rallied 17 7  in the year so far against the decline of 7 7  for the   After a tumultuous period  the company started a rebuilding process  Bausch has narrowed its focus on seven products   Vyzulta  Siliq  Bryhali  Lumify  Duobrii  Relistor and SiHy Daily  All these products have now been launched and hence the company s performance in the second half of the year is expected to be strong Zacks Rank   Stocks to Consider
Bausch currently carries a Zacks Rank  3  Hold   A couple of better ranked stocks in the healthcare sector are Galectin Therapeutics  Inc    NASDAQ GALT   and Portola Pharmaceuticals  Inc    NASDAQ PTLA    Both stocks carry a Zacks Rank  1  Strong Buy   You can see  Galectin s loss per share estimates have narrowed from 59 cents to 51 cents for 2019 in the past 60 days Portola s loss per share estimates have narrowed from  4 13 to  4 12 for 2019 in the past 60 days This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-08-06,Zacks Investment Research,https://www.investing.com/analysis/bausch-bhc-misses-on-q2-earnings--sales-raises-view-200452351,200452351
147279,368795,BHC,Jaguar Health  A Different Angle On An Old Problem,opinion,"We are initiating research on Jaguar Health Inc  NASDAQ JAGX   which is centered on the development and marketing of its drug crofelemer for diarrheal disorders  It is approved and marketed under the name Mytesi for non infectious diarrhea in HIV patients receiving anti retroviral therapy  ART  and drove almost all of the  4 4m in sales in 2018  The company hopes to expand to other indications  aims to initiate a pivotal study for targeted cancer therapy related diarrhea  CTD  and plans to leverage results from an ongoing Phase II investigator sponsored study  We initiate with a valuation of  86 5m or  4 14 per diluted share 
Consistency  not flow
Mytesi is one of only two drugs approved by the FDA under its botanical product guidance  It is an extract of the Croton lechleri tree found in the Amazon  NASDAQ AMZN  and inhibits cystic fibrosis transmembrane conductance regulator  CFTR  and the calcium dependent chloride channel  CaCC   which are responsible for controlling the quantity of water in the bowel  thus resulting in more formed stool  Importantly  this inhibition does not inhibit peristalsis unlike other available anti diarrheal medicines such as Lomotil and loperamide  The lack of significant constipation risk positions it positively for chronic use  Other indications that the company is exploring include irritable bowel syndrome  inflammatory bowel disease  congenital diarrheal disorders  idiopathic diarrhea and acute infectious diarrhea 




Unmet need but also underappreciated
The drug has a long development history dating to the 1990s and was previously marketed for HIV associated diarrhea by Salix  launched in 2013  at the time it was bought by Valeant  now Bausch Health   Diarrhea in people with HIV is under reported and under recognized as a significant contributor to poor quality of life in the 1 1 million HIV patients in the US  With the introduction of newer antiretroviral drug therapy  there has been a reduction in the incidence and or severity of diarrhea  but clinical trial data suggest a continued diarrhea prevalence of 19  
Valuation   86 5m or  4 14 per diluted share
We arrive at an initial valuation of  86 5m or  4 14 per diluted share based on a risk adjusted NPV analysis  with the value driven primarily by Mytesi for ART  We assume this program can achieve  74 1m in peak sales if it can capture 12  of the market by 2031  We expect the company to require  80m in additional capital to reach profitability in 2024  which poses significant financing risks to the company if it is not able to secure alternative funding or constrain spending 
Business description
Jaguar Health is a pharmaceutical company marketing Mytesi  crofelemer  for diarrhea associated with HIV treatment  Additionally  the company is developing the drug for a range of other diarrhea indications and has developed a set of products using the drug for animal use 
Investment summary
Company description  A GI focused drug
Jaguar is a biopharma company focused on marketing and developing the drug Mytesi  crofelemer  for the treatment of diarrheal disorders in the US  Crofelemer is a botanical drug extracted from the Croton lechleri tree that normalizes fluid content in the gut in patients with diarrhea  It is approved and marketed for symptomatic relief of non infectious diarrhea associated with HIV antiretroviral therapy  ART  in adults  and is being investigated for a range of other causes of diarrhea  the most advanced program being for CTD  which is in a Phase II investigator initiated trial  The company had  4 4m in sales in 2018  almost entirely from Mytesi 
Valuation  Initiated at  86 5m or  4 14 per diluted share
We arrive at an initial valuation of  86 5m or  4 14 per diluted share based on a risk adjusted NPV analysis  We include the ART program  the CTD program  Canalevia  a canine product for chemotherapy induced diarrhea  and unallocated costs in our model  with ART driving the majority of the valuation   66 8m   We forecast  74 1m in peak sales in 2031 for the product if it can capture 12  of the market  We may add other indications to our model if the company commits capital to further developing them 
Financials  In the process of converting debt
The company is revenue generating with  1 7m reported for Q219 and had a net loss of  16 7m  These losses are driven in large part by non cash charges associated with the recapitalization of the company and an undisclosed  4m impairment on the company s intangible assets  As part of this multi pronged recapitalization process the company has issued 10m common shares  or equivalent in convertible preferred shares  and 19m warrants  at  2 00  on a base of 0 9m split adjusted shares at the beginning of 2019  The company may substantially dilute further both to eliminate its remaining debt   7 8m in exchange notes  and to finance operations  We expect the company to require  80m in additional capital to reach profitability in 2024   30m each in 2020 and 2021  and  20m in 2022  We forecast that this is likely to be difficult using equity at the current market capitalization 
Sensitivities  Marketing and clinical challenges
The company s operations are focused primarily on marketing Mytesi for ART diarrhea  which poses a number of significant hurdles  It is more difficult for a small company like Jaguar to market a single drug because of limited resources  whereas a larger pharma company could simply add another asset to its offering  The marketing story is also difficult because it involves increasing the awareness of ART diarrhea  which is under recognized  and convincing physicians that Mytesi is needed as a solution when there are multiple prescription and OTC remedies  Mytesi has a unique profile of improving stool consistency without inhibiting peristalsis  but the company will need to shift the treatment algorithm before these details will be appreciated  Additionally  the company faces clinical risks with its development programs  similar to other companies performing clinical trials  The drug was approved for ART diarrhea on the basis of positive efficacy data  but has previously missed its endpoints for other indications such as irritable bowel syndrome  so there is no guarantee that positive data will translate between indications  The drug has been in development since the 1990s and the first patents expire in 2022  although there currently is not a pathway to develop generics to drugs approved under the FDA s botanical guidance  And finally  the company faces significant dilution risk in its efforts to reduce its debt load and to finance future operations  and it may be forced to reduce spending or seek alternate financing 
Company description  Advancing diarrhea treatment




Jaguar Health is a pharmaceutical company focused on the marketing and development of crofelemer  a drug for the treatment of diarrhea in various patient populations  The product is currently approved and marketed in the US under the trade name Mytesi for the symptomatic relief of non infectious diarrhea in adults with HIV AIDS on anti retroviral therapy  ART   The company has planned clinical programs to expand Mytesi use into a range of other possible diarrhea indications  Exhibit 1   Additionally  the company is developing the same drug for animal use under the brand Canalevia for dogs and currently markets it as Neonorm or Equilevia for large animals  although these programs are significantly deprioritized in favor of advancing Mytesi  Finally  the company has identified a similar molecule  lechlemer   which it is investigating for the treatment of cholera in preclinical studies  This program if it advances could qualify the company for a priority review voucher for targeting an underserved tropical disease 
Crofelemer background and mechanism




Crofelemer is a drug isolated from the latex of the Croton lechleri tree in the Amazon  NASDAQ AMZN   the dragon blood plant  It is only one of two prescription drugs approved by the FDA under the botanical drug guidance  which allows for the approval of products from a botanical source where the product is not a pure substance  The active component of crofelemer is a mixed proanthocyanidin oligomer of indeterminate chemical structure  Exhibit 2  that is administered orally 
Diarrhea is typically triggered by exposure of cells of the intestine  enterocytes  to pathogenic bacteria or virus  the toxins these species produce  or to other chemical toxins such as drugs  These triggers lead to a signaling cascade in the enterocytes that ultimately culminates in the activation of the CFTR and the calcium dependent chloride channel  CaCC   Both of these proteins are transmembrane ion channels responsible for regulating the concentration of chloride ions in the lumen of the gut  By extension  these channels regulate the concentration of water in the gut as the chloride and other ions drive water into the gut via osmosis  The increased fluid improves motility and ultimately the pathogens or toxins are eliminated from the gut 
Crofelemer is an inhibitor of both CFTR and CaCC  and therefore by inhibition of these proteins can prevent the formation of watery stool  CFTR  as the name implies  is also present in the lungs and other organs and is implicated in the pathogenesis of cystic fibrosis in an unrelated fashion  due to a loss of function mutation   but there is no threat of off target effects of crofelemer in other organs because it is not systemically absorbed  These proteins have been directly implicated in the pathogenesis of both a range of infectious diarrhea conditions as well as drug induced diarrhea and inhibition is effective at preventing watery stool in animal models 




History of crofelemer
Crofelemer as a therapeutic agent has a long business history  The drug was initially discovered at Shaman Pharmaceuticals in the 1990s  a company headed at the time by current Jaguar CEO Lisa Conte  Shaman was also developing crofelemer for the treatment of ART associated diarrhea  but declared bankruptcy in 2001 after the FDA requested additional clinical trials  The intellectual property was then purchased by Napo Pharmaceuticals  also headed by Lisa Conte  with the goal of pursuing the requested clinical studies with the support of development partners  The company unsuccessfully attempted to develop the drug for irritable bowel syndrome with diarrhea  IBS D  with partner Trine Pharmaceuticals after a Phase IIb study failed to show improvement in stool consistency  although it reached statistical significance for improvement in pain   Napo then shifted its focus back to ART associated diarrhea and partnered with Salix Pharmaceuticals in 2008 to finance the completion of a Phase III study in exchange for rights to US and European markets  The drug was approved in 2013  under the trade name Fulyzaq  However  Napo sued Salix for breach of contract and accused the company of deliberately deprioritizing crofelemer in favor of Salix s own drug Xifaxan  which had popular use off label as a treatment for IBS D  Xifaxan has subsequently been approved for IBS D   In the meantime  in 2013 the initial incarnation of Jaguar was formed as an opportunity to develop crofelemer for animal use  the rights to which were uncontested  Also during this period  Salix was embroiled in a scandal involving channel stuffing and the company was acquired by Valeant Pharmaceuticals  NYSE BHC   now Bausch Health   The lawsuit was settled in 2016 and all rights to crofelemer transferred back to Napo  which began selling the drug again in 2017  Napo was subsequently acquired by Jaguar in 2017  forming the current incarnation of the company 
Crofelemer is protected by three Orange Book patents covering the use of the drug for the treatment of secretory diarrhea broadly  expires in 2022  and ART associated diarrhea  two patents  expiring in 2031   All patents are on the method of use because as a natural substance  crofelemer is not subject to composition of matter patents  We would expect these 2031 patents to be challenged if the drug is successful  However  the product s special status as a botanical extract may give it additional IP protection because there is currently no established pathway for the development of generic versions of drugs approved under the botanical drug guidance of the FDA  The agency has stated that it intends to provide a product specific guidance document on crofelemer to aid in the development of such generics  although the document has not been published  and there is no timeline provided  This is in line with greater efforts of the agency to promote the approval of generic drugs  and we do not consider the special status of Mytesi to be perpetually protective 
Clinical trial experience




Crofelemer has been examined in a range of clinical studies against diarrhea indications  For its approved indication of ART associated diarrhea  it was evaluated in a 374 person  placebo controlled Phase III study  The trial examined three dose levels of the drug  125mg  250mg and 500mg bid  versus placebo  and the selected dose was examined in a one month evaluation phase  followed up by a five month uncontrolled observation period  The primary endpoint of the study was the number of  monthly responders   subjects with less than or equal to two watery stools per week for more than two weeks out of a month  It was found that the selected dose  125mg bid  had a monthly responder rate of 17 6  compared to 8 0  for the placebo  p 0 0096  at the end of the one month evaluation period  However  patient responses continued to improve over the five month evaluation period  Exhibit 4  
The rate of adverse events in the study was lower for the crofelemer arm than for placebo  A larger analysis provided on the FDA label for Mytesi looking at all the patients across trials that received 125mg of drug for ART associated diarrhea compared to placebo  504 patients total  found a relatively benign safety profile  The most common adverse events that occurred more frequently than placebo were upper respiratory infection  6    bronchitis  4   and cough  4   
The results from other clinical studies have been mixed  Exhibit 5   The drug previously showed a positive treatment effect for traveler s diarrhea  as measured by a reduction in time to the first solid stool  TLUS48   Patients reported solid stool in seven to 10 hours on crofelemer  compared to 44 hours on average with placebo  In a separate study  the drug also demonstrated improvement in a range of metrics for patients with acute infectious diarrhea  improvement in weight  frequency  and consistency of stools  as well as a greater number of resolutions within the first 48 hours  79  vs 28  p
However  in other trials  even though positive trends were observed  these effects did not reach statistical significance  Of particular importance is the IBS D clinical study performed in collaboration with Trine Pharmaceuticals in patients with IBS D  The study failed to demonstrate a statistically significant improvement in stool consistency  However  the study s primary investigators noted that there appeared to be improvement in the number of discomfort free days for patients in the study  after three months on the highest dose  500mg bid   24 3  of patient days were discomfort free with crofelemer compared to 13 1  without  p 0 03  




The HIV associated diarrhea market
Mytesi is approved in the US for the treatment of non infectious diarrhea in HIV patients on ART  HIV D  and is the only drug approved with this indication  According to the US Department of Health  there are approximately 1 1 million people living with HIV in the US  of which the majority  six out of seven  are diagnosed  The department estimates that an additional 38 700 became infected in 2017  However  despite the widespread availability of ART treatments to control the disease  there remains room to improve adherence  a 2011 meta analysis found an adherence rate of 62  
Diarrhea is common in patients with HIV  although results vary  one survey suggested that approximately 60  of patients receiving ART had diarrhea in the preceding month  There are multiple causes of the condition in these patients that can be roughly broken into two classes  infectious and non infectious diarrhea  Infectious diarrhea is when an opportunistic infection colonizes and irritates the gut  whereas non infectious diarrhea can either be caused by ART treatment  ART treatment associated diarrhea  or  HIV enteropathy  in which the HIV infection itself leads to deterioration of the lining of the gut 




Clinical trial data suggests that up to 19  of diarrhea cases are attributable to ART therapy  One study chronicling the advent of ART therapy from 1995 to 1997 found that incidence of diarrhea remained constant in HIV patients  but the infectious variety declined from 53  of cases to 13  of cases as ART became more established  This reduction in infectious diarrhea can cause diarrhea as a whole to be under recognized as a result of ART  because diarrhea rates may not change significantly when patients begin receiving ART  but these patients may see improvement when treated with Mytesi 
The HIV treatment market is constantly evolving as new anti retroviral agents are developed and regimens are refined  Although improvements have been made  diarrhea continues to be a significant medical need in this patient population  Jaguar studied this in a retrospective study using NIH data from 38 clinical trials and found that diarrhea rates in these patients have fallen insignificantly between 2008 and 2016 and are approximately 18   An example of this phenomenon is the case of the nucleotide reverse transcriptase inhibitor  NTRI  tenofovir  which is the cornerstone of most ART regimens  Tenofovir has been reported to be associated with diarrhea rates as high as 16   depending on the study  It is provided as one of two commonly available prodrugs  tenofovir disoproxil fumarate  TDF  Truvada  is the historically available molecule  but tenofovir alafenamide  TAF  Vemlidy  was subsequently developed as an alternative that allows for substantially lower circulating levels of drug and the potential to avoid the associated nephrotoxicity  Both prodrugs are currently in use  but there is a trend toward increasing use of TAF containing regimens  However  when considering rates of ART associated diarrhea  TAF does not appear to provide a benefit and had similar rates of associated diarrhea in clinical trials  5  for both TAF and TDF  per the Vemlidy label  
In addition to ART associated diarrhea  Mytesi can potentially be used to treat diarrhea stemming from HIV enteropathy  HIV enteropathy is a negative diagnosis characterized by the presence of diarrhea without any infectious or other identifiable cause  The pathology of HIV contributes to a progressive deterioration of the lining of the gut that culminates in chronic diarrhea after many years of treatment  Unfortunately  there is little epidemiological data to separate HIV enteropathy from other forms of HIV associated diarrhea 
Commercial hurdles
Jaguar faces a unique set of commercial hurdles marketing Mytesi  First  the company must communicate the importance of treating diarrhea in this patient population  The extent of diarrhea in HIV infected individuals is underappreciated  as is the degree to which it affects both their quality of life and adherence to their ART regimen  ART has had little impact on rates of diarrhea  but this is largely due to high baseline rates  as described above  Additionally  although treatment has improved  ART has historically been associated with a range of more serious adverse effects than diarrhea  and therefore the condition has not had top priority  The company therefore engaged in efforts to communicate both the quality of life impact that treating HIV D can have  as well as the potential impact of treatment on adherence of ART regimens  The company collected data from its Phase III study that quantitatively demonstrates that treatment with crofelemer can improve a range of quality of life factors  in particular an increased ability to perform work and leisure activities  p




Additionally  the company must communicate the benefit of Mytesi over other commonly available diarrhea treatments  Antidiarrheals can be divided into three classes  absorbants  antimotility agents and antisecretory agents  Exhibit 7   Absorbants bind bacterial toxins and water to improve stool consistency  but are rarely used for HIV D because of the potential to interfere with oral ART medications  The antimotility agents are the most widely employed for diarrhea by slowing the transit of stool  However  these agents can cause constipation as a side effect  especially in cases where the diarrhea may be intermittent  and may not be appropriate for use as a prophylactic in these cases  Moreover  antimotility agents can be contraindicated for certain infectious forms of diarrhea  Antisecretory agents  such as Mytesi  operate by decreasing the amount of water delivered to the gut  Octreotide is the only other antisecretory agent approved in the US  although it is used off label for this purpose  Results are inconclusive for the treatment HIV D  and its use is limited due to side effects 
Jaguar currently has nine salespeople promoting the drug in the US following a recent salesforce reduction of up to 10 that was announced in August 2019  In order to expand its commercial footprint and reach more providers  Jaguar signed an agreement in June 2018 with RedHill Biopharma to co promote Mytesi in 36 territories across the US  details on which specific territories or areas have not been disclosed  that are not currently being served by Jaguar s internal salesforce  Sales under the agreement have been insignificant to date  Further details have not been released  Additionally  in September 2018  the company signed an agreement with Knight Therapeutics to commercialize the drug in Canada and Israel  Jaguar is entitled to a transfer price as well as up to  18m in regulatory and sales milestones  The product has widespread reimbursement in the US  90  of lives in AIDS Drug Assistance Programs  ADAPs   top 10 commercial insurers  245m lives   top 10 Medicare plans  2 4m lives  and Medicaid in all 50 states 
Cancer therapy related diarrhea
Although the specialty market of ART related diarrhea in the US is of limited size  the commercialization of Mytesi in this space demonstrates Jaguar s ability to operate a supply chain that started with sustainably harvested trees in the rainforest  and the effectiveness and safety of the product  Additionally  bringing Mytesi to market has required the company to develop refined messaging and educational initiatives regarding the benefits of a new way of treating diarrhea with a chronically safe agent  as opposed to the use of anti peristaltic alternatives such as Imodium and Loperamide  The company has outlined a clinical pathway forward toward expanding the approved indications for crofelemer to leverage some of this groundwork 
The most advanced clinical program is cancer therapy related diarrhea  CTD   which is currently in ongoing investigator initiated trials  IIT   GI adverse events are common in patients being treated for cancer with estimates as high as 40  of standard dose chemotherapy patients  Diarrhea is also a common adverse event for a range of targeted cancer therapies  Notably  drugs that target the ErbB family of growth receptors  which includes EGFR and HER2  typically have diarrhea as the most common adverse event  This is true of both monoclonal antibodies targeting these receptors as well as a tyrosine kinase inhibitors  TKIs   Rates of diarrhea seen in clinical trials for this class range from around 45  for most to over 90  for Gilotrif  afatinib  Boehringer Ingelheim  and Nerlynx  neratinib  Puma  more detail below   Moreover  these can be complicating factors for treatment  and GI issues are a major cause of discontinuations  delays and dosage adjustments 




The ongoing clinical study is sponsored by Georgetown University and funded by Genentech  Exhibit 8   The study is examining the use crofelemer for diarrhea in patients undergoing treatment for HER2  breast cancer  Diarrhea is a frequent problem in these patients  driven by both chemotherapy and the available targeted therapies  Herceptin  trastuzumab   7 1bn 2018 sales  is the standard of care for these patients for both induction and adjuvant therapy and is associated with high rates of diarrhea in both settings  This clinical trial will be examining patients treated with Herceptin and Perjeta  pertuzumab   2 8bn 2018 sales   the latter of which typically exacerbates patient diarrhea  66 8  with Perjeta compared to 46 3  with Herceptin and docetaxel alone  The study is expected to have an interim readout on the first 23 patients in Q319  which we believe will inform the direction of the CTD program 
In addition to the above IIT  the product is being tested in another trial sponsored by the University of California San Francisco in collaboration with Puma Biotechnology  but without the participation of Jaguar  Patients in the study will receive Nerlynx as the adjuvant treatment  Nerlynx is a tyrosine kinase inhibitor  TKI  that was effective in clinical trials at preventing future metastases  but it is characterized by pervasive and severe diarrhea  95  of patients have some form of diarrhea  40  at grade 3  The Nerlynx label includes a direction to initiate prophylactic loperamide before the first dose  We expect this level of diarrhea to be a major limiting factor on sales of the drug   200m in 2018   as well as potentially limiting future expansion of the drug into other indications 
Additionally the company recently reported top line results from an animal study in dogs that is informative for CTD  The study examined 24 healthy beagles who were given the maximally tolerated dose of a specific undisclosed TKI and 125mg Mytesi twice a day  bid   four times a day  qid   or none at all  placebo   The study used a responder analysis similar to that used in the pivotal trial for HIV associated diarrhea  where responders were counted as dogs with less than seven watery stools per week for at least two weeks out of the 28 day treatment period  Seven of eight dogs in the qid group were responders  p 0 02  as were six of eight in the bid group  p 0 03  compared to three of eight in the placebo arm  Although the study is in dogs  these results are in line with previous studies and suggest that Mytesi may be useful in this particular variety of diarrhea 
The size of the addressable market for CTD will depend on the scope of future clinical study  and this will depend on future feedback from the FDA  The most attractive scenario would be one in which the drug can be tested and approved for diarrhea caused by a broad class of drugs  as opposed to individual cancer indications   We believe that this pathway should be possible considering the approval process for drugs used to treat chemotherapy induced nausea and vomiting  CINV   Drugs approved for CINV have been approved based on trials centering on groups of treatment regimens instead of certain diseases  One scenario would be if the drug can seek approval for diarrhea secondary to drugs that target the ErbB family  This would also expand the potential indications to other solid tumors such as lung cancer and renal cancer  among others   We estimate that there are over 100 000 person years of drug exposure for these drugs per year  However  the most attractive scenario is one in which the drug would be broadly approved for alleviation of diarrhea secondary to both targeted treatment and chemotherapy  An estimated 650 000 patients in the US undergo chemotherapy each year  and the success of the CINV market highlights the opportunities  The leading CINV drug Emend  aprepitant  Merck  had peak US sales of  356m  with an estimated 149 000 patient years per year 
The company met with the FDA in March 2019 to discuss the clinical trial design for the pivotal study  including discussions of a  basket  study including multiple cancer agents  According to the most recent reports  the company is still finalizing the design with the agency for the anticipated basket label  However  the FDA did agree in the meeting that no additional preclinical safety studies or drug interaction studies were needed and that the product s chemistry  manufacturing and controls  CMC  were sufficient 
Canalevia
The company is also advancing a different crofelemer product for a similar indication in dogs  Canalevia for chemotherapy induced diarrhea  CID   The company announced in June 2019 that it had completed the clinical data for the final technical section of its new animal drug application  NADA  and would be submitting it in Q319  and that these data indicate that the product is potentially also safe in puppies  We expect the primary market for this drug to be dogs undergoing chemotherapy for the treatment of canine lymphoma  which affects 20 100 dogs per 100 000  It is the primary cancer indication in dogs that is not treated surgically and can be well addressed with standard chemotherapies  Chemotherapy is also used post surgically for soft tissue sarcomas  35 122 per 100 000   which may provide an additional market 
The company has also stated that it intends to file for approval of the product for exercise induced diarrhea  EID  in dogs  The company completed safety studies for the program in 2015  The indication is poorly understood and there is limited research into the subject  but it appears that strenuous exercise can lead to immune disturbances that translate into gastrointestinal irritation in some dogs  This has been studied the most extensively in Alaskan sled dogs  where it was seen that dogs had increased frequency of gastric erosions and ulcerations as well as increased intestinal permeability following a race  We expect this indication to be minor compared to CID given its poorly defined nature and intermittent presentation 
The company is seeking approval through the Minor Use and Minor Species Act  MUMS   intended to promote approval of animal drugs that are used in either limited indications or in less prevalent species  It allows drugs to be marketed before all the necessary efficacy data has been collected and allows for post marketing studies to provide this information  The program is modelled on the orphan drug program for human indications  and its structure is fundamentally similar  Canalevia has already received a MUMS designation for CID and the FDA has indicated EID would qualify as a minor use  The company has stated it intends to seek approval and launch the product for CID in 2020 
Other future programs
The company s other human use development programs are not currently in the clinic but it may expand into them depending on resources  All of these programs center on the anti diarrheal activity of the drug  These include potential new indications such as short bowel syndrome  which has orphan drug designation  as well as revising previous programs such as IBS D to build on prior clinical experience  The company has not released specific timing regarding the initiation of any of these proposed studies 




The company s cholera program is different than for other indications because it is being performed with the drug candidate lechlemer instead of crofelemer  Lechlemer is also an extract of the Croton lechleri tree with similar properties to crofelemer and reportedly similar activity  Jaguar decided to use lechlemer instead of crofelemer because it will potentially enable it to receive a priority review voucher  PRV  if the drug is approved for the indication  PRVs are awarded to companies that receive approval for certain classes of disease that the FDA wants to encourage investment in  In this case  cholera is included in the tropical disease PRV program  Only newly approved drugs can receive a PRV  thus excluding crofelemer  After approval  the PRV can be sold to another drug company for a significant amount of money  previous sales have been for between  68m and  350m  and the latest transaction  to our knowledge  was for  105m  GW Pharmaceuticals to an undisclosed company  
Sensitivities
Jaguar faces a set of risks associated with both its commercial operations and future development  The company is commercializing Mytesi internally  which means it must bear the whole cost of its marketing  whereas a larger company could rely on a salesforce established to sell multiple drugs  The company has signed the promotional agreement with RedHill  although the latter is in a similar position as a small biotechnology company marketing a small portfolio of products and the collaboration has not produced any fruit to date  Adding to this is the fact that the marketing problem for Mytesi is particularly complicated because it involves changing certain perceptions with regards to the prevalence  severity and importance of addressing ART associated diarrhea  Campaigns with an educational component such as this can take many years to develop 
The company also faces the unavoidable risk associated with clinical development  The drug is in clinical trials for CTD  although these were not started by Jaguar and therefore may not be designed or executed with the intent of getting approval  Moreover  as with other investigator initiated trials  the scope of these studies is more limited and the drug is only being tested in a small number of clinical sites  If the company choses to progress with the program  we expect pivotal studies to require a substantial number of patients  over 1 000  and carry significant costs 
Finally  the company must raise a substantial amount of capital to cover its marketing and development costs  We estimate that Jaguar will require at least  80m in additional capital to reach profitability in 2024 if the CTD program advances  If the CTD program does not advance  we forecast profitability in 2027 on ART sales alone and an additional expense of  12m  Raising capital to maintain operations could result in substantial dilution and addressing these needs in the past has diluted earlier shareholders  the company started 2019 with 0 9m split adjusted shares and has issued 10m more shares  or equivalents  and 19 5m warrants by August 2019 
The conversion of this debt is ongoing  and we expect further dilution to be very likely  Raising this much capital given the current market capitalization is unlikely to be feasible   80m at  2 00 per share would result in 5x dilution  and if the company cannot either lift its share price substantially  obtain debt financing  or constrain its spending  future operations may be imperiled 
Valuation
We arrive at an initial valuation of  86 5m or  4 14 per diluted share based on a risk adjusted NPV analysis  We include Mytesi for ART and CTD in our valuation as well as Canalevia for canine CID 
The majority of our valuation is driven by the ART program  for which we forecast  74 1m in peak sales in 2031 at a penetration of 12   We assume relatively low penetration given the availability of effective generic and OTC alternatives  We estimate an addressable market of approximately 70 000 individuals in the US who have HIV  are diagnosed  adherent and have non infectious diarrhea  We assume a conservative 2  price growth per year  from the current  668 per month   and a 20  gross to net sales discount  COGS for Mytesi have historically been high at approximately 50   although we see this improving progressively with volume to 25   We also assume  6m in S M overhead and 10  marketing expenses  Our model also includes revenue from the Knight agreement to market in Canada and Israel  We assume a transfer price of 50  of COGS and  13m  of a possible  18m  in milestones  We assume Knight will begin commercialization in these geographies in 2021  Our discount rate is 10   which is our standard for approved products 
Of the company s proposed development programs  we include CTD because it is the only program with ongoing clinical studies  albeit studies not initiated by the company  If the ongoing IIT studies are positive  we expect Jaguar to initiate pivotal studies in 2020  We expect a pivotal trial for CTD approval to be large with over 1 100 patients  based on previous approvals for CINV   but this is mitigated by a low per patient cost of  10 000 as we expect timelines to be quick as in previous studies  Our model assumes the drug will be approved broadly for CTD  including patients on chemotherapy  as opposed to exclusively patients receiving TKIs or other ErbB inhibitors   We model approval in 2022 with similar pricing  COGS  etc  to the ART diarrhea program  We model lower S M overhead for this program   5m  as we expect there to be fewer headwinds convincing physicians of the importance of addressing this indication  Our probability of success for this program is 30   which is our standard probability for programs in Phase II  We may also adjust this parameter based on the indication targeted for pivotal trials  Our discount rate is 12 5   which is our standard for products in development 
We also include Canalevia for canine CID with lymphoma and STS as initial indications  We model pricing of  67 per month given the increased pricing pressure in the cash pay veterinary market  Our probability of success for this program is 60  based on the stage and would be higher if we could evaluate the efficacy data being provided to the agency as part of the NADA 
Each of these indications is modelled to 2031  when the product s Orange Book patents expire  Although there is not a pathway to develop generics for botanical drugs such as crofelemer  given the agency s focus on removing barriers to generic drug development  we expect it to facilitate market entrants in that event  We also only model Jaguar marketing these products in the US as we believe anything else is beyond the company s capacity short of partnerships such as those with Knight 




We also include a line item for unallocated costs to offset cash flow associated with corporate overhead and other factors  This negative NPV of  34 6m is driven primarily by high G A expenses of approximately  12m per year  We may adjust this in the future if the company institutes cost controlling measures 
Financials
The company recently underwent a major effort to recapitalize and eliminate a portion of its debt  This process took approximately six months to complete following the end of 2018 and involved multiple elements 
The conversion of  5 1m in debt through the issuance of 0 8m shares through exchange agreements with its lender Chicago Venture Partners  CVP A  16 5m registered direct offering  2 9m common shares and 10 787 preferred shares convertible to 5 4m common shares  priced at  2 00 per common share or equivalent and carrying 200  warrant coverage  at a  2 00 exercise price The issuance of  5 05m in bridge notes accompanied by warrants for the purchase of  2 8m shares  at  2 00    3 6m in bridge notes have been reported to have been repaid to dateA 1 70 reverse split in June 2019 The process has resulted in substantial dilution to the company s shares  It ended 2018 with the equivalent of 0 9m split adjusted shares  which has increased to 10 9m common shares or equivalent in convertible preferred shares as of August 2019  Moreover  the company has issued 19 2m warrants so dilution will likely continue  Including these dilutive securities  this corresponds to a dilution of 97  in the past eight months  In addition to the above bridge notes  the company ended the quarter with  7 8m in notes  10  maturing December 2020   of which  1 1m has subsequently been converted to stock under exchange agreements  The elimination of this remaining debt may result in further dilution 
We expect the company to require substantial additional capital to deliver on its development plans  We forecast that the company will need no less than  80m in additional capital to deliver on its current development plants and reach profitability in 2024  We include this as debt for illustrative purposes in our forecasts   30m each in 2020 and 2021  and  20m in 2022  However  if the company finances these costs through equity  we would expect substantial further dilution 
The company reported revenue of  1 7m for Q219  roughly flat on a sequential basis   1 6m Q119   but almost doubled  up 92   year on year  The revenue is almost entirely attributable to Mytesi  with a small portion from sales of its Neonorm products   21 000   Operational expenses were similar to previous periods and dominated by G A   3 2m versus  1 7m for R D and  2 2m for S M  The loss reported for the period was  16 7m  which is not necessarily representative as it includes  6 5m in non cash charges associated with the company s refinancing and a  4m write down on its intangible assets  for undisclosed reasons   We expect the reported loss in 2020 to be lower   28 5m  due to fewer non cash charges  but for there to be  22 9m negative cash flow for the year ",2019-08-27,Edison,https://www.investing.com/analysis/jaguar-health-a-different-angle-on-an-old-problem-200458865,200458865
147280,368796,BHC,Aerie Secures Positive CHMP Opinion For Eye Drug Rhokiinsa,opinion,Aerie Pharmaceuticals  Inc    NASDAQ AERI   announced that the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  has rendered a positive opinion recommending a marketing approval for Rhokiinsa  netarsudil ophthalmic solution 0 02   to reduce elevated intraocular pressure  IOP  in adult patients with open angle glaucoma or ocular hypertension Rhokiinsa is already marketed as Rhopressa in the United States for the same indication If approved  Rhokiinsa will be available in all EU member states along with Iceland  Norway and Liechtenstein  A final decision is expected within the next two months Shares of Aerie have plunged 35 4  so far this year against the  increase of 7  We remind investors that in December 2017  Aerie s lead drug Rhopressa was approved by the FDA for the reduction of elevated IOP in patients with open angle glaucoma or ocular hypertension  The drug was launched toward the end of April 2018  Aerie s second drug Rocklatan  a once daily  quadruple action  fixed dose combination of Rhopressa and Pfizer s   NYSE PFE   Xalatan  was approved by the FDA in March 2019 to lower the elevated IOP in patients with open angle glaucoma or ocular hypertension Also  Aerie plans to submit an Marketing Authorisation Application  MAA  for Rocklatan in Europe on the potential approval of Rhokiinsa in the region  Rocklatan will be marketed under the trade name of Roclanda in Europe  A phase III Mercury 3 study on Rocklatan continues to progress in Europe Meanwhile  in July 2019  Aerie completed enrollment in the parallel group phase II study on Rhopressa 0 02  in Japan  The study closed the recruitment ahead of schedule with data expected by this year end The uptake of Rhopressa has been strong so far  The drug continues to gain traction with an increase in covered lives under various medicare plans  Approval in additional countries should further boost its sales  However  Rhopressa is likely to face a tough competition from Bausch Health s   NYSE BHC   Vyzulta  which is also approved for the treatment of patients suffering open angle glaucoma or ocular hypertension Zacks Rank   Stock to ConsiderAerie currently carries a Zacks Rank  4  Sell  A better ranked stock in the same sector is FibroGen  Inc   NASDAQ FGEN    which sports a Zacks Rank  1  Strong Buy   You can see  FibroGen s loss per share estimates have been narrowed 66 1  for 2019 and 40 6  for 2020 over the past 60 days Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2019-09-23,Zacks Investment Research,https://www.investing.com/analysis/aerie-secures-positive-chmp-opinion-for-eye-drug-rhokiinsa-200467216,200467216
147281,368797,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 19 ,news,"Investing com   Canada stocks were higher after the close on Wednesday  as gains in the Healthcare  Energy and Clean Technology sectors led shares higher 
At the close in Toronto  the S P TSX Composite rose 0 19  
The best performers of the session on the S P TSX Composite were Bausch Health Companies Inc  TO BHC   which rose 8 79  or 2 22 points to trade at 27 47 at the close  Meanwhile  Eldorado Gold Corp  TO ELD  added 8 00  or 0 32 points to end at 4 32 and Canopy Growth Corp  TO WEED  was up 7 48  or 2 740 points to 39 350 in late trade 
The worst performers of the session were  First Quantum Minerals Ltd    TO FM   which fell 4 35  or 0 48 points to trade at 10 56 at the close  Barrick Gold Corporation  TO ABX  declined 3 64  or 0 67 points to end at 17 76 and  Norbord Inc   TO OSB  was down 3 47  or 1 26 points to 35 04 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 576 to 519 and 93 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 0 28  to 24 91 
Gold Futures for February delivery was up 0 30  or 3 85 to  1285 15 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in February rose 2 64  or 1 20 to hit  46 61 a barrel  while the March Brent oil contract rose 2 34  or 1 26 to trade at  55 06 a barrel 
CAD USD was up 0 41  to 0 7361  while CAD EUR rose 1 49  to 0 6489 
The US Dollar Index Futures was up 0 69  at 96 395 ",2019-01-02,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade-sptsx-composite-up-019-1735480,1735480
147282,368798,BHC,Bausch Health up 5  on 2019 outlook,news,Bausch Health Companies  BHC  5 3   is up on average volume in response to its corporate presentation at JP Morgan s Healthcare Conference  Highlights 2019 outlook  total revenue should be up from 2018  Cash flow ops should be more than  1B and will be used to pay down debt and for possible  bolt on  acquisitions  Sales from its  significant seven  products should double to   300M  CORE initiative should deliver more than  75M in operational efficiencies Four late stage programs ongoing or planned in Salix unit  two for Rifaximin and two for Xifaxan  Three year CAGR of revenue expected to be 4   6  and 5   8  for non GAAP EBITDA  JPM19Now read ,2019-01-07,Seeking Alpha,https://www.investing.com/news/stock-market-news/bausch-health-up-5-on-2019-outlook-1739674,1739674
147283,368799,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 33 ,news,"Investing com   Canada stocks were lower after the close on Tuesday  as losses in the Clean Technology  Industrials and Energy sectors led shares lower 
At the close in Toronto  the S P TSX Composite declined 0 33  
The best performers of the session on the S P TSX Composite were  Maple Leaf Foods Inc    TO MFI   which rose 7 34  or 1 99 points to trade at 29 10 at the close  Meanwhile  Bausch Health Companies Inc  TO BHC  added 6 77  or 2 22 points to end at 35 00 and  Ensign Energy Services Inc   TO ESI  was up 4 54  or 0 24 points to 5 53 in late trade 
The worst performers of the session were  Northland Power Inc    TO NPI   which fell 9 25  or 2 38 points to trade at 23 36 at the close   Badger Daylighting Ltd    TO BAD  declined 3 64  or 1 51 points to end at 40 00 and  ARC Resources Ltd    TO ARX  was down 3 40  or 0 33 points to 9 39 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 562 to 503 and 124 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 0 66  to 12 26 
Gold Futures for April delivery was up 0 38  or 4 95 to  1306 45 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in May fell 0 39  or 0 23 to hit  59 15 a barrel  while the May Brent oil contract fell 0 04  or 0 03 to trade at  67 51 a barrel 
CAD USD was up 0 15  to 0 7510  while CAD EUR fell 0 05  to 0 6612 
The US Dollar Index Futures was down 0 16  at 95 828 ",2019-03-19,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade-sptsx-composite-down-033-1812196,1812196
147284,368800,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 06 ,news,"Investing com   Canada stocks were lower after the close on Wednesday  as losses in the Consumer Discretionary  Healthcare and Industrials sectors led shares lower 
At the close in Toronto  the S P TSX Composite fell 0 06  
The best performers of the session on the S P TSX Composite were Westshore Terminals Investment Corp  TO WTE   which rose 11 83  or 2 17 points to trade at 20 52 at the close  Meanwhile   MEG Energy Corp   TO MEG  added 9 50  or 0 48 points to end at 5 53 and  Crescent Point Energy Corp    TO CPG  was up 9 27  or 0 37 points to 4 36 in late trade 
The worst performers of the session were BRP Inc  TO DOO   which fell 3 72  or 1 39 points to trade at 35 98 at the close  Bausch Health Companies Inc  TO BHC  declined 3 69  or 1 29 points to end at 33 71 and TFI International Inc  TO TFII  was down 3 58  or 1 43 points to 38 54 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 564 to 498 and 130 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 7 59  to 13 19 
Gold Futures for April delivery was up 0 52  or 6 75 to  1313 25 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in May rose 1 35  or 0 80 to hit  60 09 a barrel  while the May Brent oil contract rose 1 14  or 0 77 to trade at  68 38 a barrel 
CAD USD was up 0 17  to 0 7519  while CAD EUR fell 0 38  to 0 6586 
The US Dollar Index Futures was down 0 43  at 95 415 ",2019-03-20,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade-sptsx-composite-down-006-1813495,1813495
147285,368801,BHC,Short   distort  The ugly war between CEOs and activist critics,news,"By Lawrence Delevingne NEW YORK  Reuters    On the morning of July 11  Paul Pittman was on a corn farm in Western Illinois  unaware his company had taken a devastating hit  Just before the stock market opened  an anonymous short seller named  Rota Fortunae  posted on Twitter and financial website Seeking Alpha that Pittman s small real estate investment trust  Farmland Partners Inc  had engaged in dubious transactions and risked  insolvency    The posting pushed shares down enough to make thousands of previously purchased stock options profitable  according to a later expert analysis  in turn causing more selling by those on the other side of the trade who committed to buy shares at a higher set price  The accelerating losses were probably compounded by high frequency trading algorithms activated by price swings and negative keywords  according to that analysis  Pittman s stomach churned when he checked his smartphone around noon  Shares were off almost 40 percent   Graphic     The game was rigged   Pittman  56  told Reuters  What followed exemplified a new  ugly phase in a war between companies and activist short sellers  with businesses fighting back against social media fueled attacks and investors accusing executives of trying to muzzle critics  Farmland sued Rota Fortunae   Latin for  wheel of fortune    and other unnamed individuals alleging a  malicious scheme  to profit from the spread of false information and well timed stock options  The short seller  a Texas based individual whose identity has been kept secret  sent a statement to Reuters via an attorney that the litigation aimed to  intimidate and choke critical opinion  and that the idea of crashing the stock through  sophisticated trading  was  utter hogwash   It is all under the watch of the U S  Securities and Exchange Commission  which has been briefed on the matter  The stand off reflects a broader debate over how to balance the desire to keep public companies accountable with concerns over market manipulation   Short selling  said to be as old as stock markets  used to be a low profile affair where bearish investors relied on the media  analysts or regulators to take the lead in exposing over valued companies  New tools such as Twitter and Seeking Alpha changed that  creating a small but prominent group of brash public activists  Successful campaigns that exposed corporate fraud or dubious practices  including Carson Block s Sino Forest Corp takedown and Andrew Left s shorting of Valeant Pharmaceuticals International Inc  NYSE BHC   underscored short sellers  role as market watchdogs  Such victories  coupled with elevated stock valuations  helped spur record numbers of short campaigns  according to industry tracker Activist Insight  Activist Insight data show such campaigns can have a noticeable impact on stock prices  A 2017 working paper by researchers Yu Ting Forester Wong and Wuyang Zhao also showed they weigh on target companies  investments  dividends and access to financing  Block  Left and other prominent short sellers interviewed by Reuters say they do thorough research and help keep companies honest  Yet targeted businesses say many short campaigns waged this decade amount to  short and distort  schemes  They accuse some activists of spreading false or misleading information to drive a stock down and then quickly cash out  a mirror image of  pump and dump   where unscrupulous investors promote speculative stocks before selling out at the top   Cases against short sellers are rare  though  given free speech protections and companies hesitant to put themselves under the microscope of regulators  lawyers say   SHORT IDEAS AND OPTIONS Recent research provides fresh fodder for the debate  Columbia Law School securities expert Joshua Mitts said in a working paper that he had looked at 1 720 pseudonymous short idea posts on Seeking Alpha between 2010 and 2017 and found that 86 percent were preceded by  extraordinary  options trading  Mitts told Reuters his review of the posts found that  like with Farmland  many short sellers appeared to use fast expiring put options bought before the release of a report to spur more selling by underwriters   Shorts have to rely on good research  not trading tricks  to punish a stock   said Mitts  whose work has led to paid consulting for Farmland and other companies   He has also found other unusual trading patterns  including dozens of cases of  spoofing  and  layering   illegal trading strategies of placing and canceling orders to create a false impression of demand or supply  Mitts said  however  that high frequency traders were probably responsible  not activists  Prominent activists deny engaging in practices described by Mitts and say they rarely use options  Instead  they would typically borrow stocks and immediately sell them in anticipation of a price drop  so they can buy them back for less and pocket the difference   I m sure there are a few anonymous guys out there doing tricky stuff  but it s not a systemic problem   Left said   One smaller short seller said he used put options in conjunction with Seeking Alpha posts to make larger bets given limited capital  but emphasized making unfounded claims could backfire   With options you can get totally destroyed   said the investor  who requested anonymity   A bad thesis can be debunked almost instantly   Activist Insight  which has analyzed hundreds of campaigns  found many cases where target share prices went up  not down   So far Mitts is virtually alone in analyzing trading activity around short campaigns  but his findings have already drawn the attention of a top U S  regulator  SEC Commissioner Robert Jackson told Reuters the research was  important  and challenged his agency to  identify folks who are dancing a very fine line between trading and market manipulation    The question  Jackson said  was whether the regulator would go after short sellers who engage in fraud as forcefully as it investigates companies for bad behavior   I hope the answer to that question will be yes   A hint came last September  when the SEC brought a rare  short and distort  case against hedge fund manager Gregory Lemelson for making false claims about Ligand Pharmaceuticals Inc  an allegation which Lemelson has denied   Jackson said  however  laws on anonymity and free speech could limit any steps that went beyond straightforward cases involving false information  On March 12  for example  a New York state judge dismissed a lawsuit against short sellers by Indian media company Eros International PLC  noting their opinions on Seeking Alpha and elsewhere were substantiated and therefore protected  Still  companies are increasingly retaliating with lawsuits  hiring private investigators and using other aggressive tactics  according to some activists  Block  for example  said he has faced  constant  legal threats  at least one undercover operative  and a failed  50 million investigation to discredit his research    More than ever  bad companies are trying to shoot the messenger through any means available   Block said  FARM WAR In the days after Rota s post  Farmland issued a public rebuttal and Pittman  a former farmer and financial executive  said the company had to go on an   I am not a crook  tour  in meetings and calls with investors and business partners   Most were sympathetic  Pittman said  including farmers who had traded land for stock  but Farmland lost a potential partnership and had to cut staff from 17 to 13  George Moriarty  executive editor of Seeking Alpha  said that courts have respected the site s status as a neutral platform and that its staff vetted all posts  In this case  Rota made  limited factual corrections  after Seeking Alpha contacted him about Farmland s rebuttal  Still  shares have never quite recovered  and Rota told Reuters that Farmland has yet to substantively address his concerns   Stock analysts said Rota s language was dramatic relative to the underlying issues and instead focused on broader business challenges and the potential costs of fighting back  Farmland recently reported about  1 6 million in extra expenses over 2018  before insurance  citing Rota s campaign  That included defending against a related shareholder class action and legal costs from its suit against the short seller  Mitts has submitted his opinion on put options in the case  a pattern he said he discovered independently during his academic research   The short seller behind the Rota moniker told Reuters he planned to challenge Mitts  assertions and would continue his defense of first amendment rights  Farmland s lawyers said Rota s free speech argument was undercut by his acknowledgement of payments received for research on Farmland  Whatever happens in court  the SEC is watching  Rota submitted his Farmland analysis to the agency s whistleblower hotline  while Farmland later briefed SEC staff on its side  
The SEC declined to comment  but on Jan  29 it denied Farmland s request for records on Rota and options trading because  according to a letter revealed in a court filing  related information was in an  investigative file  from an  on going law enforcement proceeding  ",2019-03-21,Reuters,https://www.investing.com/news/stock-market-news/short--distort-the-ugly-war-between-ceos-and-activist-critics-1813828,1813828
147286,368802,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 49 ,news,"Investing com   Canada stocks were higher after the close on Friday  as gains in the Energy  IT and Financials sectors led shares higher 
At the close in Toronto  the S P TSX Composite gained 0 49  to hit a new 6 months high 
The best performers of the session on the S P TSX Composite were Canopy Growth Corp  TO WEED   which rose 5 46  or 2 920 points to trade at 56 370 at the close  Meanwhile   Encana  Corporation  TO ECA  added 5 43  or 0 52 points to end at 10 09 and  Crescent Point Energy Corp    TO CPG  was up 5 04  or 0 27 points to 5 63 in late trade 
The worst performers of the session were Bausch Health Companies Inc  TO BHC   which fell 4 78  or 1 66 points to trade at 33 08 at the close   Torex Gold Resources Inc   TO TXG  declined 3 93  or 0 550 points to end at 13 440 and  MAG Silver Corp   TO MAG  was down 3 79  or 0 51 points to 12 95 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 621 to 443 and 136 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 7 75  to 10 83 
Gold Futures for June delivery was up 0 03  or 0 35 to  1293 65 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in May rose 0 35  or 0 22 to hit  63 80 a barrel  while the June Brent oil contract rose 0 97  or 0 69 to trade at  71 52 a barrel 
CAD USD was up 0 46  to 0 7503  while CAD EUR rose 0 12  to 0 6644 
The US Dollar Index Futures was down 0 26  at 96 560 ",2019-04-12,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade-sptsx-composite-up-049-1835277,1835277
147287,368803,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 25 ,news,"Investing com   Canada stocks were higher after the close on Wednesday  as gains in the Energy  Consumer Discretionary and Industrials sectors led shares higher 
At the close in Toronto  the S P TSX Composite gained 0 25  to hit a new 6 months high 
The best performers of the session on the S P TSX Composite were Hexo Corp  TO HEXO   which rose 12 03  or 0 9500 points to trade at 8 8500 at the close  Meanwhile   Lundin Mining  Corporation  TO LUN  added 6 15  or 0 460 points to end at 7 940 and  CannTrust  Holdings Inc  TO TRST  was up 6 04  or 0 5500 points to 9 6600 in late trade 
The worst performers of the session were  Alaris Royalty Corp    TO AD   which fell 10 10  or 2 040 points to trade at 18 160 at the close   Aphria Inc   TO APHA  declined 9 59  or 1 110 points to end at 10 470 and Bausch Health Companies Inc  TO BHC  was down 4 50  or 1 45 points to 30 77 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 533 to 527 and 131 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 2 51  to 11 01 
Gold Futures for June delivery was down 0 08  or 1 00 to  1276 20 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in May fell 0 47  or 0 30 to hit  63 75 a barrel  while the June Brent oil contract unchanged 0 00  or 0 00 to trade at  71 62 a barrel 
CAD USD was down 0 01  to 0 7493  while CAD EUR fell 0 02  to 0 6631 
The US Dollar Index Futures was down 0 00  at 96 648 ",2019-04-17,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade-sptsx-composite-up-025-1839177,1839177
147304,368820,BHC,Aerie  AERI  Q1 Earnings Beat  Rhopressa Misses Estimates,opinion,"Shares of Aerie Pharmaceuticals  Inc    NASDAQ AERI   are trading down 5 4  after the company reported mixed results for the first quarter  The company reported a loss of 78 cents in the first quarter 2019  narrower than the Zacks Consensus Estimate of a loss of 91 cents and the year ago loss of 83 cents 
Aerie s stock has gained 6  in the year so far compared with the  s growth of 8 3  

 
In December 2017  Rhopressa was approved by the FDA for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension  The drug was launched by the end of April 2018 
Rhopressa s revenues came in at  10 9 million in the quarter  missing the Zacks Consensus Estimate of  12 7 million 
Quarter in Detail
Rhopressa revenues reflect a higher proportion of Medicare Part D rebates which are steeper than commercial rebates 
In the reported quarter  research and development expenses increased to  17 9 million from  13 million in the year ago quarter  Selling  general and administrative expenses surged to  36 3 million from  22 9 million in the year ago quarter 
Rhopressa now has preferred brand Tier 2 market access for approximately 75  of lives covered under Medicare Part D plans  Rhopressa also has approximately 90  of lives covered under commercial plans  including 55  in preferred brand Tier 2 and 35  in Tier 3 
Pipeline Updates
In Mar 2019  Aerie announced that the FDA has approved Rocklatan 0 02  0 005  to reduce elevated intraocular pressure  IOP  in patients with open angle glaucoma or ocular hypertension  Rocklatan is a once daily  quadruple action fixed dose combination of Rhopressa  netarsudil  and Pfizer s   NYSE PFE   Xalatan  latanoprost  
A phase III trial  Mercury 3  on Rocklatan continues to progress in Europe 
Aerie s retina program   AR 13503  Rho kinase and Protein kinase C inhibitor implant  and AR 1105  dexamethasone steroid implant  continues to advance as well  The IND  Investigational New Drug application  for AR 13503  Rho kinase and Protein kinase C inhibitor implant  was accepted by the FDA  last month  Clinical trials are expected to begin in the second quarter of 2019 for wet age related macular degeneration and DME  diabetic macular edema  
In March 2019  a phase II study was initiated on AR 1105 for macular edema due to RVO  retinal vein occlusion   Safety and efficacy data for AR 1105 will be evaluated at six months after dosing 
2019 Guidance
Aerie reiterated its annual guidance  The company expects full year 2019 net revenues in the range of  110 million to  120 million 
Our Take
Aerie reported mixed results for the fourth quarter  Rhopressa sales miss estimates due to higher rebates  Nevertheless  the approval of second drug  Rocklatan is a big boost for the company and should propel sales in the coming quarters even though competition is stiff from the likes of Bausch Health s   NYSE BHC   Vyzulta  among others 
Zacks Rank   Another Key Pick
Aerie currently carries a Zacks Rank  3  Hold  
A better ranked stock in the healthcare sector is Bristol Myers Squibb   NYSE BMY     which sports a Rank  2  Buy   You can see  
Bristol Myers  earnings per share estimates have increased from  4 76 to  4 93 for 2020 in the past 60 days 
Breakout Biotech Stocks with Triple Digit Profit Potential
The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases 
Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-05-08,Zacks Investment Research,https://www.investing.com/analysis/aerie-aeri-q1-earnings-beat-rhopressa-misses-estimates-200419074,200419074
147305,368821,BHC,Bausch Health  BHC  Catches Eye  Stock Jumps 6 2 ,opinion,Bausch Health Companies Inc    NYSE BHC   was a big mover last session  as the company saw its shares rise more than 6  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This stock  which remained volatile and traded within the range of  20 52  24 49 in the past one month time frame  witnessed a sharp increase yesterday The company has seen no changes when it comes to estimate revision over the past few weeks  while the Zacks Consensus Estimate for the current quarter has also remained unchanged  The recent price action is encouraging though  so make sure to keep a close watch on this firm in the near future Bausch Health currently has a Zacks Rank  2  Buy  while its  is 0 00  Bausch Health Cos Inc  Price   Another stock worth considering in the Medical   Generic Drugs industry is Adamas Pharmaceuticals  Inc    NASDAQ ADMS   which carries a Zacks Rank  2  You can see  Is BHC going up  Or down  Predict to see what others think Up or DownToday s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-06-20,Zacks Investment Research,https://www.investing.com/analysis/bausch-health-bhc-catches-eye-stock-jumps-62-200433644,200433644
147306,368822,BHC,Dova Receives Approval For Doptelet In Europe  Stock Up,opinion,"Shares of Dova Pharmaceuticals  Inc    NASDAQ DOVA   gained 3 3  on Jun 26 after the company s lead drug  Doptelet  received marketing authorization from the European Commission for treating severe thrombocytopenia in adult patients with chronic liver disease   CLD   who are scheduled to undergo an invasive procedure  The authorization allows the company to market the drug in 28 countries constituting the European Union  plus Iceland  Norway  and Liechtenstein The company is currently seeking partnerships for commercialization of the drug in Europe  The drug has been available in the United States since last year  The company has a co promotion agreement with the Salix division of Bausch Health Companies   NYSE BHC    for commercialization of Doptelet in the United States Shares of Dova have increased 39 8  so far this year compared with the  s rise of 8 5    The approval of the drug in Europe was based on data from two phase III studies  which evaluated two doses of Doptelet   40 mg and 60 mg   in patients with thrombocytopenia and CLD  Treatment with the drug increased the proportion of patients who did not require platelet transfusions or rescue procedures for bleeding up to seven days following a scheduled procedure  The increase in the number of patients was superior compared to a placebo  The drug also achieved superior results compared to placebo in increasing the proportion of patients with platelet count equal to or greater than 50 000  L and increase in platelet count from baseline The drug has generated sales of  11 7 million since its approval in May 2018 in the United States  The recent approval in Europe is expected to increase the sales of the drug following a successful launch Dova is also developing Doptelet as a treatment for chronic immune thrombocytopenia   ITP   and chemotherapy induced thrombocytopenia   CIT    A supplemental new drug application is under review in the United States seeking label expansion of the drug to include ITP patients  A decision is expected shortly  An approval will boost the prospects of the drug  A phase III study is evaluating the drug in CIT patients  Top line data is expected in the first half of 2020 Doptelet faces competition from Shionogi s Mulpleta  lusutrombopag  for its approved indication in the United States and Europe  Moreover  there are several drugs approved for treating ITP including Rigel Pharmaceuticals   NASDAQ RIGL   Tavalisse  Novartis    NYSE NVS   Promacta and Amgen s Nplate  Several other companies including Bristol Myers are developing their candidate for ITP indication There is no approved drug for the treatment of CIT  Amgen  NASDAQ AMGN  is evaluating Nplate in a late stage study in CIT patients Dova Pharmaceuticals  Inc  Price
    Zacks RankDova currently carries a Zacks Rank  3  Hold   You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-06-26,Zacks Investment Research,https://www.investing.com/analysis/dova-receives-approval-for-doptelet-in-europe-stock-up-200435239,200435239
147307,368823,BHC,Bausch Gains 38 9  YTD On Product Launches   Debt Reduction ,opinion,Shares of Bausch Health Companies Inc    NYSE BHC   have rallied 38 9  in the year so far  outperforming the  growth of 3 9   The company develops  manufactures and markets a wide range of branded  generic and over the counter  OTC  products  After a tumultuous period  it began a turnaround journey in 2018 and the efforts toward the same have been reaping encouraging results so far Bausch has narrowed its focus on seven recently launched or expected to be launched products  pending completion of testing and receipt of FDA approval  The products include Vyzulta  Siliq  Bryhali  psoriasis   Lumify  Duobrii  Relistor and SiHy Daily  Four of these seven products were launched in 2018  The company has other products in its pipeline as well A couple of product launches boosted investor sentiment last month  Bausch launched psoriasis lotion  Duobrii  in the United States  The FDA has approved Duobrii Lotion for the topical treatment of plaque psoriasis in adults in April 2019   The company already has Siliq in its portfolio for psoriasis Bausch also announced the U S  launch of Bausch   Lomb ULTRA Multifocal for Astigmatism contact lenses for patients with both astigmatism and presbyopia Meanwhile  the Salix business continues to drive growth and contribute to the top line  In particular  increased sales of Xifaxan are boosting the segment  The company recently settled the Xifaxan IP litigation  which should preserve market exclusivity until 2028  The company also entered an exclusive agreement with Dova Pharmaceuticals  Inc    NASDAQ DOVA   to co promote Doptelet in the United States for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure  The addition of Trulance from the Synergy acquisition has bolstered the franchise In the meantime  investors cheered Bausch s announcement of clearing an additional  100 million of its senior secured term loans in June 2019  using cash generated from operations  This led the company to eliminate all mandatory amortization for the first quarter of 2020  The company s efforts to sell non core assets and clear huge levels of debt are commendable Though it is still difficult to comment on the slow rebuilding process  we expect the momentum to pick up gradually as Bausch strengthens its ophthalmology franchise and Salix business Zacks Rank   Other Stocks to ConsiderBausch currently carries a Zacks Rank  2  Buy   A couple of other similar ranked stocks from the same sector are Adamas Pharmaceuticals  Inc    NASDAQ ADMS   and Acasti Pharma  Inc    NASDAQ ACST     You can see  Loss estimates for Adamas for 2019 have narrowed to  3 77 from  4 14 in the past 60 days Loss estimates for Acasti for 2021 have narrowed by 6 cents to 11 cents in the past 60 days Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-07-05,Zacks Investment Research,https://www.investing.com/analysis/bausch-gains-389-ytd-on-product-launches--debt-reduction-200437262,200437262
147308,368824,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 41 ,news,"Investing com   Canada stocks were lower after the close on Wednesday  as losses in the Industrials  Financials and Telecoms sectors led shares lower 
At the close in Toronto  the S P TSX Composite fell 0 41  to hit a new 3 months low 
The best performers of the session on the S P TSX Composite were  New Gold Inc   TO NGD   which rose 22 33  or 0 230 points to trade at 1 260 at the close  Meanwhile  Bausch Health Companies Inc  TO BHC  added 12 76  or 3 46 points to end at 30 58 and Hudson s Bay Company  TO HBC  was up 7 80  or 0 82 points to 11 40 in late trade 
The worst performers of the session were  Aphria Inc   TO APH   which fell 3 66  or 0 790 points to trade at 20 820 at the close   AltaGas Ltd   TO ALA  declined 3 02  or 0 76 points to end at 24 44 and  Boyd Group Income Fund   TO BYD u  was down 2 56  or 3 38 points to 128 60 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 557 to 519 and 147 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 0 95  to 14 58 
Gold Futures for December delivery was up 0 78  or 9 40 to  1211 60 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in October rose 1 49  or 1 03 to hit  70 28 a barrel  while the November Brent oil contract rose 0 81  or 0 64 to trade at  79 70 a barrel 
CAD USD was up 0 51  to 0 7692  while CAD EUR rose 0 30  to 0 6614 
The US Dollar Index Futures was down 0 26  at 94 80 ",2018-09-12,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade-sptsx-composite-down-041-1608042,1608042
147309,368825,BHC,Bausch Health unit moves to settle charges it misled investors  SEC,news,"WASHINGTON  Reuters    Salix Pharmaceuticals  a unit of Bausch Health Companies Inc  TO BHC   has moved to settle charges brought by the U S  Securities and Exchange Commission that it misled investors about the company s prospects  the SEC said on Friday  As part of the proposed settlement  which must be approved by a U S  district court  Salix agreed to an SEC order to avoid future violations of antifraud and corporate reporting provisions of federal securities laws  the agency said  A former chief financial officer at Salix  Adam Derbyshire  was also charged and agreed to a settlement in which he will pay more than  1 million  the SEC said  A lawyer for Derbyshire said he had no comment on the settlement  The alleged misconduct occurred before Salix was acquired by Valeant Pharmaceuticals  NYSE BHC  International  which is now known as Bausch Health  according to the agency  
In a statement  Salix said it was pleased to reach the settlement  and has  completely transformed  since its acquisition by Bausch in 2015 ",2018-09-28,Reuters,https://www.investing.com/news/economy-news/bausch-health-subsidiary-moves-to-settle-charges-it-misled-investors-sec-1628071,1628071
147310,368826,BHC,Ex Valeant  Philidor executives get prison for fraud,news,"By Jonathan Stempel NEW YORK  Reuters    A former executive at Valeant Pharmaceuticals International Inc  NYSE BHC  and the former head of a start up mail order pharmacy were sentenced to one year in prison on Tuesday after being convicted of defrauding the drugmaker through a secret kickback scheme  Gary Tanner  41  the former Valeant executive  and Andrew Davenport  50  the former chief executive of Philidor Rx Services LLC  were also ordered to forfeit  9 7 million  representing the alleged kickback  The sentences were imposed by U S  District Judge Loretta Preska in Manhattan  Both defendants had been convicted in May on four charges  including honest services wire fraud and conspiracy to commit money laundering  Prosecutors had recommended prison terms of between 2 1 2 and 10 years for Tanner  and 2 1 2 and eight years for Davenport  The defendants said no prison time was justified  Lawyers for Tanner did not immediately respond to requests for comment  Sharon McCarthy  a lawyer for Davenport  said her client plans to appeal his conviction  but that the sentence was  extremely fair   The case was the first criminal prosecution arising from multiple probes into Valeant s business practices  including its ties to the now defunct Philidor  Those ties began drawing scrutiny in October 2015  when investors learned that Valeant had in 2014 acquired an option to buy Philidor  and was suspected of using it to boost sales  The revelations contributed to a steep fall in Valeant s share price that was compounded by the probes and the Laval  Quebec based company s heavy debt load  Management was overhauled  and Valeant changed its name to Bausch Health Cos in July  taken from the name of its Bausch   Lomb eye care unit  Tanner had managed Valeant s relationship with Philidor as well as Valeant s  alternative fulfillment  program  through which the drugmaker sought to increase prescriptions for its own drugs instead of cheaper generic substitutes  Prosecutors accused Tanner of steering Valeant business to Philidor  while concealing a  9 7 million kickback from Davenport that came from the roughly  50 million Davenport received when Valeant acquired the option to buy his company   I deeply regret giving money to Gary Tanner   Davenport told Preska  Prosecutors said that to keep the scheme secret  Tanner often used an email account with the name  Brian Wilson  to communicate with Davenport and sabotage potential business with rival pharmacies   Tanner was entrusted to manage Valeant s relationship with Davenport s company   U S  Attorney Geoffrey Berman said in a statement   Instead  they devised a scheme to pillage Valeant and share the proceeds     
The case is U S  v Tanner et al  U S  District Court  Southern  NYSE SO  District of New York  No  17 cr 00061 ",2018-10-30,Reuters,https://www.investing.com/news/stock-market-news/exvaleant-philidor-executives-get-prison-for-fraud-1666265,1666265
147311,368827,BHC,Bausch Health to refinance certain debt,news,Bausch Health Companies  NYSE BHC  plans to amend its existing credit agreement in order to borrow  750M in new term B loans and issue  750M in secured debt  Net proceeds will be used to refinance its outstanding  1 5B of 7 500  Senior Notes due 2021 Now read ,2018-11-08,Seeking Alpha,https://www.investing.com/news/stock-market-news/bausch-health-to-refinance-certain-debt-1679673,1679673
147312,368828,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 56 ,news,"Investing com   Canada stocks were lower after the close on Monday  as losses in the Healthcare  IT and Consumer Discretionary sectors led shares lower 
At the close in Toronto  the S P TSX Composite declined 0 56  
The best performers of the session on the S P TSX Composite were  Bombardier Inc   TO BBDb   which rose 22 99  or 0 385 points to trade at 2 060 at the close  Meanwhile   Ensign Energy Services Inc   TO ESI  added 7 16  or 0 38 points to end at 5 69 and  Precision Drilling  Corporation  TO PD  was up 6 44  or 0 21 points to 3 47 in late trade 
The worst performers of the session were Shopify Inc  TO SHOP   which fell 11 30  or 22 470 points to trade at 176 330 at the close  Bausch Health Companies Inc  TO BHC  declined 7 02  or 2 34 points to end at 30 98 and Canopy Growth Corp  TO WEED  was down 6 87  or 3 180 points to 43 140 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 770 to 363 and 100 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 2 64  to 17 88 
Gold Futures for December delivery was up 0 30  or 3 70 to  1224 50 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in January rose 1 59  or 0 90 to hit  57 36 a barrel  while the January Brent oil contract rose 0 24  or 0 16 to trade at  66 92 a barrel 
CAD USD was down 0 22  to 0 7588  while CAD EUR fell 0 53  to 0 6626 
The US Dollar Index Futures was down 0 25  at 96 09 ",2018-11-19,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade-sptsx-composite-down-056-1694103,1694103
147315,368831,BHC,Bausch Health borrows  1 5B under new loan facility,news,"Bausch Health Companies  NYSE BHC  inked an incremental term loan facility under which it borrowed  1 5B to help fund its tender offer for its outstanding 7 5  Senior Notes due 2021 
The new loan accrues interest at 1 75  with respect to base rate borrowings 
Now read ",2018-11-27,Seeking Alpha,https://www.investing.com/news/stock-market-news/bausch-health-borrows-15b-under-new-loan-facility-1702404,1702404
147319,368835,BHC,Bausch  BHC  Q4 Earnings Beat Estimates  Revenues Down Y Y ,opinion,"Bausch Health Companies Inc    NYSE BHC   reported better than expected results for the fourth quarter of 2018  The company s adjusted earnings per share of  1 05 beat the Zacks Consensus Estimate of  0 88 but was down from  1 98 reported in the year ago quarter 
Total revenues of  2 12 billion also exceeded the Zacks Consensus Estimate of  2 09  but was down 2  from the year ago quarter s figure 
Quarter in Detail 
Revenues in the Bausch   Lomb   International segment were  1 2 billion  approximately flat with the year ago quarter s figure  primarily due to divestitures and discontinuations  Excluding the impact of discontinuations and divestitures  the Bausch   Lomb International segment organically improved approximately 5   The increase was primarily due to higher volumes despite a planned channel inventory reduction of  10 million in the Global Ophtho Rx business 
Salix segment revenues came in at  426 million  roughly flat year over year as 12  growth in Xifaxan was offset by a planned channel inventory reduction of  47 million and generic competition following the loss of exclusivity for Uceris 
Ortho Dermatologics segment revenues were  165 million  down 2  year over year due to lower volumes  This was partially offset by 32  revenue growth in the Global Solta business  
Diversified Products segment revenues were  325 million  down 11  from the year ago quarter  primarily due to the impact of divestitures and discontinuations 
2018 Results
Revenues came in at  8 4 million  which was down 4  from 2017 but surpassed the Zacks Consensus Estimate of  8 34 billion  Earnings of  4 01 also beat the Zacks Consensus Estimate of  3 81 
2019 Guidance
Revenues are expected between  8 30 billion and  8 50 billion  The Zacks Consensus Estimate is  8 51 billion 
Our Take
Bausch s performance in the fourth quarter was encouraging  After a tumultuous period  Bausch started a rebuilding process  The company also changed its name  Even though it is still early to comment on the rebuilding process  Bausch s efforts to sell non core assets and pay down huge levels of debt are commendable  The company recorded 1  organic growth in 2018 and reduced debt by more than  1 billion  Bausch repaid  400 million of debt in the fourth quarter of 2018 
The Bausch   Lomb International segment registered 4  organic growth in 2018  driven by volume growth across all segments  The company recently announced that a subsidiary of Bausch Health acquired the U S  rights to Eton Pharmaceuticals    NASDAQ ETON   EM 100  an experimental eye drop  EM 100 has been submitted to the FDA for review  Upon approval  the eye drop will be the first over the counter  OTC  preservative free formulation eye drop for the treatment of ocular itching associated with allergic conjunctivitis 
Bausch s stock has gained 32 8  in the year so far compared with growth of 10 2  for the  

 
Bausch s Salix business continues to drive growth and contribute to the top line  In particular  increased sales of Xiaflex and Relistor are boosting the segment   However  the dermatology market is challenging 
While the guidance for 2019 wasn t that impressive  we do expect momentum to pick up  Bausch has narrowed focus on seven recently launched or expected to be launched products pending completion of testing and receipt of FDA approval  The company launched 10 key products during 2018  including two copromotions  Four of the Significant Seven products were launched during 2018 and the company expects a decision from the FDA on Duobrii shortly 
Zacks Rank   Stocks to Consider
Bausch currently carries a Zacks Rank  3  Hold  
Some better ranked stocks in the healthcare sector include Bristol Myers Squibb Company   NYSE BMY   and GlaxoSmithKline plc   NYSE GSK    both carrying a Zacks Rank  2  Buy   You can see  
Bristol Myers  earnings per share estimates have increased from  4 07 to  4 16 for 2019 in the past 60 days 
GlaxoSmithKline s earnings per share estimates have increased from  2 86 to  2 95 for 2019 in the past 60 days 
Today s Best Stocks from Zacks
Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  
This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-02-21,Zacks Investment Research,https://www.investing.com/analysis/bausch-bhc-q4-earnings-beat-estimates-revenues-down-yy-200391114,200391114
147320,368836,BHC,Is Bausch Health Companies  BHC  A Great Stock For Value Investors ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Bausch Health Companies Inc    NYSE BHC   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Bausch Health Companies has a trailing twelve months PE ratio of 5 8  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 compares in at about 17 4  If we focus on the stock s long term PE trend  the current level puts Bausch Health Companies  current PE ratio slightly below its midpoint  which is 5 9  over the past five years Further  the stock s PE compares favorably with the industry s trailing twelve months PE ratio  which stands at 7 8  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers We should also point out that Bausch Health Companies has a forward PE ratio  price relative to this year s earnings  of just 5 9  so it is fair to expect an increase in the company s share price in the near future     P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  Bausch Health Companies has a P S ratio of about 0 9  This is substantially lower than the S P 500 average  which comes in at 3 2 right now  Also  as we can see in the chart below  this is somewhat below the highs for this stock in particular over the past few years If anything  this suggests some level of undervalued trading at least compared to historical norms Broad Value OutlookIn aggregate  Bausch Health Companies currently has a Value Style Score of A  putting it into the top 20  of all stocks we cover from this look  This makes BHC a solid choice for value investors  and some of its other key metrics make this pretty clear too For example  the PEG ratio for Bausch Health Companies is just 0 3  a level that is considerably lower than the industry average of 1 1  The PEG ratio is a modified PE ratio that takes into account the stock s earnings growth rate  Additionally  its P CF ratio  another great indicator of value  comes in at 1 9  which is somewhat better than the industry average of 4 6  Clearly  BHC is a solid choice on the value front from multiple angles What About the Stock Overall Though Bausch Health Companies might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth grade of D and a Momentum score of A  This gives BHC a VGM score or its overarching fundamental grade of A   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been encouraging  The current quarter has seen one estimate go higher in the past sixty days and two lower  while the full year estimate has seen six upward and two downward revisions in the same time period This has had a positive impact on the consensus estimate  as the current quarter consensus estimate has risen 4 7  in the past two months  while the full year estimate has increased 3 1   You can see the consensus estimate trend and recent price action for the stock in the chart below Bausch Health Cos Inc  Price and Consensus    Despite this positive trend  the stock has a Zacks Rank  3  Hold   which indicates expectations of in line performance from the company in the near term Bottom LineBausch Health Companies is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  However  with a sluggish industry rank  bottom 41  out of more than 250 industries  and a Zacks Rank  3  it is hard to get too excited about this company overall  In fact  over the past one year  the sector has clearly underperformed the broader market  as you can see below So  value investors might want to wait for broader factors to turn favorable in this name first  but once that happens  this stock could be a compelling pick Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-03-10,Zacks Investment Research,https://www.investing.com/analysis/is-bausch-health-companies-bhc-a-great-stock-for-value-investors-200396402,200396402
147322,368838,BHC,Aldeyra s Eye Drug Meets Main Goal In Study  Shares Surge,opinion,"Shares of Aldeyra Therapeutics  Inc    NASDAQ ALDX   surged by about 36  after the company announced positive top line results from the phase III ALLEVIATE study  evaluating pipeline product  reproxalap topical ophthalmic solution in patients with allergic conjunctivitis 
The study met the primary endpoint and the key secondary endpoint for both concentrations  0 25  and 0 5  of reproxalap  Aldeyra s shares have rallied 16 3  in the past year  against the  s decline of 13 5  

 
The study assessed the efficacy and safety of 0 25  and 0 5  concentrations of reproxalap topical ophthalmic solutions compared to vehicle in 318 patients  approximately 100 per arm  with seasonal allergic conjunctivitis  In the study  patients treated with 0 25  and 0 5  reproxalap demonstrated statistically significant reduction in ocular itching   the primary endpoint   compared to the patients treated with vehicle 
Two point responder rates  a key secondary endpoint  for 0 25  and 0 5  reproxalap were statistically greater than that of vehicle treated patients  confirming the clinical relevance of the observed primary endpoint improvements  The results of the only completed phase III study on the candidate are consistent with the positive results from five prior phase II studies in ocular inflammation 
Aldeyra plans to meet with regulatory authorities in the second half of 2019 to discuss the ALLEVIATE results and potential submission of the marketing application for the candidate  
Bausch Health Companies Inc    NYSE BHC   also submitted an application for an eye drop  EM 100  which is under review with the FDA  Upon approval  the eye drop will be the first over the counter  OTC  preservative free formulation eye drop for the treatment of ocular itching associated with allergic conjunctivitis  Bausch acquired the U S  rights to EM 100 from Eton Pharmaceuticals in February 2019 Aldeyra Therapeutics  Inc  Price

    
Zacks Rank   Stocks to Consider
Aldyera is a Zacks Rank  3  Hold  stock currently 
Some better ranked stocks worth considering are AstraZeneca Plc    NYSE AZN   and Roche Holding  SIX ROG  AG   OTC RHHBY    each carrying a Zacks Rank  2  Buy   You can see  
AstraZeneca s earnings per share estimates have increased from  1 74 to  1 79 for 2019 and from  2 14 to  2 20 for 2020 in the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters  with average of 106 40  
Roche s earnings per share estimates have increased from  2 31 to  2 35 for 2019 and from  2 34 to  2 37 for 2020 over the past 90 days 
Today s Best Stocks from Zacks 
Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  
This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-03-27,Zacks Investment Research,https://www.investing.com/analysis/aldeyras-eye-drug-meets-main-goal-in-study-shares-surge-200401627,200401627
147324,368840,BHC,What s In The Cards For Bausch Health  BHC  Q1 Earnings ,opinion,"Bausch Health Companies Inc    NYSE BHC   is scheduled to report first quarter 2019 results on May 6  before the market opens In the last reported quarter  the company s earnings beat estimates by 19 3   Bausch s earnings track record has been pretty decent so far  The company beat earnings expectations in the last four quarters  delivering an average positive surprise of 88 3  Bausch s stock has gained 3 3  in the past six months against 11 7  decline of the   Factors Likely to Impact ResultsBausch conducts business in four operating segments   the Bausch   Lomb International segment  the Salix segment  the Ortho Dermatologics segment and the Diversified Products segment Approximately 75  of the company s total 2018 revenues were generated by the Bausch   Lomb International and the Salix segments  Hence  the focus will be on these two segments in the first quarter The Salix business continues to drive growth and contribute to the top line  In particular  increased sales of Xifaxan  Apriso and Relistonare should drive revenues in the first quarter Bausch launched 10 products in 2018  which should result in incremental revenues in the first quarter  Investors will also focus on new drug approvals in the to be reported quarter  In February 2019  Bausch announced that the FDA has approved Lotemax SM  loteprednol etabonate ophthalmic gel  0 38   a new gel formulation for the treatment of postoperative inflammation and pain following ocular surgery Meanwhile  investors are expected to focus on pipeline development  apart from the regular top and bottom line numbers in the upcoming quarterly results  Bausch has narrowed focus on seven recently launched or expected to be launched products pending completion of testing and receipt of FDA approval  The products include Vyzulta  Siliq  Bryhali  psoriasis   Lumify  Duobrii  Relistor and SiHy Daily  Among these  the FDA recently approved Duobrii for the topical treatment of plaque psoriasis in adults  We expect an update on the launch of the same and a tentative increase in guidance The focus will also be on the company s efforts to pay debt  as it had been under the scanner for its huge levels of debt  Bausch repaid  400 million of debt in the fourth quarter of 2018 and  1 billion in 2018 Earnings WhispersOur proven model does not conclusively show that Bausch will beat on earnings in the quarter to be reported  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  Unfortunately  that is not the case here  as you will see below Earnings ESP  Earnings ESP for Bausch is  2 40   This is because the Zacks Consensus Estimate stands at 89 cents and the Most Accurate Estimate at 87 cents  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Bausch carries a Zacks Rank  2  which is favorable  However  the negative ESP makes surprise prediction difficult We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Bausch Health Cos Inc  Price  Consensus and EPS Surprise
    Stocks to ConsiderHere are some companies you may consider  as our model shows that these have the right combination of elements to deliver a beat in the to be reported quarter Gilead Sciences  Inc    NASDAQ GILD   has an Earnings ESP of  1 54  and a Zacks Rank  2  The company is scheduled to release financial figures on May 2  You can see  Aduro Biotech  Inc    NASDAQ ADRO   has an Earnings ESP of  82 00  and a Zacks Rank of 2 Mallinckrodt plc   NYSE MNK   has an Earnings ESP of  0 25  and a Zacks Rank of 3  The company is scheduled to report first quarter results on May 7 Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-04-30,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-cards-for-bausch-health-bhc-q1-earnings-200412862,200412862
147325,368841,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 38 ,news,"Investing com   Canada stocks were higher after the close on Wednesday  as gains in the Healthcare  Materials and IT sectors led shares higher 
At the close in Toronto  the S P TSX Composite added 0 38  to hit a new 3 months high 
The best performers of the session on the S P TSX Composite were  Aurora Cannabis  Inc  TO ACB   which rose 12 53  or 1 090 points to trade at 9 790 at the close  Meanwhile  Valeant Pharmaceuticals International Inc  TO VRX  added 7 52  or 2 30 points to end at 32 90 and  First Quantum Minerals Ltd    TO FM  was up 7 09  or 1 51 points to 22 82 in late trade 
The worst performers of the session were  IAMGold  Corporation  TO IMG   which fell 3 88  or 0 310 points to trade at 7 670 at the close   Empire Company Ltd   TO EMPa  declined 3 67  or 0 91 points to end at 23 89 and Dream Global Real Estate Investment Trust  TO DRG u  was down 3 06  or 0 460 points to 14 580 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 560 to 534 and 141 ended unchanged 
Shares in Valeant Pharmaceuticals International Inc  TO VRX  rose to 52 week highs  gaining 7 52  or 2 30 to 32 90  Shares in First Quantum Minerals Ltd   TO FM  rose to 3 years highs  up 7 09  or 1 51 to 22 82  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 6 63  to 12 26 
Gold Futures for August delivery was down 0 11  or 1 40 to  1300 80 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in July fell 0 79  or 0 52 to hit  65 00 a barrel  while the August Brent oil contract rose 0 49  or 0 37 to trade at  75 75 a barrel 
CAD USD was up 0 12  to 0 7720  while CAD EUR fell 0 40  to 0 6557 
The US Dollar Index Futures was down 0 25  at 93 62 ",2018-06-06,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade-sptsx-composite-up-038-1483322,1483322
147326,368842,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 31 ,news,"Investing com   Canada stocks were higher after the close on Monday  as gains in the Energy  Consumer Discretionary and REITs sectors led shares higher 
At the close in Toronto  the S P TSX Composite rose 0 31  to hit a new 3 months high 
The best performers of the session on the S P TSX Composite were  Canada Goose Holdings  Inc  TO GOOS   which rose 9 83  or 7 67 points to trade at 85 68 at the close  Meanwhile   Bombardier Inc   TO BBDb  added 6 38  or 0 310 points to end at 5 170 and  Lucara Diamond Corp   TO LUC  was up 6 10  or 0 130 points to 2 260 in late trade 
The worst performers of the session were  Baytex Energy  Corp  TO BTE   which fell 12 35  or 0 63 points to trade at 4 47 at the close  Valeant Pharmaceuticals International Inc  TO VRX  declined 12 35  or 4 38 points to end at 31 09 and  Raging River Exploration Inc    TO RRX  was down 10 03  or 0 63 points to 5 65 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 596 to 485 and 144 ended unchanged 
Shares in Canada Goose Holdings Inc  TO GOOS  rose to all time highs  rising 9 83  or 7 67 to 85 68  Shares in Bombardier Inc  TO BBDb  rose to 3 years highs  rising 6 38  or 0 310 to 5 170  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 2 87  to 12 18 
Gold Futures for August delivery was up 0 20  or 2 60 to  1281 10 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in August rose 1 23  or 0 80 to hit  65 65 a barrel  while the August Brent oil contract rose 2 46  or 1 81 to trade at  75 25 a barrel 
CAD USD was up 0 04  to 0 7575  while CAD EUR fell 0 09  to 0 6520 
The US Dollar Index Futures was down 0 01  at 94 44 ",2018-06-18,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade-sptsx-composite-up-031-1497484,1497484
147327,368843,BHC,Bausch Health Q2 revenues down 5   shares up 2  premarket,news,Bausch Health Companies  BHC  Q2 results  Revenues   2 128M   4 7    R D Expense   2 100M   4 5    SG A   28M   15 2   Segment Sales  Bausch   Lomb International   1 209M   1 1    Salix   441M   14 0    Ortho Dermatologics   142M   12 3    Diversified Products   336M   27 1   Net Loss    873M   Non GAAP Net Income   327M   9 7    Loss Per Share    2 49   CF Ops   222M   22 4   XIFAXAN revenue increased by 26  Y Y RELISTOR franchise revenue increased by 43  Y Y 2018 Guidance  Revenues   8 15B   8 35B  non GAAP EBITDA   3 20B   3 35B from  3 15B   3 30B Shares are up 2  premarketNow read ,2018-08-07,Seeking Alpha,https://www.investing.com/news/stock-market-news/bausch-health-q2-revenues-down-5-shares-up-2-premarket-1563089,1563089
147332,368848,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 57 ,news,"Investing com   Canada stocks were lower after the close on Friday  as losses in the Healthcare  Consumer Staples and Utilities sectors led shares lower 
At the close in Toronto  the S P TSX Composite declined 0 57  
The best performers of the session on the S P TSX Composite were  Pretium Resources  Inc   TO PVG   which rose 19 39  or 1 97 points to trade at 12 13 at the close  Meanwhile   Enerflex Ltd    TO EFX  added 9 37  or 1 42 points to end at 16 57 and  Ritchie Bros  Auctioneers Inc    TO RBA  was up 8 70  or 3 950 points to 49 340 in late trade 
The worst performers of the session were  NuVista Energy Ltd    TO NVA   which fell 10 69  or 0 920 points to trade at 7 690 at the close   Uni Select Inc    TO UNS  declined 6 65  or 1 45 points to end at 20 35 and Bausch Health Companies Inc  TO BHC  was down 5 35  or 1 62 points to 28 68 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 624 to 406 and 143 ended unchanged 
Shares in Ritchie Bros  Auctioneers Inc   TO RBA  rose to 52 week highs  up 8 70  or 3 950 to 49 340  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 0 08  to 12 34 
Gold Futures for December delivery was down 0 07  or 0 80 to  1219 10 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in September rose 1 36  or 0 91 to hit  67 72 a barrel  while the October Brent oil contract rose 1 18  or 0 85 to trade at  72 92 a barrel 
CAD USD was down 0 55  to 0 7621  while CAD EUR rose 0 47  to 0 6679 
The US Dollar Index Futures was up 0 73  at 96 16 ",2018-08-10,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade-sptsx-composite-down-057-1570034,1570034
147345,368861,BHC,Healthcare   Top 5 Gainers   Losers as of 11 00 AM  05 08 2018 ,news,Gainers  AMDA  113   PRPH  42   GNPX  15   VRX  15   TCMD  15  Losers  ARLZ  59   XTLB  20   NVRO  15   SBOT  15   HLTH  14  Now read ,2018-05-08,Seeking Alpha,https://www.investing.com/news/stock-market-news/healthcare--top-5-gainers--losers-as-of-1100-am-05082018-1436506,1436506
147346,368862,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 19 ,news,"Investing com   Canada stocks were higher after the close on Tuesday  as gains in the Healthcare  IT and Materials sectors led shares higher 
At the close in Toronto  the S P TSX Composite rose 0 19  to hit a new 3 months high 
The best performers of the session on the S P TSX Composite were  Nevsun Resources Ltd   TO NSU   which rose 16 75  or 0 640 points to trade at 4 460 at the close  Meanwhile   IAMGold  Corporation  TO IMG  added 8 88  or 0 650 points to end at 7 970 and Valeant Pharmaceuticals International Inc  TO VRX  was up 8 87  or 2 08 points to 25 54 in late trade 
The worst performers of the session were  Labrador Iron Ore Royalty Corp   TO LIF   which fell 10 67  or 2 57 points to trade at 21 51 at the close   WestJet Airlines Ltd   TO WJA  declined 9 77  or 2 16 points to end at 19 94 and  Seven Generations Energy Ltd   TO VII  was down 5 14  or 0 89 points to 16 41 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 545 to 534 and 139 ended unchanged 
Shares in Nevsun Resources Ltd  TO NSU  rose to 52 week highs  gaining 16 75  or 0 640 to 4 460  Shares in WestJet Airlines Ltd  TO WJA  fell to 52 week lows  falling 9 77  or 2 16 to 19 94  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 0 37  to 13 49 
Gold Futures for June delivery was up 0 05  or 0 70 to  1314 80 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in June fell 1 46  or 1 03 to hit  69 70 a barrel  while the July Brent oil contract fell 0 67  or 0 51 to trade at  75 66 a barrel 
CAD USD was down 0 54  to 0 7721  while CAD EUR fell 0 05  to 0 6508 
The US Dollar Index Futures was up 0 36  at 92 94 ",2018-05-08,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade-sptsx-composite-up-019-1437216,1437216
147347,368863,BHC,Ex Valeant  Philidor executives convicted of kickback scheme,news,"By Brendan Pierson NEW YORK  Reuters    A former Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX  executive and the former chief of mail order pharmacy Philidor Rx Services were found guilty on Tuesday of defrauding Valeant through a multimillion dollar kickback scheme  The verdict  handed up by a jury in Manhattan federal court  comes on the heels of Valeant s announcement that it will change its name to Bausch Health Companies Inc as it seeks to distance itself from a series of scandals under its previous management  Gary Tanner  a former senior director at Valeant  and Andrew Davenport  the former head of the now defunct Philidor  were convicted of fraud and conspiracy  Lawyers for the two defendants were not immediately available for comment  The two week trial of Tanner and Davenport put a spotlight on the relationship between Valeant and Philidor  which had drawn concern from investors and regulators  Philidor was founded in 2013 with Valeant s help  and the vast majority of the drugs it dispensed were Valeant s  Prosecutors claimed that Valeant was the victim of a scheme in which Tanner passed inside information to Davenport to bolster Philidor s business as Valeant s primary pharmacy partner  In exchange for Tanner s help  prosecutors said  Davenport paid Tanner nearly  10 million when Valeant exercised an option to buy Philidor  taking  40 million for himself  At times using the fake name  Brian Wilson   Tanner sabotaged potential deals between Valeant and other pharmacies  according to prosecutors  The defendants  lawyers argued that there was nothing illegal about the dealings between the two men  or between Valeant and Philidor  They said Tanner was hired by Valeant to help Philidor grow and that the companies  close relationship made Valeant hundreds of millions of dollars  Valeant s stock fell sharply in October 2015 after it disclosed it had been subpoenaed by U S  prosecutors over various business practices  Later that month  a short selling firm published a report claiming Valeant hid its ties to Philidor  and used the pharmacy to artificially inflate sales to drive up prices  
The company has denied any wrongdoing in connection with Philidor ",2018-05-22,Reuters,https://www.investing.com/news/stock-market-news/exvaleant-philidor-executives-convicted-of-kickback-scheme-1457734,1457734
147348,368864,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 50 ,news,"Investing com   Canada stocks were higher after the close on Tuesday  as gains in the Healthcare  Materials and IT sectors led shares higher 
At the close in Toronto  the S P TSX Composite added 0 50  
The best performers of the session on the S P TSX Composite were Valeant Pharmaceuticals International Inc  TO VRX   which rose 7 63  or 2 17 points to trade at 30 60 at the close  Meanwhile   Aurora Cannabis  Inc  TO ACB  added 6 36  or 0 520 points to end at 8 700 and Element Fleet Management Corp  TO EFN  was up 5 49  or 0 31 points to 5 96 in late trade 
The worst performers of the session were  Alacer Gold  Corp  TO ASR   which fell 4 53  or 0 110 points to trade at 2 320 at the close   Dorel Industries Inc   TO DIIb  declined 2 93  or 0 66 points to end at 21 83 and  Seven Generations Energy Ltd   TO VII  was down 2 23  or 0 35 points to 15 35 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 624 to 466 and 141 ended unchanged 
Shares in Valeant Pharmaceuticals International Inc  TO VRX  rose to 52 week highs  rising 7 63  or 2 17 to 30 60  Shares in Dorel Industries Inc  TO DIIb  fell to 5 year lows  falling 2 93  or 0 66 to 21 83  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 1 39  to 13 13 
Gold Futures for August delivery was up 0 28  or 3 60 to  1300 90 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in July rose 0 94  or 0 61 to hit  65 36 a barrel  while the August Brent oil contract fell 0 40  or 0 30 to trade at  74 99 a barrel 
CAD USD was down 0 31  to 0 7708  while CAD EUR fell 0 45  to 0 6580 
The US Dollar Index Futures was down 0 17  at 93 86 ",2018-06-05,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade-sptsx-composite-up-050-1481507,1481507
147351,368867,BHC,4 Stocks To Watch Today  BHC  CIEN  PYX  SEED ,opinion,"Bausch Health Companies Inc  NYSE BHC   a swing trade of ours  surged on Monday  gaining 1 40  or 6   to 25 57  on 7 8 million shares  That s the biggest volume in about six weeks  It looks to me like it wants to explode through Monday s high at 26 18 and take out resistance  If it gets through that  my next target is 28 3 4  followed by 32 
Ciena Corp  NYSE CIEN   which I put a swing on  broke out on Monday  I like the looks of this  It was a key day for this stock  jumping 1 62  or 5   to 33 64  on 6 9 million shares  I don t know if it will go much higher than that  We ll keep close taps on it  Resistance is at 35  the secondary target is in the high 30 s 
Pyxus International Inc  NYSE PYX   along with several other marijuana stocks  recovered  On Monday  it jumped 3 43  or 15   to 26 42  on 2 2 million shares  It broke the declining channel of the last four weeks  I m looking for an extension  The near term target will be about 30  and then 34 
Origin Agritech Ltd  NASDAQ SEED   although it s been choppy for the last two months with its many ups and downs  it finally formed a wedge and popped out of it on Monday  running 53 cents  or 7   to 7 98  on 109 168 shares traded  Key resistance is in the 9 9 1 2 zone  Beyond that  we re looking at 11 and 13 1 2 
Stocks on the long side included Acacia Communications  Inc   ACIA   AngloGold Ashanti Limited  AU   Bausch Health Companies Inc   BHC   Canopy Growth Corporation  CGC   Ciena Corporation  CIEN   Ceragon Networks Ltd   CRNT   CV Sciences  Inc   CVSI   Fred s  Inc   FRED   Turtle Beach Corporation  HEAR   Kandi Technologies Group  Inc   KNDI   Eli Lilly and Company  NYSE LLY   Pyxus International  Inc   PYX   Origin Agritech Limited  SEED   Southwestern Energy Company  NYSE SWN   Energy Fuels Inc   UUUU   and Yulong Eco Materials Limited  YECO  
Watch video here ",2018-11-05,Harry Boxer,https://www.investing.com/analysis/bhc-cien-pyx-seed-200355157,200355157
147352,368868,BHC,Is Bausch Health  BHC  A Great Stock For Value Investors ,opinion,"Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Bausch Health Cos Inc    NYSE BHC   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Bausch Health has a trailing twelve months PE ratio of 5 9  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 stands at about 17 5x  If we focus on the long term PE trend  Bausch Health s current PE level puts it below its midpoint over the past five years  with the number having risen rapidly over the past few months Further  the stock s PE also compares favorably with the broader industry s trailing twelve months PE ratio  which stands at 8 8  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers We should also point out that Bausch Health has a forward PE ratio  price relative to this year s earnings  of 6 6  which is tad higher than the current level  So it is fair to expect an increase in the company s share price in the near term P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  Bausch Health has a P S ratio of about 1  This is a bit lower than the S P 500 average  which comes in at 3 2x right now  Also  as we can see in the chart below  this is well below the highs for this stock in particular over the past few years If anything  BHC is in the lower end of its range in the time period from a P S metric  suggesting some level of undervalued trading at least compared to historical norms Broad Value OutlookIn aggregate  Bausch Health currently has a Value Score of A  putting it into the top 20  of all stocks we cover from this look  This makes Bausch Health a solid choice for value investors What About the Stock Overall Though Bausch Health might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth Score of A and a Momentum Score of B  This gives ANIP a Zacks VGM score   or its overarching fundamental grade   of A   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been upbeat  The current quarter has seen four estimates go upper  while two lower in the past sixty days  while the full year estimate has seen seven up and no down in the same time period This has had just a small impact on the consensus estimate though as the current quarter consensus estimate has increased by 7 2  in the past two months  while the full year estimate has increased by 10 1   You can see the consensus estimate trend and recent price action for the stock in the chart below Bausch Health Cos Inc  Price and Consensus
     This positive trend signifies bullish analyst sentiment  and its Zacks Rank  1  Strong Buy  indicates robust fundamentals and expectations of outperformance in the near term Bottom LineBausch Health is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  Further  a strong industry rank  among Top 26  of more than 250 industries  instills our confidence However  over the past two years  the broader industry has clearly underperformed the market at large  as you can see below We believe  despite an unsatisfactory past industry performance  a good industry and Zacks rank signal that the stock is likely to benefit from favorable broader factors in the immediate future  Add to this robust value metrics  and we believe that we have a strong value contender in Bausch Health Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-11-19,Zacks Investment Research,https://www.investing.com/analysis/is-bausch-health-bhc-a-great-stock-for-value-investors-200361107,200361107
147369,368885,BHC,Ackman exits Nike stake with  100 million in profit  source,news,"By Svea Herbst Bayliss and Uday Sampath Kumar  Reuters    Investor William Ackman has stepped out of his  Nike   N NKE  sneakers  at least in a financial sense  The billionaire investor s hedge fund Pershing Square  NYSE SQ  Capital Management earned roughly  100 million in profit when it cashed out of its 0 71 percent stake in the sportswear company recently  a person familiar with the move said on Thursday  Two months ago  the activist investor told clients that Pershing Square had taken a rare passive stake in Nike at the end of 2017  when the stock was trading at around  53 a share and that the bet had already earned them a roughly 30 percent gain  Ackman  a passionate tennis player  is often photographed on courts wearing Nike apparel ranging from shoes to shirts to wrist bands  The Wall Street Journal first reported the hedge fund s exit from the Dow component  The quick gains on Nike will be welcome news for Ackman s investors who have watched him post losses for three consecutive years when long held investments on Valeant  TO VRX  and against  Herbalife   N HLF  weighed on returns  He exited Valeant last year and got out of Herbalife earlier this year  In January  Ackman told his investors that he was making changes to return the prominent firm to its glory days by shrinking his team  becoming more involved in the investment process again and leaving the marketing to someone else   The firm generated compound returns of 21 per cent a year net of fees over 11 years from its launch to the end of 2014  Then it lost money in 2015  2016  and 2017  So far  he has largely stuck to his plans to keep a lower profile  There was no big announcement that he had exited Herbalife and there was not much fanfare around the Nike investment either  Still  Ackman s private hedge funds are again in the red for 2018  nursing losses of roughly 3 7 percent as the broader stock market  as measured by the S P 500  is roughly flat for the year  Pershing Square  which traditionally makes investments where it seeks to make changes in the board room  has left Nike at roughly the same time the company is grappling with issues surrounding its culture  There have been complaints about workplace behavior and Trevor Edwards  an executive who had been seen as a possible successor to the CEO  is leaving  
Nike is scheduled to report its third quarter earnings after markets close on Thursday ",2018-03-22,Reuters,https://www.investing.com/news/stock-market-news/ackman-exits-nike-stake-with-100-million-in-profit-source-1355057,1355057
147371,368887,BHC,Ex Valeant official accused of kickback scheme faces trial,news,"By Brendan Pierson NEW YORK  Reuters    A former Valeant Pharmaceuticals International Inc  NYSE VRX  executive and the former head of mail order pharmacy Philidor Rx Services will face trial Thursday on charges they orchestrated a multimillion dollar kickback scheme  more than two years after Valeant drew scrutiny for its business practices  Gary Tanner  formerly a senior director at Valeant  and Andrew Davenport  formerly chief executive officer of Philidor  have pleaded not guilty to charges including wire fraud and money laundering conspiracy  Prosecutors and the two men s lawyers are expected to make opening statements to jurors on Thursday morning  Lawyers for Tanner and Davenport could not immediately be reached for comment  Prosecutors have said Tanner and Davenport worked together in secret to steer business and funding from Valeant to Philidor  They said the scheme netted Davenport  40 million   10 million of which was secretly kicked back to Tanner  Founded in 2013  the now defunct Philidor was a specialty mail order pharmacy formed with Valeant s assistance  At least 90 percent of the drugs it dispensed were Valeant branded products  according to prosecutors  Valeant was a victim of the scheme  which deprived the company of Tanner s  honest services   prosecutors said   Our company has cooperated with the authorities throughout the course of the investigation  and now  trial   said Valeant spokesman Lanie Keller   Today  Valeant is focused on improving people s lives with our health care products   The drugmaker s stock fell sharply in October 2015 after it disclosed it had been subpoenaed by U S  prosecutors over various business practices  Later that month  a short selling firm published a report claiming Valeant hid its ties to Philidor and used the pharmacy to artificially inflate sales in order to drive up prices  Valeant has denied wrongdoing related to Philidor  
In March 2017  billionaire investor William Ackman and his Pershing Square  NYSE SQ  International Fund sold their stake of roughly 8 percent in Valeant at a  3 billion loss  Ackman had been engaged in a public effort to save the company for about 18 months ",2018-05-03,Reuters,https://www.investing.com/news/stock-market-news/exvaleant-official-accused-of-kickback-scheme-faces-trial-1428580,1428580
147372,368888,BHC,Stock Exchange  Do You Trade The 50 Day Moving Average ,opinion,"The Stock Exchange is all about trading  Each week we do the following 

Discuss an important issue for traders 
highlight several technical trading methods  including current ideas 
feature advice from top traders and writers  and 
provide a few  minority  reactions from fundamental analysts 

We also have some fun  We welcome comments  links  and ideas to help us improve this resource for traders  If you have some ideas  please join in 
Review 
Our previous Stock Exchange asked the question  Are You Out Of Your Comfort Zone  We reviewed how traders must adapt to changing market conditions rather than sticking to old trading methods that were once profitable  but are now destructive  If you missed it  a glance at your news feed will show that the key points remain relevant 
This Week  Do You Trade the 50 Day Moving Average 
The following chart shows the S P 500 basically skipped along the top of its 50 day moving average for most of the last year 

And the same is largely true for the NASDAQ 

This basic technical trading indicator  50 day moving average  is used by so many market participants that it often serves as a magnet  and then support or resistance  However  when something sends the market through this level  many stops are often triggered  thereby increasing the market move  For example  here is a look at the S P 500 over the last week 

The market was down moderately on Wednesday of this week  Feb 28th   but then collapsed around the 50 day moving average  Regarding such market moves  our models do not anticipate down moves  but do exit in time to avoid the big losses  According to an  from Morningstar earlier this week  active management has most of its advantages in down markets 
Another advantage of our models is when our performance is staying even with the markets  our returns still have a significantly low correlation  which is powerful for risk management purposes  it helps keep volatility lower  
Model Performance 
Per reader feedback  we re continuing to share the performance of our trading models  This week we have extended the performance reporting back further  to 12 months 

Important to note  we find that blending a trend following   momentum model  Athena  with a mean reversion   dip buying model  Holmes  provides two strategies  effective in their own right  that are not correlated with each other or with the overall market  By combining the two  we can get more diversity  lower risk  and a smoother string of returns 
And for these reasons  I am changing the  Trade with Jeff  offer at Seeking Alpha to include a 50 50 split between Holmes and Athena  Current participants have already agreed to this  Since our costs on Athena are lower  we have also lowered the fees for the combination 
If you have been thinking about giving it a try  click through at the bottom of this post for more information  Also  readers are invited to write to main at newarc dot com for our free  brief description of how we created the Stock Exchange models 
Expert Picks From The Models 
This week s Stock Exchange is being edited by Blue Harbinger 
Holmes  This week I like Wayfair  NYSE W   I purchased shares on 2 23 when the price was down  Are you familiar with this stock 
Blue Harbinger  Yes  Holmes I am familiar  Wayfair basically sells all kinds of stuff online  both domestically and internationally  through a variety of websites  The company is not profitable  but sales and the stock price have both been growing rapidly  especially over the last year  For your reference  here is a look at the Fast Graph 

Holmes  That is interesting information  but I like the shares because I am a  dip buyer   and Wayfair s dip over the last week is the sort of set up I like to see  From the chart below  you can see it is below its 50 day moving average  and it has attractive upside over the next six weeks 

BH  That dip is because the market didn t especially like the company s latest earnings announcement  The share price seems to be bouncing off the 200 day moving average though  What do you have to say about that Holmes 
Holmes  I am aware of the 200 day and 50 day moving averages  I typically hold my position for about 6 weeks  so why don t you check back in with me on this one then 
BH  Sure  How about you  Road Runner what have you got for us this week 
Road Runner  I bought CenturyLink  NYSE CTL  on 2 28  How do you like that one 
BH  Yikes  Really  You bought a stock with a 12 4  dividend yield  Isn t that a bit of a red flag for you  Holmes  I m worried you re doing what I often refer to as  yield chasing  
RR  I m not investing in this stock for the dividend  I typically hold for only about four weeks  And you know this  BH we discuss it almost every week  I like to buy stocks at the low end of a rising channel  as shown for CTL in the following chart 

BH  Well  the telecom business is capital intensive  which could create challenges in our current rising interest rate environment  Plus its share price is down 50  in the last 5 years  Here is a look at the Fast Graph 

RR  Again  4 weeks is my typical holding period  I like the setup on this one  Check back with me then 
BH  Fine  How about you Felix what have you got for us 
Felix  I sold my Valeant  NYSE VRX  shares on 2 26  I purchased them back on 5 8 17 

BH  Looks like it was a bumpy ride  but you mad money  And based on the performance table earlier in this report  it looks like you ve been making a lot of money over the last year  Felix 
Felix  Thanks for noticing  My momentum strategy has been in style  Check out the performance of momentum stocks versus other styles over the last year  in this table as of February month end 

BH  Interesting data  Felix  thanks for sharing 
Felix  I also ran the Russell 2000 small cap index stocks through my model this week  and I m sharing my top 20 in the following ranking 

BH  I see Mulesoft NYSE MULE  on your list  It s a small cap cloud Software as a Service company with tremendous growth and a lot of room to run  I ve been keeping an eye on that one  Anyway  how about you Oscar what have you got for us this week 
Oscar  This week I ran the diverse and comprehensive ETF universe through my model  and I m sharing my top 20 rankings in the following table 

BH  I see U S  Oil USO on your list  But I thought you were a momentum trader  Oscar  Isn t oil down  I know the energy sector is way down based on the table Felix shared earlier 
Oscar  Yes I am a momentum trader  I typically hold for about 6 weeks  and yes oil is down  but it has started to rebound already after its big decline in early February 
BH  Interesting that oil is rebounding but the energy sector is not  But I suppose part of that is news from the new Fed chair that this latest batch of market volatility won t stop the Fed from raising interest rates  A lot of energy companies rely heaviliy on debt to fund growth  and higher rates means more expensive growth 
Conclusion 
The simple 50 day moving average is a popular guidepost and risk indicator for many technical traders  As long as the market stays close  things have been calm  but when it breaks through  stop orders kick in  and market conditions can become increasingly volatile  Our active models don t anticipate down moves  but they do avoid the biggest losses  Another advantage of our models are their blended approach  which helps generate strong returns with a lower market correlation something very valuable for volatility reduction purposes 
Background On The Stock Exchange 
Each week  Felix and Oscar host a poker game for some of their friends  Since they are all traders  they love to discuss their best current ideas before the game starts  They like to call this their  Stock Exchange    Check out  for more background   Their methods are excellent  as you know if you have been following the series  Since the time frames and risk profiles differ  so do the stock ideas  You get to be a fly on the wall from my report  I am usually the only human present and the only one using any fundamental analysis 
The result  Several expert ideas each week from traders  and a brief comment on the fundamentals from the human investor  The models are named to make it easy to remember their trading personalities 

Getting Updates 
Readers are welcome to suggest individual stocks and or ETFs to be added to our model lists  We keep a running list of all securities our readers recommend  and we share the results within this weekly  Stock Exchange  series when feasible  Send your ideas to  etf at newarc dot com   Also  we will share additional information about the models  including test data  with those interested in investing  Suggestions and comments about this weekly  Stock Exchange  report are welcome ",2018-03-02,Jeff Miller,https://www.investing.com/analysis/stock-exchange-do-you-trade-the-50day-moving-average-200295477,200295477
147373,368889,BHC,Valeant  VRX  Down On Q4 Earnings Miss  Issues Drab  18 View ,opinion,"Shares of Valeant Pharmaceuticals Inc    NYSE VRX   tumbled 9 2  after the company reported disappointed results for the fourth quarter results on Feb 28  The guidance for 2018 disappointed investors too  Notably  Valeant s stock moved up 19 9  over a year compared with the   gain of 1 1  The company s adjusted earnings per share of 98 cents missed the Zacks Consensus Estimate of 99 cents by a penny and was down from  1 11 per share in the year ago quarter However  total revenues of  2 16 billion topped the Zacks Consensus Estimate of  2 20 billion but declined 10  from the year ago quarter The impact of the discontinuation of divestitures and lower volumes in the Diversified Products segment along with the loss of exclusivity for a basket of products  and the Ortho Dermatologics business led to the disappointing results  Revenues were also negatively affected by the unfavorable impact of foreign exchange  The decline was partially offset by higher volumes and increased international pricing in Bausch   Lomb International segment  primarily the U S  Consumer Products business Valeant Pharmaceuticals International  Inc  Price and Consensus
    Quarter in DetailRevenues in the Bausch   Lomb   International segment were  1 2 billion  down 5  year over year  Excluding the impact of discontinuation of divestitures  primarily the skin care divestiture  and foreign exchange  the Bausch   Lomb International segment organically grew by approximately 4  year over year driven by increased volumes in the global Consumer  International and Global Vision Care businesses The Branded Rx segment revenues were  602 million  down 19  due to a decrease in sales which primarily reflects lower volumes in the Ortho Dermatologics business and the loss of sales due to the divestiture of Dendreon Pharmaceuticals LLC  This was partially offset by increased sales in Salix The U S  Diversified Products segment revenues were  335 million  down 16  year over year due to decreases in volume and price attributed to the previously reported loss of exclusivity for a basket of products Research and development expenses were  90 million in the reported quarter  down 3 2  from the year ago quarter Selling  General and Administrative costs were  632 million compared with  658 million in the year ago quarter The company received clearance for the Thermage FLX System to non invasively smooth skin on the face  eyes and body  Earlier  the company received the FDA filing acceptance for the NDA for Plenvu  NER1006   a novel  low volume polyethylene glycol based bowel preparation for colonoscopies  The FDA also approved its new psoriasis treatment  Siliq  following which the drug was launched  The company inked a deal with AstraZeneca plc   NYSE AZN   for Siliq but the agreement had to be amended  The company also obtained FDA approval of Vyzulta  a treatment option for glaucoma  The FDA also approved Lumify  the over the counter eye drop with low dose brimonidine for the treatment of eye redness Valeant has completed 13 divestitures since the beginning of 2016  including skin care brands  CeraVe  AcneFree and AMBI   Dendreon Pharmaceuticals  iNova Pharmaceuticals  Obagi Medical Products and Sprout Pharmaceuticals 2017 ResultsRevenues declined 10  to  8 7 billion in 2017 from a year ago 2018 GuidanceThe company expects total revenues in the range of  8 10  8 30 billion Our TakeAlthough fourth quarter results missed earnings  the company beat on sales  The Bausch   Lomb International segment and Salix businesses are doing well  Xifaxan achieved blockbuster status of  1 billion of sales as of January 2018  New drug approvals are also expected to boost growth and offset the weakness in the dermatology segment  The FDA recently approved Vyzulta for open angle glaucoma which too should boost the topline given the potential of the targeted market   11 billion by 2020  After a tumultuous period  Valeant started a rebuilding process with its CEO  Joseph C  Papa  Even though it is still early to comment on the rebuilding process  but the company s efforts to sell non core assets and pay down huge levels of debt is commendable  As of Feb 28  2018  the company has reduced total debt by approximately  6 7 billion since the end of first quarter 2016  The dermatology market continues to be challenging and is expected to decline in 2018 as compared to 2017   Hence  it might be a while before the company turnarounds as management had projected Zacks Rank   Key PicksValeant currently carries a Zacks Rank  4  Sell  A couple of better ranked stocks in the health care sector are Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and Ligand Pharmaceuticals Incorporated   NASDAQ LGND    While Regeneron sports a Zacks Rank  1  Strong Buy   Ligand carries a Zacks Rank  2  Buy   You can see  Regeneron s earnings per share estimates have moved up from  17 13 to  18 65 and from  20 37 to  21 56 for 2018 and 2019  respectively  in the last 30 days  The company pulled off a positive earnings surprise in three of the last four quarters  with an average beat of 9 15  Ligand s earnings per share estimates have moved up from  3 78 to  4 15 for 2018 in the last 30 days  The company delivered a positive earnings surprise in three out of the trailing four quarters  with an average beat of 24 88  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-03-04,Zacks Investment Research,https://www.investing.com/analysis/valeant-vrx-down-on-q4-earnings-miss-issues-drab-18-view-200295917,200295917
147374,368890,BHC,3 Sell Rated Drug Stocks Investors Should Avoid For Now ,opinion,"The performance of the drug industry in first quarter 2018 has been an encouraging one with quite a few companies  beatings both earnings as well as revenue estimates The overall investor sentiment toward pharma and biotech stocks has improved of late as investors are focusing more on fundamentals than on issues like drug pricing  While drug pricing will continue to pose as a major deterrent  thanks to the government increased emphasis on making drugs affordable  new drug approvals and label expansion of existing drugs should help companies maintain the momentum in 2018  The year 2017 saw a number of drugs like Rhopressa  Tymlos  Ozempic  Vyzulta  Siliq  Trulance  Hemlibra  among others getting approval   Lutathera  Ilumya  Symdeko  Biktarvy  Erleada have already been approved in 2018 and investors are expected to keep their focus on the same Mergers and acquisitions remain another key area of investor focus  While 2017 was pretty ho hum on this front with just a few key deals  2018 is expected to see a surge in M A primarily due to lower U S  tax rates   Taking a clue from Gilead Sciences   NASDAQ GILD   acquisition of Kite Pharma  Celgene   NASDAQ CELG   recently acquired Juno Therapeutics to gain traction in the promising CAR T space   Sanofi   NYSE SNY   acquired Bioverativ Inc  which focuses on therapies for hemophilia and other rare blood disorders  The company has also obtained anti trust clearances in connection with its previously announced acquisition of Ablynx   While strong pipelines  innovative treatments  impressive results  growing demand for drugs especially for rare to treat diseases  an aging population and increased health care spending should support growth in this sector  caution is to be exercised when picking stocks for investing Here are a few sell rated stocks which should be strictly avoided for now Valeant Pharmaceuticals International  Inc    NYSE VRX     Canada based specialty pharma company  Valeant  has been in troubled waters for quite some time now  Valeant s guidance for 2018 was disappointing  After a tumultuous period  Valeant started a rebuilding process with its CEO  Joseph C  Papa   The company has reduced total debt by approximately  6 7 billion since the end of first quarter 2016  However  the dermatology business remains challenging and is expected to decline in 2018 as compared to 2017   Quite a few of its drugs are facing generic competition  Hence  it might be a while before the company turn arounds as management had projected  The company currently carries a Zacks Rank  4  Sell    Valeant s shares have declined 25 6  in the last three months  compared with  s fall of 2 8    Endo International plc   NASDAQ ENDP    Ireland based Endo is a global specialty pharmaceutical company focused on generic and branded pharmaceuticals  Endo s guidance for 2018 was way below expectations  The generics business is under tremendous pressure due to the loss of marketing exclusivity for the first to file products ezetimibe tablets and quetiapine ER tablets in the first half of 2017  The branded pharmaceuticals business was impacted by continued generic competition for established products  product divestitures and ceasing shipments of Opana ER and this is expected to continue further  Endo withdrew opioid pain medication Opana ER  oxymorphone hydrochloride extended release  from the market following FDA s request in June 2017   The company divested its non core assets such as Belbuca and restructured its pain franchise to focus particularly on specialty branded business  However  this Zacks Rank  5  Strong Sell  company is expected to face challenging business conditions in 2018  Endo s shares have lost 25 8  in the last three months worse than the  s decline of 2 8    Aerie Pharmaceuticals  Inc    NASDAQ AERI    Irvine  CA based Aerie Pharmaceuticals focuses on the development and commercialization of eye disease therapies  including glaucoma and other eye diseases  Aerie received a significant boost with the recent approval of lead drug Rhopressa for the lowering of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension   However  Rhopressa faces stiff competition from established branded and generic pharmaceutical companies  such as Novartis  Simbrinza and Travtan  and Allergan s Lumigan  as well as other smaller biotechnology and pharmaceutical companies  Valeant s Vyzulta was recently approved for open angle glaucoma or ocular hypertension  Rhopressa will face a tough time in gaining market share due to competition from these products  Hence  we advise investors to steer clear of this Zacks Rank  4 stock for the time being  Aerie s shares have fallen 13 8  in the last three months  worse than the  s decline of 2 8   

 
You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-03-26,Zacks Investment Research,https://www.investing.com/analysis/3-sellrated-drug-stocks-investors-should-avoid-for-now-200301136,200301136
147375,368891,BHC,4 Stocks Popping Right Now  APPN  PI  QURE  USAT ,opinion,"Appian Corp  NASDAQ APPN   one of our swing trades that broke out of a base flag  is now breaking out again  popping 91 cents  or 2 7   to 34 49  on 410 324 shares traded on Tuesday  It looks to me like a run to the 38 39 zone  followed by 43  It s been up for nine days in a row  but it s not getting ahead of itself though 
Impinj Inc  NASDAQ PI  had a big move on Tuesday  jumping 2 40  or 13   to 20 48  on 1 22 million shares  I obviously put a swing on it when it popped and pulled back  it faded a little bit  popped for one day  pulled back for four days  and had another big pop on Tuesday  It needs a follow through  and if it gets one  and it takes out 21 21 15  targets are 24 and 27 
Uniqure NV  NASDAQ QURE  keeps going and had another pop and breakout on Tuesday  running up another 2 04  or 5 8   to 37 10  on 330 492 shares traded  The tight little coil took it to new highs at 37 11  closing just a penny off the high  I would have to say the least this stock will see is the mid 40 s at some point 
USA Technologies Inc  NASDAQ USAT  has been great since we had a swing on it in November  It hit targets one and two so far  and on Tuesday  after flagging  it looks like it s starting to move again with a pop of 30 cents  or 2 2   to 13 85  on 496 726 shares traded  Watch for a pop above 14  and then a move to 16 and 18 
Stocks on the long side included Appian Corporation  APPN   ArQule  Inc   ARQL   Array BioPharma Inc   ARRY   CareDx  Inc  CDNA   Cerus Corporation  CERS   Canopy Growth Corporation  CGC   Coherus BioSciences  Inc   CHRS   3D Systems Corporation  NYSE DDD   Endologix  Inc   ELGX   Evolus  Inc   EOLS   EXACT Sciences Corporation  NASDAQ EXAS   Fossil Group  Inc   FOSL   Intelsat S A   I   Iridium Communications Inc   IRDM   Macy s  Inc   NYSE M   MEI Pharma  Inc   MEIP   Impinj  Inc   PI   uniQure N V   QURE   Teladoc  Inc   TDOC   Tilly s  Inc   TLYS   Twitter  Inc   TWTR   Unisys Corporation  UIS   USA Technologies  Inc   USAT   Valeant Pharmaceuticals  NYSE VRX  International  Inc   VRX   and Weight Watchers International Inc  NYSE WTW  
Watch video here ",2018-06-06,Harry Boxer,https://www.investing.com/analysis/appn-pi-qure-usat-200322466,200322466
147376,368892,BHC,Valeant  VRX  Up 19 3  Since Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for Valeant Pharmaceuticals International  Inc    NYSE VRX    Shares have added about 19 3  in that time frame 
Will the recent positive trend continue leading up to its next earnings release  or is VRX due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers Valeant Beats on Earnings in Q1  Raises ViewValeant reported better than expected results for the first quarter results  The increase in guidance for 2018 was encouraging too The company s adjusted earnings per share of  0 89 beat the Zacks Consensus Estimate of  0 23 and was also up from  0  78 per share in the year ago quarter Total revenues of  1 99 billion also topped the Zacks Consensus Estimate of  1 98 billion but declined 5 4  from the year ago quarter Quarter in DetailRevenues in the Bausch   Lomb   International segment were  1 1 billion  down 3  year over year  Excluding the impact of discontinuation of divestitures  primarily the skin care divestiture  and foreign exchange  the Bausch   Lomb International segment organically improved by approximately 2  year over year driven by growth in the Global Vision Care business The Branded Rx segment revenues were  593 million  down 6  due to divestitures and discontinuations and decline in the Ortho Dermatologics business  This was partially offset by increased sales in Salix which was up by 40   Xifaxan was up 49  while Relistor improved 54    The FDA approved Plenvu  a 1 liter bowel cleansing preparation for colonoscopies  which is expected to be available in the third quarter of 2018 The FDA earlier approved its new psoriasis treatment  Siliq  following which the drug was launched and expanded  The company inked a deal with AstraZeneca for Siliq but the agreement had to be amended  The FDA accepted New Drug Applications for Altreno  IDP 121   an acne treatment in lotion form  PDUFA action date of Aug 27  2018 and Bryhali  IDP 122   a topical treatment for plaque psoriasis  PDUFA action date of Oct 5  2018 The U S  Diversified Products segment revenues were  299 million  down 14  year over year due to previously reported loss of exclusivity for a basket of products and the impact of the 2017 divestitures and discontinuations Research and development expenses were  92 million in the reported quarter  down 4 2  from the year ago quarter Selling  General and Administrative costs were  587 million compared with  651 million in the year ago quarter The company repaid approximately  280 million of debt with cash in hand in the first quarter of 2018 Concurrently  Valeant announced that the company will change its name to Bausch Health Companies Inc   effective July 2018 2018 GuidanceThe company expects total revenues in the range of  8 15  8 35 billion  up from the earlier projected range of  8 10  8 30 billion  
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates  There have been three revisions higher for the current quarter compared to two lower Valeant Pharmaceuticals International  Inc  Price and Consensus    VGM Scores
At this time  VRX has a subpar Growth Score of D  Its Momentum is doing a lot better with a B  The stock was allocated a grade of A on the value side  putting it in the top 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Our style scores indicate that the stock is more suitable for value investors than momentum investors 
Outlook
Estimates have been broadly trending upward for the stock and the magnitude of these revisions looks promising  Interestingly  VRX has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-06-06,Zacks Investment Research,https://www.investing.com/analysis/valeant-vrx-up-193-since-earnings-report-can-it-continue-200322949,200322949
147395,368911,BHC,A lawsuit a day  U S  securities class actions soar,news,By Jonathan Stempel  Reuters    The number of class action lawsuits in the United States accusing companies of fraud and other securities law violations soared in 2017  topping one a day even as the value of settlements plunged  a study released on Monday shows  There were 432 shareholder lawsuits accusing companies of making false or misleading statements or concealing bad news about their businesses or mergers  up 44 percent from 300 in 2016  NERA Economic Consulting said in the study  That number was the highest since a federal law to curb frivolous lawsuits  the Private Securities Litigation Reform Act  took effect in 1995  without taking into account  laddering  cases related to initial public offerings  NERA  based in New York  said much of the jump came from lawsuits objecting to mergers  which more than doubled for a second straight year  to 197  The number of settlements excluding merger cases also rose  to 148 from 113 a year earlier  but averaged less than  25 million each  Meanwhile  the number of dismissals rose to a record 205 from 146   We re seeing generally an increase in what I would call  smaller cases   which are  poor quality  lawsuits often being dismissed or settled for pennies on the dollar   said Brian Lutz  who defends companies as co chair of the securities litigation practice at Gibson  Dunn   Crutcher   Securities litigation for companies large and small has become common   The pickup in merger related lawsuits came after Delaware state court judges soured on settlements requiring companies merely to reveal often immaterial details about their mergers  Judges found these  disclosure only  settlements a common way for lawyers to win easy paydays without doing much for shareholder clients  About half of the Fortune 500 companies are incorporated in Delaware  NERA said the number of traditional securities class actions  often following revelations of weak financial results or regulatory probes  rose to 216 last year from 195 in 2016  Fifty five targeted non U S  companies  up from 44  The biggest settlement   210 million  resolved claims that Salix Pharmaceuticals  now part of Canada s Valeant Pharmaceuticals International Inc  NYSE VRX   misrepresented inventory levels  Last year was the first since 1998 that no settlement reached  250 million  NERA said  A  7 2 billion settlement in 2006 over energy company Enron Corp s collapse remains the largest ever  IPO laddering is where investors implicitly agree with underwriters to buy more shares in the market as a condition of investing in an IPO  This can lead to gains for both parties  and let insiders sell stock at prices inflated by laddering ,2018-01-29,Reuters,https://www.investing.com/news/stock-market-news/a-lawsuit-a-day-us-securities-class-actions-soar-1166801,1166801
147396,368912,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 35 ,news,"Investing com   Canada stocks were higher after the close on Tuesday  as gains in the Healthcare  Consumer Discretionary and Clean Technology sectors led shares higher 
At the close in Toronto  the S P TSX Composite added 0 35  
The best performers of the session on the S P TSX Composite were Canopy Growth Corp  TO WEED   which rose 18 67  or 4 530 points to trade at 28 800 at the close  Meanwhile   Aphria Inc   TO APH  added 17 60  or 2 490 points to end at 16 640 and Valeant Pharmaceuticals International Inc  TO VRX  was up 5 49  or 1 19 points to 22 86 in late trade 
The worst performers of the session were Element Fleet Management Corp  TO EFN   which fell 28 68  or 2 28 points to trade at 5 67 at the close   Torex Gold Resources Inc   TO TXG  declined 8 11  or 0 980 points to end at 11 110 and Klondex Mines Ltd  TO KDX  was down 7 39  or 0 190 points to 2 380 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 714 to 479 and 93 ended unchanged 
Shares in Element Fleet Management Corp  TO EFN  fell to 5 year lows  down 28 68  or 2 28 to 5 67  Shares in Klondex Mines Ltd  TO KDX  fell to 52 week lows  losing 7 39  or 0 190 to 2 380  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 2 23  to 18 80 a new 52 week high 
Gold Futures for April delivery was down 0 84  or 11 20 to  1325 30 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in March fell 1 11  or 0 71 to hit  63 44 a barrel  while the April Brent oil contract fell 1 06  or 0 72 to trade at  66 90 a barrel 
CAD USD was up 0 18  to 0 7991  while CAD EUR rose 0 17  to 0 6459 
The US Dollar Index Futures was unchanged 0 00  at 89 57 ",2018-02-06,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade-sptsx-composite-up-035-1205840,1205840
147397,368913,BHC,Valeant revenue forecast fizzles as competition heats up  shares dip,news," Reuters    Valeant Pharmaceuticals  N VRX   TO VRX  on Wednesday gave a weaker than expected revenue forecast for 2018  as several of its major drugs face more competition from generics  The Canada based drugmaker s revenue will also be pressured as the company continues selling off businesses to free up cash and reduce its debt burden of some  25 billion  Valeant has already divested its Dendreon cancer treatment unit as well as several skin care brands acquired during a debt fueled deal making binge under former CEO Mike  Pearson   LON PSON    Since the end of the first quarter of 2016  we ve reduced our total debt by more than 20 percent  and we will continue to address our debt  as well as reduce expenses   said Valeant Chief Executive Officer Joseph Papa  Valeant has also sharpened its focus on more profitable products including its Bausch and Lomb eye care line and treatments for Wilson s disease and gastrointestinal diseases  The Wilson s disease treatment is expected to face competition from Teva Pharmaceuticals   TA TEVA  generic version launched earlier in February  Other Valeant products including heart drug Nitropress  a top selling product once criticized for its steep price  also face mounting competition from generics  Valeant forecast 2018 revenue of  8 10 billion to  8 30 billion  Analysts on average were expecting  8 34 billion  according to Thomson Reuters I B E S  The drugmaker s U S  listed shares fell 9 percent to  16 84 in premarket trading following the news  The stock  which hit a peak of over  250 in 2015  has languished under  30 for much of the past two years amid intense scrutiny into the company s drug price hikes and its unorthodox use of a specialty pharmacy to boost sales  On Wednesday  Valeant said it would pay  58 million to resolve a class action lawsuit by buyers of its acne medication Solodyn  who allege that a Valeant owned company sought to delay the launch of cheaper  generic versions of Solodyn  in violation of antitrust laws  Valeant reported a net income of  513 million in the fourth quarter ended Dec  31  compared to a loss of  515 million a year earlier  helped by a one time benefit of  1 32 billion from new U S  tax laws  Excluding one time items  Valeant earned 98 cents per share  edging past analysts  estimates of 97 cents  
Revenue fell 10 percent to  2 16 billion  just shy of analysts  expectations of  2 17 billion ",2018-02-28,Reuters,https://www.investing.com/news/stock-market-news/valeant-reports-profit-in-fourth-quarter-on-13-billion-tax-benefit-1316484,1316484
147398,368914,BHC,Canada stocks lower at close of trade  S P TSX Composite down 1 36 ,news,"Investing com   Canada stocks were lower after the close on Wednesday  as losses in the Energy  Healthcare and Industrials sectors led shares lower 
At the close in Toronto  the S P TSX Composite declined 1 36  
The best performers of the session on the S P TSX Composite were  TransAlta  Corp  TO TA   which rose 7 67  or 0 51 points to trade at 7 16 at the close  Meanwhile   Aphria Inc   TO APH  added 5 84  or 0 730 points to end at 13 230 and  Tahoe Resources Inc   TO THO  was up 5 02  or 0 30 points to 6 28 in late trade 
The worst performers of the session were Valeant Pharmaceuticals International Inc  TO VRX   which fell 11 54  or 2 74 points to trade at 21 01 at the close  Peyto Exploration Development Corp  TO PEY  declined 8 77  or 0 98 points to end at 10 19 and  MEG Energy Corp   TO MEG  was down 7 86  or 0 43 points to 5 04 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 651 to 479 and 126 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 6 71  to 15 91 
Gold Futures for April delivery was up 0 05  or 0 60 to  1319 20 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in April fell 2 21  or 1 39 to hit  61 62 a barrel  while the May Brent oil contract fell 2 69  or 1 79 to trade at  64 73 a barrel 
CAD USD was down 0 42  to 0 7793  while CAD EUR fell 0 16  to 0 6388 
The US Dollar Index Futures was up 0 31  at 90 59 ",2018-02-28,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade-sptsx-composite-down-136-1318070,1318070
147399,368915,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 03 ,news,"Investing com   Canada stocks were higher after the close on Wednesday  as gains in the Consumer Staples  IT and Materials sectors led shares higher 
At the close in Toronto  the S P TSX Composite rose 0 03  
The best performers of the session on the S P TSX Composite were Klondex Mines Ltd  TO KDX   which rose 6 49  or 0 120 points to trade at 1 970 at the close  Meanwhile   Mitel Networks Corporation   TO MNW  added 5 77  or 0 65 points to end at 11 92 and Valeant Pharmaceuticals International Inc  TO VRX  was up 5 37  or 1 12 points to 21 98 in late trade 
The worst performers of the session were  Stella Jones Inc    TO SJ   which fell 6 15  or 2 91 points to trade at 44 39 at the close  Hudson s Bay Company  TO HBC  declined 4 64  or 0 45 points to end at 9 24 and  Yamana Gold Inc   TO YRI  was down 3 92  or 0 14 points to 3 43 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 585 to 530 and 134 ended unchanged 
Shares in Mitel Networks Corporation  TO MNW  rose to 52 week highs  up 5 77  or 0 65 to 11 92  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 0 81  to 12 26 a new 1 month low 
Gold Futures for April delivery was down 0 13  or 1 70 to  1325 40 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in April rose 0 33  or 0 20 to hit  60 91 a barrel  while the May Brent oil contract rose 0 28  or 0 18 to trade at  64 82 a barrel 
CAD USD was up 0 05  to 0 7717  while CAD EUR rose 0 19  to 0 6241 
The US Dollar Index Futures was up 0 06  at 89 75 ",2018-03-14,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade-sptsx-composite-up-003-1342151,1342151
147403,368919,BHC,Valeant  VRX  Touches 52 Week High  Is The Stock Officially Back ,opinion,"Shares of Valeant Pharmaceuticals   NYSE VRX   surged more than 2  higher on Wednesday morning  touching a new 52 week high in the process  The embattled pharma stock continues to polarize investors  but its recent recovery is starting to gain momentum  As we approach the New Year  it is time to ask  is Valeant officially back 
Shares are still a long way from their highs of mid 2015  but the stock has climbed about 90  since the beginning of November  Valeant s run comes as investors gear up for the company to begin sales of its new glaucoma treatment  Vyzulta  which should start this month Valeant Pharmaceuticals International  Inc  Price and Consensus   
 
According to analysts surveyed by   Vyzulta is projected to generate about  174 million of revenue by 2021  while the company s new ocular redness treatment  Luminesse  is expected to bring in about  38 million that year 
On top of Vyzulta and Luminesse  Valeant should benefit from sales of other new drugs  such as Siliq  a psoriasis medication  and IDP 118  a topical lotion that is currently being reviewed by the Food and Drug Administration 
Valeant has languished near  14 per share for most of the year  At those levels  new drug approvals attracted the attention of value investors  including Dimensional Fund Advisors LP  which more than tripled its stake in the pharma firm during the third quarter 
But Wall Street analysts remain lukewarm on both the stock and the company s near term prospects  The average analyst price target for VRX still sits at just  17  and earnings estimates for the upcoming fiscal year are not looking great 
Based on our latest consensus estimates  we expect Valeant to report full year earnings of  3 59 per share in 2018  That figure would represent a 7  slump from this year s projected full year profits  which are expected to be down about 30  
Valeant is finally starting to rebound  but investors should not expect volatility to disappear  However  the stock could be attractive to buy and hold investors looking to cash in on the company s new drugs somewhere down the line 
Want more stock market analysis from this author  Make sure to follow   on Twitter 
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research  It s not the one you think ",2017-12-13,Zacks Investment Research,https://www.investing.com/analysis/valeant-vrx-touches-52week-high-is-the-stock-officially-back-200272992,200272992
147404,368920,BHC,4 Stocks To Watch  ADMS  MARK  PIRS  QURE,opinion,"Adamas Pharmaceuticals  Inc   NASDAQ ADMS  has a falling wedge that formed over the last couple weeks that looks like it popped out on Thursday  jumping 2 04  or 6 33  to 34 27  on 868 176 shares traded  That s not huge volume  but the technicals held up well  It looks like it s time for it to move up and test 38  and then the low 40 s 
Remark Holdings  Inc   NASDAQ MARK  has an interesting pattern  After three days of popping  and then a pullback  it had an inside day on Thursday on lower volume  running up 25 cents  or 2 82   to 9 11  on 1 24 million shares traded  It has great technicals and a wedge forming  If this wedge pops  I m going to look for a retest quickly of the 10 75  80 range  Once it gets through that  targets are 12 12 1 2  and then 14 15 
Pieris Pharmaceuticals  Inc   NASDAQ PIRS  is a recent swing trade of ours that I re added on Thursday as it broke out of a downward flag  It popped 33 cents  or 6   to 6 26  on 512 897 shares traded on Thursday  I m anticipating a breakout  and rush through the 6 65 area  and then we re looking at 8 00  On a longer term timeframe  the channels call for a move up toward 12 
uniQure N V   NASDAQ QURE  was up 85 cents  or 5   to 17 86  on 273 380 shares traded on Thursday  I really like the look of this chart  It appears that it s four waves up and wave five has started  Resistance is in the 19 zone  If it gets through that  targets are 21 and 25 
On the long side  stocks included Adamas Pharmaceuticals  Inc   NASDAQ ADMS   Apptio  Inc   NASDAQ APTI   Boyd Gaming Corporation  NYSE BYD   General Cannabis Corp   OTC CANN   Dicerna Pharmaceuticals  Inc   NASDAQ DRNA   Editas Medicine Inc   NASDAQ EDIT   Fate Therapeutics  Inc   NASDAQ FATE   The Finish Line  Inc   NASDAQ FINL   Remark Holdings  Inc   MARK   Pieris Pharmaceuticals  Inc   NASDAQ PIRS   uniQure N V   QURE   Canopy Growth Corporation  TWMJF   Valeant Pharmaceuticals International Inc  NYSE VRX   SolarWindow Technologies  Inc   OTC WNDW   United States Steel Corp   NYSE X   and XOMA Corporation  NASDAQ XOMA  ",2017-12-22,Harry Boxer,https://www.investing.com/analysis/adms-mark-pirs-qure-200275239,200275239
147405,368921,BHC,Mallinckrodt To Buy Sucampo For  1 2B To Diversify Portfolio,opinion,"In a bid to revive its declining business beleaguered Mallinckrodt plc   NYSE MNK   announced plans to acquire Sucampo Pharmaceuticals   NASDAQ SCMP   Details of the DealMallinckrodt  will commence a cash tender offer to purchase the outstanding shares of Sucampo s common stock for  18 00 per share  The total transaction value  including Sucampo s debt is approximately  1 2 billion Mallinckrodt expects to fund the acquisition through borrowings under its existing revolving credit facility  a new secured term loan facility and or cash on hand Rationale of The DealThe Sucampo acquisition will add two approved drugs   Amitiza and Rescula to Mallinckrodt s portfolio  Amitiza is approved for treatment of chronic idiopathic constipation  CIC  in adults  irritable bowel syndrome with constipation  IBS C  in women 18 years of age and older  and opioid induced constipation  OIC  in adult patients with chronic  non cancer pain  including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation Sucampo is looking to expand the drug s label as well  A supplemental New Drug Application  sNDA  for Amitiza in children 6 to 17 years of age with pediatric functional constipation has been accepted by the FDA on a priority review basis  A decision is expected by Jan 28  2018 The acquisition also adds Rescula to Mallinckrodt s portfolio along with experimental candidates VTS 270 and CPP 1X sulindac  VTS 270 is in phase III development for Niemann Pick Type C and enjoys an orphan drug designation in the United States  A NDA filing is expected in 2018  CPP 1X sulindac is also in phase III development for Familial Adenomatous Polyposis under a collaborative agreement between Cancer Prevention Pharmaceuticals  CPP  and Sucampo   The candidate enjoys both orphan drug designation and fast track designation in the United States The transaction will be accretive to the bottom line by 30 cents in 2018 and at least double that amount in 2019  assuming a first quarter 2018 close Our TakeMallinckrodt is looking to diversify its portfolio with the Sucampo acquisition and counter the decline in sales of existing drugs Mallinckrodt  like Valeant Pharmaceuticals International Inc    NYSE VRX   has always been on the look out for acquisitions to expand diversify its portfolio  However  the company has been under tremendous pressure in 2017   Mallinckrodt s stock has tumbled 52 9  year to date  compared with the  decline of 26 1 The company s largest product  Acthar s  sales declined in the third quarter as the payer environment has become increasingly complex for specialty drugs  A large number of prescriptions were unfilled beyond the level management expected  The weakness in the sales is expected to persist in the fourth quarter  The pricing of the drug has also been under scanner Moreover  the generic segment continues to face weakness as various product categories are witnessing stiff competition  which is hurting both volumes and prices  The company expects double digit decline in revenues from this segment  The company has also received much censure for the misuse of opioid drugs  Moreover  the company suffered a setback after a U S  District Court invalidated 11 patents covering its second largest product Inomax   We remind investors that in February 2015  Mallinckrodt along with its subsidiaries filed suit in the U S  District Court for the District of Delaware against Praxair  Inc    NYSE PX   following receipt of a January 2015 notice from the latter  The notice was regarding Praxair s submission of an ANDA containing a Paragraph IV patent certification with the FDA for a generic version of Inomax Subsequently  in July 2016  Mallinckrodt filed a second suit against Praxair following receipt of a Paragraph IV notice concerning three additional patents recently added to the FDA Orange Book regarding its ANDA for a generic version of Inomax  Thereafter  a third suit was filed in September 2016  Mallinckrodt plans to appeal against the decision and stated that Inomax has patent protection till 2018 On the other hand  Sucampo s shares surged 5 9  on the acquisition deal Though the addition of Amitiza will add to Mallinckrodt s sales  it might not be enough to counter the decline in Acthar sales 
Zacks Rank 
Mallinckrodt currently carries a Zacks Rank  5  Strong Sell  
You can see  
Wall Street s Next Amazon  NASDAQ AMZN 
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-12-26,Zacks Investment Research,https://www.investing.com/analysis/mallinckrodt-to-buy-sucampo-for-12b-to-diversify-portfolio-200276116,200276116
147406,368922,BHC,Valeant Signals Buy After Retracing To Major Support,opinion,Shares of Valeant Pharmaceuticals  NYSE VRX  traded near  25 just a few weeks ago  The run to  25 started from  11 and was non stop for two plus months  Investors should have been expecting a pull back and they got it  The question now is  where is it a buy  The answer is  17 75  Not only is it the former pivot high from July 2017  but it is also a 50  Fibonacci retracement point  With both factors coinciding  it alerts investors to major support and likely the start of the next leg up ,2018-02-01,Gareth Soloway,https://www.investing.com/analysis/valeant-signals-buy-after-retracing-to-major-support-200286033,200286033
147407,368923,BHC,20 High Yield Bonds Selling Off  These 3 Are Worth Considering,opinion,"High yield bonds can be an attractive source of income and capital appreciation  Their prices are often driven more by company specific idiosyncrasies than by macroeconomic interest rate risks  And depending on your situation  they can be a valuable addition to a diversified investment portfolio  This report highlights 20 high yield bonds that are down big  and then reviews 3 specific bonds that we believe are worth considering 
The Market Rover is all about idea generation  Each week we screen the market  focusing on a different investment theme  in search of interesting investment opportunities  We then highlight a few of our favorites from the list  This report is intended to be a resource for investment idea generation 
This Week  
20 High Yield Bonds Down Big  These 3 Are Worth Considering   
Considering interest rates remain very low by historical standards  and they re also rising not good for bond prices   many investors have been focusing almost entirely on healthy dividend paying stocks with some capital appreciation potential  or at least less volatility and less downside risk than many non dividend paying stocks   However  many investors often completely overlook high yield bonds which can offer not only high yields but also significant capital appreciation opportunities  when they re trading at a discount   To be clear  high yield bonds are generally riskier that low yield bonds  that s why the yields are high   but not always  the rating agencies are often reactive in their ratings  not proactive   plus high yield bonds can often offer asymmetric return opportunities that are skewed in your favor 
For your consideration  here is a list of 20 high yield bonds that are currently trading at discounted prices and offer interesting return opportunities 

Also for your consideration  here are three bonds from the list that we currently find very interesting 
1  CBL   Associates  NYSE CBL  2023 Bonds  Yield  7 5 
CBL is a retail shopping mall REIT  and it is one of those  battleground  equity ideas where investors argue passionately on both the  buy  and  sell  sides of the isle  For example  bull Rida Morwa and his team have been beating the table for months about the attractiveness of CBL equity  and    We have no interest in owning CBL s 16 8  dividend yield equity  but the bonds are interesting to us 
What s interesting to us about the bonds  is that despite all the turmoil in the equity space  CBL equity is down about 80  in the last 5 years   the bonds have held up relatively well until the last week whereby they ve just finally sold off  they currently trade at around 90 cents on the dollar as shown in the following chart  

CBL announced dismal earnings earlier this month and the equity sold off again  and importantly Moody s just finally  to  junk  status  However  per managements earnings call  when asked about debt covenants  CFO Farzana Khaleel explained 

We still have plenty of room  The lines of credit  similarly  we have plenty of room  So I don t   when we do add   when we pay off a loan and added to the unencumbered pool  it gives us more capacity  So I don t necessarily think that we have any concern that we are hitting any of these metrics
Yes  Our debt level has come down  We re at  4 7 billion  A year ago  we were at  4 9 billion  So yes 
For 2018  the debt number will come down by the fact that we ll give back Acadiana Malls  that s  125 million  And amortization brings the debt level down  So it does come down  yes  And it will continue to go down  particularly with the amortization  We have all  50 million in amortization each year 

In our view  CBL debt is now very interesting after the credit rating downgrade  finally   the recent sell off  a lot of institutions must sell when a bond falls below investment grade  thereby contributing to the recent sell off   and management s continued focus on improving  Said differently  these bonds offer an attractive yield and may actually have more upside potential than down at this point  These bonds are worth considering  and we are watching them closely 
2  Teva Pharmaceutical  NYSE TEVA  2022 Bonds  Yield  4 9  
Teva develops and markets generic and specialty medicines  it offers a 4 1  dividend yield  and the stock price is down about 70  in the last 30 months  The company has struggled in recent years considering it s had some pipeline missteps  its branded segment is shrinking  and it faces a lot of low cost competition  However the bonds are interesting 

With only a 2 95  coupon  the yield on these bonds has currently risen to over 4 9  as the price has fallen  as shown in the above chart  However  despite the decline  there are reasons to believe this company will improve  and bondholders will continue to receive coupon payments and capital appreciation as the bond price will eventually recover to par  it traded over par as recently as mid 2017  
For example  just a few days ago we received news that Warren Buffett s Berkshire Hathaway  NYSE BRKa  has taken a position in the equity  which caused the equity share price to jump significantly  
And aside from Buffett  Teva does have continuing strong revenues  and opportunities to improve its debt and earnings via its large operating scale and resources  According to CEO Kaare Schultz during last week s earnings call 

 we re deleveraging and reducing our debt on an ongoing basis  

We suspect the bonds are far safer than their discounted price suggests 
3  Energy Transfer Equity  NYSE ETE  2023 Bonds  Yield  4 9 
If you re not comfortable with the risks of owning shares of Energy Transfer Equity  you might consider the lower risk bonds  currently offering a 4 9  yield and trading at a discounted 97 cents on the dollar  these bonds were trading at a premium earlier this year  

The company owns interests in energy assets  crude oil  natural gas  natural gas liquids  through 100  ownership interests in Energy Transfer Partners  ETP  and Energy Transfer LNG 
The bonds sold off modestly this year as the market sold off and after a negative article is the Wall Street Journal on February 8th   
Why Tax Law Likely Means Lower Revenue for Pipeline Operators 
We believe fears and the sell off are overblown with regards to the equity and especially with regards to the debt sell off  Even the article itself suggested Energy Transfer Equity would be less affected than other companies  per the following graphic 

In our view  these 2023 bonds are safer than their 4 9  yield suggests  the fears are overblown  and the recent sell off creates an attractive discounted price for new fixed income buyers to consider 
If you are looking for more high yield bond ideas  we ve highlighted 3 more from the above list in the members only version of this report 
Market Rover  20 High Yield Bonds Selling Off  These 5 Are Worth Considering
Technical Trading Ideas  Stock Exchange
In addition to fundamentals  we pay attention to short term technical indicators when entering new positions  For example  Valeant was on our list of 20 bonds above  and it s one we follow from both a debt and equity standpoint  For more information on Valeant s recent stock price technicals  check out Jeff Miller s Stock Exchange report from this week  Were You Stopped Out  We edit this report for Jeff  and Valeant s stock was covered this week  We also have more to say about Valeant s bonds later in this report 
More Perspective on the Market 
Outside of Blue Harbinger  we manage investment accounts for individuals and institutions  And these in person interactions often provide very good perspective for the things we write about at Blue Harbinger  For example  here is the feedback we gave to a long term investor a week ago when asked about the sharp market sell off 

 The market did have the biggest volatility in years over the last few days  When that happens  a lot of people try to get clever with their  buys  and  sells   and that s when a lot of costly mistakes get made  People often end up selling everything and then they miss out on the subsequent rebound  You guys are back in the positive  and the best thing to do is remember you re in it for the long term  and you re going to do better than all the dummies that sold everything out of fear yesterday  

In our view  the perspective provided in the above quote also corroborates well with the technical trading article referenced earlier  Were You Stopped Out   
Case Study  Valeant  NYSE VRX  Bonds
Valeant bonds were among the 20 ideas listed in the table earlier in this report  We also covered Valeant s equity  briefly  from a technical standpoint  as described earlier in this report  i e Were You Stopped Out    However  we believe the strong performance of Valeant s bonds over the last year is a good case study 

For example  we contribute research and portfolio management services to a private investment vehicle  and Valeant bonds have been one of the more interesting investment ideas within that fund  as described in this Barron s video and this CNBC video  More specifically  the videos provide some very good ideas about what to look for when investing in high yield bonds 
Conclusion 
High yield bonds are risky  And they are not for everyone  However  if you re interested in wading into this space  there are some very interesting opportunities to pick up attractive yield  and price appreciation  with risk versus reward profiles that are often skewed in your favor ",2018-02-19,Blue Harbinger,https://www.investing.com/analysis/market-rover-20-high-yield-bonds-sellingoff-these-3-are-worth-considering-200291648,200291648
147419,368935,BHC,Valeant pays down additional  300M of debt  shares ahead 3  premarket,news,Valeant Pharmaceuticals  NYSE VRX  announces that it has paid down an additional  300M of its outstanding senior secured term loans using cash on hand  It has now reduced its debt by more than  6 5B since Q1 2016 At year end 2017  the company s total debt was   25 7B Shares are up 3  premarket on increased volume Now read ,2018-01-03,Seeking Alpha,https://www.investing.com/news/stock-market-news/valeant-pays-down-additional-300m-of-debt-shares-ahead-3-premarket-1056922,1056922
147423,368939,BHC,Company News For Nov 8  2017,opinion,Shares of Avis Budget Group  Inc    NASDAQ CAR   fell 15 1  after reporting third quarter revenues of  2 752 million  missing the Zacks Consensus Estimate of  2 776 millionValeant Pharmaceuticals International  Inc s   NYSE VRX   shares increased 17 1  after posting third quarter adjusted earnings of  1 04 per share  beating the Zacks Consensus Estimate of  0 90Shares of Mallinckrodt Public Limited Company   NYSE MNK   slumped 35 5  after reporting third quarter revenues of  793 9 million  lower than the Zacks Consensus Estimate of  807 millionTrueCar  Inc s   NASDAQ TRUE   shares plunged 35 3  after posting third quarter revenues of  82 4 million  coming below the Zacks Consensus Estimate of  86 7 million,2017-11-07,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-nov-8-2017-200263572,200263572
147424,368940,BHC,Valeant Pharmaceuticals  VRX  In Focus  Stock Moves 5 5  Higher,opinion,"Valeant Pharmaceuticals International  Inc    NYSE VRX   was a big mover last session  as the company saw its shares rise nearly 6  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This breaks the recent trend of the company  as the stock is now trading above the volatile price range of  11 06 to  14 94 in the past one month time frame The stock gained after the company reported that Joseph C  Papa  chairman and chief executive officer  and Arthur J  Shannon  senior vice president and head of Investor Relations and Communications  are scheduled to participate at the Stifel 2017 Healthcare Conference in New York on Nov  14  2017 The company has seen a mixed track record when it comes to estimate revisions of four increase and one decrease over the past few weeks  while the Zacks Consensus Estimate for the current quarter hasn t been in a trend either  The recent price action is encouraging though  so make sure to keep a close watch on this firm in the near future 
Valeant Pharmaceuticalscurrently has a Zacks Rank  3  Hold  while its  is negative 
Valeant Pharmaceuticals International  Inc  Price   A better ranked stock in the Medical sector is Advanced Accelerator Applications S A    NASDAQ AAAP    which currently carries a Zacks Rank  1  Strong Buy   You can see  Is VRX going up  Or down  Predict to see what others think   or  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-11-08,Zacks Investment Research,https://www.investing.com/analysis/valeant-pharmaceuticals-vrx-in-focus-stock-moves-55-higher-200263812,200263812
147425,368941,BHC,Valeant  VRX  Earnings And Revenues Beat In Q3  Stock Up,opinion,"Shares of Valeant Pharmaceuticals Inc    NYSE VRX   rallied 23 6  after the company reported better than expected third quarter results on Nov 7 

Notably  Valeant s stock has increased 26 7  in the last six months compared with the  loss of 2 2  
The company s adjusted earnings per share of  1 04 beat the Zacks Consensus Estimate of 90 cents but was down from  1 46 per share in the year ago quarter 
However  total revenues of  2 21 billion topped the Zacks Consensus Estimate of  2 17 billion but declined 10 5  from the year ago quarter  The decrease was primarily attributed to declining volumes in the Diversified Products in the United States and Branded Rx segments due to the loss of exclusivity for a basket of products 
The fall in revenues can also be blamed upon the discontinuations of divestitures and unfavorable foreign exchange  The decline was partially offset by increased sales in the Bausch   Lomb International segment and Salix business Valeant Pharmaceuticals International  Inc  Price and Consensus
 

   Quarter in Detail
Revenues in the Bausch   Lomb   International segment were  1 2 billion  up 1  year over year  Excluding the impact of discontinuation of divestitures  primarily the skin care divestiture  and foreign exchange  the Bausch   Lomb International segment organically grew by approximately 6  year over year driven by increased volumes in the global Consumer  International and Global Vision Care businesses 
The Branded Rx segment revenues were  633 million  down 17  due to a decrease in sales which primarily reflects lower volumes in the Ortho Dermatologics business and the loss of sales due to the divestiture of Dendreon Pharmaceuticals LLC  This was partially offset by increased sales in Salix  
The U S  Diversified Products segment revenues were  332 million  down 29 4  year over year due to decreases in volume and price attributed to the previously reported loss of exclusivity for a basket of products 
Research and development expenses were  81 million in the reported quarter  down 19 8  from the year ago quarter 
Selling  General and Administrative costs were  623 million compared with  661 million in the year ago quarter 
During the quarter  the company received clearance for the Thermage FLX System to non invasively smooth skin on the face  eyes and body  Earlier  the company received the FDA filing acceptance for the NDA for Plenvu  NER1006   a novel  low volume polyethylene glycol based bowel preparation for colonoscopies  The FDA also approved its new psoriasis treatment  Siliq and the drug has been launched  The company had an agreement with AstraZeneca plc   NYSE AZN   for Siliq but the agreement has been amended 
2017 Guidance
The company expects total revenues in the range of  8 65  8 80 billion  down from  8 70  8 90 billion projected earlier  The updated guidance reflects the impact of the sales of the CeraVe  AcneFree and AMBI skin care brands  the sale of Dendreon Pharmaceuticals LLC  the sale of the iNova Pharmaceuticals business  and the sale of the Obagi Medical Products business  which is expected to close before the end of this year 
Our Take
Although third quarter results were encouraging  the company trimmed its guidance due to recent divestitures  After a tumultuous period  Valeant started a rebuilding process with its CEO  Joseph C  Papa  Even though it is still early to comment on the rebuilding process  but the company s efforts to sell non core assets and pay down huge levels of debt is commendable and should bode well in the upcoming quarters  As of Nov 7  2017  the company has reduced total debt by approximately  6 billion since the end of first quarter 2016 
The company is also divesting Sprout Pharmaceuticals and ADDYI businesses 
The Bausch   Lomb International segment and Salix businesses are doing well  In particular  uptake of Xifaxan and the launch of Relistor tablets drove prescription growth by 61   New drug approvals are also expected to boost growth and offset the weakness in the dermatology segment  The FDA recently approved Vyzulta for open angle glaucoma  Meanwhile  pricing in the dermatology business is beginning to stabilize 
Zacks Rank   Key Picks
Valeant currently carries a Zacks Rank  3  Hold  
Some better ranked health care stocks in the same space are Ligand Pharmaceuticals Inc    NASDAQ LGND   and Adaptimmune Therapeutics plc   NASDAQ ADAP    Both companies sport a Zacks Rank  1  Strong Buy   You can see  
Ligand s earnings per share estimates have moved up from  3 68 to  3 70 for 2018 over the last 30 days  The company delivered positive earnings surprises in two of the trailing four quarters  with an average beat of 6 19  
Adaptimmune s loss per share estimates have narrowed from 96 cents to 72 cents for 2017 and from 90 cents to 75 cents for 2018 over the last 60 days  The company reported positive earnings surprises in three of the trailing four quarters  with an average beat of 24 79  
Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-11-09,Zacks Investment Research,https://www.investing.com/analysis/valeant-vrx-earnings-and-revenues-beat-in-q3-stock-up-200263755,200263755
147426,368942,BHC,Valeant  VRX  In Focus  Stock Moves 11 7  Higher,opinion,Valeant Pharmaceuticals International  Inc    NYSE VRX   was a big mover last session  as the company saw its shares rise nearly 12  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This continues the recent uptrend for the company as the stock is now up 34 9  in the past one month time frame The company has seen three positive estimate revisions in the past few months  while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few months  suggesting that more solid trading could be ahead for Valeant  So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road Valeant currently has a Zacks Rank  3  Hold  while its  is 0 00  Valeant Pharmaceuticals International  Inc  Price   A better ranked stock in the Medical  sector is Collegium Pharmaceutical  Inc    NASDAQ COLL    which currently carries a Zacks Rank  2  Buy   You can see  Is VRX going up  Or down  Predict to see what others think   or Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-12-10,Zacks Investment Research,https://www.investing.com/analysis/valeant-vrx-in-focus-stock-moves-117-higher-200272178,200272178
147427,368943,BHC,This Pharma Play Has Major Upside,opinion,"In recent weeks  pharma plays like Valeant Pharmaceuticals  NYSE VRX  and Teva Pharma Industries  NYSE TEVA  have surged  Valeant is up almost 100  since October and Teva is up nearly 50   In other words  pharma has become a hot sector as Trump s corporate tax cuts near finalization 
One pharma stock that is lagging but has a gorgeous bull flag is Endo International  NASDAQ ENDP   Endo is on my watch list and if its bull flag breaks out  pushing price over  7 75  it will be a strong buy with major upside potential to  10 65 ",2017-12-11,Gareth Soloway,https://www.investing.com/analysis/this-pharma-play-has-major-upside-200272115,200272115
147428,368944,BHC,4 Stocks To Watch  MARK  OSTK  RIOT  ROKU,opinion,"Remark Holdings  Inc   NASDAQ MARK  is looking really good  and I love the way it acted on Monday  It had a breakout of a wedge on Friday  which was a big move  On Monday  it was up 92 cents  or 10 4   to 9 76  on 3 6 million shares traded  and it took it to a high of 10 34  I think this stock is headed to 13 
Overstock com  Inc   NASDAQ OSTK  had a spectacular session  jumping 9 92  or 22   to 55 00  on 5 6 million shares traded  That was a huge snapback out of the trading range  Now  it may be headed for a retest of 59 60  and maybe it will get to 64 5  before it moves to a long term advance  which could take it substantially higher 
Riot Blockchain  Inc   NASDAQ RIOT   which to me  looks like the swing trade is working great  It exploded  and wedged  and exploded out again on Monday  running up 7 22  or 45 1 2   to 23 08  on over 20 million shares traded  That was huge volume for this stock  If it gets through here  and gaps up on Tuesday  I m looking for 29 30 immediately 
Roku Inc  NASDAQ ROKU  popped 3 19  or 7   to 47 98  on 10 3 million shares traded on Monday  It s been popping out across resistance for the last seven days  I m looking for a quick retest of 51 3 4  and then I m looking at 60 
On the long side  stocks included Aurora Cannabis Inc   OTC ACBFF   Canopy Growth Corporation  TWMJF   Aradigm Corporation  NASDAQ ARDM   General Cannabis Corp   OTC CANN   Century Aluminum Co   NASDAQ CENX   CenturyLink  Inc   NYSE CTL   Fitbit Inc   NYSE FIT   Bitcoin Investment Trust  OTC GBTC   U S  Global Investors  Inc   NASDAQ GROW   Marathon Patent Group  Inc   NASDAQ MARA   MGT Capital Investments  Inc   OTC MGTI   Remark Holdings  Inc   MARK   Overstock com  Inc   NASDAQ OSTK   Riot Blockchain  Inc   NASDAQ RIOT   Roku Inc  ROKU   Sunesis Pharmaceuticals  Inc   SNSS   SORL Auto Parts  Inc   SORL   Social Reality  Inc   SRAX   Seven Stars Cloud Group  Inc   SSC   Valeant Pharmaceuticals  NYSE VRX  International  Inc   VRX   INTERSECT ENT  INC   XENT   and Xunlei Limited  XNET  ",2017-12-11,Harry Boxer,https://www.investing.com/analysis/mark-ostk-riot-roku-200272318,200272318
147438,368954,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 04 ,news,"Investing com   Canada stocks were higher after the close on Monday  as gains in the Healthcare  IT and Consumer Discretionary sectors led shares higher 
At the close in Toronto  the S P TSX Composite gained 0 04  
The best performers of the session on the S P TSX Composite were  Home Capital Group Inc    TO HCG   which rose 7 02  or 1 10 points to trade at 16 77 at the close  Meanwhile  Valeant Pharmaceuticals International Inc  TO VRX  added 6 06  or 1 14 points to end at 19 94 and  DHX Media Ltd  B  TO DHXb  was up 4 59  or 0 18 points to 4 10 in late trade 
The worst performers of the session were Klondex Mines Ltd  TO KDX   which fell 4 60  or 0 150 points to trade at 3 110 at the close  Detour Gold Corporation  TO DGC  declined 4 10  or 0 57 points to end at 13 34 and  Tahoe Resources Inc   TO THO  was down 4 02  or 0 24 points to 5 73 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 589 to 543 and 118 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 28 11  to 9 36 a new 1 month low 
Gold Futures for December delivery was down 1 47  or 19 06 to  1277 44 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in January fell 0 55  or 0 31 to hit  56 40 a barrel  while the January Brent oil contract fell 0 89  or 0 56 to trade at  62 16 a barrel 
CAD USD was down 0 37  to 0 7802  while CAD EUR rose 0 11  to 0 6649 
The US Dollar Index Futures was up 0 41  at 93 99 ",2017-11-20,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade-sptsx-composite-up-004-890369,890369
147439,368955,BHC,Valeant prices upsized debt offering,news,Valeant Pharmaceuticals  NYSE VRX  prices its  1 5B  up from  1B  offering of 9 000  senior notes due 2025 at 98 611   Net proceeds will be used to repurchase  1 5B of its outstandings 7 000  senior notes due 2020  6 375  senior notes due 2020 and up to  200M of its 5 375  senior notes due 2020 The notes will be guaranteed by each of Valeant s subsidiaries that are guarantors under its credit agreement and existing senior notes Closing date is December 18 Now read ,2017-12-05,Seeking Alpha,https://www.investing.com/news/stock-market-news/valeant-prices-upsized-debt-offering-953180,953180
147440,368956,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 61 ,news,"Investing com   Canada stocks were higher after the close on Thursday  as gains in the Healthcare  IT and Consumer Discretionary sectors led shares higher 
At the close in Toronto  the S P TSX Composite rose 0 61  
The best performers of the session on the S P TSX Composite were Eldorado Gold Corporation  TO ELD   which rose 6 34  or 0 09 points to trade at 1 51 at the close  Meanwhile  Valeant Pharmaceuticals International Inc  TO VRX  added 5 39  or 1 16 points to end at 22 68 and  Dollarama Inc   TO DOL  was up 5 26  or 7 88 points to 157 61 in late trade 
The worst performers of the session were  Advantage Oil   Gas  Ltd   TO AAV   which fell 5 74  or 0 310 points to trade at 5 090 at the close   Bonavista Energy Corp   TO BNP  declined 5 10  or 0 100 points to end at 1 860 and Enerplus Corporation  TO ERF  was down 4 34  or 0 51 points to 11 25 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 641 to 477 and 159 ended unchanged 
Shares in Advantage Oil   Gas Ltd   TO AAV  fell to 52 week lows  falling 5 74  or 0 310 to 5 090  Shares in Valeant Pharmaceuticals International Inc  TO VRX  rose to 52 week highs  gaining 5 39  or 1 16 to 22 68  Shares in Bonavista Energy Corp  TO BNP  fell to 52 week lows  losing 5 10  or 0 100 to 1 860  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 4 14  to 11 36 
Gold Futures for February delivery was down 1 33  or 16 90 to  1249 20 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in January rose 1 18  or 0 66 to hit  56 62 a barrel  while the February Brent oil contract rose 1 50  or 0 92 to trade at  62 14 a barrel 
CAD USD was down 0 54  to 0 7779  while CAD EUR fell 0 32  to 0 6608 
The US Dollar Index Futures was up 0 24  at 93 75 ",2017-12-07,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade-sptsx-composite-up-061-967779,967779
147441,368957,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 52 ,news,"Investing com   Canada stocks were higher after the close on Friday  as gains in the Healthcare  Industrials and IT sectors led shares higher 
At the close in Toronto  the S P TSX Composite rose 0 52  
The best performers of the session on the S P TSX Composite were Valeant Pharmaceuticals International Inc  TO VRX   which rose 11 82  or 2 68 points to trade at 25 36 at the close  Meanwhile  Canopy Growth Corp  TO WEED  added 6 41  or 1 170 points to end at 19 420 and  Lucara Diamond Corp   TO LUC  was up 5 53  or 0 130 points to 2 480 in late trade 
The worst performers of the session were  Cascades Inc    TO CAS   which fell 3 03  or 0 42 points to trade at 13 44 at the close  Hudson s Bay Company  TO HBC  declined 2 24  or 0 23 points to end at 10 02 and  TransAlta  Corp  TO TA  was down 2 01  or 0 16 points to 7 82 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 752 to 384 and 141 ended unchanged 
Shares in Valeant Pharmaceuticals International Inc  TO VRX  rose to 52 week highs  rising 11 82  or 2 68 to 25 36  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 2 21  to 11 08 
Gold Futures for February delivery was down 0 25  or 3 10 to  1250 00 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in January rose 1 15  or 0 65 to hit  57 34 a barrel  while the February Brent oil contract rose 1 83  or 1 14 to trade at  63 34 a barrel 
CAD USD was down 0 01  to 0 7773  while CAD EUR fell 0 03  to 0 6606 
The US Dollar Index Futures was up 0 13  at 93 87 ",2017-12-08,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade-sptsx-composite-up-052-972838,972838
147442,368958,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 08 ,news,"Investing com   Canada stocks were higher after the close on Tuesday  as gains in the Healthcare  Materials and Consumer Discretionary sectors led shares higher 
At the close in Toronto  the S P TSX Composite added 0 08  to hit a new 1 month high 
The best performers of the session on the S P TSX Composite were Element Fleet Management Corp  TO EFN   which rose 8 73  or 0 84 points to trade at 10 46 at the close  Meanwhile  Hudson s Bay Company  TO HBC  added 6 63  or 0 67 points to end at 10 78 and Valeant Pharmaceuticals International Inc  TO VRX  was up 6 54  or 1 73 points to 28 18 in late trade 
The worst performers of the session were  Torex Gold Resources Inc   TO TXG   which fell 5 79  or 0 730 points to trade at 11 870 at the close   Trican Well Service Ltd    TO TCW  declined 5 43  or 0 220 points to end at 3 830 and  Birchcliff Energy Ltd    TO BIR  was down 4 78  or 0 21 points to 4 18 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 572 to 564 and 146 ended unchanged 
Shares in Torex Gold Resources Inc  TO TXG  fell to 52 week lows  falling 5 79  or 0 730 to 11 870  Shares in Valeant Pharmaceuticals International Inc  TO VRX  rose to 52 week highs  up 6 54  or 1 73 to 28 18  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 1 16  to 11 09 
Gold Futures for February delivery was down 0 05  or 0 60 to  1246 30 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in January fell 1 31  or 0 76 to hit  57 23 a barrel  while the February Brent oil contract fell 1 76  or 1 14 to trade at  63 55 a barrel 
CAD USD was down 0 09  to 0 7771  while CAD EUR rose 0 12  to 0 6615 
The US Dollar Index Futures was up 0 09  at 94 02 ",2017-12-12,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade-sptsx-composite-up-008-984567,984567
147443,368959,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 72 ,news,"Investing com   Canada stocks were lower after the close on Thursday  as losses in the Healthcare  Energy and Consumer Discretionary sectors led shares lower 
At the close in Toronto  the S P TSX Composite lost 0 72  
The best performers of the session on the S P TSX Composite were  Mitel Networks Corporation   TO MNW   which rose 10 69  or 1 01 points to trade at 10 46 at the close  Meanwhile   Semafo Inc    TO SMF  added 3 87  or 0 13 points to end at 3 49 and  Sandstorm Gold Ltd    TO SSL  was up 3 79  or 0 220 points to 6 020 in late trade 
The worst performers of the session were Valeant Pharmaceuticals International Inc  TO VRX   which fell 11 27  or 3 19 points to trade at 25 11 at the close   Cenovus Energy  Inc  TO CVE  declined 5 46  or 0 65 points to end at 11 26 and  Crew Energy Inc   TO CR  was down 5 40  or 0 19 points to 3 33 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 687 to 460 and 151 ended unchanged 
Shares in Crew Energy Inc  TO CR  fell to 52 week lows  falling 5 40  or 0 19 to 3 33  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 5 86  to 11 20 
Gold Futures for February delivery was up 0 50  or 6 30 to  1254 90 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in January rose 1 06  or 0 60 to hit  57 20 a barrel  while the February Brent oil contract rose 1 65  or 1 03 to trade at  63 47 a barrel 
CAD USD was up 0 14  to 0 7810  while CAD EUR rose 0 50  to 0 6630 
The US Dollar Index Futures was up 0 24  at 93 62 ",2017-12-14,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade-sptsx-composite-down-072-994646,994646
147446,368962,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 53 ,news,"Investing com   Canada stocks were higher after the close on Monday  as gains in the Healthcare  Energy and Materials sectors led shares higher 
At the close in Toronto  the S P TSX Composite gained 0 53  
The best performers of the session on the S P TSX Composite were Valeant Pharmaceuticals International Inc  TO VRX   which rose 7 44  or 1 89 points to trade at 27 28 at the close  Meanwhile   Birchcliff Energy Ltd    TO BIR  added 6 68  or 0 26 points to end at 4 15 and Canopy Growth Corp  TO WEED  was up 6 35  or 1 230 points to 20 610 in late trade 
The worst performers of the session were  Badger Daylighting Ltd    TO BAD   which fell 3 22  or 0 90 points to trade at 27 01 at the close  Inter Pipeline Ltd  TO IPL  declined 2 21  or 0 60 points to end at 26 60 and  North West Company Inc   TO NWC  was down 1 67  or 0 52 points to 30 60 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 713 to 434 and 151 ended unchanged 
Shares in Canopy Growth Corp  TO WEED  rose to all time highs  gaining 6 35  or 1 230 to 20 610  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 1 30  to 10 93 
Gold Futures for February delivery was up 0 57  or 7 20 to  1264 70 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in February fell 0 09  or 0 05 to hit  57 28 a barrel  while the February Brent oil contract rose 0 24  or 0 15 to trade at  63 38 a barrel 
CAD USD was down 0 09  to 0 7765  while CAD EUR fell 0 30  to 0 6594 
The US Dollar Index Futures was down 0 24  at 93 24 ",2017-12-18,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade-sptsx-composite-up-053-1006301,1006301
147447,368963,BHC,EyeGate nabs new U S  patent covering EGP 437  shares ahead 4 ,news,The USPTO issues Patent No  9 820 935 to EyeGate Pharmaceuticals  EYEG  4 1   covering the method of delivering corticosteroids through iontophoresis to the eye  the mechanism of action of candidate EGP 437  licensed to Valeant Pharmaceuticals  NYSE VRX  Now read ,2017-12-19,Seeking Alpha,https://www.investing.com/news/stock-market-news/eyegate-nabs-new-us-patent-covering-egp437-shares-ahead-4-1009939,1009939
147448,368964,BHC,FDA OK s B L s Lumify eye drop for ocular redness,news,The FDA approves Valeant Pharmaceuticals  VRX  0 2   unit Bausch   Lomb s LUMIFY  brimonidine tartrate ophthalmic solution 0 025    an over the counter  OTC  eye drop  for the treatment of ocular redness  The company says it is the first and only OTC low dose brimonidine tartrate approved in the U S  for the indication LUMIFY will be available at major retailers in Q2 2018 Now read ,2017-12-22,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-bls-lumify-eye-drop-for-ocular-redness-1025336,1025336
147451,368967,BHC,Why Did Valeant Pharmaceuticals  VRX  Stock Fall Today ,opinion,"Shares of Valeant Pharmaceuticals   NYSE VRX   fell more than 7  in morning trading Tuesday  following a key analyst s warning that the struggling company still has  numerous weaknesses  in its business 
In a cautious note to clients today  Mizuho s Irina Koffler highlighted her concerns about Valeant s second quarter investor presentation and lowered her price target for the stock to  7 from  8 
 Our valuation relies in part on SOTP analysis and we note that EBITA margins in the Diversified segment dropped from  81  in 2016 to 73  YTD  This business remains very critical to Valeant and in 2Q 17 Diversified revenue declined 27 3  Y Y   Koffler wrote 
 Our other main takeaways from the detailed 2Q 17 slides are that the company divested a number of its remaining 2Q 17 growth drivers within B L International  Dendreon  and Obagi  leaving behind less attractive businesses  
Despite surpassing the Zacks Consensus Estimate by an impressive 8 25  in the most recent quarter  Valeant still has a massive pile of debt to be worried about  The company has already pared down its debt by about  4 8 billion and looks to be on its way to easily hit its  5 billion target  but as Koffler notes  this could be at the expense of key growth drivers 
Ultimately  Koffler reiterated her  Underperform  rating on Valeant   We expect Valeant to miss its 2017 revenue and EBITDA guidance  and FactSet consensus 2018 estimates still appear too high   she concluded 
Koffler s hesitant note comes just a few days after the news that Valeant might be facing another legal battle  Last week  mutual fund company Lord Abbett   Co  filed a securities fraud lawsuit against Valeant  alleging that it was sold the company s debt securities at an artificially inflated price based on misleading information provided by Valeant 
Valeant has set aside about  162 million to handle its legal troubles  but with Lord Abbett seeking up to  80 billion in damages and with Justice Department and regulatory investigations looming it looks like the company may have underestimated its challenges 
Still  Valeant remains a Zacks Rank  3  Hold  and currently sports an overall VGM grade of  B  
Want more stock market analysis from this author  Make sure to follow   on Twitter 
Zacks  10 Minute Stock Picking Secret
Since 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars 
But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month ",2017-08-29,Zacks Investment Research,https://www.investing.com/analysis/why-did-valeant-pharmaceuticals-vrx-stock-fall-today-200210248,200210248
147452,368968,BHC,The Fallacy Of Value Investing  With Neil Woodford ,opinion,"This week  star London based fund manager Neil Woodford talked about his recent poor performance  mainly as a result of the huge losses suffered in his holding in Provident Financial 
Below is the chart  which tells its own sorry story 

In the articles I have read  Woodford appeared to be lamenting the  hysteria  and  irrational behaviour  of traders and investors in the market  The price gaps in June and August were as a result of profit warnings being announced  the second of which led to a reported loss suffered in excess of  300m across his funds 
Maybe the hysteria he is talking about was actually other traders and investors reacting to seeing those profit warnings  and they simply cut their losses and moved on 
When I come across situations like this  I am reminded of a story Ed Seykota once told 

One evening  while having dinner with a fundamentalist  I accidentally knocked a sharp knife off the edge of the table  He watched the knife twirl through the air  as it came to rest with the pointed end sticking into his shoe   Why didn t you move your foot   I exclaimed   I was waiting for it to come back up   he replied 

Of course  the danger in looking for  value  is that what appears to be cheap  can end up being a lot cheaper  and consequently better value  a few weeks or months later if a downtrend takes hold 
 I believe Provident Financial shares started the day undervalued  and have become even more so as a result of the market s reaction to today s news   Neil Woodford  22 August 2017
The trend is clearly down  Where is the bottom  Can it go lower 
It was interesting to note that  in the aftermath of the latest profit warning  he started talking about price earnings ratios  dividend yields etc   in an attempt to put some positive spin on the situation  Sure  like the  assumed resumption of the payment of a dividend  he talked about would be a justifiable reason for holding onto a  300m  loss 
 I don t believe that there is a problem with owning a large stake in a business that is profoundly undervalued  
 It s a great portfolio  one that I own and want to own more of  The short term performance is painful and is difficult  but it isn t a permanent loss of capital   Neil Woodford  07 September 2017
I have long talked about the merits of long term investors including a trend following element in their selection process  Even a simple metric such as the 200 day moving average would help  Tellingly  price had been oscillating above and below the 200 day moving average for over a year  and dipped below it again just ahead of the first profit warning back in June  Of course  it is way below that now 

A couple of years ago  I had the pleasure of meeting a portfolio manager who works at a major investment bank in the City of London  Although their portfolio recommendations are fundamental based  and determined by committee   plus they are restricted in their selection process to the constituents of the FTSE 350  it was noticeable when he said that they experienced an upturn in performance when they added a trend filter to help with the timing of their buying and selling activity 
Of course  this was not a surprise to my friend  who had an encyclopedic knowledge of trend following and its merits  It was the first time someone starting quoting Dickson Watts  Speculation as a Fine Art to me 
I am not setting out to diss Woodford here  He has a long and successful track record in what he does  And obviously to achieve what he has  there has been some stocks held for a very long time to generate the big returns required to offset the occasional big losses such as this 
And I accept and understand that when you run such a fund  and hold such concentrated positions in a stock  it would be impossible to sell out in one go  Woodford s funds owned a significant chunk of the Provident stock   a bit similar to the approach of   
But his approach couldn t be further from my own  or of those who consider price and its movements to be their primary concern 
I am least hopeful that individual traders who read this post will appreciate the potential devastation a holding like this can cause in your own investment portfolio or trading account  not to mention the emotional upheaval 
It s the age old principle again of cutting your losses at the first sign of trouble  Taking a small loss is frustrating  but it sure beats taking the mother of all losses ",2017-09-10,Trader Steve,https://www.investing.com/analysis/the-fallacy-of-value-investing--with-neil-woodford-200212344,200212344
147453,368969,BHC,Pricing Pressure  Competition Remain Headwinds For Pharma Stocks,opinion,"While the drug pricing issue no longer remains a major headwind for pharma and biotech stocks  it will nevertheless remain a headline risk until the Trump administration comes out with a policy for controlling drug prices  The sector  previously a Wall Street favorite  was hit hard by political rhetoric and increasing media and public focus on the high prices of drugs  With the drug pricing controversy gaining steam since September 2015  companies like Valeant saw their share prices plunging as they found themselves in the midst of the controversy 
According to the April 2017 Kaiser Health Tracking poll  six in ten Americans believe affordability of prescription drugs should be a top priority for the President and Congress   focus should be on ensuring the affordability of high cost drugs to people who need them and taking steps to lower prescription drug prices 
Some of the options favored by the public for drug price control include getting drug companies to reduce prices for medications for people on Medicare  making it easier for generics to enter the market  and requiring drug companies to provide information on how drug prices are set 
Although the pharma and biotech sectors have rebounded in 2017  drug companies may find it a bit difficult to justify their high prices by citing the years and funds that go into bringing new treatments to market and the need to invest in R D to bring additional treatments to market 
Biosimilars a Key Headwind
Another challenge being faced by the sector is the recent entry of biosimilar competition in the United States  While a relatively new area  the market for biosimilars is huge and highly lucrative with several blockbuster biologics including Humira and Lantus slated to lose patent protection by 2020  Biosimilars are expected to reduce healthcare costs and provide a large number of patients with access to much needed biologic treatments 
According to research released by the IMS Institute for Healthcare Informatics last year  increasing acceptance of biosimilars across different therapeutic areas plus an active pipeline of 56 candidates are expected to lead to total savings of about  110 billion to health systems across Europe and the United States through 2020  The report further says that by 2020  biosimilars will start competing with biologics that have annual sales of  50 billion 
Biosimilars are also gaining acceptance across formularies  Although there is still low visibility on how well biosimilars will perform or how much of the market they will be able to capture  the focus on making expensive drugs more affordable and formulary coverage for biosimilars could very well make it challenging for innovator companies to hold on to market share for their blockbuster drugs 
Generics Pose a Threat
Quite a few of the big players in the drug industry are looking at loss of patent protection for major blockbuster drugs  With generics and biosimilars breathing down their necks  many of these companies are looking towards new products to pick up pace and make up for lost sales  However  products like Repatha and Praluent are yet to ramp up significantly  With efforts on to control drug prices  the FDA is focusing on speeding up the generic drug approval process especially for third  fourth  or fifth generics which leads to rapid erosion of branded drug sales 
Slowdown in Sales of Mature Products 
Many companies like Amgen  NASDAQ AMGN  are facing a slowdown in sales of mature products in their portfolios  At the same time  new product sales are yet to pick up significantly  Many of these companies are also facing loss of patent protection  which means generics or biosimilars  as the case may be  could enter the market soon and lead to price erosion 
Pricing Pressure to Hit Sales
While concerns regarding the drug pricing issue may have taken a backseat for the time being  pharma and biotech companies remain wary of increasing scrutiny of drug prices  Moreover  with increasing competition in the market and the entry of innovative treatments  pricing pressure is expected to hit sales 
Regulatory Setbacks
Although the FDA has already surpassed last year s tally of new drug approvals  there were a few companies that failed to gain approval for their drugs this year and were issued complete response letters  CRLs  by the agency  A CRL is issued by the FDA to inform the company that its application will not be approved in its present form  There could be several reasons for the same including insufficient data to support approval as well as manufacturing issues 
Some of the companies that are facing a delay in getting their drugs approved include Mylan  NASDAQ MYL   biosimilar version of Amgen s Neulasta   Johnson   Johnson  NYSE JNJ   sirukumab for the treatment of moderately to severely active rheumatoid arthritis   Valeant  Vesneo   eye drug   and Amgen and UCB  Evenity for the treatment of postmenopausal women with osteoporosis  
Mylan NV  MYL  is a Zacks Rank  2  Buy  stock   you can see  
Stocks to Avoid
As concerns regarding pricing pressure  slowdown in legacy product sales and biosimilar competition continue to keep the sector volatile  it would be prudent to stay away from stocks that have not been able to win analysts  confidence and carry an unfavorable Zacks Rank 
Companies like Acorda Therapeutics  ACOR   BioMarin Pharmaceutical  BMRN   Valeant Pharmaceuticals  NYSE VRX  International  VRX   Merck  MRK   Teva Pharmaceuticals  TEVA  and Sanofi  PA SASY   SNY  are all sell ranked stocks  While Merck and BioMarin are Zacks Rank  4  Sell  stocks  Sanofi  Teva  Acorda and Valeant carry a Zacks Rank  5  Strong Sell   To know more about this sector  check out our latest  
5 Trades Could Profit  Big League  from Trump Policies
If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course 
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-10-18,Zacks Investment Research,https://www.investing.com/analysis/pricing-pressure-competition-remain-headwinds-for-pharma-stocks-200219668,200219668
147467,368983,BHC,The Zacks Analyst Blog Highlights  Valeant Pharmaceuticals International  Flexion Therapeutics  Ignyta And Anika Therapeutics,opinion,"For Immediate Release

	Chicago  IL   July 18  2017   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Valeant Pharmaceuticals  NYSE VRX  International  Inc   NYSE           Flexion Therapeutics  Inc   NASDAQ           Ignyta  Inc   NASDAQ          and Anika Therapeutics  Inc   NASDAQ          

	Today  Zacks is promoting its   Buy   stock recommendations     

Here are highlights from Monday s Analyst Blog  

4 Sell Ranked Drug Stocks to Avoid Ahead of Q2 Earnings 

	Earnings season for the biotech and pharma sector kicks off this week with industry bellwether Johnson   Johnson  NYSE JNJ  reporting second quarter results tomorrow before the market opens  Swiss pharma giant Novartis  which was in the news recently related to a favorable FDA advisory panel recommendation for its CAR T cell therapy  will also be reporting second quarter results tomorrow 

	As of Jul 14  2017  about 30 S P 500 members or 9 3  of the index s total market capitalization have reported results  A look at our  article shows that total earnings for these companies are up 13 8  from the year ago quarter while revenues are up 6  
	As far as the Medical sector is concerned  revenues are expected to increase 3 7  though earnings are expected to decline 1   This is in contrast to the first quarter when earnings rose 5 6  on revenue growth of 5 7  
	While overall sentiment towards pharma and biotech stocks has improved significantly in 2017 with investors focusing more on fundamentals than on issues like drug pricing  it would make sense to avoid drug companies that are sell ranked stocks and do not look well positioned ahead of 2Q earnings  We have zeroed in on 4 stocks that have a Sell rank    Zacks Rank  4  Sell  or  5  Strong Sell  and have a negative  for the second quarter Valeant Pharmaceuticals International  Inc    NYSE          Canada based specialty pharma company  Valeant  has been in the headlines mainly due to the drug pricing controversy and its relationship with Philidor  The Zacks Rank  5 stock  which missed earnings expectations in two of the last four quarters and revenue expectations in the first quarter of 2017  has a negative earnings ESP of 9 38  for the second quarter of 2017  The company  which has been working on simplifying its operating model and reducing debt  will be reporting results on Aug 8  Earnings estimates for 2017 are down 0 5  over the last 30 days Flexion Therapeutics  Inc    NASDAQ          Burlington  MA based Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel  local therapies for the treatment of patients with musculoskeletal conditions  beginning with osteoarthritis  The Zacks Rank  4 stock  which missed loss estimates in two of the last four quarters  has a negative earnings ESP of 7 5  for the second quarter of 2017  Loss estimates for the June quarter and 2017 are up 1 3  and 0 6   respectively  over the last 7 days  Flexion is expected to report second quarter results on Aug 2 

Ignyta  Inc    NASDAQ          San Diego  CA based Ignyta is focused on precision medicine in oncology  The Zacks Rank  4 stock  which posted a wider than expected loss in two of the last three quarters  has a negative earnings ESP of 13 12  for the second quarter of 2017  Loss estimates for the June quarter and 2017 are up 17 3  and 1 9   respectively  over the last 30 days  Ignyta is expected to report second quarter results on Aug 8 Anika Therapeutics  Inc    NASDAQ          Bedford  MA based Anika is a global  integrated orthopedic medicines company  The Zacks Rank  5 stock  which missed first quarter earnings estimates  has a negative earnings ESP of 4 55  for the second quarter of 2017  While earnings estimates for the June quarter are down 10 2  over the last 30 days  full year 2017 estimates are down 5 6  during this period  Anika will be reporting second quarter results on Jul 26  Year to date  the company s shares are down 5 8   underperforming the Zacks categorized  industry which is up almost 9  
	While you can uncover the best stocks to buy or sell before they re reported with our    you can see   Today s Stocks from Zacks  Hottest Strategies
	It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively 
	And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation  

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  









	Follow us on Twitter  

	Join us on Facebook  NASDAQ FB   

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact

	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2017-07-17,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-valeant-pharmaceuticals-international,-flexion-therapeutics,-ignyta-and-anika-therapeutics-200201782",200201782
147471,368987,BHC,Valeant  VRX  To Sell Obagi For  190 Million To Lower Debt,opinion,Valeant Pharmaceuticals International  Inc    NYSE VRX   announced that it has entered into an agreement to sell its Obagi Medical Products business for  190 million in cash to Haitong International Zhonghua Finance Acquisition Fund I  L P The company acquired Obagi in 2013  Obagi products help minimize the appearance of premature skin aging  skin damage  hyperpigmentation  acne and sun damage Debt reduction continues to be a priority for Valeant  The company will use proceeds from the sale to permanently repay term loan debt under its senior secured credit facility  The transaction is expected to close in the second half of 2017 The divestiture of non core assets should help the company streamline its product portfolio and focus on core areas of dermatology and lower debt  The company expects to pay down  5 billion of debt from divestiture proceeds within 18 months from Aug 2016  The company reduced its debt by  4 3 billion since the first quarter of 2016 The company earlier sold its equity interests in Dendreon Pharmaceuticals  Inc  to the China based Sanpower Group Co  Ltd  Once an acquisition giant  Valeant has been caught up in various controversies due to price hike of specialty drugs  erroneous financial reporting and termination of contracts with Philidor Rx Services  After a tumultuous period  Valeant started a rebuilding process with its new CEO  Joseph C  Papa  Even though it is still early to comment on the rebuilding process  but the company s efforts to sell non core assets and pay down huge levels of debt is commendable and should bode well in the upcoming quarters  The dermatology business witnessed some positive trends as the average selling price stabilized  The GI business continues to struggle with weak sales of Xifaxan but is expected to gain market share with an improved sales Shares of Valeant have underperformed the Zacks classified  industry in the last one year  The stock has lost 30 2  against the industry s 0 6  gain Zacks Rank and Stocks to ConsiderValeant carries a Zacks Rank  5  Strong Sell  Some better ranked health care stocks in the same space are Enzo Biochem  Inc    NYSE ENZ    Sanofi   NYSE SNY    and Exelixis  Inc    NASDAQ EXEL     While Enzo Biochem and Exelixis sport a Zacks Rank  1  Strong Buy   Sanofi carries a Zacks Rank  2  Buy   You can see  Enzo Biochem s loss per share estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018  over the last 60 days  The company delivered positive earnings surprises in each of the trailing four quarters  with an average beat of 55 83  Exelixis has delivered positive earnings surprises in all the four trailing quarters with an average beat of 512 11   Exelixis s shares have soared 75 4  so far this year Sanofi s earnings per share estimates increased from  3 08 to  3 18 for 2017 and from  3 26 to  3 30 for 2018  over last 60 days  The company delivered positive earnings surprises in three of the trailing four quarters  with an average beat of 5 10  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-07-18,Zacks Investment Research,https://www.investing.com/analysis/valeant-(vrx)-to-sell-obagi-for-$190-million-to-lower-debt-200202108,200202108
147472,368988,BHC,Facebook  Valeant Pharmaceuticals And Advanced Micro Devices Highlighted As Zacks Bull And Bear Of The Day,opinion,"For Immediate Release

	Chicago  IL  July 26  2017   highlights Facebook  NASDAQ FB   NASDAQ          as the Bull of the Day Valeant Pharmaceuticals  NYSE VRX   NYSE       as the Bear of the Day  In addition  Zacks Equity Research provides analysis on Advanced Micro Devices  NASDAQ AMD   Inc   NASDAQ        

	Here is a synopsis of all five stocks 

   

Facebook   NASDAQ          reports Q2 earnings today after the close and any investor who gets excited about advertising sales growth of 45  year over year  and 15  sequentially  should read this article and get ready to buy FB shares on any dip Points on Why It s All About the Ecosystem1  Consensus Projections   Raised Estimates
	Facebook is expected to report just over  9 billion in ad revenues for the quarter and  1 13 EPS  representing 49  profit growth  Since the company will be evaluated on many other growth metrics besides the top and bottom lines  my last point will briefly address the  What if they miss   question 
	What s been fascinating for me to watch as a Facebook bull in the face of so many who doubt the ad growth can continue is how estimates have just kept moving higher all year  In January  we started out with the consensus for full year 2017 revenues projected to be under  36 billion in ad sales  fully 98  of total revs   or 32  growth 
	In the past few weeks  as analysts have done more channel checks  the numbers have climbed to just over  38 billion in advertising revenues for over 40  top line growth  And the 2018 estimates keep getting bumped too with revenues to hit over  49 billion and EPS of  6  representing 28  and 24  growth 2  Ad Inventory Shrinking 
	Part of the doubt about how Facebook could continue to grow ad sales as such a clip was that even they warned about reaching capacity on the News Feed for ads  But this is clearly the right side of the supply and demand curve to be on 
	As Facebook COO Sheryl Sandberg said last quarter  they diligently track the impact of  ad loads  on the user experience  going for quality and relevance over quantity and annoyance  my paraphrase  
	The key has been to innovate and execute on a plan to shift more advertising to Instagram where social audience targeting can be just as effective as on the core FB feeds 3  Instagram Leapfrogs Snapchat
	Instagram hit 700 million total users and 400 million DAUs  daily active users  as of Facebook s last quarterly report May 3  The real growth has come from Instagram Stories which has greatly surpassed that of rival they copied  Snapchat 
	Stories passed 250 million DAUs in June  up from 200 million in April  150 million in January  and 100 million in October    only two months after launch 
	While the company is taking their time to monetize Instagram  we could see a dramatic shift forward in those efforts in Q2  They might even begin to break out Instagram revenue as a segment  Until then  analysts estimate the photo sharing app could generate over  4 billion  or 10    to Facebook s top line 

	Bear 

Valeant Pharmaceuticals  NYSE         shares have more than doubled since late April as much of the pessimism that was priced into the beleaguered medical empire was likely over done near  10 

	Obviously  with projected EPS this year of over  3 50  the stock appears to be a terrific bargain  even today near  18 and under 5X 
	But VRX is still getting put in the cellar of the Zacks Rank because estimates were reduced recently by 2 analysts  And consistent with the longer term evaporation of the franchise  next year s projections are only registering 0 66  top line growth and 4 4  on the bottom 
	The earnings picture could turn around for VRX at any time  but right now analysts are not that optimistic 
	Valeant is in the middle of a large debt reduction program  While it sells non core assets  there is probably more uncertainty about the timing of a lasting sales and profit turnaround 
	For instance  just last week Valeant announced an agreement to sell its Obagi Medical Products business for  190 million in cash to Haitong International Zhonghua Finance Corporation  The  190 million sale price is over 55  below the  437 million VRX paid for Obagi in April 2013 
	Some investment bank analysts see more uncertainty ahead  They cite still high leverage and believe that recent deals  including divestitures of iNova and Dendreon  have had limited impacts on the overall leverage situation 
	Until the estimates start going back up for next year  it may be time to shed VRX shares near this  18 resistance level while you can 

	Additional content 



Strong Sales Help AMD Post Q2 Earnings  Revenue Beats 

Advanced Micro Devices  Inc    NASDAQ         just released its second quarter 2017 financial results  posting a GAAP loss of  0 02 per share and revenues of  1 22 billion  Currently  AMD is a Zacks Rank  3  Hold  and is up 8 08  to  15 25 per share in after hours trading shortly after its earnings report was released 

AMD  

Beat earnings estimates   Adjusting for stock option expenses  the company posted a loss of one cent per share  beating the Zacks Consensus Estimate of a loss of one cent per share  On a GAAP basis  AMD reported a loss of two cents per share  and on a non GAAP basis  the chipmaker posted a profit of two cents per share 

Beat revenue estimates   The company saw revenue figures of  1 22 billion  topping our consensus estimate of  1 15 billion 

	The chipmaker s quarterly revenue jumped 19  year over year and 24  sequentially  spurred by higher revenue figures from its computing and graphics sector  AMD reported operating income of  25 million  but a net loss of  16 million 

	AMD s computing and graphics segment revenue jumped 51  year over year to  659 million  which was helped demand for its Ryzen desktop processors 

	AMD projects revenues to increase roughly 23  sequentially  plus or minus 3   for the third quarter  The company expects full year revenue to jump  by a mid to high teens     which is up from the company s last guidance projections of low double digit revenue growth 

	 Our second quarter results demonstrate strong growth driven by leadership products and focused execution   AMD president and CEO Dr  Lisa Su said in a statement 

	 Our Ryzen desktop processors  Vega GPUs  and EPYC datacenter products have received tremendous industry recognition  We are very pleased with our improved financial performance  including double digit revenue growth and year over year gross margin expansion on the strength of our new products  

About the Bull and Bear of the Day 

	Every day  the analysts at Zacks Equity Research select two stocks that are likely to outperform  Bull  or underperform  Bear  the markets over the next 3 6 months 

About Zacks Equity Research

	Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

	Continuous analyst coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  







	Follow us on Twitter  

	Join us on Facebook  

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact

	Zacks Investment Research

	800 767 3771 ext  9339





	Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer   

Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2017-07-25,Zacks Investment Research,"https://www.investing.com/analysis/facebook,-valeant-pharmaceuticals-and-advanced-micro-devices-highlighted-as-zacks-bull-and-bear-of-the-day-200203568",200203568
147473,368989,BHC,SPY Breaks Higher  Reverses On Strong Volume,opinion," Some people dream of success  while other people get up every morning and make it happen     Wayne Huizenga
The stock action is what you d expect in August  choppy  with no direction 
A few trades here and there may pop up but mostly cash seems to be best to me still 
Valeant Pharmaceuticals International Inc  NYSE VRX  was a perfect example of how many earnings releases have been affecting stocks  but in double speed 
VRX ran up hard and then came all the way back by the end of the day 
Chop 

SPDR S P 500  NYSE SPY  was acting great and broke higher into new highs but then reversed on strong volume 
This tells me we ve got a correction coming 
Time will tell but I think we should get some deep value in a quick strong move lower ",2017-08-09,Warren Bevan,https://www.investing.com/analysis/summer-sitting-200206143,200206143
147474,368990,BHC,Valeant  VRX  Beats Q2 Earnings  Sales In Line  Trims View,opinion,"Shares of Valeant Pharmaceuticals Inc    NYSE VRX   surged 1 76  after the company announced that it is on target with its debt reduction plans 

Valeant s stock lost 12  against the  gain of 5 5  
The company s adjusted earnings per share of  1 05 beat the Zacks Consensus Estimate of 97 cents 
However  total revenue came in at  2 2 billion  roughly in line with the Zacks Consensus Estimate of  2 2 billion but declined 7 7  from the year ago quarter  The year over year decline was due to lower volume and price in the U S  Diversified Products segment  as a result of the loss of exclusivity for a number of products and the dermatology business Valeant Pharmaceuticals International  Inc  Price and EPS Surprise

 
   Quarter in Detail
Revenues in the Bausch   Lomb   International segment were  1 2 billion  down 3  year over year due to impact of divestitures  Excluding the impact of the skincare divestiture and foreign exchange  the Bausch   Lomb International segment organically grew by approximately 6  
The Branded Rx segment revenues were  636 million  down 3  due to lower volumes in the dermatology business and the impact of divestitures and discontinuations in the Salix business which was partially offset by 13  revenue growth in the Salix business 
The U S  Diversified Products segment revenues were  356  down 27  year over year due to decreases in volume and price attributed to the previously reported loss of exclusivity for a basket of products 
Research and development expenses were  94 million in the reported quarter  down 24 2  from the year ago quarter 
Selling  General and Administrative costs were  659 million compared with  671 million in the year ago quarter 
During the quarter  the company completed sale of Dendreon Pharmaceuticals LLC and used net proceeds to pay down  811 million of senior secured term loan  Valeant will also redeem the remaining  500 million aggregate principal amount of outstanding 6 75  Senior Notes due 2018  The company has also decided to sell iNova Pharmaceuticals and Obagi Medical Products businesses for  930 million and  190 million in cash  respectively  to close in the second half of 2017  On a positive note  the company received FDA filing acceptance for the NDA for Plenvu  NER1006   a novel  low volume polyethylene glycol based bowel preparation for colonoscopies  Earlier  the FDA approved its new psoriasis treatment  Siliq  The company had an agreement with AstraZeneca plc   NYSE AZN   for Siliq but the agreement has been amended 
2017 Guidance Trimmed
The company expects total revenue in the range of  8 70  8 90 billion  down from  8 90  9 10 billion projected earlier  The updated guidance reflects the impact of the sale of the CeraVe  AcneFree and AMBI skincare brands and the sale of Dendreon Pharmaceuticals LLC  However  the guidance does not reflect the impact of the sales of the iNova Pharmaceuticals and Obagi Medical Products businesses  which are both expected to close in the second half of the year 
Our Take
Although second quarter results were encouraging  the company trimmed its guidance due to recent divestitures  The company expects to meet its target of  5 billion debt reduction ahead of schedule  The Bausch   Lomb International segment and Salix businesses together represented 73  of revenue in the quarter 
After a tumultuous period  Valeant started a rebuilding process with its new CEO  Joseph C  Papa  Even though it is still early to comment on the rebuilding process  but the company s efforts to sell non core assets and pay down huge levels of debt is commendable and should bode well in the upcoming quarters  The company still has  27 6 billion of debt as of Jun 30  2017 
Zacks Rank   Key Picks
Valeant currently carries a Zacks Rank  3  Hold  
Some better ranked stocks in the health care sector are Aduro Biotech  Inc    NASDAQ ADRO   and Gilead Sciences  Inc    NASDAQ GILD    Both stocks carry a Zacks Rank  2  Buy   You can see  
Aduro Biotech s loss per share estimates narrowed from  1 46 to  1 36 for 2017 over the last 30 days  The company delivered positive earnings surprises in two of the four trailing quarters with an average beat of 2 53  
Gilead s earnings per share estimates increased from  7 92 to  8 53 for 2017  over the last 30 days following strong results in the second quarter  The company delivered positive earnings surprises in three of the trailing four quarters  with an average beat of 8 18  ",2017-08-09,Zacks Investment Research,https://www.investing.com/analysis/valeant-vrx-beats-q2-earnings-sales-in-line-trims-view-200206322,200206322
147476,368992,BHC,The Zacks Analyst Blog Highlights  Mylan  Perrigo  Esperion s  Zynerba And Valeant ,opinion,For Immediate ReleaseChicago  IL   August 14  2017   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog includeMylan  NASDAQ   NASDAQ MYL       Perrigo  NYSE   NYSE PRGO       Esperion Up on Positive Mid Stage Data  Esperion s  NASDAQ   NASDAQ ESPR      Zynerba Plunges as STAR 1 Fails to Shine  Zynerba  NASDAQ   NASDAQ ZYNE      and Valeant Gets CRL for Eye Drop  Valeant  NYSE   NYSE VRX        Today  Zacks is promoting its   Buy   stock recommendations    Here are highlights from Friday s Analyst Blog  Pharma Stock Roundup  Mylan Misses  Perrigo Tops  Zynerba PlungesSecond quarter earnings season is drawing to a close with most major companies having reported results  This week  companies like Endo  Mylan  NASDAQ       Novo Nordisk  CO NOVOb  and Perrigo  NYSE      presented their second quarter results Recap of the Week s Most Important StoriesA Look at Q2 Earnings Results  Mylan s second quarter results were disappointing with the company missing on both earnings and revenues and cutting its outlook  Also read     Mylan has pushed back all major product launches in the U S  from 2017 to 2018 reflecting ongoing challenges and the uncertain U S  regulatory environment  These product launches include generic versions of Advair and Copaxone  Escalating price erosion in the generics market remains a major challenge  Meanwhile  Mylan got a subpoena from the U S  Department of Justice   DOJ   in late Jul 2017 seeking information relating to opioids manufactured  marketed or sold by the company from Jan 1  2013 to Dec 31  2016  Mylan has lost 15 4  of its value year to date versus the 15 8  decline of its  Perrigo s second quarter results were better than expected with the company raising its outlook  Also read     Novo Nordisk also topped earnings estimates and raised its outlook  Meanwhile  Endo  which topped earnings and revenue estimates  lowered its outlook  Also read     Endo stock has lost 54 2  of its value year to date versus the 1 8  decline of its  Perrigo is a Zacks Rank  3  Hold  stock  You can see  Esperion Up on Positive Mid Stage Data  Esperion s  NASDAQ      shares were up 15 4  on positive top line data from a study evaluating the company s bempedoic acid and Zetia  ezetimibe  combination plus Lipitor versus placebo in patients with hypercholesterolemia  The mid stage triplet oral therapy study met its primary endpoint of greater LDL C lowering compared to placebo  The company intends to conduct additional studies next year and expects to file for FDA approval of the combination by the first quarter of 2019 Zynerba Plunges as STAR 1 Fails to Shine  Zynerba  NASDAQ      saw its shares plunging 55 7  on disappointing mid stage data on the company s experimental cannabinoid treatment  ZYN002  Results from the double blind placebo controlled STAR 1 study in adult epilepsy patients with focal seizures showed that both doses of ZYN002 failed to meet the endpoints compared to placebo  Focus has now shifted to a couple more studies being conducted with ZYN002   osteoarthritis  top line data expected in Aug 2017  and Fragile X syndrome  top line data expected in Sep 2017    Valeant Gets CRL for Eye Drop  Valeant  NYSE       which reported second quarter results this week  Also read     got a complete response letter   CRL   from the FDA for its new drug application   NDA   for Vyzulta  latanoprostene bunod ophthalmic solution  0 024    The company is looking to gain approval for the use of the intraocular pressure lowering single agent eye drop in patients with open angle glaucoma or ocular hypertension  While no safety or efficacy concerns were raised by the FDA  the CRL referred to a Current Good Manufacturing Practice   CGMP   inspection at Bausch   Lomb s manufacturing facility in Tampa  FL  Valeant is working on resolving manufacturing quality issues at the Tampa plant and will be working with the agency to determine the path forward About Zacks Equity ResearchZacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  Follow us on Twitter  Join us on Facebook  NASDAQ FB   Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates  Media ContactZacks Investment Research800 767 3771 ext  9339 Past performance is no guarantee of future results  Inherent in any investment is the potential for loss This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ,2017-08-13,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-mylan-perrigo-esperions-zynerba-and-valeant-200207071,200207071
147477,368993,BHC,Healthcare   Top 5 Gainers   Losers as of 11 00 am,news,Gainers  MYO  65   KND  29   XOMA  18   VRX  16   CLDX  14  Losers  SELB  46   FPRX  44   TLGT  40   MNK  31   VCYT  21  Now read ,2017-11-07,Seeking Alpha,https://www.investing.com/news/stock-market-news/healthcare--top-5-gainers--losers-as-of-1100-am-839578,839578
147478,368994,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 25 ,news,"Investing com   Canada stocks were higher after the close on Tuesday  as gains in the Healthcare  REITs and Real Estate sectors led shares higher 
At the close in Toronto  the S P TSX Composite rose 0 25  to hit a new all time high 
The best performers of the session on the S P TSX Composite were Valeant Pharmaceuticals International Inc  TO VRX   which rose 17 24  or 2 66 points to trade at 18 09 at the close  Meanwhile  Kirkland Lake Gold Ltd  TO KL  added 7 55  or 1 310 points to end at 18 650 and  Canadian Apartment Properties REIT   TO CAR u  was up 4 33  or 1 51 points to 36 41 in late trade 
The worst performers of the session were  Torex Gold Resources Inc   TO TXG   which fell 18 86  or 3 290 points to trade at 14 150 at the close   Tahoe Resources Inc   TO THO  declined 7 80  or 0 48 points to end at 5 67 and  Alaris Royalty Corp    TO AD  was down 6 39  or 1 280 points to 18 740 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 597 to 527 and 132 ended unchanged 
Shares in Torex Gold Resources Inc  TO TXG  fell to 52 week lows  losing 18 86  or 3 290 to 14 150  Shares in Canadian Apartment Properties REIT  TO CAR u  rose to all time highs  gaining 4 33  or 1 51 to 36 41  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 14 76  to 11 49 
Gold Futures for December delivery was down 0 39  or 5 04 to  1276 56 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in December fell 0 21  or 0 12 to hit  57 23 a barrel  while the January Brent oil contract fell 0 81  or 0 52 to trade at  63 75 a barrel 
CAD USD was down 0 56  to 0 7827  while CAD EUR fell 0 38  to 0 6753 
The US Dollar Index Futures was up 0 19  at 94 80 ",2017-11-07,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade-sptsx-composite-up-025-839743,839743
147479,368995,BHC,EyeGate completes enrollment in mid stage study of EGP 437  shares ahead 2 ,news,EyeGate Pharmaceuticals  EYEG  1 8   announces the completion of enrollment in a Phase 2b clinical trial evaluating EGP 437 for the treatment of pain and inflammation in patients who have undergone cataract surgery  Topline data should be available in Q1 The event triggers a milestone payment from Valeant Pharmaceuticals  NYSE VRX  EGP 437 is a reformulated topically active corticosteroid  dexamethasone  that is delivered to the eye through the EyeGate II Delivery System Global exclusive licensee Valeant will commercialize EGP 437  once approved  through its Bausch   Lomb unit Previously  Enrollment underway in EyeGate s mid stage study of EGP 437 in cataract surgery patients  Aug  1 Now read ,2017-11-08,Seeking Alpha,https://www.investing.com/news/stock-market-news/eyegate-completes-enrollment-in-midstage-study-of-egp437-shares-ahead-2-840387,840387
147481,368997,BHC,SPY  Just A Normal Correction At The Right Time Of Year,opinion," You will fall  And when you fall  the winner always gets up  and the loser stays down   Arnold Schwarzenegger
Some more volatility came into stocks on Thursday as summer rolls on 
Miners were strong Wednesday and foretold the gold strength Thursday as often happens and now gold and silver are once again on the verge of a breakout  after being rejected strongly from those levels Monday 
I m mostly just doing some day trading  and a top pick for that is Valeant Pharmaceuticals International Inc  NYSE VRX   since it s very liquid and moves fast 
I will be establishing a position in VRX once the signal comes  but until then  it s a fine day trading vehicle I ve found 
So  looks like we will see more corrective action which is great  so enjoy the summer 
I m trying to eek out a couple or few early trades and then take the afternoons off if the weather is sunshiny 

SPDR S P 500  NYSE SPY  closed definitively below the 50 day average on heavy volume 
I d enjoy a move down to the gap area at 238 but who knows in this wild and very strong market overall 
In my view  the bull market still has legs  but needs a rest ",2017-08-18,Warren Bevan,https://www.investing.com/analysis/its-just-a-normal-correction-at-the-right-time-of-year-200208048,200208048
147487,369003,BHC,Canada s Shopify slides after Citron criticism,news,"By Solarina Ho TORONTO  Reuters     Shopify Inc   TO SHOP   N SHOP  shares fell by over 11 percent on Wednesday after short seller Citron Research said the Canadian provider of online retailing software was overvalued  according to traders and analysts  Citron s Andrew Left criticized the company s marketing practices in a report released on Wednesday  saying it uses a network of affiliates to promote its services and  oversells  the potential for profit  The stock  which had been trading near all time highs recently  closed down around 11 5 percent at  103 in New York and C 129 in Toronto  Citron  which profits from bets that stock prices will fall  set an immediate price target of  60  A Shopify spokeswoman declined to comment  In the past  the 13 year old Shopify has said partners are an important part of its business and while it  can not expect every single merchant to succeed  we are confident that Shopify gives merchants the best chance at success    In its last quarterly report  the  10 2 billion market cap company said it has more than half a million merchants using Shopify to launch stores  including major brands like  Visa Inc   N V  and BuzzFeed  The company  which makes money from subscription and payment processing fees  has yet to turn a profit   It s a high quality company with a high quality management team   said Samad Samana  a senior research analyst with Stephens Inc  who declined to comment specifically on Citron s report  Shopify s business was  trending in the right direction   he said  adding that profit margins would come over time  Trading volume was more than 12 times its 90 day average in the United States and about five times in Toronto  Comments by Left  the founder of Citron  often affect share prices  He sparked an investigation into the relationship between Valeant Pharmaceuticals  NYSE VRX  International  TO VRX  and now shuttered Philidor with a report issued in October 2015  
He was banned for five years from the Hong Kong market last year  after a tribunal found him culpable of market misconduct over one of its research reports  Left said at the time the decision did not properly reflect the case ",2017-10-04,Reuters,https://www.investing.com/news/stock-market-news/shopify-slides-after-citron-criticizes-marketing-business-model-536890,536890
147488,369004,BHC,Ackman reaches out to ADP retail investors  softens image,news,"By Svea Herbst Bayliss BOSTON  Reuters    Billionaire investor William Ackman took his fight for board seats at Automatic Data Processing Inc  NASDAQ ADP  to retail investors on Tuesday in an unusually public format where he detailed his successes and failures and urged all to cast their votes  For one hour  the Wall Street hedge fund manager spoke in a live webinar  fielding questions from Main Street investors about ADP s culture  the company s earnings potential and what expertise he would bring  all while trying to soften his image of an impatient investor who likes to fire people   This is your company and you get to decide   Ackman said  urging retail investors to vote their shares   The decision to vote your shares is as important as voting for president of the United States   he said  before showing a short tutorial on exactly how to vote for him  The 51 year old hedge fund manager is pushing ADP to cut bureaucracy  consolidate its real estate holdings and enhance technology  all to boost earnings  He is seeking control of three seats out of ADP s board of 10  Ackman s effort to reach retail investors illustrates just how critical this group  which owns 28 percent of ADP  is in determining the outcome of the battle between himself and the human resources software company at the Nov  7 vote  Ackman s  10 billion hedge fund  Pershing Square  NYSE SQ  Capital Management  holds an 8 3 percent economic stake in ADP but has only a 2 percent voting stake  Until recently  retail investors have been largely ignored in proxy contests  partly because employees  retirees and amateur investors are often seen to side with management if they vote their shares at all  For Ackman  who has won and lost proxy battles  the stakes are high  While he has returned an average 15 percent a year over the last decade  his reputation has been hobbled by two years of double digit losses in 2016 and 2015  and a number of prominent investors have pulled money out  The importance of retail investors was illustrated on Tuesday as another activist  Trian Fund Management s Nelson Peltz  appears to have lost his bid for one seat on the board at Procter   Gamble Co  On the webinar  Ackman acknowledged mistakes like his bet on Valeant Pharmaceuticals  NYSE VRX  Inc  on which he took a more than  3 billion loss when he finally sold his stake  But he spent more time detailing achievements at Canadian Pacific Railway Ltd  Zoetis Inc  NYSE ZTS  and Air Products   Chemicals Inc  and laid out the amount of money he and the two other board candidates have riding on ADP s future success  
 We would have skin in the game   Ackman said  He also said he is open to having top executives stay and would not envision large scale layoffs ",2017-10-10,Reuters,https://www.investing.com/news/stock-market-news/ackman-reaches-out-to-adp-retail-investors-softens-image-539707,539707
147489,369005,BHC,Valeant s Culprimine facing new generic competitors,news,Valeant Pharmaceuticals   VRX  1   aggressive price hikes have attracted generic interlopers to its Cuprimine  penicillamine  franchise Amerigen Pharmaceuticals Limited and Biophore India Pharmaceuticals Pvt Ltd  are collaborating on a generic version of the Wilson s disease med as well as other penicillamine based products  Amerigen has filed an ANDA with the FDA for the Cuprimine generic which is currently under review Now read ,2017-10-24,Seeking Alpha,https://www.investing.com/news/stock-market-news/valeants-culprimine-facing-new-generic-competitors-546717,546717
147491,369007,BHC,Company News For June 20  2017,opinion,     Shares of Rice Energy Inc    NYSE RICE   surged 24 8  after EQT Corporation   NYSE EQT   decided to purchase Rice Energy for  6 7 billion     Rigel Pharmaceuticals  Inc  s   NASDAQ RIGL   shares soared 11 2  after the company declared that its New Drug Application  NDA  was approved by the U S  FDA for use of Tavalisse        Shares of Novadaq Technologies Inc    NASDAQ NVDQ   skyrocketed 95  after the company revealed that Stryker Corporation   NYSE SYK   has agreed to purchase Novadaq for 701 million     Valeant Pharmaceuticals International s   NYSE VRX   gained 6 4  following the news that John Paulson has joined the company s Board,2017-06-19,Zacks Investment Research,"https://www.investing.com/analysis/company-news-for-june-20,-2017-200196340",200196340
147492,369008,BHC,FDA accepts Valeant s marketing application for psoriasis lotion IDP 118  action date June 18  2018,news,The FDA accepts for review Valeant Pharmaceuticals  VRX  3 4   unit Ortho Dermatologics  New Drug Application  NDA  seeking approval for IDP 118  halobetasol propionate and tazarotene  lotion for the topical treatment of plaque psoriasis  The agency s action date is June 18  2018 Now read ,2017-11-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-accepts-valeants-marketing-application-for-psoriasis-lotion-idp118-action-date-june-18-2018-762909,762909
147493,369009,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 09 ,news,"Investing com   Canada stocks were lower after the close on Thursday  as losses in the Healthcare  Utilities and Clean Technology sectors led shares lower 
At the close in Toronto  the S P TSX Composite declined 0 09  
The best performers of the session on the S P TSX Composite were  Kinaxis Inc   TO KXS   which rose 12 14  or 7 68 points to trade at 70 96 at the close  Meanwhile  Kirkland Lake Gold Ltd  TO KL  added 10 53  or 1 630 points to end at 17 110 and  ProMetic Life Sciences Inc    TO PLI  was up 8 27  or 0 110 points to 1 440 in late trade 
The worst performers of the session were  Sleep Country Canada Holdings Inc   TO ZZZ   which fell 13 01  or 5 02 points to trade at 33 58 at the close  Valeant Pharmaceuticals International Inc  TO VRX  declined 7 56  or 1 16 points to end at 14 18 and Imperial Oil Limited  TO IMO  was down 5 52  or 2 29 points to 39 17 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 581 to 522 and 137 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 3 29  to 13 81 a new 1 month high 
Gold Futures for December delivery was down 0 05  or 0 70 to  1276 60 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in December rose 0 79  or 0 43 to hit  54 73 a barrel  while the January Brent oil contract fell 0 08  or 0 05 to trade at  60 70 a barrel 
CAD USD was down 0 01  to 0 7806  while CAD EUR fell 0 01  to 0 6696 
The US Dollar Index Futures was down 0 08  at 94 62 ",2017-11-02,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade-sptsx-composite-down-009-763145,763145
147496,369012,BHC,Stocks Start Week Strong,opinion,"U S  stocks began the week with solid gains as technology issues led a broad based advance that pushed the Dow and S P to fresh record highs  while the NASDAQ saw the largest percentage gain for the day  The advance for equities lacked a clear catalyst as the domestic docket was devoid of any major releases today and will remain blank again tomorrow  Treasuries  Gold and crude oil prices were lower and the U S  dollar was nicely higher 
The Dow Jones Industrial Average  DJIA  rose 145 points  0 7   to 21 529  the S P 500 Index advanced 20 points  0 8   to 2 453  and the NASDAQ Composite rallied 87 points  1 4   to 6 239  In moderate volume  801 million shares were traded on the NYSE and 2 0 billion shares changed hands on the NASDAQ  WTI crude oil declined  0 54 to  44 39 per barrel and wholesale gasoline  was unchanged at  1 45 per gallon  Elsewhere  the Bloomberg gold spot price decreased  9 17 to  1 244 56 per ounce  and the gollar index  a comparison of the U S  dollar to six major world currencies  was 0 4  higher at 97 56 
Shares of Valeant Pharmaceuticals International Inc   NYSE VRX  13  traded nicely higher  after it was announced that billionaire hedge fund manager John Paulson  its largest shareholder  will join the board of the struggling drugmaker in an effort to aid in its turnaround  The move comes only months after fellow fund manager Bill Ackman  a long time champion of VRX  bailed  with the company posting an 80  loss from its peak in 2015 amid drug pricing and accounting scandals 
The NASDAQ jumped back on track after a dismal performance last week  when the index lagged the Dow and S P 500 due to pressure on technology issues  This week is  Tech Week  at the White House  as President Trump will meet with executives from a number of top technology firms  where he is expected to solicit their help in speeding up the process of modernizing the federal government s technology  as well as discussions on cyber security 
Slow start to week s economic calendar
Treasuries finished lower with the economic calendar void of any major releases today  The yields on the 2 Year and 10 Year notes were 4 basis points  bps  higher at 1 36  and 2 19   and the 30 Year bond rate was up 1 bp at 2 79  
Treasury yields have been in a trading range lately amid a host of domestic and European political uncertainty  mixed economic data  and last week s highly expected rate hike by the Fed and details of the process in beginning to shrink its inflated balance sheet sometime this year 
The economic calendar is sparse this week  with tomorrow s ledger also bare  while later in the week investors will get some housing data with the releases of new and existing home sales  as well as weekly MBA Mortgage Applications  Manufacturing and business activity will also be on tap  with data from Markit s preliminary Manufacturing and Services PMIs and the Kansas City Fed Manufacturing Index  Other reports of note include weekly initial jobless claims and the Index of Leading Economic Indicators 
As well  a number of Federal Reserve officials are slated to speak at various engagements throughout the week 
Equities in Europe and Asia end higher European equities finished broadly higher  with politics taking center stage  while also getting a tailwind from last week s extension of loan agreements to Greece by its creditors that ended speculation over whether the country would be able to meet large bond payments coming due in July  The second round of parliamentary elections in France over the weekend ushered in a solid win for newly elected President Macron  with his Republic on the Move party  along with an ally in the Modem centrist party  producing an absolute majority  paving the way for easy passage of Macron s reform program 
The British pound was modestly lower versus the U S  dollar  as Brexit negotiations began in Brussels today  and amid a cloud of uncertainty in the U K  following reports over the weekend that the nation s senior conservative leaders are preparing to initiate a challenge to Prime Minister May s leadership if she softens her stance on Brexit  The euro also lost modest ground versus the greenback and bond yields in the region were lower  Amid the political turmoil overseas  including upcoming elections in Italy and Germany later this year  Economic news was sparse  with April industrial output in Italy declining and housing prices in the U K  ticked lower for June 
Stocks in Asia began the trading week higher across the board on the heels of Friday s fresh high for the Dow in the U S   as well as optimism in China with regard to an upcoming MSCI decision  Japanese equities increased  with the yen gliding lower during the session and following a report that showed an unexpected trade deficit  as the nation s imports exhibited surprising strength  while exports fell short of expectations 
Mainland Chinese stocks rose and shares trading in Hong Kong jumped amid increased hopes that MSCI will include the Asian nation s A shares in its emerging markets indexes when it announces its decision later this week  while showing little reaction to data that showed housing prices continue to steadily rise  Australian securities returned from a long holiday weekend to finish higher  despite Moody s downgrade of twelve of the nation s lenders  including its four largest banks  while Indian listings traded higher and South Korean equities gained ground 
The international docket for tomorrow will include department store sales from Japan  leading indicators from China  house price data from Australia  PPI from Germany and the current account for the Eurozone ",2017-06-20,Marvin Clark,https://www.investing.com/analysis/stocks-start-week-strong-200196139,200196139
147498,369014,BHC,Valeant s  VRX  NDA For Bowel Cleansing Drug Accepted By FDA ,opinion,"Valeant Pharmaceuticals International  Inc  s   NYSE VRX   wholly owned subsidiary  Salix Pharmaceuticals  announced that the FDA has accepted its New Drug Application for Plenvu  NER1006  A low volume  1L  polyethylene glycol based bowel preparation  Plenvu  has been developed for whole bowel cleansing  with added focus on the ascending colon  This  in turn  is expected to enhance bowel cleansing and the overall experience relating to colonoscopy We note that Salix licensed the drug from Norgine in Aug 2016  The drug  upon approval  will offer the lowest solution for an FDA approved bowel cleanser in the market  The drug will have an edge over high preparation volumes which sometimes can be a deterrent in patients completing their regimen In Apr 2015  Valeant acquired erstwhile Salix  a specialty pharmaceutical company with a portfolio of over 20 marketed products  including Xifaxan  Uceris  Apriso  Glumetza and Relistor to expand in gastrointestinal market Shares of Valeant Pharma have underperformed the Zacks classified  industry in the last one year  The stock lost 14 8  against the industry s 8 2  gain The approval of new drugs should boost Valeant s top line  The company has been caught up in various controversies due to price hike of specialty drugs  erroneous financial reporting and termination of contracts with Philidor Rx Services  Valeant started a rebuilding process with its new CEO  Joseph C  Papa in 2016  Even though it is still early to comment on the rebuilding process but the company s efforts to sell non core assets and pay down huge levels of debt is commendable and should bode well in the upcoming quarters  The dermatology business saw some positive trends as the average selling price stabilized  The GI business continues to struggle with weak sales of Xifaxan but should see gain in market share with an increased sales force 
Zacks Rank and Stocks to Consider
Valeant Pharma carries a Zacks Rank  3  Hold  
Some better ranked stocks in the health care sector include VIVUS  Inc    NASDAQ VVUS     MEI Pharma  Inc    NASDAQ MEIP   and Sanofi   NYSE SNY    
While VIVUS and MEI Pharma sport a Zacks Rank  1  Strong Buy   Sanofi carries a Zacks Rank  2  Buy   You can see  
VIVUS  loss per share estimates narrowed from 50 cents to 39 cents for 2017 over the last 60 days  The company delivered positive earnings surprises in the trailing four quarters  with an average beat of 233 69  
MEI Pharma s estimates moved up from a loss per share of 1 cent to gain per share of the same for 2017  over the last 60 days  The company posted positive earnings surprises in three of the trailing four quarters  with an average beat of 66 56   Sanofi s earnings per share estimates increased from  3 00 to  3 18 for 2017 over last 60 days  The company posted positive earnings surprises in three of the trailing four quarters  with an average beat of 5 10  
Today s Stocks from Zacks  Hottest Strategies 
It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively 
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-06-28,Zacks Investment Research,https://www.investing.com/analysis/valeant's-(vrx)-nda-for-bowel-cleansing-drug-accepted-by-fda-200198374,200198374
147499,369015,BHC,Pricing  Competition Remain Headwinds For Pharma In 2017,opinion,"Although fears regarding the drug pricing issue have waned  it will nevertheless remain a headwind until the Trump administration comes out with a policy for controlling drug prices  Drug pricing is an issue that weighed on pharma and biotech stocks for more than a year  The sector  which previously had a stellar run  started its downward trend in Sep 2015 when a single tweet by Democratic Presidential candidate Hillary Clinton sent pharma and biotech stocks tumbling  Clinton s  price gouging tweet  was in response to a huge price hike  about 5 000   taken by Turing Pharmaceuticals for a drug that was approved by the FDA way back in 1953 Since then  companies like Valeant    saw their share prices plunging as they found themselves in the midst of the drug pricing controversy Although pharma and biotech shares rallied post election in November on hopes that drug pricing would not be a key focus area under a Trump presidency  the relief rally turned out to be short lived following President Trump s views regarding drug pricing  Trump made it clear that he does not like what happened to drug prices and he will bring down drug prices According to the Apr 2017 Kaiser Health Tracking poll  six in ten Americans believe affordability of prescription drugs should be a top priority for the President and Congress    focus should be on ensuring the affordability of high cost drugs to people who need them and taking steps to lower prescription drug prices Some of the options favored by the public for drug price control include getting drug companies to reduce prices for medications for people on Medicare  making it easier for generics to enter the market  and requiring drug companies to provide information on how drug prices are set Although the pharma and biotech sectors have rebounded in 2017  drug companies may find it a bit difficult to justify their high prices by citing the years and funds that go into bringing new treatments to market and the need to invest in R D to bring additional treatments to market Biosimilars Changing the Competitive ScenarioAnother challenge being faced by the sector is the recent entry of biosimilar competition in the U S  While a relatively new area  the market for biosimilars is huge and highly lucrative with several blockbuster biologics including Humira and Lantus slated to lose patent protection by 2020  Biosimilars are expected to reduce healthcare costs and provide a large number of patients with access to much needed biologic treatments According to research released by the IMS Institute for Healthcare Informatics last year  increasing acceptance of biosimilars across different therapeutic areas plus an active pipeline of 56 candidates are expected to lead to total savings of about  110 billion to health systems across Europe and the U S  through 2020 The report further says that by 2020  biosimilars will start competing with biologics that have annual sales of  50 billion  Several companies are working on bringing biosimilars to market for reference products like Johnson   Johnson s Remicade  Amgen s    Enbrel  Roche Biogen s Rituxan and AbbVie s Humira Biosimilars are also gaining acceptance across formularies  Although there is still low visibility on how well biosimilars will perform or how much of the market they will be able to capture  the focus on making expensive drugs more affordable and formulary coverage for biosimilars could very well make it challenging for innovator companies to hold on to market share for their blockbuster drugs Generics Pose a ThreatQuite a few of the big players in the drug industry are looking at loss of patent protection for major blockbuster drugs  With generics and biosimilars breathing down their necks  many of these companies are looking towards new products to pick up the pace and make up for lost sales  While several new products were approved last year  many like Orkambi  Repatha and Praluent failed to live up to expectations Moreover  with efforts on to control drug prices  chances are high that the approval process for generics could be made smoother Fewer FDA Approvals in 2016There was a notable dip in FDA novel drug approvals in 2016 with the agency giving its nod to 22 treatments during the year  Compare this to 45 approvals in 2015 and 41 in 2014 and the 2016 numbers look really disappointing It s not like a fewer number of applications were submitted in 2016    as of Dec 9  2016  36 new molecular entity  NME  applications were submitted  in line with the average NME filings of 35 over the past decade However  a pretty high number of applications got complete response letters  CRLs  from the agency    a CRL is issued by the FDA to inform the company that its application will not be approved in its present form  There could be several reasons for the same including insufficient data to support approval as well as manufacturing issues Some of the drugs that got CRLs in 2016 include Spectrum Pharma s Qapzola  immediate intravesical instillation post transurethral resection of bladder tumors in patients with non muscle invasive bladder cancer   Dynavax s experimental hepatitis B vaccine Heplisav B  Advanced Accelerator s Lutathera  treatment of gastroenteropancreatic neuroendocrine tumors in adults   and AstraZeneca s ZS 9  hyperkalemia   AstraZeneca is a Zacks Rank  2  Buy  stock    you can see  
Stocks to AvoidAs concerns surrounding the drug pricing issue continue to keep the sector volatile  it would be prudent to stay away from stocks that have not been able to win analysts  confidence and carry an unfavorable Zacks Rank of  4  Sell  or  5  Strong Sell  Juno Therapeutics  Inc      Juno is focused on developing innovative cellular immunotherapies for the treatment of cancer  The company  however  suffered a setback with its most advanced pipeline candidate being discontinued following the emergence of safety issues  While the company is moving ahead with other candidates in its pipeline  Juno currently holds a Zacks Rank  4 Obesity focused Orexigen Therapeutics  Inc     is also a Zacks Rank  4 stock  The company has a disappointing earnings track record with first quarter loss coming in well above estimates  The average earnings surprise over the last four quarters is  104 4  while loss estimates for 2017 have gone up 21 5  over the last 60 days Companies like Eli Lilly and Company  NYSE LLY     and Adamas are also Zacks Rank  4 stocks while stocks like AMAG Pharmaceuticals  Inc     and Dr  Reddy s Laboratories Limited    hold a Zacks Rank  5  Lilly has underperformed the Zacks categorized  with shares gaining 12 9  compared to the industry gain of 14 9  To know more about this sector  check out our  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-06-29,Zacks Investment Research,"https://www.investing.com/analysis/pricing,-competition-remain-headwinds-for-pharma-in-2017-200198382",200198382
147500,369016,BHC,VRX  After The Towel Is Thrown,opinion,"Bill Ackman had a famously bad time with Valeant Pharmaceuticals  NYSE VRX   which crashed from  263 to the single digits  Last March  having suffered terrible losses for his fund  Ackman  threw in the towel  and dumped his position  prompting even  
So did the stock instantly soar higher  No  that would be a little too neat  wouldn t it  The stock did indeed keep falling for a few more weeks  losing another 20  or so of its value  making Ackman looked like he at least salvaged something out of the mess  However  it soon found support on a trendline that I had pointed out went back nearly two decades   

Looking more closely  you can see how the  towel throw  timing related to the ultimate bottom 

In sum  the stock is up about 60  from where the Ackman capitulation took place  showing that even billionaires can make really regrettable decisions ",2017-07-14,Tim Knight,https://www.investing.com/analysis/after-the-towel-is-thrown-200201048,200201048
147510,369026,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 20 ,news,"Investing com   Canada stocks were higher after the close on Tuesday  as gains in the Materials  Industrials and Energy sectors led shares higher 
At the close in Toronto  the S P TSX Composite added 0 20  
The best performers of the session on the S P TSX Composite were  ProMetic Life Sciences Inc    TO PLI   which rose 25 00  or 0 300 points to trade at 1 500 at the close  Meanwhile   Toromont Industries Ltd    TO TIH  added 9 79  or 4 88 points to end at 54 75 and MacDonald Dettwiler and Associates Ltd  TO MDA  was up 5 05  or 3 30 points to 68 65 in late trade 
The worst performers of the session were Valeant Pharmaceuticals International Inc  TO VRX   which fell 6 64  or 1 18 points to trade at 16 58 at the close   Klondex Mines Ltd    TO KDX  declined 3 15  or 0 130 points to end at 4 000 and  Bombardier Inc   TO BBDb  was down 2 77  or 0 070 points to 2 460 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 581 to 518 and 115 ended unchanged 
Shares in Toromont Industries Ltd   TO TIH  rose to all time highs  up 9 79  or 4 88 to 54 75  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 5 83  to 12 75 a new 1 month low 
Gold Futures for December delivery was down 0 10  or 1 27 to  1314 03 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in October fell 0 41  or 0 19 to hit  46 38 a barrel  while the November Brent oil contract rose 0 45  or 0 23 to trade at  51 65 a barrel 
CAD USD was down 0 13  to 0 7985  while CAD EUR fell 0 06  to 0 6670 
The US Dollar Index Futures was up 0 12  at 92 28 ",2017-08-29,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade-sptsx-composite-up-020-523589,523589
147511,369027,BHC,Teva s migraine candidate fremanezumab shows significant treatment benefit in late stage study,news,A Phase 3 clinical trial  HALO  assessing Teva Pharmaceutical Industries   TEVA  22 1   fremanezumab for the prevention of migraine demonstrated its efficacy for all 25 primary and secondary analyses in both monthly and quarterly dosing regimens  The results were presented at the 18th Congress of the International Headache Society in Vancouver  Canada Patients with chronic migraine treated with fremanezumab experienced a statistically significant reduction in the number of migraine days of at least moderate severity compared to placebo   4 6 days  monthly    4 3 days  quarterly    2 5 days placebo  p 0 0001  Other endpoints included improvements in quality of life and health measures  less work productivity loss and significant reductions in impairment activity outside of work Previously  Teva s fremanezumab successful in late stage migraine study  U S  marketing application expected this year  shares up 1   May 31 Previously  Teva finally gets a new CEO  Sept  11 Now read ,2017-09-11,Seeking Alpha,https://www.investing.com/news/stock-market-news/tevas-migraine-candidate-fremanezumab-shows-significant-treatment-benefit-in-latestage-study-527499,527499
147512,369028,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 37 ,news,"Investing com   Canada stocks were higher after the close on Monday  as gains in the Healthcare  IT and Energy sectors led shares higher 
At the close in Toronto  the S P TSX Composite added 0 37  
The best performers of the session on the S P TSX Composite were  Tahoe Resources Inc   TO THO   which rose 33 74  or 1 92 points to trade at 7 61 at the close  Meanwhile   Cascades Inc    TO CAS  added 5 82  or 0 82 points to end at 14 92 and Valeant Pharmaceuticals International Inc  TO VRX  was up 4 18  or 0 69 points to 17 21 in late trade 
The worst performers of the session were  Alamos Gold Inc   TO AGI   which fell 16 10  or 1 65 points to trade at 8 60 at the close   Alacer Gold  Corp  TO ASR  declined 7 56  or 0 170 points to end at 2 080 and  Novagold Resources Inc    TO NG  was down 7 44  or 0 41 points to 5 10 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 610 to 487 and 125 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 60 83  to 4 63 a new 6 months low 
Gold Futures for December delivery was down 1 45  or 19 53 to  1331 67 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in October rose 1 16  or 0 55 to hit  48 03 a barrel  while the November Brent oil contract fell 0 02  or 0 01 to trade at  53 77 a barrel 
CAD USD was up 0 29  to 0 8249  while CAD EUR rose 0 99  to 0 6903 
The US Dollar Index Futures was up 0 69  at 91 94 ",2017-09-11,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade-sptsx-composite-up-037-527569,527569
147513,369029,BHC,Drug industry on tenterhooks as Maryland price gouging law nears,news,"By Deena Beasley  Reuters    As U S  consumer outrage grows over prescription drug prices  state authorities and patient advocates in Maryland are preparing to enforce the nation s first law designed to punish drugmaker price gouging   The state Attorney General s office said it will field complaints and investigate  unconscionable increases  in essential generic medicines when the closely watched law takes effect Oct  1  Drugmakers fear the Maryland law will embolden other states and are seeking a court injunction  Both sides made their arguments on Thursday before a U S  District Court judge in Baltimore  who could decide on an injunction in the coming days   Anticipating the law will survive the legal challenge  the Attorney General s office said it is working with health economists at Johns Hopkins University to identify price spikes  which are not made public by drugmakers  Patient advocacy groups are urging consumers to report increased costs for their medicines  Maryland Citizens  Health Initiative will add an option to report price gouging to its website   Pharmaceutical companies have so far dodged stricter federal oversight despite growing outrage over price hikes  Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX  raised the price of heart medications Isuprel by about 720 percent and Nitropress by 310 percent  after acquiring them in 2015  Mylan NV  O MYL  raised the price of its life saving EpiPen six fold between 2008 and 2016  But states  struggling to cover rising healthcare costs  are taking up the fight  At least 176 bills on pharmaceutical pricing and payment have been introduced this year in 36 states  according to the National Conference of State Legislatures   Maryland s law is the most aggressive legislation to be passed so far  and allows the state to levy fines and order a reversal of price increases  The Association for Accessible Medicines  a generic industry trade group that filed the lawsuit  argues that the law is unconstitutional because it does not define price gouging and amounts to intervention by an individual state in interstate commerce    The issue of drug pricing is a national issue     not something that should be handled piecemeal in 50 different ways   said Jeff Francer  general counsel for the trade group which represents companies like Teva Pharmaceutical  NYSE TEVA  Industries Ltd  TA TEVA  and  Novartis  AG s  S NOVN  Sandoz unit  Maryland Attorney General Brian Frosh said that states have a well defined role to play in policing  unconscionable  business activity against consumers  especially when they have no other recourse  He cited consumer contracts for telephone service  which are non negotiable   DEFINING GOUGING The measure applies only to older  off patent drugs  Generic copies of branded products  usually much cheaper than the originals  account for around 89 percent of U S  prescription volume  but only 26 percent of total drug spending  according to Quintiles IMS Holdings Inc  N Q    But price spikes on some critical treatments have hit consumers hard  The U S  Government Accountability Office last year found that 315 generic drugs more than doubled in price since 2010   Maryland s Frosh said the aim is to deter future steep increases  Before the law was passed  drugmakers had suggested setting a minimum increase of 100 percent as a threshold for investigation  but state officials feared that would incentivize price hikes up to that point  according to Frosh s office  Several states have passed laws requiring drugmakers to disclose price increases  but the Maryland law is one of a few drawing the most attention from the drug industry  Nevada has been sued by two industry trade groups after passing in June a law requiring diabetes drugmakers to justify price increases above a certain amount  Ohio voters next year will decide on a ballot measure requiring drugmakers to offer state groups the same discounts given to the federal Department of Veterans Affairs  A similar measure failed in California last year  but the state s legislature this week approved a drug pricing bill requiring drugmakers to justify price increases over 16 percent in a two year period  It now goes to the state s governor for a final decision  
 The states have decided to try and deal with this on their own   said David Gibbons an attorney at Hyman  Phelps   McNamara  which specializes in pharmaceutical and biotechnology companies ",2017-09-15,Reuters,https://www.investing.com/news/stock-market-news/drug-industry-on-tenterhooks-as-maryland-pricegouging-law-nears-529302,529302
147514,369030,BHC,FDA tentatively OKs Perrigo s generic Acanya,news,The FDA tentatively approves Perrigo s  PRGO  0 6   generic version of Valeant Pharmaceuticals   VRX  0 6   acne treatment ACANYA  clindamycin phosphate and benzoyl peroxide  Gel Tentative approval means that Perrigo s marketing application meets the standards for approval  but patent issues need to be resolved  although the company says it settled litigation with Valeant and Dow Pharmaceutical Services Now read ,2017-09-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-tentatively-oks-perrigos-generic-acanya-529986,529986
147516,369032,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 06 ,news,"Investing com   Canada stocks were higher after the close on Thursday  as gains in the IT  Materials and Utilities sectors led shares higher 
At the close in Toronto  the S P TSX Composite rose 0 06  to hit a new 3 months high 
The best performers of the session on the S P TSX Composite were BlackBerry Ltd  TO BB   which rose 12 75  or 1 47 points to trade at 13 00 at the close  Meanwhile   Superior Plus Corp   TO SPB  added 6 05  or 0 71 points to end at 12 45 and  HudBay Minerals  Inc   TO HBM  was up 5 89  or 0 52 points to 9 35 in late trade 
The worst performers of the session were  DHX Media Ltd  B  TO DHXb   which fell 16 11  or 0 97 points to trade at 5 05 at the close  Valeant Pharmaceuticals International Inc  TO VRX  declined 4 84  or 0 87 points to end at 17 09 and Peyto Exploration Development Corp  TO PEY  was down 4 57  or 0 99 points to 20 66 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 720 to 384 and 132 ended unchanged 
Shares in DHX Media Ltd B  TO DHXb  fell to 3 years lows  down 16 11  or 0 97 to 5 05  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 14 80  to 12 33 
Gold Futures for December delivery was up 0 19  or 2 39 to  1290 19 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in November fell 1 07  or 0 56 to hit  51 58 a barrel  while the December Brent oil contract fell 0 57  or 0 33 to trade at  57 24 a barrel 
CAD USD was up 0 05  to 0 8042  while CAD EUR rose 0 01  to 0 6825 
The US Dollar Index Futures was down 0 30  at 92 99 ",2017-09-28,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade-sptsx-composite-up-006-534378,534378
147521,369037,BHC,Astrazeneca  AZN  Gets Positive CHMP Opinion For Brodalumab,opinion,"Astrazeneca  LON AZN  PLC   NYSE AZN   and its partner LEO Pharma received a positive opinion from the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA   The Committee recommended the approval of brodalumab for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy  We note that the CHMP s positive opinion on brodalumab will be reviewed by the European Commission 
Brodalumab is a human monoclonal antibody that binds to the interleukin 17  IL 17  receptor and inhibits inflammatory signaling by blocking the binding of several types of IL 17 to the receptor  Also  it prevents the body from receiving signals that may lead to inflammation 
Astrazeneca s shares are up 24  year to date  comparing favorably with an increase of 8 6  witnessed by the Zacks classified Large Cap Pharma industry 

Notably  the recommendation follows the FDA approval received in Feb 2017 and the approval by the Japanese Pharmaceuticals and Medical Devices Agency  in 2016  In Feb 2017  Astrazeneca and its partner Valeant Pharmaceuticals   NYSE VRX   received approval for brodalumab under the brand name Siliq injection for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies 
In fact  LEO Pharma has exclusive rights to develop and commercialize brodalumab in Europe  Additionally  Valeant Pharmaceuticals has the exclusive license to develop and commercialize the antibody  except in Europe  Japan and certain other Asian countries where rights are held by Kyowa Hakko Kirin Co   Ltd through an agreement with Amgen   NASDAQ AMGN   Astrazeneca PLC Price   Zacks Rank   Stocks to Consider
Astrazeneca currently has a Zacks Rank  3  Hold   A better ranked stock in the health care sector includes VIVUS  Inc    NASDAQ VVUS   sporting a Zacks Rank  1  Strong Buy   You can see  
VIVUS  loss per share estimates narrowed from 50 cents to 39 cents for 2017 over the last 60 days  The company posted positive earnings surprises in all of the four trailing quarters  with an average beat of 233 69  
Zacks  2017 IPO Watch List
Before looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time  One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ",2017-05-22,Zacks Investment Research,https://www.investing.com/analysis/astrazeneca-(azn)-gets-positive-chmp-opinion-for-brodalumab-200190675,200190675
147522,369038,BHC,Valeant completes sale of iNova Pharma netting  920M in cash,news,Valeant Pharmaceuticals  NYSE VRX  completes the sale of iNova Pharmaceuticals to a company jointly owned by Pacific Equity Partners and The  Carlyle Group   NASDAQ CG  for  930M  Net proceeds of   920M will be used to pay down debt The company says revenue and non GAAP EBITDA from iNova in Q4 would have been  65M and  35M  respectively Previously  Valeant divests iNova Pharmaceuticals unit for  930M in cash  shares ahead 5  premarket  June 8 Now read ,2017-09-29,Seeking Alpha,https://www.investing.com/news/stock-market-news/valeant-completes-sale-of-inova-pharma-netting-920m-in-cash-534594,534594
147523,369039,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 11 ,news,"Investing com   Canada stocks were higher after the close on Friday  as gains in the Healthcare  IT and Clean Technology sectors led shares higher 
At the close in Toronto  the S P TSX Composite rose 0 11  to hit a new 3 months high 
The best performers of the session on the S P TSX Composite were BlackBerry Ltd  TO BB   which rose 7 31  or 0 95 points to trade at 13 95 at the close  Meanwhile  Valeant Pharmaceuticals International Inc  TO VRX  added 4 62  or 0 79 points to end at 17 88 and  DHX Media Ltd  B  TO DHXb  was up 3 56  or 0 18 points to 5 23 in late trade 
The worst performers of the session were  IAMGold  Corporation  TO IMG   which fell 7 96  or 0 660 points to trade at 7 630 at the close   Norbord Inc   TO OSB  declined 7 53  or 3 87 points to end at 47 51 and Eldorado Gold Corporation  TO ELD  was down 4 20  or 0 12 points to 2 74 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 678 to 450 and 135 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 13 94  to 10 74 
Gold Futures for December delivery was down 0 48  or 6 15 to  1282 55 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in November rose 0 06  or 0 03 to hit  51 59 a barrel  while the December Brent oil contract fell 0 82  or 0 47 to trade at  56 69 a barrel 
CAD USD was down 0 48  to 0 8015  while CAD EUR fell 0 70  to 0 6780 
The US Dollar Index Futures was down 0 06  at 92 89 ",2017-09-29,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade-sptsx-composite-up-011-534834,534834
147526,369042,BHC,Here s Why Mallinckrodt  MNK  Shares Are Lower Today,opinion,"On Monday  shares of pharmaceutical company Mallinckrodt Plc    NYSE MNK   are slipping  down about 5  to  40 50 per share in afternoon trading MNK dropped about 8  in heavy morning trading after a  from short seller Citron Research targeted the company 
Citron s report focused on Mallinckrodt s key drug H P  Acthar Gel  which can be used for many types of diseases including multiple sclerosis  dermatological diseases  and respiratory diseases  But due to huge price increases over the years  Acthar s price tag comes in at almost  40 000 a vial  the drug brings in over  1 billion in revenue for Mallinckrodt 
The report goes on to reference comments made by Everett Neville  pharmacy benefits manager Express Scripts    NASDAQ ESRX   Senior Vice President  Supply Chain and Specialty  who criticized Acthar   I don t think it s a very great   it s a pretty poor drug with a very limited need   he said on a call hosted by Citigroup  NYSE C  analysts  Interestingly  Express Scripts is the sole distributor of Acthar 
 Express Scripts has FINALLY changed its stance on Acthar and the effect will send shares of Mallinckrodt to ZERO   the report claimed   The words of Express Scripts management will echo through the halls of Medicare and insurance companies as Acthar has finally met the truth  it is an old drug that is way too expensive and not as good as its competition  
This is not new behavior for Citron  who has targeted both Mallinckrodt and Express Scripts in the past  comparing the former to Valeant   NYSE VRX   and the latter to Philidor Rx Services 
MNK stock is down over 14  year to date  and is a  3  Hold  on the Zacks Rank 
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon  electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2017-06-05,Zacks Investment Research,https://www.investing.com/analysis/here's-why-mallinckrodt-(mnk)-shares-are-lower-today-200193298,200193298
147547,369063,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 26 ,news,"Investing com   Canada stocks were lower after the close on Wednesday  as losses in the Healthcare  IT and Clean Technology sectors led shares lower 
At the close in Toronto  the S P TSX Composite declined 0 26  
The best performers of the session on the S P TSX Composite were  Semafo Inc    TO SMF   which rose 18 08  or 0 49 points to trade at 3 20 at the close  Meanwhile   Stantec  Inc   TO STN  added 9 38  or 2 95 points to end at 34 40 and  Finning International Inc    TO FTT  was up 8 94  or 2 31 points to 28 16 in late trade 
The worst performers of the session were  Kinaxis Inc   TO KXS   which fell 16 55  or 13 19 points to trade at 66 50 at the close  Valeant Pharmaceuticals International Inc  TO VRX  declined 9 57  or 1 89 points to end at 17 85 and  Ritchie Bros  Auctioneers Inc    TO RBA  was down 5 65  or 2 120 points to 35 420 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 748 to 373 and 124 ended unchanged 
Shares in Finning International Inc   TO FTT  rose to 52 week highs  gaining 8 94  or 2 31 to 28 16  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 0 40  to 12 57 
Gold Futures for December delivery was up 1 53  or 19 33 to  1281 93 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in September rose 0 85  or 0 42 to hit  49 59 a barrel  while the October Brent oil contract rose 1 13  or 0 59 to trade at  52 73 a barrel 
CAD USD was down 0 32  to 0 7869  while CAD EUR fell 0 27  to 0 6696 
The US Dollar Index Futures was down 0 07  at 93 41 ",2017-08-09,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade-sptsx-composite-down-026-516722,516722
147548,369064,BHC,Valeant s success at fixing Tampa manufacturing issues a plus for Aerie Pharma,news,Aerie Pharmaceuticals  NASDAQ AERI  was up 4  after hours yesterday  no premarket trades have been reported yet  on the news that Valeant Pharmaceuticals  NYSE VRX  has finally fixed the manufacturing problems at its Bausch   Lomb site in Tampa  FL The development is a positive for Aerie because Rhopressa  netarsudil ophthalmic solution  is manufactured there  Valeant s success is timely  Aerie s U S  marketing application is currently under FDA review with an action date of February 28  2018 Previously  FDA sets action date of February 28  2018 for Rhopressa NDA  May 15 Previously  FDA OK with Valeant s B   L site in Florida  overhang removed from regulatory submissions  shares ahead 1  after hours  Aug  16 Now read ,2017-08-17,Seeking Alpha,https://www.investing.com/news/stock-market-news/valeants-success-at-fixing-tampa-manufacturing-issues-a-plus-for-aerie-pharma-519653,519653
147549,369065,BHC,Valeant up 4  on resolution of manufacturing issues at Tampa site,news,Valeant Pharmaceuticals  VRX  3 7   is up in early trading on the heels of its announcement that it has resolved the manufacturing issues at its B   L site in Tampa  FL Previously  FDA OK with Valeant s B   L site in Florida  overhang removed from regulatory submissions  shares ahead 1  after hours  Aug  16 Now read ,2017-08-17,Seeking Alpha,https://www.investing.com/news/stock-market-news/valeant-up-4-on-resolution-of-manufacturing-issues-at-tampa-site-519723,519723
147550,369066,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 13 ,news,"Investing com   Canada stocks were lower after the close on Friday  as losses in the IT  Healthcare and Consumer Staples sectors led shares lower 
At the close in Toronto  the S P TSX Composite fell 0 13  
The best performers of the session on the S P TSX Composite were  Aecon Group Inc    TO ARE   which rose 20 22  or 2 90 points to trade at 17 24 at the close  Meanwhile  Hudson s Bay Company  TO HBC  added 14 16  or 1 42 points to end at 11 45 and  ProMetic Life Sciences Inc    TO PLI  was up 6 90  or 0 080 points to 1 240 in late trade 
The worst performers of the session were  Tahoe Resources Inc   TO THO   which fell 18 66  or 1 28 points to trade at 5 58 at the close  Valeant Pharmaceuticals International Inc  TO VRX  declined 4 45  or 0 82 points to end at 17 62 and Element Fleet Management Corp  TO EFN  was down 4 03  or 0 37 points to 8 82 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 611 to 418 and 174 ended unchanged 
Shares in Tahoe Resources Inc  TO THO  fell to all time lows  falling 18 66  or 1 28 to 5 58  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 2 73  to 12 46 
Gold Futures for December delivery was up 0 33  or 4 27 to  1296 27 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in October rose 0 78  or 0 37 to hit  47 80 a barrel  while the October Brent oil contract rose 0 63  or 0 33 to trade at  52 37 a barrel 
CAD USD was up 0 33  to 0 8012  while CAD EUR fell 0 71  to 0 6720 
The US Dollar Index Futures was down 0 82  at 92 47 ",2017-08-25,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade-sptsx-composite-down-013-522637,522637
147551,369067,BHC,Premarket analyst action   healthcare,news,DarioHealth  NASDAQ DRIO  initiated with Buy rating and  3 50  75  upside  price target by Aegis Capital AveXis  NASDAQ AVXS  initiated with Reduce rating and  52  46  downside risk  price target by Instinet  Shares are down 3  premarket on light volume Juno Therapeutics  NASDAQ JUNO  upgraded to Outperform by Raymond James  Upgraded to Outperform by Wedbush  Shares are up 1  premarket on light volume Loxo Oncology  NASDAQ LOXO  downgraded to Market Perform by JMP Securities Valeant Pharmaceuticals  NYSE VRX  price target lowered to  7  51  downside risk  by Mizuho Securities  Shares are down 1  premarket on light volume Source  BloombergNow read ,2017-08-29,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-analyst-action--healthcare-523399,523399
147552,369068,BHC,Healthcare   Top 5 Gainers   Losers as of 11 00 am,news,Gainers  RNN  23   JUNO  16  IMGN  15   CTLT  14   PRQR  10  Losers  ACOR  27   TNDM  12   VRX  9   MESO  7   AKAO  6  Now read ,2017-08-29,Seeking Alpha,https://www.investing.com/news/stock-market-news/healthcare--top-5-gainers--losers-as-of-1100-am-523470,523470
147558,369074,BHC,Will Valeant Recover Or Go To Zero ,opinion,"In some cases  a stock crashes due to circumstances beyond its control  Valeant Pharmaceuticals  NYSE VRX  is not one of those cases  Valeant stock is edging toward zero and most of the investing public understands why 
In 2016  a scandal came out of Valeant that rocked the pharmaceutical world  The conglomerate had participated in a series of extremely unethical price rigging schemes for important drugs  It also apparently maintained  pay to play  relationships with several specialty pharmacies    another giant ethical no no 
As a result  Valeant stock is down almost 85  in the last year 

On the other hand  when companies are in this bad shape  one of two things can happen  They can go under    or they can eventually recover  creating the ultimate contrarian buy opportunity 
We saw the latter scenario play out with Deutsche Bank  NYSE DB   NYSE  DB  in the last year  Most analysts left the stock for dead after its Brexit troubles in mid 2016  But it survived and recovered  handing incredible gains to investors who bought the bottom 
Thus  in this crisis period for Valeant stock  Investment U readers are wondering    what are its prospects for recovery  Is the scandalized pharmaceutical company a good contrarian buy 
To find out  we ran Valeant stock through the Investment U Fundamental Factor Test   As a reminder  our checklist looks at six key metrics to diagnose the financial health of a stock  
Earnings per Share   EPS  Growth  Valeant stock is off to a spectacularly bad start in our analysis  The pharmaceutical industry generally manages healthy earnings growth   averaging 46 79  in the last year  Valeant s earnings growth rate over the same period is  524   It s gone below zero 
Price to Earnings   P E   And since Valeant stock s earnings are now in the negatives  we can t calculate a P E ratio  Strike two 
Debt to Equity  Once again  Valeant does nonsensically bad on this metric  Its debt to equity ratio is a whopping 712 40   Its competitors have a reasonable average debt burden of 49 97  
Free cash flow per share growth  FCF  As a whole  pharmaceutical companies are quite cash rich right now  The average firm in the space has grown free cash flow per share by 89 90  in the last year  Valeant has seen it sink  28 06  
Profit Margins  In case it wasn t clear already  Valeant is bleeding money right now  Its profit margin of  49 14  is well below the industry average of 19 56  
Return on Equity  In our last metric    Valeant is still failing  Early stage investors have lost  42 45  on their Valeant equity in the last year  By contrast  the pharma industry has been kind to most investors  handing them an average gain of 17 90  
As you can see  Valeant stock got shut out on all six key metrics  Earnings  valuation  debt  cash flow  profits  returns   no matter what you look at  Valeant is below average 
At least from a fundamental analysis perspective  it seems safe to say that Valeant stock is irredeemable 
Granted  we can t guarantee that it won t recover  Crazier things have happened  But not even Deutsche Bank was this far gone  The prospects for Valeant getting out of this are pretty limited 
For these reasons  Valeant stock has earned a grade of F  Get rid of it if you haven t already 
Fundamental Factor Test Score
F  Sell  One key metric or less ",2017-02-08,Investment U,https://www.investing.com/analysis/will-valeant-recover-or-go-to-zero-200175102,200175102
147559,369075,BHC,Prince Valeant,opinion,"It s said that Bill Ackman holds some 12 million shares of Valeant Pharmaceuticals  NYSE VRX   though at much higher prices 
Valeant s major trend line break means there is essentially no limit to how low this stock can go 

The good news is that analysts once again totally earned their seven figure salaries by helping investors near and far avoid this debacle with their spot on  short every share you can get  rating 
Just Kidding",2017-03-07,Tim Knight,https://www.investing.com/analysis/prince-valeant-200178096,200178096
147560,369076,BHC,Fanaticism  2017 Crash 2017 Or More Bull Market,opinion,"A fanatic is a man that does what he thinks the Lord would do if He knew the facts of the case 

   Finley Peter Dunne
Not too long ago this bull market was one of the most hated in history  that no longer appears to be the case  Throughout the unpopular phase of this bull market  we consistently and much to the dismay of many penguins  oops we mean experts  stated that every pullback should have been treated as a buying opportunity  There were two reasons for this  market sentiment was consistently negative  and the trend was up 
We even penned an article before Trump won stating that a Trump win like Brexit would prove to be a buying opportunity  As expected after the initial panic of having to deal with A Trump Presidency  the markets recouped their losses and never looked back  We were so bullish that on De 15  2016 we provided our subscribers with the path we expected the Dow to take in 2017 

To be fair  we expected the markets to let out some steam as indicated the chart above  but the Dow only hesitated at 20 000 for a bit before surging like a rocket  Many experts were predicting the end of this bull at that time  some of which had for the most part been on the right side of the market  A stock market crash is not something we were ready for  and we voiced this sentiment in several articles in late 2016 and in Jan  and Feb  of this year  We were waiting for a pullback as the sentiment at the time  Dec  2016  had turned quite bullish  Long story short  our targets have been hit and they have been hit a lot faster than we expected  One would almost be tempted to state that we are in the feeding frenzy stage which usually represents the last stage of a Bull Market  However  the crowd is not euphoric  so this would rule that option out at least for now  So what s going on  Well  it appears to be fanaticism or madness  The markets are operating out of the realm of reality 
Fanaticism is a different emotion from euphoria  it is a form of madness  and it is hard to analyze an insane person as there is no discernible pattern  at least not immediately  History is not replete with such situations  so we need to spot these new patterns in real time  This emotion does not expire as fast as Euphoria or Fear  it can be maintained for a prolonged period  Thus  when one encounters it  the safest play is to take a defensive position  Assume the outlook is worse than it is  but without letting the panic factor seep into the equation 
The data is twisted  on the one hand  the sentiment is far from Bullish  but on the other hand  more money is flowing into the markets  and our indicators are now in the extremely overbought ranges on the long term weekly and monthly charts  Just because the outlook is different does not mean we need to start becoming anxious  Panic is not something we favor or look kindly at  panic is a useless emotion  One has to be prudent when it comes to the markets  and we have been right on the money regarding this bull market for a long time  We do not want to let arrogance take over  common sense which we value highly dictates that caution  and not fear is warranted  Thus  prudent traders would do well to tighten their stops and if committing new funds  look for companies that are selling at a huge discount or trading in the extremely oversold ranges  If the markets pull back suddenly your risk will be limited 
This market will pullback  however  no one call tell it when to pull back especially when the primary emotion driving this market is fanaticism  It is relatively easy to determine a market s trajectory if the emotion is euphoria or fear  but fanaticism is something different  As stated it is a form of madness and insanity is not easy to spot  especially if it is in stealth mode 
We are not going to pen another thousand words telling you why this stock market should crash or soar or anything like that  The bottom line is the market does not care about what if scenarios  What if scenarios are for people that have too much time on their hands to talk about useless concepts that most likely will not come to pass  Let s deal with reality
Let s first take a look at the data 
Polarization is spreading or contaminating the bullish and bearish camps  It has been a long time since we have the sentiment so evenly divided between the two camps  This week exactly 37  are bullish  and exactly 37  are bearish  with 26  falling in the neutral camp  One would normally expect the bullish sentiment to soar through the roof  euphoria is clearly not gripping the market  and neither is panic  When we combine the bears with the individuals from the neutral camp  we arrive at a figure of 63   The masses appear to be uneasy  the key word is  appear  for insanity is operating in stealth mode for now 

We spotted traces of fanaticism late last year  and that is why we briefly addressed this topic in late Dec  of 2016 and early January  The trend is gathering in intensity  and it could be with us or for some time  If this trend picks up  then this bull market could last longer than the most ardent of bulls ever envisioned  but there will be at least one correction that will break the backs of almost all the bulls and make the bears believe that a new bear market has started  Sadly  both of these chaps will be wrong  A stock market crash  a bear market  etc  all come down to perception as is the case with the truth or a lie  Alter the angle of observance and the perception changes  it all depends on when you got into the market or out of it 

Our proprietary anxiety index is also getting infected with the polarization flu  it is sitting right at the 50  mark  These are all subtle clues that something new is taking place in the background  Trend investing comes down to identifying the primary trend  it does not mean that the market cannot and will not pull back while it is an uptrend  In the long run the market tends to revert to the mean  currently  the market is trading almost two standard deviations from the mean  Thus regardless of the trend  one of the two things needs to happen


Our indicators pullback into the oversold ranges  preferably the extremely oversold ranges  Currently  they are trading in the extremely overbought ranges on the weekly charts and overbought ranges on the monthly charts


A sharp correction that drives many bulls to join hands with the Bears  A long term bull market has to experience one back breaking correction  We do not know when this will occur  but the sooner  the better as  the higher it trades  the more painful the correction will be especially for those that embraced this bull market very late in the cycle


Ideally  both of the above occur simultaneously  and at that point  one could start conjuring images of Dow 24K  To do this  the above two need to occur simultaneously 
Shockingly  V readings have surged a whopping 100 points in just two days  In just one week they have moved 160 points  a new three day record and a new record  What can we say  expect what will appear to be chaos regarding human emotions  weather  politics and market movements  However  remember there is no such thing as true chaos as chaos has a pattern  Thus embrace this development for we are trend players and not chickens that squawk the moment we smell change  For the umpteenth  we are going to raise all the overbought and extreme ranges as V readings show no sign of letting up  If you look at the reading going back to Dec 16  2009  you can see how insanely high this indicator is trading  Note that when we launched this indicator  readings were in the 300 ranges  This further cements the argument that the central driving theme in the world  and not just the U S  is going to be to  polarize the masses   Do not become part of the crowd for they are going to go insane and lose a lot in the process  you  on the other hand  could stand to benefit tremendously provided you do not lose control  Market Update Feb  20  2017
The crowd has gone insane at least when it come to the markets  Remember  that the mass mindset does not refer to just the small players  Hedge fund managers and even big players are all part of the mass mentality  Look at Bill Ackman  he finally conceded defeat and sold his position in Valeant Pharmaceuticals  NYSE VRX  at what could very well turn out to be the bottom  Would it not have made sense to sell it earlier  why now  when the stock is trading close to the levels it was trading in 2005 well before it took off   a classic example of the mass mindset in action  buying when you should have been selling and selling when buying probably makes more sense 
Individuals falsely assume that big hedge funds or mutual funds cannot be part of the mass mindset  Some of the biggest players are nothing but cattle  they just give the impression that they know what they are doing  but in the end  they are just following each other to the Promised Land  which usually turns out to be den full of vipers  Insanity  madness  is a very powerful force  never underestimate it 
Conclusion
As insanity is the main driving force  caution is called for  and we are going to change our tactics  At this point  the Markets are trading in the extremely overbought ranges on both the weekly and monthly charts  We are not stating that the markets are going to crash or that they need to crash  What we are stating is that common sense says that an old bull market such as this one needs to let out a healthy dose of steam  At this point  the risk to reward ratio is not strongly in our favor  We still view substantial pullbacks as buying opportunities unless the trend changes  but the pullback would have to sharp in nature 

A fanatic is one who can t change his mind and won t change the subject 

   Winston Churchill",2017-03-15,Sol Palha,"https://www.investing.com/analysis/fanaticism,-2017-crash-2017-or-more-bull-market-200179037",200179037
147561,369077,BHC,The Valeant Disaster And Why I Switched To Trend Following ,opinion,"Valeant Pharmaceuticals  NYSE VRX  is a great example of why I switched my trading philosophy to trend following from an approach that more heavily used fundamental analysis  I ve found over the years that big problems in either an individual stock or and index of stocks are hard to diagnose and determine the best course of action using pure fundamental analysis  Often you find that buying a dip in an emerging bear market can lead to disaster and big losses  Trend following using stage analysis provides simple rules that can be followed to avoid big downtrends whether they are in an individual stock or an index of stocks 
Find the video below ",2017-03-17,Justin Smyth,https://www.investing.com/analysis/the-valeant-disaster-and-why-i-switched-to-trend-following-200179236,200179236
147562,369078,BHC,Valeant  VRX  Q1 Earnings   Revenues Miss  View Raised,opinion,"Shares of Valeant Pharmaceuticals Inc    NYSE VRX   surged significantly after the company raised the annual guidance for 2017 concurrent with the first quarter 2017 earnings 

 
We note that the shares of Valeant have underperformed the Zacks classified  industry in the last year  The stock lost 12  as compared to the industry s gain of 5 5  
The company s adjusted earnings per share of 78 cents missed the Zacks Consensus Estimate of 96 cents 
However  total revenue came in at  2 10 billion missing the Zacks Consensus Estimate of  2 16 billion and declined 11  from the year ago quarter  The year over year decline was due to lower volumes in the U S  Diversified Products and Branded Rx segments as a result of the loss of exclusivity for a number of products and challenging market dynamics  Revenues were also negatively affected by foreign currencies  divestitures and discontinuations  and a modest decrease in average realized pricing 
Quarter in Detail
Revenues in the Bausch   Lomb   International segment were  1 15 billion  up 0 3  year over year driven by increases in international volumes  particularly in Europe  the Middle East  South Africa  Asia and Australia which were partially offset by declines in volumes in the U S 
Average realized pricing across the segment increased mainly from the international business units  However  volume and pricing gains were partially offset by the unfavorable impact of foreign currency and the impact of divestitures and discontinuations 
Revenues in the Branded Rx segment were  604 million  down 9  in the year ago quarter mainly due to decreased volumes in the dermatology and Salix business units due to the loss of exclusivity of certain product lines  continued generic competition and the impact of an increase in the prevalence of high deductible medical plans 
Nevertheless  pricing improved in the dermatology business  driven by lower customer subsidies and accommodations and higher wholesaler selling prices  The Salix business benefited from higher wholesale selling prices and favorable chargeback  These increases were partially offset by higher managed care rebates particularly in the dermatology business 
Revenues in the U S  Diversified Products segment were  355 million  a decline of 37  year over year due to a decrease in volume and lower average realized prices which in turn were attributed to loss of exclusivity for products in the segment 
Research and development expenses were  96 million in the reported quarter  down 6 8  from the year ago quarter 
Selling  General and Administrative costs were  661 million compared with  813 million in the year ago quarter 
During the quarter  the company reduced debt by  1 3 billion  On a cumulative basis  the company reduced total debt by  3 6 billion since the end of the first quarter of 2016  Moreover  the company completed more than  1 3 billion in asset sales  including the earlier than expected closure of the sale of the CeraVe  AcneFree and AMBI skincare brands  
On a positive note  the FDA approved its new psoriasis treatment  Siliq  The company also resubmitted its glaucoma treatment  Vyzulta  latanoprostene bunod  in Feb 2017 and the FDA granted a PDUFA date of Aug 24  Meanwhile  the company completed two successful phase III studies on IDP 118  a topical psoriasis treatment  The company recruited and launched a new primary care sales force for Xifaxan  The company also licensed EGP 437 from EyeGate Pharmaceuticals for a new eye care indication 
2017 Guidance    
The company continues to expect total revenue in the range of  8 90  9 10 billion but raised its guidance for adjusted EBITDA by  50 million  The company will close the sale of Dendreon to Sanpower Group for  819 9 million in mid 2017  The company plans to use the proceeds from the divestiture to pay down its high levels of debt 
Our Take
Although first quarter results missed estimates  the company raised its guidance for EBITDA  After a tumultuous period  Valeant started a rebuilding process with its new CEO  Joseph C  Papa  Even though it is still early to comment on the rebuilding process  but the company s efforts to sell non core assets and pay down huge levels of debt is commendable and should bode well in the upcoming quarters  The company still has  28 5 billion of debt as of Mar 31  2017 
The dermatology business saw some positive trends as the average selling price stabilized  The GI business continues to struggle with weak sales of Xifaxan  However  the drug should see gain in market share with an increased sales force 
Zacks Rank   Key Picks
Valeant currently carries a Zacks Rank  3  Hold  
Some better ranked stocks in the health care sector are Infinity Pharmaceuticals  Inc    NASDAQ INFI    Galena Biopharma  Inc    NASDAQ GALE   and BioTime  Inc    NYSE BTX    While Galena sports a Zacks Rank  1  Strong Buy   BioTime and Infinity carry a Zacks Rank  2  Buy   You can see  
Infinity s loss per share estimates narrowed from  1 43 to  1 03 and from  1 75 to  1 52 for 2017 and 2018  respectively over the last 60 days  The company posted positive earnings surprises in three of the four trailing quarters  with an average beat of 36 64  
Galena s loss per share estimates narrowed from  2 03 to 58 cents for 2017 over the last 60 days  The company posted positive earnings surprises in two of the four trailing quarters  with an average beat of 53 83  
BioTime s loss per share estimates narrowed 60 9  to 18 cents for 2017 over the last 60 days  The company posted a positive earnings surprise in two of the four trailing quarters with an average beat of 12 32  
Looking for Ideas with Even Greater Upside 
Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ",2017-05-10,Zacks Investment Research,"https://www.investing.com/analysis/valeant-(vrx)-q1-earnings---revenues-miss,-view-raised-200188407",200188407
147572,369088,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 47 ,news,"Investing com   Canada stocks were higher after the close on Thursday  as gains in the Healthcare  Materials and IT sectors led shares higher 
At the close in Toronto  the S P TSX Composite rose 0 47  
The best performers of the session on the S P TSX Composite were  Home Capital Group Inc    TO HCG   which rose 27 18  or 4 06 points to trade at 19 00 at the close  Meanwhile  Valeant Pharmaceuticals International Inc  TO VRX  added 12 57  or 2 29 points to end at 20 51 and  Genworth MI Canada Inc    TO MIC  was up 11 54  or 3 84 points to 37 11 in late trade 
The worst performers of the session were  Klondex Mines Ltd    TO KDX   which fell 7 30  or 0 360 points to trade at 4 570 at the close   Bombardier Inc   TO BBDb  declined 3 63  or 0 090 points to end at 2 390 and  Ritchie Bros  Auctioneers Inc    TO RBA  was down 3 29  or 1 250 points to 36 800 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 667 to 449 and 132 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 17 81  to 13 03 
Gold Futures for August delivery was up 0 46  or 5 69 to  1251 49 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in August rose 0 47  or 0 20 to hit  42 73 a barrel  while the August Brent oil contract rose 0 89  or 0 40 to trade at  45 22 a barrel 
CAD USD was up 0 77  to 0 7557  while CAD EUR rose 0 94  to 0 6777 
The US Dollar Index Futures was up 0 03  at 97 25 ",2017-06-22,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.47-498430,498430
147573,369089,BHC,Optimism over potential debt equity swap fueling buying in Valeant   Evercore ISI  shares up 9 ,news,Evercore ISI s Umer Raffat says the rebound in Valeant Pharmaceuticals  VRX  8 9   is being largely driven by speculation that the company will execute some level of debt equity swap as a means to cut its mountain of debt  almost  29B at the end of Q1 Mr  Raffat says the possibility of a swap further reduces the odds that the equity will be worth nothing  If EBITDA can consistently cover more than just debt service  then it bodes well for price stability appreciation Now read ,2017-06-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/optimism-over-potential-debt-equity-swap-fueling-buying-in-valeant---evercore-isi;-shares-up-9-499346,499346
147574,369090,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 02 ,news,"Investing com   Canada stocks were lower after the close on Monday  as losses in the Materials  Energy and Financials sectors led shares lower 
At the close in Toronto  the S P TSX Composite declined 0 02  
The best performers of the session on the S P TSX Composite were Valeant Pharmaceuticals International Inc  TO VRX   which rose 8 03  or 1 68 points to trade at 22 61 at the close  Meanwhile  BlackBerry Ltd  TO BB  added 5 68  or 0 73 points to end at 13 59 and Hudson s Bay Company  TO HBC  was up 4 34  or 0 49 points to 11 78 in late trade 
The worst performers of the session were  ShawCor Ltd    TO SCL   which fell 5 82  or 1 63 points to trade at 26 37 at the close   Home Capital Group Inc    TO HCG  declined 4 67  or 0 87 points to end at 17 74 and Element Fleet Management Corp  TO EFN  was down 3 67  or 0 33 points to 8 67 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 620 to 460 and 150 ended unchanged 
Shares in ShawCor Ltd   TO SCL  fell to 52 week lows  falling 5 82  or 1 63 to 26 37  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 30 09  to 8 62 
Gold Futures for August delivery was down 0 92  or 11 55 to  1244 85 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in August rose 0 93  or 0 40 to hit  43 41 a barrel  while the September Brent oil contract rose 0 72  or 0 33 to trade at  46 08 a barrel 
CAD USD was up 0 15  to 0 7548  while CAD EUR rose 0 25  to 0 6751 
The US Dollar Index Futures was up 0 13  at 97 11 ",2017-06-26,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-0.02-499404,499404
147575,369091,BHC,Short seller Cohodes hits Canada again with latest target  Exchange Income,news,By Jennifer Ablan and Alastair Sharp NEW YORK TORONTO  Reuters    Short seller Marc Cohodes  who has bet against the shares of six Canadian based companies including Valeant Pharmaceuticals International Inc  NYSE VRX  and Home Capital Group Inc  said on Wednesday that he is targeting yet another Canadian firm   Exchange Income Corp  Cohodes told Reuters that Exchange Income   a Winnipeg based company focused on opportunities in aerospace and aviation services and equipment  and manufacturing   does not generate enough cash to pay the juicy dividend it provides investors  Exchange Income Corp said in a statement that the report is based on a number of statements  assumptions and opinions with which  we strenuously disagree   Cohodes  targeting of Exchange is the latest in a string of moves against Canadian companies this year  adding to the short position in excavation company Badger Daylighting he made public in May  That same month U S  hedge fund Muddy Waters said it was short Asanko Gold   Short interest in Canada s biggest banks spiked late in 2015 and remained elevated until April this year as some investors took bets on the collapse of the country s housing market and that a rout in commodities markets would lead to a surge in bad loans  But those positions  along with record short bets against the Canadian dollar  have simmered down in recent months as prices for oil and copper have stabilized  moves by the government to cool sharp jumps in Toronto and Vancouver house prices take effect  and as the central bank turned hawkish  Cohodes said his focus on Canadian firms stems from his belief that there is no cohesive watchdog for nefarious company activity in the country  which lacks a federal regulator   Cohodes  who worked at a short selling hedge fund but now raises chickens in California and invests his own money  has also targeted Intertain Group Ltd  Concordia International Corp and Equitable Group Inc  Wendy Berman  a securities lawyer with Cassels Brock in Toronto  said the patchwork of provincial regulators can lead to spotty enforcement of lapses in corporate reporting   Without a national securities regulator  you don t have a national  enforcement  agenda  you have a local agenda  Berman said  adding that the provincial regulators vary in terms of their resources  experience and priorities  Efforts to create a national body have long been stymied by political bickering  with a cooperative body incorporating the federal government and those provinces that have agreed to sign up not due to launch until 2018  Exchange Income Corp shares fell as much as 10 percent to C 29 38 soon after the Reuters report  but pared losses and were last down 6 3 percent in early afternoon trade    They don t have the cash flow  earnings or any form of business to generate a dividend yet they call it Exchange Income   Cohodes said in a telephone interview  Exchange said it has maintained a consistent strategy since its inception in 2004  enabling it to grow profitably and return a reliable and growing dividend to its shareholders    Nothing has changed   the company said  adding that since 2004 it has paid shareholders C 300 million in dividends while maintaining a strong balance sheet with limited leverage  RECENT BETS PAID OFF Cohodes  recent bets have paid off with the collapse of Valeant and Concordia and to some extent Home Capital  which Cohodes considers the  highlight  of his year so far  until Warren Buffett s Berkshire Hathaway  NYSE BRKa  Inc last month agreed to make an equity infusion   Shortsellers have been profitable in Exchange Income so far this year   said Ihor Dusaniwsky  head of research at S3 Partners  adding that they made 14 75 percent  year to date  He said short sellers will fail to get significant short exposure in the stock because of the limited supply and as the cost to borrow the stock goes up  Cohodes declined to disclose the size of his EIC short positions  In November  Exchange Income announced that for the fourth time in the last 24 months  the company was increasing its dividend to an annualized rate of C 2 10  up 4 5 percent  Yet over the last five years  the company has increased its debt load by C 427 million and issued over C 230 million of shares to fund its C 700 million deficit  Cohodes said ,2017-07-05,Reuters,https://www.investing.com/news/stock-market-news/short-seller-cohodes-targets-yet-another-canadian-firm:-exchange-income-502252,502252
147577,369093,BHC,Valeant jettisons Obagi unit for  190M in cash  shares ahead 1  premarket,news,Valeant Pharmaceuticals  NYSE VRX  inks an agreement to sell its Obagi Medical Products business to Haitong International Zhonghua Finance Acquisition Fund I  L P  for  190M in cash The company says the skin care products maker would have contributed revenues and non GAAP EBITDA of  85M and  30M  respectively  to 2017 results The transaction should close in H2  Proceeds will be used to pay down debt Shares are up 1  premarket on light volume Now read ,2017-07-17,Seeking Alpha,https://www.investing.com/news/stock-market-news/valeant-jettisons-obagi-unit-for-$190m-in-cash;-shares-ahead-1-premarket-506246,506246
147579,369095,BHC,Democrats take aim at big companies in economic blueprint,news,"By Amanda Becker WASHINGTON  Reuters    U S  Democrats unveiled an economic platform on Monday that included plans to address unfair market competition  rising pharmaceuticals costs and stagnant wages  Democrats proposed new standards that companies must meet to complete large mergers and enhanced post merger reviews  singling out the airline  telecommunications  beer  food and eyeglass industries as areas of concern in the proposal dubbed  A Better Deal  for working Americans   Last year  Republicans proposed legislative goals with a similar title   A Better Way   The Democrats  platform is a move to regroup ahead of the 2018 midterm congressional elections  after Hillary Clinton s loss to Republican President Donald Trump in 2016  Republicans control both the House and the Senate  Senator Chuck Schumer  the top Democrat in the U S  Senate  accused Trump of running a populist election campaign and then abandoning working people for special interests once in the White House   We can t delude anyone that this Congress will begin passing our priorities tomorrow but we have to start presenting our vision for the country s future   Schumer said at a kickoff event in the town of Berryville  Virginia  Accompanying Schumer was House Minority Leader Nancy Pelosi  Senators Elizabeth Warren  Chris Van Hollen and Amy Klobuchar  and Representatives Hakeem Jeffries and David Cicilline  among others  Democrats want to create an independent government agency that would crack down on drug companies that raise prices excessively  They also want to allow Medicare  the government health insurance program for the elderly  to negotiate prices with manufacturers  Additionally  drug companies would need to justify big price hikes to the government  Policy proposals provided to reporters singled out a few companies by name  including Turing Pharmaceuticals and Valeant Pharmaceuticals International Inc  NYSE VRX   One document criticized United Continental Holdings Inc for the  brutal assault  of a United passenger who was already seated on an overbooked flight and refused to give up his seat for a crew member   Separately  if AT T  NYSE T  Inc s purchase of  Time Warner  Inc  NYSE TWX  succeeds  it would allow the  resulting behemoths  to  unfairly discriminate  against smaller distributors  one document stated  When Anheuser Busch InBev  the world s largest beer maker  purchased SABMiller  LON SAB   the second largest beer company  it put smaller brewers at a disadvantage  the documents said  Mergers between  Dow Chemical   NYSE DOW  Co and DuPont  NYSE DD    Monsanto   NYSE MON  Co with  Bayer AG   DE BAYGN  and  Syngenta  AG  SIX SYNN  with ChemChina  threaten the safety of food and agriculture in America   one document said  
Democrats will also propose doubling federal support for apprenticeship programs  a tax credit for employers that hire and train workers that make a liveable wage  and encouraging partnerships between companies and public high schools and community colleges ",2017-07-24,Reuters,https://www.investing.com/news/economy-news/democrats-take-aim-at-big-companies-in-economic-blueprint-508921,508921
147583,369099,BHC,Why Valeant Pharmaceuticals  VRX  Could Be Positioned For A Slump,opinion,Similar to wise buying decisions  exiting certain underperformers at the right time helps maximize portfolio returns  Selling off losers can be difficult  but if both the share price and estimates are falling  it could be time to get rid of the security before more losses hit your portfolio One such stock that you may want to consider dropping is Valeant Pharmaceuticals International  Inc    NYSE VRX    which has witnessed a significant price decline in the past four weeks  and it has seen negative earnings estimate revisions for the current quarter and the current year  A Zacks Rank  5  Strong Sell  further confirms weakness in VRX A key reason for this move has been the negative trend in earnings estimate revisions  For the full year  we have seen 8 estimates moving down in the past 30 days  compared with no upward revisions  This trend has caused the consensus estimate to trend lower  going from  6 51 a share a month ago to its current level of  5 48 Also  for the current quarter  Stein Mart has seen 8 downward estimates revisions versus no revisions in the opposite direction  dragging the consensus estimate down to  1 34 a share from  2 05 over the past 30 days   VALEANT PHARMA Price and Consensus   The stock also has seen some pretty dismal trading lately  as the share price has dropped 19 8  in the past month So it may not be a good decision to keep this stock in your portfolio anymore  at least if you don t have a long time horizon to wait If you are still interested in the Medical   Drugs industry  you may instead consider a better ranked stock   Sucampo Pharmaceuticals  Inc    NASDAQ SCMP    The stock currently holds a Zacks Rank  1  Strong Buy  and may be a better selection at this time  You can see  Confidential from ZacksBeyond this Tale of the Tape  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-12-06,Zacks Investment Research,https://www.investing.com/analysis/why-valeant-pharmaceuticals-(vrx)-could-be-positioned-for-a-slump-200168694,200168694
147584,369100,BHC,Pfizer  PFE  Fined For Price Hike Of Anti Epilepsy Drug In UK,opinion,"Leading pharma company Pfizer Inc    NYSE PFE   was levied a fine of  107 million   84 2 million  by the Competition and Markets Authority  CMA  of the UK upon finding that it had violated competition laws by charging excessive and unfair prices for its anti epilepsy drug  phenytoin sodium capsules  The CMA has also imposed a penalty of  5 2 million on the company s distributor Flynn Pharma In a recent interview with Time magazine  President elect Donald Trump clarified that his intentions were misinterpreted and that he intends to target excessive drug price hikes  Most pharma biotech stocks saw their share prices slipping yesterday in response to Trump s comments  Pfizer s shares declined 1 2  in Wednesday s trading In fact  Pfizer s shares have fallen 3 4  year to date  comparing favorably to the decline of 7 8  for the Zacks classified Large Cap Pharma industry Coming back to the latest news  the abovementioned penalties came on the heels of an overnight price hike of up to 2 600  for the drug after it was deliberately de branded in Sep 2012  Price of one 100mg pack of the drug skyrocketed to  67 50 from  2 83  before finally settling at  54 00 in May 2014  Moreover  prices in the UK were higher than that in any other European country The CMA has ordered the companies to reduce their prices  To do this  the companies have been granted 30 working days to 4 months to lower prices in order to ensure undisturbed supply of the drug to patients who rely on it Note that phenytoin sodium is indicated for the treatment of epilepsy to prevent and control seizures  and is presently used by about 48 000 patients in the UK Previously  Pfizer used to market the drug as Epanutin and in Sep 2012  it sold the UK distribution rights to Flynn Pharma  Following the transition of rights  the product was de branded  which means that Pfizer was no longer subject to price regulation PFIZER INC Price and Consensus
    Note that like several others  Mylan N V    NASDAQ MYL   has lately been under the spotlight for the massive price hike of its lifesaving auto injector  EpiPen  facing criticism from lawmakers  consumers and the common people alike  In Oct 2016  the company agreed to a  465 million settlement with the U S  Department of Justice  DoJ  and other government agencies regarding the classification of EpiPen for purposes of the Medicaid Drug Rebate Program Meanwhile  Valeant Pharmaceuticals International  Inc    NYSE VRX   has been making it to the headlines for all the wrong reasons like a massive price hike of specialty drugs  erroneous financial reporting and termination of important contractsZacks Rank   Key PicksPfizer currently carries a Zacks Rank  3  Hold   Sucampo Pharmaceuticals  Inc    NASDAQ SCMP   is a better ranked stock in the health care sector  sporting a Zacks Rank  1  Strong Buy   You can see  Sucampo s earnings estimates increased from  1 03 to  1 22 for 2016 and from  1 30 to  1 58 for 2017 over the last 60 days  The company posted a positive surprise in all of the four trailing quarters with an average beat of 35 55  Zacks  Best Private Investment IdeasIn addition to the recommendations that are available to the public on our website  how would you like to follow all Zacks  private buys and sells in real time Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors  Starting today  for the next month  you can have unrestricted access ",2016-12-07,Zacks Investment Research,https://www.investing.com/analysis/pfizer-(pfe)-fined-for-price-hike-of-anti-epilepsy-drug-in-uk-200169009,200169009
147585,369101,BHC,Enrollment underway in EyeGate s mid stage study of EGP 437 in cataract surgery patients,news,The first patient has been enrolled in EyeGate Pharmaceuticals   EYEG  8 2   Phase 2b clinical trial assessing its EGP 437 combination product for the treatment of pain and inflammation in patients who have undergone cataract surgery with implantation of a monofocal posterior chamber intraocular lens  IOL  The co primary endpoints of the 100 subject study are the proportion of patients with an anterior chamber cell count of zero at day 7 and the proportion of patients with a pain score of zero at day 1  The estimated primary completion date is November EGP 437 is a reformulated topically active corticosteroid  dexamethasone  that is delivered to the eye through the EyeGate II Delivery System Global exclusive licensee Valeant Pharmaceuticals  NYSE VRX  will commercialize EGP 437  once approved  through its Bausch   Lomb unit Now read ,2017-08-01,Seeking Alpha,https://www.investing.com/news/stock-market-news/enrollment-underway-in-eyegates-midstage-study-of-egp437-in-cataract-surgery-patients-512983,512983
147586,369102,BHC,2 Biotech Stocks That Are Screaming Buys Into The New Year  VRX  GILD,opinion,"Are you ready for a biotech blitz  Tax loss selling has a week to go and it is keeping value biotech down  With everything in the stock market priced to perfection but biotech  it is the one area that screams value and major pop coming  My two favorite trades are Valeant Pharmaceuticals Intl Inc  NYSE VRX  and Gilead Sciences  Inc   NASDAQ NASDAQ GILD   Valeant has more risk  but the upside is substantially more  I have a potential target of  30  an over 100  gain in early 2017  Gilead is a safer play  with upside of between 10 20   but much more limited downside  Both have overly taken a beating on tax selling 
Compare these stocks to industrial stocks or other sectors  Stocks growing earnings at 0 5  are trading at higher P E s than many of these biotech stocks growing at 20 30  per year  It is insane but a pure result of tax loss selling  The bottom line is this  if there is one sector that will see all sellers dump in December 2016 and have almost no sellers in January 2017 it is biotech  Anyone who is going to sell their losing biotech position will do so in the next week  Start accumulating these like me  Check out these charts   ",2016-12-23,Jenny Rebekka,https://www.investing.com/analysis/2-biotech-stocks-that-are-screaming-buys-into-the-new-year-200170701,200170701
147587,369103,BHC,The Valeant Wages Of Sin,opinion,"Valeant Pharmaceuticals  NYSE VRX     which among others  has been a very big thorn in Bill Ackman s side    fell nearly 95  in just 18 months  Ninety  Five  Percent  Pretty amazing for such a large organization 
I wanted to point out  by way of those green tint marks  that present prices are in the range of what  over the decades  has been a decent series of higher lows  To be clear  I m not buying this creature  but for those with a very long view  it might be worth a look  Just this morning  I noticed Valeant has managed to sell off over  2 billion in assets to reduce its debt  so the stock is already responding favorably ",2017-01-10,Tim Knight,https://www.investing.com/analysis/the-valeant-wages-of-sin-200172040,200172040
147604,369120,BHC,5 Stocks To Watch Before The Market Opens On Election Day,opinion,"CVS Caremark  NYSE CVS   The healthcare industry has been hit hardest ahead of the election with both nominees having taken a hardened stance on the sector  Shares of  are trading 15  lower this year despite a string of robust year over year comparisons  Analysts are expecting the retail drug chain to maintain its robust growth of the past few quarters and deliver a 22  increase on the bottom line and 17  on the top  The recently completed acquisitions of Omnicare and Target Pharmacy  while still in the integration process  are expected to provide new support to top line growth  Profitability and same store sales should continue to be adversely impacted by the introduction of generic drugs  In the second quarter genericization dragged down pharmacy same store sales by 355 basis points  The potential merger of Rite Aid  NYSE RAD  and Walgreens  NASDAQ WBA  coupled with the off chance that Amazon  NASDAQ AMZN  opens up convenience stores could severely impact CVS  long term outlook  In the meantime  analysts are optimistic that CVS can maintain its robust growth of the past few quarters 
Valeant Pharmaceuticals  NYSE VRX    was one of the best performing stocks on Wall Street in the first half of 2015  but over the past 12 months and a price gouging scandal  shares have bottomed out  After reaching highs of over  250 per share  the stock has plummeted over 90   to all time lows  where it is today  The ongoing freefall forced management to oust now former CEO Michael Pearson  who led the company through the thick of its price hikes  With several new board members  one being infamous hedge fund manager Bill Ackman  and a new CEO  Valeant is still fumbling  Its most recent report delivered a nearly 50  decline on the bottom line and 10  on the top  With no signs of improving anytime soon  the upcoming quarter is shaping up to be another disaster 
SeaWorld Entertainment  NYSE SEAS    s financial performance and share prices have trended lower in recent quarters driven by lower traffic trends and a growing list of negative publicity surrounding animal cruelty  In the second quarter both earnings and revenue delivered 5  declines from a year earlier blamed on a decline on Latin American attendance  softness in the Orlando market  and an unfavorable storm season  Ongoing efforts to ease these concerns through promotional campaigns and jump start traffic trends haven t gained traction and will likely take their toll on the bottom line  Additional investments into new rides and extending hours of operation haven t swayed analysts expectations which are calling for a 7  decline in earnings and 3  in sales 
Wayfair  NYSE W    is falling victim to a theme plaguing many recent IPOs  mounting losses and decelerating revenue growth  In the second quarter the ecommerce platform posted a 187  decline on the bottom line and has yet to deliver a profitable quarter since going public in late 2014  Over this time revenue growth has dropped significantly with expectations of delivered a 42  increase in the third quarter  During the quarter  Wayfair introduced a number of new partnerships and initiatives to help re energize margins and traffic trends  Some of these include deals with HGTV and A E Networks along with a new augmented reality app will have enhance the consumer s experience 
Carrols Restaurants Group  NASDAQ TAST   Strong results from McDonald s  NYSE MCD  this earnings season sets a favorable tone for the remaining fast food chains which include  and Wendy s  NASDAQ WEN  this week  Carrols Restaurant Group is best known for owning and operating over 725 Burger King stores in the United States  The company continues to be in the process of acquiring more Burger King locations  During the third quarter Carrols acquired 10 additional stores that are expected to support the top line  Burger King s strong brand  frequent menu innovation and ongoing promotional initiatives have proved resilient despite challenges in the quick service industry  Analysts at Estimize are expecting the continued addition of new stores to carry financial performance to a 25  increase on the bottom line and 12  on the top ",2016-11-08,Estimize,https://www.investing.com/analysis/5-stocks-to-watch-before-the-market-opens-on-election-day-200163305,200163305
147605,369121,BHC,Company News For November 09  2016,opinion,"     Shares of Valeant Pharmaceuticals International Inc  NYSE VRX     plunged 21 7  after the company said it expects its earnings per share to be 5 30 to  5 50 for the year  lower than its previous guidance of  6 60 to  7
	     Shares of CVS Health Corp  NYSE CVS     plummeted 11 8  after the company said it currently expects earnings per share in the range of  5 77  5 83 this year  lower than its earlier guidance of  5 81  5 89
	     Shares of D R  Horton  Inc     declined 5 5  after the company posted fiscal fourth quarter earnings of  0 75 per share which missed the Zacks Consensus Estimate of  0 77
	     Hertz Global Holdings  Inc s    shares tanked 22 5  after the company reported third quarter earnings per share of  1 58 that fell short of the Zacks Consensus Estimate of  2 81",2016-11-08,Zacks Investment Research,"https://www.investing.com/analysis/company-news-for-november-09,-2016-200163688",200163688
147606,369122,BHC,Valeant Pharmaceuticals Stock Shares Take A Beating On Missed,opinion,"Valeant Pharmaceuticals  NYSE VRX 
Shares of Valeant Pharmaceuticals were trading lower after they released weaker than expected Q3 earnings  Earnings per share came in at  1 55 which was 20 cents lower than expected along with revenues that came in at  2 48 billion  also lower than expected  The miss on earnings was bad but to top it off they lowered forward guidance for the year with revenues estimated to come in between the range of  9 55 and  9 9 billion with earlier estimates at  10 1 billion 
VRX Technicals


VRX opened Tuesday sharply lower after missing big on earnings  which sank the stock more than 26  in premarket trading  Shares were able to rebound slightly when markets opened but didn t even come close to filling the gap  As you can see in the daily chart above shares have been very heavy with the only recent buying coming in when they announced they were selling some assets  VRX has been in the headlines a lot lately and most of the news has been negative as it has been for a long time now  I can t justify holding this long term but it has created plenty of opportunities for scalping and short term swing trades 
Comments On Earnings
Valeant CFO  feels good  about  quality  of revised 2016 guidance Valeant CFO Paul Herendeen said on the company s Q3 earnings call that Valeant is a turnaround  and

as with many turnarounds  improvements can sometimes take longer than expected   If you ask me how I feel about the quality of our revised guidance  I ll tell you that I feel good about it  not the level certainly  but the quality of the estimate  But I ll have more confidence when we put out our 2017 guidance and more confidence at the end of Q1 2017 and so on But there could still be some surprises yet to be discovered  I m not trying to alarm anyone or walk away from our revised guidance  I m just letting you know that as time passes  our confidence in our forecasts and our guidance will improve 

Company Profile
Valeant Pharmaceuticals International  Inc  is a multinational specialty pharmaceutical company that develops manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology  eye health  neurology  and branded generics  The company operates through two operating and reportable segments   i  Developed Markets and  ii  Emerging Markets  The Developed Markets segment consists of  i  sales in the U S  of pharmaceutical products  OTC products  and medical device products  as well as alliance and contract service revenues  in the areas of eye health  dermatology and podiatry  aesthetics and dentistry   ii  sales in the U S  of pharmaceutical products indicated for the treatment of neurological and other diseases  as well as alliance revenue from the licensing of various products it developed or acquired  and  iii  pharmaceutical products  OTC products  and medical device products sold in Canada  Australia  New Zealand  Western Europe and Japan 
The Emerging Markets segment consists of branded generic pharmaceutical products and pharmaceuticals  OTC products  and medical device products  Products are sold primarily in Central and Eastern Europe  primarily Poland and Russia   Asia  Latin America  Mexico  Brazil  and Argentina and exports out of Mexico to other Latin American markets   Africa and the Middle East  Valeant Pharmaceuticals was founded on March 29  1994 and is headquartered in Laval  Canada ",2016-11-08,Ticker.tv News,https://www.investing.com/analysis/valeant-pharmaceuticals-$vrx-stock-shares-take-a-beating-on-missed-200163569,200163569
147607,369123,BHC,Should You Get Rid Of Valeant Pharmaceuticals International  VRX  Now ,opinion,Similar to wise buying decisions  exiting certain underperformers at the right time helps maximize portfolio returns  Selling off losers can be difficult  but if both the share price and estimates are falling  it could be time to get rid of the security before more losses hit your portfolio One such stock that you may want to consider dropping is Valeant Pharmaceuticals International  Inc    NYSE VRX    which has witnessed a significant price decline in the past four weeks  and it has seen negative earnings estimate revisions for the current quarter and the current year  A Zacks Rank  5  Strong Sell  further confirms weakness in VRX A key reason for this move has been the negative trend in earnings estimate revisions  For the full year  we have seen 5 estimates moving down in the past 30 days  compared with no upward revisions  This trend has caused the consensus estimate to trend lower  going from  6 53 a share a month ago to its current level of  5 43 Also  for the current quarter  Valeant Pharmaceuticals has seen 5 downward estimate revisions versus no revisions in the opposite direction  dragging the consensus estimate down to  1 56 a share from  2 06 over the past 30 days   The stock also has seen some pretty dismal trading lately  as the share price has dropped 18 0  in the past month VALEANT PHARMA Price and Consensus   So it may not be a good decision to keep this stock in your portfolio anymore  at least if you don t have a long time horizon to wait If you are still interested in the Medical Drugs industry  you may instead consider a better ranked stock   Sucampo Pharmaceuticals  Inc   SCMP   The stock currently holds a Zacks Rank  1  Strong Buy  and may be a better selection at this time  You can see  Confidential from ZacksBeyond this Tale of the Tape  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-11-15,Zacks Investment Research,https://www.investing.com/analysis/should-you-get-rid-of-valeant-pharmaceuticals-international-(vrx)-now-200165022,200165022
147609,369125,BHC,Valeant  VRX  Ups Sales Force To Support Xifaxan Relistor,opinion,"Valeant Pharmaceuticals International  Inc    NYSE VRX   announced that it is expanding its sales force to reach primary care physicians  The new sales force team is going to promote the company s two products  Xifaxan for irritable bowel syndrome with diarrhea  IBS D  and Relistor for opioid induced constipation  OIC  Valeant Pharmaceuticals and partner Progenics Pharmaceuticals  Inc    NASDAQ PGNX   commercially launched their constipation tablets  Relistor  methylnaltrexone bromide  in the U S  in September this year  Relistor Tablets  450 mg once daily  were approved to treat OIC in adults with chronic non cancer pain in July  Progenics has exclusively licensed the development and commercialization rights for Relistor to Valeant Valeant Pharmaceuticals and its wholly owned subsidiary  Salix Pharmaceuticals  Inc  received FDA approval for Xifaxan  rifaximin  550 mg for the treatment of irritable bowel syndrome  IBS D  in adults in May 2015  However  the drug has performed below expectations due to higher managed care rebates  The sales force expansion strategy is aimed at getting at better patient access for the drug The company s share price is down 3 81   though the Zacks Classified Drugs industry has seen growth of 7 55  in the past one month VALEANT PHARMA Price
    Valeant is a Zacks Rank  5  Strong Sell  stock  It has been in the spotlight for all the wrong reasons in recent times like a price hike of specialty drugs  erroneous financial reporting  and termination of contracts with Philidor Rx Services  The company has also been the subject of a pricing controversy over the last few months with politicians and media focusing on the high pricing of drugs  Adding to its woes  mutual fund investor T  Rowe Price filed a lawsuit against the company  However  Valeant has been quite aggressive on the acquisition front  which has been driving growth  The share price of the company is down more than 80  year to date A couple of better ranked stocks in the healthcare sector include Heska Corporation   NASDAQ HSKA    Arbutus Biopharma Corporation   NASDAQ ABUS    Heska sports a Zacks Rank  1  Strong Buy  while Arbutus carries a Zacks Rank  2  Buy   You can see the  Heska s earnings estimates increased from  1 13 per share to  1 35 for 2016 and from  1 38 per share to  1 53 for 2017  over the last 60 days  The company posted positive surprises in each of the four trailing quarters  with an average beat of 301 64   Share price has increased 93 31  year to date for the company Arbutus  loss estimates narrowed from  2 15 to  1 74 per share for 2016 and from  1 96 to  1 51 per share for 2017 over the last 60 days  The company posted positive surprises in three of the trailing four quarters  with an average beat of 59 31  Zacks  Top Investment Ideas for Long Term Profit How would you like to see our best recommendations to help you find today s most promising long term stocks  Starting now  you can look inside our portfolios featuring stocks under  10  income stocks  value investments and more  These picks  which have double and triple digit profit potential  are rarely available to the public  But you can see them now ",2016-11-29,Zacks Investment Research,https://www.investing.com/analysis/valeant-(vrx)-ups-sales-force-to-support-xifaxan-relistor-200167396,200167396
147610,369126,BHC,Drugmaker Perrigo says CEO Hendrickson plans to retire,news," Reuters    Drugmaker  Perrigo Co  Plc  N PRGO  said on Monday that Chief Executive John Hendrickson planned to retire  an announcement that comes a little more than a year after the company veteran got the top job  Perrigo did not specify when Hendrickson would leave  but said he would stay on until a replacement was appointed and for a 60 day transition period after that  Hendrickson  who joined Perrigo in 1989  became CEO in April last year after Joseph Papa left to join Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX   That change was a few months after Perrigo convinced its investors to reject an unwanted takeover offer from Mylan NV  O MYL   in part by citing its potential to perform well on a standalone basis  Since then  Perrigo has largely disappointed investors  reducing its earnings forecast on more than one occasion in response to pressure on its generic drugs business and disappointing performance of its Omega Pharma unit  The dour results also prompted activist hedge fund Starboard Value LP to pressurize the company to sell assets to unlock value for shareholders  Perrigo settled with Starboard in February by giving it board representation and agreeing to sell the company s royalty stream from the multiple sclerosis drug  Tysabri  for up to  2 85 billion  Hendrickson s planned retirement will be the company s second top level executive departure in about three months after Chief Financial Officer Judy Brown stepped down in February  The company has been operating with an interim finance head since  However  Hendrickson s departure comes after the Ireland based company issued a buoyant first quarter report last week and said it was up to date with its regulatory filings  The company had delayed it annual filing to review past accounting practices  specifically how it had recognized revenue from Tysabri sales  Perrigo s shares were down 2 5 percent at  70 after the bell on Monday  Since Hendrickson s appointment  the stock has fallen about 26 percent  
The company said it had formed a committee to search for Hendrickson s replacement ",2017-06-05,Reuters,https://www.investing.com/news/stock-market-news/drugmaker-perrigo-says-ceo-hendrickson-plans-to-retire-492089,492089
147611,369127,BHC,Small is lucrative for Wachtell  corporate America s legal defense force,news,"By Greg Roumeliotis NEW YORK  Reuters    Every Tuesday  partners and associates at Wachtell  Lipton  Rosen   Katz gather for a communal lunch in the dining room of the law firm s Manhattan offices  Food ordered from top New York restaurants is served  but the real attraction is Martin Lipton  one of the firm s co founders and corporate America s most famous consigliere  The father of the  poison pill    a key defense strategy used against hostile takeovers   Lipton has helped build the firm into the most lucrative legal outfit in the world  a go to shop for companies seeking to seal complex deals or repel suitors and activist investors  The weekly lunch is just one of the ways the 85 year old stays in touch with new associates and reinforces the firm s close knit culture  where young law graduates are often paired with senior partners to work on big deals  Partners say a flat structure and relatively small size   Wachtell s lawyer headcount of about 260 is roughly half of its closest rival Cravath  Swaine   Moore   is key to the firm s success   The firm s concentrated business model contrasts with the strategy of many law firms to become one stop shops for deals  from navigating niche regulatory processes to sorting through labyrinthine tax affairs  Lipton is confident that his strategy of concentrating on high stakes corporate situations will persist  according to interviews with several senior partners at the firm  This is because corporate America continues to turn to Wachtell as its top legal gun for hire    Wachtell s business model is to be the firm you go to when you are not willing to take any risk at all   said Stephen Gillers  a New York University School of Law professor   They know that in the big M A cases  legal fees  no matter how big they are  are insignificant to the value of concluding the deal    When French drug giant Sanofi SA  PA SASY  threatened U S cancer drug company Medivation Inc with a  9 3 billion hostile bid last year  for example  Medivation called Wachtell despite having an existing external legal adviser  Cooley  Cooley helped Medivation to go public in 2004 and is best known for advising on initial public offerings and defending against patent and class action lawsuits  Cooley and Medivation declined to comment  MOST LUCRATIVE  With some U S  companies domiciled overseas  Wachtell s partners often have to adapt their techniques to different jurisdictions   Rather than opening offices internationally as some of their rivals have done  Wachtell s lawyers fly out to advise  staying weeks in some cases to see a case through  and turn to other law firms to assist them   Wachtell did consider opening a London office in recent years  but decided against it  partner at the firm said  The feeling among the firm s senior partners was that expansion would dilute its culture  which is based around forming ad hoc teams to deal with situations  all from the one office in Manhattan   Keeping itself small has helped Wachtell become the most lucrative law firm in the world  with the average partner making a profit last year of  5 8 million  according to trade publication American Lawyer  The top 100 law firms averaged profit per partner of  1 66 million  Capping the workforce also means that partners do not have an army of associates to foist work onto    We work harder on average than other places  the work is very partner heavy  It s the type of work where vast experience is critical   said Daniel Neff  co chairman of Wachtell s executive committee   No one is more experienced than Lipton  referred to as Marty by clients and colleagues  He continues to work on high profile cases including  most recently  advising General Motors Co s  N GM  board of directors on its defense against activist hedge fund Greenlight Capital  as well metal parts maker  Arconic Inc   N ARNC  on its settlement with activist hedge fund Elliott Management Corp   Besides Lipton  two of the other three founding partners  Leonard Rosen and George Katz  have died  However  like Lipton  founding partner Herbert Wachtell remains active at 84 practicing law  focusing on corporate litigation  which is the firm s other major area of strength  M A ROYALTY Lipton has built a bench of seasoned deal lawyers who now account for the majority of the business that comes through the door  They include Neff and Edward Herlihy  who formally lead the firm as co managing partners  as well as Andrew Brownstein  David Katz  Steven Rosenblum  Adam Emmerich and Andrew Nussbaum  among others   When  Perrigo Co  Plc  N PRGO  turned to Wachtell in 2015 to defend against a  35 billion offer from Mylan NV  O MYL   it was a 45 year old partner  Igor Kirman  that the Irish domiciled generic drug maker chose to lead its defense in three continents  Perrigo subsequently defeated what was the largest hostile bid ever rejected by a company s shareholders   It was a given for me that by turning to Wachtell we would get excellent legal advice  But Igor also took very complex issues and simplified them so Perrigo s board could understand   said Joseph Papa  Perrigo s former CEO who now leads Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX   Lipton remains influential  fielding calls and studying cases every day from his 31st floor office  which is filled with memorabilia from major deals stretching back to the 1970s    Lipton is royalty in the M A bar  There is no immediate successor to the status that he has achieved   said Gillers   
 The fact that clients still ask for him at the age of 85 shows you that the most important assets of a lawyer are his experience and judgment  ",2017-06-08,Reuters,"https://www.investing.com/news/stock-market-news/small-is-lucrative-for-wachtell,-corporate-america's-legal-defense-force-493191",493191
147612,369128,BHC,FDA wants Endo s Opana ER off the market due to abuse potential  shares down 14  after hours,news,In an unprecedented  but not unexpected action  the FDA has notified Endo International s  NASDAQ ENDP  Pharmaceuticals unit that it wants opioid pain med OPANA ER  oxymorphone HCl  removed from the market due to its abuse potential The medication was first approved in 2006 and was replaced by an abuse deterrent formulation 2012 designed to make the drug resistant to physical and chemical manipulation  The new version met the regulatory standards for approval  but the data failed to show that the reformulation would reduce abuse misuse to a meaningful degree The agency has asked the company to voluntarily withdraw the product from the market  If it balks at doing so  the regulator will withdraw approval In March  a joint meeting of FDA advisory committees voted 18   8 that the benefits of OPANA ER no longer outweigh the risks OPANA ER generated sales of  35 7M in Q1  representing 3 4  of the company s total revenues and 4 9  of U S  Generic Pharma sales Shares are down 14  after hours on robust volume Insys Therapeutics  NASDAQ INSY  is down 4  in sympathy Previously  Endo International gets Ad Comm thumbs down on opioid OPANA ER  March 15 Now read ,2017-06-08,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-wants-endo's-opana-er-off-the-market-due-to-abuse-potential;-shares-down-14-after-hours-493559,493559
147613,369129,BHC,Billionaire investor Paulson joins Valeant board  shares jump,news,"By Svea Herbst Bayliss  Reuters    Billionaire investor John Paulson  whose hedge fund firm is the biggest owner of Valeant Pharmaceuticals International Inc  TO VRX   N VRX  shares  on Monday joined the ailing drug company s board as it restructures to repay debt  Investors appeared to see Paulson s becoming a director as a vote of confidence in Valeant  sending its U S  listed shares up 5 1  percent at  13 29  The move comes as Valeant sells off assets to pay down its  30 billion debt   With his significant business and financial expertise  John will be a strong addition to the board   Valeant Chief Executive Officer Joe Papa said in a statement   His experience will be especially valuable as we continue to execute on our transformational strategy to turnaround Valeant   The 61 year old Paulson  best known for a bet against the overheated housing market that earned his firm  15 billion in 2007  has not served on many corporate boards  He is currently a director at insurer American International Group Inc  N AIG   which recently removed its CEO  A Paulson spokesman declined to comment  Paulson   Co  owns 19 4 million shares  or 5 7 percent of Canada based Valeant  His firm  like many other hedge funds  has suffered heavy losses as Valeant s stock price plummeted some 96 percent since mid 2015 after it became embroiled in an accounting scandal and was investigated for hefty price hikes  The stock price is still 80 percent off its peak  Paulson will be the second investor along with Robert Hale  a partner at hedge fund firm ValueAct  to sit on the 11 person board that was overhauled a year ago by activist investor William Ackman  who was long the company s biggest public supporter  Ackman recruited Papa after firing former CEO Michael  Pearson   LON PSON  who grew Valeant into one of the hedge fund industry s most widely owned companies  Paulson will work with Papa and other board members to narrow Valeant s focus to its dermatology  gastrointestinal and eye care businesses and sell off other assets  In November talks to sell Salix  one of its crown jewels  to Japanese company Takeda  T 4502  fell apart  A few months later in March  Ackman abruptly sold his position and exited the board but not before the Valeant investment cost his firm  Pershing Square  NYSE SQ  Capital Management  some  3 billion in losses  Valeant has also taken a bite out of Paulson s performance  His firm s assets  which had  36 billion in assets at its peak in 2011  have shrunk to roughly  10 billion with Paulson s personal assets making up the bulk of the capital  Last year Paulson Partners Enhanced merger arbitrage fund tumbled 50 percent before falling further in early 2017  
Also  a string of employees have been leaving  Most recently  portfolio manager Sheru Chowdry  who co managed the Paulson Credit Opportunities Fund along with Ty Wallach  said he would leave ",2017-06-19,Reuters,https://www.investing.com/news/stock-market-news/valeant's-largest-shareholder-john-paulson-joins-board-496825,496825
147614,369130,BHC,Paulson s board seat in Valeant may not be much help to his underwater position   Bloomberg,news,Beaten down Valeant Pharmaceuticals  VRX  5 1   is slowly trying to regain some degree of upward momentum after bottoming at  8 36 on April 21  Shares popped 8  early in the session on the news that hedge fund star John Paulson joined the board Bloomberg Gadfly columnist Max Nisen says the move may not be much help to either Mr  Paulson  underwater   1B with his stake  or the company  Given his track record in pharma  there is scant evidence that he can reprise his colossal win with credit default swaps about a decade ago  Eight of his nine positions listed in the article  about half of his holdings  are losers so far His Valeant position is down about 90   but he is undeterred  adding 10M shares in the past two years Mr  Nisen cites the example of hedge fund honcho Bill Ackman  who also had a board seat  lost big and bailed out after the company failed to show any hint of a turnaround  Mr  Paulson has a steep hill to climb to break even  considering the company s stifling debt of  28 5B and stagnant core business Now read ,2017-06-19,Seeking Alpha,https://www.investing.com/news/stock-market-news/paulson's-board-seat-in-valeant-may-not-be-much-help-to-his-underwater-position---bloomberg-496986,496986
147615,369131,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 48 ,news,"Investing com   Canada stocks were higher after the close on Monday  as gains in the Healthcare  IT and Consumer Discretionary sectors led shares higher 
At the close in Toronto  the S P TSX Composite added 0 48  
The best performers of the session on the S P TSX Composite were Hudson s Bay Company  TO HBC   which rose 15 09  or 1 34 points to trade at 10 22 at the close  Meanwhile   ProMetic Life Sciences Inc    TO PLI  added 11 52  or 0 190 points to end at 1 840 and Valeant Pharmaceuticals International Inc  TO VRX  was up 5 89  or 0 99 points to 17 79 in late trade 
The worst performers of the session were  NexGen Energy Ltd    TO NXE   which fell 7 78  or 0 210 points to trade at 2 490 at the close   Lucara Diamond Corp   TO LUC  declined 4 11  or 0 120 points to end at 2 800 and Canadian Energy Services   Technology Corp  TO CEU  was down 3 48  or 0 200 points to 5 550 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 584 to 548 and 115 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 6 95  to 13 26 
Gold Futures for August delivery was down 0 91  or 11 41 to  1245 09 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in August fell 1 40  or 0 63 to hit  44 34 a barrel  while the August Brent oil contract fell 1 03  or 0 49 to trade at  46 88 a barrel 
CAD USD was down 0 01  to 0 7567  while CAD EUR rose 0 40  to 0 6786 
The US Dollar Index Futures was up 0 37  at 97 22 ",2017-06-19,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.48-497002,497002
147626,369142,BHC,BioDelivery Sciences  BDSI  Board Appoints New Members,opinion,"BioDelivery Sciences International  Inc    NASDAQ BDSI   announced a couple of changes in its management  While Timothy C  Tyson has been appointed to the company s board of directors as an independent member  Dr  Mark A  Sirgo  the present President and Chief Executive Officer  CEO  and board member  will function as Vice Chairman  in addition to his present roles Effective immediately  these changes were made in an attempt to strengthen BioDelivery s board level leadership Tyson had previously served as Avara Pharmaceutical Service s Chairman and CEO  Icagen Inc  s Chairman and Aptuit LLC s Chairman and CEO Tyson is expected to bring about dramatic transformations in the company s structure with his 30 years of experience in the pharmaceuticals industry  He has successfully filled senior executive level leadership positions  handling key functional areas such as sales and marketing  manufacturing and supply  and research and development  These reflect his exposure to a broad variety of responsibilities Between 2002 and 2008  Tyson was appointed as the Chief Operating Officer  President  and CEO of Valeant Pharmaceuticals International   NYSE VRX    Prior to this appointment  he had been employed by GlaxoSmithKline   NYSE GSK   for 14 years  where he was responsible for multiple divisions BioDelivery expects the addition of Tyson to its board to be beneficial for the company s business  The company s board of directors currently has 8 members  of which 6 are independent BioDelivery is a specialty pharmaceutical company focused on the development and commercialization of treatments for pain and addiction  The company utilizes its novel and proprietary BioErodible MucoAdhesive  BEMA  technology for the development of products The company s portfolio currently comprises three approved products   Onsolis  Bunavail and Belbuca BIODELIVERY SCI Price
    Zacks Rank   Key PicksBioDelivery currently carries a Zacks Rank  3  Hold   Another better ranked stock in health care sector is ARIAD Pharmaceuticals Inc    NASDAQ ARIA    The stock sports a Zacks Rank  1  Strong Buy   You can see ARIAD s loss estimates narrowed from 25 cents to 8 cents for 2016  while that for 2017 narrowed from 64 cents to 48 cents during the last 60 days  The company has beaten earnings estimates twice in the last four quarters  bringing the average surprise to 153 4   Its stock price has surged 116 7  year to date Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-06,Zacks Investment Research,https://www.investing.com/analysis/biodelivery-sciences-(bdsi)-board-appoints-new-members-200157701,200157701
147627,369143,BHC,Headline Risk Is Still Poison For These Stocks,opinion,"Stock picking is hard  Most institutional and retail stock pickers underperform the indexes  But every investor could improve the likelihood they beat the market by following one rule 
Avoid high profile  controversial companies where an adverse news event could produce an overnight price collapse 
Three stocks have proven the utility of this investing rule in spades  Valeant Pharmaceuticals  NYSE VRX   Wells Fargo  NYSE WFC  and Mylan Labs  NASDAQ MYL   All three have been scrutinized for behavior labeled unethical by some and illegal by others  and all three have cost their investors in a big way because of it 
In February  I cautioned that an upcoming Congressional investigation into Valeant s pricing policies might unveil further malfeasance by the company s management  VRX was  92 then  It closed at  22 today  While the hearings produced no bombshells  a few weeks later management reported disappointing fourth quarter earnings and drastically lowered earnings guidance for 2017  The stock dropped 40  to  36 in a single day  and has slid lower since 
Had folks followed my rule  they would have unloaded Valeant as soon as news surfaced that it had a lengthy history of buying prescription and OTC drugs  with money borrowed via multiple Wall Street bond offerings  and then drastically raising drug prices  The stock was still over  200 when these damning stories first emerged  But many investors including a who s who of the hedge fund industry held onto their Valeant stakes  betting that good times were sure to return as the negative press faded and headline risk abated  Even Wall Street  experts  who openly acknowledged the company s troubles refused to believe things could get significantly worse 
On September 28th  2015  with Valeant s stock still trading for  199 share  Nomura analyst Shibani Malhotra initiated coverage on the company  In a thorough 46 page report  Malhotra rightly called VRX a  controversial company that polarizes investors  and noted its  aggressive pace of M A  which some perceive as an unsustainable  roll up  strategy   And yet  Malhotra still rated the company a buy  pegging its upside at  335 share and its downside at a mere  180 only  19  or 10 percent  less than the stock was trading for on the day the report was issued 
Oops 
One year later  the rot within Valeant is still being unearthed  and its stock keeps on falling  Just this week Wall Street analyst David Maris dug up another example of quasi criminal behavior  Apparently Valeant induced doctors to prescribe its second biggest product  the antidepressant Wellbutrin XL  through the obscure mail order pharmacy  Direct Success   Even though much cheaper generic competitors to Wellbutrin existed  Valeant increased Wellbutrin s list price 11 times over the last few years to  17 000 annually  Who knows when  or if  another negative story around Valeant is discovered  But with over  30 billion of debt and now shrinking revenues  it s an extremely risky stock that could very well zero out  Now that is a downside risk 
The recent Wells and Mylan scandals could drag on just as long as the Valeant saga  and potential investors in either company would be wise to remember all the false bottoms we ve seen in Valeant s stock since it first started sliding 
Mylan has followed the Valeant playbook  buying a much needed drug and then rapidly raising its price  Because Medicare and Medicaid are often the ultimate payors  a large portion of these price hikes have been borne by American taxpayers  In Mylan s case the product was the epipen  used to avert anaphylactic shock for folks with severe allergies  Mylan s CEO  who is among the highest paid CEO s in America  was criticized for this price gouging at a recent congressional hearing  but she has retained her job  and her eight figure annual compensation 
Wells Fargo had a multi year program of  cross selling  products  like credit cards  to customers who had not requested them  Last week longtime Wells CEO John Stumpf resigned over the scandal  but not before first blaming  and firing  5 300 employees and the head of Wells  consumer operations  I suspect these were not  rogue  employees  just folks following an internal culture that promoted unethical and illegal behavior in order to stay employed  Thankfully  the head of the consumer finance protection bureau  Senator Elizabeth Warren  lambasted Stumpf at a recent Senate hearing 
In all three examples the time to sell was the day these scandals broke  Even today all three stocks should be sold  as headline risk persists  The Mylan story is far from over and Valeant continues to prove Charlie Munger correct when he called it a  sewer  
As for Wells  I believe our government would have been well within its rights  per the Treasury Department s oversight of all FDIC insured institutions to place it under conservatorship  as it did with Fannie Mae and Freddie Mac after the 2008 financial crisis  The company s stock would have zeroed out  and that would have put the entire financial services industry on notice that predatory behavior will not be tolerated  While a drastic step  I fear such action is necessary to prevent further abuse  Instead Wells  investors  including Warren Buffett  have remained silent  It appears protecting the company s share price is more important to these folks than treating American consumers and taxpayers fairly",2016-10-21,Scott Fearon,https://www.investing.com/analysis/headline-risk-is-still-poison-for-these-stocks-200159974,200159974
147628,369144,BHC,Orexigen  OREX  Posts Narrower than Expected Loss In Q3,opinion,"Orexigen Therapeutics  Inc    NASDAQ OREX   reported a loss of  1 01 per share in the third quarter of 2016  narrower than the Zacks Consensus Estimate of  2 13 but wider than the year ago loss of 86 cents Quarterly revenues came in at approximately  7 million  down from to  10 million in the year ago quarter  which included an anniversary milestone earned from Takeda Pharmaceutical Company Limited   OTC TKPYY    Revenues were also missed the Zacks Consensus Estimate of  16 million Quarterly DetailOrexigen recorded Contrave sales of  5 3 million in the U S   following its Aug 2016 acquisition of the U S  rights to the product  Royalties on U S  sales of Contrave were  0 9 million  The company also received collaborative income of  0 9 million As per IMS Health data  Contrave scrips were down 13 6  sequentially to 165 141 in the third quarter of 2016 While R D expenses declined 40 4  from the year ago period to  5 3 million  general and administrative expenses were up 190  to  35 1 million Meanwhile  Orexigen s Central and Eastern European  CEE  partner  Valeant Pharmaceuticals International  Inc    NYSE VRX    launched Mysimba  EU brand name for Contrave  in five countries  Valeant expects to launch the drug in six additional CEE countries by 2016 end  and in Greece and Cyprus in the first quarter of 2017 GuidanceOrexigen expects cash operating expenses of  160  180 million in 2016  Contrave U S  net sales are envisioned in the range of  47  52 million While R D spend is projected in the range of  44  49 million  the company anticipates spending  80   90 million on sales and marketing  General and administrative expenses are estimated in the range of  36  41 million Total annual cash operating expenses are expected in the range of  180  200 million during the 2017 2019 period  This includes annual sales and marketing expenses of about  80  100 million  External R D expenses are projected to be  15  20 million per year in 2016 and 2017  and an average of  50 million a year from 2018 through 2021  doe to costs related to the cardiovascular outcomes study Orexigen expects to achieve profitability in 2019  with U S  sales in the range of  160 million  260 million Contrave s market share  which was 6  in Aug and Sep 2016  is expected to be mostly flat in the fourth quarter  followed by growth in the first half of 2017  Annual market share growth is expected in the range of 2 6  during the 2017 2019 timeframe OREXIGEN THERAP Price  Consensus and EPS Surprise
 

   Zacks Rank   Key PicksOrexigen carries a Zacks Rank  3  Hold   Infinity Pharmaceuticals  Inc    NASDAQ INFI   is a better  ranked stock in the healthcare sector  sporting a Zacks Rank  1  Strong Buy   You can see  Infinity s loss estimates narrowed from  3 84 to  3 79 for 2016 but remained unchanged for 2017 over the last 60 days  The company has posted a positive surprise in all of the four trailing quarters with an average beat of 67 62  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-11-04,Zacks Investment Research,https://www.investing.com/analysis/orexigen-(orex)-posts-narrower-than-expected-loss-in-q3-200162909,200162909
147629,369145,BHC,Valeant swings to profit on tax gain  raises forecast,news,"By Ankur Banerjee  Reuters    Canada s Valeant Pharmaceuticals International Inc  N VRX   TO VRX  reported its first profit in six quarters  helped by a one time tax gain  and raised its full year earnings forecast  sending its U S  shares up 13 percent in premarket trading  Laval  Quebec based Valeant has been trying to rebuild its business and regain investor confidence after the company came under investigations over its accounting and pricing practices  The company said it now expects 2017 adjusted earnings before interest  tax  depreciation and amortization  EBITDA  of  3 60  3 75 billion  up from its previous forecast of  3 55  3 70 billion  Valeant has been focusing on its dermatology  eyecare and gastrointestinal units while selling off some other assets as it looks to pay down its heavy debt  racked up after years of acquisitions  The troubled drugmaker said it had lowered its debt by  1 3 billion in the latest quarter  and that its long term debt was  28 54 billion as of March 31  Valeant is on pace to meet its target of repaying  5 billion in debt between August 2016 and February 2018  Chief Executive Joe Papa told shareholders last week  Net income attributable to Valeant was  628 million  or  1 79 per share  in the first quarter ended March 31  compared with a loss of  374 million  or  1 08 per share  a year ago  The latest results included a one time income tax benefit of  908 million related to an internal restructuring  The company said its adjusted net income was  273 million  On a per share basis  Valeant s earnings were 78 cents per share  below the average estimate of 82 cents  according to Thomson Reuters I B  E S  Revenue fell to  2 11 billion from  2 37 billion  missing the average estimate of  2 18 billion  Revenue at its branded Rx unit  which houses the dermatology and Salix businesses  fell 9 percent to  604 million in the quarter  primarily driven by decreased volumes  Valeant said the decrease in volume was partially offset by an increase in average realized prices  partly due to lower customer subsidies and accommodations and higher wholesaler selling prices  
 The focus point has not been volume but to stabilize average selling price and we do believe we have done that  at this point   Scott Hirsch  Senior Vice President of Business Strategy and Communication told Reuters ",2017-05-09,Reuters,https://www.investing.com/news/stock-market-news/tax-benefit-helps-valeant-post-quarterly-profit-vs.-year-ago-loss-481608,481608
147630,369146,BHC,Wall St higher as earnings digested ,news,Investing com   U S  stocks were higher Tuesday as investors digested the latest batch of earnings The DJI was up 0 13  at 10 15 ET  The S P 500 added 0 17  The tech heavy Nasdaq composite put on 0 47  Both the Nasdaq composite and the S P touched fresh record highs The CBOE Volatility Index remained near 23 year lows The dollar was higher with the odds of a Fed rate hike in June stood at over 80  Oil retreated ahead of API stockpile data  NYSE Valeant  jumped 12 56  to  10 93 as the pharma raised its EBITDA guidance for 2017 ,2017-05-09,Investing.com,https://www.investing.com/news/stock-market-news/wall-st-higher-as-earnings-digested-481794,481794
147632,369148,BHC,Pricing Issues Continue To Weigh On The Pharma Sector,opinion,"Sector Remains Volatile on Drug Pricing Issues
Drug pricing is an issue that has been weighing on pharma and biotech stocks for more than a year now  The sector  which previously had a stellar run  started its downward trend in Sep 2015 when a single tweet by Democratic Presidential candidate Hillary Clinton sent pharma and biotech stocks tumbling  Clinton s  price gouging tweet  was in response to a huge price hike  about 5 000   taken by Turing Pharmaceuticals for a drug that was approved by the FDA way back in 1953 
Since then  focus on the drug pricing issue has gone up and companies like Valeant and Mylan  NASDAQ MYL  have seen their share prices plunging as they find themselves in the midst of the drug pricing controversy  Moreover  insulin drugmakers like Lilly  LLY  and Novo Nordisk  CO NOVOb   NVO  are also under attack with Senator Bernie Sanders posting a series of tweets questioning the prices of their insulin drugs  Lilly is a Zacks Rank  3 stock  You can see  
And then there is Proposition 61   California s ballot measure to ensure that the State of California is able to negotiate with drug companies for drug prices that do not exceed the price paid for the same drugs by the U S  Department of Veterans Affairs  DVA   Not surprisingly  the drug industry is fighting this proposition 
According to the Oct 2016 Kaiser Health Tracking poll  affordability of prescription drugs remains at the top of the public s priority list for the President and Congress    focus should be on ensuring the affordability of high cost drugs to people who need them and taking steps to lower prescription drug prices 
In Sep 2016  Democratic Presidential candidate Hillary Clinton announced a health care plan that will address the excessive price hikes of treatments that have been around for years and also reaffirmed her earlier broader plan  announced in Sep 2015  with the aim to lower drug prices for all Americans 
Given the current scenario  drug companies may find it a bit difficult to justify their high prices by citing the years and funds that go into bringing new treatments to market and the need to invest in R D to bring additional treatments to market  With elections round the corner andPresidential candidates  policymakers  the media and the general public focusing on the high price tags for drugs  this issue is not likely to die down easily 
Biosimilars Changing the Competitive Scenario
Another challenge being faced by the sector is the recent entry of biosimilar competition in the U S  While a relatively new area  the market for biosimilars is huge and highly lucrative with several blockbuster biologics including Humira and Lantus slated to lose patent protection by 2020  Biosimilars are expected to reduce healthcare costs and provide a large number of patients with access to much needed biologic treatments 
According to new research released by the IMS Institute for Healthcare Informatics earlier this year  increasing acceptance of biosimilars across different therapeutic areas plus an active pipeline of 56 candidates are expected to lead to total savings of about  110 billion to health systems across Europe and the U S  through 2020 
The report further says that by 2020  biosimilars will start competing with biologics that currently have annual sales of  50 billion  About 30 companies are developing biosimilars of 16 molecules   most of the biosimilars in development are for reference products like Johnson   Johnson s Remicade  Amgen s  AMGN  Enbrel  Roche Biogen s Rituxan and AbbVie s Humira 
Biosimilars are also gaining acceptance across formularies  CVS Health  NYSE CVS  announced that biosimilars and follow on biologics will be a key part of its 2017 standard formulary strategy  replacing higher cost drugs within the categories  Similar steps have been taken or are being contemplated by other formularies as well 
Although there is still low visibility on how well biosimilars will perform or how much of the market they will be able to capture  the focus on making expensive drugs more affordable and formulary coverage for biosimilars could very well make it challenging for innovator companies to hold on to market share for their blockbuster drugs 
Will New Products Make Up for Lost Sales 
Quite a few of the big players in the drug industry are looking at loss of patent protection for major blockbuster drugs  With generics and biosimilars breathing down their necks  many of these companies are looking towards new products to pick up the pace and make up for lost sales  While several new products were approved last year  many like Orkambi  Repatha and Praluent failed to live up to expectations 
Vertex  VRTX  lowered its 2016 guidance for cystic fibrosis treatment Orkambi in September to reflect slower refills in the U S  during the summer months of July and August as well as a slower than expected launch in Germany 
Meanwhile  PCSK9 inhibitors  Repatha and Praluent  which are expected to bring in blockbuster sales  are yet to see a significant ramp up  Sales of these products are not likely to pick up significantly until the availability of favorable cardiovascular outcomes study data 
Stocks to Avoid
As concerns surrounding the drug pricing issue continue to keep the sector volatile  it would be prudent to stay away from stocks that have not been able to win analysts  confidence and carry an unfavorable Zacks Rank 
Valeant Pharmaceuticals  NYSE VRX  International  Inc   VRX   Valeant  a Zacks Rank  5  Strong Sell  stock  is one of the companies hit hard by the pricing controversy due to its strategy of acquiring companies and selling their drugs at higher prices  Shares are down 75 8  so far in 2016 while earnings estimates for both 2016  down 0 3   and 2017  down 0 8   have been revised downwards over the last 30 days 
Mylan N V   MYL   Mylan is another company that finds itself mired deep in the drug pricing controversy given the price hikes taken for its life saving combination product EpiPen  This Zacks Rank  4  Sell  stock has seen its share price declining 30 3  so far in 2016  While earnings estimates for 2016 are down 2 6  over the last 30 days  2017 estimates are down 2 3  
Gilead Sciences Inc  NASDAQ GILD    GILD   Gilead  a Zacks Rank  5 stock  missed earnings estimates in the recently reported third quarter with the company s hepatitis C virus  HCV  franchise remaining under pressure  Shares are down 24 4  so far in 2016  Estimates for 2016 are down 0 4  over the past 30 days while 2017 estimates are down 1 8  
To know more about this sector  check out our latest  
 
Confidential from Zacks 
Beyond this Industry Outlook  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-11-04,Zacks Investment Research,https://www.investing.com/analysis/pricing-issues-continue-to-weigh-on-the-pharma-sector-200163002,200163002
147633,369149,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 53 ,news,"Investing com   Canada stocks were lower after the close on Tuesday  as losses in the IT  Energy and Financials sectors led shares lower 
At the close in Toronto  the S P TSX Composite declined 0 53  
The best performers of the session on the S P TSX Composite were  Home Capital Group Inc    TO HCG   which rose 29 72  or 2 03 points to trade at 8 86 at the close  Meanwhile  Valeant Pharmaceuticals International Inc  TO VRX  added 24 10  or 3 22 points to end at 16 58 and  Semafo Inc    TO SMF  was up 5 36  or 0 15 points to 2 95 in late trade 
The worst performers of the session were  Open Text  Corp  TO OTEX   which fell 5 31  or 2 53 points to trade at 45 13 at the close   Ensign Energy Services Inc   TO ESI  declined 4 60  or 0 36 points to end at 7 47 and Canopy Growth Corp  TO WEED  was down 4 49  or 0 390 points to 8 300 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 576 to 568 and 124 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 5 07  to 12 85 
Gold Futures for June delivery was down 0 44  or 5 36 to  1221 74 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in June fell 0 97  or 0 45 to hit  45 98 a barrel  while the July Brent oil contract fell 1 09  or 0 54 to trade at  48 80 a barrel 
CAD USD was down 0 29  to 0 7283  while CAD EUR rose 0 15  to 0 6696 
The US Dollar Index Futures was up 0 41  at 99 44 ",2017-05-09,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-0.53-481984,481984
147634,369150,BHC,Zacks Industry Outlook Highlights  Amgen  Vertex  Valeant Pharmaceuticals International  Mylan N V  And Gilead Sciences,opinion,"For Immediate Release

	Chicago  IL   November 07  2016   Today  Zacks Equity Research discusses the Pharmaceuticals  Part 3  including Amgen  NASDAQ AMGN     NASDAQ         Vertex    NASDAQ        Valeant Pharmaceuticals  NYSE VRX  International  Inc     NYSE       Mylan  NASDAQ MYL  N V     NASDAQ         and  Gilead Sciences Inc  NASDAQ GILD      NASDAQ      

	Industry  Pharmaceuticals  Part 3

	Link  

Sector Remains Volatile on Drug Pricing Issues

	Drug pricing is an issue that has been weighing on pharma and biotech stocks for more than a year now  The sector  which previously had a stellar run  started its downward trend in Sep 2015 when a single tweet by Democratic Presidential candidate Hillary Clinton sent pharma and biotech stocks tumbling  Clinton s  price gouging tweet  was in response to a huge price hike  about 5 000   taken by Turing Pharmaceuticals for a drug that was approved by the FDA way back in 1953 

	Since then  focus on the drug pricing issue has gone up and companies like Valeant and Mylan have seen their share prices plunging as they find themselves in the midst of the drug pricing controversy  Moreover  insulin drugmakers are also under attack with Senator Bernie Sanders posting a series of tweets questioning the prices of their insulin drugs  Lilly is a Zacks Rank  3 stock  You can see   

	And then there is Proposition 61   California s ballot measure to ensure that the State of California is able to negotiate with drug companies for drug prices that do not exceed the price paid for the same drugs by the U S  Department of Veterans Affairs  DVA   Not surprisingly  the drug industry is fighting this proposition 

	According to the Oct 2016 Kaiser Health Tracking poll  affordability of prescription drugs remains at the top of the public s priority list for the President and Congress    focus should be on ensuring the affordability of high cost drugs to people who need them and taking steps to lower prescription drug prices 

	In Sep 2016  Democratic Presidential candidate Hillary Clinton announced a health care plan that will address the excessive price hikes of treatments that have been around for years and also reaffirmed her earlier broader plan  announced in Sep 2015  with the aim to lower drug prices for all Americans 

	Given the current scenario  drug companies may find it a bit difficult to justify their high prices by citing the years and funds that go into bringing new treatments to market and the need to invest in R D to bring additional treatments to market  With elections round the corner andPresidential candidates  policymakers  the media and the general public focusing on the high price tags for drugs  this issue is not likely to die down easily 

Biosimilars Changing the Competitive Scenario

	Another challenge being faced by the sector is the recent entry of biosimilar competition in the U S  While a relatively new area  the market for biosimilars is huge and highly lucrative with several blockbuster biologics including Humira and Lantus slated to lose patent protection by 2020  Biosimilars are expected to reduce healthcare costs and provide a large number of patients with access to much needed biologic treatments 

	According to new research released by the IMS Institute for Healthcare Informatics earlier this year  increasing acceptance of biosimilars across different therapeutic areas plus an active pipeline of 56 candidates are expected to lead to total savings of about  110 billion to health systems across Europe and the U S  through 2020 

	The report further says that by 2020  biosimilars will start competing with biologics that currently have annual sales of  50 billion  About 30 companies are developing biosimilars of 16 molecules   most of the biosimilars in development are for reference products like Johnson   Johnson s Remicade  Amgen s    NASDAQ         Enbrel  Roche Biogen s Rituxan and AbbVie s Humira 

	Biosimilars are also gaining acceptance across formularies  CVS Health  NYSE CVS  announced that biosimilars and follow on biologics will be a key part of its 2017 standard formulary strategy  replacing higher cost drugs within the categories  Similar steps have been taken or are being contemplated by other formularies as well 

	Although there is still low visibility on how well biosimilars will perform or how much of the market they will be able to capture  the focus on making expensive drugs more affordable and formulary coverage for biosimilars could very well make it challenging for innovator companies to hold on to market share for their blockbuster drugs 

Will New Products Make Up for Lost Sales 

	Quite a few of the big players in the drug industry are looking at loss of patent protection for major blockbuster drugs  With generics and biosimilars breathing down their necks  many of these companies are looking towards new products to pick up the pace and make up for lost sales  While several new products were approved last year  many like Orkambi  Repatha and Praluent failed to live up to expectations 

Vertex    NASDAQ         lowered its 2016 guidance for cystic fibrosis treatment Orkambi in September to reflect slower refills in the U S  during the summer months of July and August as well as a slower than expected launch in Germany 

	Meanwhile  PCSK9 inhibitors  Repatha and Praluent  which are expected to bring in blockbuster sales  are yet to see a significant ramp up  Sales of these products are not likely to pick up significantly until the availability of favorable cardiovascular outcomes study data 

Stocks to Avoid

	As concerns surrounding the drug pricing issue continue to keep the sector volatile  it would be prudent to stay away from stocks that have not been able to win analysts  confidence and carry an unfavorable Zacks Rank 

Valeant Pharmaceuticals International  Inc     NYSE            Valeant  a Zacks Rank  5  Strong Sell  stock  is one of the companies hit hard by the pricing controversy due to its strategy of acquiring companies and selling their drugs at higher prices  Shares are down 75 8  so far in 2016 while earnings estimates for both 2016  down 0 3   and 2017  down 0 8   have been revised downwards over the last 30 days 

Mylan N V     NASDAQ            Mylan is another company that finds itself mired deep in the drug pricing controversy given the price hikes taken for its life saving combination product EpiPen  This Zacks Rank  4  Sell  stock has seen its share price declining 30 3  so far in 2016  While earnings estimates for 2016 are down 2 6  over the last 30 days  2017 estimates are down 2 3  

Gilead Sciences Inc     NASDAQ            Gilead  a Zacks Rank  5 stock  missed earnings estimates in the recently reported third quarter with the company s hepatitis C virus  HCV  franchise remaining under pressure  Shares are down 24 4  so far in 2016  Estimates for 2016 are down 0 4  over the past 30 days while 2017 estimates are down 1 8  

	To know more about this sector  check out our latest  

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  











	Follow us on Twitter  

	Join us on Facebook  

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact
	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-11-06,Zacks Investment Research,"https://www.investing.com/analysis/zacks-industry-outlook-highlights:-amgen,-vertex,-valeant-pharmaceuticals-international,-mylan-n.v.-and-gilead-sciences-200163141",200163141
147635,369151,BHC,Valeant and Mylan perk up after Teva earnings beat,news,Premarket buying  albeit modest  moves generic drug firms Valeant Pharmaceuticals  NYSE VRX   and Mylan N V   NASDAQ MYL  up 1  on the heels of Teva s Q1 results released this morning  The company beat non GAAP EPS and reaffirmed guidance for the year  It also stated that it expects to realize  1 5B in synergies and cost reductions by the end of 2017 Source  BloombergNow read ,2017-05-11,Seeking Alpha,https://www.investing.com/news/stock-market-news/valeant-and-mylan-perk-up-after-teva-earnings-beat-483047,483047
147637,369153,BHC,Teva launches generic Glumetza in U S ,news,Teva Pharmaceutical Industries  TEVA  0 9   launches its generic version of Valeant Pharmaceuticals   VRX  4 7   diabetes med Glumetza  metformin hydrochloride  in the U S  According to IMS Heath  the market is   1 03B Now read ,2017-05-15,Seeking Alpha,https://www.investing.com/news/stock-market-news/teva-launches-generic-glumetza-in-u.s.-484497,484497
147638,369154,BHC,Canada stocks lower at close of trade  S P TSX Composite down 1 73 ,news,"Investing com   Canada stocks were lower after the close on Wednesday  as losses in the Healthcare  IT and Industrials sectors led shares lower 
At the close in Toronto  the S P TSX Composite fell 1 73  to hit a new 1 month low 
The best performers of the session on the S P TSX Composite were  Fortuna Silver Mines  Inc  TO FVI   which rose 4 05  or 0 25 points to trade at 6 42 at the close  Meanwhile  Kirkland Lake Gold Ltd  TO KL  added 3 96  or 0 390 points to end at 10 240 and  Pan American Silver  Corp  TO PAAS  was up 3 15  or 0 76 points to 24 88 in late trade 
The worst performers of the session were  Sierra Wireless Inc    TO SW   which fell 6 99  or 2 69 points to trade at 35 77 at the close   HudBay Minerals  Inc   TO HBM  declined 6 58  or 0 51 points to end at 7 24 and Valeant Pharmaceuticals International Inc  TO VRX  was down 5 54  or 1 06 points to 18 07 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 901 to 276 and 127 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 9 84  to 14 85 
Gold Futures for June delivery was up 1 90  or 23 49 to  1259 89 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in June rose 0 70  or 0 34 to hit  49 00 a barrel  while the July Brent oil contract rose 0 97  or 0 50 to trade at  52 15 a barrel 
CAD USD was down 0 01  to 0 7349  while CAD EUR fell 0 68  to 0 6586 
The US Dollar Index Futures was down 0 74  at 97 37 ",2017-05-17,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-1.73-485606,485606
147652,369168,BHC,Valeant Pharmaceuticals  VRX  Appoints New CFO  Stock Gains 7 2 ,opinion,"Shares of Valeant Pharmaceuticals   NYSE VRX   were up over 7  in midday trading on Monday after the company announced the appointment of a new Chief Financial Officer  CFO   Monday s stock movement reflects is yet another continuation in the company s rollercoaster story 
Earlier in August  shares of Valeant  after the company reported an earnings miss but issued a positive outlook   Two days later  shares  following reports that the company is under criminal investigation 
The investigation concerns Valeant s relationship with specialty pharmacy Philidor Rx  with claims that it worked with the company to boost sales but hid the relationship from insurers  defrauding them in the process 
Investigations aren t new for Valeant  which has seen its stock decline over 90  over the last 12 months due to multiple SEC and congressional probes into its price hikes for drug products 
Still  many see the arrival of a new CFO as the beginning of a turnaround for the troubled company  Mad Money on CNBC s Jim Cramer  that bringing in a high quality CFO  could change things  and that  Valeant shareholders should cheer this move  
Regardless  it is difficult to remain optimistic on a company that has been blighted by successive challenges  The company has seen two upward and one downward earnings estimate revision for the current quarter  representing a consensus estimate of  1 79 in earnings per share  This however  is still six cents lower than the consensus estimate of 60 days ago 
Furthermore  the company has seen multiple downward earnings estimate revisions for the current fiscal year  Current estimate stand at  6 64 in earnings per share  down from the  6 86 estimate of 60 days ago 
The chart below reflects the many woes that have plagued the company in recent times VALEANT PHARMA Price   While the move to bring in new executive management is to be welcomed  investors still have plenty of reason to remain skeptical of Valeant s future prospects  The company did receive lender approval to amend its credit facility  a move that will help improve its financial condition  However  the aforementioned investigation is ongoing 
Investors should maintain a watchful eye for new developments before deciding on a potential play 
Valeant currently sits at a Zacks Rank  3  Hold  ",2016-08-22,Zacks Investment Research,"https://www.investing.com/analysis/valeant-pharmaceuticals-(vrx)-appoints-new-cfo,-stock-gains-7.2-200149364",200149364
147653,369169,BHC,Economic Calendar And Watch List  August 22nd  2016,opinion,"Morning Notes

US Futures are slightly lower along with European markets also trading lower as the price of crude oil takes nearly a  3  hit early  Iran commented that they would be boosting oil supplies by upwards of 150K BPD since the reopening of several of their oil fields  Asian stocks closed mostly mixed 


Technicals



The SPY  NYSE SPY  consolidated throughout last week while holding higher price levels which could potentially mean more highs in the near term  Support will lie at the low of Friday s range at  217 74  followed by the upper support pivot at  217 30  then  217 02   216 78  and  215 83  Resistance will lie at the high of Friday s range at  218 75  then  218 90  and all time highs at  219 50 

Small Cap Watch List

 Please refer to the momentum scanners displayed live in the chat room for potential plays at the market open  


  Others On Watch  

Valeant Pharmaceuticals International Inc  NYSE VRX 

Economic Calendar

8 30 July Chicago Fed national activity index

11 00 USDA weekly grain export inspections

3 00 USDA Jul Cold Storage

4 00 USDA Weekly Crop Progress

Notable Earnings Before Open

NONE


Notable Earnings After Close

NONE",2016-08-22,Warrior Trading,https://www.investing.com/analysis/economic-calendar---watch-list-8-22-2016-200149266,200149266
147656,369172,BHC,Valeant Pharmaceuiticals Stock  Skyrocketing On CFO News,opinion,"Valeant Pharmaceuticals  NYSE VRX  
Valeant Pharmaceuticals is having an incredible day in the market today  and for good reason  The company announced the appointment of a new CFO  Today  we ll talk about the news  how the stock reacted  and what we can expect to see from VRX ahead  So  let s get right to it   
VRX Appoints Paul Herendeen As CFO
Valeant Pharmaceuticals has been through quite a bit as of late  After being caught in a scandal and shown to have been lying to investors  the stock has fallen dramatically  However  there s a new CEO in town  and he is making some big changes  One of the most recent changes was an announcement early Monday morning that the company has hired Paul Herendeed as the CFO  This is the latest in a string of management changes that we ve seen in VRX since the Philidor scandal that left the company in shambles 
Paul Herendeen was previously an executive at the animal healthcare company known as Zoetis  ZTS   In the announcement  we learned that Herendeen will be replacing Robert Rosiello  effective immediately 
It was also announced that Rosiello will not be leaving VRX entirely  Moving forward  he will stay on board at the company as the executive vice president of corporate development and strategy 
How The Stock Reacted To The News
As mentioned above  Valeant Pharmaceuticals is having an incredibly strong day in the market  After all  any moves that shake up existing management and continue to rebrand the way people view the company will likely lead to positive movement in the market  Currently  12 55   the stock is trading at  31 05 per share after a gain of  2 31 per share or 8 04  thus far today 
What I m Expecting To See Moving Forward
Moving forward  there is a relatively mixed view among analysts  Personally  I have an overwhelmingly bullish opinion of what we can expect to see from VRX ahead  At the end of the day  the company did make a mistake that came to light late last year  and the stock did tank as a result  However  since then  we ve seen several changes at the company  They are no longer working with Philidor  management has changed significantly  new contracts have been opened  and more  The announcement today of Herendeen being appointed as the company s CFO is just another point that shows that we re working with what could be perceived as an entirely new company  One that had nothing to do with the scandal 
With that said  looking at VRX from this point of view  the stock is incredibly promising  When we talk about Valeant Pharmaceuticals  we re talking about a company that has amassed a massive amount of products  many of which have proven to be successful  Also  the pipeline the company has is really second to none  Moving forward  I m expecting to see an incredibly strong recovery as the company works to regain its footing and trust among investors  All in all  I m expecting to see strong gains from the stock in the long run ",2016-08-23,Joshua Rodriguez,https://www.investing.com/analysis/valeant-pharmaceuiticals-(vrx)-stock:-skyrocketing-on-cfo-news-200149428,200149428
147657,369173,BHC,Here s Why I m Bullish Valeant,opinion,"Valeant Pharmaceuticals  NYSE VRX  is one of the most heavily debated stocks in the pharmaceutical space  and for good reason  Late last year  the company was caught in the middle of a scandal that led to declining investor sentiment  a completely shift in management  and a massive decline in the price of its stock  However  since the scandal  many see the company as one that has turned around completely  Personally  I side with the bulls on VRX  Today  we ll talk about why 
Morgan Stanley Upgrade
If you follow my work  you know that I never advise blindly following the opinions of analysts  The truth is that they are only human  which means they too are subject to error  However  recently a Morgan Stanley  NYSE MS  analyst by the name of David Risinger upgraded the stock  In so doing  he noted some key points 
In his comments  Risinger made a point of the fact that Joseph Papa has really shifted management around  turning it into a more trusted company  He also said that the new management team seems to be making the right moves  which should lead to growth for VRX  He also went into NOLs that offset tax issues associated with asset sales and upcoming consideration payments  Finally  he was impressed with the fact that the company is on the right track toward paying off debt  Here s a key quote from the release that outlines 4 reasons that Risinger decided to upgrade VRX 

Papa had been in discussions with new CFO Paul Herendeen for a few months to bring him on board  Papa did not commit and say that Herendeen has  bought in  to 2H16 guidance  but commented that Herendeen had spent a lot of time trying to understand the business before taking the role 
The company has approximately  2B of NOLs in the U S  and  2B in Canada  which help offset tax leakage in asset sales 
Mgmt  believes investigation related settlements are two years away at minimum  Once fines settlements are  estimable and probable  then the company will reserve cash for settlements in restricted cash  as per accounting rules   
Upcoming contingent consideration payments include   150M for brodalumab approval and  50M for Relistor oral  We already factor in  400M of contingent consideration in 2H16 in our cash flow model 

It s A New Company
When we talk about VRX  we re talking about a new company with the same products and others coming on board  The reality is that any company is only as strong as the management that runs it  Unfortunately  the previous management team that was part of the company made huge mistakes  However  Papa knew that he had to shake things up and bring other people in to really revamp the process and improve the company  Since his start with Valeant  he has done just that 
At the end of the day  VRX has a strong lineup of great products  It has agreements with leaders in the industry to sell these products  Now  the company has a new management team that s focused on increasing sales  paying off debt  and returning value to shareholders  All in all  I believe that we ve seen a complete 180  and that this stock will climb from here ",2016-08-26,Joshua Rodriguez,https://www.investing.com/analysis/here's-why-i'm-bullish-valeant-200150336,200150336
147658,369174,BHC,Orexigen Stock Up On Commercialization Deal For Contrave,opinion,"Orexigen Therapeutics  Inc  s   NASDAQ OREX   shares were up 4 2  after the company announced that it has entered into a commercialization and distributorship agreement with Valeant Canada  a subsidiary of Valeant Pharmaceuticals International  Inc    NYSE VRX    for its obesity drug  Contrave  EU trade name  Mysimba   in Canada Under the terms of the agreement  Valeant will be responsible for a regulatory approval in Canada and for all commercialization activity and expenses  On the other hand  Orexigen would supply Contrave tablets for an agreed transfer price  based on certain potential regulatory and sales milestone payments A regulatory application for Contrave in Canada is expected to be filed by Jan 2017 OREXIGEN THERAP Price
    Note that Contrave was approved in the U S  in 2014  as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index  BMI  of 30 kg m2 or greater  obese   or 27 kg m2 or greater  overweight  in the presence of at least one weight related comorbid condition We remind investors that in Mar 2016  Orexigen struck a deal with Valeant to commercialize Mysimba across 19 countries in central and eastern Europe  The companies anticipate a launch of the drug in 11 countries by the fourth quarter of 2016  This would be followed by its launch in two more countries in the first quarter of 2017 According to data from Statistics Canada  almost two thirds of adult Canadians are either overweight or obese  It has been estimated that each year  the economic burden of obesity ranges from  4 6  7 1 billion in Canada The obesity market is already crowded with drugs like Belviq  Qsymia and Saxenda  among others and competition intensifying with the entry of new products Orexigen currently has a Zacks Rank  3  Hold   A couple of better ranked stocks in the health care sector include Pacira Pharmaceuticals  Inc    NASDAQ PCRX   and ANI Pharmaceuticals  Inc    NASDAQ ANIP    Both the stocks sport a Zacks Rank  1  Strong Buy  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-08-30,Zacks Investment Research,https://www.investing.com/analysis/orexigen-stock-up-on-commercialization-deal-for-contrave-200151096,200151096
147665,369181,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 17 ,news,"Investing com   Canada stocks were lower after the close on Wednesday  as losses in the Healthcare  IT and Financials sectors led shares lower 
At the close in Toronto  the S P TSX Composite lost 0 17  
The best performers of the session on the S P TSX Composite were Hudson s Bay Company  TO HBC   which rose 7 73  or 0 75 points to trade at 10 45 at the close  Meanwhile   Raging River Exploration Inc    TO RRX  added 3 90  or 0 37 points to end at 9 86 and OceanaGold Corporation  TO OGC  was up 3 59  or 0 150 points to 4 330 in late trade 
The worst performers of the session were Valeant Pharmaceuticals International Inc  TO VRX   which fell 6 30  or 0 86 points to trade at 12 79 at the close   Martinrea International Inc    TO MRE  declined 2 79  or 0 27 points to end at 9 42 and  Bonavista Energy Corp   TO BNP  was down 2 31  or 0 080 points to 3 380 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 636 to 514 and 145 ended unchanged 
Shares in Valeant Pharmaceuticals International Inc  TO VRX  fell to 5 year lows  losing 6 30  or 0 86 to 12 79  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 21 14  to 9 44 a new 1 month low 
Gold Futures for June delivery was down 0 04  or 0 45 to  1257 95 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in May fell 0 31  or 0 16 to hit  50 87 a barrel  while the June Brent oil contract fell 0 15  or 0 08 to trade at  54 09 a barrel 
CAD USD was down 0 21  to 0 7446  while CAD EUR fell 0 21  to 0 6976 
The US Dollar Index Futures was down 0 04  at 100 38 ",2017-04-05,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-0.17-471825,471825
147666,369182,BHC,Exclusive  Billionaire investor Julian Robertson pulls plug on prot g s fund,news,By Lawrence Delevingne and Svea Herbst Bayliss NEW YORK BOSTON  Reuters    Billionaire investor Julian Robertson is shutting a portfolio that let outsiders bet with him on would be star managers and has exited entirely from former prot g e Nehal Chopra s Ratan Capital Management  according to recent regulatory filings  The closure of Tiger Management Advisors LLC s six year old Tiger Accelerator Fund comes after poor performance and sharp declines in assets at its underlying hedge fund firms  For now  it marks the end of retired hedge fund legend Robertson s side business of gathering other people s money to invest in smaller hedge funds  even though he left open the possibility of pursuing such a strategy again   For nearly two decades  Robertson has made investments with roughly three dozen hedge funds  including a number run by his former employees  whose firms are often referred to as  Tiger Cubs   in a nod to the name of Robertson s hedge fund Tiger Management   The Tiger Accelerator Fund was unusual in that it grouped six such individual funds together and allowed investors  who might not be able to afford getting into some of the other funds that Robertson backs  to track the billionaire s best new prospects  The fund gave them stakes as limited partners and let them share in the revenue  It managed just  28 5 million of outside capital as of Dec  31  2016  according to a Securities and Exchange Commission filing made on March 30  That is down more than 90 percent from  450 million at its launch in 2011  which marked Robertson s return to accepting outside capital  a practice he had ended in 2000 when he shut his hedge fund  A spokesman for Robertson  84  declined to comment  Tiger Accelerator joins the growing list of failed hedge funds hurt by investors flocking to the exits in the face of high fees and sluggish returns  Data from Hedge Fund Research show 1 057 portfolios shuttered last year  the most liquidations since 2009  Among the latest wave of managers supported by Robertson  the reversal of fortune at Chopra s Ratan Capital Management has been particularly stark  Her fund  named after the Hindi word for jewel  grew quickly to manage more than  1 billion  with capital from a public pension fund in New York and the family foundation of Robert Kraft  owner of the New England Patriots  Working in the same Park Avenue  New York City building as Tiger  Ratan produced three straight years of double digit gains until a big bet on drugmaker Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX  soured and hurt the fund in 2015 and 2016  The fund managed just  375 million as of Dec  31  according to its latest regulatory filing  Robertson has pulled out of the Ratan fund completely according to a separate March 30 SEC filing  Most of the other five Tiger seedlings have also suffered  Tiger Veda closed down in November 2015  Cascabel Management shut down in the first half of 2015  Robertson pulled his money out of Long Oar Global Investors LLC in early 2014  and the firm is no longer registered with the SEC  an indication that it is either out of business or manages less than  100 million   Tiger Eye Capital  now the largest of the Tiger Accelerator Fund cohort of managers  has seen its assets drop to  923 million at the end of last year from  1 4 billion at the start of 2016  according to a recent SEC filing  Teewinot Capital Advisors LLC decided to stop managing money for the Tiger Accelerator portfolio in the third quarter of 2016  a source familiar with the matter said  At the end of last year  Teewinot managed  154 million  up from  138 million in April 2015  Representatives for the six funds either declined to comment or did not respond to requests for comment  For more on the history of the Tiger Accelerator Fund  click here      DIASPORA DELIVERS MIXED RESULTS  Some of the managers in the fund initially posted strong performance and assets grew significantly  especially at Tiger Eye and Ratan  As a result  early investors in the Tiger Accelerator Fund appear to have made money  As of August 2015  about  15 million has been paid out by Tiger Accelerator to investors from their minority stakes in the underlying hedge funds  people familiar with the matter told Reuters   A more up to date figure was not available  The fund has been run day to day by Chief Investment Officer Gil Caffray and President Alex Robertson  Julian s son   Julian Robertson s personal wealth continued to climb even as the Tiger Accelerator Fund has stumbled  Forbes puts his net worth at  3 8 billion  up from  3 4 billion in 2015 and  1 5 billion in 2000  Robertson had more than  230 million invested with the six newcomers in the Tiger Accelerator Fund in January 2011 before raising outside capital with the help of  Morgan Stanley   NYSE MS  marketers  according to fund materials seen by Reuters  While many members of the Tiger diaspora boast strong long term results  some have struggled lately  Tiger Global Management  led by Robertson prot g  Chase Coleman  lost 15 percent last year  This year the firm s hedge fund is making money again  having returned 13 5 percent in the first quarter  an investor said  Another Tiger seeded firm  Hound Partners LLC  ended 2016 with a 2 3 percent loss and is roughly flat this year after a 1 1 percent gain in March  an investor said  And Viking Global Investors  led by former Robertson deputy Andreas Halvorsen  ended 2016 with a 4 percent loss  but is up 4 9 percent this year  an investor said  Representatives for those funds declined to comment ,2017-04-06,Reuters,https://www.investing.com/news/stock-market-news/exclusive:-billionaire-investor-julian-robertson-pulls-plug-on-protgs-fund-472336,472336
147668,369184,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 40 ,news,"Investing com   Canada stocks were lower after the close on Tuesday  as losses in the Energy  Healthcare and Financials sectors led shares lower 
At the close in Toronto  the S P TSX Composite lost 0 40  
The best performers of the session on the S P TSX Composite were  ProMetic Life Sciences Inc    TO PLI   which rose 2 94  or 0 060 points to trade at 2 100 at the close  Meanwhile  Amaya Inc  TO AYA  added 2 90  or 0 66 points to end at 23 39 and  Osisko Gold Ro   TO OR  was up 2 61  or 0 39 points to 15 34 in late trade 
The worst performers of the session were Valeant Pharmaceuticals International Inc  TO VRX   which fell 5 14  or 0 65 points to trade at 11 99 at the close   Ivanhoe Mines Ltd    TO IVN  declined 5 12  or 0 270 points to end at 5 000 and  Lundin Mining  Corporation  TO LUN  was down 4 83  or 0 360 points to 7 090 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 761 to 396 and 124 ended unchanged 
Shares in Valeant Pharmaceuticals International Inc  TO VRX  fell to 5 year lows  down 5 14  or 0 65 to 11 99  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 19 36  to 15 60 a new 1 month high 
Gold Futures for June delivery was down 0 07  or 0 90 to  1291 00 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in May fell 0 02  or 0 01 to hit  52 64 a barrel  while the June Brent oil contract fell 0 49  or 0 27 to trade at  55 09 a barrel 
CAD USD was down 0 57  to 0 7466  while CAD EUR fell 1 33  to 0 6962 
The US Dollar Index Futures was down 0 79  at 99 41 ",2017-04-18,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-0.40-475149,475149
147669,369185,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 07 ,news,"Investing com   Canada stocks were lower after the close on Friday  as losses in the Healthcare  Financials and Clean Technology sectors led shares lower 
At the close in Toronto  the S P TSX Composite declined 0 07  
The best performers of the session on the S P TSX Composite were  Home Capital Group Inc    TO HCG   which rose 8 70  or 1 54 points to trade at 19 25 at the close  Meanwhile  Kinross Gold Corporation  TO K  added 2 76  or 0 14 points to end at 5 22 and Le Groupe Jean Coutu PJC Inc  TO PJCa  was up 2 41  or 0 52 points to 22 07 in late trade 
The worst performers of the session were  Dorel Industries Inc   TO DIIb   which fell 4 99  or 1 68 points to trade at 32 00 at the close  Valeant Pharmaceuticals International Inc  TO VRX  declined 4 42  or 0 53 points to end at 11 45 and  Nevsun Resources Ltd    TO NSU  was down 3 56  or 0 120 points to 3 250 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 673 to 468 and 130 ended unchanged 
Shares in Valeant Pharmaceuticals International Inc  TO VRX  fell to 5 year lows  falling 4 42  or 0 53 to 11 45  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 11 57  to 12 15 
Gold Futures for June delivery was up 0 21  or 2 70 to  1286 50 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in June fell 2 21  or 1 12 to hit  49 59 a barrel  while the June Brent oil contract fell 2 00  or 1 06 to trade at  51 93 a barrel 
CAD USD was down 0 24  to 0 7406  while CAD EUR fell 0 17  to 0 6915 
The US Dollar Index Futures was up 0 07  at 99 78 ",2017-04-21,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-0.07-476374,476374
147670,369186,BHC,Big hedge funds  assets edge lower in 2016  Billion Dollar Club survey,news,By Svea Herbst Bayliss BOSTON  Reuters    Assets managed by the largest hedge funds slipped in 2016 in their first calendar year decline since the financial crisis  according to a survey released on Thursday by data and news provider Hedge Fund Intelligence  The twice annual Billion Dollar Club report showed that the 309 largest hedge funds oversaw assets of  1 88 trillion at the beginning of January 2017  This marks a 0 04 percent contraction from a year earlier  Assets declined last year at more than half of the hedge funds managing more than  1 billion  also a first since the financial crisis  The data tracks roughly two thirds of the entire hedge fund universe  which is generally estimated to oversee  3 trillion  It illustrates the difficulties the industry has faced as investors like pension funds are pulling money out in response to hedge funds  lackluster returns and high fees  The biggest decline in assets was at Och Ziff Capital Management  one of only a handful of publicly traded hedge funds  Its assets dropped by  11 1 billion to  33 5 billion  the survey said  Och Ziff last year settled charges with the U S  Justice Department that some employees had bribed officials in Africa  A number of pension funds  including the state of Rhode Island  dropped the firm as they pulled back their exposure to hedge funds  York Capital Management s assets dropped to  16 2 billion from  22 3 billion  Paulson   Co  one of a number of hedge funds to lose a lot of money on Valeant Pharmaceuticals International Inc  NYSE VRX   showed a decrease to  9 82 billion from  14 21 billion  the survey reported  But there were winners as well  Bridgewater Associates retained its spot as the biggest hedge fund as its assets climbed to  122 3 billion from  104 2 billion   Indeed Bridgewater and AQR Capital Management controlled 10 24 percent of the Billion Dollar Club s assets  This was the first time the two biggest firms in the exclusive club jointly oversaw more than 10 percent   Representatives for the funds either declined to comment or did not respond to requests seeking comment  A notable new entrant is distressed debt investment firm Silver Rock Financial  which received funding from junk bond investor Michael Milken and had  2 3 billion at the start of 2017   Assets shrank at Folger Hill Asset Management and TPG Axon Capital Management  which were dropped from the club ,2017-04-27,Reuters,https://www.investing.com/news/stock-market-news/big-hedge-funds-see-assets-shrink:-billion-dollar-club-survey-478080,478080
147671,369187,BHC,Drug maker Valeant on course to debt repayment target  CEO,news,"LAVAL  Quebec  Reuters    Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX   weighed down by debt from years of acquisitions  is on pace to meeting its target of repaying  5 billion in debt between August  2016 and February  2018  Chief Executive Joe Papa told shareholders on Tuesday  
Repayment is expected to come from asset sale proceeds and free cash flow  and the company has earlier announced sales that will generate up front proceeds of  2 35 billion ",2017-05-02,Reuters,https://www.investing.com/news/stock-market-news/drug-maker-valeant-on-course-to-debt-repayment-target:-ceo-479355,479355
147672,369188,BHC,Valeant Pharma considering a name change  CEO says,news,Valeant Pharmaceuticals  VRX  4 1   is considering a name change  as it seeks to move away from the bad publicity that has dogged the company amid harsh criticism of its business practices and future prospects  No final decision has been made but the company is  very serious  in considering the idea  CEO Joe Papa says at VRX s annual shareholders meeting Papa also says VRX in on pace to meet its target to pay down  5B of debt from divestiture proceeds and free cash flow by February 2018 Now read  JPMorgan  NYSE JPM  Agrees Valeant Is Likely Worthless,2017-05-02,Seeking Alpha,"https://www.investing.com/news/stock-market-news/valeant-pharma-considering-a-name-change,-ceo-says-479386",479386
147673,369189,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 28 ,news,"Investing com   Canada stocks were higher after the close on Tuesday  as gains in the Healthcare  Industrials and Consumer Staples sectors led shares higher 
At the close in Toronto  the S P TSX Composite rose 0 28  
The best performers of the session on the S P TSX Composite were  Home Capital Group Inc    TO HCG   which rose 11 35  or 0 79 points to trade at 7 75 at the close  Meanwhile  Colliers International Group Inc  TO CIGI  added 6 76  or 4 64 points to end at 73 24 and Valeant Pharmaceuticals International Inc  TO VRX  was up 6 73  or 0 89 points to 14 11 in late trade 
The worst performers of the session were  Guyana Goldfields Inc    TO GUY   which fell 4 41  or 0 280 points to trade at 6 070 at the close   Alamos Gold Inc   TO AGI  declined 4 10  or 0 40 points to end at 9 23 and  Norbord Inc   TO OSB  was down 3 81  or 1 61 points to 40 65 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 572 to 548 and 142 ended unchanged 
Shares in Colliers International Group Inc  TO CIGI  rose to all time highs  gaining 6 76  or 4 64 to 73 24  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 4 73  to 12 29 
Gold Futures for June delivery was up 0 21  or 2 69 to  1258 19 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in June fell 2 50  or 1 22 to hit  47 62 a barrel  while the July Brent oil contract fell 2 17  or 1 12 to trade at  50 40 a barrel 
CAD USD was down 0 23  to 0 7293  while CAD EUR fell 0 46  to 0 6675 
The US Dollar Index Futures was down 0 15  at 98 83 ",2017-05-02,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.28-479504,479504
147676,369192,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 45 ,news,"Investing com   Canada stocks were higher after the close on Monday  as gains in the Energy  REITs and Clean Technology sectors led shares higher 
At the close in Toronto  the S P TSX Composite rose 0 45  
The best performers of the session on the S P TSX Composite were  Home Capital Group Inc    TO HCG   which rose 16 75  or 0 98 points to trade at 6 83 at the close  Meanwhile   NexGen Energy Ltd    TO NXE  added 8 67  or 0 260 points to end at 3 260 and  Bonavista Energy Corp   TO BNP  was up 6 93  or 0 210 points to 3 240 in late trade 
The worst performers of the session were Canopy Growth Corp  TO WEED   which fell 2 91  or 0 260 points to trade at 8 690 at the close  Valeant Pharmaceuticals International Inc  TO VRX  declined 2 77  or 0 38 points to end at 13 36 and  Badger Daylighting Ltd    TO BAD  was down 2 77  or 0 87 points to 30 55 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 667 to 467 and 145 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 0 25  to 12 21 
Gold Futures for June delivery was up 0 04  or 0 46 to  1227 36 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in June rose 0 58  or 0 27 to hit  46 49 a barrel  while the July Brent oil contract rose 0 65  or 0 32 to trade at  49 42 a barrel 
CAD USD was down 0 38  to 0 7299  while CAD EUR rose 0 33  to 0 6682 
The US Dollar Index Futures was up 0 58  at 98 99 ",2017-05-08,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.45-481310,481310
147682,369198,BHC,4 Stocks To Watch  AMBA  CPE  CWEI  DEPO,opinion,"It was a distinctly different market on Tuesday  First it was up sharply in the morning making new all time highs on the S P 500  then a nice  solid pullback  5 wave decline midday  before a late bounce brought them back to close just slightly positive on the day  Nevertheless  we have a lot of stocks that we are watching that are doing very well  Let s take a look at them 
Ambarella  Inc   NASDAQ AMBA   a swing trade of ours  is doing well  It had a solid decline from mid 2015 to early 2016  formed a base  broke out  flagged  and ran up in a nice channel  It s getting up near my target near the Dec high  up around the 64 65 range  which could be reached rather shortly  It was up 1 83 to 61 08  or 3   on 1 3 million shares  It has 9 24 days to cover 
Callon Petroleum Company  NYSE CPE  popped 42 cents to 12 84  or 3 38   on 6 7 million shares on Tuesday  I have been watching this stock for a very long time  After a crumbling in 2007 8  going from 28 all the way down to under a dollar  it based out over the last several years  then popped  and consolidated for a year and a half  It went up to resistance  held it  continued to hold  formed a 3 month consolidation  and then spiked up in the last six days  going from about 10 34 to 13 25  It may consolidate  but I think the target right now is just under 15  and then 17 and 19 1 2  I put it out as a swing on Tuesday  It may be a little early  but it has momentum  It has 5 2 days to cover  so we may see an extension 
Clayton Williams Energy  Inc   NYSE CWEI  is one of the best acting stocks of ours for this year for a swing trade  having gone from 19 to 54  It did back off late on Tuesday  closing up 1 34 to 51 78  or 2 66   on 643 168 shares traded  My target was 54 55  and we reached that  It looks to me like it has a very strong pattern  The most recent moves have taken it from a low of 6 35 to 54  That s huge  If it gets near mid to high 60 s that would be a stellar move  This stock has come a long way  It has 4 94 days to cover 
DepoMed Inc   NASDAQ DEPO  had a nice pop on Tuesday after a pullback  up 26 cents to 21 49  or 1 22   on 1 15 million shares  but it didn t hold high  The reason I like it is because of the way the OBV is acting  The wedge that it was in is broken  It s been up for five days in a row and the pullback held support  I m going to look for a breakout above Tuesday s high at 22 02  and a move to 25  or better  It has 11 days to cover 
Stocks on the long side included Advaxis  Inc   NASDAQ ADXS   Ambarella  Inc   AMBA   ANI Pharmaceuticals  Inc   NASDAQ ANIP   Accelerate Diagnostics  Inc   NASDAQ AXDX   Sotheby s  NYSE BID   Bellicum Pharmaceuticals  Inc   NASDAQ BLCM   The Chemours Company  NYSE CC   Callon Petroleum Company  CPE   Castlight Health  Inc   NYSE CSLT   Clayton Williams Energy  Inc   CWEI   DepoMed Inc   DEPO   Gigamon Inc   NYSE GIMO   Horizon Pharma plc  NASDAQ HZNP   INSYS Therapeutics  Inc   NASDAQ INSY   Inphi Corporation  NYSE IPHI   MeetMe Inc   NASDAQ MEET   Nevro Corp   NYSE NVRO   Aratana Therapeutics  Inc   NASDAQ PETX   Progenics Pharmaceuticals  Inc   NASDAQ PGNX   Rackspace Hosting  Inc   NYSE RAX   Resolute Energy Corporation  NYSE REN   Rapid7  Inc   NASDAQ RPD   Synergy Pharmaceuticals  Inc   NASDAQ SGYP   Valeant Pharmaceuticals  NYSE VRX   Weibo Corporation  NASDAQ WB   and Yirendai Ltd   NYSE YRD  ",2016-08-09,Harry Boxer,"https://www.investing.com/analysis/amba,-cpe,-cwei,-depo-200147029",200147029
147683,369199,BHC,Stocks Finish Nearly Flat In Choppy Session,opinion,"U S  equities finished near the unchanged mark in a session that saw a marked swing in and out of negative territory  as investors weighed some lackluster earnings reports  fairly upbeat domestic economic data  and uninspiring inflation reports out of China  Meanwhile  Treasuries and gold were higher  but crude oil prices and the U S  dollar were lower 
The Dow Jones Industrial Average  DJIA  gained 4 points to 18 533  the S P 500 Index inched nearly 1 point higher to 2 182 and the Nasdaq Composite rose 12 points  0 2   to 5 225  In moderate volume  775 million shares were traded on the NYSE and 1 6 billion shares changed hands on the Nasdaq  WTI crude oil lost  0 25 to  42 77 per barrel  wholesale gasoline was  0 01 lower at  1 35 per gallon and the Bloomberg gold spot price rose  5 11 to  1 340 42 per ounce  Elsewhere  the Dollar Index a comparison of the U S  dollar to six major world currencies was 0 3  lower at 96 13 
Gap Inc   NYSE GPS  27  reported a 4 0  year over year  y y  drop in July same store sales  versus the FactSet estimate of a 1 0  decline  as sales at its Gap and Banana Republic segments fell  while its Old Navy unit posted flat sales  GPS were solidly lower 
Valeant Pharmaceuticals International Inc   NYSE VRX  28  achieved 2Q earnings per share  EPS  ex items of  1 40  versus the expected  1 47  as revenues declined 11 0  y y to  2 4 billion  compared to the projected  2 5 billion  However  shares were sharply higher as the company reaffirmed its full year guidance and announced plans to divest assets 
Coach Inc   NYSE COH  41  posted fiscal 4Q EPS ex items of  0 45  above the projected  0 41  as revenues rose 15 0  y y to  1 2 billion  roughly in line with forecasts  North American retail same store sales rose 2 0  y y  slightly above estimates and the first increase in in over 12 quarters  COH traded lower as the company s 4Q revenue growth and full year EPS guidance are garnering some scrutiny among analysts 
Hertz Global Holdings Inc   HTZ  45  announced 2Q profits ex items of  0 41 per share  including unanticipated net charges making it unclear if the figure was comparable to the projected  0 29  Revenues declined 2 0  y y to  2 3 billion  in line with expectations  HTZ issued full year EPS guidance that was below estimates and shares were solidly lower 
Wayfair Inc  NYSE W    W  39  fell sharply after the home furnishing retailer posted a 2Q loss of  0 43 per share  compared to the forecasted loss of  0 40 per share  and issued 3Q revenue guidance that missed expectations 
Small business optimism ticks higher The National Federation of Independent Business  NFIB  Small Business Optimism Index for July ticked higher to 94 6 from June s 94 5 level  where the Bloomberg forecast had called for it to remain 
Preliminary 2Q nonfarm productivity    declined 0 5  on an annualized basis  versus expectations of a 0 4  gain  following the unrevised 0 6  fall seen in the 1Q  However  unit labor costs rose 2 0   versus the forecast calling for a 1 8  increase  Unit labor costs were revised lower to a decrease of 0 2  in 1Q 
Wholesale inventories    rose 0 3  month over month  m m  in June  compared to forecasts calling for a flat reading and May s upwardly revised 0 2  gain  Sales were up 1 9  m m  and the inventory to sales ratio the amount of time it would take to deplete inventories at the current sales pace fell to a 1 33 months level from the 1 35 posted in May 
Treasuries were higher  as the yield on the 2 Year note was 2 basis points  bps  lower at 0 71   while the yields on the 10 Year note and the 30 Year bond fell 5 bps to 1 54  and 2 26   respectively 
Tomorrow s  will be fairly light  with the only scheduled reports being the Job Openings and Labor Turnover Survey  JOLTS   a measure of unmet demand for labor  expected to show 5 5 million jobs were available to be filled in June  matching that in May  as well as MBA Mortgage Applications 
Europe higher following earnings  Asia mixed following Chinese inflation dataEuropean equities finished higher  with a plethora of earnings reports that were mostly positive bolstering positive sentiment  while basic materials led a broad based advance across the major sectors  Focus on the impact of the late June vote in the U K  to leave the European Union  EU  on economic data continued  with U K  industrial production ticking higher in June  while manufacturing output declined slightly more than expected  The British pound came under some pressure versus the U S  dollar  briefly falling below the  1 30 mark for the first time since early July amid the Brexit vote fallout  German exports rose by a smaller amount than anticipated in June  and the euro ticked higher versus the U S  dollar  while bond yields in the region were mostly lower 
Stocks in Asia finished mixed  with yesterday s rebound in crude oil prices lending support  along with maintained losses in the yen  while traders digested some Chinese inflation data and monetary policy decision in India  Japanese securities advanced  with the yen holding onto yesterday s weakness  while those listed in Australia gained modest ground  led by strength in oil   gas issues  and South Korean stocks also moved higher  Mainland Chinese equities rose  while Hong Kong s market dipped slightly  following data that showed the nation s consumer price inflation rose by 1 8  y y in July  matching forecasts  but a deceleration from the prior month s 1 9  rise  while producer price inflation declined 1 7   after falling 2 6  in June  compared to the projected 2 0  drop  The data comes ahead of this week s plethora of reads on industrial production and retail sales  along with lending figures for last month  Finally  stocks in India declined on the heels of the monetary policy decision from the Reserve Bank of India  where it kept its benchmark interest rates unchanged  as expected 
For tomorrow  the international economic calendar will offer machine orders  the Tertiary Index and inflation data from Japan  South Korea s unemployment rate  and industrial production from France ",2016-08-10,Marvin Clark,https://www.investing.com/analysis/stocks-finish-nearly-flat-in-choppy-session-200147115,200147115
147684,369200,BHC,If You Own Valeant  VRX  Stock  You May Want To Sell Now,opinion,"On Thursday  shares of pharmaceutical company Valeant Pharmaceuticals Inc    NYSE VRX   are crashing  down almost 10  in late morning trading following reports that the company is under a criminal investigation 
According to   U S  prosecutors opened a criminal investigation into Valeant s relationship with a specialty pharmacy  Philidor Rx Services  that helped improve its drug sales  and whether or not it hid this relationship from insurers 
Lawyers at the U S  Attorney s Manhattan based office are figuring out if Valeant s ties with Philidor resulted in defrauding insurers 
 We have been fully cooperating with the authorities throughout the investigation  and we are in frequent contact and continue to cooperate with the U S  Attorney s Office   Valeant said in a statement   Valeant takes these matters seriously and intends to uphold the highest standards of ethical conduct  
It was just last year that Valeant came under scrutiny over issues including its business practices  in particular with Philidor  The company cut ties with the pharmacy last October after reports surfaced that Philidor had allegedly used tactics to gain more insurance reimbursements for Valeant drugs 
Valeant has already admitted that about  58 million of incorrectly marked sales were tied to Philidor  Joseph Papa  the drug maker s new CEO  has made efforts to put these issues behind Valeant like hiking its drug prices and using Philidor to distribute these newly expensive medicines and to gain back shareholder trust 
Investors  too  were hoping the worst was behind Valeant  The company  solid second quarter results on August 9  Despite a loss in profit  the company reaffirmed positive full year guidance  sending its stock soaring over 18  
VRX stock has declined more than 90  over the past 12 months due to multiple SEC and Congressional probes into its price hikes  This current investigation into its business practices is not likely to have a positive impact on Valeant shares  and it may be a wise decision to sell before its stock falls even further VALEANT PHARMA Price  Consensus and EPS Surprise  ",2016-08-11,Zacks Investment Research,"https://www.investing.com/analysis/if-you-own-valeant-(vrx)-stock,-you-may-want-to-sell-now-200147489",200147489
147685,369201,BHC,Company News For August 19  2016,opinion,"     Shares of Cisco Systems  NASDAQ CSCO   Inc     dropped 0 8  after the network equipment provider declared that it will trim 5 500 jobs
	     Shares of NetApp  NASDAQ NTAP   Inc     soared 17 4  after the company posted fiscal first quarter earnings per share of  0 28 beating the Zacks Consensus Estimate of  0 18
	     Shares of Hormel Foods Corporation  NYSE HRL     gained 1 9  after the company reported third quarter fiscal 2016 earnings per share of  0 36 that beat the Zacks Consensus Estimate of  0 34
	     Valeant Pharmaceuticals  NYSE VRX  International  Inc  s    shares dropped 2 7  after T  Rowe Price Group  Inc     alleged that Valeant Pharmaceuticals was involved in  a fraudulent scheme  that cost T Rowe s investors billions of dollars",2016-08-18,Zacks Investment Research,"https://www.investing.com/analysis/company-news-for-august-19,-2016-200148960",200148960
147692,369208,BHC,SEC nominee Clayton vows separation from his Wall Street law firm,news,By Amanda Becker WASHINGTON  Reuters    Wall Street attorney Jay Clayton will recuse himself from matters involving  Barclays   LON BARC  Bank   Deutsche Bank  AG  DE DBKGn  and other clients he has recently represented if confirmed to head the U S  Securities and Exchange Commission under the terms of an ethics agreement disclosed on Wednesday  Barclays Bank  Deutsche Bank AG  UBS Securities  Royal Bank of Canada  Ally Financial and Pershing Square  NYSE SQ  were among the financial firms listed as Clayton s clients at Sullivan   Cromwell  according to a form filed with the Office of Government Ethics  Under the agreement  Clayton will not participate in SEC matters involving the firm for one year  He will also recuse himself from matters involving his former clients for one year after he last provided them legal services  The SEC currently has only two members   Republican Michael Piwowar and Democrat Kara Stein   and they often disagree about policy matters  Should Clayton be confirmed and then recuse himself  the agency will be left deadlocked until other commissioners are nominated and confirmed  At full force  the SEC has five voting members  including the chair  Clayton also promised to divest  within 90 days of confirmation  some 176 assets collectively worth millions of dollars  He did not reply to a request for comment   Clayton and his wife  Gretchen Butler Clayton  reported assets between  52 3 million and  130 4 million  Because nominees for Executive Branch positions report their assets in broad ranges  it is impossible to calculate a nominee s exact net worth  He has assets related to his employment at Sullivan   Cromwell worth between  2 5 million and  8 4 million  the OGE form shows  His wife works at Goldman Sachs   Co  NYSE GS   and has assets related to her role at the investment bank worth between  1 1 million and  2 8 million  She has said she will resign her job if he is confirmed  The form also does not detail the specific assets from which Clayton will divest to comply with federal ethics laws  But in his March 3 letter to an ethics officer  Clayton did indicate that he will seek to take advantage of a tax benefit that allows government officials to defer paying capital gains taxes on assets they sell to satisfy ethics requirements  potentially saving him millions of dollars  As a Wall Street attorney  Clayton has worked on notable deals including the initial public offering of  Alibaba   NYSE BABA  Group Holding Ltd  Valeant Pharmaceuticals  NYSE VRX   the subject of federal investigations related to drug pricing  was listed as one of his clients  Clayton also reported having two corporate clients he could not name due to pending investigations that are not yet public  The SEC is an independent federal agency tasked with enforcing securities laws and regulating the country s stock and options exchanges  Agency nominees are reviewed by the U S  Senate Banking Committee  which is set to hold Clayton s initial confirmation hearing on March 23 ,2017-03-08,Reuters,https://www.investing.com/news/stock-market-news/sec-nominee-clayton-vows-separation-from-his-wall-street-law-firm-464681,464681
147693,369209,BHC,Sessions asks 46 Obama era U S  attorneys to resign,news,"By Joel Schectman and Mark Hosenball WASHINGTON  Reuters    U S  Attorney General Jeff Sessions abruptly asked the remaining 46 chief federal prosecutors left over from the Obama administration to resign on Friday  including Manhattan U S  Attorney Preet Bharara  who had been asked to stay on in November by then President elect Donald Trump  Although U S  attorneys are political appointees  and the request from Trump s Justice Department is part of a routine process  the move came as a surprise  Not every new administration replaces all U S  attorneys at once   A Justice Department spokeswoman confirmed the resignation requests included Bharara  whose office handles some of the most critical business and criminal cases passing through the federal judicial system  Bharara met with Trump in Trump Tower on Nov  30  After  Bharara told reporters the two had a  good meeting  and he had agreed to stay on  On Friday  Bharara was unsure where he stood because he did not know if the person who contacted him about resigning was aware that Trump had asked him to remain in office  according to a source familiar with the matter   It was not immediately clear if all resignations would ultimately be accepted  A Justice Department spokesman said on Friday Trump had called Dana Boente  acting U S  deputy attorney general  to decline his resignation   Trump also called Maryland U S  Attorney Rod Rosenstein  his pick to take over as deputy attorney general  to keep him in his post  the spokesman said   CORRUPTION CRUSADER  Bharara  appointed by Democratic President Barack Obama in 2009  has pursued an aggressive push against corruption in state and city politics and is known for his prosecution of white collar criminal cases  He also has been overseeing a federal probe into New York City Mayor Bill de Blasio s fundraising  In November  he announced charges against two defendants in connection with what he called a multimillion dollar fraud and kickback scheme at Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX   He has also brought dozens of successful cases against insider traders  including a  1 8 billion settlement and plea deal in 2013 with hedge fund SAC Capital Advisors LP  His office has secured settlements with companies including General Motors Co  N GM  and JPMorgan Chase   Co  N JPM   won several convictions and guilty pleas of former employees of Ponzi scheme operator Bernard Madoff  and prosecuted Suleiman Abu Ghaith  a son in law of the late al Qaeda leader Osama bin Laden  Bharara s priorities have often matched those set by Obama s Justice Department  which potentially puts him at odds with the Trump administration  Amid an increase in civil rights investigations nationally  for example  Bharara s office joined a lawsuit that led to a settlement in 2015 aimed at reducing violence in New York City s Rikers Island jail complex  U S  Senator Chuck Schumer  a Democrat  said in a statement that he was  troubled  to learn of the requests for resignations   particularly that of Preet Bharara   As Schumer s chief counsel  Bharara helped lead the investigation of the dismissals of U S  attorneys in 2006 during the George W  Bush administration  Robert Capers  U S  Attorney in Brooklyn  issued a statement saying he had been asked to resign  He said Bridget Rohde  the chief assistant U S  attorney in that office  would take over his role in an acting capacity  
The Justice Department said on Friday   Until the new U S  attorneys are confirmed  the dedicated career prosecutors in our U S  attorney s offices will continue the great work of the department in investigating  prosecuting  and deterring the most violent offenders  ",2017-03-11,Reuters,https://www.investing.com/news/politics-news/remaining-46-u.s.-attorneys-hired-by-obama-asked-to-resign:-justice-dept.-465384,465384
147694,369210,BHC,Valeant s  VRX  Brodalumab BLA Up For Review In The U S ,opinion,"Valeant Pharmaceuticals International  Inc  s   NYSE VRX   Biologic License Application  BLA  for brodalumab is up for review by an FDA panel  The FDA Dermatologic and Ophthalmic Drugs Advisory Committee  DODAC  is slated to meet on Jul 19 to review the application 
Note that the briefing documents that were released last week do not appear promising 
We remind investors that Amgen   NASDAQ AMGN   had submitted the first Investigational New Drug Application  IND  for brodalumab in 2008  Thereafter  the sponsorship of the program was granted to AstraZeneca   NYSE AZN    which subsequently transferred the same to Valeant 
Valeant s BLA contains 21 studies that were conducted by Amgen and four studies that were conducted by Amgen s partner in Japan  The candidate met all primary endpoints across the three pivotal phase III studies 
The most common adverse events associated with brodalumab were nasopharyngitis  upper respiratory tract infection  arthralgia and headache  However  events of suicidal ideation and behavior  along with major cardiovascular events  constituted the greatest risks  These events are considered important potential risks and will be the focus of the advisory committee 
We note that Amgen s decision to terminate the co development deal with AstraZeneca was essentially due to events of suicidal ideation and behavior in the brodalumab program  which the former believed would likely lead to restrictive labeling by the FDA  The company believed that such labeling requirements would limit the eligible patient population for the product upon approval 
Suicidal ideation and behavior was identified as a potential risk in 2014  quite late in the brodalumab psoriasis development program  when most patients had already completed 52 weeks of study 
Hence  we believe that the FDA advisory committee will focus on this aspect while reviewing the BLA and the outcome may not be favorable  In fact  even if a positive recommendation is given  the labeling would be accompanied by precautions and warnings 
Valeant currently carries a Zacks Rank  5  Strong Sell   Investors interested in the health sector may consider Bristol Myers Squibb Company   NYSE BMY    which currently sports a Zacks Rank  1  Strong Buy  ",2016-07-18,Zacks Investment Research,https://www.investing.com/analysis/valeant's-(vrx)-brodalumab-bla-up-for-review-in-the-u.s.-200142542,200142542
147696,369212,BHC,Ackman s Pershing Square sells Valeant stake  takes  3 billion loss,news,"By Svea Herbst Bayliss BOSTON  Reuters    Billionaire investor William Ackman walked away from Valeant Pharmaceuticals International Inc  NYSE VRX  on Monday with a loss of more than  3 billion as he sold his entire stake in the struggling drug company after trying to rescue it for some 18 months  The abrupt and unexpected move by the powerful activist investor sent Valeant shares tumbling almost 10 percent in after hours trading  They have lost 95 percent of their value since mid 2015  For Ackman  it marked a dramatic climbdown from his vocal support of the company  but should help soothe his own investors who had begun to show signs of concern about mounting losses in his portfolio   We elected to sell our investment and realize a large tax loss which will enable us to dedicate more time to our other portfolio companies and new investment opportunities   Ackman said in a statement  Ackman s Pershing Square  NYSE SQ  Capital Management became one of Valeant s biggest investors in 2015 when it sunk some  3 2 billion into the company  At its peak the Valeant stake was worth roughly  4 billion  Pershing Square said on Monday the Valeant position  at its current market value  represented 1 5 percent to 3 percent of its various funds   Already one of the hedge fund industry s most vocal investors  Ackman turned himself into Valeant s biggest cheerleader and fixer  even as the stock price plunged amid U S  regulators  probe of Valeant s pricing policies and problems at its specialty pharmacy unit  Philidor  After securing a board seat  Ackman replaced the chief executive  overhauled the board of directors and made some asset sales  But the biggest move   trying to sell Salix  the company s gastro intestinal division  to Japanese company Takeda   eluded Ackman after advanced negotiations failed to lead to a sale  He sold Pershing s 18 1 million shares of Valeant on Monday  plus about 8 8 million under his own name  together representing almost 8 percent of Valeant overall  according to Reuters data  BIG DROP  Ackman s fund bought into Valeant when the stock was trading near  190 a share and he watched it surge to  260 a share during the summer of 2015  But regulatory scrutiny and other concerns caused the stock price to sharply tumble after August 2015   The stock has fallen 16 percent since January even as many other stocks have been buoyed by hopes of stronger economic growth and increased merger activity  The shares closed at  12 11 on the New York Stock Exchange on Monday  and dipped to  10 93 in after hours trading  That long decline has tarnished Ackman s reputation as an investor and wreaked havoc on his portfolio   After gaining 37 percent in 2014  his Pershing Square International Fund lost 16 6 percent in 2015 and 10 2 percent in 2016  largely because of the Valeant losses  Monday s move mirrored a similar exit in the summer of 2013 when Ackman sold his entire stake in retailer J C  Penney and stepped off the board after having failed to fix the company   Ackman never  never gives up  at least not until a year or two after everyone else has given up   said Erik Gordon  a professor of law and business at the University of Michigan  Pershing Square was Valeant s second largest owner after hedge fund Paulson   Co  a regulatory filing shows  Hedge fund ValueAct Holdings is the third biggest owner  For Ackman s investors   pension funds across the country and wealthy private investors   the losses were beginning to wear and speculation had been mounting that they might not endure another year of declines  Ackman s gains at the start of the year have already turned into losses  
It takes two years for investors to exit Pershing Square Capital Management  but Ackman has protected himself by building permanent capital of roughly  6 billion  which should ensure that his roughly  12 billion hedge fund can endure some investor departures ",2017-03-14,Reuters,https://www.investing.com/news/stock-market-news/ackman's-pershing-square-exits-ailing-investment-in-valeant-465803,465803
147697,369213,BHC,Valeant Progenics Relistor Ok d  FDA Panel Backs Brodalumab,opinion,Valeant Pharmaceuticals International  Inc    NYSE VRX   has received positive news on the regulatory front  Its constipation drug  Relistor  received regulatory approval in the U S   while the FDA Advisory Committee gave a recommendation favoring the approval of its psoriasis treatment  brodalumab Relistor s ApprovalThe FDA has approved Valeant and Progenics Pharmaceuticals  Inc  s   NASDAQ PGNX   Relistor tablets  450 mg once daily  for the treatment of opioid induced constipation  OIC  in adults with chronic non cancer pain Valeant expects to begin sales in the third quarter of 2016 We note that a subcutaneous injectable version of Relistor  12 mg and 8 mg  is already approved in the U S  for the treatment of OIC in adults with chronic non cancer pain and for the treatment of OIC in adults with advanced illness who are receiving palliative care We remind investors that Valeant had in licensed development and commercialization rights for Relistor from Progenics following the acquisition of Salix Pharmaceuticals in Apr 2015 Approval of the oral formulation for the drug should expand the eligible patient population  thereby boosting the company s top line  We expect investor focus to remain on the commercialization of Relistor for the recently approved indication Drugs that are currently approved for the treatment of OIC in patients with chronic pain include Movantik and Amitiza VALEANT PHARMA Price   FDA Drug Advisory Committee s Opinion for BrodalumabValeant also announced that the FDA s Dermatologic and Ophthalmic Drugs Advisory Committee has voted  18 0  in favor of an approval of brodalumab injection  210 mg  for the treatment of moderate to severe plaque psoriasis in adults  The committee s opinion was  however  accompanied by conditions related to product labeling and post marketing risk management obligations We note that the FDA generally takes the advisory committee s recommendation into consideration when reviewing candidates but is not bound by the same  The Biologics License Application  BLA  for brodalumab was accepted by the FDA for review in Jan 2016 and a decision is expected by Nov 16  2016 Brodalumab is currently under review in the EU  while the Japanese Ministry of Health  Labour and Welfare gave the regulatory nod this July We remind investors that earlier this month  the company announced that its partner AstraZeneca plc   NYSE AZN   has amended its license related to brodalumab  As per the amendment  AstraZeneca had terminated Valeant s rights to develop and commercialize the product in Europe  However  Valeant still has the license to develop and commercialize brodalumab in the U S  and other territories  except in Japan and certain other Asian countries We note that the psoriasis market is already crowded given the presence of products like Stelara  Enbrel and Otezla among others Valeant currently carries a Zacks Rank  5  Strong Sell   Investors interested in the health sector may consider Nektar Therapeutics   NASDAQ NKTR    which currently sports a Zacks Rank  1  Strong Buy  Want the latest recommendations from Zacks Investment Research  Today  y u can download 7 Best Stocks for the Next 30 Days ,2016-07-19,Zacks Investment Research,https://www.investing.com/analysis/valeant-progenics-relistor-ok'd;-fda-panel-backs-brodalumab-200143014,200143014
147699,369215,BHC,LPC  Valeant refinancing on track despite Ackman stock sale,news,"By Jonathan Schwarzberg NEW YORK  Reuters    Drugmaker Valeant Pharmaceuticals  NYSE VRX  will not see any changes to its planned refinancing in the wake of billionaire William Ackman and his hedge fund Pershing Square  NYSE SQ  selling its share of the company  sources said  Valeant is extending the maturity date on three loans to 2022 in order to match the maturity date of its term loan F  The company is also paying down revolving credit debt and its term loan A debt as part of the refinancing effort  which includes the US 3 25bn sale of secured notes  The company  which has approximately US 30bn in debt  saw its stock drop to all time lows as it dipped under US 11 per share on Tuesday after news emerged that Ackman and his hedge funder were selling their entire position of approximately 27 million shares  The stock was trading north of US 250m during mid 2015   The amendment has been approved and the term loan F will be allocating today   said a source familiar with the transaction   The deal has been finalized and is not impacted by the Ackman news   Valeant asked lenders to allow it to extend the maturity on three term loans to match the 2022 maturity of its term loan F  The company also requested the removal of two covenants requiring a specific interest coverage amount and setting a maximum amount of secured leverage  The amount of debt being added to the loan due in 2022 totaled US 3 06bn  Both the existing loan and add on are priced at 475bp over Libor with a 0 75  floor  The add on priced at a discount of 99 75 cents on the dollar   Barclays   LON BARC  led the transaction  The bank also led the sale of US 1 25bn of 6 5  notes due in March 2022 and US 2bn of 7  notes due in March 2024  Both were issued on a secured basis  The new notes traded down about 0 8 points with the 6 5  notes on the Ackman news settling at 101 and the 7  notes trading at 101 25  according to MarketAxess data  The company s unsecured notes fell by as many as 2 25 points  The loan debt traded better and remained unchanged  The existing term loan F was trading in the 100 375 100 75 context on Tuesday  sources said  
Barclays declined comment  Valeant did not immediately return a request for comment ",2017-03-14,Reuters,https://www.investing.com/news/stock-market-news/lpc:-valeant-refinancing-on-track-despite-ackman-stock-sale-466069,466069
147700,369216,BHC,Canada stocks lower at close of trade  S P TSX Composite down 1 06 ,news,"Investing com   Canada stocks were lower after the close on Tuesday  as losses in the Healthcare  Materials and Consumer Staples sectors led shares lower 
At the close in Toronto  the S P TSX Composite fell 1 06  to hit a new 1 month low 
The best performers of the session on the S P TSX Composite were  Gildan Activewear  Inc   TO GIL   which rose 1 69  or 0 58 points to trade at 34 93 at the close  Meanwhile   Pure Industrial REIT   TO AAR u  added 1 77  or 0 10 points to end at 6 04 and  Sierra Wireless Inc    TO SW  was up 1 58  or 0 58 points to 37 22 in late trade 
The worst performers of the session were Valeant Pharmaceuticals International Inc  TO VRX   which fell 9 99  or 1 62 points to trade at 14 59 at the close   Pretium Resources  Inc   TO PVG  declined 7 53  or 0 99 points to end at 12 16 and  NuVista Energy Ltd    TO NVA  was down 7 53  or 0 450 points to 5 530 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 826 to 327 and 138 ended unchanged 
Shares in Valeant Pharmaceuticals International Inc  TO VRX  fell to 5 year lows  falling 9 99  or 1 62 to 14 59  Shares in Pure Industrial REIT  TO AAR u  rose to all time highs  gaining 1 77  or 0 10 to 6 04  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 7 39  to 15 40 a new 3 months high 
Gold Futures for April delivery was down 0 45  or 5 45 to  1197 65 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in April fell 1 01  or 0 49 to hit  47 91 a barrel  while the May Brent oil contract fell 0 49  or 0 25 to trade at  51 10 a barrel 
CAD USD was down 0 35  to 0 7413  while CAD EUR rose 0 13  to 0 6990 
The US Dollar Index Futures was up 0 40  at 101 66 ",2017-03-14,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-1.06-466093,466093
147701,369217,BHC,Valeant shares fall as Ackman exit highlights company s challenges,news,"By Svea Herbst Bayliss and Michael Flaherty BOSTON  Reuters    Valeant Pharmaceuticals  NYSE VRX  Inc s stock price fell to its lowest level in eight years on Tuesday after the abrupt exit of its biggest supporter put renewed focus on the Canadian company s most pressing problem  raising capital to cut its roughly  30 billion debt pile  Billionaire investor William Ackman spent more than a year trying to revive Valeant s stock price by helping to overhaul management  refresh the company s board  and push for asset sales  But in a surprise move announced on Monday he said he had sold his entire stake  some 27 million shares  and would be leaving the company s board  He explained the investment was requiring a  disproportionately  large amount of time and resources   nL2N1GQ1IN  This has been his biggest loser since launching his fund in 2004  On Tuesday  the Canadian company s U S  listed shares dropped 10 percent to  10 50  their lowest since May 2009  and a fraction of the near  190 a share Ackman s Pershing Square  NYSE SQ  Capital Management paid for them in early 2015  He announced his stake in March 2015 and shares surged to  260 a share a few months later  Probes into its business practices  accounting and drug pricing caused a collapse in Valeant s shares and the company is now offloading assets to try and pay down debt  amassed during a years long acquisition spree  Its new management team refinanced the company s debt burden last week  giving it more breathing room to repay creditors  Its newly issued notes traded down about 0 8 percentage points on Tuesday   Last week  Valeant told investors that revenue could fall as much as 8 percent this year but that it had paid down about  1 billion in debt and would put proceeds from the sale of its Dendreon cancer treatment business and three skincare brands for  2 12 billion  announced earlier  to that purpose   At Valeant right now  it is all about divestitures   said Umer Raffat  an analyst at Evercore ISI  The company committed itself to raise some  5 billion in assets from asset sales by the middle of next year  The company has also mulled selling the surgical tools unit of its Bausch   Lomb eye care division and letting go of some additional dermatology brands plus several international businesses  Ackman played a critical role in trying to push management to sell assets  according to an analyst and three people familiar with his actions   However  his biggest goal of selling the company s gastrointestinal unit Salix to Japan s Takeda was not reached after a disagreement over price  one person said on Tuesday  There were mixed reactions to Ackman s exit   With     one of its most vocal supporters selling its stake near the low for the past 10 years  we see this as a vote of no confidence for the stock and that things are continuing to go from bad to worse for Valeant   said  Wells Fargo   NYSE WFC  analyst David Maris  who rates the stock an underperform  But one investor in Ackman s fund  Pershing Square Capital Management  said his departure could give management more room to act and eventually pave the way for other investors to step back in  Ackman s concentrated bets and brash declarations   he once said Valeant would hit  448 a share by 2019   have made him a polarizing figure on Wall Street with some investors keen to take the opposing view from him  Hedge funds  which can flip stocks quickly  owned 28 percent of Valeant s shares at the end of last year  according to data from Goldman Sachs  NYSE GS   Valeant has long been one of the hedge fund industry s favorite bets  But some 9 percent of Valeant s shares were lent out to short sellers betting that the stock would go down  according to the bank  OTHER ACTIVISTS Ackman first bought Valeant as a passive investment  saying he was happy with management  He shifted gears a year ago when the company faced several probes   Ackman secured board seats for himself and a colleague  fired then chief executive Michael  Pearson   LON PSON   and helped persuade Joseph Papa to join Valeant as CEO   He played a significantly more hands on role than other investors  including activist fund ValueAct  which had helped build the company by recruiting Pearson to the top job years ago  John Paulson s Paulson   Co  which tends to keep a low profile and serve on few boards  is now Valeant s biggest investor with ValueAct  which has one board seat  its second largest  ValueAct did not respond to requests for comment and Paulson could not be reached  
With Ackman and his firm s vice chairman  Steve Fraidin  stepping off the board at the next annual meeting  there is a question of who might take their seats  It is unclear whether Paulson might put forth a representative or ValueAct  which once had two seats but has been trimming its exposure  might add another person ",2017-03-14,Reuters,https://www.investing.com/news/stock-market-news/valeant-shares-fall-as-ackman-exit-highlights-company's-challenges-466109,466109
147702,369218,BHC,4 Things To Watch When Gilead Sciences Reports On Monday,opinion,"by Clement Thibault
Gilead Sciences  NASDAQ GILD   a global biopharmaceutical company  reports Q2 results on Monday  after the close 

1  Revenue and earnings forecast
Gilead Sciences  forecast for Q2 is  3 02 EPS on  7 83B revenue  Should Gilead meet this EPS forecast  it would indicate that the company hasn t grown its EPS this past quarter the first time since 2013  Gilead had a spectacular 2015  beating EPS estimates by 10  or more each quarter  In Q1 2015  the company reported EPS of 2 94 vs 2 32 expected  which made for a very welcome 26  upside surprise  Unfortunately  so far  2016 hasn t been nearly as impressive  Reports for Q4 2015 and Q1 2016 beat EPS estimates by a paltry 1   at  3 03 per share  The slowdown is also reflected in its current share price   86 55 as of Friday s close  a far cry from its all time high of  123 37 during June 2014 

2  Hepatitis C  GILD s core business
Right now  the two major diseases treated by Gilead s medicines are HIV and Hepatits C  Its two biggest products  both blockbusters  are Hepatits C  HCV  medications  Sovaldi and Harvoni  Together  these meds account for almost half of the company s revenue 
Understandably  during Monday s report the focus will be on their recent performance  In Q1  Gilead s HCV product sales fell by 6  year over year  to  4 3B  The problematic market for Gilead is the United States 
For the better part of the past three years  Gilead had a monopoly in the field of HCV drugs  which allowed it to accrue uncontested profits  At the end of April however  AbbVie Inc  NYSE ABBV  launched its competitive HCV drug  Viekira Pak  which followed Merck s  NYSE MRK  competitive offering  Zepatier  launched at the beginning of the year  The increased competition led to an inevitable loss of market share and a price war  Harvoni sells for 94K for the length of the treatment  Sovaldi for 84K  while Merck s Zepatier costs 54K for the identical course 
All three companies are applying for approval in China  where it is estimated that 10 to 20 million Chinese citizens have Hepatitis C  Perhaps more significant in the short term  on June 28 the FDA approved Epculsa  Gilead s newest HCV treatment  which is effective for all six major forms of HCV   the first of its kind  For comparison  Harvoni is used primarily to treat genotype 1  the most common form of Hepatitis C in the US and Europe 
Because of the recent introduction  the new drug s financial impact won t be visible in the coming report  but its longer term effect could be significant in upcoming quarters 

3  Balance Sheet and Valuation
Perhaps one of the most compelling reasons for owning Gilead is its strong balance sheet  The  115B company has over  21B in cash assets  and is engaged in a stock buyback program which has taken over  8 billion worth of shares out of circulation  Its current liabilities are under  11B  which means Gilead has a ratio of Cash Current Liabilities of almost 2  Pharmaceutical giants GlaxoSmithKline  NYSE GSK   AbbVie and Merck all have a ratio of below 1 
The company s operating income for Q1 was  4 6B on  7 8B total revenue  meaning its operating margin is 59   which compares very well against Merck s 17  or AbbVie s 37   As of today  the company has a very low P E ratio of 7 4  significantly less than the industry average of 40  As if these numbers weren t impressive enough  the company also has over  17 7B of free cash flow  which means it trades at under 7 times its cash flow 
During June 2015  Gilead started handing back some of its excess cash to investors in the form of dividends  The dividend  which began as a quarterly  0 43 payout  grew to  0 47   a 9  increase   as recently as last month  With its current cash situation  it looks as if GILD will be able to grow its dividend when and as it wishes for the foreseeable future 

4  Developments in the R D pipeline
Stock prices often reflect future expected value  rather than present worth  For pharmaceutical companies  their R D pipeline may arguably be just as if not more important than their current product lineup  If that s the case  what s in Gilead s pipeline  We ve already mentioned Epculsa  above  which is expected to reclaim at least some of Gilead s lost HCV revenue  GILD s next big prospect is Simtuzumab  which is currently in a phase 2 study  The drug aims to treat nonalcoholic steatohepatitis  NASH   If approved  it is expected to generate well over  10B in annual sales  Behind these two products  Gilead has seven late stage clinical trials and 16 additional phase two studies in the works  While its R D expenses  at  3B annually  are lower than Merck s or AbbVie s  they are on par with similarly sized GlaxoSmithKline  which indicates there s no scrimping at Gilead s end 
Conclusion
Gilead currently generates over  32B in annual revenue  It can no longer be considered an up and comer  as its share price has already exploded from the mid 30s in late 2012 to regularly being priced at over  110  which happened in 2014 and 2015 
Both its current performance and future prospects are looking good  Why then is it so undervalued 

With a P E ratio of 7 4  it appears the market is discounting any future growth  and may have already priced in a decline in profitability  We believe this is an incorrect assessment of the company and its potential 
An alternative explanation could be that unfortunately Gilead has been dragged down by the pharma sector as a whole  As evident by the current performance of the popular SPDR S P Biotech ETF  NYSE XBI   which is now trading at  59 35 well below its all time high of  91 1 a year ago the entire sector is still hurting  nor has it recovered from the early 2016 Valeant  NYSE VRX  price gouging fiasco which pulled the sector down significantly 
Notwithstanding all of the above  we believe it s merely a matter of time before Gilead s share price recovers  The company s revenues are immense  its operating margin is extraordinary  cash is flowing freely  and the company is buying back stock 
The way we see it  Gilead is like a high end race car  spinning its wheels at the starting line  held back only by the weight of the sector in which it operates  Once that drag is removed  we believe it will take off at top speed  potentially leaving at least some competitors in the dust ",2016-07-24,Clement Thibault/Investing.com ,https://www.investing.com/analysis/4-things-to-watch-when-gilead-sciences-reports-on-monday-200143735,200143735
147703,369219,BHC,Is Valeant The Next Enron ,opinion,"Earlier this year in March  Valeant Pharmaceuticals  NYSE VRX  stock plunged in one day from  70 to  36  I had not paid much attention to the VRX saga until then  When I examined the financials I was quite aghast with what looked to be the potential for  
The financials are riddled with multiple accounting improprieties  if not outright fraud  The balance sheet sports over  31 billion in debt against just  9 billion in tangible assets  It s tangible net worth is negative  32 6 billion 
I stopped following the Valeant saga once Bill Ackman made a lot of noise announcing a new CEO and board  I figured the stock would bob and weave before and after every press release Ackman crafted to generate interest in the stock  Early April was  on the stock  although I ve considered featuring it my  as a great short idea 
But today  VRX stock caught my attention because it dropped over 6  on heavy volume for no apparent reason  Upon closer inspection  it looks like VRX may be in danger of violating its debt covenants this year 
VRX appears to be in an irreversible debt spiral  Valeant s current credit rating from Moody s is B2  VRX s ratings have been on a downward path for several years  Typically this is an irreversible path that eventually leads to bankruptcy of some kind or a pre pack debt restructuring 
I was fooling around with graphs earlier and noticed an absolutely stunning similarity between Enron s stock and Valeant s stock 


Where there s smoke in the stock market  there s usually fire  At some point I would bet   in fact I am betting with puts   that VRX shareholders are going to get doused with napalm But hey  stock and bond investors should be grateful  Moody s had Enron rated triple A until just before it filed for bankruptcy  At least with VRX  Moody s has been gracious enough to give investors a  heads up  ",2016-08-02,David I. Kranzler,https://www.investing.com/analysis/is-valeant-the-next-enron-200145586,200145586
147704,369220,BHC,Mattress Firm Stock Is In The Danger Zone,opinion,"A beaten down company will always find its suitors  those wanting to  pick up the pieces  or buy the bottom  This week s Danger Zone pick is down 32  year to date  but it is not a good value and carries high downside risk  Unsustainable revenue growth  destructive acquisitions  and declining profits land Mattress Firm  NASDAQ MFRM   31 share  in the Danger Zone 
Revenue Growth Masks Soaring Losses
Mattress Firm s   the true cash flows of the business  have declined from   14 million in fiscal 2012 to   111 million over the trailing twelve months  These losses come despite revenue growing from  704 million in fiscal 2012 to  2 5 billion in fiscal 2015  or 38  compounded annually 
Revenues have continued to grow to  2 8 billion over the last twelve months  Figure 1 highlights the disconnect between revenue and cash flow  See the reconciliation of Mattress Firm s GAAP net income to economic earnings  
Figure 1  MFRM s Losses Grow Despite Revenue Growth

In its quest be the leading mattress retailer  since 2013  MFRM has made over 15 separate acquisitions for upwards of  1 4 billion  Most recently  the firm paid  795 million for the acquisition of HMK Mattress Holdings in February 2016  While these acquisitions are   they are highly dilutive to cash flows and MFRM s balance sheet 
From 2013 2016  Mattress Firm s debt grew 42  compounded annually to  2 1 billion  Over the last twelve months  debt has ballooned to nearly  2 9 billion  more than double the current market cap 
The telltale sign that these acquisitions have been a raw deal for investors is the steady deterioration of MFRM s return on invested capital     Since earning a 10  ROIC in 2012  Mattress Firm s ROIC has more than halved to a bottom quintile 4  over the last twelve months  Similarly  MFRM has burned  1 6 billion in free cash flow from 2013 2016  and over the last twelve months  FCF sits at   603 million 
Executive Compensation Rewards Destroying Shareholder Value
Apart from base salaries  executives at Mattress Firm receive annual cash bonuses and long term stock based awards  The cash bonuses are granted solely for meeting adjusted EBITDA targets  As seen in Figure 2 below  adjusted EBITDA presents MFRM in a much more positive light than the true profits of the business  which misalign executives incentives with those of investors 
By removing costs such as compensation expense or acquisition costs  executives can grow the top line and adjusted metrics with little or no attention paid to the economics of their actions  Additionally  we ve seen the damaging effects that incentivizing executives with stock price targets can have  particularly at Valeant Pharmaceuticals  NYSE VRX  
The best way to create shareholder value  and align executives with the best interest of shareholders  is to tie performance bonuses to ROIC because there is a  
Adjusted EBITDA Rises While Profits Decline
Investors analyzing non GAAP metrics would believe Mattress Firm s business is achieving great success  Mattress Firm is a prime example of how companies  of the business  Here are expenses MFRM has removed when calculating its non GAAP metrics  including adjusted EBITDA  adjusted EPS  and adjusted cash EPS 
Loss on store closing and impairment of store assets
Loss from debt extinguishment
Stock based compensation
Secondary offering costs
Acquisition related costs
ERP system implementation costs
These costs have a material impact on results  particularly acquisition related costs  In 2016  MFRM removed  23 million  35  of GAAP net income  in acquisition related costs to calculate its adjusted EBITDA  After removing these costs  MFRM is able to report non GAAP results that are not only much improved from economic earnings  but rapidly rising when cash flows are declining 
Adjusted EBITDA grew from  87 million in 2012 to  255 million in 2016  or 31  compounded annually  Over this same time  GAAP net income grew 17  compounded annually while economic earnings declined from   14 million to   55 million  or  41  compounded annually  per Figure 2 
Figure 2  Misleading Non GAAP Metrics

Low Profitability In A High Margin Industry
The retail mattress market is well known to have exorbitantly high markup on its products  Such markup provides excellent opportunity for profits  which ultimately breeds competition  The mattress market is highly fragmented  and MFRM faces competition from regional and local stores such as America s Mattress  retail furniture stores like Ashley Furniture  Haverty s  and Rooms to Go  department stores like Macy s and J C  Penney  and large retailers like Wal Mart  Costco  and Amazon 
This list doesn t even mention the new start up online mattress retailers such as Casper  Tuft   Needle  Saatva  and Leesa  Unfortunately for investors  MFRM has not been able to translate these high markup prices to high margins or a high ROIC  As seen in Figure 3  MFRM s ROIC ranks well below most competitors and its margins hardly surpass big box retailers better known for selling products with razor thin margins 
Figure 3  MFRM s  Retail Like  Profitability

Bull Hopes Rest On Happy Ending to Roll Up
First  we ve seen this movie before  In my experience on Wall Street  going on 20 years   there have been precious few roll ups that have a happy ending  Most of them end with investors realizing the emperor has no clothes  or the consolidator has no cash flows 
Roll ups make the insiders  corporate executives and Wall street bankers  lots of money  and investors should not be surprised to see these folks touting the roll up plan  Remember that these insiders  interests are not aligned with yours  As we detail below  Mattress Firm s roll up pitch fits the description of a roll up scheme very well 
Prior to the HMK Mattress Holdings acquisition  the mattress market was highly fragmented  Post acquisition  MFRM stated the combined firm would have a 21  share of the mattress market  As market share climbs  roll up strategies become harder to execute  because the impact of acquisitions becomes ever smaller 
As such  those betting on the future growth of Mattress Firm are betting on the inevitable end of the roll up and successful  more importantly profitable  integration of all the acquired firms 
However  without the constant acquisitions to grow the top line and poor organic growth  the bull case appears rather weak  Since 2012  total sales have grown on average 38  each year  Excluding new stores  comparable store sales have grown only 4  on average each year since 2012 
Even the revenue growth numbers are misleading  Once the roll up strategy comes to an end  revenue growth will follow the negative trend that profits have been setting for years 
Investors have taken note of the lack of organic growth at MFRM  but as we ll show below  even after falling 32  YTD  MFRM is still priced for significant profit growth  Such profit growth is unlikely to be achieved with such low comparable store sales 
The current expectations baked into the stock price require the acquisitions to continue  but also become immediately profitable  which has not occurred as of yet 
Even if you think the roll up strategy will work  you have to be mindful of new entrants providing mattresses at much cheaper price points  Online mattress firms  such as Casper and Tuft   Needle  cut out middlemen like Mattress Firm  They are more profitable because they don t require the costly overhead of showrooms or commissioned sales staff as they ship mattresses directly to buyers 
While this shift in business model is certainly too new to judge its overall effect  there is no debating that cutting out middlemen and providing consumers cheaper products is a threat to the viability of Mattress Firm s business model 
The largest risk to the bear case is what we call     With a stock price that is down YTD  another firm could step in and acquire MFRM at a value that is much higher than the current market price  As we ll show below  only in the event a firm is willing to destroy shareholder value is MFRM worth more than its current share price 
Unraveling Roll Up Worth Acquiring 
The biggest risk to our thesis  apart from MFRM continuing to acquire smaller competitors to maintain non GAAP growth  would be if an outside firm was to acquire MFRM at a value at or above today s price 
Despite being the industry leader  we ll show below that Mattress Firm is not an attractive acquisition target because unless a buyer is willing to destroy shareholder value  an acquisition at current prices would be unwise 
To begin  MFRM has liabilities that investors may not be aware of that make it more expensive than the accounting numbers suggest 
 1 4 billion in   122  of market cap 
 52 million in   5  of market cap 
 19 million in   2  of market cap 
 8 million in    1  of market cap 
After adjusting for these liabilities  which total 129  of market cap  we can model multiple purchase price scenarios  Even in the most optimistic of scenarios MFRM is worth less than the current share price 
Figure 4 shows what we think Wal Mart should pay for MFRM  given different growth scenarios that account for the capital outlay required to achieve such a scenario  Because MFRM is the largest mattress retailer  any acquiring firm would likely be another furniture store or big box retailer 
WMT acquiring MFRM could lead to more efficient supply chain management  cost reductions due to WMT s massive distribution footprint  or even increased sales through marketing efforts or integration of MFRM s products into WMT stores  However  there are limits on how much WMT would pay for MFRM given the cash flows being acquired
Each implied price is based on a DCF scenario  linked below  assuming different levels of future revenue growth 
  51  in  estimated  year one  6  in  estimated  year two  and 4  in  estimated  year 3 and beyond 
  51  in  estimated  year one  6  in  estimated  year two  and 6  in  estimated  year 3 and beyond 
  51  in  estimated  year one  6  in  estimated  year two  and 8  in  estimated  year 3 and beyond
In each scenario  the estimated revenue growth rates in year one and two equal the consensus estimates for 2016  51   and 2017  6    For the subsequent years  we use 4  in scenario one because it represents the average same store sales growth since 2012 
We use 6  in scenario two because it represents a continuation of 2017 expectations  We use 8  in scenario three because it represents the average 2017 expected revenue growth rate of all 47 Household Durables firms under coverage 
Additionally  we assume MFRM s invested capital increases  968 million in estimated year 1  which is equivalent to the change in net working capital and fixed assets after the acquisition of HMK Mattress Holdings  This acquisition grew MFRM s store count by over 40  and accounts for much of the revenue growth expected in estimated year 1 
We  then  conservatively assume that WMT can grow MFRM s revenue and NOPAT free cash flow without any incremental capital outlays after year 1  an unlikely and very optimistic scenario  We also assume MFRM achieves a 7  NOPAT free cash flow margin  which is the highest margin achieved since 2013 when acquisition activity began ramping up 
For reference  MFRM s current NOPAT margin is 4 6   This assumption  while optimistic  creates a scenario where acquisitions stop post takeover  and the new parent firm focuses on profitability not topline growth  As shown below  even in this best case scenario  MFRM is not worth acquiring at current prices 
The resulting implied values for MFRM in each scenario represent the maximum amount WMT should pay for MFRM  given the expected cash flows and the costs to achieve those cash flows 
Figure 4  The Best Case Scenario Value for MFRM If Acquired

  values in millions except per share amounts 
  value destroyed equals the difference between implied price and acquisition at current market price plus net assets liabilities 
Figure 4 shows that even if Mattress Firm can grow revenue 15  compounded annually  achieve 7  NOPAT margins  and require no excess capital spending  beyond year 1  for the next five years  the most WMT should pay for the firm is  24 share   a 23  downside from current price 
Note in even the most optimistic scenario that the average ROIC over five years only equals 8   which is slightly below WMT s 10  ROIC  In order to achieve an ROIC equal to its current ROIC  WMT would either need to pay below  24 share  or grow MFRM s revenue greater than 15  compounded annually while spending  0 in incremental invested capital 
Without Acquisition  Shares Remain Overvalued
On its own  MFRM still has unrealistically high expectations already baked into the current stock price  Specifically  to justify the current price of  31 share  MFRM must maintain 2016 NOPAT margins  6   and 
In this scenario  MFRM would be generating over  7 4 billion in revenue 11 years from now  For reference  MFRM notes in its 2016 10 K that the entire U S  retail market totaled  14 billion in 2014  of which specialty mattress retailers accounted for 47  of sales 
Put another way  current expectations imply MFRM reaching a sales volume that is greater than the market share of all retail mattress firms in 2014  MFRM must take significant market share from any and all competition over the next decade  which seems unlikely given disruptive new competition and common antitrust laws made to stop exactly such an event 
Even if we assume MFRM can maintain 2016 NOPAT margins and   the stock is only worth  16 share today   a 48  downside 
Each of these scenarios also assumes the company is able to grow revenue and NOPAT without spending on working capital or fixed assets after  estimated  year 1  an assumption that is unlikely  even if the firm ceased destructive acquisitions 
We make assumption to show investors just how optimistic they must be about the future cash flows of this company to warrant owning the stock  For reference  MFRM s invested capital has grown on average  501 million  20  of 2016 revenue  each year since 2013 
Catalyst  MFRM Runs Out Of Options
Mattress Firm finds itself in a tough position  It has acquired its way to the top of the market  but has none of the profits to show for it  Moving forward  MFRM has a few options each of which do not meet the expectations baked into the stock price 
Continue the roll up strategy  MFRM could continue acquiring smaller competitors in an effort to grow the top line and boost non GAAP metrics  However  this option may be difficult  as the firm s total debt is now more than double its market cap  which could make funding future acquisitions difficult  At the same time  the firm s non GAAP earnings cannot cover its cash costs  and with MFRM s climbing debt  it could only be a matter of time before the costs of the debt outweigh the benefits of acquiring additional revenue 
Focus on organic growth  MFRM could cease its roll up strategy and focus on growing its organic business  However  as noted above  without rapid sales growth  and cost cutting  it s hard to see the organic growth at MFRM reaching levels that meet the expectations already baked into the stock price 
At the end of the day  neither of these options meets the current expectations embedded in the market price  If MFRM ends the roll up  its growth story comes to a fast end  and the firm s valuation would adjust accordingly  At the same time  if it abandons the roll up  investors will quickly realize the emperor has no clothes 
Insider Action Is Strong While Short Interest Is High
Over the past 12 months 2 7 million insider shares have been purchased and 204 000 have been sold for a net effect of 2 5 million insider shares purchases  These purchases represent 7  of shares outstanding  which is a strong number for insider purchases  Additionally  there are 7 2 million shares sold short  or just over 19  of shares outstanding 
Impact of Footnotes Adjustments and Forensic Accounting
In order to derive the true recurring cash flows  an accurate invested capital  and a real shareholder value  we made the following adjustments to Mattress Firm s 2016 10 K 
Income Statement  we made  199 million of adjustments with a net effect of removing  88 million in non operating expenses  3  of revenue   We removed  143 million related to  and  56 million related to   See all adjustments made to MFRM s income statement  
Balance Sheet  we made  1 6 billion of adjustments to calculate invested capital with a net increase of  1 2 million  The most notable adjustment was  1 4 billion  100  of net assets  related to   See all adjustments to MFRM s balance sheet  
Valuation  we made  2 9 billion of adjustments with a net effect of decreasing shareholder value by  2 9 billion  There were no adjustments that increased shareholder value  The largest adjustment was the removal of  2 9 billion  254  of market cap  due to   which includes  1 4 billion in  
Dangerous Funds That Hold MFRM
The following funds receive our Dangerous or worse rating and allocate significantly to Mattress Firm 
Monteagle Funds  Texas Fund  TEXCX    1 9  allocation and Dangerous rating 
Wasatch Core Growth Fund  WGROX    1 3  allocation and Dangerous rating 
Disclosure  David Trainer and Kyle Guske II receive no compensation to write about any specific stock  style  or theme ",2016-08-03,David Trainer,https://www.investing.com/analysis/danger-zone:-mattress-firm-(mfrm)-200145735,200145735
147705,369221,BHC,Valeant Pharma  VRX  Posts Q2 Profit Loss  Soars On Positive Outlook,opinion,"On Tuesday  shares of struggling pharmaceutical company Valeant Pharmaceuticals Inc    NYSE VRX   are soaring  up over 18  in mid morning trading after the company reported its second quarter fiscal 2016 results 
Valeant reported adjusted earnings per share of  1 40  excludes  2 28 from non recurring items   missing the Zacks Consensus Estimate of  1 59 per share and declining 45 7  year over year 
Total revenues came in at  2 4 billion  lagging behind our consensus estimate of  2 592 billion and falling 11 4  year over year  This was mostly due to a decline in product sales revenues from its existing business and negative foreign currency exchange impact 
 We continue to make progress towards stabilizing the organization   said Joseph C  Papa  chairman and CEO   We are also announcing a new strategic direction for Valeant today  which  at its heart has a mission to improve patients  lives  and will involve reorganizing our company and reporting segments  
Cash flow from operations was  448 million  up 9  from the prior year period 
As a result  Valeant affirmed its full year guidance  EPS is expected to fall in the range of  6 60 7 00 per share on revenues in the range of  9 9 10 1 billion 
  Although it will take time to implement and execute our turnaround plan  I am confident that we will show progress in the coming quarters   Mr  Papa continued 
The company also announced that they have agreed to sell the brodalumab EU rights  Synergetics USA OEM business  and Ruconestfor a total upfront payment of  181 million in order to streamline its portfolio on the second quarter 
VRX currently holds a  4  Sell  on the Zacks Rank VALEANT PHARMA Price  Consensus and EPS Surprise  ",2016-08-09,Zacks Investment Research,"https://www.investing.com/analysis/valeant-pharma-(vrx)-posts-q2-profit-loss,-soars-on-positive-outlook-200146945",200146945
147706,369222,BHC,Here s 5 Medical Stocks Soaring After Earnings Today,opinion,"Second quarter earnings season may be wrapping up  but a plethora of companies in the medical industry were yet to report until this week  Several key drug  biotech  and medical instruments companies reported earnings on Monday and Tuesday  and there was a lot of good news to go around 
A quick glance at Tuesday s biggest movers shows that many medical related stocks are making big gains following earnings announcements  Check out these five companies that are in the green following their most recent reports 
1        OPKO Health    NASDAQ OPK   
OPKO Health is a multinational biopharmaceutical and diagnostics company  The company announced its earnings results after the closing bell Monday  OPKO beat out the Zacks Consensus Estimate  which called for a breakeven quarter  posting earnings of two cents per share  Quarterly revenues came in at  357 million  which crushed our consensus estimate of  31 million  The stock quickly popped nearly 4  in after hours trading Monday before coming back down a bit Tuesday morning  Shares are currently up about 1 5  on the day 
 
2        ICU Medical Inc     NASDAQ ICUI   
ICU Medical  a leading supplier of disposable connections systems for use in intravenous therapies  also released its earnings report on Monday afternoon  The company posted earnings of 98 cents per share  which cruised past the Zacks Consensus Estimate of 89 cents  Quarterly revenues of  97 million also beat our estimate of  90 million  Shares of ICUI jumped over 5 5  in after hours trading  and the stock is now up nearly 7  from Monday s close 
 
3        Nevro Corp     NYSE NVRO   
Nevro Corp is a medical device company that develops neuromodulation platforms for the treatment of chronic pain  The company  on Monday  posting a loss of 31 cents per share  The Zacks Consensus Estimate called for a loss of 46 cents per share  Nevro also posted revenue of  55 4 million  which beat our consensus estimate of  45 million  Shares of NVRO gained nearly 10  in after hours trading and continued to climb Tuesday  The stock is up about 15  today 
 
4        Valeant Pharmaceuticals    NYSE VRX   
Valeant Pharmaceuticals  the struggling pharma giant  released its  on Tuesday morning  Its EPS of  1 40 and revenue of  2 4 billion both missed our consensus estimates  but investors were encouraged by other aspects of the reports  Valeant announced a new  strategic vision  and affirmed its full year guidance  which sent shares soaring  VRX gained over 18 5  in morning trading Tuesday 
 
5        Endo International plc    NASDAQ ENDP   
Endo International also announced its  on Tuesday morning  and the company also impressed investors  Endo reported earnings of 86 cents per share  beating the Zacks Consensus Estimate of 75 cents per share  The company also saw revenues of  920 9 million  which beat our estimate of  878 3 million  That revenue figure represents growth of 25  on a year over year basis  and Endo also affirmed its full year guidance  Shares of ENDP gained over 22  in morning trading 
 
Bottom Line
For those who follow the   these earnings results will come as no surprise  Across the board  medical related industries have been impressive recently  Investors should continue to check out these sectors for other stocks that could post big gains ",2016-08-09,Zacks Investment Research,https://www.investing.com/analysis/here's-5-medical-stocks-soaring-after-earnings-today-200147002,200147002
147711,369227,BHC,This Crushed Biotech Leader Is Trying To Break Out,opinion,"When you think of stocks that have been crushed  Valeant Pharmaceuticals  NYSE VRX  comes to mind 
How bad has it been for VRX  How about a 90  decline in less than a year  which may have something to do with the biotech sector s huge under performance compared to the broad market over the past 12 months 

We believe that for the broad market to keep going higher  it wants needs biotech and financials to start doing better  
So far  the only thing Valeant has proven is that investors want out of the stock 
If VRX is to start heading higher  it has to first prove it can break free from its 1 year falling channel  which is where it lost 90  of its value 
What VRX does with the test of resistance at  1  should have a big impact on the stock  the biotech sector and the broad markets 
So keep a close eye on Valeant to see if it keeps selling off or if  perhaps  this time is different ",2016-08-09,Chris Kimble,https://www.investing.com/analysis/this-crushed-biotech-leader-is-trying-to-break-out-200146990,200146990
147718,369234,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 84 ,news,"Investing com   Canada stocks were higher after the close on Tuesday  as gains in the Energy  IT and Materials sectors led shares higher 
At the close in Toronto  the S P TSX Composite added 0 84  to hit a new 52 week high 
The best performers of the session on the S P TSX Composite were  TORC Oil   Gas  Ltd   TO TOG   which rose 7 58  or 0 53 points to trade at 7 52 at the close  Meanwhile   HudBay Minerals  Inc   TO HBM  added 7 17  or 0 67 points to end at 10 01 and  Teck Resources Ltd  B  TO TECKb  was up 6 85  or 2 19 points to 34 18 in late trade 
The worst performers of the session were  New Gold Inc    TO NGD   which fell 5 42  or 0 310 points to trade at 5 410 at the close   Guyana Goldfields Inc    TO GUY  declined 3 53  or 0 220 points to end at 6 010 and Valeant Pharmaceuticals International Inc  TO VRX  was down 3 50  or 0 65 points to 17 91 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 796 to 384 and 126 ended unchanged 
Shares in HudBay Minerals Inc   TO HBM  rose to 52 week highs  rising 7 17  or 0 67 to 10 01  Shares in Valeant Pharmaceuticals International Inc  TO VRX  fell to 5 year lows  losing 3 50  or 0 65 to 17 91  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 10 14  to 11 52 
Gold for February delivery was down 0 51  or 6 25 to  1209 35 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in March rose 0 61  or 0 32 to hit  53 07 a barrel  while the March Brent oil contract rose 0 14  or 0 08 to trade at  55 31 a barrel 
CAD USD was up 0 58  to 0 7598  while CAD EUR rose 0 90  to 0 7079 
The US Dollar Index was up 0 31  at 100 26 ",2017-01-24,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.84-455411,455411
147719,369235,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 19 ,news,"Investing com   Canada stocks were higher after the close on Tuesday  as gains in the Healthcare  Energy and Consumer Discretionary sectors led shares higher 
At the close in Toronto  the S P TSX Composite gained 0 19  to hit a new all time high 
The best performers of the session on the S P TSX Composite were Valeant Pharmaceuticals International Inc  TO VRX   which rose 6 43  or 1 26 points to trade at 20 86 at the close  Meanwhile   Cameco  Corp  TO CCO  added 5 22  or 0 80 points to end at 16 14 and  Lucara Diamond Corp   TO LUC  was up 3 53  or 0 110 points to 3 230 in late trade 
The worst performers of the session were OceanaGold Corporation  TO OGC   which fell 6 32  or 0 280 points to trade at 4 150 at the close   DHX Media Ltd  B  TO DHXb  declined 5 91  or 0 37 points to end at 5 89 and  Bombardier Inc   TO BBDb  was down 3 10  or 0 080 points to 2 500 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 591 to 574 and 143 ended unchanged 
Shares in DHX Media Ltd B  TO DHXb  fell to 52 week lows  losing 5 91  or 0 37 to 5 89  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 205 04  to 12 11 
Gold Futures for April delivery was up 0 30  or 3 70 to  1229 50 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in March rose 0 49  or 0 26 to hit  53 19 a barrel  while the April Brent oil contract rose 0 59  or 0 33 to trade at  55 92 a barrel 
CAD USD was down 0 04  to 0 7647  while CAD EUR rose 0 14  to 0 7229 
The US Dollar Index Futures was up 0 20  at 101 20 ",2017-02-14,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.19-459894,459894
147720,369236,BHC,Valeant adjusted profit beats Street  but net loss widens,news," Reuters    Canada s Valeant Pharmaceuticals International Inc  N VRX   TO VRX  reported a better than expected quarterly profit on Tuesday  helped by lower costs and strength in its Bausch and Lomb eyecare business  but its net loss widened and the company said it was feeling pricing pressure  U S  listed shares were off at  15 83 in pre market trading compared with a close of  16 71  A year ago  shares closed at  76 95  Since taking the helm last year  Chief Executive Joseph Papa has been trying to rebuild Valeant s business and regain investor confidence after the company came under investigation over its accounting and pricing practices  Laval  Quebec based Valeant has also faced intense political scrutiny for hiking its drug prices as well as for the unorthodox use of a specialty pharmacy to boost sales  Net loss attributable to Valeant widened to  515 million  or  1 47 per share in the fourth quarter ended Dec  31  from  385 million  or  1 12 per share  a year earlier  Excluding items  it earned  1 26 per share  beating analysts  average estimate of  1 19  according to Thomson Reuters I B E S  Selling  general and administrative costs declined 10 5 percent to  665 million  Revenue fell 12 9 percent to  2 40 billion  but exceeded the average expectation of  2 33 billion  Valeant has also been shedding assets to reduce its debt load of about  30 billion  It announced the sale of its Dendreon cancer treatment business and three skincare brands for  2 12 billion last month  
The company said it expected 2017 revenue of  8 90 billion  9 10 billion  Analysts were expecting revenue of  8 96 billion ",2017-02-28,Reuters,"https://www.investing.com/news/stock-market-news/valeant-adjusted-profit-beats-street,-but-net-loss-widens-462610",462610
147721,369237,BHC,Canada stocks higher at close of trade  S P TSX Composite up 1 30 ,news,"Investing com   Canada stocks were higher after the close on Wednesday  as gains in the Materials  Industrials and Financials sectors led shares higher 
At the close in Toronto  the S P TSX Composite added 1 30  
The best performers of the session on the S P TSX Composite were  Ivanhoe Mines Ltd    TO IVN   which rose 14 81  or 0 570 points to trade at 4 420 at the close  Meanwhile   HudBay Minerals  Inc   TO HBM  added 10 16  or 1 04 points to end at 11 34 and  Sleep Country Canada Holdings Inc   TO ZZZ  was up 9 54  or 2 79 points to 32 04 in late trade 
The worst performers of the session were Valeant Pharmaceuticals International Inc  TO VRX   which fell 3 65  or 0 69 points to trade at 18 20 at the close  Dream Global Real Estate Investment Trust  TO DRG u  declined 3 55  or 0 350 points to end at 9 520 and  DHX Media Ltd  B  TO DHXb  was down 2 92  or 0 17 points to 5 65 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 856 to 347 and 122 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 7 65  to 13 40 
Gold Futures for April delivery was down 0 32  or 4 05 to  1249 85 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in April fell 0 63  or 0 34 to hit  53 67 a barrel  while the May Brent oil contract fell 0 42  or 0 24 to trade at  56 27 a barrel 
CAD USD was down 0 40  to 0 7494  while CAD EUR fell 0 06  to 0 7105 
The US Dollar Index Futures was up 0 41  at 101 75 ",2017-03-01,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-1.30-463136,463136
147724,369240,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 46 ,news,"Investing com   Canada stocks were higher after the close on Friday  as gains in the Materials  Energy and Industrials sectors led shares higher 
At the close in Toronto  the S P TSX Composite added 0 46  
The best performers of the session on the S P TSX Composite were  Martinrea International Inc    TO MRE   which rose 7 58  or 0 65 points to trade at 9 23 at the close  Meanwhile  OceanaGold Corporation  TO OGC  added 6 23  or 0 230 points to end at 3 920 and  TransAlta  Corp  TO TA  was up 6 10  or 0 43 points to 7 48 in late trade 
The worst performers of the session were Valeant Pharmaceuticals International Inc  TO VRX   which fell 5 05  or 0 93 points to trade at 17 48 at the close  Peyto Exploration Development Corp  TO PEY  declined 4 15  or 1 15 points to end at 26 56 and  Kinaxis Inc   TO KXS  was down 3 93  or 2 97 points to 72 65 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 661 to 488 and 145 ended unchanged 
Shares in Valeant Pharmaceuticals International Inc  TO VRX  fell to 5 year lows  falling 5 05  or 0 93 to 17 48  Shares in Peyto Exploration Development Corp  TO PEY  fell to 52 week lows  falling 4 15  or 1 15 to 26 56  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 9 39  to 11 58 
Gold Futures for April delivery was up 0 18  or 2 25 to  1235 15 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in April rose 1 16  or 0 61 to hit  53 22 a barrel  while the May Brent oil contract rose 1 31  or 0 72 to trade at  55 80 a barrel 
CAD USD was up 0 15  to 0 7474  while CAD EUR fell 1 01  to 0 7037 
The US Dollar Index Futures was down 0 78  at 101 36 ",2017-03-03,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.46-463751,463751
147726,369242,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 13 ,news,"Investing com   Canada stocks were lower after the close on Tuesday  as losses in the Healthcare  Materials and Clean Technology sectors led shares lower 
At the close in Toronto  the S P TSX Composite lost 0 13  
The best performers of the session on the S P TSX Composite were Amaya Inc  TO AYA   which rose 5 75  or 1 09 points to trade at 20 06 at the close  Meanwhile   Torex Gold Resources Inc   TO TXG  added 4 51  or 1 070 points to end at 24 790 and  Semafo Inc    TO SMF  was up 3 71  or 0 14 points to 3 91 in late trade 
The worst performers of the session were  HudBay Minerals  Inc   TO HBM   which fell 7 34  or 0 76 points to trade at 9 60 at the close  Valeant Pharmaceuticals International Inc  TO VRX  declined 5 76  or 0 96 points to end at 15 70 and  Ivanhoe Mines Ltd    TO IVN  was down 5 29  or 0 210 points to 3 760 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 674 to 476 and 133 ended unchanged 
Shares in Valeant Pharmaceuticals International Inc  TO VRX  fell to 5 year lows  falling 5 76  or 0 96 to 15 70  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 4 25  to 11 49 
Gold Futures for April delivery was down 0 80  or 9 75 to  1215 75 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in April fell 0 17  or 0 09 to hit  53 11 a barrel  while the May Brent oil contract fell 0 20  or 0 11 to trade at  55 90 a barrel 
CAD USD was down 0 07  to 0 7453  while CAD EUR rose 0 09  to 0 7054 
The US Dollar Index Futures was up 0 14  at 101 81 ",2017-03-07,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-0.13-464440,464440
147731,369247,BHC,Valeant Pharmaceuticals Stock  Gains On Coming,opinion,"Valeant Pharmaceuticals  NYSE VRX  
Valeant Pharmaceuticals has been an incredibly interesting stock to follow for nearly a year now  Late last year  news surfaced that the company had misled its investors using a relationship with its biggest customer  Since then  the stock has declined dramatically  However  the company has made several changes to improve its business and appease investors  Now  there s a big conversation surrounding whether or not the stock will recover  Today  we ll talk about the scandal that led to the declines  what we ve seen from the company since  and why I believe that VRX will likely soar in the long run 
The Scandal That Started It All
For quite some time  VRX had a relationship with a pharmacy known as Philidor  This pharmacy just so happened to be the company s largest customer  generating massive amounts of sales  However  the actual sales generated weren t enough for Valeant  Instead of simply reporting the numbers as is  the company padded the numbers  misleading investors to believe that more money was being made than the actual sales would have allowed for 
This could have stayed under wraps for quite some time  However  late last year  there were several questions surrounding VRX and their pricing practices  As a result  the government launched an investigation into the company  Of course  when government investigations are going on  analysts want to investigate as well  This is where Citron comes in 
An analyst firm known as Citron decided to launch their own independent investigation into VRX  During their investigation  they found the misleading statements made by Valeant  and the relationship with Philidor that allowed the scandal to happen  Soon  Citron published a report  making the scandal public and calling Valeant the Enron of the pharmaceutical industry 
VRX Has Made Big Changes Since The Scandal
Since the scandal  VRX has been forced to make several changes to the way it does things  After all  the old way doesn t work if it allows for the misleading of investors  So  the changes started with a cancellation of he agreement with Philidor  the agreement that made the scandal possible 
Shortly after announcing that the company had cut ties with Philidor  Valeant announced something new  The company would be signing an agreement with Walgreens Boots Alliance Inc  NASDAQ WBA  under which Walgreens would start to carry their products  This would help with the amount of sales lost due to the Philidor cancellation 
Finally  VRX has also made several changes to management  First and foremost  the company replaced the CEO  J  Michael Pearson  with a well respected member of the Pharmaceuticals industry  Joseph Papa  On top of that  the company has also added two members to its Board of Directors   one being Activist Investor Bill Ackman 
Why I Believe The Stock Will Climb From Here
There s no denying the fact that Valeant Pharmaceuticals was in the wrong when it comes to the Philidor scandal  However  that doesn t mean that the company is dead in the water  VRX has fallen by far more than 70  at this point  but has not lost nearly that much in revenue nor earnings  While it may take some time to regain investor trust  with the changes the company has made  things are turning positive in a big way  So  in the long run  buying now will likely lead to big gains 
What Do You Think 
Where do you think VRX is headed moving forward and why  Let us know your opinion in the comments below ",2016-06-19,Joshua Rodriguez,https://www.investing.com/analysis/valeant-pharmaceuticals-(vrx)-stock:-gains-on-coming-200136739,200136739
147732,369248,BHC,We Like Valeant Pharmaceuticals For A Trade ,opinion,"Considering it costs  2 5 to  5 Billion from the initial Research phase to bringing a new drug to market  the  32 Billion in VRX Debt given their other assets  and proven drug portfolio makes this stock look cheap here on a valuation basis 
I bet I could find a buyer willing to pay  50 a share for Valeant Pharmaceuticals  NYSE VRX  over the weekend if Bill Ackman wasn t in such a hole on this stock  and needs a much higher price given the average stock price on his accumulated share stake 
Given that there is going to be further consolidation in this space  and the high costs associated with organically generating new drugs for the marketplace with no guarantees of success   VRX looks like an attractive take out candidate to me  Their debt is actually in line with many utilities trading at much higher valuations with much lower revenue generation capabilities from both an overall margins and gross profit standpoint 
Below you find the video  ",2016-06-26,EconMatters,https://www.investing.com/analysis/we-like-valeant-pharmaceuticals-for-a-trade-200138215,200138215
147733,369249,BHC,Big Pharma On The Hunt For Profit,opinion,"With a record  724 billion worth of mergers and acquisitions  M A  in the pharmaceutical sector  2015 would be a truly difficult year to duplicate   much less follow 
Especially since much of that M A activity was conducted by specialty pharmaceutical companies  whose business model is now in disrepute after the fall of Valeant Pharmaceuticals International  NYSE VRX  
That model involved serial acquisitions of companies possessing the rights to niche drugs  and then skyrocketing the price of those drugs 
This leaves just the pharmaceutical giants in the M A game  And they seem most willing to play  despite the collapse of the  160 billion merger between Pfizer  NYSE PFE  and Allergan  NYSE AGN pa  
The Need for Speed
Just look at what happened on April 28  when three deals   totaling  45 billion   were announced  The assets included Abbott Laboratories  NYSE ABT   Abbvie  NYSE ABBV   and Sanofi  NYSE SNY  
Big pharma companies like Pfizer  Merck  NYSE MRK  and others are looking to find growth anywhere they see a glimpse of profit 
These wily acquisitions  however  are bound to push U S  politicians to clamp down on price hikes  which was once a fairly easy way for big pharma to increase earnings  But without moderation  the general public is balking at paying higher prices for drugs that were once more affordable 
This leaves pharmaceutical companies scrambling for a new way to maximize their sales without further aggravating the powers that be  And it s looking like the beaten down biotechnology sector is the perfect avenue 
For instance  in May  Pfizer bought the small biotech firm Anacor Pharmaceuticals for  5 2 billion  Anacor is developing an eczema drug that Pfizer believes could lead to peak annual sales of more than  2 billion 
Low interest rates are also aiding the big pharma companies in their hunt for profit  because it is still relatively easy to borrow money at practically nothing to fund purchases 
In fact  the Financial Times reports that the major pharma companies have already accrued more than  50 billion in debt since the start of 2016  That is the second highest sum in two decades 
It would appear that the big pharmaceutical companies are loading up on ammo to pursue those smaller biotechnology companies   like Pfizer s deal 
Precision M A
The difference from then until now is that large pharma companies have become a lot more focused 
Most large pharmaceutical companies are pursuing what Joe Jiminez  CEO of Novartis AG  NYSE NVS   calls  precision  M A 
Jiminez explains that this kind of deal making is a drastic change from the mega mergers of the past  which often left the newly merged company with nothing more than a collection of assets and cultures that really didn t fit well together 
But now  instead of having exposure to a wide swath of therapies  most big pharma firms are focusing on just a few segments   vaccines  for example 
Vaccines are a growing business  with viruses like Zika in the headlines  There are only the  big four  left in the vaccine business  the aforementioned Pfizer  Merck  Sanofi and GlaxoSmithKline  NYSE GSK  
This means that drug companies will likely be facing less than a handful of other competitors in a specialty market  rather the wild free for all of the past where many companies competed against one other in nearly every disease category 
Of course  there are always exceptions 
Johnson   Johnson
In the case of big pharma  the exception is Johnson   Johnson  NYSE JNJ   which still follows a conglomerate approach to the healthcare industry  JNJ is the world s largest healthcare company  with three main divisions   consumer products  pharmaceuticals and medical devices 
It has come under increasing pressure from activist investors like Artisan Partners Limited Partnership  which wants it to split those sectors into three separate companies 
JNJ has  for the most part  sat out the M A spree of the past couple years  But I expect the company to make a splash this year with acquisitions for its pharmaceuticals division 
With much of its over  18 billion in cash  trapped  overseas  and with the Brexit knocking down U K  and European assets  I would not be surprised to see even the conservative Johnson   Johnson go on a shopping spree in the U K    a country which has a lot of promising biotech firms 
It needs the growth perhaps more so than even the other big pharmaceutical companies 
With drug pricing under pressure from multiple sources  expect big pharma   even JNJ   to remain on the hunt for small  fast growing biotech companies 
Good investing ",2016-06-30,Wall Street Daily,https://www.investing.com/analysis/big-pharma-on-the-hunt-for-profit-200139196,200139196
147734,369250,BHC,Valeant Pharmaceuticals Stock  Gaining On Licensing Changes,opinion,"Valeant Pharmaceuticals  NYSE VRX  
Valeant Pharmaceuticals is having an incredible day in the market today and for good reason  The company made an announcement early this morning with regard to an agreement it has with AstraZeneca PLC  NYSE AZN   Today  we ll talk about the announcement  how the market reacted to the news  and what we can expect to see from VRX moving forward  So  let s get right to it 
VRX Announces Amendments To AZN Agreement
In August of 2015  Valeant Pharmaceuticals entered into an agreement with AstraZeneca surrounding a drug known as brodalumab  Brodalumab is an IL 17 receptor monoclonal antibody  The treatment is currently under regulatory review for patients with moderate to severe plaque psoriasis 
According to the announcement today  the two companies have decided to terminate the company s right to develop and commercialize the treatment in Europe  Under the amended agreement  VRX will maintain the license to develop and commercialize the treatment in the United States  The company will also retain the license to develop and commercialize brodalumab in the remainder of territories outside of the United States 
In exchange for VRX agreeing to terminate rights in Europe  AZN will offer payment  First and foremost  there will be an upfront payment of a currently undisclosed amount  On top of that  Valeant Pharmaceuticals will still be receiving certain sales based milestone payments  Finally  one of the pre launch milestone payments has been reduced  but is still active  In a statement  Joseph C  Papa  Chairman and CEO at VRX had the following to offer 

 We are pleased with this new licensing arrangement for broadalumab  which enables us to more sharply focus our efforts on delivering this important treatment to patients in the U S  and other key markets  while providing us with immediate value and significant ongoing exposure to the treatment s commercialization in Europe  Our current focus is on the upcoming advisory panel  where we will have the opportunity to discuss brodalumab treatment options for adult patients with moderate to severe plaque psoriasis and provide information about this novel antibody we are developing  

How The Market Reacted To The News
As investors  one of the first things that we learn is that the news moves the market  Any time positive news is released with regard to a publicly traded company  we can expect to see gains in the value of the stock associated with the company  The news released by VRX today was overwhelmingly positive  So naturally  we re seeing gains in the value of the stock  Currently  11 58   the stock is trading at  20 92 per share after a gain of  0 81 per share or 4 03  thus far today 
What We Can Expect To See Moving Forward
Moving forward  I have an overwhelmingly bullish opinion of what we can expect to see from VRX  First and foremost  I m excited about today s amended agreement news  As a result of the amended agreement  Valeant Pharmaceuticals not will receive immediate payments  On top of that  the company will also be receiving milestone payments as the treatment makes it to the market  However  today s announcement isn t the only reason that I maintain a bullish opinion of what we can expect to see from VRX 
Throughout the past several months  the company has been struggling as the result of the Philidor scandal  However  since the scandal  we ve seen nothing but positive news  With a new CEO  new board members  new contracts and more  it seems as though VRX is finally headed in the right direction  All in all  I m expecting to see long run gains from the stock 
What Do You Think 
Where do you think VRX is headed ",2016-07-03,Modest Money,https://www.investing.com/analysis/valeant-pharmaceuticals-(vrx)-stock:-gaining-on-licensing-changes-200139659,200139659
147735,369251,BHC,Valeant  VRX  Loses European Rights To Psoriasis Candidate,opinion,Valeant Pharmaceuticals International  Inc    NYSE VRX   announced that its partner AstraZeneca   NYSE AZN   has amended the company s license to its pipeline candidate  brodalumab As per the amendment  AstraZeneca has decided to terminate Valeant s rights to develop and commercialize brodalumab in Europe  We note that brodalumab  an IL 17 receptor monoclonal antibody  is currently under regulatory review for the treatment of patients with moderate to severe plaque psoriasis The companies had inked the agreement in Aug 2015  which granted Valeant an exclusive license to develop and commercialize brodalumab globally  other than Japan and certain other Asian countries However  as per the amended agreement  Valeant will continue to hold the license to develop and commercialize brodalumab in the U S  and the remainder of the territory outside Europe  In lieu of the termination of rights in Europe  AstraZeneca will pay an upfront fee to Valeant  along with certain sales based milestone payments  Additionally  one of the pre launch milestones  which would be paid by Valeant to AstraZeneca  has been reduced Earlier  in 2016  FDA accepted the Biologics License Application  BLA  brodalumab for review  as submitted by AstraZeneca and Valeant  and assigned a Prescription Drug User Fee Act  PDUFA  action date of Nov 16  2016  The Dermatologic and Ophthalmic Drugs Advisory Committee is scheduled to review the BLA on July 19 With the termination of Valeant s rights  the company will now focus on the approval and commercialization of brodalumab in the U S  Meanwhile  AstraZeneca has granted LEO Pharma the rights to develop and commercialize brodalumab in Europe VALEANT PHARMA Price and Consensus   Given its current state of affairs  it is imperative for Valeant to develop its pipeline  The company has been making headlines of late  for all the wrong reasons like a price hike of specialty drugs  erroneous financial reporting and termination of contracts with Philidor Rx Services  The company also delayed its earnings release due to the review of certain accounting practices  As if the delayed results were not enough  a slash in guidance hints at more troubled conditions ahead  We believe management transition issues  heavy debt levels and persistent organizational distractions will continue to impact the company s business Investors interested in the health care sector may consider stocks like United Therapeutics Corporation   NASDAQ UTHR   and Eisai Co   Ltd    OTC ESALY   ,2016-07-05,Zacks Investment Research,https://www.investing.com/analysis/valeant-(vrx)-loses-european-rights-to-psoriasis-candidate-200140317,200140317
147736,369252,BHC,Company News For July 14  2016,opinion,"  Valeant Pharmaceuticals  NYSE VRX  International  Inc s    shares slumped 6 9  after its second biggest shareholder  Sequoia Fund exited the company


	  Shares of Teva Pharmaceutical Industries  NYSE TEVA  Limited    rose 3 8  after forecasting second quarter adjusted earnings between  1 19 to  1 22 per share  compared to previous projection of  1 16 to  1 20


	  Nokia  HE NOKIA  Corporation s    shares increased 5 4  after announcing that its cross licensing agreement with Samsung  KS 005930  will be expanded


	  Shares of Healthcare Services Group Inc     plunged 6 9  after reporting second quarter earnings of  0 26 per share  missing the Zacks Consensus Estimate by a cent",2016-07-13,Zacks Investment Research,"https://www.investing.com/analysis/company-news-for-july-14,-2016-200141857",200141857
147753,369269,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 08 ,news,"Investing com   Canada stocks were higher after the close on Wednesday  as gains in the Industrials  REITs and Real Estate sectors led shares higher 
At the close in Toronto  the S P TSX Composite rose 0 08  
The best performers of the session on the S P TSX Composite were  NuVista Energy Ltd    TO NVA   which rose 5 37  or 0 350 points to trade at 6 870 at the close  Meanwhile  Fairfax Financial Holdings Limited  TO FFH  added 4 88  or 31 00 points to end at 666 00 and Eldorado Gold Corporation  TO ELD  was up 4 04  or 0 16 points to 4 12 in late trade 
The worst performers of the session were  ProMetic Life Sciences Inc    TO PLI   which fell 4 22  or 0 070 points to trade at 1 590 at the close  Valeant Pharmaceuticals International Inc  TO VRX  declined 3 11  or 0 61 points to end at 19 02 and Le Groupe Jean Coutu PJC Inc  TO PJCa  was down 2 86  or 0 61 points to 20 75 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 776 to 439 and 118 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 4 01  to 10 29 
Gold for February delivery was down 0 11  or 1 20 to  1132 40 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in February fell 1 41  or 0 75 to hit  52 55 a barrel  while the February Brent oil contract fell 1 46  or 0 81 to trade at  54 54 a barrel 
CAD USD was down 0 33  to 0 7455  while CAD EUR fell 0 64  to 0 7155 
The US Dollar Index was down 0 22  at 103 03 ",2016-12-21,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.08-449275,449275
147754,369270,BHC,Democrats lean on drug pricing as Obamacare repeal looms,news,By Susan Cornwell and Caroline Humer WASHINGTON NEW YORK  Reuters    Democrats are showing little interest in cooperating with the Republicans who control Congress on legislation to dismantle the Obamacare health insurance law but some are signaling a willingness to collaborate on action to curb rising drug prices  Republican U S  President elect Donald Trump pledged two weeks ago to bring down drug prices  addressing an issue that could appeal to voters in both parties  He did not say how he would accomplish this although he previously suggested he was open to allowing importation of cheaper medicines from overseas  Nineteen Senate Democrats this week urged Trump to push the issue with Republican lawmakers  many of whom have resisted government action to rein in medication costs  Persistently rising drug prices have imposed a heavy burden on consumers  Many Americans cannot afford their medicines or face increasing co pays on prescription drugs  The 2010 Affordable Care Act  dubbed Obamacare  enabled about 20 million Americans who previously had no medical insurance to get coverage  It is considered outgoing Democratic President Barack Obama s signature legislative achievement and an important accomplishment for his party  Republicans  who will control both the White House and in 2017  condemn it as a government overreach  Trump and congressional Republicans have vowed to repeal and replace it  Senate Majority Leader Mitch McConnell has said senators will start the repeal process shortly after Jan  1  Trump takes office on Jan  20  A House of Representatives leadership aide told reporters drug pricing was one of several areas Republicans would use to reach out to Democrats to solicit their involvement in Obamacare replacement legislation  along with the Medicaid insurance program for the poor  and children s healthcare    We are going to try and find where the other side wants to engage   the aide said  Democrats may be difficult to persuade  Democratic Senator Amy Klobuchar of Minnesota said drug pricing proposals might have been part of a bipartisan healthcare reform package to address Obamacare issues  if Republicans were not insisting on repeal first  placing the two parties in opposite camps    My vision before the election was that we would have some form of reform package  and now that s murky because of this effort to repeal   Klobuchar said in a telephone interview  PROCEDURAL HURDLES Republican lawmakers have angered Democrats with their plan to use arcane congressional budget procedures to repeal Obamacare as quickly as possible  without having to secure any Democratic votes  This approach would thwart procedural hurdles Democrats could pursue under normal circumstances  Republicans including Senator John Thune of South Dakota  a member of his party s Senate leadership  have said they want Democrats to work with them to replace Obamacare once it is repealed  They will almost certainly need them   In the 100 seat Senate  Republicans need a super majority of 60 to clear procedural hurdles and pass replacement legislation  With 52 Republican senators  they would need to attract at least eight Democrats   If they genuinely wanted to work with us on fixing the Affordable Care Act  we would have that conversation before they repealed   Democratic Senator Chris Coons of Delaware said of the Republicans  Americans can obtain health insurance from private insurers through the Affordable Care Act by buying it on state or federally run exchanges  In 2016  costs on the individual insurance market rose  Insurers including UnitedHealth Group Inc  NYSE UNH  and  Aetna Inc   NYSE AET  pulled out for 2017  saying they were losing too much money  More insurers may drop out for 2018  making insurance plans more expensive   Lawmakers in both parties expressed outrage after Mylan  NASDAQ MYL  NV raised the price of a pair of the generic drugmaker s lifesaving EpiPen allergy treatments to more than  600 this year from  100 in 2008  Klobuchar has worked with Iowa Republican Senator Charles Grassley on drug pricing issues  introducing legislation that would help put an end to brand name drug companies paying generic drugmakers to delay marketing low cost competing medications  She was among the Democrats who sent Trump the letter on drug costs  They suggested five areas of cooperation  allowing the Medicare insurance program for the elderly to negotiate prescription prices  increasing transparency  stopping abusive pricing  encouraging incentives for innovation  and supporting generic competition for branded drugs  In addition  Republican Senator Susan Collins of Maine Democratic Senator Claire McCaskill of Missouri this week released a report detailing drug pricing abuses at Valeant Pharmaceuticals  NYSE VRX  International and Turing Pharmaceuticals  Health policy expert Joe Antos of the American Enterprise Institute think tank said Democrats may refuse to work on Obamacare replacement legislation for some time  especially if Republicans delay the repeal s effective date by up to three years   Democrats can just say  we don t have to do it now   Antos said  Stuart Butler of the Brookings Institution think tank said it will get harder for Democrats to stay on the sidelines after a repeal because hospitals  insurers and Americans who may lose their coverage will press for action   I think they  Democrats  will get as much political capital out of not engaging as they can  and then I think their own constituents will start to push them   Butler said ,2016-12-22,Reuters,https://www.investing.com/news/politics-news/democrats-lean-on-drug-pricing-as-obamacare-repeal-looms-449517,449517
147755,369271,BHC,Japan s Takeda to buy U S  cancer drug maker Ariad in  5 2 billion deal,news," Reuters    Japan s Takeda Pharmaceutical Co Ltd  T 4502  said on Monday it would buy cancer drug maker  Ariad Pharmaceuticals  Inc  O ARIA  in a deal valued at  5 20 billion  to beef up its oncology pipeline  Ariad stock was up 74 7 percent at  23 98 in premarket trading  Takeda has agreed to pay  24 in cash for each Ariad share  a premium of about 75 percent to its Friday close   Ariad s leukemia drug  Iclusig  which is expected to generate sales of  170 million  180 million in 2016  came under fire in October for  staggering  price increases  A U S  Food and Drug Administration decision on its lung cancer treatment brigatinib  which is being touted as a potential blockbuster  is expected by April 29  Cancer treatment is a target for many large drugmakers  with high prices being paid for promising assets  such as Medivation  which was bought by  Pfizer  Inc  N PFE  for  14 billion  Takeda s negotiations to acquire Valeant Pharmaceuticals  NYSE VRX  International Inc s  TO VRX  Salix stomach drug business have stalled over price disagreements  Reuters reported in November  citing people familiar with the matter   The Ariad deal  which Takeda plans to fund by taking on  4 billion in new debt as well as existing cash  is expected to close by the end of February  Ariad had long term debt of about  522 million as of Sept  30  according to a regulatory filing   
The equity value of the deal  which is expected to add to Takeda earnings in 2018  is  4 66 billion  according to Reuters calculations ",2017-01-09,Reuters,https://www.investing.com/news/stock-market-news/japan's-takeda-to-buy-u.s.-cancer-drug-maker-ariad-in-$5.2-billion-deal-451922,451922
147756,369272,BHC,European stocks struggle with retail stocks and banks in focus  DAX flat,news,"Investing com   European stocks were trading mostly lower on Tuesday  while investors chewed over news from the retail sector and kept their eye on developments with Italian banks 
Nearing midday in Europe  the benchmark Euro Stoxx 50 lost 0 15   France s CAC 40 fell 0 13   although Germany s DAX 30 edged slightly higher  up 0 01  
On a light calendar day for economic reports  French industrial output rose 2 2  month on month in November  beating a forecast for a gain of 0 6  
Earlier  China registered its largest increase in producer prices since September 2011  in what could be a sign of stabilization in the world s second largest economy on the same day that the director of the National Development and Reform Commission  NDRC  Xu Shaoshi said that the Chinese economy was expected to have grown 6 7  in 2016 
China also saw annualized inflation ease in December to 2 1   coming in below expectations for it to hold at 2 3  
On the European company front  all eyes were in movements in the retail sector 
Over in the U K   WM Morrison  LON MRW   Britain s fourth largest supermarket chain  increased its profit forecast on Tuesday after registering its strongest Christmas sales in seven years  while the U K  s largest chain  Tesco   LON TSCO  managed to beat out competitors during the holiday season  according to a report from market researcher Kantar Worldpanel 
Both retailers were near the top of the Euro Stoxx 600 with gains of more than 3  
In the euro zone s largest economy  shares in German retailer  Metro AG   DE MEOG  slumped nearly 2  after reporting sluggish sales in its fiscal first quarter 
In M A  French cosmetics dealer L Oreal  PA OREP  announced it would buy three skincare brands from Valeant Pharmaceuticals  TO VRX  for  1 3 billion 
Leading the Euro Stoxx 600 lower  shares in  Just Eat   LON JE  tumbled 8  as the online food delivery firm saw order growth continued its downward trend 
European banks were also under downward pressure as concern about Italian banks continued to dampen sentiment  Popolare di Vicenza and Veneto Banca which were rescued last year were to propose a deal with shareholders that could cost them  600 million   634 million   according to a Reuters  report 
Meanwhile  oil prices edged higher on Tuesday  after suffering their biggest one day loss in six weeks in the prior session amid doubts over the implementation of a planned deal by global crude producers to scale back output 
Energy stocks were trading higher  as French oil and gas major  Total  SA  PA TOTF  advanced 0 29    Italy s  ENI   MI ENI  gained 0 78   while Norwegian rival  Statoil   OL STL  rose 0 25  
Financial stocks were mostly lower  as French lenders  BNP Paribas   PA BNPP  traded down 0 36  though  Societe Generale   PA SOGN  gained 0 45   while Germany s  Deutsche Bank   DE DBKGn  and Commerzbank  DE CBKG  slumped 2 65  and 2 88   respectively 
Among peripheral lenders  Italy s  Intesa Sanpaolo   MI ISP  was off 1 13  and Unicredit  MI CRDI  sank 2 99   while Spanish banks BBVA  MC BBVA  fell 2 43  and  Banco Santander   MC SAN  retreated 0 37  
In London  the commodity heavy FTSE 100 once again broke the general trend in Europe  inching up 0 06  as sterling continued to show weakness  A cheap pound drives up the value of multinational firms listed on the index  as it means their overseas earnings are worth more when converted into the British currency 
Shares in  Glencore   LON GLEN  rose 1 10    Anglo American   LON AAL  soared 4 76   while BHP Billiton  LON BLT  and  Rio Tinto   LON RIO  jumped 2 39  and 3 32   respectively 
Energy stocks were mixed  as  BP   LON BP  lost 0 76  but rival Royal Dutch Shell  LON RDSa  advanced 0 13  
Financial stocks were also lower as shares in  HSBC Holdings   LON HSBA  slipped 0 01  and the Royal Bank of Scotland  LON RBS  slumped 2 15   while  Barclays   LON BARC  and Lloyds Banking  LON LLOY  fell 1 15  and 0 46   respectively 
In the U S   equity markets pointed to a flat open  The Dow Jones Industrial Average futures was unchanged  S P 500 futures dropped 0 02   while the Nasdaq 100 futures inched up 0 01  ",2017-01-10,Investing.com,https://www.investing.com/news/stock-market-news/european-stocks-struggle-with-retail-stocks-and-banks-in-focus;-dax-flat-452125,452125
147757,369273,BHC,Valeant to sell assets for  2 12 billion to ease debt load,news," Reuters    Valeant Pharmaceuticals  NYSE VRX  International  TO VRX  is selling its Dendreon cancer business and three skincare brands for about  2 12 billion as the troubled Canadian drugmaker looks to pay down its more than  30 billion debt  Valeant s U S  listed shares rose 15 percent to  17 65 in premarket trading on Tuesday  The company is trying to regain investor confidence after its stock declined nearly 90 percent in the past year over disclosures that it secretly worked with a specialty pharmacy to boost sales of its medicines  Laval  Quebec based Valeant is the subject of a number of recent investigations related to specialty pharmacy  including by congressional panels and the U S  Securities and Commission  French cosmetics group L Oreal  PA OREP  is buying CeraVe  AcneFree and Ambi from Valeant for about  1 3 billion in cash  Valeant is also selling its Dendreon unit to China s Sanpower Group Co Ltd  SPGCL UL  for  819 9 million  Valeant bought bankrupt Dendreon in 2015 for about  300 million   With this sale  we are better aligning our product portfolio with Valeant s new operating strategy by exiting the urological oncology business  which is one of our non core assets   Valeant Chief Executive Joseph Papa said in a statement on Monday  The deals could be the first of a series of divestitures for Valeant  whose growth was fueled by an acquisition spree that left it saddled with a huge pile of debt  Mizuho Securities USA analyst Irina Koffler said she also expects Valeant to divest its dental business as well as its interests in some geographies  Founded in 2005  CeraVe develops cleansers  moisturizers and baby products and is one of the fastest growing active skin care brands in the United States  L Oreal said  AcneFree provides acne treatments and skin cleansers  while Ambi makes products to treat dark spots and brighten skin  L Oreal said the three brands would stand alongside the likes of Vichy and La Roche Posay in its Active Cosmetics division  which is among its strongest in terms of growth and resilience to slowdowns in consumer spending in the past three to four years  L Oreal paid nearly eight times the brand s combined annual revenue of  168 million as it expands into one of the fastest growing areas of the beauty industry  
Separately  Valeant said its lotion for plaque psoriasis  IDP 118  which is a combination formulation of two common treatments   halobetasol propionate and tazarotene   was more effective and reduced irritation in patients in a key study ",2017-01-10,Reuters,https://www.investing.com/news/stock-market-news/l'oreal-to-buy-three-skincare-brands-from-valeant-for-$1.3-billion-452100,452100
147758,369274,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 42 ,news,"Investing com   Canada stocks were higher after the close on Wednesday  as gains in the Clean Technology  Financials and Materials sectors led shares higher 
At the close in Toronto  the S P TSX Composite rose 0 42  
The best performers of the session on the S P TSX Composite were  Teck Resources Ltd  B  TO TECKb   which rose 6 65  or 1 97 points to trade at 31 60 at the close  Meanwhile   Bombardier Inc   TO BBDb  added 4 86  or 0 120 points to end at 2 590 and  Air Canada   TO AC  was up 4 71  or 0 640 points to 14 230 in late trade 
The worst performers of the session were Hudson s Bay Company  TO HBC   which fell 7 48  or 0 76 points to trade at 9 40 at the close  Valeant Pharmaceuticals International Inc  TO VRX  declined 6 92  or 1 51 points to end at 20 31 and  ProMetic Life Sciences Inc    TO PLI  was down 4 76  or 0 110 points to 2 200 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 711 to 450 and 129 ended unchanged 
Shares in Hudson s Bay Company  TO HBC  fell to all time lows  falling 7 48  or 0 76 to 9 40  Shares in Bombardier Inc  TO BBDb  rose to 52 week highs  up 4 86  or 0 120 to 2 590  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 10 62  to 11 53 
Gold for February delivery was up 0 55  or 6 50 to  1192 00 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in February rose 3 15  or 1 60 to hit  52 42 a barrel  while the March Brent oil contract rose 3 17  or 1 70 to trade at  55 34 a barrel 
CAD USD was up 0 40  to 0 7589  while CAD EUR rose 0 17  to 0 7172 
The US Dollar Index was down 0 28  at 101 72 ",2017-01-11,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.42-452574,452574
147763,369279,BHC,Company News For June 08  2016,opinion,"  Hertz Global Holdings  Inc s    shares increased 5 9  after the activist investor Carl Icahn raised his stake in the company from 14 3  to 15 2 


  Shares of Axiall Corporation    jumped 8 8  on news that Lotte Chemical will bid to acquire the company for  3 1 billion


  Valeant Pharmaceuticals  NYSE VRX  International  Inc s    shares slumped 14 6  after forecasting full year earnings at  6 60  7 00 per share  down from previous projection of  8 50  9 50 per share


  Shares of United Natural Foods  Inc     surged 14  after reporting fiscal third quarter earnings of  0 76 per share  beating the Zacks Consensus Estimate of  0 66",2016-06-07,Zacks Investment Research,"https://www.investing.com/analysis/company-news-for-june-08,-2016-200134753",200134753
147764,369280,BHC,Valeant Dives On Earnings,opinion,"Valeant Pharmaceuticals  NYSE VRX  is having a rough day in the market today  following up on losses that we saw from the stock yesterday  The reason for the decline is relatively simple  The company reported earnings that were well below expectations  and guidance wasn t much better  Nonetheless  don t count VRX out just yet  Today  we ll talk about earnings  how the market reacted to the news  and why the stock can still climb moving forward 
VRX Releases Upsetting Results
As mentioned above  Valeant Pharmaceuticals is having an incredibly rough time after reporting earnings for the first quarter  Here s what we saw from the report   

Earnings Per Share   In terms of earnings per share  VRX missed the mark in a big way  During the quarter  analysts were expecting that the company would generate earnings in the amount of  0 28 per share  However  the company actually generated a loss in the amount of  1 08 per share  missing expectations by a wide margin 
Revenue   In terms of revenue  VRX also missed the mark  While the company saw revenue increase by 9 3  quarter over quarter  analysts were expecting to see the figure come in at  2 38 billion  However  the company actually reported revenue in the amount of  2 37 billion 
Guidance   While both earnings and revenue proved to be concerning the most concerning part of the report  proved to be guidance  Valeant Pharmaceuticals has reduced its full year outlook yet again  For the year 2016  VRX is expecting to generate earnings between  6 60 and  7 per share  This falls well short of the previous guidance between  8 50 and  9 per share as well as analyst estimates which sit around  8 47 per share 

While the report was overwhelmingly negative  the company has made progress with regard to stabilizing the organization following the Philidor scandal  In a statement  Joseph Papa  CEO at VRX had the following to offer   

We have made progress toward stabilizing the organization over the past few months  and we expect to file our financial results in a timely manner going forward    Valeant Pharmaceuticals has a portfolio of world class brands  a strong new product pipeline and dedicated leaders who are committed to doing what is right and what is necessary to turn this company around by re engaging our workforce  rebuilding our relationships with prescribers  patients and payors  and regaining the trust of our debtholders and shareholders 

How The Market Reacted To The News
As investors  one of the first things that we learn is that the news moves the market  Any time there is positive news released with regard to a publicly traded company  we can expect to see gains in the value of the stock associated with the company as a result  However  the news that was released surrounding VRX was anything but positive  As a result  we re seeing declines in the value of the stock at the moment  Currently  12 28   VRX is trading at  23 82 per share after a loss of  0 82 per share or 3 33  thus far today  This follows wide losses we saw from the stock yesterday as well 
VRX Can Still Climb
There s no denying the fact that the earnings report released by Valeant Pharmaceuticals was overwhelmingly negative  However  it s important to keep in mind the fact that this was the first report since the Philidor scandal  Since the scandal  we ve seen a CEO change  board changes  and an agreement signed with Walgreens  Not to mention  with the 70   decline we ve seen since the scandal  the bad news was already priced in  Moving forward  I m expecting for Joseph Papa to do wonderful things with VRX  With a strong pipeline  great products  and a willingness to claw its way out of the hole it currently sits in  VRX looks like it s likely to head upward in the long run ",2016-06-08,Joshua Rodriguez,https://www.investing.com/analysis/valeant-dives-on-earnings-200134823,200134823
147765,369281,BHC,Under Armour Hopes To Hold Support,opinion,"Few stocks have outperformed the S P 500 by a wider margin than Under Armour  NYSE UA  since the 2009 lows  Despite recent declines  UA has outperformed the broad market by more than 1 000  during the past 6 years 

Below looks at Under Armour s current chart pattern 

UA remains inside a uniform rising channel since the 2009 lows  As mentioned above  a Head and Shoulders topping pattern is NOT proven at this time  UA is testing dual support at  1   which seems important to hold for this high flying stock 
Why is it important to hold at support  Check out below what happens when a stock creates an Eiffel Tower pattern and support gives way 

Restoration Hardware  NYSE RH  and Valeant Pharmaceuticals  NYSE VRX  were high flyers over the past few years  Once support was taken out  sellers came forward 
UA has been an upside leader over the past few years  The Power of the Pattern feels this is NOT your typical support test for UA ",2016-06-09,Chris Kimble,https://www.investing.com/analysis/under-armour-hopes-to-hold-support-200134968,200134968
147766,369282,BHC,Valeant s CEO Bought VRX Shares  But Here s Why You Shouldn t,opinion,"Joseph Papa  CEO of the controversial Valeant Pharmaceuticals   NYSE VRX    disclosed his purchase of 202 000 shares of VRX stock at the price of  24 48 per share   The total transaction is valued at close to  5 million  and disclosure of the purchase has helped to boost investor sentiment on Valeant shares today   Should you be bullish on Valeant though   Shares have lost a lot of weight over the last year  but the 89  stock price loss is warranted   Valeant shares have faced major backlash because of congressional and SEC investigations over its accounting methods  
VRX stock has lost 19  of its value in June because it missed first quarter earnings expectations   Upon the Q1 earnings release  VRX has also lowered its own earnings expectations for this year   This has left the sentiment on Valeant extremely bearish for the most part 
Valeant is a Zacks Rank  5  Strong Sell   and for good reason   After all  18 analysts have revised their quarterly earnings expectations lower for VRX over the last 60 days   No analysts have revised earnings expectations higher for this quarter  next quarter  the current year  or even the next fiscal year   20 analysts have lowered their EPS estimates for this fiscal year  as well as the next VALEANT PHARMA Revenue  Quarterly YoY Growth    Our quarterly EPS consensus has trended lower over the last 3 months   The estimate is 42  lower compared to where it was just 90 days ago   What s even more alarming is the fact that our current year EPS consensus has shrunk by 43 95  over the last 90 days  
As estimates trend lower  you may be better off waiting for VRX s EPS expectations to bottom out  as we have yet to find out what the company s true earnings potential is 
Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-06-13,Zacks Investment Research,"https://www.investing.com/analysis/valeant's-ceo-bought-vrx-shares,-but-here's-why-you-shouldn't-200135667",200135667
147778,369294,BHC,Valeant says it was the victim of Davenport and Tanner s fraudulent actions,news,In a statement  Valeant Pharmaceuticals  VRX  3   says it was the one defrauded by the actions of former Philidor CEO Andrew Davenport and former company liaison Gary Tanner  It adds that Mr  Tanner left the company on September 13  2015 and Mr  Davenport was never in the employ of Valeant The company continues to cooperate with authorities in the matter ,2016-11-17,Seeking Alpha,https://www.investing.com/news/stock-market-news/valeant-says-it-was-the-victim-of-davenport-and-tanner's-fraudulent-actions-441872,441872
147779,369295,BHC,Valeant s liaison with Philidor paid millions to promote Philidor interest  including acquisition option,news,More details are emerging from the federal complaint against former Valeant Pharmaceuticals  VRX  0 4   Philidor liaison Gary Tanner  Philidor  through CEO Andrew Davenport  paid Mr  Tanner up to  10M to promote Philidor s interests in Valeant including convincing management to purchase an option to acquire the specialty pharmacy According to the complaint  Mr  Tanner was in charge of  alternative fulfillment  which was the practice of using mail order pharmacies to funnel prescriptions for branded drugs instead of generics The alleged kickbacks ensured that Mr  Tanner resisted efforts by Valeant management to establish relationships with Philidor competitors  He was also instrumental in persuading management to enter into the December 2014 purchase option agreement Philidor grew from a tiny start up to a 450 employee strong operation due almost entirely to Valeant  which accounted for at least 90  of its dispensing volume before collapsing Both men were arrested this morning ,2016-11-17,Seeking Alpha,"https://www.investing.com/news/stock-market-news/valeant's-liaison-with-philidor-paid-millions-to-promote-philidor-interest,-including-acquisition-option-441933",441933
147780,369296,BHC,Ex Valeant executive  ex pharmacy CEO charged for fraud scheme,news,"By Nate Raymond NEW YORK  Reuters    U S  prosecutors on Thursday filed charges against a former Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX  executive and a former CEO of mail order pharmacy Philidor Rx Services  alleging they engaged in a multimillion dollar fraud and kickback scheme  Federal prosecutors in Manhattan accused Gary Tanner  a former senior Valeant director  of secretly agreeing with former Philidor CEO Andrew Davenport to pay  100 million for the right to buy the specialty pharmacy  which is now defunct  That deal resulted in Davenport earning  40 million   10 million of which he secretly kicked back to Tanner  who used his position to expand the number of Valeant products sold through Philidor  prosecutors said  They said the investigation of Laval  Quebec based Valeant and Philidor is continuing  The Federal Bureau of Investigation arrested Tanner  39  and Davenport  48  on Thursday morning at their residences in Arizona and Pennsylvania  respectively  authorities said  Their lawyers did not respond to requests for comment  Valeant said in a statement that Tanner no longer works for the company and that the charges included allegations that the defendants defrauded the drugmaker  It said it is cooperating with authorities  The development is the latest to hit Valeant  whose stock has plunged more than 90 percent since August 2015 amid intense criticism of its drug pricing and business practices and various investigations  Valeant  whose biggest investor is Bill Ackman s Pershing Square  NYSE SQ  Capital Management  has disclosed it received subpoenas seeking information related to its ties to Philidor and its accounting treatment for sales by specialty pharmacies  INVESTIGATION CONTINUES At a news conference  Manhattan U S  Attorney Preet Bharara said investigators continuing looking for potential corruption and fraud at Valeant that may have harmed shareholders and the marketplace  Tanner and Davenport were expected to appear in court on Thursday  They face four counts  including conspiracy to commit wire fraud and conspiracy to commit money laundering  Valeant shares fell 5 percent early Thursday after news of the arrests broke  The price recovered following Bharara s news conference  trading up 0 79 percent  or 19 cents  at  24 22 in New York  Founded in 2013  Philidor was a specialty mail order pharmacy formed with Valeant s assistance  prosecutors said  At least 90 percent of the drugs it dispensed were Valeant branded products  they said  Valeant s ties to Philidor emerged in October 2015 following a report issued by short selling firm Citron Research focused partly on Philidor  Up until that month  neither the nature of Valeant s relationship to Philidor nor its increasing dependence on the pharmacy to achieve its sales and profitability goals  had been disclosed to the public  the complaint said  Following subsequent revelations  several insurers terminated contracts with Philidor and Valeant cut ties with the pharmacy  Philidor terminated its operations in January  In March  Valeant announced that CEO Michael  Pearson   LON PSON  would leave  as the company said a board investigation of its dealings with Philidor found accounting problems dating to December 2014  Valeant at that time said the committee found that  improper conduct  by former Chief Financial Officer Howard Schiller and the company s corporate controller contributed to the pharmaceutical company s need to restate results  Schiller  who stepped down in 2015 and left Valeant s board this year  has denied wrongdoing  Lawyers for Pearson and Schiller did not respond to requests for comment on Thursday  
The case is U S  v  Tanner  U S  District Court  Southern District of New York  No  16 mj 7388 ",2016-11-17,Reuters,https://www.investing.com/news/stock-market-news/u.s.-unveils-criminal-charges-in-valeant-probe:-prosecutors-441798,441798
147781,369297,BHC,Wells Fargo says Valeant s legal risks warrant bearish rating,news,Wells Fargo   NYSE WFC  analyst David Maris tells investors that Valeant Pharmaceuticals  VRX  0 4   has no reserves established to pay for any legal liabilities  a significant risk in his view  considering today s arrests of Andrew Davenport and Gary Tanner and the multitude of lawsuits against the company and its affiliates He rates the stock Underperform with a  10   13 target price range  35  downside risk from the midpoint  ,2016-11-17,Seeking Alpha,https://www.investing.com/news/stock-market-news/wells-fargo-says-valeant's-legal-risks-warrant-bearish-rating-441964,441964
147782,369298,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 55 ,news,"Investing com   Canada stocks were higher after the close on Wednesday  as gains in the Energy  Industrials and Clean Technology sectors led shares higher 
At the close in Toronto  the S P TSX Composite added 0 55  
The best performers of the session on the S P TSX Composite were Enerplus Corporation  TO ERF   which rose 17 37  or 1 72 points to trade at 11 62 at the close  Meanwhile   Precision Drilling  Corporation  TO PD  added 17 11  or 1 04 points to end at 7 12 and  TORC Oil   Gas  Ltd   TO TOG  was up 16 97  or 1 22 points to 8 41 in late trade 
The worst performers of the session were Valeant Pharmaceuticals International Inc  TO VRX   which fell 7 85  or 1 81 points to trade at 21 24 at the close  Detour Gold Corporation  TO DGC  declined 4 52  or 0 81 points to end at 17 12 and  Asanko Gold Inc   TO AKG  was down 4 46  or 0 220 points to 4 710 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 691 to 495 and 138 ended unchanged 
Shares in Enerplus Corporation  TO ERF  rose to 52 week highs  rising 17 37  or 1 72 to 11 62  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 12 51  to 13 15 
Gold for February delivery was down 1 31  or 15 65 to  1175 15 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in January rose 8 49  or 3 84 to hit  49 07 a barrel  while the February Brent oil contract rose 8 85  or 4 19 to trade at  51 51 a barrel 
CAD USD was down 0 07  to 0 7441  while CAD EUR rose 0 52  to 0 7026 
The US Dollar Index was up 0 57  at 101 56 ",2016-11-30,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.55-444730,444730
147783,369299,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 74 ,news,"Investing com   Canada stocks were higher after the close on Wednesday  as gains in the Consumer Discretionary  IT and Consumer Staples sectors led shares higher 
At the close in Toronto  the S P TSX Composite rose 0 74  to hit a new 52 week high 
The best performers of the session on the S P TSX Composite were DH Corp  TO DH   which rose 13 97  or 2 68 points to trade at 21 87 at the close  Meanwhile   Martinrea International Inc    TO MRE  added 7 41  or 0 58 points to end at 8 41 and  Transcontinental Inc   TO TCLa  was up 6 75  or 1 32 points to 20 87 in late trade 
The worst performers of the session were  ProMetic Life Sciences Inc    TO PLI   which fell 4 59  or 0 100 points to trade at 2 080 at the close   Alacer Gold  Corp  TO ASR  declined 4 17  or 0 100 points to end at 2 300 and Valeant Pharmaceuticals International Inc  TO VRX  was down 3 76  or 0 78 points to 19 95 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 649 to 550 and 127 ended unchanged 
Shares in Transcontinental Inc  TO TCLa  rose to 52 week highs  gaining 6 75  or 1 32 to 20 87  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 3 29  to 9 69 a new 3 months low 
Gold for February delivery was up 0 35  or 4 05 to  1174 15 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in January fell 2 12  or 1 08 to hit  49 85 a barrel  while the February Brent oil contract fell 1 67  or 0 90 to trade at  53 03 a barrel 
CAD USD was up 0 35  to 0 7553  while CAD EUR unchanged 0 00  to 0 7026 
The US Dollar Index was down 0 26  at 100 25 ",2016-12-07,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.74-446351,446351
147784,369300,BHC,Short seller Citron calls Express Scripts drug price culprit,news,By Deena Beasley  Reuters    Short seller Citron Research s Andrew Left has turned his sights on Express Scripts Holding Co  calling the pharmacy benefit manager  PBM  the  culprit behind pharmaceutical price gouging   Shares of Express Scripts  the largest PBM in the United States  fell 6 7 percent to close at  70 75 on Nasdaq  Citron  which profits from bets that stock prices will fall  set a price target of  45 on the company s shares   Express Scripts  is Philidor of the pharma industry   therealdonaldtrump promises to fix drug pricing  Two words  EXPRESS SCRIPTS   Citron tweeted on Thursday   President elect Donald Trump  in a Time magazine article on Wednesday  said he would  bring down drug prices    We make money when our clients save money   Express Scripts said in comments emailed on Thursday   The vast majority of rebates we negotiate go directly back to our clients    PBMs like Express Scripts manage prescription drug plans for employers and insurers  Philidor Rx Services  now closed  was a mail order pharmacy linked to efforts by Valeant Pharmaceuticals International Inc  NYSE VRX  to steer prescriptions to its high priced drugs   Left  during an interview on CNBC  said Express Scripts benefits from the  opaqueness  of drug pricing  but  by no means am I saying that this company is a fraud   PBMs have in recent years taken an increasingly aggressive stance in price negotiations with pharmaceutical companies  in some cases limiting access to rival drugs in specific categories in return for discounts to list prices or rebates  Shares of Express Scripts have struggled for most of this year after a major customer  health insurer Anthem Inc  sued the company over drug rebates  Citron sparked the investigation into the relationship between Valeant and now shuttered Philidor with a report issued in October 2015  A former Valeant executive and the former CEO of Philidor were arrested last month on charges that they engaged in a multimillion dollar fraud and kickback scheme  Shares of drugstore operator CVS Health Corp  NYSE CVS   which has a PBM unit  fell 3 percent to close at  78 11 on the New York Stock Exchange ,2016-12-09,Reuters,https://www.investing.com/news/stock-market-news/citron-calls-express-scripts-culprit-in-drug-price-gouging-446613,446613
147785,369301,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 16 ,news,"Investing com   Canada stocks were lower after the close on Monday  as losses in the Industrials  Healthcare and Clean Technology sectors led shares lower 
At the close in Toronto  the S P TSX Composite lost 0 16  
The best performers of the session on the S P TSX Composite were  Baytex Energy  Corp  TO BTE   which rose 9 50  or 0 61 points to trade at 7 03 at the close  Meanwhile   MEG Energy Corp   TO MEG  added 7 74  or 0 64 points to end at 8 91 and  Alamos Gold Inc   TO AGI  was up 6 51  or 0 52 points to 8 51 in late trade 
The worst performers of the session were Valeant Pharmaceuticals International Inc  TO VRX   which fell 5 15  or 1 05 points to trade at 19 32 at the close   Centerra Gold Inc   TO CG  declined 4 58  or 0 32 points to end at 6 67 and  HudBay Minerals  Inc   TO HBM  was down 4 17  or 0 39 points to 8 97 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 670 to 528 and 117 ended unchanged 
Shares in Valeant Pharmaceuticals International Inc  TO VRX  fell to 5 year lows  down 5 15  or 1 05 to 19 32  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 2 33  to 9 24 a new 3 months low 
Gold for February delivery was up 0 19  or 2 15 to  1164 05 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in January rose 2 04  or 1 05 to hit  52 55 a barrel  while the February Brent oil contract rose 2 23  or 1 21 to trade at  55 54 a barrel 
CAD USD was up 0 33  to 0 7613  while CAD EUR fell 0 31  to 0 7163 
The US Dollar Index was down 0 58  at 101 01 ",2016-12-12,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-0.16-447285,447285
147792,369308,BHC,Valeant Pharmaceuticals Stock  Climbing On Takeover Rejection,opinion,"Valeant Pharmaceuticals  NYSE VRX  
Valeant Pharmaceuticals is having an incredibly strong day in the market today  and for good reason  News surfaced that the company has made the decision to decline a joint takeover bid  Today  we ll talk about the details of the bid  how the market reacted to the news  and what we can expect to see from VRX moving forward  So  let s get right to it 
VRX Rejects Takeover Bid
For some time now  Valeant Pharmaceuticals has been struggling  However  at this point  the company is on a clear path to recovery  So  it s no surprise that we re starting to see takeover bids  Recently  a biotechnology company out of Japan  Takeda Pharmaceutical Co   Ltd   T 4502   and a private equity firm known as TPG  made an offer to takeover the company  If the takeover were successful  Takeda would focus on Salix Pharmaceuticals while TPG would handle the rest  However  VRX made the decision to reject the offer 
While the takeover bid didn t come with a firm price  it seems as though VRX wouldn t be willing to sell at just about any reasonable price at the moment  In fact  Mizuho analyst  Irina Koffer  said that she doesn t think the larger shareholders are willing to part with the stock at the moment  This is even if a strong premium were offered  Here s what she had to say 
 We think that large shareholders and Valeant Board members are so far underwater on their positions that they may be resistant to a potential bid which may  undervalue  the company  
How The Market Reacted To The News
As investors  we know that the news moves the market  Any time there is positive news associated with a publicly traded company  we can expect to see gains in that company s stock as a result  Adversely  negative news will generally cause declines  In this particular case  the news was overwhelmingly positive  First and foremost  investors tend to get excited when takeover bids are offered  However  in this particular case  the news that the company declined the bid is even more positive  The reality is that VRX has fallen dramatically  and many investors believed that declines would continue  If the management of the company felt the same  they would have sold out quickly  However  Valeant isn t ready for that  they see more gains coming  As a result  we re seeing strong movement in the value of the stock today  Currently  10 40   VRX is trading at  28 93 per share after a gain of  1 99 per share or 7 39  thus far today 
What We Can Expect To See Moving Forward
Over the past month or so  I have been very forthcoming about my bullish opinion on VRX  The reality is that the company fell on an incredibly hard time  It had to deal with a scandal going public  which caused the loss of its biggest customer  However  in the months following the scandal  we ve seen incredible positivity  The company has switched out it s CEO  added members to its Board of Directors  and even signed a contract with Walgreens Boots Alliance Inc  NASDAQ WBA  for the sale of its treatments  While I know that it s going to take quite a while for investors to become confident in the stock once again  it s clear to me at this point that VRX is incredibly undervalued  The reality is that the company has made it over the hurdle and is now once again moving forward  As a result  I m expecting to see gains in the value of the stock moving forward ",2016-05-29,Modest Money,https://www.investing.com/analysis/valeant-pharmaceuticals-(vrx)-stock:-climbing-on-takeover-rejection!-200132759,200132759
147793,369309,BHC,Valeant Pharmaceuticals Stock Takeover Target ,opinion,"Valeant Pharmaceuticals International  Inc  NYSE VRX 
Valeant Pharmaceuticals  the Canada based multinational specialty pharmaceutical company  has been under close scrutiny in the past several months as it has lost nearly 90  of its share price since August of 2015 on a string of negative news along with questionable business operations  In recent headlines  speculation has surfaced that VRX could stand to be a potential takeover target 
Analyst Expectations
An analyst at Piper Jaffray had the following comments on VRX 

Valeant takeover rejection report  difficult to fathom   says Piper Jaffray  Piper Jaffray analyst David Amsellem noted the report claiming that Valeant  VRX  previously rejected a takeover offer from Takeda  OTC TKPYY  and TPG prior to appointing Joe Papa as CEO  but said he finds it  difficult to fathom  why a buyer would have interest in the entire asset portfolio  since he believes the value of its segments to be  meaningfully  below the company s  31B in total debt outstanding  Amsellem  who thinks there would be significant strategic interest in Valeant s gastroenterology assets  believes that any strategic activity will come in the form of asset sales or a breakup of the company  The firm keeps an Underweight rating on Valeant shares    

VRX Technicals

Since August of 2015  VRX has plunged  230  or 90   VRX was once the most valuable company in Canada until the recent collapse fueled by constant negative news on their internal business practices 
Trading just off the lows  VRX does have huge risk reward potential as it starts to consolidate near its recent lows  Geometrically speaking  VRX has been slowly attempting to form a falling wedge pattern for several months and is nearing a completed pattern  Falling wedge patterns can resolve explosively to the upside once a proper resolution occurs  Ideally  a break of the falling wedge to the upside on high relative volume would signal a shift in momentum as the buy pressure pours in 
About Valeant Pharmaceuticals International  Inc  
Valeant Pharmaceuticals International  Inc   incorporated on August 9  2013  is a specialty pharmaceutical and medical device company  The Company is engaged in developing  manufacturing  and marketing a range of branded  generic and branded generic pharmaceuticals  over the counter  OTC  products  and medical devices  contact lenses  intraocular lenses  ophthalmic surgical equipment  and aesthetics devices   which are marketed directly or indirectly in over 100 countries  The Company focuses on eye health  dermatology and neurology therapeutic classes  primarily on branded generics  OTC products and medical devices  The Company operates through two segments  developed markets and emerging markets ",2016-05-31,Warrior Trading,https://www.investing.com/analysis/valeant-pharmaceuticals-$vrx-stock-takeover-target-200132955,200132955
147794,369310,BHC,Here s Why Valeant Pharmaceuticals  VRX  Is Crashing Today,opinion,"On Tuesday  shares of struggling pharmaceutical company Valent Pharmaceuticals Inc    NYSE VRX   are crashing  down almost 15  in morning trading after the company reported dismal first quarter results 
Valeant  which is under scrutiny regarding its business and accounting practices  reported adjusted earnings per share of  1 27  missing the Zacks Consensus Estimate of  1 42 per share and decreasing 45 7  year over year  this number excludes  2 35 from non recurring items  Revenues  however  came in at  2 4 billion  beating the Zacks Consensus Estimate of  2 345 billion and increasing 9  year over year 
 The first quarter s results reflect  in part  the impact of significant disruption this organization has faced over the past nine months   said Joseph Papa  chairman and chief executive officer   This has been a difficult period for Valeant and its stakeholders  and while there are some challenges to work through in certain business operations in 2016  such as our U S  dermatology unit  the majority of our businesses are performing according to expectations  
As a result  Valeant slashed its full year earnings forecast to  6 60  7 00 per share  down from  8 50  9 50 per share  Revenue guidance was also cut  and the company now expects  9 9 billion  10 1 billion for the year compared to original projections of  11 billion  11 2 billion 
In late April  Valeant filed its 2015 financial report  calming concerns about a potential default on its debt of over  30 billion  The company missed the original deadline of March 15  which prompted an in house review of its accounting practices  the probe discovered problems dating back to 2014 ",2016-06-06,Zacks Investment Research,https://www.investing.com/analysis/here's-why-valeant-pharmaceuticals-(vrx)-is-crashing-today-200134560,200134560
147795,369311,BHC,Is It Time To Buy Valeant Pharmaceuticals ,opinion,"Valeant Pharmaceuticals  NYSE VRX 
Health Care   Pharmaceuticals   Reports June 7  Before Market Opens
Key Takeaways
The Estimize consensus is calling for earnings per share of  1 46 on  2 36 billion in revenue  4 cents higher than Wall Street on the bottom line and nearly  10 million on the top
Last month Valeant reiterated its Q1 guidance of  2 3 2 4 billion in revenue and earnings between  1 30 1 55
In its analyst call  Valeant must put to rest concerns over the  31 billion in long term debt and also deliver a viable growth strategy 
Valeant Pharmaceuticals is prepared to announce its first quarter results tomorrow before the market opens  This earnings report marks the second since a scandal last fall put the company in the public eye  Since then  the stock has dropped over 90   Michael Pearson  was ousted as CEO  and Bill Ackman was placed on the board in an attempt to save the company  Tomorrow also marks the first report under new CEO Joseph Papa and will give investors an early indication of the company s vision 
The Estimize consensus is calling for earnings per share of  1 46 on  2 36 billion in revenue  4 cents higher than Wall Street on the bottom line and nearly  10 million on the top  Compared to a year earlier this represents a 24  decline in earnings while sales are expected to grow by 13   Both earnings and revenue estimates have been cut by double digits since its last report  reflecting analysts negative sentiment towards the company  Just last month  Valeant confirmed Q1 earnings would fall within guidance given in its fourth quarter analyst call  Total revenue is expected in the range of  2 3 2 4 billion while EPS is forecasted in the range of  1 30 1 55 
For investors  the actual numbers are not as important as what is said during the analyst call  The company s old strategy of profitability  splash acquisitions and drug price increases  is no longer viable  Investors still don t have an idea for what to expect moving forward  Meanwhile  Valeant s fundamentals remain frightening  The company had over  31 billion in long term debt at the end of 2015  Without the possibility of raising its drug prices  Valeant will struggle to finance its debt  The company has already received multiple default notices associated with delayed filings of financial reports to the SEC 
With all these big questions remaining  everything hinges on what CEO Joseph Papa has to say tomorrow  If he can put investor s concerns to rest  the stock could be in store for a quick pop  Otherwise  shareholders should expect more of the same and perhaps another double digit decline 
Do you think VRX can beat estimates ",2016-06-07,Estimize,https://www.investing.com/analysis/is-it-time-to-buy-valeant-pharmaceuticals-200134323,200134323
147810,369326,BHC,Valeant gets investigative subpoena over former ties with Philidor,news, Reuters    Canadian drugmaker Valeant Pharmaceuticals International Inc  N VRX   TO VRX  said on Wednesday it received an investigative subpoena from the California Department of Insurance in September over its ties to pharmacies and marketing  The request follows allegations against Valeant that it used speciality pharmacy Philidor Rx Services Llc to force customers to pay higher prices for its drugs  The subpoena seeks materials including documents concerning Valeant s former relationship with Philidor  now defunct  and certain California based pharmacies  the marketing and distribution of its products in California  the company said in a filing  Valeant  which owns eye care products maker Bausch   Lomb  used Philidor to overcome insurer reimbursement rejections of its medications  with Philidor resubmitting claims to insurers until they were approved  according to numerous media reports late last year  It has since severed ties with the pharmacy company  The company said it was cooperating with the investigation ,2016-11-09,Reuters,https://www.investing.com/news/stock-market-news/valeant-gets-investigative-subpoena-over-former-ties-with-philidor-439377,439377
147811,369327,BHC,Valeant gets subpoena over Philidor ties,news,Valeant  NYSE VRX  received an investigative subpoena from the California Department of Insurance in September following allegations that it forced customers to pay higher prices for its drugs The request seeks materials including documents concerning Valeant s former relationship with Philidor  now defunct  and certain pharmacies responsible for the marketing and distribution of its products in California SEC Form 10 Q,2016-11-10,Seeking Alpha,https://www.investing.com/news/stock-market-news/valeant-gets-subpoena-over-philidor-ties-439416,439416
147812,369328,BHC,Valeant may seek to clean up its name by changing it  Ackman,news,"By Carl O Donnell and Svea Herbst Bayliss NEW YORK  Reuters    Valeant Pharmaceuticals  NYSE VRX  International Plc  TO VRX   the drugmaker that became a poster child for high drug prices during the U S  election season  may change its name to help boost its reputation  board member and top investor William Ackman told CNBC on Wednesday   A name change would be the latest effort by the company to break from its past  after hiring a new chief executive  overhauling the board and exploring billions of dollars in asset sales to pay down a  30 billion debt load   Valeant s stock has declined more than 90 percent in the past year  erasing nearly  90 billion in market capitalization  over disclosures that it secretly worked with a specialty pharmacy to boost sales of its medicines  The company is the subject of multiple investigations by federal agencies and state prosecutors   Former Valeant  Chief Executive  Michael  Pearson   LON PSON  went crazy in my opinion   Ackman said during his interview with CNBC   A number of names are being considered  including taking on the well known moniker of its largest business  eyecare specialist Bausch   Lomb  according to people familiar with the matter  who asked not to be named because they were not authorized to speak to the media  There has been no final decision to change its name at all  they added   Previously named Biovail and based in the United States  the drugmaker acquired Canada s Valeant in 2010 and chose that as its corporate identity   The acquisition  a so called  tax inversion  because Valeant moved its headquarters to low tax Canada  was a key step in its aggressive  debt financed dealmaking spree under Pearson  The acquisitions helped reshape the specialty pharmaceutical industry and eventually left Valeant with around  30 billion in debt   Some of the high points of Pearson s buying binge include its  8 7 billion acquisition of Bausch   Lomb in 2013 and its  14 5 billion purchase of stomach drug company Salix Pharmaceuticals in 2015   The deals made Valeant a darling of Wall Street  attracting such big name hedge funds as Ackman s Pershing Square  NYSE SQ  Capital Management and the Sequoia Fund and notching returns in excess of 1 000 percent during Pearson s tenure  
In recent weeks  Valeant has been exploring a sale of its Salix business  according to media reports  that could fetch around  10 billion and would leave Bausch   Lomb as the largest single business in the company ",2016-11-10,Reuters,https://www.investing.com/news/stock-market-news/valeant-may-seek-to-clean-up-its-name-by-changing-it:-ackman-439820,439820
147813,369329,BHC,Ackman  Valeant may seek name change,news,Valeant  NYSE VRX  may change its name to help boost its reputation  board member Bill Ackman told CNBC A number of names are being considered  including the well known moniker of its largest business  eyecare specialist Bausch   Lomb That would be the latest effort by Valeant to break from its past  after hiring a new CEO  overhauling its board and exploring billions of dollars in asset sales to pay down debt of over  30B ,2016-11-11,Seeking Alpha,https://www.investing.com/news/stock-market-news/ackman:-valeant-may-seek-name-change-439862,439862
147814,369330,BHC,NY Attorney s complaint includes alleged  10M kickback to Tanner,news,An excerpt from the NY District Attorney s complaint against former Valeant  VRX  5 4   Philidor liaison Gary Tanner alleges that he accepted  10M in kickbacks that were laundered through a series of shell companies with the aim of concealing the nature of the money Previously  NY District Attorney to hold press conference today to announce charges against former Philidor liaison Tanner  Valeant down 5   Nov  17 ,2016-11-17,Seeking Alpha,https://www.investing.com/news/stock-market-news/ny-attorney's-complaint-includes-alleged-$10m-kickback-to-tanner-441855,441855
147815,369331,BHC,Former Philidor chief Davenport arrested,news,Former Philidor CEO Andy Davenport was arrested this morning and charged with  engaging in a multi million dollar fraud and kickback scheme   Valeant  VRX  4 5   liaison Gary Tanner was also arrested Previously  NY District Attorney to hold press conference today to announce charges against former Philidor liaison Tanner  Valeant down 5   Nov  17 ,2016-11-17,Seeking Alpha,https://www.investing.com/news/stock-market-news/former-philidor-chief-davenport-arrested-441854,441854
147821,369337,BHC,Valeant Pharmaceutical Stock  Gains On The Horizons,opinion,"Valeant Pharmaceuticals  NYSE VRX  
Valeant Pharmaceuticals has had an incredibly hard time in the market as of late  and for good reason  Late last year  it was uncovered that the company was using its relationship with a pharmacy to fluff the numbers and make it look like it was doing better than it actually was  However  we ve seen quite a bit of change since the scandal  So  I believe that we re finally nearing the bottom of the declines  Today  we ll talk about the scandal  what s changed since  and what we can expect to see from VRX moving forward 
The VRX Scandal
Late last year  an analyst firm known as Citron decided to do some digging into Valeant  After all  the company had come under fire for pricing practices  but the stock was climbing  When Citron released their report  it was something that no one expected to see  According to their report  VRX and its biggest client  a pharmacy known as Philidor were giving false statements to investors  In fact  in the report  Citron called Valeant Pharmaceuticals the Enron of the pharmaceutical industry 
While I didn t want to believe the claims  more and more evidence came out proving that VRX had indeed done the wrong thing  Soon  the stock started to fall like a brick dropped from the empire state building  Unfortunately  there was no denying the facts anymore  it was time for Valeant to admit to the wrong doing  and make some changes 
That s Exactly What Happened
Once the Philidor scandal was uncovered  VRX found themselves trapped between a rock and a hard place  The company had to admit that it had done wrong  and make changes to make things whole again  That s exactly what happened  Here are some of the changes we ve seen since the Philidor scandal 
Philidor Agreement Was Canceled   Shortly after the news surfaced  VRX announced that it had canceled the agreement it had with Philidor  Of course  this excited investors  but it also meant that the company was giving up its biggest customer 
Walgreens   Valeant knew that without Philidor  it had to come up with something to keep sales rolling  After all  the pharmacy was their biggest customer  However  shortly after the news that the agreement between VRX and Philidor had been canceled  we heard the announcement of a new agreement  Walgreens had agreed to sell Valeant products  Although this didn t make up for sales loss completely  it did put a big dent into the lower sales volume issue 
Board Changes   As time passed  it was clear that VRX needed changes to management  After all  the management at the company allowed the scandal to happen  As a result  the company announced the addition of two activist investor board members 
CEO Changes   When it comes to things going wrong at a company  the end of the blame lies with the CEO of the company  As a result  it was announced recently that J  Michael Pearson  LON PSON  would be stepping down from his position as CEO of VRX  In his place  Joseph Papa was named the new leader of the company 
What We Can Expect To See Moving Forward
At this point  I m incredibly impressed with the changes that we ve seen at Valeant Pharmaceuticals  While it is going to take time to win back the trust of investors  the company is clearly headed in the right direction now  All in all  I m expecting to see long run gains on the stock ",2016-05-13,Modest Money,https://www.investing.com/analysis/valeant-pharmaceuticals-(vrx)-stock:-gains-on-the-horizons!-200129681,200129681
147822,369338,BHC,2 Drug Stocks  Earnings To Watch This Week  VRX And XBIT,opinion,"The Q1 earnings season is almost coming to an end with 91 8   as of May 13  of the S P 500 members having already reported results  The Retail sector is the only one at this stage that has a sizeable number of reports still to come But how has this particular earnings season panned out so far  By now it is no secret that the season has been marked by  low expectations   Though growth was hard to come by  results were not as dismal as was widely expected with several companies delivering positive surprises for both earnings as well as revenues Still  Q1 is headed to be the fourth straight quarter of earnings declines for the index  And what is more concerning  this trend of earnings declines is expected to continue into the second quarter as well  As most of the remaining companies report Q1 results over the coming days  things will gain more clarity With the majority of pharma and major biotech companies having released their earnings results  Medical is one of the few sectors witnessing earnings and revenue growth in Q1  Our Q1 scorecard shows that 96 2  of the Medical sector has reported results with earnings growth of 7 7  on revenue growth of 9 8   The blended beat stands at 64 7   the percentage of companies that have beaten both earnings as well as revenue estimates  Notably  the Medical sector is anticipated to be one of the seven sectors to record earnings growth  7 6   in Q1 Among drug stocks lined up to report this week  let s take a sneak peek at two such companies Headquartered in Austin  TX  XBiotech  Inc    NASDAQ XBIT   is a development stage biopharmaceutical company focused on the discovery  development and commercialization of therapeutic antibodies based on its True Human proprietary technology  The company has a robust pipeline of antibody therapies targeting oncology  inflammatory conditions and infectious diseases  The company is scheduled to report first quarter results on May 18 
XBiotech  which started trading from Apr 2015  has delivered disappointing performances in both its reported quarters with the company missing estimates with a negative surprise of 31 43   The company has a Zacks Rank  3  Hold  and an  of 0 00  for the first quarter thereby making a surprise prediction difficult this quarter 
Valeant Pharmaceuticals International  Inc    NYSE VRX   is a specialty pharmaceutical and medical device company  contact lenses  intraocular lenses  ophthalmic surgical equipment  and aesthetics devices  that develops  manufactures and markets a broad range of pharmaceutical products targeting areas of dermatology  gastrointestinal disorder  eye health  neurology and branded generics 
This Laval  Canada based company has been under the scanner since late 2015 for raising drug prices and practicing a business model that involved limited investment in research and development  The company follows a strategy of acquiring companies and selling their drugs at higher prices 
The company s performance so far has been mixed with earnings beats in two quarters  in line results in one and a miss in the other  Overall  the company has delivered a positive earnings surprise of 0 18   The company s Zacks Rank  5  Strong Sell  when combined with an ESP of  7 19  makes a surprise prediction unlikely this quarter  Valeant is expected to report first quarter results on May 18 ",2016-05-16,Zacks Investment Research,https://www.investing.com/analysis/2-drug-stocks'-earnings-to-watch-this-week:-vrx-and-xbit-200130482,200130482
147823,369339,BHC,This Week In Valeant Pharmaceuticals  VRX  News,opinion,"Only a few things in life are certain  death  taxes  and Valeant Pharmaceuticals   NYSE VRX   making headlines  Well  at least that s what is has seemed like for the past several months  and the insanity that is VRX is continuing this week with a fresh swath of news from the company 
The first interesting thing to note is that the T  Rowe Price Health Sciences Fund  which held a 6 37  stake in Valeant at the end of 2015  revealed that it sold 90  of its position in the company during the first quarter 
Interestingly enough  this T  Rowe Price fund is managed by Taymour Tamaddon  who has been one of Valeant s biggest supporters for years  As  reports  Tamaddon has recommended Valeant since his days as a junior analyst over a decade ago  so it is certainly noteworthy that he and his fund have basically moved on 
While Tamaddon may finally be getting bearish on Valeant  another notable investor recently announced their support for VRX as a long term hold  Andrew Left  founder of short selling firm Citron Research  told  yesterday that he  wouldn t be surprised if there s a bounce  in the embattled drug stock 
 I don t think they re going to make any decisions that are going to torpedo the company   Left said in the interview 
Speaking of company decisions  Valeant has certainly made a few interesting ones recently  First of all  the company announced that it will reward some of its top executives with multi million dollar bonuses after navigating the company through  challenging times  
Chief financial officer Robert L  Rosiello  and executives Dr  Ari Kellen and Anne C  Whitaker will rake in  1 million retention bonuses in 2016 following the company s many recent struggles  including an accounting scandal  regulatory investigations  and pricing criticisms 
Valeant also  that it would be expanding a discount program for Nitropress and Isuprel  two expensive heart drugs  The company said that all hospitals are now eligible for at least a 10  rebate on the drugs  with some qualifying for a rebate of 40  
 Under this new program  the discounts we previously implemented for Nitropress and Isuprel will be simplified and more accessible   said Valeant chief executive Joseph Papa 
Valeant previously received criticism for its pricing of Nitropress and Isuprel  The company acquired the treatments in February of last year and immediately raised the prices of the already established drugs 
It is certainly shaping up to be another busy week for Valeant and its investors with all of this news  As always  you ll want to keep your eyes on the headlines for the latest regarding this stock ",2016-05-17,Zacks Investment Research,https://www.investing.com/analysis/this-week-in-valeant-pharmaceuticals-(vrx)-news-200130525,200130525
147824,369340,BHC,Economic Calendar And Watch Lists  HD  TJX,opinion,"Morning Notes
US Futures are relatively flat this morning while European stocks trade slightly higher as the price of crude edges higher again  closing in on 7 month highs  The Home Depot  NYSE HD  reported better than expected Q1 earnings and raised its full year forecast which is giving a lift to retail names  Asian stocks closed mostly higher 
Technicals

The SPY  NYSE SPY  traded back higher in yesterday s session after coming off of three prior day s losses  Support will lie at the 50 Day SMA at  205 51  followed by the support pivot at  205 25  and then yesterday s low at  204 89  Resistance will lie at the resistance pivot at  207  followed by yesterday s high at  207 34 
Small Cap Watch List
 Please refer to the momentum scanners displayed live in the chat room for potential plays at the market open  
  Others On Watch  
Perrigo Co  NYSE PRGO 
TJX Companies Inc  NYSE TJX 
Valeant Pharmaceuticals International Inc  NYSE VRX 
Home Depot Inc  NYSE HD 
Economic Calendar
8 30 Apr housing starts expected  3 3  to 1 125M
8 30 Apr CPI expected  0 3  m m and  1 1  y y
9 15 Apr industrial production expected  0 3   Mar  0 6 
12 00 San Francisco Fed President John Williams and Atlanta Fed President Dennis Lockhart speak
Notable Earnings Before Open
HD  The Home Depot   EPS Est   1 34  Rev Est   22 35B
TJX  TJX Co s   EPS Est    70  Rev Est   7 29B
Notable Earnings After Close
NONE
May 17th Swing Watch List
QEP Resources Inc  NYSE QEP    Long entry over 18 38  stop 18  Add spot over 18 70  Room here is to 20 00 
Immunomedics Inc  NASDAQ IMMU    Long entry over 3 92  add spot over 4 00  Stop is 3 72  Target is 4 30 4 40 short term 
Michael Kors Holdings Limited  NYSE KORS    A sweet reversal setup over 42 00  when we get a bullish confirmation of trend reversal  Will look to use a call spread on this trade  but long will be over 42  not a moment sooner 
Electronic Arts Inc  NASDAQ EA    Moving up higher into overbought territory following earnings  we are just waiting for the return to reality here  Looking for a short off 77 or under 76  Room is down to 73 50 and then 71 50 ",2016-05-17,Warrior Trading,https://www.investing.com/analysis/economic-calendar---watch-lists-5-17-2016-200130399,200130399
147825,369341,BHC,Economic Calendar And Watch Lists  SPY  VRX,opinion,"Morning Notes
US Futures are slightly lower this morning  while European stocks trade lower by over  1  as new fears arise regarding the state of the global economy after Eurozone May markit PMI came in lower than expected  Asian markets closed mixed 
Technicals

The SPDR S P 500  NYSE SPY  closed back above the critical support pivot that lies at  205 25 to close out Friday s session  Support will lie at the low of Friday s range at  204 86  followed by  204 54 and  202 78  Resistance will lie at the resistance pivot at  205 25  followed by the 50 day SMA at  205 95  Friday s high at  206 10  then  206 30   206 80  and finally the upper resistance pivot at  207 
Small Cap Watch List
Valeant Pharmaceuticals  NYSE VRX 
Economic Calendar
8 00 San Francisco Fed President John Williams speaks
9 45 Prelim May Markit manufacturing PMI expected  0 2 to 51 0
11 00 USDA weekly grain export inspections
3 00 USDA Apr Cold Storage
4 00 USDA Weekly Crop Progress
Notable Earnings Before Open
NONE
Notable Earnings After Close
NONE",2016-05-23,Warrior Trading,https://www.investing.com/analysis/economic-calendar---watch-lists-5-23-2016-200131576,200131576
147826,369342,BHC,Fed Rate Rise Not Enough For Currency Peace,opinion,"Last week  several Fed officials suggested they might raise interest rates at the Fed meeting scheduled for June 14 and 15 
The dollar strengthened and the gold price declined following their statement  suggesting the  Currency Cold War  of the last few years may be ending 
However  the likely 0 25  rate increase is nowhere near enough to end the Currency Cold War  or even reduce the chance of a hot war 
So long as interest rates remain below the inflation rate  the financial system is unstable and heading for a crash 
Rates Not Rising Enough
Another Fed rate rise in June will take the federal funds target range to 0 50  to 0 75  
However  inflation is still around 2   the  core  consumer price index was up 2 1  in the 12 months to May   Hence real interest rates are still below negative 1  
What s more  the Fed is unlikely to undertake the four rate rises that were forecast at the beginning of the year  At most  the Fed is likely to raise rates just one more time at the four remaining Federal Open Market Committee meetings in 2016 
At that rate of progress  with rates rising at 0 50  per annum  the federal funds rate won t reach a target rate of 2  to 2 25   level with inflation  until the middle of 2019 
Given that the Bank of England  the European Central Bank  ECB   and the Bank of Japan  BoJ  are pursuing more stimulative policies  the Currency Cold War will continue  or be replaced with something worse 
Negative real interest rates cause the amount of free money sloshing around to increase exponentially  because borrowing is so cheap   especially when money is injected into the system  as the ECB and the BoJ are doing  That  in turn  leads to wild currency fluctuations  not the milder  slower moves that occur when money is expensive and speculators are scarce 
We now know the picture won t change with the arrival of a new President in January   supports Janet Yellen and her easy money policies  while  has now confessed himself a  low interest rate guy    a pity nobody asked him this question earlier in the primary process  when it might have made a difference 
If nothing disrupts the U S  economy  the achingly slow interest rate rises will continue 
Trouble Ahead
In practice  disruption is likely to arrive well before 2019 
The current low rate policy  which has been in effect since 2008  brought about a massive flood of  malinvestment   These misguided investments will have to be washed out of the economy before healthy growth can resume 
Think of Valeant Pharmaceuticals International Inc  NYSE VRX   the drug company whose business model was to buy smaller companies  jack up the prices of their drugs by 100  to 500   and hope the drug buyers wouldn t notice  That s  30 billion of wobbly debt  right there 
Then there are the energy master limited partnerships like Breitbart Energy Partners LP  NASDAQ BBEP  that bought assets when oil was  100 per barrel and hoped the derivatives market would take away their oil price risk  It didn t 
Then there are the gigantic hotel projects  several times the size of the market  whose empty silence makes you feel like a Pharaoh buried under a pyramid when you visit 
Finally  there s the high tech taxi service valued at  50 billion   maybe healthy  but massively inflated in value 
The unhealthiness of the current economy is demonstrated by productivity growth  averaging only 0 6  annually over the last five years and negative in the last quarter  compared to an average of 2  annually before 2007  Frankly  it s unlikely the current economy can continue until 2019 without a massive financial crisis  however hard the Fed may attempt to avoid one 
At the point  the Fed and other central banks may come to their senses  ending the Currency Cold War  Unfortunately  they ll most likely push us into negative interest rates  intensifying it   though that would give us some wonderful profit opportunities  if we re nimble 
Another possibility is that continued stimulus will be accompanied by a true attempt to push the dollar down  possibly accompanied by Trumpean tariffs  At that point  the Currency Cold War will turn hot 
But with my Currency and Capital new Hillary Hedge  or Trump Trade  of a long term gold call option  we re ready for that  too 
Good investing ",2016-05-25,Wall Street Daily,https://www.investing.com/analysis/fed-rate-rise-not-enough-for-currency-peace-200132017,200132017
147827,369343,BHC,Danger Zone  XPO Logistics,opinion,"Stop us if you ve heard this scenario before  soaring debt  significant shareholder dilution  multiple large acquisitions  and executives paid for stock price performance  all of which results in massive revenue growth with no profits  No we re not talking about Valeant  NYSE VRX  or Perrigo  NYSE PRGO  or any prior Danger Zone stocks  We re talking about XPO Logistics  NYSE XPO   which looks like another roll up scheme  for the Danger Zone this week 
Acquisitions Boost Revenue While Killing Profits and Diluting Investors
Over the past few years  XPO Logistics has engaged in aggressive acquisitions that have fueled revenue growth upwards of 100  compounded annually over the past five years  These acquisitions  specifically the buyouts of Norbert Dentressangle and of Con way Freight  which totaled over  6 5 billion  were done with little regard to the economic cash flow repercussions  As can be seen in Figure 1  XPO Logistics  economic earnings  the true cash flows of business  have declined from  1 million in 2010 to   310 million in 2015  See the reconciliation of XPO Logistics  GAAP net income to economic earnings  

Sources  New Constructs  LLC and company filings
Aside from negative economic earnings  XPO s return on invested capital  ROIC  has fallen from 12  in 2010 to a bottom quintile 2  over the last twelve months 
Major Dilution  Acquisitions Funded At Expense Of Investors 
Adding to the issues  XPO has greatly increased debt and diluted shareholders over this time frame  2010 2015  XPO s debt grew over 290  compounded annually to  7 3 billion  238  of market cap   Its shares outstanding grew from 33 million to 110 million  or 27  compounded annually from 2010 2015  Essentially  XPO funded its acquisition based growth at the expense of shareholders  while deriving no profits 
Shareholder Destructive Acquisitions Driven By Misaligned Executive Compensation
We blame XPO s executive compensation plan for the acquisitions that dilute shareholders  grow debt and lose money  Apart from cash bonuses  which are tied to meeting  adjusted EBITDA  goals  over 80  of the CEO s pay and over 50  of other executives  pay is awarded via long term incentive restricted stock units  RSUs  
Vesting of these RSU s is tied directly to stock price and  adjusted cash earnings per share   Essentially  management has been incentivized to grow XPO s stock price at almost any cost   7 5 million in 2015 RSUs vest if XPO trades above  60 share for 20 consecutive days prior to April 2  2018  or above  86 share for 20 consecutive days prior to September 2  2020  and the company can meet the cash EPS goals  In 2016  executives were granted  38 million in RSU s for the 2016 2019 period that vest based upon the achievement of target  adjusted cash flow per share  metrics  Executives were given the green light for on an acquisition spree and as the high low fallacy shows  executives can increase EPS through value destructive acquisitions  all while profiting for themselves  One other important note about XPO s executive compensation plan  it s strictly focused on non GAAP metrics  an issue we detail below 
You Cannot Pay Your Debtors With Non GAAP Earnings
Investors only following XPO management s presentations might believe the company is a high flying success  especially when it comes to  adjusted EBITDA   the company s go to metric to present its operations  When looking through this noise  the underlying economics of the business reveal a much worse situation per Figure 1  Here are the expenses XPO removes to calculate its non GAAP metrics  including adjusted EBITDA and adjusted net income 
Transaction   integration costs
Foreign currency losses
Rebranding costs
Debt commitment fees
Accelerated amortization
In 2015  XPO Logistics  non GAAP net income was a   37 million  compared to   246 million GAAP net income and   310 million economic earnings  Figure 2 shows the discrepancies between GAAP  non GAAP  adjusted EBITDA  and economic earnings from 2013 2015  We would take a longer look  but adjusted EBITDA and adjusted net income were not used until 2013 

Sources  New Constructs  LLC and company filings
Low Profitability Puts XPO Logistics At A Disadvantage
XPO Logistics operates across many different forms of freight  including full truckload  FTL   less than truckload  LTL   global forwarding  supply chain logistics  and last mile delivery for heavy goods  By encompassing so many different aspects of the freight industry  XPO faces numerous competitors  Unfortunately  XPO s multifaceted approach leaves it operating much less profitably than its competition  including  but not limited to  Landstar System  NASDAQ LSTR   C H  Robinson Worldwide  NASDAQ CHRW   United Parcel Service  NYSE UPS   and FedEx Corporation  NYSE FDX   Each of these competitors has a higher ROIC and NOPAT margin than XPO  A lower ROIC and NOPAT margin mean lower pricing flexibility  Lack of pricing flexibility is a big disadvantage in an industry where transport rates can greatly impact purchase decisions and profit margins  See Figure 3 for more details 

Sources  New Constructs  LLC and company filings 
Bull Hopes Rest On Continued Acquisitions
From 2013 2015  XPO grew revenue from less than  1 billion to over  7 billion  For bulls of XPO  these acquisitions were integral in building different facets of XPO s operations  despite the massive value destroyed  However  such hopes ignore key challenges facing the industry and XPO 
First  the industry is highly competitive  and as e commerce grows in popularity  freight transportation and the delivery of goods will become even more commoditized  As a result  pricing power will only get weaker for the industry at large  Given how unprofitable XPO is today  it is at a competitive disadvantage in terms of pricing power and will have a harder time with price pressure than its competitors 
Second  demand for XPO services could shrink  In March 2016  Amazon  NASDAQ AMZN  announced it was leasing 20 planes and starting its own air freight service  While there are few firms with as much sway in the retail ecommerce industry  Amazon taking back control of its logistics chain could be a sign of things to come for the freight industry 
The biggest risk to our thesis  as with all roll up schemes  is that investors continue to turn a blind eye to the value destruction occurring and  instead  focus on revenue and  adjusted EBITDA  growth  As long as the company can continue this  albeit value destructive  growth  bulls will tout the ability of management to expand the business  find  accretive  deals  and continue believing that profits are right around the corner  In this scenario  the stock price could remain overvalued for some time 
Acquisition Hopes Cannot Justify Valuation
XPO Logistics  CEO  Brad Jacobs is no stranger to building companies with a takeover endgame  He founded United Waste Systems in 1989  acquired over 250 companies  and then sold to Waste Management  WM  in 1997  Similarly  he entered into a deal to sell United Rentals to a private equity firm in 2007  but the deal fell through amidst the economic collapse in 2008  Could XPO just be another company being built up to ultimately be acquired  If so  XPO has hidden liabilities that make it more expensive than the accounting numbers suggest 
 1 8 billion in off balance sheet debt  58  of market cap 
 716 million in deferred tax liability  23  of market cap 
 355 million in minority interests  12  of market cap 
 257 million in underfunded pensions  8  of market cap 
 23 million in outstanding employee stock options   1  of market cap 
After adjusting for these hidden liabilities  which add up to 102  of market cap   we can model multiple purchase price scenarios  Unfortunately for investors  only in the best of scenarios does XPO warrant a takeover at a price higher than today s 
To highlight how overvalued XPO is  Figures 4 and 5 show what we think UPS should pay for XPO to ensure the deal is truly accretive to UPS s shareholder value  Each implied price is based on a  goal ROIC  assuming different levels of revenue growth  We chose to assess the economic value of XPO after 5 years at three different levels of revenue growth  15   18  and 23   These levels were chosen to represent reasonable scenarios for revenue growth over the next five years assuming that UPS would put a stop to the value destroying acquisitions 
There are limits on how much UPS should pay for XPO to earn a proper return  given the NOPAT or cash flows being acquired  For each of the scenarios  we assume XPO achieves a 4  NOPAT margin post acquisition  This margin is more than double XPO s current margin  1 7    but lower than UPS s 8  margin  which is higher due to United Parcel Services  highly profitable domestic and international package delivery segment  We give XPO a slight increase in margins due to UPS s ability to cross sell within its larger Logistics segment and aggressively attract retain customers using resources from UPS s profitable business lines 

Sources  New Constructs  LLC and company filings  
The first  goal ROIC  is UPS s weighted average cost of capital  WACC  or 6   Figure 4 shows the prices UPS should pay for XPO assuming different levels of revenue growth achieved post acquisition  Only if XPO can continue growing revenue at double digits each year for the next five years and earn a 4  NOPAT margin is the firm worth more than its current share price of  27 share  We include this scenario to provide a  best case  view  Regardless  any deal that only achieves a 6  ROIC would be value neutral  as the return on the deal would equal UPS s WACC 

Sources  New Constructs  LLC and company filings  
Figure 5 shows the next  goal ROIC  of 8   which is UPS s current ROIC  This deal would be truly accretive to shareholders as it would maintain UPS s ROIC  Any purchase price below this would actually increase ROIC  which is directly correlated to increasing valuation  In the best case growth scenario  the most UPS should pay for XPO is  18 share  33  downside  
Without A Takeover  Organic Growth Expectations Are Unrealistic
To justify its current stock price   27 share  via organic growth  XPO must grow NOPAT by 28  compounded annually for 19 years  For context  in this scenario XPO would be generating over  800 billion in revenue 19 years from now  or greater than the entire U S  trucking industry in 2015  A more realistic  but still optimistic scenario  given that XPO focuses on organic growth and ditches costly acquisitions assumes XPO can grow NOPAT by 19  compounded annually for the next decade  the stock is worth only  4 share today   an 85  downside 
Catalyst  Unraveling of The Roll Up Scheme Will Sink Shares
XPO and other firms that use acquisitions to significantly grow become reliant upon acquisitions to meet not only internal goals for compensation  but also external expectations  However  this roll up strategy cannot go on forever  When they end  stock prices can crash rather violently especially when there has been significant shareholder value destruction  As we saw with Valeant  when the government and analysts alike began asking questions about its business  the economics of the business were revealed to be rather hollow  XPO is in a similar predicament  While its acquisitions can create a rosy  superficial picture of the business  the economics of the company are in decline 
XPO may have entered a vicious cycle in which it must find acquisitions to meet growth expectations  but in doing these deals  management is only putting further strain on the fundamentals of the business  Banks don t have unlimited appetite for risk  and there may come a time when XPO is no longer a company to whom banks will be willing to lend  In either scenario  funding is harder to get  acquisitions become harder to find  and expectations become harder to meet  While we can t predict when this house of cards will fall  we do know this roll up practice cannot go on forever  We ve said it before  and we ll say it again  non GAAP earnings  or  adjusted EBITDA  can t make the cash payments required to run a company  Look for an earnings miss  or multiple misses  to reveal that the picture being portrayed by XPO management is not as rosy as they d like you to believe 
Insider Sales Rather Low But Short Interest Is High
Over the past 12 months 5 6 million shares have been purchased and 107 000 shares have been sold for a net effect of 5 5 million insider shares purchased  These purchases represent 5  of shares outstanding  Additionally  there are 16 7 million shares sold short  or just over 15  of shares outstanding 
Impact of Footnotes Adjustments and Forensic Accounting
In order to derive the true recurring cash flows  an accurate invested capital  and a real shareholder value  we made the following adjustments to XPO Logistics  2015 10 K 
Income Statement  we made  785 million of adjustments with a net effect of removing  368 million in non operating expenses  5  of revenue   We removed  577 million related to non operating expenses and  208 million related to non operating income  See all adjustments made to XPO s income statement  
Balance Sheet  we made  7 4 billion of adjustments to calculate invested capital with a net decrease of  3 1 billion  The most notable adjustment was  3 8 billion  38  of net assets  related to midyear acquisitions  See all adjustments to XPO s balance sheet  
Valuation  we made  8 8 billion of adjustments with a net effect of decreasing shareholder value by  8 8 billion  There were no adjustments that increased shareholder value  One of the largest adjustments was the removal of  1 8 billion  61  of market cap  due to off balance sheet operating leases 
Dangerous Funds That Hold XPO
The following funds receive our Dangerous or worse rating and allocate significantly to XPO Logistics 
RidgeWorth Aggressive Growth Stock Fund  SCATX    5 5  allocation and Very Dangerous rating 
Zevenbergen Growth Fund  ZVNBX    5 2  allocation and Very Dangerous rating 
Zevenbergen Genea Fund  ZVGNX    3 4  allocation and Very Dangerous rating
This article originally published  on May 16  2016
Disclosure  David Trainer and Kyle Guske II receive no compensation to write about any specific stock  style  or theme ",2016-05-25,David Trainer,https://www.investing.com/analysis/danger-zone:-xpo-logistics-(xpo)-200132106,200132106
147840,369356,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 08 ,news,"Investing com   Canada stocks were lower after the close on Thursday  as losses in the Healthcare  Clean Technology and Utilities sectors led shares lower 
At the close in Toronto  the S P TSX Composite declined 0 08  
The best performers of the session on the S P TSX Composite were Kinross Gold Corporation  TO K   which rose 8 86  or 0 46 points to trade at 5 65 at the close  Meanwhile   HudBay Minerals  Inc   TO HBM  added 6 57  or 0 37 points to end at 6 00 and  Encana  Corporation  TO ECA  was up 5 60  or 0 70 points to 13 19 in late trade 
The worst performers of the session were Valeant Pharmaceuticals International Inc  TO VRX   which fell 8 75  or 2 48 points to trade at 25 86 at the close   ProMetic Life Sciences Inc    TO PLI  declined 6 74  or 0 190 points to end at 2 630 and Linamar Corporation  TO LNR  was down 5 98  or 3 17 points to 49 80 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 636 to 512 and 143 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 8 72  to 17 45 a new 1 month high 
Gold for December delivery was down 0 28  or 3 65 to  1304 55 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in December fell 1 59  or 0 72 to hit  44 62 a barrel  while the January Brent oil contract fell 1 17  or 0 55 to trade at  46 31 a barrel 
CAD USD was up 0 04  to 0 7470  while CAD EUR fell 0 04  to 0 6725 
The US Dollar Index was down 0 24  at 97 16 ",2016-11-03,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-0.08-437471,437471
147841,369357,BHC,After  195 million in talc verdicts  J J strives to change court,news,"By Brendan Pierson  Reuters    After a  67 5 million jury verdict against Johnson   Johnson  N JNJ  on Oct  27 marked its third straight trial defeat in an onslaught of lawsuits claiming its talc based products cause ovarian cancer  the company is hoping to reverse the trend by having the cases heard in a different court  All three awards  totaling around  195 million  were handed down in state court in St  Louis  Missouri  with the same judge presiding  Women or their families have filed 2 500 similar claims  the vast majority in the same court  which is one of several in the United States that attracts consumer lawsuits  The plaintiffs claim studies show J J s Baby Powder and Shower to Shower products  when used in the vaginal area  increase the risk of ovarian cancer  The company counters that larger  more comprehensive studies show no such link  In a court filing in August  J J argued the case should be dismissed because plaintiffs  lawyers tainted the St  Louis jury pool  The company said the other side spent almost  10 million on national and local television commercials in the previous year  with a disproportionate share of them running in St  Louis  The women s lawyers have denied J J s claim  The company also contended that  because most of them are not from St  Louis and the New Jersey based company has no strong ties to the area  the cases should not have been heard there  The judge rejected both arguments  John Beisner  one of the top lawyers representing J J  said the company plans to make the same arguments to the Missouri Court of Appeals  If the St  Louis court is found not to have jurisdiction  the cases would have to be refiled elsewhere   Beisner compared the St  Louis verdicts to a favorable ruling in September from a state court judge in New Jersey  That judge  who is presiding over some 200 talc cases  disqualified the plaintiffs  experts on the grounds that their scientific testimony was too speculative  In the same decision  he dismissed the first two cases set for trial and the ruling is being appealed  J J unsuccessfully tried to block the testimony of the experts in St  Louis on similar grounds  The company will make the same challenge on appeal  Beisner said   Last week s  70 million verdict followed Missouri jury awards of  72 million in February and  55 million in May  The first big talc verdict in February was won by the family of Jacqueline Fox  who died in October 2015  Their lawyers said she used J J Baby Powder and Shower to Shower Powder daily for 35 years for genital hygiene before she was diagnosed with ovarian cancer in 2013  Jere Beasley  whose firm has filed hundreds of talc cases  including the three Missouri wins and two New Jersey dismissals  said the verdicts should prompt J J to make a deal    If I were representing them  I would say  folks  we need to sit down and regroup and start trying to settle these cases   he said   LARGE VERDICTS Large verdicts are relatively common in major product liability cases  and they are often reduced or overturned on appeal  One lawsuit against Merck  NYSE MRK    Co over its recalled painkiller Vioxx produced a  253 million verdict in 2005  which was thrown out three years later  Merck eventually settled most Vioxx cases for  4 85 billion in 2007   Shareholders in J J  which had sales of  70 billion last year  have so far shrugged off the three talc verdicts  the first of the cases to go to trial  But if the trend continues  liability could mount  The company has not reported setting aside any litigation reserve to deal with talc cases  as it has with previous claims over antipsychotic drug Rispardal and recalled hip implants  J J no longer sells Shower to Shower  which was acquired by Valeant Pharmaceuticals  NYSE VRX  in 2012  Though not a major seller on its own  Baby Powder is a recognized symbol of J J s baby care line  which brought in  2 billion in revenue in 2015  Some legal experts said it made sense for J J to fight on   Ordinarily I would say three verdicts like that would prompt you to think about settlement   said University of Georgia Law School professor Elizabeth Burch  who researches product liability cases  but she said J J s case is somewhat different  A settlement would not necessarily cap J J s liability  Burch said  because its talc products are still on the market  unlike companies whose products have been recalled  Howard Erichson  a professor at Fordham School of Law  said the company also had valid concerns about the impact of a settlement on its position in the market  
 This is not Vioxx  This is not asbestos   Erichson said   This is a case where the company wants to defend its brand  and is not going to be anxious to announce a big settlement that appears to concede that the product is harmful ",2016-11-06,Reuters,"https://www.investing.com/news/stock-market-news/after-$195-million-in-talc-verdicts,-j-amp;j-strives-to-change-court-438120",438120
147842,369358,BHC,Progenics nabs  50M in debt financing,news,Progenics Pharmaceuticals   PGNX  3 9   inks a  50M RELISTOR royalty backed debt deal with Healthcare Royalty Partners  The non recourse term loan is secured by and will be repaid from royalties on future sales of the medication to treat opioid induced constipation In Q3  RELISTOR distributor Valeant Pharmaceuticals  VRX  0 8   booked sales of  22 1M which translated to  3 3M in royalties for Progenics ,2016-11-07,Seeking Alpha,https://www.investing.com/news/stock-market-news/progenics-nabs-$50m-in-debt-financing-438397,438397
147843,369359,BHC,U S  stocks point to lower open as Americans head to the polls,news,"Investing com   U S  stocks pointed to a modestly lower open on Tuesday morning  as financial markets awaited the outcome of the U S  presidential election  with most investors cautiously betting on a win by Democrat Hillary Clinton 
The blue chip Dow futures dipped 26 points  or 0 14   by 6 55AM ET  11 55GMT   the S P 500 futures inched down 5 points  or 0 2   while the tech heavy Nasdaq 100 futures slumped 10 points  or 0 19  
U S  stocks snapped a nine day losing streak on Monday to rack up their biggest one day percentage gain since March  after the FBI said that no charges were warranted in the case of Democrat Hillary Clinton s use of a private email server  lifting a cloud over her presidential campaign 
The highly anticipated U S  Presidential Election will be held on Tuesday  The Congressional Elections for the Senate and the House of Representatives will also be held today 
The first exit polls  which are a projection  are expected to come out on Tuesday night at around 7 00PM ET  00 00 GMT on Wednesday   Results will be declared state by state 
If the outcome is clear  the television networks are expected to make their official call at 11 00PM ET  04 00 GMT Wednesday  
Global financial markets were rattled last week by signs the U S  presidential election race between Democrat candidate Hillary Clinton and Republican nominee Donald Trump was tightening 
However  hopes for a Clinton win mounted after FBI Director James Comey informed Congress over the weekend that it had  not changed its conclusions  on the private email server maintained by the Democratic candidate
According to the final Reuters Ipsos States of the Nation project  Democrat Hillary Clinton has about a 90  chance of defeating Republican Donald Trump in the race for the White House 
Market players have tended to see Clinton as the candidate of the status quo  while there is greater uncertainty over what a Trump victory might mean for U S  foreign policy  international trade deals and the domestic economy 
Among active pre market movers  Valeant Pharmaceuticals  NYSE VRX  saw shares drop almost 8  after it slashed its guidance for the year as earnings for the latest quarter topped estimates but revenue slid more than expected 
Shares of Hertz Global Holdings  NYSE HTZ  sank 33  ahead of the open after the car rental company late Monday reported a sharp drop in quarterly profit and cut its outlook 
On the upside  News Corp  NASDAQ NWSA  gained almost 5  after reporting fiscal first quarter results that were roughly in line with analyst estimates 
Elsewhere  European and U K  stock markets were mixed in cautious trade  as markets were jittery before the results of the U S  presidential election  Earlier  Asian shares closed mostly higher 
In the currency market  the U S  dollar index  which measures the greenback s strength against a trade weighted basket of six major currencies  was little changed at 97 75 early Tuesday 
Meanwhile  oil futures extended gains from the prior session as traders continued to weigh prospects of a coordinated production cut among major global oil producers ",2016-11-08,Investing.com,https://www.investing.com/news/stock-market-news/u.s.-stocks-point-to-lower-open-as-americans-head-to-the-polls-438651,438651
147844,369360,BHC,Valeant Pharmaceuticals Q3 sales down 11   non GAAP earnings down 36   cash flow ops down 22   guidance lowered  shares down 7  premarket,news,Valeant Pharmaceuticals  NYSE VRX  Q3 results   M   Total Revenues  2 479 6   11 0    Product Sales  2 443 6   11 1   Bausch   Lomb  1 161 8   3 8    Branded Rx  847 3   23 3    U S  Diversified Products  470 5   16 5   Net Income   1 219 1    999    Non GAAP Net Income  543 0   35 7    EBITDA   14 0    101 2    Non GAAP EBITDA  1 162 7   20 9    EPS   3 49    999    Non GAAP EPS  1 55   35 7    CF Ops  569 9   22 2   Consensus view was non GAAP EPS of  1 75 on revenues of  2 5B 2016 Guidance  Total Revenues   9 55B   9 65B from  9 9B   10 1B  Non GAAP EBITDA   4 25B   4 35B from  4 80B   4 95B  Non GAAP EPS   5 30   5 50 from  6 60   7 00 Shares are off 7  premarket on robust volume ,2016-11-08,Seeking Alpha,https://www.investing.com/news/stock-market-news/valeant-pharmaceuticals-q3-sales-down-11;-non-gaap-earnings-down-36;-cash-flow-ops-down-22;-guidance-lowered;-shares-down-7-premarket-438665,438665
147845,369361,BHC,Valeant down 8  as Q3 earnings miss estimates  guidance cut ,news,Investors com   Valeant Pharmaceuticals  NYSE VRX  shares sharply lower Tuesday as Q3 earnings miss estimates  Valeant shares were down 8  at  17 50 in pre market trade Valeant Q3 adjusted EPS  1 55 vs estimate  1 75 and  2 41 a year earlier Revenues down 11  yoy at  2 48 bn vs estimate of 2 54 bn Cuts FY EPS guidance to  5 30  5 50 from  6 60  7 00 Revenue guidance lowered to  9 55  9 65 bn from   9 9  10 1 bn,2016-11-08,Investing.com,https://www.investing.com/news/stock-market-news/valeant-down-8-as-q3-earnings-miss-estimates;-guidance-cut-438660,438660
147846,369362,BHC,Wall St lower ahead of U S  election result ,news,Investing com   U S  stocks lower early Tuesday as investors fretted about outcome of presidential race The DJI was down 0 20  at 09 45 ET  while the S P 500 shed 0 24   The tech heavy Nasdaq composite gave up 0 30   Clinton tipped to beat Trump in what would be considered a market friendly result  Oil futures turned lower after holding steady earlier on with U S  crude off 0 91  at  44 48  Valeant  NYSE VRX plunges 24 05  to  14 53 after missing Q3 estimates  cut in FY guidance ,2016-11-08,Investing.com,https://www.investing.com/news/stock-market-news/wall-st-lower-ahead-of-u.s.-election-result-438746,438746
147847,369363,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 03 ,news,"Investing com   Canada stocks were higher after the close on Tuesday  as gains in the Materials  Consumer Discretionary and REITs sectors led shares higher 
At the close in Toronto  the S P TSX Composite rose 0 03  
The best performers of the session on the S P TSX Composite were  HudBay Minerals  Inc   TO HBM   which rose 9 06  or 0 59 points to trade at 7 10 at the close  Meanwhile   Labrador Iron Ore Royalty Corp   TO LIF  added 8 72  or 1 29 points to end at 16 09 and  First Quantum Minerals Ltd    TO FM  was up 8 41  or 1 06 points to 13 66 in late trade 
The worst performers of the session were Valeant Pharmaceuticals International Inc  TO VRX   which fell 21 91  or 5 59 points to trade at 19 92 at the close   Stella Jones Inc    TO SJ  declined 7 52  or 3 61 points to end at 44 37 and  Computer Modelling Group Ltd    TO CMG  was down 6 31  or 0 61 points to 9 05 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 587 to 536 and 151 ended unchanged 
Shares in Valeant Pharmaceuticals International Inc  TO VRX  fell to 5 year lows  down 21 91  or 5 59 to 19 92  Shares in Labrador Iron Ore Royalty Corp  TO LIF  rose to 52 week highs  rising 8 72  or 1 29 to 16 09  Shares in First Quantum Minerals Ltd   TO FM  rose to 52 week highs  gaining 8 41  or 1 06 to 13 66  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 7 57  to 15 75 
Gold for December delivery was down 0 27  or 3 50 to  1275 90 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in December fell 0 38  or 0 17 to hit  44 72 a barrel  while the January Brent oil contract fell 0 82  or 0 38 to trade at  45 77 a barrel 
CAD USD was up 0 59  to 0 7525  while CAD EUR rose 0 75  to 0 6829 
The US Dollar Index was up 0 15  at 97 93 ",2016-11-08,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.03-438878,438878
147851,369367,BHC,Valeant receives warning letter from FDA related to NY manufacturing site,news,Valeant Pharmaceuticals  VRX  7 6   has received a warning letter from the FDA regarding quality systems violations at its Rochester  NY manufacturing site  The violations were noted during an on site inspection in late August Specifically  the inspection found that the company s SPAG 2 and ONSET Mixing Pen devices are considered adulterated because validation activities were either not performed or documented  The inspector also noted that corrective and preventative actions pertaining to field notification for the mixing pen were incomplete since they did not detail or document how the adulteration affected products in inventory and that its non conformance investigations were not always completed documented A warning letter establishes prior notice to the company that the regulatory violations should be resolved promptly  Failure to do so could result in more significant actions from the FDA  but the vast majority are addressed satisfactorily ,2016-11-09,Seeking Alpha,https://www.investing.com/news/stock-market-news/valeant-receives-warning-letter-from-fda-related-to-ny-manufacturing-site-439307,439307
147853,369369,BHC,Monday s Stock Trades  PRGO  VRX  XRX And More ,opinion,"Monday s stock trades  Perrigo  NYSE PRGO   Valeant Pharmaceuticals  NYSE VRX   Xerox  NYSE XRX  and more 
See video below ",2016-04-25,Nicholas Santiago,"https://www.investing.com/analysis/monday-39;s-stock-trades:-prgo,-vrx,-xrx---more-200126345",200126345
147854,369370,BHC,Economic Calendar And Watch Lists  ADMS  WETF  TSE,opinion,"Morning Notes
US Futures are slightly lower this morning while European stocks are trading lower by roughly   50  after the price of crude and metals slid lower  Asian stocks closed predominantly lower 
Technicals

The SPDR S P 500  NYSE SPY  support levels for today are at the low of Friday s range at  207 91  followed by  207   206 84  and  206 25  Resistance will lie at the high of Friday s range at  209 29  followed by macro descending resistance at  210  and the high of Thursday s range at  210 25 
Small Cap Watch List
Valeant Pharmaceuticals  NYSE VRX 
Perrigo Co  NYSE PRGO 
Economic Calendar
10 00 Mar new home sales expected  1 6  to 520 000
10 30 Apr Dallas Fed manufacturing activity expected  3 6 to  10 0
11 00 USDA weekly grain export inspections
1 00 Treasury auctions  26 billion of 2 Year T notes
4 00 USDA Weekly Crop Progress
Notable Earnings Before Open
HAL  Halliburton  NYSE HAL    EPS Est    04  Rev Est   4 16B
XRX  Xerox Corp  NYSE XRX    EPS Est    23  Rev Est   4 24B
UTX  United Technologies  NYSE UTX    EPS Est   1 39  Rev Est   13 18B
Notable Earnings After Close
ESRX  Express Scripts  NASDAQ ESRX    EPS Est   1 23  Rev Est   25 2B
April 25th Swing Watch List
Adamas Phar  NASDAQ ADMS    A breakout setup after a series of bull flag breaks following a consolidation period  This trades under long term resistance at 19 00  Over that  and this can really open up quickly  Long entry is over 19 00  stop 18 50  Target is 19 75 and then somewhere under 21 00 
WisdomTree Investments Inc  NASDAQ WETF    A liquid financial under a great resistance breakout spot just ahead of earnings  Long entry is over 12 90  stop 12 60  Add spot at 13 00 with a target of 13 856 and then 14 50 
Trinseo SA  NYSE TSE    After a massive rip into new highs for nearly a month now  the RSI is overbought and the dojis are piling up  Looking for a move back to 40  Short entry under 43  add under 42 86  Stop will be 44 00 ",2016-04-26,Warrior Trading,https://www.investing.com/analysis/economic-calendar---watch-lists-4-25-2016-200126389,200126389
147855,369371,BHC,A Stark Lesson From The SunEdison Collapse,opinion,"Solar energy company Sunedison Inc  NYSE SUNE  filed for bankruptcy on April 21 
This event demonstrates the weaknesses of a business model dependent on renewable energy subsidies   especially when the subsidies have only just begun to lessen  never mind dry up altogether 
It also demonstrates the folly of over leveraged business models 
Sadly  the biggest losers from SunEdison s bankruptcy will be bondholders  especially those who invested in SunEdison s many securitization vehicles 
Among securitization vehicles  income investors should avoid debt and equity in the  yield cos  actively peddled by Wall Street 
If you re unfamiliar with the term  yield cos are basically corporations that typically own renewable energy assets like solar farms and wind farms  But they own the more stable  cash producing operating assets  rather than more capital intensive areas like research and development and construction 
The goal is to deliver greater earnings  which are paid to investors through dividends  In short  they re designed to strip out some of the risk of investing in renewable energy 
However  SunEdison s yield cos differed from other securitization vehicles because they involved issuing equity rather than debt  Solar power and other renewable energy plants were hived off into separate companies  which then financed themselves with IPOs  issuing dividend paying equity to investors and assuming a whole pile of debt 
Two such companies were formed from SunEdison   TerraForm Power Inc  NASDAQ TERP  and TerraForm Global Inc  NASDAQ GLBL  
The Problem With Yield Cos
There were several problems with the structure 
First  the yield cos  income depended on the amount paid by utilities and consumers for power  as well as on any subsidies they received  As power prices declined along with oil and gas prices  subsidies also declined and yield cos  revenues weren t able to sustain their dividend payments 
Second  the leverage was too great  At its formation  TerraForm Power had almost no tangible equity in its capitalization 
Third  since SunEdison controlled the yield cos  it could force them to enter into unattractive transactions   such as the failed takeover bid for Vivint Solar Inc  NYSE VSLR   a rooftop solar panel installer  Indeed  as SunEdison ran short of cash  it was able to transfer cash from the yield cos 
This combination of problems has caused share prices of both TerraForm Power and TerraForm Global to decline by 75  in the past six months 
Now that SunEdison has filed for bankruptcy  the future of the yield cos is highly uncertain 
SunEdison s creditors will undoubtedly attempt to get at the better assets and revenue streams of TerraForm Power and TerraForm Global  arguing that SUNE controls both companies  so their assets should be made available to the creditors 
Meanwhile  the yield cos  own debt will require servicing  and there may not be enough cash flow to do so 
The obvious vulnerability is the yield cos  dividends   which currently provide investors with a double digit yield  They ll almost certainly be cut back or  more likely  eliminated altogether 
Avoid These Investments
You won t be surprised to learn that SunEdison was a favorite investment of several hedge funds  This kind of aggressive financing driven growth is a favorite tool of that sector 
Of course  the Fed has helped this strategy by keeping interest rates below the inflation rate for nearly eight years  This encouraged all kinds of dopey schemes   such as the one undertaken by Valeant Pharmaceuticals International Inc   NYSE VRX  
However  my advice isn t to avoid investing in hedge fund driven get rich quick schemes  As an income investor  this should be obvious 
Instead  beyond get rich quick schemes  there s a problem in investing in securitization structures in general   whether debt or equity 
After all  you ve probably heard about the  5 billion fine imposed on Goldman Sachs  NYSE GS   partly for misstating the quality of subprime mortgages it securitized 
From the email traffic  we know that in some cases Goldman Sachs executives had inspected mortgage portfolios and discovered that they didn t fit the description in the prospectuses used to sell the securities 
I don t want to channel Senator Bernie Sanders  but in my view  a fine   where the cost falls on the Goldman Sachs  shareholders of 2016   a decade after the problems occurred is the wrong punishment  If there was evidence of fraud  someone at Goldman Sachs should have gone to jail 
We ll never keep Wall Street steering towards the white side of the many gray areas involved in finance if we don t invoke the ultimate penalty 
Goldman s 2006 malfeasances were only possible because once you ve bundled assets up into a securitization package  it s impossible to know what you have in there 
The rating agencies may give it a stellar credit rating  but the near impossible task of assessing it is evidenced by the fact that the rating agencies themselves were fooled by the mortgage securitizations of 2006 07  And after all  home mortgages are a pretty simple asset 
Part of the problem is that Wall Street has no clue how to manage risk properly  as it uses Gaussian mathematical models based on assumptions that simply aren t true 
As a retail investor in a securitized debt or equity  you re buying the ultimate pig in a poke  The seller knows more about what s in there than you  but you can t trust either his ethics or his competence to have disclosed it completely 
And in any event  a proper disclosure may be 200 pages long  and who has time to read it all 
So as an income investor  avoid securitization structures   no matter how attractive the immediate dividend may seem 
Good investing ",2016-04-26,Wall Street Daily,https://www.investing.com/analysis/a-stark-lesson-from-the-sunedison-collapse-200126485,200126485
147856,369372,BHC,Economic Calendar And Watch Lists  TAC  SBH,opinion,"Morning Notes
US Futures are slightly lower while European stocks trade lower by  1  as markets await the US payroll data as it may provide additional clues as to the timing of the next Fed rate hike  Asian stocks closed mostly lower 
Technicals

The SPDR S P 500  NYSE SPY  edged lower again in yesterday s session closing back below the critical support pivot at  205 25  Support will lie at the low of yesterday s range at  204 47  followed closely by the low of Wednesday at  204 42  the 50 Day SMA at  204 25  and finally  203 70  Resistance will lie at the resistance pivot at  205 25  followed by the high of yesterday s range at  205 98   206 80  and the next critical resistance pivot at  207 
Small Cap Watch List
 Please refer to the momentum scanners displayed live in the chat room for potential plays at the market open  
  Others On Watch  
Herbalife LTD  NYSE HLF 
Valeant Pharmaceuticals International Inc  NYSE VRX 
Endo International PLC  NASDAQ ENDP 
Economic Calendar
8 30 Apr non farm payrolls expected  200 000
8 30 Apr avg hourly earnings expected  0 3  m m and  2 4  y y
3 00 Mar consumer credit expected   16 0 billion
Notable Earnings Before Open
EXC  Exelon  NYSE EXC    EPS Est    66  Rev Est   7 52B
WY  Weyerhaeuser Company  NYSE WY    EPS Est    20  Rev Est   N A
Notable Earnings After Close
NONE
May 6th Swing Watch List
TransAlta Corp  NYSE TAC    Not normally a fan of power plays  but I like this for a move back toward 7   Long entry is over 5 29  stop 5 00  Add spot over 5 57 and then look to sell thru 6 and 7 
Sally Beauty Holdings Inc  NYSE SBH    On short watch for a move lower thru 200EMA support following an earnings miss  Sitting on massive support at 30 00  l00k for a break toward 29 00 if 30 falls  Short entry is under 30  stop 30 50 ",2016-05-06,Warrior Trading,https://www.investing.com/analysis/economic-calendar---watch-lists-5-6-2016-200128443,200128443
147857,369373,BHC,Valeant Pharmaceuticals Stock  Time For A Big Recovery,opinion,"Valeant Pharmaceuticals  NYSE VRX 
Valeant Pharmaceuticals has had an incredibly rough time in the market as of late  and for good reason  After Citron exposed the company s relationship with Philidor and called Valeant the Enron of the pharmaceutical industry  investors got cold feet and started to push for facts  Unfortunately  Citron was correct  The relationship helped VRX to fluff the numbers 
However  there has been quite a bit that has changed since then  In fact  just last week  the company made two announcements that are fueling my bullish opinion looking ahead  Today  we ll talk about the recent changes  other changes we ve seen from VRX  and what we can expect to see from the stock moving forward 
So  let s get right to it   
Valeant Pharmaceuticals Partners With IBM  NYSE IBM 
Recently  it was announced that a wholly owned subsidiary of VRX  Bausch   Lomb  will be working with IBM  The goal is to develop the first app of its kind for iPhone and iPad  The app will be designed to assist surgeons who perform cataract surgery 
The new app is expected to streamline the workflow for these physicians by offering patient information  clinical insights and intraocular lens selection guidance  If this app works out well  it will likely prove to be a great thing for both VRX and IBM 
Patient Access And Pricing
One of the factors that has been haunting Valeant is patient access  Unfortunately  the company has made a name for itself as a company that overprices treatments  As a result  VRX has formed a new Patient Access and Pricing Committee 
The new committee will be responsible for pricing all of the company s drugs and will initially be chaired by the CEO of the company  Joseph Papa  The Committee will be made up of a team of VRX employees that will include scientists  doctors  and other executives of the company  In a statement  CEO  Joseph Papa had the following to offer   

 Valeant has made mistakes in how it priced its drugs in the past  and we are committed to ensuring those mistakes are not repeated    This new committee will take a disciplined approach to reviewing the company s pricing of drugs  and will consider the impact on patients  doctors  and our health care industry partners  Valeant s number one priority is ensuring patients can access the medicines they need  

Other Changes VRX Has Made Since The Philidor Scandal
When the Philidor scandal hit  it hit hard  and as a result  Valeant had to make some big changes in order to appease its investors  As a result  we saw management changes that would likely change the game for the company 
First and foremost  when something wrong happens at a publicly traded company  the CEO is the final point of blame  As a result  the CEO during the scandal  J  Michael Pearson resigned from his post  leading to Joseph Papa taking on the role  Also  VRX added some big names  including Bill Ackman to its board of directors 
However  management changes weren t the only changes that were made  After canceling its relationship with Philidor  VRX had to make up for losses in sales  In order to do so  the company contracted with Walgreens  which has helped pick up their prescription numbers in a big way 
What We Can Expect To See Moving Forward
Moving forward  I have an overwhelmingly bullish expectation of what we can expect to see from VRX  The reality is that while the company is down at the moment  thanks to the Philidor scandal  the scandal is over  At this point  Valeant is making the right moves  and those moves will pay off in the long run  All in all  I m expecting to see gains from the stock 
What Do You Think 
Where do you think VRX is headed moving forward and why  Let us know your opinion in the comments below ",2016-05-08,Joshua Rodriguez,https://www.investing.com/analysis/valeant-pharmaceuticals-(vrx)-stock:-time-for-a-big-recovery-200128481,200128481
147870,369386,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 53 ,news,"Investing com   Canada stocks were lower after the close on Monday  as losses in the Healthcare  Consumer Staples and Consumer Discretionary sectors led shares lower 
At the close in Toronto  the S P TSX Composite declined 0 53  
The best performers of the session on the S P TSX Composite were  Ivanhoe Mines Ltd    TO IVN   which rose 5 99  or 0 130 points to trade at 2 300 at the close  Meanwhile   Encana  Corporation  TO ECA  added 2 59  or 0 31 points to end at 12 30 and  Teck Resources Ltd   TO TCKb  was up 2 13  or 0 51 points to 24 46 in late trade 
The worst performers of the session were Valeant Pharmaceuticals International Inc  TO VRX   which fell 6 27  or 2 29 points to trade at 34 25 at the close   Intertain Group   TO IT  declined 3 83  or 0 46 points to end at 11 56 and Canadian Energy Services   Technology Corp  TO CEU  was down 3 72  or 0 180 points to 4 660 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 707 to 453 and 129 ended unchanged 
Shares in Ivanhoe Mines Ltd   TO IVN  rose to 52 week highs  up 5 99  or 0 130 to 2 300  Shares in Teck Resources Ltd  TO TCKb  rose to 52 week highs  rising 2 13  or 0 51 to 24 46  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 18 38  to 15 07 
Gold for December delivery was down 0 05  or 0 70 to  1341 00 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in November rose 2 45  or 1 09 to hit  45 57 a barrel  while the December Brent oil contract rose 2 26  or 1 05 to trade at  47 53 a barrel 
CAD USD was down 0 43  to 0 7560  while CAD EUR fell 0 67  to 0 6718 
The US Dollar Index was down 0 22  at 95 20 ",2016-09-26,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-0.53-428568,428568
147871,369387,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 16 ,news,"Investing com   Canada stocks were higher after the close on Thursday  as gains in the Energy  Telecoms and Utilities sectors led shares higher 
At the close in Toronto  the S P TSX Composite added 0 16  
The best performers of the session on the S P TSX Composite were  Encana  Corporation  TO ECA   which rose 8 31  or 1 02 points to trade at 13 29 at the close  Meanwhile   MEG Energy Corp   TO MEG  added 7 39  or 0 41 points to end at 5 96 and  Brookfield Business Partners  LP  TO BBU u  was up 5 88  or 1 92 points to 34 55 in late trade 
The worst performers of the session were  SNC Lavalin Group Inc    TO SNC   which fell 6 99  or 3 84 points to trade at 51 10 at the close  Valeant Pharmaceuticals International Inc  TO VRX  declined 4 71  or 1 63 points to end at 32 95 and BlackBerry Ltd  TO BB  was down 4 13  or 0 45 points to 10 44 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 581 to 571 and 130 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 0 07  to 14 16 
Gold for December delivery was up 0 02  or 0 25 to  1323 95 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in November rose 1 47  or 0 69 to hit  47 74 a barrel  while the December Brent oil contract rose 0 93  or 0 46 to trade at  49 70 a barrel 
CAD USD was down 0 46  to 0 7610  while CAD EUR fell 0 51  to 0 6780 
The US Dollar Index was up 0 12  at 95 42 ",2016-09-29,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.16-429446,429446
147872,369388,BHC,How Trump  Clinton would fix the  crazy  U S  health system,news,"By Caroline Humer and Emily Stephenson  Reuters    When former President Bill Clinton called parts of Obamacare  crazy   he put his wife Hillary Clinton on the defensive and gave much needed ammunition to her Republican rival for the presidency  Donald Trump  who wants to scrap it  Bill Clinton said this month that while millions more Americans now have insurance coverage under President Barack Obama s signature 2010 healthcare law  small businesses and some families are still  getting killed  by surging healthcare costs  He later clarified that he was not criticizing the entire initiative  he was just making an argument for fixing it   Still  Clinton s comments may not have been so crazy  He put a spotlight on an uncomfortable truth  after six years  billions of dollars and a sweeping reform that stands as Obama s single biggest domestic policy achievement  health care is still unaffordable for many Americans  Americans are growing increasingly anxious about rising healthcare costs  and critics of the law have said it is not living up to its promises  Two of the nation s largest health insurers  Aetna  NYSE AET  and United Healthcare  are also pulling out of the state based health insurance exchanges that are the best known creations of Obamacare  Clinton says she wants to save the best of Obamacare  also known as the Affordable Care Act  while reducing costs  Trump says it is an expensive  disaster  that is on track to implode in 2017  He wants to replace it with something cheaper  Whoever wins the presidency on Nov  8 will likely face pressure to move quickly to reshape a healthcare initiative that affects millions of Americans  WHY CONSERVATIVES THINK OBAMACARE IS CRAZY Republicans opposed Obamacare from the start  labeling it a government intrusion into the healthcare market  Some of them say the individual exchanges where Americans shop online for coverage are already in a  death spiral   They warn that with fewer consumers using the exchanges  more health insurers will exit them  sending premiums even higher  and further deterring people from signing up  As the U S  population ages  U S  spending on healthcare    2 9 trillion in 2014   is projected to rise to more than one fifth of the nation s gross domestic product  Spending rates under Obamacare did slow for a time  but they are on the rise again  Trump has proposed getting rid of the exchanges and setting up tax free health savings accounts for people with high deductible insurance plans  He has also said he would set up state based high risk pools for people with medical conditions that make it hard to get coverage on their own  He also wants to allow companies to sell insurance across state lines to boost competition and drive down prices  His advisers say he would draw on a plan proposed by Republicans in the U S  House of Representatives  which includes a refundable tax credit to help Americans buy individual plans  Republicans  like Trump  also want to change how they fund Medicaid  which serves poor families  Obamacare increased federal funding to states that expanded the program to more people with low incomes  Now Trump wants to limit funding by switching to pre set  block grants  Health policy experts are skeptical selling insurance across state lines would do much to rein in health insurance costs  And health wonks on both sides of the aisle said Republicans would likely balk at any proposals that threatened to yank health insurance away from 20 million people   Even Republican members of the House and the Senate are going to end up resisting rolling back the Medicaid expansion if that means that lots of people in their states would go uninsured   said Jim Capretta  a health policy expert at the right leaning American Enterprise Institute   LIBERALS DON T THINK IT S CRAZY  BUT    Liberals like former Democratic presidential candidate Bernie Sanders haven t called Obamacare crazy  but Sanders does believe it doesn t go nearly far enough  During his campaign  he proposed replacing it with a single payer insurance system he called  Medicare for all   based on the government plan for elderly and disabled Americans  Hillary Clinton s plan doesn t go that far  but she would build on Obamacare by expanding tax credits for people shopping on the individual marketplaces  letting Americans buy into Medicare at a younger age  and adding a  public option   or a government run insurance plan to compete with private insurers on the exchanges   She has also proposed reducing Americans  out of pocket expenses outside their private insurance by offering a new refundable tax credit  and she would give states more federal funding to expand Medicaid for low income people  Two thirds of states expanded Medicaid under the 2010 law  and that s where most of the newly insured people got coverage  Policy experts said that after Obama leaves office  more Republican led states that objected to a plan so closely identified with Obama might be willing to expand Medicaid too   Clinton s ability to expand tax incentives likely depends on which party controls the U S  Congress  And while some states could act independently to launch public plans on their exchanges  many Republicans view the idea as wildly expensive and would strongly resist any effort by Clinton to require them nationwide  WHAT EVERYONE THINKS IS CRAZY   DRUG PRICES Obamacare did little to deal with soaring drug prices for lifesaving treatments like Mylan  NASDAQ MYL  NV s EpiPen  Democrats and Republicans say that s a problem for the next president  even though it s getting little attention on the campaign trail  Trump and Clinton both want Americans to be allowed to buy cheaper drugs from overseas  Americans pay the highest prices in the world for drugs   Former Democratic U S  Representative Henry Waxman made a similar proposal in 2009  but he was defeated by pressure from drug companies  which would likely oppose it again   Clinton says Medicare should negotiate drug prices with companies  using its 55 million users to get a better deal  Trump made a similar call during the Republican primaries but it does not appear on his campaign website now  Some health policy experts believe drug companies would respond to lower prices for Medicare patients by raising prices for everyone else  And to negotiate better prices  Medicare would have to be willing to stop covering certain drugs  which would be unpopular  they say  Clinton has also suggested creating a commission that would watch for sudden spikes in prices of older life saving drugs  a proposal that health policy experts said is achievable through rule making rather than legislation  She has also proposed a cap on drug co payments  Clinton has already put Wall Street on watch  Her tweets have brought down shares of Mylan and Valeant Pharmaceuticals  NYSE VRX  International  which helped push many institutional investors out of healthcare stocks  
Drug companies are already responding to political pressure  Botox maker  Allergan Inc   NYSE AGN pa   for example  recently committed to keeping price increases below 10 percent ",2016-10-18,Reuters,"https://www.investing.com/news/politics-news/how-trump,-clinton-would-fix-the-'crazy'-u.s.-health-system-433052",433052
147873,369389,BHC,Investors find love for bonds again  except for munis,news,By Trevor Hunnicutt NEW YORK  Reuters    U S  based bond funds charged back into the good graces of investors during the latest week  attracting  3 4 billion  Lipper data showed on Thursday  Investors pulled the same amount from U S  based stock funds during the seven days through Oct  19  the research service said  The week also marked a dour milestone for municipal bond funds  which broke a streak of inflows that lasted 54 weeks and showered more than  60 billion into a debt market that finances U S  cities and states  By contrast  investment grade corporate debt funds rebounded  taking in  2 4 billion of cash after  666 million in outflows the week before  the data showed  The bonds have been popular this year for investors seeking refuge from perceived risks in other markets even though a potential U S  rate hike this year could slice bond prices   It may be that equities are so distasteful  and bonds offer better returns than money markets   said Pat Keon  research analyst for Thomson Reuters Lipper  Money market funds recorded  7 7 billion in outflows during the same period  the data showed  Investors park cash in those funds  but they have been moving money elsewhere as U S  regulatory reforms took effect on Friday requiring some funds to let their share prices float with the market  Sentiment around stocks was mixed  with stock exchange traded funds taking in money as mutual funds focused on that market extended a long streak of withdrawals  The stock withdrawals were focused almost exclusively on funds invested in U S  equities  Healthcare sector funds posted  646 million in outflows  bleeding the most cash since May  Hillary Clinton  the Democratic nominee in the Nov  8 U S  presidential race  has pushed for lower drug prices in statements that hurt shares of Mylan  NASDAQ MYL  NV and Valeant Pharmaceuticals  NYSE VRX  International  Chinese stock funds took in  257 million in their 10th straight week of inflows  Data on Wednesday showed that China s economy grew at a steady 6 7 percent  further easing fears that a  hard landing  for that economy might derail global growth ,2016-10-20,Reuters,https://www.investing.com/news/economy-news/investors-migrate-from-stocks-to-bonds-in-latest-week:-lipper-433762,433762
147876,369392,BHC,Exclusive  Ackman s Pershing Square shakes up fees amid losses,news,By Lawrence Delevingne NEW YORK  Reuters    Billionaire investor Bill Ackman s Pershing Square  NYSE SQ  Capital Management is offering its hedge fund clients new fee arrangements following a second straight year of losses  according to a letter to investors on Thursday seen by Reuters  Known for making big  concentrated bets on stocks and agitating for them publicly  Pershing Square will offer starting Jan  1 a new share class to existing and future clients in which it will not charge any performance fee on gains less than 5 percent  after that  the performance fee will be 30 percent  Current investors are being offered a one time chance to opt into the new cost scheme  The new share class is in response to requests from existing clients  including a large pension fund  according to a person familiar with the situation    The fee arrangement was designed to accommodate certain investors that expressed interest in retaining a greater share of returns in low to moderate return scenarios in return for rewarding us with a greater share of returns in higher return scenarios   Pershing Square wrote in the letter  A spokesman for Pershing Square declined to comment  Investors have the option to stay with the old system  where the fund charges 20 percent on all positive returns  long the industry standard  The firm will continue to charge a 1 5 percent management fee for all share classes  and clients are not charged performance fees for investment gains below previous losses on their capital  a so called high water mark  The math works out so that investors in the new share class will get a fee break should Pershing Square gain less than 15 percent but face increased costs above that  Pershing Square has averaged gains of about 15 percent net of fees since inception in 2004  The issue is moot for now  The firm s flagship Pershing Square International Ltd fund is down 17 4 percent this year through Oct  11  according to private performance information seen by Reuters  The same fund fell 16 6 percent in 2015 due to losing bets on pharmaceutical firm Valeant  TO VRX  and dietary supplements maker  Herbalife   N HLF    Pershing Square also told clients in the letter that they could invest additional money with the firm that would be subject to the existing high water mark  In other words  clients will not pay any performance fees on new capital until Pershing Square recovers from its previous losses   We would like to extend an opportunity to our existing investors who have remained committed to Pershing Square during the most challenging performance period in the history of our firm   the letter said  REVERSAL OF FORTUNE Ackman is suffering a stark reversal after being the toast of Wall Street in 2014 when he notched up a 37 2 percent gain in his International fund  among the best performances in the industry   Recent losses have pushed down firm assets  Pershing managed  11 4 billion as of September 30  according to a firm disclosure  down from  16 5 billion as of September 30  2015  Amanda Haynes Dale  co founder and managing director of New York based hedge fund investor Pan Reliance Capital Advisors  approved of the new fee options    I think it s fair   said Haynes Dale  who is not a client   It s a greater alignment of interests for investors   But Jacob Walthour  chief executive officer of Blueprint Capital Advisors  which works with institutional investors to invest in hedge funds  criticized the move  He said it wasn t fair to charge an even higher fee on gains over 5 percent given the losses that Ackman has clocked up   This is like driving a car the wrong way down a one way street   Walthour said  Industrywide  incentive fees are headed toward 10 percent with the addition of hurdles  not 30     Raising fees at any level of return is unacceptable when you think of the financial condition of our nation s pension funds   he added   The greed and arrogance in this industry just never ceases to amaze me   While  2 and 20  has long been seen as the industry norm in reference to management and performance fee percentages  the actual numbers are falling as hedge funds around the world cut fees to retain investors amid weak returns  The average annual management fee has declined to 1 39 percent from 1 44 in 2015 and 1 68 about a decade ago  according to the data from industry monitor Eurekahedge  Funds have also cut performance fees  from an average of 18 77 percent in 2007 to 16 69 percent today  Other large hedge fund managers to cut their fees this year include Brevan Howard Asset Management  Caxton Associates and Och Ziff Capital Management Group  N OZM  ,2016-10-28,Reuters,https://www.investing.com/news/stock-market-news/exclusive:-ackman's-pershing-square-shakes-up-fees-amid-losses-435789,435789
147877,369393,BHC,After 80  Decline This Pharma Stock Could Bounce,opinion,"Could an opportunity be taking place after an 80  decline in Valeant s  NYSE VRX  price 
Yes
Valeant Pharma has been in the news  for all the wrong reasons  since last summer  The news has been bad and its price action has been even worse 
The huge decline in VRX over the past 9 months has the stock testing two long term support lines that have been around for some 16 to 20 years  with both of them meeting at  1  above 
Momentum is deeply oversold and volume has shot up  potentially reflecting panic selling 
A bounce could take place in this very hard hit stock at  1   which is hitting an almost must hold support zone  If support does not hold  it would be bad for the stock and could be hard on the Bio Tech sector  What VRX does at  1  is very important ",2016-04-22,Chris Kimble,"https://www.investing.com/analysis/bounce-could-take-place,-after-80-decline,-says-joe-friday-200126039",200126039
147878,369394,BHC,Valeant Pharmaceuticals Stock  The Bears Come Out To Play,opinion,"Valeant Pharmaceuticals  NYSE VRX  
Valeant Pharmaceuticals is having a great day in the market  However  for many the recent upswing we ve seen in the stock is a shocker  After all  VRX has been falling for quite some time  Today  we ll talk about why the stock has had such a rough time in the market as of late  why we re starting to see gains  and what we can expect to see from VRX moving forward  So  let s get right to it 
Why Valeant Pharmaceuticals Has Had Such A Rough Time
As mentioned above  VRX has been struggling in the market for quite some time now  and for good reason  You see  the company had a relationship with a pharmacy known as Philidor  However  the relationship wasn t a positive one  In fact  it was uncovered that VRX was using its relationship with Philidor in order to fudge the numbers and make their company look like it was doing better than expected 
The story started when an analyst firm known as Citron announced that it had done a thorough investigation of Valeant and that things simply weren t adding up  In their report  Citron called VRX the Enron of the pharmaceutical industry  While no one wanted to believe it  the proof was in the pudding  Valeant had been lying to its shareholders  and that didn t bode very well  As a result  the company has been forced to make some big changes  The first of which was canceling the agreement it had with Philidor 
Other Changes VRX Has Made Since
There have been a couple big changes Valeant Pharmaceuticals has made since its cancellation of the agreement with Philidor  Here s what we ve seen 
Walgreens Boots Alliance Inc  NASDAQ WBA    When VRX cancelled its agreement with Philidor  investors cheered  However  there was some bad  The reality is that Philidor was Valeant s biggest customer  So  canceling the agreement meant a big decline in sales  However  shortly after the cancellation  VRX signed a big deal with Walgreens  and that deal has helped to push the company s sales back upward 
CEO Changes   The CEO of any company is the ultimate reason things happen  good and bad  So  the Philidor scandal fell largely on the shoulders of the company s CEO  As a result  it was announced that the CEO would be resigning  At the moment  VRX is in the midst of a search for a new leader 
Board Changes   Since the Philidor issue  VRX has made several changes to management  This included changes to its board of directors  In fact  the company has made a couple of additions to its Board 
Why The Stock Is Climbing Now
Since the Philidor scandal  VRX has fallen in a big way  giving up more than 70  of its share price  However  since the scandal  we ve seen a ton of positive changes from the company  In fact  VRX recently announced that it is very close to finding its new CEO  At this point  I believe that investors are starting to see that Valeant is doing things the right way and that the declines we saw on the stock are now presenting a strong opportunity  This is leading to momentous gains for the stock  In fact  currently  11 31   VRX is trading at  35 82 per share after a gain of  2 47 per share or 7 41  thus far today  All in all  things are starting to look up for the stock ",2016-04-24,Modest Money,https://www.investing.com/analysis/valeant-pharmaceuticals-(vrx)-stock:-the-bears-come-out-to-play-200126078,200126078
147879,369395,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 33 ,news,"Investing com   Canada stocks were lower after the close on Friday  as losses in the Energy  Healthcare and Real Estate sectors led shares lower 
At the close in Toronto  the S P TSX Composite lost 0 33  
The best performers of the session on the S P TSX Composite were  TransForce Inc    TO TFI   which rose 8 98  or 2 44 points to trade at 29 60 at the close  Meanwhile   New Gold Inc    TO NGD  added 6 11  or 0 310 points to end at 5 380 and  Novagold Resources Inc    TO NG  was up 3 92  or 0 25 points to 6 63 in late trade 
The worst performers of the session were Colliers International Group  TO CIG   which fell 9 79  or 5 19 points to trade at 47 81 at the close  Valeant Pharmaceuticals International Inc  TO VRX  declined 7 89  or 2 33 points to end at 27 21 and  Precision Drilling  Corporation  TO PD  was down 5 64  or 0 36 points to 6 02 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 568 to 557 and 157 ended unchanged 
Shares in TransForce Inc   TO TFI  rose to 52 week highs  rising 8 98  or 2 44 to 29 60  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 10 38  to 15 20 
Gold for December delivery was up 0 47  or 6 00 to  1275 50 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in December fell 2 11  or 1 05 to hit  48 67 a barrel  while the December Brent oil contract fell 1 53  or 0 77 to trade at  49 70 a barrel 
CAD USD was down 0 03  to 0 7470  while CAD EUR fell 0 89  to 0 6794 
The US Dollar Index was down 0 62  at 98 31 ",2016-10-28,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-0.33-435827,435827
147882,369398,BHC,Valeant ex CEO  ex CFO focus of U S  criminal probe  Bloomberg,news," Reuters    U S  prosecutors are focusing on Valeant Pharmaceuticals International Inc s  TO VRX  former chief executive and chief financial officer as they build a fraud case against the drugmaker  Bloomberg reported  The case against Valeant could yield charges within weeks  the report said  citing people familiar with the matter     U S  authorities are looking into potential accounting fraud charges related to Valeant s hidden ties to Philidor Rx Services LLC  a specialty pharmacy company that the company secretly controlled  Bloomberg reported  Prosecutors are examining the actions of Michael  Pearson   LON PSON   Valeant s former CEO  and Howard Schiller  the ex CFO who led the company on an interim basis when Pearson went on medical leave  the report said  Valeant s U S  listed shares  N VRX  closed down 12 4 percent at  17 82  The company could not be immediately reached for comment  A spokesman for Manhattan U S  Attorney Preet Bharara declined to comment  The Wall Street Journal had reported in August that U S  prosecutors had opened a criminal investigation into Valeant over whether it hid from insurers its relationship with Philidor that helped boost its drug sales  Valeant has seen its market value fall by some 90 percent in the last year as its drug pricing and other business practices prompted investigations by multiple U S  government agencies and by Congress  The drugmaker has taken a series of steps to restore investor trust  including cutting off ties with Philidor last October  conducting an internal review of that relationship  overhauling its board of directors and appointing new leaders to run its main businesses  
Earlier this year Laval  Quebec based Valeant replaced Pearson with  Perrigo Co  Plc s  N PRGO  CEO  Joseph Papa  Pearson led Valeant since 2008 and drove its growth through serial acquisitions ",2016-10-31,Reuters,"https://www.investing.com/news/stock-market-news/valeant-ex-ceo,-ex-cfo-focus-of-u.s.-criminal-probe:-bloomberg-436285",436285
147884,369400,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 01 ,news,"Investing com   Canada stocks were higher after the close on Monday  as gains in the Materials  IT and Consumer Discretionary sectors led shares higher 
At the close in Toronto  the S P TSX Composite rose 0 01  
The best performers of the session on the S P TSX Composite were  Kirkland Lake Gold Inc    TO KLG   which rose 13 28  or 1 09 points to trade at 9 30 at the close  Meanwhile   Kinaxis Inc   TO KXS  added 5 56  or 3 45 points to end at 65 54 and  Endeavour Mining Corp   TO EDV  was up 5 52  or 1 370 points to 26 200 in late trade 
The worst performers of the session were Valeant Pharmaceuticals International Inc  TO VRX   which fell 12 02  or 3 27 points to trade at 23 94 at the close  Eldorado Gold Corporation  TO ELD  declined 4 94  or 0 22 points to end at 4 23 and  Encana  Corporation  TO ECA  was down 4 62  or 0 62 points to 12 79 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 621 to 521 and 135 ended unchanged 
Shares in Valeant Pharmaceuticals International Inc  TO VRX  fell to 5 year lows  falling 12 02  or 3 27 to 23 94  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 7 70  to 16 37 a new 1 month high 
Gold for December delivery was up 0 15  or 1 95 to  1278 75 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in December fell 4 05  or 1 97 to hit  46 73 a barrel  while the January Brent oil contract fell 4 26  or 2 16 to trade at  48 52 a barrel 
CAD USD was down 0 25  to 0 7451  while CAD EUR fell 0 10  to 0 6787 
The US Dollar Index was up 0 03  at 98 34 ",2016-10-31,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.01-436291,436291
147887,369403,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 06 ,news,"Investing com   Canada stocks were lower after the close on Tuesday  as losses in the Consumer Discretionary  Industrials and Clean Technology sectors led shares lower 
At the close in Toronto  the S P TSX Composite lost 0 06  
The best performers of the session on the S P TSX Composite were Valeant Pharmaceuticals International Inc  TO VRX   which rose 30 24  or 7 24 points to trade at 31 18 at the close  Meanwhile   First Majestic Silver  Corp   TO FR  added 7 61  or 0 82 points to end at 11 59 and  Ivanhoe Mines Ltd    TO IVN  was up 7 18  or 0 150 points to 2 240 in late trade 
The worst performers of the session were  Finning International Inc    TO FTT   which fell 3 85  or 0 96 points to trade at 24 00 at the close   Genworth MI Canada Inc    TO MIC  declined 3 78  or 1 10 points to end at 28 03 and  Cameco  Corp  TO CCO  was down 3 68  or 0 38 points to 9 95 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 643 to 472 and 165 ended unchanged 
Shares in Cameco Corp  TO CCO  fell to 5 year lows  falling 3 68  or 0 38 to 9 95  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 13 99  to 14 08 
Gold for December delivery was up 1 29  or 16 45 to  1289 55 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in December fell 0 13  or 0 06 to hit  46 80 a barrel  while the January Brent oil contract fell 0 58  or 0 28 to trade at  48 33 a barrel 
CAD USD was up 0 27  to 0 7473  while CAD EUR fell 0 53  to 0 6754 
The US Dollar Index was down 0 56  at 97 77 ",2016-11-01,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-0.06-436621,436621
147890,369406,BHC,Canada stocks lower at close of trade  S P TSX Composite down 1 24 ,news,"Investing com   Canada stocks were lower after the close on Wednesday  as losses in the Healthcare  Materials and Energy sectors led shares lower 
At the close in Toronto  the S P TSX Composite fell 1 24  
The best performers of the session on the S P TSX Composite were  Cameco  Corp  TO CCO   which rose 12 06  or 1 20 points to trade at 11 15 at the close  Meanwhile   Sleep Country Canada Holdings Inc   TO ZZZ  added 4 10  or 1 15 points to end at 29 19 and  Veresen Inc    TO VSN  was up 3 19  or 0 39 points to 12 63 in late trade 
The worst performers of the session were Detour Gold Corporation  TO DGC   which fell 18 78  or 4 91 points to trade at 21 23 at the close   Aecon Group Inc    TO ARE  declined 15 96  or 2 73 points to end at 14 38 and Valeant Pharmaceuticals International Inc  TO VRX  was down 9 11  or 2 84 points to 28 34 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 837 to 337 and 128 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 12 83  to 16 01 
Gold for December delivery was up 0 81  or 10 40 to  1298 40 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in December fell 2 57  or 1 20 to hit  45 47 a barrel  while the January Brent oil contract fell 2 14  or 1 03 to trade at  47 11 a barrel 
CAD USD was down 0 13  to 0 7458  while CAD EUR fell 0 39  to 0 6728 
The US Dollar Index was down 0 31  at 97 46 ",2016-11-02,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-1.24-437017,437017
147894,369410,BHC,Up Is The New Black ,opinion,"Watching the Valeant Pharmaceuticals  NYSE VRX  disaster unfold has  for those who are bystanders like us  resembled viewing an express train hurtling off an unfinished bridge into the ravine below  taking with it the reputations of some highly regarded investors  You ll find no criticism here   professional humility has always been part of our DNA   but if it wasn t  enduring the 58 2  collapse in Master Limited Partnerships  MLPs  from August 31st  2014 to February 11th  2016 assured an additional helping  those dates and figures are imprinted in my memory   Watching someone else s catastrophe is an awe inspiring distraction  in the same way that one feels sorrow for the victims of a foreign earthquake while assuring oneself of the sensible choice to not live on a fault line  We ll resist the self satisfied observation that Valeant s fall eclipsed even the most hated energy infrastructure MLP  During a stunningly brief period of a few months from August 5th  2015 through last Friday  down for VRX investors was a long way   a staggering 89 7  
We have no opinion on VRX and certainly wouldn t suggest that its collapse was obvious  But it s often the case that fund flows develop their own momentum  While Pershing Square and ValueAct  two large hedge fund investors in VRX  can manage their exposure to this calamity with little regard to fund withdrawals given their long lock ups  the asset base of Sequoia s mutual fund  SEQUX  is at the daily whim of its investors  Having similarly peaked with VRX on August 5th  SEQUX is down 33 5  and redemptions are likely causing unwilling selling of VRX by its managers  Morningstar s placing of its rating under review can t have helped their fund marketers 

Whatever the true value of VRX  in the short term Ben Graham said the market s a voting machine  and investing in public equities forces you to endure the popularity  or loss thereof  of your holdings  MLPs certainly found that even as their security prices offered ever greater discounts to value  the marginal investor was nonetheless more often a seller rather than a buyer 
It s worth revisiting the above chart  originally shown in early January  see    which remains our best explanation for the substantial dislocation we endured  Although MLP distributions  in red  used to comfortably exceed new capital raised  in blue   the Shale Revolution gradually reversed this relationship by creating an ongoing need for new infrastructure which required financing  The increasing shortfall between cash paid to investors via distributions and cash taken back via IPOs and secondaries was  for a time  met with new money from mutual funds and ETFs  in green  until falling prices induced the more recent investors to curtail inflows and eventually switch to outflows 
Ultimately  institutional flows from non traditional MLP investors were attracted  see    Although operating performance of midstream MLPs wasn t immune to the collapse in oil  their stock prices often fell by many multiples of their drop in EBITDA  We continue to believe that what happened exposed the financing model of MLPs far more than their operating results  and that the flow of funds explanation is the most likely cause 
One pre requisite for buyers to overwhelm sellers is excessive pessimism  and VRX is at least approaching that zip code  21 of 23 analysts following the stock were bullish prior to last Tuesday s earnings call  following which there was an undignified rush for the relative anonymity of a target price close to the current market  One firm slashed its target price from  200 to  70  on Friday VRX closed at under  27   MLPs saw something similar over the past several weeks  see   as sell side analysts reacted as humans to the relentless criticism their bullish forecasts received from investors apportioning blame for their losses 
On recent trends  MLPs should soon be positive for the year  The last time that could be said was May 8  2015  Over the following seven and a half months the sector turned in its worst year ever  Whether or not February 11th  58 2  below the August 2014 high  was the low for MLPs  it couldn t be so without sufficient Wall Street analysts giving up  Industry mutual fund flows were heavily negative into the end of 2015  and there s evidence more recently that flows are turning  We re still 43  below the market peak  It is at least no longer unfashionable to expect rising MLP prices 
On Thursday  TransCanada  NYSE TRP  announced that they had agreed to acquire Columbia Pipeline Group  NYSE CPGX  for  10 2BN in cash  of which  4BN was funded with the proceeds of a TRP secondary offering of equity   The Wall Street Journal had reported on the negotiations several days earlier  TRP of course is behind the Keystone XL pipeline project which was eventually blocked by the Administration  further challenging Canada s E P companies as they seek ways to ship crude oil from Alberta to foreign markets 
CPGX is the General Partner that controls 15 000 miles of natural gas pipelines  mostly at the GP level  although their MLP Columbia Pipeline Partners  NYSE CPPL  holds some of the assets  TRP saw no need to acquire CPPL  since their acquisition of CPGX already gives them control of CPPL and thereby retains the ability to continue dropdowns into the MLP where assets can be more cheaply financed  although crucially this financing option isn t currently available  The deal is the classic use of the MLP GP structure  CPGX as the GP is analogous to a hedge fund manager  and CPPL is the hedge fund  Owning CPGX provides control of CPPL  CPGX  or now TRP  can eventually move assets into CPPL and continue to earn Incentive Distribution Rights on them  similar to a hedge fund manager earning a fee on assets in his hedge fund 

Although the acquisition valued CPGX at 19X 2016 estimated EV EBITDA compared with TRP s 12 75X  TRP expects the transaction to be accretive from 2017 as some of the CPPL backlog drops into production  TRP expects to finance  8BN of projects at CPGX over the next four years  earning  5 5BN in EBITDA over that time and exiting 2020 at a  1 7BN run rate  The cancellation of Keystone and delay in another big project  Energy East  has left room in TRP s budget  in addition to which TRP s size leaves it better placed to finance this kind of backlog 
Prior to the deal  CPGX was yielding 2 25   Moreover  CPGX and CPPL moved sharply in opposite directions following the announcement  as the market reflected the control premium paid for CPGX that wasn t necessary for CPPL  This illustrates why owning MLP GPs is better than owning MLPs 
We were invested in CPGX until Friday and remain invested in TRP ",2016-03-21,Simon Lack,https://www.investing.com/analysis/up-is-the-new-black-200122242,200122242
147895,369411,BHC,Bill Ackman And Valeant Pharmaceuticals ,opinion,"The big news this past week was the bloody nose that Bill Ackman and his Pershing Square fund received regarding their investment in Valeant Pharmaceuticals  NYSE VRX  
Following a dire update  the stock plunged to levels not seen since 2011  and has dropped almost 90   yes  you read that correctly  from its all time highs above  260 back in August As Ackman is an investor rather than a trader  I ve shown the chart below on a weekly timeframe to show a longer term perspective  but however you look at it  the chart is just plain ugly if you are trying to go long as a trader  or are currently holding as an investor  The downtrend has clearly been in place for several months  Price tells you all you need to know 
Whenever I come across situations like this  I am reminded of the story Ed Seykota once told 

 One evening  while having dinner with a fundamentalist  I accidentally knocked a sharp knife off the edge of the table  He watched the knife twirl through the air  as it came to rest with the pointed end sticking into his shoe   Why didn t you move your foot   I exclaimed   I was waiting for it to come back up  he replied  

The problem with holding such large volumes of shares in a company  Pershing currently hold over 30 million shares  which is more than 5  of the issued share capital   is that when price goes against you  it can be difficult to unload your holding without starting to make price go even further against you 
As it is  Pershing clocked up losses of more than  1 billion on Tuesday alone  in the immediate aftermath of the announcement 
So  it looks like Ackman  at best  will be stuck in a losing position for a while to come  But there s always someone worse off  According to  report  the Sequoia fund is currently holding an even bigger stake in Valeant  which accounted for 20  of its assets 
As a trend follower  the odds are only in your favour when the direction of your trade is aligned to the price trend of the stock or instrument you are holding  On that basis  anyone who follows price trends would have exited long positions in Valeant a while back and would be safely in cash  or may be sitting in a short position after getting the appropriate entry signal 
So what can you learn from this as a trader 
Richard Donchian summed it up very well As Donchian said   don t lose money 
If something goes against you  get out and move on 
Aim to keep your losses as small as possible 
You never want to see a trade turn into a long term investment simply as a result of not taking a small loss when you had a chance 
Remember that preservation of capital is key to you surviving 
I could go on with all the clich s  but  hopefully  you get my point 
Even if you follow company fundamentals  a simple trend following system will help you with the  timing  of your entries and exits  and help you avoid scenarios like this 
As I ve said many times when I come across charts like this  what appears to be cheap now  may be even cheaper in 6 months time   ",2016-03-21,Trader Steve,https://www.investing.com/analysis/bill-ackman-and-valeant-pharmaceuticals-200122332,200122332
147896,369412,BHC,Valeant Pharmaceuticals  VRX  Stock  Here s Why It s Climbing Today,opinion,"Valeant Pharmaceuticals  NYSE VRX  has had an incredibly hard time in the market as of late  and for good reason  After the company s relationship with an underground pharmacy known as Philidor came to light in the media  many questions were raised  As a result  the company had to cease business with the pharmacy which just so happened to be its biggest customer  Soon sales fell and further questions came up about the stock  Nonetheless  VRX is up big in the market today after big changes were announced with regard to the management of the company  Here s what s happening   
Bill Ackman Will Be On The Board Of Directors
It was announced earlier this morning that Bill Ackman will be added to the board of directors at VRX  After all of the hardship the company has faced  they needed to bring on a high profile expert that would help the business grow  Now  I ve followed Ackman for quite some time  and I have to say I m not a huge fan of him as much as I know of him  on a personal level  However  when it comes to business  the guy is an absolute genius  So  taking that into account  it s overwhelmingly clear why investors are so happy that Ackman is being brought onto the board of directors 
J  Michael Pearson Will Be Stepping Down
J  Michael Pearson has served as the CEO of VRX for quite some time now  However  following the issues the company has faced as of late  he will be stepping down  While Valeant Pharmaceuticals searches for a successor to Pearson  he will maintain his role as CEO 
In a statement  Pearson had the following to say   

 It s been a privilege to lead Valeant for the past eight years    While I regret the controversies that have adversely impacted our business over the past several months  I know that Valeant is a strong and resilient company  and I am committed to doing everything I can to ensure a smooth transition to new leadership  

Robert Ingram  chairman of the board also had a bit to say about the transition to a new CEO  Here s what he had to say   

 While the past few months have been difficult  Valeant has a collection of leading brands  valuable franchises and great people  and I am confident that the company will be able to rebuild its reputation and thrive under new leadership  We thank Mike for his dedicated service to Valeant and for agreeing to stay on until we conclude our search  As a colleague and a friend he will be missed  and we wish him the best for the future  

How The Market Reacted To The News
As investors  we know that any time there is positive news with regard to a publicly traded company  we can expect to see gains in the value of the company  While management changes aren t always positive news  the fact that Bill Ackman will be taking a seat on the board at VRX and that the company is looking for a new CEO is definitely positive news  As a result  we re seeing strong growth in the value of the stock today  Currently  10 45   VRX is trading at  30 40 per share after a gain of  3 42 per share or 12 68  thus far today 
What We Can Expect To See Moving Forward
Moving forward  I have an overwhelmingly positive view of what we can expect to see from VRX  The reality is that Valeant Pharmaceuticals has an incredible growth story  one that has required them to make it over hurdles in the past  Every time  they have done just fine  Now  with the new leadership coming on board  things are looking better than ever  Sure  VRX is in a rough patch at the moment  but the sun always shines after a rainy day ",2016-03-21,Joshua Rodriguez,https://www.investing.com/analysis/valeant-pharmaceuticals-(vrx)-stock:-heres-why-its-climbing-today-200122365,200122365
147897,369413,BHC,Can Specialty Pharma Survive Valeant s Toxic Collapse ,opinion,"by Clement Thibault
Recently we checked in with the Pharma sector  where the prevailing business model of spending  sometimes lavishly  on research and development in order to bring to market an exclusive blockbuster drug has long been  and remains  the industry standard  Recently  however  some specialty pharma companies most notably and notoriously Valeant Pharmaceuticals  NYSE VRX   have tried a bit of disruption  using aggressive acquisitions and attendant steep price hikes to drive the business 
Valeant s ongoing collapse  in part due to the toxic PR accompanying its aggressive pricing policies  but perhaps as much due to its   has pulled down an assortment of biotechs in its wake  as market participants seem to be fleeing the sector  When we published our original Pharma article  VRX was trading for  61 31 a share  Since then  on March 15  2016  Valeant issued a downgraded outlook for 2016  lowering its expected annual EPS to around  9 5  down from  13 25 13 75  Moreover  CEO Michael Pearson claimed on the company s conference call that the company understands that  The world has changed   which probably means the end of operations under its current business model  Add to all that a  600 million  typo  in the company s press release concerning its expected future EBITDA  and you ve got a real mess on your hands 

Unsurprisingly  the events of that day cut Valeant s value by as much as 51   after it closed at  33 51  And the carnage isn t over 
As of yesterday  the stock is trading even lower   31 89 at close  A potential recovery will be possible but only if Valeant is able to regain the public s trust  But firing CEO Pearson and naming investor Bill Ackman to the board has not stopped the bleeding  With  30B dollars in long term debt and a business model that has now crashed and burned  it s hard to see Valeant ever returning to its mid 2015 high of  263 81 
So is the specialty pharma sector finished  Or is it just Valeant s business model that needs to be scrapped 
A few other  strikingly similar companies have been dragged down by Valeant  Horizon Pharma PLC  NASDAQ HZNP   Endo International PLC  NASDAQ ENDP  and Mallinckrodt  NYSE MNK  have all lost well over 50  in the past six months 
Endo stood at  88 54 in August  and now trades at  30 81  down 65  

Mallinckrodt  which traded for  125 85 in August  is now at 61 05  down 54  

Finally  Horizon fell from  37 to  as of yesterday s close   15 74  57  less than what it used to be 


For each company mentioned above  losses are primarily due to the fact that their ongoing strategies of mergers and acquisitions mirror the model Valeant relied on  But should each of these companies be tarred with the same brush 
In Valeant s case the damage from this business model is glaringly apparent in the company s balance sheets and income statements  Valeant s long term debt jumped from  10 5 to  30 billion dollars  while its R D investment grew by a mere  40 million  to a total of  96 million  In comparison  Pfizer  NYSE PFE  spends about 2 billion annually in R D   50 times the amount VRX allocated 
Endo International s long term debt has grown from  3 to 8 billion dollars  following acquisitions of five pharmaceutical companies in 2013 2014 alone  Its focus on M A is obvious from its slim R D costs just  44 million Similarly  Horizon has added  1 1 billion of long term debt to its balance sheet  while at the same time spending only  13 million on R D 
The numbers seemingly implicate Mallinckrodt as well  which  from just  9 million of long term debt in 2012 now owes a whopping  6 5 billion  And over the same period  its R D costs rose only about 30  from  144 to  185 million  Even though Mallinckrodt s CEO  his company from Valeant  we d rather pay attention to the numbers 
While each of the three companies might be similar to VRX in some ways  each is not even close to the same amount of of trouble currently bringing down Valeant  VRX s long term debt to equity ratio is 4 75  meaning the company owes 4 75 times as much money as the value of its market cap  The ratios for Endo  Horizon and Mallinckrodt aren t even close at 1 38  0 9 and 1 23  respectively  That s not to say each is financially sound since all are still very indebted  but so are most pharma companies which first spend on development and then recoup when introducing a winner 
Looking ahead  it s our assessment that each of these three companies is probably better positioned to re adjust course  now that the pricing party has ended  And if any aren t willing to do it voluntarily     Another factor in favor of each of these three smaller companies  they have less debt to serve  and have managed to avoid the crushing public wrath now being heaped on Valeant  and on Martin Shkreli and his company  Turing Pharmaceuticals  beforehand  
While HZNP  ENDP and MNK have obviously been connected to the Turing Valeant mess  we view their situations more along the lines of collateral damage  and believe they have just momentarily fallen out of favor with investors  making them potential value buys as the dust settles  This hypothesis is supported by the joined  upward movement of the stocks this week  when the unrelated firing of Valeant s Pearson led to gains for Horizon and Mallinckrodt 
The specialty pharma market is burning right now  and related price movements are out of sync with actual performance or future outlook  Of course  we don t recommend blindly buying into specialty pharma  nor anything else  for that matter   but a little time spent on due diligence might reward the bold with double digit gains once the fires subside ",2016-03-23,Clement Thibault/Investing.com ,https://www.investing.com/analysis/can-the-biotech-sector-survive-valeant's-collapse-200122602,200122602
147898,369414,BHC,Valeant Pharmaceuticals  VRX  Stock  Will We See More Gains ,opinion,"Valeant Pharmaceuticals  NYSE VRX  has been struggling for quite some time  and for an incredibly good reason  The company has had several accounting errors and had an iffy at best relationship with an underground pharmacy known as Philidor  Soon  Citron started to call VRX the Enron of the biotechnology industry as it brought to light the issues with the company  Investors held onto the statements and VRX started to fall dramatically  When this all started  the stock was trading at over  100 per share  Now it sits around  30 per share  Nonetheless  Valeant recently closed over 7  higher as the result of a big announcement    can it go higher  Today  we ll talk about the announcement that was made  what we re seeing from Valeant Pharmaceuticals in the market today  and what we can expect to see moving forward  So  let s get right to it   
VRX Releases Information That Excites Investors
In any case  the CEO of the company is the leader  and therefore  the person to blame when something goes wrong  So  when we see something bad happen with regard to a publicly traded company  it s common practice that the CEO may step down  That s exactly what we re seeing from VRX  On Monday  it was announced that the company would be hunting for a new CEO as the current CEO will soon be stepping down  He will continue to hold his position at Valeant until a new CEO is found  On top of the CEO change  VRX made changes to its board of directors and offered an update with regard to accounting and financial reporting issues  Yesterday  the company came out and accused the former CFO of VRX of  improper conduct  that led to the misstatements in financial results  In fact  in a press release on Monday  Valeant had the following to say about its former CFO    

 The improper conduct of the company s former Chief Financial Officer and former Corporate Controller  which resulted in the provision of incorrect information to the Committee and the company s auditors  contributed to the misstatement of results  In addition  as part of this assessment of internal control over financial reporting  the company has determined that the tone at the top of the organization and the performance based environment at the company  where challenging targets were set and achieving those targets was a key performance expectation  may have been contributing factors resulting in the company s improper revenue recognition  

What We re Seeing From VRX Today
While we are still well in the beginning of the day  things are looking to be shaping up to be a great Wednesday for Valeant Pharmaceuticals  Currently  9 42   the stock is trading at  32 70 per share after a gain of  0 79 per share or 2 48  thus far today 
What We Can Expect To See Moving Forward
When it comes to VRX  it is my belief that the struggles are over for the most part  The reality is that VRX made some very big mistakes  and ultimately  the company is paying for those mistakes  However  since the issues have come to light  Valeant has made changes with regard to management  has re established realistic accounting figures  and has even signed a contract with Walgreens for the sale of their treatments  All in all  things seem to be heading back in the right direction  and I m expecting to see gains in the long run as a result ",2016-03-23,Joshua Rodriguez,https://www.investing.com/analysis/valeant-pharmaceuticals-(vrx)-stock:-will-we-see-more-gains-200122639,200122639
147899,369415,BHC,Slave To The System ,opinion,"Whenever a trend follower captures a big winning trade  outsiders often wonder if it is down to pure luck  skill or something else 
In a lot of cases  trends can start to develop in spite of the current sentiment and beliefs of many of the market participants 
Trend followers  however  approach the markets in an unemotional state   if their method tells them to enter a trade at a certain price level  they enter  Similarly  if their method tells them to exit at a certain price level  they exit  A trend follower would never get into a situation where they would allow price to start trending significantly in the opposite direction to that they are trading   witness  and the chart of Valeant Pharmaceuticals  NYSE VRX   If their exit level is hit  they get out  no questions asked  and move onto the next opportunity 
They are conditioned to exit based on price and their chosen parameters  not on opinions or beliefs about where the price on a stock or instrument may or may not go  In other words  they are slaves to their own system or method for getting in and out of their positions 
Now  there is undoubtedly luck involved in getting into a major trend on a sample size of one  And historically  trend following has a typical win rate of between 30  and 40   However  trend followers work on the premise that trends have a tendency to persist  So  they take their entry signals at the start of a potential new trend  If they are wrong  they will know quickly and will exit as soon as possible  with as little damage as possible to their equity 
If however  they do get into a position where a significant trend starts to develop  then the only skill involved is having the ability to stay in the trade until an exit signal is given  They never predict when that will be  or at what price level  The price action in the market they are trading will tell them when that time has arrived 
Psychologically  it can be very difficult for people who start to use a trend following approach to truly grasp how it works until they have been through the myriad of emotions and cycle of market conditions that accompany such an approach  lots of small losses  some small wins  and the occasional big win 
Trend following is not an approach geared toward achieving a high win rate  You have learn how to lose  small  before you can win  It is not easy telling someone they are trading well when they are clocking up small loss after small loss  But that is all part of the game  Similarly  you also have to accept that hard earned gains can be lost as part of the process when a trend starts to end or reverse  Those who can understand and accept that  along with applying strong risk control  have the best chance of success 
I talked  about how a trader friend I ve  for a few years went through this process  All his development  learning and initial frustration  in effect  was the precursor to making a big psychological breakthrough  But all through that process  he was sticking to what his basic method was telling him to do  It kept him in the game  It eliminated the possibility of big losses  He knew he was getting closer and closer 
I ll never forget the phone call I got from him when he managed to get into a few positions  the majority of which started to develop major trends  I was on holiday at the time  but we kept in touch as the profits were mounting up day after day  The urge to take profits off the table was huge  however he knew that would go against the basic premise of letting the profits run   This is really testing my mettle   he said   but NOW I truly see and understand the power of trend following  
He now trades more than one trend following system on different timeframes and is making decent returns  Whenever we chat about things  he continually refers to being a slave to his system  and stresses to himself the need for him to not listen to his own thoughts and opinions about what may or may not happen  He continues to take the positions when he gets an appropriate signal and his risk limits allow  and then he lets the markets do its thing 
And that is the way it should be ",2016-03-25,Trader Steve,https://www.investing.com/analysis/slave-to-the-system-200122872,200122872
147901,369417,BHC,Valeant Isn t A Bad Investment,opinion,"Valeant Pharmaceuticals  NYSE VRX  has had a rough time in the market as of late  and for good reason  Late last year  Citron published a report on the company and its relationship with an underground pharmacy known as Philidor  Since then  everything seemed to fall apart for the company as investors  analysts  and reporters questioned its dealings  As a result  the stock tanked dramatically  At this point  many are still holding onto the idea that VRX may be a bad investment  but is it  Today I ll explain what we ve seen since the Philidor issue and what I expect to see moving forward 
VRX Since The Philidor Issue
Valeant Pharmaceuticals has had a tough time in the market over the past several months  When Citron published the article explaining the relationship between the company and the pharmacy known as Philidor  investors lost faith  After all  Citron did call VRX the Enron of the pharmaceutical industry  As a result of the publication  investors started to ask a ton of questions  many of which went relatively unanswered  Soon enough  investors started to push for the cancellation of the agreement between VRX and Philidor  which of course  they got 
This led to a new problem for Valeant Pharmaceuticals  You see  Philidor just so happened to be the biggest customer that VRX had on the books  So  when Valeant cut Philidor out  they also cut out a massive amount of prescriptions for their treatments  Essentially  the company was stuck between a rock and a hard place  trying to figure a way out 
Shortly after the relationship between VRX and Philidor came to an end  we started to see a bit of good news from the company  Soon  Valeant signed an agreement with one of the world s largest pharmacies  Walgreens  Under the agreement  Walgreens would sell Valeant s products  While this wouldn t make up the total prescriptions lost from the Philidor issue  this was a step in the right direction  Since then  we ve seen several changes to the company  including management changes 
What We re Seeing In The Market 
As mentioned above  during the Philidor issue  VRX started to fall dramatically in the market  The company simply couldn t seem to find support  However  more recently  we ve started to see gains on the stock  In fact  today  the gains were continuing in early morning trading  Unfortunately however  the stock has fallen into the red for the day  Currently  10 24   VRX is trading at  28 96 per share after a loss of  0 02 per share or 0 07  thus far today 
What We Can Expect To See Moving Forward
While several analysts have a relatively bearish opinion of what we can expect to see from Valeant Pharmaceuticals  my opinion on the stock is very different  The reality is that VRX has fallen from well over  100 per share to under  30 per share  While we have seen declines  we ve also seen that since this issue happened  the company is recovering large amounts of sales  At this point  I believe that VRX has fallen to a key level at which it seems advantageous to get involved in the stock again  From here  I m expecting to see growth  while it may be relatively slow in the beginning  I m expecting to see growth nonetheless ",2016-03-30,Joshua Rodriguez,https://www.investing.com/analysis/valeant-pharmaceuticals-(vrx)-stock:-why-this-isnt-such-a-bad-investmen-200123378,200123378
147906,369422,BHC,Valeant Pharmaceuticals May Jump 50  On Friday,opinion,"Valeant Pharmaceuticals International  NYSE VRX  has had an ugly past 52 weeks  After trading as high as  260 per share  the stock hit a low on Thursday of  25 75 
So why on earth could it potentially rally 50  in the next month  The answer is surprisingly simple 
Thursday was the last day of the quarter  which is when hedge funds sell their biggest losers    especially those with so much media attention into quarter s end  They do this to avoid showing the position on their quarterly statement  This creates added down pressure into the end of the quarter  In addition  no hedge funds would buy prior to the new quarter for the same reason    not wanting the position on their statement  That means  come April 1  it s a whole new ball game  The selling from hedge funds should have concluded and there will be some hedge fund buyers taking positions 
Assuming no negative news from the company  there s 50  upside in this name over the next month ",2016-03-31,Gareth Soloway,https://www.investing.com/analysis/valeant-pharmaceuticals-may-jump-50-on-friday-200123561,200123561
147913,369429,BHC,Clinton calls for lower price on allergy drug EpiPen,news,"By Ginger Gibson WASHINGTON  Reuters    Democratic presidential candidate Hillary Clinton called on pharmaceutical company Mylan  NASDAQ MYL  NV to voluntarily drop the price of its severe allergy treatment drug EpiPen  which has increased in price by more than 400 percent in the past decade   That s outrageous   and it s just the latest troubling example of a company taking advantage of its consumers   Clinton said in a statement   It s wrong when drug companies put profits ahead of patients  raising prices without justifying the value behind them   Clinton frequently said during the primary that she would fight pharmaceutical companies   part of an attempt to counter criticism that she was too closely tied to the insurance industry  She has released a proposal that she says will lower drug costs for consumers  Mylan spokeswoman Nina Devlin did not respond to inquiries about Clinton s criticism of the company  Mylan acquired the product in 2007  and the price increased from  100 in 2008 to its current cost of  600  Shares of Mylan closed down more than 5 percent at  43 15 on the Nasdaq   The price of EpiPen is outrageous   said Robert Weissman  president of consumer watchdog group Public Citizen   Mylan is endangering lives and ripping off the country   Weissman said EpiPen s U S  price should be rolled back sharply  noting the product is available for as little as  112 in Canada  Many other drugmakers also routinely raise prices of their prescription drugs by 10 percent or more each year  and U S  legislation is needed to prevent such  price spikes   he added  The White House took a more cautious tone in criticizing rising drug costs  refusing to comment on the decisions of an individual company    I will observe  however  that pharmaceutical companies that often try to portray themselves as the inventors of life saving medication often do real damage to their reputation by being greedy and jacking up prices in a way that victimizes   White House spokesman Josh Earnest said at a news briefing   Clinton joins a bipartisan group of lawmakers who are calling for investigations into the price increase of EpiPens  which are preloaded injections of epinephrine  adrenaline  that people use if they are having a dangerous allergic reaction that untreated could result in death   Republican Senator Chuck Grassley  chairman of the Senate Judiciary Committee  wrote Mylan earlier in the week to ask for an explanation of the price change  Senator Amy Klobuchar  the top Democrat on the committee s antitrust subcommittee  called for an investigation by the Federal Trade Commission  On Wednesday  Republican Senator Susan Collins and Democratic Senator Claire McCaskill requested that Mylan provide a briefing for the Senate to explain the price change  Grassley and Klobuchar  along with Democratic Senators Patrick Leahy and Richard Blumenthal and Republican Senator Ron Johnson  on Wednesday said they had written to the Food and Drug Administration to ask about its approval process for alternatives to the EpiPen   Given the importance of this topic  it is imperative to understand the FDA s role with respect to EpiPens and its approval of generic equivalents that could help to increase competition and lower prices if introduced   the senators said in a statement    We have reached out to every member of Congress who has sent us a letter  and we look forward to meeting with them and responding to their questions as soon as possible   Devlin said   In January  Clinton admonished Valeant Pharmaceuticals International Inc  NYSE VRX   which raised the price of a heart drug  In the wake of a Clinton campaign blog post targeting Valeant  the company s stock fell  In March  she released a campaign ad vowing to target the company specifically   Clinton also criticized Turing Pharmaceuticals in the fall of 2015 when public ire rose after it decided to raise the price of an antiviral medication commonly used by AIDS patients and pregnant women from  13 50 a tablet to  750 each   After a single post by Clinton on the social media website Twitter critical of Turing  the company s stock price tumbled   At that time  Clinton released a comprehensive drug price plan that she says would reduce costs  Her proposal includes capping monthly out of pocket costs  expanding generic drug access and allowing Americans to buy pharmaceuticals abroad   
Republican presidential candidate Donald Trump has said little about lowering drug prices  He has proposed increasing the amount of negotiations permitted by Medicare in order to lower prices for those using the program ",2016-08-24,Reuters,https://www.investing.com/news/politics-news/clinton-calls-for-lower-price-on-allergy-drug-epipen-422139,422139
147914,369430,BHC,Mylan offers discounts on EpiPen amid wave of criticism,news,"By Toni Clarke and Ransdell Pierson  Reuters    Mylan  NASDAQ MYL  NV said on Thursday it would reduce the out of pocket costs of its emergency EpiPen allergy injection for some patients amid a wave of criticism from lawmakers and the public over the product s rapidly escalating price  The list price of the drug will remain the same  but the company said it would increase the maximum copay assistance program to  300 from  100 for patients who pay for the 2 pak in cash or who are covered by a commercial health insurer  The price of EpiPen has skyrocketed to  600 from  100 since it was acquired by Mylan in 2007   Mylan also said it is doubling the eligibility for its patient assistance program  which will eliminate out of pocket costs for uninsured and under insured patients and families  Government paid programs are not eligible for the copay assistance program  Ronny Gal  an analyst with Bernstein  said when all is said and done he estimates a total price reduction for EpiPen of 32 percent  The price rose 27 percent in the second quarter of 2016 versus the same quarter a year ago   Thus we are basically rolling back the increase of the past year   he said   In all  we estimate that today s news results in a 20 25 percent hit on EpiPen revenues   He expects that to translate into a 3 4 percent hit to Mylan s earnings per share over the next few years  He estimates the company will earn  4 77 a share in 2016 and  5 58 in 2017  Mylan is the latest company to be caught up in the growing outrage at apparently egregious drug price increases  Valeant Pharmaceuticals International Inc  NYSE VRX  and Turing Pharmaceuticals have both been publicly excoriated for similar price increases  Presidential candidate Hillary Clinton  who has spoken out against escalating drug prices   welcomes the fact that Mylan is now apparently open to taking steps to lower some of the cost sharing burdens imposed on families   Tyrone Gayle  a campaign spokesman  said in a statement  However  he added   discounts for selected customers without lowering the overall price of EpiPens are insufficient  because the excessive price will likely be passed on through higher insurance premiums   Clinton s view was echoed by Democratic lawmakers  including Rep  Elijah Cummings  who said Mylan s move is nothing but a public relations stunt that does nothing to help the majority of patients who need the drug   Offering a meager discount only after widespread bipartisan criticism is exactly the same tactic used by drug companies across the industry to distract from their exorbitant price increases   he said in a statement   Nobody is buying this PR move any more   Mylan Chief Executive Heather Bresch  defending the price in an interview on Thursday on CNBC  said her company had spent hundreds of millions of dollars improving EpiPen  including making its needle invisible  since acquiring the device from German generic drugmaker Merck  NYSE MRK  KGaA    When we picked up this product  they  Merck  weren t spending a dollar on it   said Bresch   Bresch said Mylan recoups less than half of EpiPen s list price because pharmacy benefit managers  which often require discounted prices or rebates from drugmakers  are involved  along with insurers and others  Democratic U S  Senator Amy Klobuchar said Mylan s action was a  welcome relief  to many who are struggling to afford the medication  but said it does not address the root of the problem of rising drug costs  Earlier this year  Clinton chastised drug companies for exorbitant pricing and unveiled a plan that she said would cut costs  making the issue not only a hot election discussion topic but potentially an issue that could have policy implications if she is elected  On Wednesday  Clinton pressed Mylan to voluntarily cut the EpiPen price  sending the company s share price lower and pushing down biotech stocks  Mylan shares fell more than 10 percent this week before rising 3 2 percent on Thursday after announcement of the discount program  EpiPens are preloaded injections of epinephrine  adrenaline  used in case of a dangerous allergic reaction known as anaphylaxis that could cause death if untreated  Anaphylaxis can occur in as little as a couple of minutes of exposure to the allergen  which can come in the form of food such as peanuts or insects such as bees  Certain medications or latex can also cause a severe reaction  Symptoms include itching  swelling of the lips  tongue and roof of the mouth  tight chestedness and difficulty breathing  People who are susceptible to such reactions are frequently advised to carry an EpiPen  which can deliver an immediate emergency jolt of adrenaline to reverse the symptoms   A group of lawmakers said on Wednesday they had written the U S  Food and Drug Administration asking about its approval process for alternatives to the EpiPen  FDA spokeswoman Theresa Eisenman said in a statement the agency is reviewing the questions posed in the letter  and will respond directly to the Congressional members   She noted that the FDA does not have the authority to review or approve drug prices  Bresch  daughter of Democratic U S  Senator Joe Manchin of West Virginia  said she contacted members of Congress over the past two days and asked to meet with them to discuss what she called an  unsustainable  drug pricing system  
She said one of the calls was to Senate Judiciary Committee Chairman Chuck Grassley  R Iowa   who recently wrote a letter to Mylan asking for an explanation of big EpiPen price increases ",2016-08-25,Reuters,https://www.investing.com/news/stock-market-news/mylan-cuts-patient-cost-of-epipen-422297,422297
147915,369431,BHC,Mylan to launch generic EpiPen at half the price of original,news,"By Ankur Banerjee and Ransdell Pierson  Reuters    Mylan NV  O MYL  said it would launch the first generic version of its allergy auto injector EpiPen for  300  half the price of the branded product  the drugmaker s second step in less than a week to counter the backlash over the product s steep price  The company reduced the out of pocket costs of EpiPen for some patients on Thursday  but kept the list price at about  600  a move that U S  lawmakers and Presidential candidate Hillary Clinton said was not enough  EpiPen cost about  100 in 2008  Mylan said on Monday it expected to launch the generic product  in several weeks   an unusual move considering the branded bestseller is still patent protected and major rival treatments have failed to get regulatory clearances   Our decision to launch a generic alternative to EpiPen is an extraordinary commercial response   Chief Executive Heather Bresch said Monday   We determined that bypassing the brand system in this case and offering an additional alternative was the best option   Mylan s price move failed to squelch criticism of the company s huge price increase for EpiPen since it acquired the product in 2007  The U S  House Committee on Oversight and Government Reform sent a letter to Mylan s CEO on Monday seeking documents on EpiPen pricing  including those relating to revenue from EpiPen sales since 2007  manufacturing costs  and the amount of money the company receives from federal government health care programs  And former Democratic presidential hopeful Bernie Sanders tweeted on Monday   At  300 generic EpiPens will still cost 3 times more than they did in 2007  This isn t a discount  It s a PR move   Consumer watchdog group Public Citizen said Mylan s latest move was another  convoluted mechanism to avoid plain talk   It said activists on Tuesday will deliver petitions from more than 600 000 consumers and allergy sufferers to Mylan s headquarters in Canonsburg  Pennsylvania  demanding further price cuts   We would like the company to drop the price to  100 for two EpiPens   said Public Citizen spokeswoman Angela Bradbery  adding that was about the price charged in France  She said the  petitions were gathered by it and various other consumer groups  including Consumers Union   EpiPen has a 94 percent market share for auto injector devices  which jabs a dose of the drug epinephrine into the thigh to counter dangerous allergic reactions such as to peanuts  food allergies and bee stings  The biggest danger is an allergic reaction called anaphylaxis that could cause death if untreated   Its only U S  competitor is Adrenaclick  a device sold by Impax Laboratories  O IPXL  that has not caught on with patients and doctors  The product  which is assembled by hand and is not considered by regulators to be an exact copy of EpiPen  has a list price of more than  400   Impax spokesman Mark Donohue declined to comment on whether the company would lower Adrenaclick s list price given the planned cheaper price of Mylan s generic Dr  Howard Selinger  chairman of family medicine at Quinnipiac University  said he has only written two prescriptions for Adrenaclick because it is not much cheaper than EpiPen  Many other doctors do not even know the product s name because of EpiPen s long domination  he said  Industry analysts said the biggest potential threat to EpiPen is a similar device being developed by rival generic drugmaker Teva Pharmaceutical  NYSE TEVA  Industries Ltd  TA TEVA   The U S  Food and Drug Administration in February declined to approve the product because of dosing problems  But some analysts believe Teva  after fixing the issue  could re apply for approval and have its product on the market as soon as next year  and win considerable market share  Sanofi SA  PA SASY  pulled its own device from the market last year  also on concerns of inaccurate dosage  It returned rights to the product to tiny privately held drugmaker Kaleo  Mylan has defended EpiPen s high price  saying it had spent hundreds of millions of dollars to improve the product since acquiring it in 2007  It has said it recoups less than half the list price as pharmacy benefit managers  PBM   which often require discounted prices or rebates from drugmakers  are involved  along with insurers and others  Mylan shares closed up 0 4 percent at  43 22 on the Nasdaq  amid a moderate upturn for the broader stock market  The stock had fallen 12 percent last week amid a wave of criticism over prices of EpiPen  which generates annual sales of  1 billion  Bernstein analyst Ronny Gal said though Mylan had  infinite possibilities  to handle the outcry over EpiPen prices  the generic launch was  the big one  and would help PBMs cap their costs  However  he expects Mylan to still come under fire for its prices and U S  health regulators to face more pressure to approve competing treatments  Some lawmakers last week asked the Food and Drug Administration about its approval process for rival treatments  Leerink Partners said that the generic launch only removed a near term pricing lever for Mylan as they expect the launch of Teva s version in 2018 to become a pricing headwind  
Mylan is the latest company to be caught up in the growing outrage over drug price increases  Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX  and Turing Pharmaceuticals have both been publicly excoriated for similar price increases ",2016-08-29,Reuters,https://www.investing.com/news/stock-market-news/mylan-to-launch-first-generic-to-epipen-allergy-injection-422833,422833
147916,369432,BHC,Valeant is sued over Philidor ties  alleged racketeering,news,"By Jonathan Stempel Valeant Pharmaceuticals International Inc  TO VRX   N VRX  was sued on Monday by buyers of its drugs  who accused the Canadian company of racketeering by forcing them to pay exorbitant prices  The proposed class action complaint was filed in the U S  District Court in Manhattan on behalf of unionized New York City police detectives and hotel workers  regarding Valeant s ties to the now defunct specialty pharmacy Philidor RX Services LLC  The plaintiffs accused Valeant of violating the U S  Racketeer Influenced and Corrupt Organizations Act  and seeks compensatory and triple damages for U S  health plans and others that bought its drugs from January 2013 to October 2015  Valeant did not immediately respond to requests for comment  U S  prosecutors are probing whether Valeant defrauded insurers by shrouding its ties to Philidor  the Wall Street Journal reported on Aug  10  citing people familiar with the matter  Investigators are looking at the companies  disclosures to insurers  a person familiar with the matter has told Reuters  According to Monday s complaint  Valeant steered patients and doctors away from generic equivalents and toward its branded drugs through a network of pharmacies linked to Philidor  By hiding its ties to Philidor  the complaint said  Valeant created artificial demand that let it drive up prices  including by more than 800 percent for diabetes drug Glumetza  If the Laval  Quebec based company had not done this  the plaintiffs  would have denied claims submitted by pharmacies in the Valeant Enterprise and insisted on the substitution of generic equivalents   the complaint said  Plaintiffs include the Detectives Endowment Association of the City of New York  which represents 17 500 active and retired detectives  and the New York Hotel Trades Council   Hotel Association of New York City Inc Health Benefits Fund  which serves active and retired hotel workers  
Other defendants include former Philidor Chief Executive Officer Andrew Davenport and his brother Matthew  which the complaint said held himself out as CEO in documents filed with the California State Board of Pharmacy  Neither could be reached immediately for comment  In afternoon trading  Valeant shares were down nearly 2 percent at C 39 38 in Toronto  and down 2 percent at  30 23 in New York  The case is New York Hotel Trades Council   Hotel Association of New York City Inc Health Benefits Fund et al v  Valeant Pharmaceuticals International Inc et al  U S  District Court  Southern District of New York  No  16 06779 ",2016-08-29,Reuters,"https://www.investing.com/news/stock-market-news/valeant-is-sued-over-philidor-ties,-alleged-racketeering-422950",422950
147917,369433,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 60 ,news,"Investing com   Canada stocks were lower after the close on Wednesday  as losses in the Energy  Healthcare and Materials sectors led shares lower 
At the close in Toronto  the S P TSX Composite declined 0 60  
The best performers of the session on the S P TSX Composite were  CCL Industries Inc   TO CCLb   which rose 3 37  or 8 15 points to trade at 250 25 at the close  Meanwhile   Bombardier Inc   TO BBDb  added 2 87  or 0 060 points to end at 2 150 and  Transcontinental Inc   TO TCLa  was up 2 78  or 0 52 points to 19 20 in late trade 
The worst performers of the session were Eldorado Gold Corporation  TO ELD   which fell 6 46  or 0 29 points to trade at 4 20 at the close   B2Gold Corp   TO BTO  declined 4 35  or 0 150 points to end at 3 300 and Valeant Pharmaceuticals International Inc  TO VRX  was down 3 81  or 1 51 points to 38 09 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 667 to 468 and 153 ended unchanged 
Shares in CCL Industries Inc  TO CCLb  rose to all time highs  rising 3 37  or 8 15 to 250 25  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 3 00  to 14 74 
Gold for December delivery was down 0 36  or 4 75 to  1311 75 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in October fell 3 28  or 1 52 to hit  44 83 a barrel  while the November Brent oil contract fell 3 59  or 1 75 to trade at  46 98 a barrel 
CAD USD was down 0 12  to 0 7625  while CAD EUR fell 0 23  to 0 6835 
The US Dollar Index was down 0 02  at 96 03 ",2016-08-31,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-0.60-423497,423497
147918,369434,BHC,Ackman s Pershing Square Holdings gains 5 8 percent in August,news,"By Svea Herbst Bayliss BOSTON  Reuters    Billionaire investor William Ackman s portfolios climbed nearly 6 percent in August  boosted by strong gains at drug company Valeant Pharmaceuticals International Inc  NYSE VRX  where changes that the hedge fund manager has helped push for appear to be instilling new confidence  Pershing Square  NYSE SQ  Holdings  one of the hedge fund s portfolios  climbed 5 8 percent last month  shrinking its loss for the year to 14 3 percent  an investor in the fund said  In March the fund had been down 25 6 percent  Valeant gained roughly 39 percent in the last month  A year ago  Valeant s stock began cratering amid questions about the company s business and accounting practices and its stock price is still down 87 percent in the last 52 weeks  In the last few weeks  it began recovering as the company s new chief executive officer eased worries about a possible default and the company hired a new chief legal officer and chief financial officer  Similarly bets on quick service restaurant company Restaurant Brands International and snack food maker Mondelez proved helpful  Other hedge funds also told their clients that they scored gains in August  Jana Partners  an activist fund like Ackman s Pershing Square  was up 1 percent in August  shrinking its year to date loss to 3 percent  an investor in the fund said  
Citadel s Wellington fund gained 2 4 percent in August and is now up 0 5 percent for the year  a person familiar with the figures said ",2016-09-01,Reuters,https://www.investing.com/news/stock-market-news/ackman's-pershing-square-holdings-gains-5.8-percent-in-august-423815,423815
147919,369435,BHC,Activist Starboard demands rapid changes at Perrigo,news,By Michael Flaherty NEW YORK  Reuters    Activist shareholder Starboard Value LP on Monday disclosed a 4 6 percent stake in  Perrigo Co  Plc  N PRGO  and said the Dublin based drugmaker must make immediate improvements to turn around its sagging stock price  Shares of Perrigo  whose market capitalization is around  13 billion  surged 5 7 percent to  93 81 in midday trading  The hedge fund delivered a scathing letter to Perrigo s chief executive officer  John Hendrickson  and its board on Monday  criticizing their performance since the company spurned a seven month takeover effort by generic drug maker Mylan NV  O MYL  late last year  Perrigo acknowledged receiving the letter and said it was looking forward to a  constructive and productive dialogue  with Starboard   Hendrickson replaced longtime CEO Joseph Papa  who left to head Valeant Pharmaceuticals International Inc  N VRX  in early May  Since then  Hendrickson has cut earnings expectations twice and said the company suffered during Papa s battle with Mylan  Papa in the summer of 2015 convinced investors that they would be better off refusing Mylan s  205 per share cash and stock offer  saying they could earn more if Perrigo stood alone   Unfortunately  since that time  results have gone decidedly in the wrong direction  and management s promises have been woefully unfulfilled   Starboard said  Starboard said the drugmaker should consider hiring an investment bank for advice on selling non core assets or broader strategic alternatives   The letter identifies Perrigo s prescription pharma business  known as Rx Pharmaceuticals  as one that would be attractive to other companies  It also said Perrigo should consider selling its stream of royalties from the drug Tysabri  used to treat multiple sclerosis    The most likely angle is to drive a sale of both Rx Tysabri  which could then lead to strategic interest in standalone Consumer   said RBC Capital in a research note on Monday  RBC has a  sector perform  rating on the stock  Starboard often pushes for board representation and has started more campaigns this year against companies than any other activist shareholder  according to Thomson Reuters data  Starboard is currently seeking to control the board of another pharmaceutical company   Depomed  Inc  O DEPO   which successfully resisted a hostile bid from Horizon Pharmaceutical Corp  O HZNP  last year   Starboard s letter also criticized Perrigo s management for spending  100 million to thwart Mylan s bid and for receiving bonuses for its successful defense while the company s stock has dropped 50 percent since the offer  The fund acknowledged Hendrickson s brief role as CEO but pointed out his long tenure at the company and indicated it would not be patient in awaiting a more detailed plan for changes ,2016-09-12,Reuters,https://www.investing.com/news/stock-market-news/activist-starboard-demands-rapid-changes-at-perrigo-425564,425564
147925,369441,BHC,Bill Miller  Valeant shares could post 25 30 percent returns over five years,news,"NEW YORK  Reuters    Noted value investor Bill Miller said on Tuesday that Valeant Pharmaceuticals International Inc  NYSE VRX   the troubled Canadian drugmaker  is one of his top holdings  with the company s expected cash flows making the stock attractive  Valeant s market value has fallen by some 90 percent in the last year as the company s drug pricing and other business practices prompted investigations by multiple U S  government agencies and by Congress   We think with Valeant right now  it s a completely different company   Miller said at the CNBC Institutional Investor Delivering Alpha Conference in New York   It s just a slow growth specialty pharma company that will generate a lot of free cash and you should be able to make  I think  25 to 30 percent on Valeant over the next five years   Miller  the founder and chairman of LMM  said he sees no realistic probability of government action to control drug pricing  saying there are just  lots of hearings  lots of headline risk   Valeant came under fire after it raised the price of two heart medications  Isuprel and Nitropress  by about 720 percent and 310 percent  respectively  after acquiring the drugs in 2015  Miller estimated Valeant s free cash flow yield at 25 to 30 percent   The market believes the risk is super high and I just think the free cash flows will be there   Valeant first came under scrutiny from New York prosecutors last October over its drug pricing and distribution  Media also reported at the time that it used pharmacy Philidor Rx Services to overcome insurer rejections to reimbursing its medications  with Philidor resubmitting claims to insurers until they were approved   On the broader stock market  Miller said his so called best idea was to go long on the Standard   Poor s 500 and short on the 10 year Treasury note   
 You re talking a 6 percent rate of return on stocks versus 1 5 percent return on the 10 year Treasury   Miller said   It strikes me that as I think  hedge fund investor  Paul Singer said   Treasuries are hardly a risk free asset   and I think the environment right now is the exact opposite of September 1987  ",2016-09-13,Reuters,https://www.investing.com/news/stock-market-news/bill-miller:-valeant-shares-could-post-25-30-percent-returns-over-five-years-425956,425956
147928,369444,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 67 ,news,"Investing com   Canada stocks were lower after the close on Friday  as losses in the Energy  Materials and REITs sectors led shares lower 
At the close in Toronto  the S P TSX Composite lost 0 67  
The best performers of the session on the S P TSX Composite were  Teck Resources Ltd   TO TCKb   which rose 7 54  or 1 68 points to trade at 23 95 at the close  Meanwhile   Dominion Diamond Corp   TO DDC  added 4 53  or 0 53 points to end at 12 22 and Valeant Pharmaceuticals International Inc  TO VRX  was up 4 19  or 1 47 points to 36 54 in late trade 
The worst performers of the session were  First Majestic Silver  Corp   TO FR   which fell 5 18  or 0 81 points to trade at 14 82 at the close   Seven Generations Energy Ltd   TO VII  declined 4 89  or 1 55 points to end at 30 16 and  Endeavour Mining Corp   TO EDV  was down 4 70  or 1 250 points to 25 360 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 686 to 461 and 133 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 4 94  to 13 18 
Gold for December delivery was down 0 27  or 3 65 to  1341 05 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in November fell 3 52  or 1 63 to hit  44 69 a barrel  while the November Brent oil contract fell 3 32  or 1 58 to trade at  46 07 a barrel 
CAD USD was down 0 94  to 0 7594  while CAD EUR fell 1 16  to 0 6761 
The US Dollar Index was up 0 07  at 95 38 ",2016-09-23,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-0.67-428195,428195
147929,369445,BHC,Valeant Pharmaceuticals  VRX  Stock  More Declines To Come,opinion,"Valeant Pharmaceuticals Intl Inc  NYSE VRX  
Valeant Pharmaceuticals has had a rough time over the past several months  and for good reason  A few months ago  there were big concerns among investors with regard to the relationship between Valeant Pharmaceuticals and a pharmacy known as Philidor  Since then  there has been some good and some bad news with regard to the company  Nonetheless  investors are pushing the stock downward  Today we ll talk about the relationship between Valeant and Philidor  what we ve seen from the company since the cancellation of the agreement  and what we can expect to see from VRX moving forward 
Valeant and Philidor
As mentioned above  last year there were several questions with regard to the relationship between VRX and an underground pharmacy known as Philidor  Philidor just so happened to be one of Valeant s largest customers  but there was very little information about the company  Perhaps more importantly  investors were concerned that VRX may have owned a stake in Philidor  giving them the ability to hid specific financial data in an attempt o make VRX look better on earnings reports  At the time  some investors even started to call Valeant Pharmaceuticals the Enron of the pharmaceutical industry  Soon  VRX would cut ties with Philidor  While the fact that the relationship between the two companies was coming to an end excited investors  this led to concerns of its own  Because Philidor was Valeant s largest customer  sales would surely fall  and fall dramatically  As a result  we saw massive declines in VRX for quite some time following the cancellation of the agreement between the two companies 
What Has Happened Since Philidor
Canceling the relationship with Philidor was a big hit to VRX  As mentioned above  Philidor was Valeant s largest customer  However  since the cancellation  there has been some good and some bad news from the company  Here s what we ve seen 
The Good News   The good news that we ve seen from VRX since the Philidor issue has quite a bit to do with Walgreens  NASDAQ WBA   Shortly following the news of Philidor  VRX signed an agreement with Walgreens that would make their medications largely available in Walgreens pharmacies  This is expected to increase sales in a big way  However  it s not likely to be enough to make up the losses we saw as the result of the cancellation with Philidor entirely 
The Bad News   The bad news is that VRX is getting quite a bit of political pressure  You see  VRX is known for increasing the prices of its medications on the drop of a dime  In fact  it can be argued that excessive costs of medications were what made Valeant the incredibly profitable company it has become  However  we ve seen quite a few conversations with regard to price gouging in the medical space lately  and VRX just so happens to be in the center of these conversations  As a result  investors are fearful that Valeant may be investigated and forced to reduce its prices of some of its most profitable medications 
Where VRX Is Headed From Here
While I will say that I believe Valeant is going to be just fine in the long run  at the moment  there is quite a bit of uncertainty  The company has still yet to make up for the loss in sales as the result of the agreement cancellation with Philidor  On top of that  there s quite a bit of uncertainty with regard to what s coming down the line in terms of drug pricing  The truth is that there are few things that scare investors quite like uncertainty  As a result  I m expecting to see further downward movement until VRX offers a clear path and the political issues with regard to pricing dissipate 
What Do You Think 
Where do you think VRX is headed and why ",2016-03-05,Modest Money,https://www.investing.com/analysis/valeant-pharmaceuticals-(vrx)-stock:-more-declines-to-come-200120507,200120507
147930,369446,BHC,Here s Why Valeant s Gaining,opinion,"VRX Announces 3 Additions To It s Board
Early this morning  Valeant Pharmaceuticals  NYSE VRX  announced that it has added new independent members to its board of directors  In fact  it has added three new independent directors  This is a much needed move considering the issues that the company has faced over the past several months  The additions to the VRX Board of Directors include   
Stephen Fraidin   Stephen Fraidin is the vice chairman of Pershing Square  Capital  According to Reuters  Pershing Square Capital Management is one of the largest investors with VRX  owning about 16 5 million shares 
Fred Eshelman   Fred Eshelman is the former CEO of Pharmaceutical Product Development 
Thomas Ross   Thomas Ross has severed as the president of the University of North Carolina 
In addition to the new additions to the company s board of directors  Anders Lonner has stepped down as director at the company  In a statement  Robert Ingram  chairman of the VRX Board of Directors had the following to say about the changes 

Fred s extensive experience in the pharmaceutical industry  Steve s business  legal and corporate governance acumen  and Tom s broad public policy expertise are valuable additions to the Board as we strengthen the company s corporate governance practices and move the company forward   

How The Market Reacted To The News
As investors  we know that the news ultimately moves the market  The news that new members of the Board of Directors were added were added is incredibly good news  and will likely lead to solid changes in the company  As a result  we re seeing strong movement in the value of VRX today  Currently  10 47   VRX is trading at  65 36 per share after a gain of  2 21 per share or 3 50  
Why I Maintain A Bullish Opinion On VRX
When it comes to Valeant Pharmaceuticals  the news released today is just another bit of news that lends to the bullish opinion I maintain with regard to the stock  The company has been through quite a bit in a relatively short period of time  and to regain faith among investors  a management shift is a great move  However  it s not the only reason I m bullish on VRX  Here are some others   

VRX And Walgreens  NASDAQ WBA    Valeant s problems started as the result of its relationship with Philidor  an underground pharmacy that seemed to be doing things the wrong way  While Philidor was Valeant s largest customer  it was pressured by investors to cut ties with the pharmacy  As a result  VRX gave up quite a bit in revenue from the sales of their treatments at Philidor  Nonetheless  VRX has made up a large portion of the lost sales due to its newly found relationship with Walgreens 


VRX Price   Another factor that makes me bullish on Valeant Pharmaceuticals is the price at which the stock is trading  Following tremendous downtrends as a result of the Philidor issue  VRX is trading at an incredibly low price  While the company s prescription sales are recovering  the price of the stock isn t gaining quite as much  making it undervalued in my eyes 


Positive Strategic Changes   Since the Philidor issue  VRX has made several positive strategic changes  one of which happened today when the new members were added to the board of directors 

The bottom line here is that Valeant Pharmaceuticals is a great company  While it has been dealing with more than its fair share of issues  the company has proven its ability to overcome issues in the past  and I m expecting no different today  All in all  I m expecting to see great things out of VRX moving forward ",2016-03-09,Joshua Rodriguez,https://www.investing.com/analysis/valeant-pharmaceuticals-(vrx)-stock:-heres-why-its-gaining-200120993,200120993
147931,369447,BHC,SPY Remains In Consolidation Mode,opinion,"  These are my thoughts on the SPDR S P 500  NYSE SPY  ETF in my Daily Trade Ideas  which includes many  many more charts and setups   
 What you get by achieving your goals is not as important as what you become by achieving your goals     Zig Ziglar
Today was so full of chop  and the chop came upon us very quickly  making it pretty obvious it s just the algos and computers ripping markets around and hurting those who are a bit too eager to try to get into this market 
I had a small short position in NYSE VRX from Tuesday  and then after the close the company announced they had some new board members and this made the stocks move up overnight 
I took about a  2 loss per share early in the day and it would have been worse had I held 
Nothing wrong with trying  but having success remains very tricky in this market  so I m all cash and looking to stay there until better setups complete and they are getting there 

SPY remains in consolidation mode  which is great 
Not much to do these days as I wait for setups to form  but I say often in markets like this that it s key to preserve your mental and real capital and not get chopped up 
Waiting for setups is key  albeit a bit on the boring side  but it s part of the game 
Have a nice night ",2016-03-10,Warren Bevan,https://www.investing.com/analysis/setting-up-bases-200121068,200121068
147932,369448,BHC,Valeant  Expect Declines After Earnings,opinion,"Valeant Pharmaceuticals  NYSE VRX  has been dealing with a very rough time as of late  While I would like to say the struggle is over  I don t believe that to be the case  Don t get me wrong  I ve said it before and I ll say it again  in the long run  I m expecting to see great things out of VRX  However  I believe that the company is going to hit its last hurdle before long term growth tomorrow morning  Today  we ll talk about what that hurdle is  what we can expect to see in the short term  and what we can expect to see in the long term outlook with regard to VRX 
Valeant Pharmaceuticals Is Set To Disappoint On Earnings
VRX is expected to release its earnings report for the fourth quarter of 2015 after the before the market opens tomorrow  This is what I believe will be the next  and hopefully the last hurdle for VRX to get over before we can expect to see long term growth  During the quarter  analysts have estimated that we will see  2 61 in earnings per share on revenue in the amount of  2 75 billion  If this were the case  we would see incredible year over year growth from in both EPS and revenue from  2 58 and  2 28 billion respectively  This would be great  but in reality  it doesn t seem as though this is going to happen 
The truth is that in the fourth quarter  Valeant Pharmaceuticals hit a brick wall  It was in this quarter that Citron started accusing VRX of being the Enron of the pharmaceutical industry  citing their relationship with an underground pharmacy known as Philidor as the reason they have been able to manipulate investors  As a result  Valeant was forced to cancel its agreement with Philidor  their biggest customer  This undoubtedly will cost VRX a massive amount of revenue and likely cause earnings to dive  So  I m expecting for VRX to miss earnings expectations  leading to investor fears 
What We Can Expect To See From Valeant Pharmaceuticals In The Short Term
In the short term  I have a very bearish opinion of what we can expect to see  The truth is that I think that VRX is going to dive on earnings  As investors  we know that there are few pieces of news that have the ability to move the needle in the market quite like earnings  So  with the poor earnings expectations  I m expecting for investors to react in a negative way  So tomorrow  and likely throughout the rest of the week  I m expecting to see declines on VRX 
What We Can Expect In The Long Run
In the long run  I have an overwhelmingly bullish opinion of what we can expect to see from Valeant Pharmaceuticals  While the company has struggled as of late with regard to the Philidor issue and the fact that the CEO of the company was on medical leave for more than a month  I believe that when we talk about VRX  we re talking about a strong company  I have no doubt in my mind that VRX has the ability to make a comeback from the lows we re seeing on the stock and the declines we re likely to see tomorrow  The reality is that they are already seeing a strong recovery in prescription numbers thanks to their relationship with Walgreens  On top of that  the company has a long line of incredible products  a great management team  and perhaps most importantly  an impressive track record of success  All in all  while there is a reason to be bearish in the short run  I m expecting to see long term gains from Valeant Pharmaceuticals ",2016-03-14,Joshua Rodriguez,https://www.investing.com/analysis/valeant-pharmaceuticals-(vrx)-stock:-expect-declines-after-earnings-200121526,200121526
147933,369449,BHC,Valeant Rips Through Health Care Sector,opinion,"Sympathetic selling pressure spawned by the Valeant Pharmaceuticals  NYSE VRX  debacle has negatively impacted the entire health care sector  which has pressed from its recent high at 68 55  print basis  into the 67 00 key  near term support zone 
A new reaction low print of 66 75 will trigger a near term sell signal that will project Health Care Select Sector SPDR  NYSE XLV  into the 65 25 65 00 area 
That s said  I m keeping my protective stop at 66 75 intraday in our Model ",2016-03-16,Mike Paulenoff,https://www.investing.com/analysis/valeant-rips-through-health-care-sector-200121842,200121842
147934,369450,BHC,Valeant Pharmaceuticals  The Perils Of The Debt Acquisition Model ,opinion,"Valeant Pharmaceuticals  NYSE VRX  need a  fix it  third party to come in stop the bleeding  Moreover  the current management team is stuck in the deer in headlights mode  and needs to start taking proactive steps to resolve the overhangs that our weighing down investor confidence on the street 
Below you find the video",2016-03-20,EconMatters,https://www.investing.com/analysis/valeant-pharmaceuticals---the-perils-of-the-debt-acquisition-model-200122157,200122157
147943,369459,BHC,Valeant stock falls as report of criminal probe adds to woes,news,"NEW YORK  Reuters    Valeant Pharmaceuticals International Inc  N VRX  shares fell about 11 percent on Thursday as new details about a criminal investigation into the drugmaker reignited investor concerns about the company s past business relationship with a mail order pharmacy that sold its products  News of the investigation  reported by the Wall Street Journal on Wednesday  was a setback to the Canadian company s efforts clean up its image  with some in the market concerned it could face penalties and may have to pay more to borrow as it renegotiates debt  After the article was published  Valeant said in a statement it had disclosed it was being investigated by the U S  Attorney s Office in October and that it continued to cooperate with that probe   Concern about other investigations  which focused on its drug pricing and accounting practices  had already cut its share price by about 90 percent in one year  The stock had gained 25 percent on Tuesday after Chief Executive Officer Joseph Papa  who joined in May  outlined a plan to sell assets  pay down debt and focus on dermatology  consumer and Bausch   Lomb eyecare   Lawyers at the U S  Attorney s Manhattan office are probing whether Valeant  TO VRX  obscured from insurers its relationship with a specialty pharmacy  Philidor Rx  that helped inflate its drug sales  the Journal reported on Wednesday  citing sources  The investigation could lead to criminal charges against former Philidor executives and Valeant as a company  the report added  Laval  Quebec based Valeant s U S  listed shares were down  2 91 at  24 41  It peaked at  263 81 a year ago  The investigation reflects lingering issues facing Valeant and shows that it is  nowhere close to out of the woods   said David Neuhauser  managing director of Livermore Partners  who added his firm covered its profitable short position in Valeant this quarter  INVESTOR  POLITICAL SCRUTINY Valeant s relationship with Philidor was revealed last fall  including the aggressive tactics Philidor used to receive payment from insurers  That news as well as investor and political scrutiny of its sharp drug price increases led to several investigations into pricing and its patient assistance programs  including one by the U S  Attorney s Office in New York  Valeant has more than  30 billion in long term debt and some investors have been worried that is too much  given that it may not be able to raise prices as it did before and has moved away from its strategy of growth through serial mergers and acquisitions  Valeant cut ties with Philidor last year and overhauled its board of directors  bringing on its top investor  activist Bill Ackman  After the investigations were disclosed last year  Wall Street began expecting that there could be fines issued against the company   It is not possible for us to know how this investigation will turn or if charges will be pursued    Wells Fargo   NYSE WFC  analyst David Maris said in a client note   We believe that with Valeant having such high debt  the impact of financial or commercial penalties is high   Papa told Canadian business channel BNN on Thursday that he did not want to speculate on the likelihood or magnitude of any fine   He said his sense was a resolution was  several years off  based on the track record of such probes   We know there are some issues out there and we are going to work and cooperate fully   he said   Mizuho Securities analyst Irina Koffler wrote that Valeant s credit may now be perceived as riskier and that the company may have to pay higher interest rates under loan amendments it is negotiating  
Reuters  citing sources  reported earlier this week that Valeant is offering to pay lenders a higher interest rate in order to obtain an amendment to its debt agreement that would loosen one of its covenants ",2016-08-11,Reuters,https://www.investing.com/news/stock-market-news/valeant-stock-falls-as-report-of-criminal-probe-adds-to-woes-419833,419833
147945,369461,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 20 ,news,"Investing com   Canada stocks were higher after the close on Monday  as gains in the Energy  Healthcare and Clean Technology sectors led shares higher 
At the close in Toronto  the S P TSX Composite gained 0 20  
The best performers of the session on the S P TSX Composite were Canadian Energy Services   Technology Corp  TO CEU   which rose 6 97  or 0 280 points to trade at 4 300 at the close  Meanwhile  Valeant Pharmaceuticals International Inc  TO VRX  added 6 31  or 2 04 points to end at 34 36 and  Badger Daylighting Ltd    TO BAD  was up 5 99  or 1 48 points to 26 20 in late trade 
The worst performers of the session were  Concordia Healthcare  Corp  TO CXR   which fell 6 02  or 0 78 points to trade at 12 17 at the close   B2Gold Corp   TO BTO  declined 4 68  or 0 210 points to end at 4 280 and  First Majestic Silver  Corp   TO FR  was down 3 79  or 0 89 points to 22 57 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 720 to 429 and 134 ended unchanged 
Shares in Concordia Healthcare Corp  TO CXR  fell to 52 week lows  down 6 02  or 0 78 to 12 17  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 22 16  to 13 67 
Gold for December delivery was up 0 11  or 1 45 to  1344 65 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in September rose 2 81  or 1 25 to hit  45 74 a barrel  while the October Brent oil contract rose 2 92  or 1 37 to trade at  48 34 a barrel 
CAD USD was up 0 27  to 0 7740  while CAD EUR rose 0 10  to 0 6921 
The US Dollar Index was down 0 09  at 95 59 ",2016-08-15,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.20-420447,420447
147948,369464,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 04 ,news,"Investing com   Canada stocks were lower after the close on Wednesday  as losses in the Materials  Energy and IT sectors led shares lower 
At the close in Toronto  the S P TSX Composite declined 0 04  
The best performers of the session on the S P TSX Composite were Valeant Pharmaceuticals International Inc  TO VRX   which rose 12 64  or 4 32 points to trade at 38 51 at the close  Meanwhile   Transcontinental Inc   TO TCLa  added 4 04  or 0 73 points to end at 18 82 and  Just Energy Group Inc    TO JE  was up 3 81  or 0 27 points to 7 36 in late trade 
The worst performers of the session were  HudBay Minerals  Inc   TO HBM   which fell 3 89  or 0 24 points to trade at 5 93 at the close   MAG Silver Corp    TO MAG  declined 3 53  or 0 79 points to end at 21 57 and Interfor Corp  TO IFP  was down 3 46  or 0 53 points to 14 80 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 673 to 466 and 143 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 8 44  to 13 46 
Gold for December delivery was down 0 29  or 4 00 to  1352 90 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in September rose 0 60  or 0 28 to hit  46 86 a barrel  while the October Brent oil contract rose 1 18  or 0 58 to trade at  49 81 a barrel 
CAD USD was up 0 19  to 0 7785  while CAD EUR rose 0 01  to 0 6894 
The US Dollar Index was down 0 03  at 94 72 ",2016-08-17,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-0.04-420929,420929
147950,369466,BHC,Valeant amends credit facility for second time in six months,news," Reuters    Valeant Pharmaceuticals International Inc  TO VRX   N VRX  said its lenders had approved an amendment to its credit facility  giving the drugmaker more flexibility to sell assets and repay loans by taking on other debt  The embattled drugmaker  which is amending its credit agreement for the second time in six months  agreed to increase the interest on the facility by 0 50 percent  it said in a statement on Thursday  The company s shares were up 5 3 percent at  31 58 in premarket trading  Valeant  whose long term debt stood at about  31 billion as of June 30  had asked lenders in March to amend its credit agreement to give it more time to file its financials  Reuters reported last week that Valeant offered to pay lenders higher rates to win approval for an amendment  The drugmaker has been working to restore investor trust after a year of bad news and said last week that it would sell billions of dollars of non core assets and could accept offers for its main businesses  Last fall  political concerns about Valeant s sharp drug price increases and investor scrutiny of its dealings with pharmacy Philidor RX sent Valeant s shares plunging  
Congress and several U S  government agencies also opened investigations and the company restated earnings earlier this year ",2016-08-18,Reuters,https://www.investing.com/news/stock-market-news/valeant-amends-credit-facility-for-second-time-in-six-months-421092,421092
147951,369467,BHC,Bill Ackman And Some Perspective On The Index Bubble,opinion,"He s often controversial  and usually pretty brash  But Pershing Square s  is also usually quite insightful  He s been at this game a long time  and he s had his share of big wins  and big losses  Ackman has an ego on him   What hedge fund manager doesn t   But he s also his own biggest critics  and like all good investors he learns from his mistakes 
Today  let s take a look at Ackman s   which came out last week  Ackman  like a lot of hedgies  had a terrible 2015  Here were some of his takeaways 
Not All Valuation Metrics are Equal
Ackman bet big on Valeant Pharmaceuticals  N VRX   and lost big when the stock rolled over  Per Ackman 

Principally  we missed the opportunity to trim or sell outright certain positions that approached our estimate of intrinsic value  Our biggest valuation error was assigning too much value to the so called  platform value  in certain of our holdings  We believe that  platform value  is real  but  as we have been painfully reminded  it is a much more ephemeral form of value than pharmaceutical products  operating businesses  real estate  or other assets as it depends on access to low cost capital  uniquely talented members of management  and the pricing environment for transactions   Emphasis Sizemore 

Charles here  I learned a similar lesson in 2015  Just as Ackman lost money in an acquisition hungry pharma stock  I lost money in MLPs  small cap REITs and business development companies   three sectors that would normally have very little in common  But the tie that bound them was their dependence on the capital markets for fresh funding  When the credit markets got skittish  Mr  Market relentlessly punished these sectors  and two of my holdings   Kinder Morgan  N KMI  and Teekay Corporation  N TK  were forced to slash their dividends 
Know Who You re In Bed With
Due to Ackman s high profile  he tends to attract copycats  I myself have been guilty of perusing his SEC disclosures  This creates risks of its own 

Perhaps the largest correlation in our portfolio is one that we have not previously considered  that is  the fact that we own large stakes in each of these companies  We have had the benefit of a  following  of investors who track and own many of our holdings  This has given us significantly greater clout than is reflected by our percentage ownership of these companies  and we believe that it is partially what has caused the  pop  in market price when we announce a new active investment  As a result  these active managers  performance is often closely tied with ours  When Valeant s stock price collapsed  our performance  and that of Pershing Square  N SQ  followers  were dramatically affected  Nearly all of these investment managers are subject to daily  monthly  and quarterly redemptions  and therefore  many were likely forced to liquidate substantial portions of their holdings which overlap with our own 
While it is impossible to know for sure  we believe that our continued negative outperformance in the first few weeks of the year relates primarily to forced selling of our holdings by investors whose stakes overlap with our own 

This raises a bigger issue of simply considering who the major holders of your stocks are and what their constraints or motivations might be  Returning to my own losses last year  The selloff in MLP shares was massively exacerbated by mutual funds  ETFs and   most importantly   leveraged closed end funds and hedge funds that were forced to liquidate to meet redemptions or margin calls  This were holders that were forced to sell at whatever price the market gave them 
The Index Fund Bubble  And What It Means
Finally  Bill Ackman has some insightful comments about the  bubble  in indexing  Given the lousy performance of active managers over the past decade  it s easy to see why investors continue to flock to index funds  They are cheaper in terms of fees  more tax efficient and have had better returns of late 
But here s the problem  Indexing only works when their are a sufficient number of active managers to make the market at least semi efficient  If everyone becomes a passive indexer  then the returns of the major indexes will start to lag in a major way as the stocks in the index become overowned and overpriced 
But there are other considerations too  Passive ownership essentially gives management a free pass and allows lousy management teams to stay entrenched 
As Ackman writes 

As index fund ownership grows as a percentage of shares outstanding  the voting power of index fund managers increases  While on the one hand  one might believe this is good for America as these  permanent  owners should think very long term compared with the many investors whose average holding period is less than one year 
On the other hand  there are significant drawbacks  While index fund managers are  of course  fiduciaries for their investors  the job of overseeing the governance of the tens of thousands of companies for which they are major shareholders is an incredibly burdensome and almost impossible job  Imagine having to read 20 000 proxy statements which arrive in February and March and having to vote them by May when you have not likely read the annual report  spent little time  if any  with the management or board members  and haven t been schooled in the industries which comprise the index 

Of course  this is impossible  Index managers are passive and will generally toe the line for management  Ackman points out some very significant long term effects of this  asking the proverbial question of what happens when index funds effectively control corporate America 

If the index fund trend continues  and it looks likely to do so  what happens when index funds control Corporate America  Courts have often deemed shareholders to be in control of a corporation with as little as 20  of the ownership of a company  At current rates of asset inflows  it will not be long before index funds effectively control Corporate America and the corporations of many foreign countries 
The Japanese system of cross corporate ownership  the keiretsu  has been blamed for decades of Japanese corporate underperformance and economic malaise  Large passive ownership of Corporate America by index funds risks a similar outcome without the counterbalancing force of large active investors 

The thought of corporate America turning Japanese should be enough to make even the biggest proponent of indexing pause for a moment 
Ackman says that the  greatest threat to index fund asset accumulation is deteriorating absolute returns and underperformance versus actively managed funds  because money flows into these funds with no consideration of value  I agree  and would add that this was the major rationale for the  smart beta  movement 
But perhaps the greatest takeaway here is simply to not give up on active management  When you invest outside of the mainstream  you will have returns that are outside of the mainstream  That means that there will be plenty of years when you underperform 
But if you re a good investor  it also means that there will be years where you massive outperform  So keep your chin up  Even hedge fund masters of the universe lose money some years 
Charles Sizemore is the principal of l  a wealth management firm in Dallas  Texas ",2016-02-05,Charles Sizemore,"https://www.investing.com/analysis/so,-bill-ackman-makes-some-good-points-on-the-index-bubble-383350",383350
147952,369468,BHC,Valeant Pharmaceuticals  Why We re Seeing Declines,opinion,"Valeant Pharmaceuticals  N VRX  is having a rough day in the market today after a series of mixed news  On the good side of the coin  CEO J  Michael Pearson  has completed a full recovery and has returned to his post at VRX  On the bad side of things  results have been delayed  leading to a bit of uncertainty  Today  we ll talk about the return of Pearson  what results were delayed  and what we can expect to see from VRX moving forward  So  let s get right to it   
J  Michael Pearson Has Returned
At possibly the worst timing  J  Michael Pearson took a medical leave from VRX more than a month ago has he suffered from a severe case of pneumonia  At this time  the stock struggled quite a bit as investors worried about the company s recovery without Pearson involved  Nonetheless  the team appointed to take on his role did incredibly well  Today  it was announced that Pearson would be returning to his post at Valeant effective immediately  This is incredibly good news  While the team appointed has done well  the company is definitely in need of Pearson s leadership 
While this is good news  there is some bad news that came along with the announcement  VRX was scheduled to report preliminary result from Q4 and provide updated guidance to investors relatively soon  However  given the timing of Pearson s return  the investors  call has to be pushed back  There is already a bit of uncertainty with regard to what investors can expect given the recent hardships Valeant Pharmaceuticals has faced  As a result  the delay adds to the uncertainty and is becoming a big reason for declines  In a statement  J  Michael Pearson had the following to say with regard to his return   
 I want to express my sincere gratitude to Howard for his willingness to step in and lead the company through a challenging period    I realize that recent events are disappointing to everyone and it is my responsibility to set the appropriate tone for the organization  My immediate priority will be to build stronger relationships with important constituents  such as managed care and other channel partners  regulators and government representatives  while improving Valeant s reporting procedures  internal controls and transparency  I will focus on the retention and enhancement of our management teams and employee groups around the world and ensure that we maintain a culture that adheres to the highest ethical standards  Finally  we expect to deliver strong operating performance going forward by working closely with physicians to better serve patients  and we remain committed to reducing our leverage  
How The Market Reacted To The News
As investors  we know that the news moves the market  In this particular case  there was a bit of good news in the fact that Pearson has made it back to VRX  However  there was also a bit of bad news in the fact that results and guidance are being delayed  Given the current circumstances revolving around Valeant  the delay in results and guidance is leading to investor fear  As a result  we re seeing sharp declines in the value of the stock today  Currently  10 10   VRX is trading at  73 20 per share after a loss of  7 45 per share or 9 24  thus far today 
What We Can Expect To See Moving Forward
While I know I m probably going to catch some flack for the bears for my opinion here  I believe that we re going to see relatively positive movement out of VRX moving forward  The reality is that when we talk about Valeant  we re talking about an incredible company  While they have had to get over hurdles as of late  the company has a long list of great products and has put together a solid plan for growth  Now that Pearson is back  I m expecting for things to move in the right direction relatively quickly  All in all  my view of VRX is positive ",2016-02-29,Joshua Rodriguez,https://www.investing.com/analysis/valeant-pharmaceuticals-(vrx)-stock:-why-were-seeing-declines-today-200119880,200119880
147953,369469,BHC,5 Stocks With Heavy Downward Revisions Heading Into This Week s Reports ,opinion,"Monday  February 29

Thursday  March 3

Friday  March 4


Hertz Global Holdings  Inc   N HTZ 
Industrials   Road and Rail   Reports February 29  after the close 
The Estimize community is looking for EPS of  0 06 and revenue of  2 51 billion  one cent Wall Street on the bottom line  and around  9 million below on the top line  However  our Select Consensus  which more heavily weights historically accurate analysts and recent estimates  is in line Wall Street on earnings  and  28 million below on revenues  The Estimize community has been bearish on Hertz s profitability this quarter  pushing EPS estimates down 17  in the past three months  The company has historically beaten Wall Street on the bottom line 60  of the time while only besting the Estimize EPS consensus 25  of the time 

What to Watch  Hertz Global has been struggling to perform for the past two years mostly due to competitive pressures  Just this week  Hertz s stock took a beating following a lackluster fourth quarter earnings report from rival Avis Budget Group  O CAR   Following the announcement  shares fell over 13   having dropped a total of 45 9  since the start of 2016  Hertz has been unable to improve growth metrics as the car rental industry freefalls  Competition from ride sharing rivals like Lyft and Uber have adversely impacted Hertz s revenue growth  Last quarter the company reported a 2  decline in U S  car rental revenue  while international car rentals fell a resounding 14   largely due to weak global economic conditions  High debt obligations and weaker operating cash flow also remains a top concern  Despite its misfortunes  activist investor Carl Icahn took an interest in Hertz  purchasing a 14 3  stake in the company with the hope of rectifying fleet management issues and cost inefficiencies  This year  the company also plans to spin off its equipment lease company into a separate publicly traded company 

Stratasys  Inc   O SSYS 
Information Technology   Computers and Peripherals   Reports March 3  before the open 
The Estimize community calls for EPS of   0 08 and revenue of  168 9 million  3 cents higher than the Street on the bottom line  and roughly  4 million greater on the top line  However our Select Consensus is showing a more modest beat of 2 cents  Since November 2015  the Estimize community has been bearish on Stratasys  profitability  revising EPS estimates down 63   Compared to the same period last year  current estimates predict a YoY decline in EPS and revenue of 113  and 21   respectively 

What to Watch  Once expected to be the next big thing  Stratasys and all the other 3D printing companies had another disappointing year in 2015  After losing 38  of its value in 2014  Stratasys managed to out do itself in 2015  watching shares fall an additional 71   Negative FX headwinds have been the main scapegoat for missed earnings expectations throughout the year  This in itself has effectively hampered capital investments  as well as performance of its MakerBot business  In Q3  Stratasys reported a 55  YoY revenue decline in its MakerBot business  pressuring margins as the overall popularity of 3D printing has waned  Additionally  higher operating costs from increased investments have led investors to question the company s long term profitability  As of Q3 2015  the company has no debt  allowing Stratesys to focus on improving its products  specifically 3D printing 

Ambarella  Inc   O AMBA 
Information Technology   Semiconductors   Reports March 3  after the close 
The Estimize community is looking for EPS of  0 52 and revenue of  68 0 million  5 cents higher than the Street on the bottom line  and roughly  3 million greater on the top line  The Select Consensus is slightly more bearish  with EPS of  0 50 and a sales consensus of  66 5 million  Compared to Q4 2014  this represents a project Yoy decline on the bottom line of 23  while sales are expected to rise 6   The Estimize community has been bearish on Ambarella s earnings  revising EPS estimates down 13  and revenues down 10  in the past 3 months 

What to Watch  Video and imaging chipmaker  Ambarella  has a year it would soon like to forget  After reaching highs of  126 70 in June 2015  shares of Ambarella have plummeted 65 5  in the past 8 months  The company s weak outlook has been closely tied to the disappointing growth of its biggest customer  GoPro  O GPRO   Ambarella produces the chips inside all GoPro devices  accounting for a third of the company s sales  GoPro s dismal Q4 earnings report foreshadows equally disappointing results for Ambarella come Friday  GoPro severely missed on the bottom line  reporting a loss per share of   0 08 and a 16  decline in the number of units sold YoY  Ambarella s relationship with GoPro  which was once a blessing  has become quite the burden  Last quarter  the company warned investors that Q4 sales were only expected to rise 0 5  to 4 3   compared with to its 62  growth in the March 2015 quarter  Fortunately  Ambarella is attempting to diversify its top line away from action cameras and drones and into less volatile products 

Valeant Pharmaceuticals  N VRX 
Healthcare   Pharmaceuticals   Reports March 3  after the close 
The Estimize Select Consensus calls for EPS of  2 77  9  higher than Wall Street  while revenue expectations of  2 77 billion are roughly  27 million greater than the Street s consensus  The Estimize community has been bearish on Valeant s profitability in the past three months  revising EPS estimates down 22  and sales down 11   That said  the company has consistently delivered positive earnings surprises  beating Wall Street s EPS estimates 88  of the time 

What to Watch  In the past year  Valeant has been in the limelight for all the wrong reasons  Shares have taken a steep dive  falling 58 4  in the past 12 months following claims that the company was raising prices without discretion but also booking phantom sales under a separate company  Philidor  After vehemently denying this  Valeant announced an earnings restatement ahead of its fourth quarter earnings to reclaim  58 million worth of wrongly booked sales  Investors responded positively to the news  giving shares a 4 4  boost  The restatement is expected to be minimal  increasing FY2015 EPS by  0 09  In focus during the upcoming earnings release will be updates on Valeant s distribution partnership with Walgreens  product performance  and any ramifications following recent accounting missteps  Valeant s ability to continue consolidating with competitors and grow are largely contingent on how the company addresses its high debt level  Last quarter Valeant reported a leverage ratio of 4 87  reflecting its relatively low financial leverage  The company s recent partnership with Walgreens should help offset losses incurred after parting ways with speciality pharmacy Philidor  Through key partnerships and cost reducing strategies  Valeant is expected to cut  2 25 billion in debt by the end of 2016 

SunEdison  Inc   N SUNE 
Information Technology   Semiconductors   Reports March 4  before the open 
The Estimize consensus calls for EPS of   0 85  14 cents higher than Wall Street  with revenue expectations of  800 million around  100 million less than the Street  The Select Consensus on the other hand  is showing a greater loss on the bottom line  with EPS of   0 90  The Estimize community has maintained a pessimistic stance on SunEdison  revising EPS estimates down 20  since the company last reported  Compared to the same period last year  current estimates predict a resounding profit decline of 412   On average  the company has consistently missed on the bottom line  reporting negative earnings surprises in each of the past 3 quarters 

What to Watch  This past year has not been kind to SunEdison  The company missed profit estimates for each quarter of 2015  leading to a 92 9  decline in stock price for the year  Earnings per share losses were primarily incurred from significant increases in marketing costs and interest expenses from a high debt burden  However  top line performance and volume growth were better than expected 
The solar industry has experienced a significant downturn in recent years  as new laws and regulations have reduced the favorable subsidies these companies receive  In the third quarter  the company s G A expenses rose 135   with interest expenses nearly doubling as they work to repay a  11 7 billion debt load  As a result  SunEdison has reported a net loss of  1 16 billion in the past 12 months 
In an effort to bolster its financials  SunEdison has insisted it will refocus its solar material operations and cut costs to reach cash flow breakeven by the end of 2016  The company s sustained focus on expanding through acquisitions and strategic partnerships is an encouraging first step to reaching this goal  This past year  SunEdison entered the energy storage market with the acquisition of Solar Grid Storage and has planned to form second publicly traded company in YieldCo  Ahead of the company s fourth quarter earnings  investors will be looking for more information on acquisitions and growth initiatives to restore their confidence 
Original post",2016-03-01,Estimize,https://www.investing.com/analysis/5-stocks-with-heavy-downward-revisions-heading-into-this-weeks-reports-200119911,200119911
147954,369470,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 01 ,news,"Investing com   Canada stocks were lower after the close on Thursday  as losses in the Healthcare  Consumer Staples and Financials sectors led shares lower 
At the close in Toronto  the S P TSX Composite lost 0 01  
The best performers of the session on the S P TSX Composite were  MEG Energy Corp   TO MEG   which rose 6 83  or 0 41 points to trade at 6 41 at the close  Meanwhile  Canadian Energy Services   Technology Corp  TO CEU  added 6 13  or 0 280 points to end at 4 850 and  Encana  Corporation  TO ECA  was up 5 89  or 0 72 points to 12 95 in late trade 
The worst performers of the session were Extendicare Inc  TO EXE   which fell 3 60  or 0 32 points to trade at 8 58 at the close  Valeant Pharmaceuticals International Inc  TO VRX  declined 3 43  or 1 32 points to end at 37 19 and  West Fraser Timber Co  Ltd    TO WFT  was down 3 19  or 1 38 points to 41 92 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 622 to 495 and 155 ended unchanged 
Shares in Encana Corporation  TO ECA  rose to 52 week highs  up 5 89  or 0 72 to 12 95  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 0 67  to 13 41 
Gold for December delivery was up 0 61  or 8 25 to  1357 05 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in September rose 3 21  or 1 50 to hit  48 29 a barrel  while the October Brent oil contract rose 2 03  or 1 01 to trade at  50 86 a barrel 
CAD USD was up 0 57  to 0 7830  while CAD EUR unchanged 0 00  to 0 6895 
The US Dollar Index was down 0 61  at 94 11 ",2016-08-18,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-0.01-421171,421171
147956,369472,BHC,Early Resiliency Falls Flat,opinion,"The early gains in U S  equities dissipated as quickly as they occurred  with stocks closing at their lows  as another tumble in China and disappointing reads on the economic front overshadowed support from commodity related issues amid a rise crude oil price and further stimulus measures from China  Treasuries were mostly higher  gold saw a nice gain  while the U S  dollar was flat 
The Dow Jones Industrial Average  DJIA  declined 124 points  0 7   to 16 516 and the S P 500 Index was 16 points  0 8   lower at 1 932  and the Nasdaq Composite lost 36 points  0 7   to 4 558  In heavy volume  1 3 billion shares were traded on the NYSE and 2 0 billion shares changed hands on the Nasdaq  WTI crude oil rose  0 97 to  33 75 per barrel  wholesale gasoline increased  0 02 to  1 32 per gallon  and the Bloomberg gold spot price gained  16 44 to  1 239 90 per ounce  Elsewhere  the Dollar Index a comparison of the U S  dollar to six major world currencies was nearly unchanged at 98 17 
Valeant Pharmaceuticals International Inc   N VRX  66  announced the return of its Chief Executive Officer  CEO   J  Michael Pearson  L PSON   following his recovery from severe pneumonia and other complications  effective immediately  Also  Robert A  Ingram has been appointed Chairman of the Board as the company has separated the roles of Chairman and CEO  As a result  VRX withdrew its prior financial guidance as it will be rescheduling its previously announced call to discuss preliminary 4Q 2015 results  deliver a business review  and provide updated guidance for 2016  Separately  the company disclosed that it is under investigation by the Securities and Exchange Commission for a previously undisclosed inquiry  VRX has not indicated what the investigation is focused on  Shares were over 18  lower 
Berkshire Hathaway Inc   N BRKa   N BRKb  134  traded nicely higher after the company posted stronger than expected 4Q earnings  on revenues that rose 7 0  year over year  y y  to  51 8 billion 
Regional manufacturing and pending home sales reports miss forecasts 
Pending home sales declined 2 5  month over month  m m  in January  versus the Bloomberg projection of a 0 5  rise and following the upwardly revised 0 9  gain registered in December  Compared to last year  sales were 0 9  lower  versus forecasts of a 3 8  rise  Pending home sales reflect contract signings and are used as a gauge of the pipeline of existing home sales  which unexpectedly rose in January 
The Chicago Purchasing Managers Index fell back into contraction territory  below 50   dropping to 47 6 in February from 55 6 in January  and versus expectations of a decrease to 52 5  The index has been in contraction territory for three of the last four months  as production and new orders posted  significant declines   while employment hit the lowest since November 2009 
The Dallas Fed Manufacturing Index improved to  31 8 for February from January s unrevised  34 6 level which was the lowest since April 2009 with economists forecasting an improvement to  30 0  However  a reading below zero denotes contraction 
Today s February manufacturing reports come ahead of tomorrow s key national reads on the sector  headlined by the ISM Manufacturing Index  expected to tick higher to 48 5  from 48 2 in January  but remain in contraction territory  below 50  for the fifth straight month  However  Markit s Manufacturing PMI Index is projected to remain in expansion territory  above 50  after being revised slightly higher to 51 2 from the preliminary reading of 51 0  but down from January s 52 4 level  In addition  construction spending will be reported  with economists expecting a 0 5  m m increase for January  as well as February auto sales to be released throughout the day 
At this point the leading economic indicators continue to point to a decent U S  economic picture  Further  other indicators are not consistent with an impending recession  U S  consumers continue to improve their financial position and represent 69  of US GDP  The low unemployment rate and continued historically low initial claims for unemployment may finally be pressuring wages higher  This should help to boost consumer spending  illustrated by a nice gain in retail sales  which doesn t foretell a coming recession 
Treasuries were mixed  as the yield on the 2 year note ticked 1 basis point  bp  lower to 0 79   while the yields on the 10 year note and the 30 year bond fell 3 bps to 1 73  and 2 61   respectively 
Europe shows late day charge to finish mostly higher  Asia lower European equities finished mostly higher  courtesy of a late session rally that was led by strength in the energy sector as crude oil prices gained ground  Also  stocks found some support from the announcement out of China of further stimulus measures in the form of a cut to its banking sector reserve requirement ratio  Traders digested some mixed economic data in the region  while some expressed disappointment with the lack of any concrete stimulus measures following the G 20 meeting in Shanghai over the weekend  Also  festering pressure on the financial sector hamstrung the markets  while political uncertainty in Ireland remained on the heels of its election results over the weekend  The Eurozone s Consumer Price Index  CPI  estimate declined 0 2  y y  after January s 0 3  increase  and compared to the flat reading that economists had expected  In other economic news  German retail sales rose 0 7  m m in January  after decreasing 0 2  in the month prior  and compared to the 0 3  gain that was projected  The euro traded lower versus the U S  dollar  while bond yields in the region mostly moved to the downside 
Stocks in Asia finished mostly to the downside to begin the week  with the Chinese markets falling amid disappointment regarding the lack of an announcement of further stimulus measures over the weekend from the Chinese government and at the conclusion of the G 20 meeting in Shanghai  Also  global growth concerns remained ahead of this week s plethora of world economic data  However  after the closing bell  the People s Bank of China  PBoC  announced the reduction of the banking sector s reserve requirement ratio  RRR  the amount that banks need to keep on reserve instead of being used in the financial system by 50 bps to 17 00  
Japanese equities traded lower  with the yen rallying amid heightened risk aversion  while the nation posted some mixed economic data  The country s preliminary January industrial production rose 3 7  m m  after dropping 1 7  in December  and compared to the expected gain of 3 2   However  Japan s retail sales dropped 1 1  m m last month  on the heels of December s 0 2  decline  and versus the forecasted 0 1  increase  Stocks in India decreased as traders digested the nation s key annual budget  with some expressing disappointment regarding the tax proposals of the report  per Bloomberg  Meantime  markets in Australia finished flat  while South Korean securities were lower 
Tomorrow s international economic calendar will offer the Markit Manufacturing PMI Index from China and Japan  while the island nation will also report personal income  and employment data  South Korea s trade balance  and building approvals from Australia  From across the pond will come trade data  the Ifo Business Climate Index and GDP from Germany  while France will report confidence figures 
Schwab Center for Financial Research   SCFR   is a division of Charles Schwab  N SCHW    Co   Inc  The information contained herein is obtained from third party sources and believed to be reliable  but its accuracy or completeness is not guaranteed  This report is for informational purposes only and is not a solicitation  or a recommendation that any particular investor should purchase or sell any particular security  The investment information mentioned here may not be suitable for everyone  Each investor needs to review an investment strategy for his or her own particular situation before making any investment decision  All expressions of opinions are subject to change without notice in reaction to shifting market conditions ",2016-03-01,Marvin Clark,https://www.investing.com/analysis/early-resiliency-falls-flat-200119934,200119934
147958,369474,BHC,Valeant hires Zoetis s Paul Herendeen as CFO,news," Reuters    Valeant Pharmaceuticals International Inc  TO VRX  named  Zoetis Inc   N ZTS  executive Paul Herendeen as its chief financial officer  replacing Robert Rosiello  the latest in a series of management changes at the Canadian drugmaker  Valeant s U S  listed shares  N VRX  were up 5 percent in premarket trading on Monday  The embattled drugmaker is trying to regain investor confidence following a tumultuous past year in which its pricing strategy and ties to a specialty pharmacy led to a wider political and regulatory scrutiny  hammering its stock   Laval  Quebec based Valeant tapped  Perrigo Co  Plc s  N PRGO  Chief Executive  Joseph Papa  to replace long time CEO Michael  Pearson   LON PSON  earlier this year  Valeant also named a new general counsel and announced the departure of its public relations head earlier this month  Rosiello will remain at Valeant as executive vice president  corporate development and strategy  the company said  Zoetis on Sunday promoted Glenn David as its CFO  
Up to Friday s close of  28 74  Valeant s stock had fallen 72 percent this year ",2016-08-22,Reuters,https://www.investing.com/news/stock-market-news/valeant-names-former-zoetis-executive-paul-herendeen-as-cfo-421592,421592
147961,369477,BHC,Valeant shares jump as new CFO named ,news,Investing com   Valeant  NYSE VRX shares jump as pharmaceutical firm names new CFO Valeant was up 4 2  in pre market trade as Paul Herendeen appointed CFO  The former Zoetis executive will take over from Robert Rosiello immediately Rosiello will remain as Valeant executive vice president for corporate development ,2016-08-22,Investing.com,https://www.investing.com/news/stock-market-news/valeant-shares-jump-as-new-cfo-named-421613,421613
147963,369479,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 41 ,news,"Investing com   Canada stocks were higher after the close on Monday  as gains in the Healthcare  Consumer Staples and Real Estate sectors led shares higher 
At the close in Toronto  the S P TSX Composite gained 0 41  
The best performers of the session on the S P TSX Composite were Parkland Fuel Corporation  TO PKI   which rose 15 92  or 4 02 points to trade at 29 27 at the close  Meanwhile  Valeant Pharmaceuticals International Inc  TO VRX  added 9 71  or 3 59 points to end at 40 55 and  Alimentation Couche Tard Inc   TO ATDb  was up 7 45  or 4 63 points to 66 78 in late trade 
The worst performers of the session were  MEG Energy Corp   TO MEG   which fell 6 23  or 0 39 points to trade at 5 87 at the close   B2Gold Corp   TO BTO  declined 4 94  or 0 210 points to end at 4 040 and  Baytex Energy  Corp  TO BTE  was down 4 40  or 0 31 points to 6 74 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 598 to 550 and 133 ended unchanged 
Shares in Parkland Fuel Corporation  TO PKI  rose to all time highs  rising 15 92  or 4 02 to 29 27  Shares in Alimentation Couche Tard Inc  TO ATDb  rose to all time highs  gaining 7 45  or 4 63 to 66 78  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 5 76  to 14 14 
Gold for December delivery was down 0 28  or 3 75 to  1342 45 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in October fell 3 44  or 1 69 to hit  47 42 a barrel  while the October Brent oil contract fell 3 38  or 1 72 to trade at  49 16 a barrel 
CAD USD was down 0 72  to 0 7717  while CAD EUR fell 0 60  to 0 6820 
The US Dollar Index was up 0 03  at 94 51 ",2016-08-22,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.41-421712,421712
147966,369482,BHC,Update  Bull Market Still Depends On What This Stock Does,opinion,"Could one stock really tell you where the broad market heads  Joe Friday shared he thought so on November the 13th in the chart below  Bio tech stock Valeant Pharma  N VRX  had been slammed the prior few months and the broad market dipped along with it 
The chart below reflected that VRX was testing five support lines at one time at  3   along with oversold momentum at  1  and volume was sky high at  2   which could have reflected panic selling  All of these conditions would suggest this price point was key for the stock and maybe the broad markets 
Since the Joe Friday post  VRX is up over 28  in less than 3 weeks

We remain of the opinion that what Bio Tech does going forward is key for the broad markets and VRX is an important part of the puzzle  We shared of late that Bio tech was up 250  more than the S P 500  from the 2011 lows and highs of this year 
Below  an update on VRX 

The 28  rally in the past couple of weeks has VRX up against falling channel resistance at  1  above 
The Power of the Pattern continues to believe  what happens at  1  above  will have profound impact on VRX going forward and could well impact the broad markets as well  Stay tuned friends  this could be a BIG DEAL for both bulls and bears   ",2015-12-02,Chris Kimble,"https://www.investing.com/analysis/bull-market-depends-on-what-this-stock-does-(update),-says-joe-273148",273148
147969,369485,BHC,All Eyes On Valeant While It Delivered Up To 45 ,opinion,"Joe Friday saw an opportunity in hard hit Valeant Pharmaceuticals International Inc  N VRX  on Friday November the 13th  which was 21 trading days ago  Boy did that end up being a lucky day  as VRX shot up 45   following the post 
Joe liked the following conditions in VRX  Momentum the most oversold since 2009  Volume was shooting way up  looked like panic selling  and VRX was hitting 15 year channel support and four other support lines  at the same time   See original post here  
The Power of the Pattern attempts to find low risk high reward entry points  One looked to be taking place at  3  above  as it was hitting five support lines at the same time  Below looks at the performance of VRX  since the posting on 11 13 

Yesterday  VRX had the  7th best day  in its history and the best single day returns since January of 2011 
The table below reflects that VRX just had its best 21 day returns since 2000 

We ve continue to find the opportunities in the broad market limiting  with overhead resistance just overhead at the 2 150 zone  We believe huge opportunities like VRX  continue to present themselves and that 2016 should be one of the best years  to make monies in a long  long time ",2015-12-15,Chris Kimble,https://www.investing.com/analysis/joe-friday-had-his-eye-on-valeant-(vrx)-and-it-delivered-(up-45)-376130,376130
147971,369487,BHC,Credit Distress Is Not Contained,opinion,"By early 2007  homeowners in the United States were already in trouble  Many were having serious problems making their mortgage payments 
But former Federal Reserve Chair Ben Bernanke downplayed the risks 
On March 28  2007  he reassured Congress   The impact on the broader economy and financial markets of the problems in the subprime  mortgage  market seems likely to be contained  
Instead  the ensuing fallout would be so severe that the word  subprime  would forever be associated with the credit crisis 
Today  contagion risks are being dismissed in a similar fashion 
Many say that the problems in the high yield corporate bond market are confined to the energy sector 
For those who harbor this misguided view  I present the following chart of high yield credit spreads by sector 

Corporate bond credit spreads basically reflect the perceived risk of default  The wider the spread  the higher the risk  and  thus  the more yield demanded by bond investors 
In July 2014  every single sector   including energy   had an average credit spread below 400 basis points  market value weighted average spread  
Less than two years later  not a single sector s average credit spread is below 400 basis points  bps  
Of course  energy companies are leading the way  as spreads have blown out past 1200 bps  Credit distress in the energy sector is only part of the story  though 
The second widest spreads belong to the industrial sector   not the materials sector  Yes  the credit markets realize we re in an  
However  even the  safe  sectors are experiencing strains 
At over 650 bps  utilities spreads are the fourth widest of all the sectors 
High yield healthcare spreads have widened from below 300 bps just a few months ago to nearly 500 bps  I talked about how Valeant Pharmaceuticals International Inc  N VRX  was the top  issuer this year 
Problems are accelerating  too 
Last week   made waves when it announced that it was suspending withdrawals in its high yield distressed debt mutual fund  Then on Friday  hedge fund firm Stone Lion Capital Partners also suspended redemptions in a credit fund 
Naturally  funds throwing up gates won t engender confidence among credit investors  Rather  it will lead to more risk aversion  which will impact junk bonds in every sector 
As a whole  high yield bonds experienced a monumental mispricing in 2013 and 2014  Companies issued record amounts of bonds at miniscule yields to quench investor demand  Call it a credit bubble if you like 
Due to the collapse in crude oil prices  the energy sector was simply the weakest link and the first to run into major problems 
Ultimately  credit distress isn t contained  The credit cycle has turned  and a default wave in corporate bonds approaches 
Safe  and high yield  investing ",2015-12-16,Alan Gula,https://www.investing.com/analysis/credit-distress-is-not-contained-376052,376052
147972,369488,BHC,4 Stocks To Watch  FXCM  JRJC  LL  SEDG,opinion,"It was another great day on Wall Street on Wednesday  Despite the interest rate rise  the market bought the news  taking them higher and closing at the highs for the day  It was a strong session  A lot of stocks that we follow came back  and a lot of stocks that have been strong are thrusting  So  let s take a look and see what they re doing 
FXCM Inc   N FXCM  has had an interesting few days  First it popped on Tuesday  it pulled back  held support  and then popped again on Wednesday  up another 2 40 to 9 16  or 35 5   on 1 7 million shares  Based on the way it s acting  and with the volume coming into it after coming down so far  it may be wanting to go higher  It took out the downtrend  and it may be a good candidate for a move up to 10 10 35 as early as Thursday  There s some key resistance up in that zone  If it gets through that  this is a stock that could make it to the 12 1 2 range 
China Finance Online Co   Ltd   O JRJC  exploded on Wednesday on a very surprising earnings report  The entire trend line was taken out a few days ago  and on Wednesday  it ran up to resistance to the March highs  and backed off just a little bit  Still  it had a wonderful day  up 1 74 to 6 30  or 38   on 6 5 million shares  If it continues  or if it forms a consolidation here  that may be a nice set up to take it up to the 8 1 2 9 1 4 range  It has 6 2 days to cover 
Lumber Liquidators Holdings  Inc   N LL  had another great day on Wednesday  After the pop on Tuesday  it ran again on Wednesday  up another 1 15 to 18 68  or 6 6   on 1 8 million shares  Still  it has about 7 days to cover  It looks like it may take a shot at running up towards 21 1 2 3 4  which is the next target 
SolarEdge Technologies  Inc   O SEDG  was highlighted on Tuesday because it broke out of a trend line above the moving average  On Wednesday  it popped another 3 76 to 25 75  or 17   on 3 9 million shares  That s big volume for this stock  It got right up to resistance and closed pretty well  The next target is 24  and if it can catch momentum  it could run up to the mid 30 s eventually  It has 2 7 days to cover 
Other stocks on the long side include Advaxis  Inc   O ADXS   Second Sight Medical Products  Inc   O EYES   Five Prime Therapeutics  Inc   O FPRX   JinkoSolar Holding Co   Ltd   N JKS   China Finance Online Co   Ltd   O JRJC   Direxion Daily S P Biotech Bull 3X ETF  N LABU   PTC Therapeutics  Inc   O PTCT   SolarCity Corporation  O SCTY   Solar3D  Inc   O SLTD   SunEdison  Inc   N SUNE   Guggenheim Solar ETF  N TAN   TerraForm Power  Inc   O TERP   and Valeant Pharmaceuticals International  Inc   N VRX  ",2015-12-17,Harry Boxer,"https://www.investing.com/analysis/fxcm,-jrjc,-ll,-sedg-376201",376201
147977,369493,BHC,Valeant CEO seeing unsolicited buyer interest for core assets,news," b Reuters    Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX  has fielded unsolicited interest in its core assets from potential buyers and although the company is not actively shopping them  it will consider all offers  Chief Executive Joe Papa said on Tuesday  
Papa declined to comment on whether he had received interest in a takeover of Valeant since assuming the helm in May ",2016-08-09,Reuters,https://www.investing.com/news/stock-market-news/valeant-ceo-seeing-unsolicited-buyer-interest-for-core-assets-419341,419341
147978,369494,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 31 ,news,"Investing com   Canada stocks were higher after the close on Tuesday  as gains in the Healthcare  Consumer Staples and Telecoms sectors led shares higher 
At the close in Toronto  the S P TSX Composite gained 0 31  to hit a new 52 week high 
The best performers of the session on the S P TSX Composite were Valeant Pharmaceuticals International Inc  TO VRX   which rose 24 97  or 7 37 points to trade at 36 88 at the close  Meanwhile   Guyana Goldfields Inc    TO GUY  added 5 44  or 0 460 points to end at 8 920 and Premium Brands Holdings Corporation  TO PBH  was up 5 21  or 2 95 points to 59 60 in late trade 
The worst performers of the session were  Ritchie Bros  Auctioneers Inc    TO RBA   which fell 10 84  or 4 680 points to trade at 38 500 at the close   IAMGold  Corporation  TO IMG  declined 10 70  or 0 800 points to end at 6 680 and  Bonavista Energy Corp   TO BNP  was down 3 29  or 0 130 points to 3 820 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 626 to 530 and 133 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 3 09  to 12 22 
Gold for December delivery was up 0 31  or 4 20 to  1345 50 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in September fell 0 60  or 0 26 to hit  42 76 a barrel  while the October Brent oil contract fell 0 88  or 0 40 to trade at  44 99 a barrel 
CAD USD was up 0 33  to 0 7625  while CAD EUR rose 0 10  to 0 6861 
The US Dollar Index was down 0 21  at 96 09 ",2016-08-09,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.31-419391,419391
147979,369495,BHC,Valeant looks to sell billions in assets to cut debt  stock soars,news,"By Rod Nickel and Caroline Humer  Reuters    Valeant Pharmaceuticals International Inc  N VRX   TO VRX  will sell billions of dollars of non core assets and could accept offers for its main businesses  its chief executive said on Tuesday  as the drugmaker worked to restore investor trust after a year of bad news  Valeant s U S  shares rose more than 25 percent  touching a two month high  after the company outlined its reorganization and sell off plan  and also confirmed full year forecasts  Even so  the stock is down nearly 90 percent from a year ago  Last fall  political concerns about Valeant s sharp drug price increases and investor scrutiny of its dealings with pharmacy Philidor RX dragged down Valeant s shares  Congress and several U S  government agencies also opened investigations and the company restated earnings earlier this year  Since then  its largest investor and board member  activist Bill Ackman  has been leading a drive to try to stabilize the company  New Chief Executive Joe Papa joined in May  replacing longtime CEO Mike  Pearson   LON PSON   Papa announced a few small sales on Tuesday  and said Valeant was eyeing  8 billion worth of sales for non core assets  He added in an interview that he may go further  after receiving unsolicited interest in core businesses as well  Valeant s Bausch   Lomb eyecare  dermatology  Salix gastrointestinal and consumer over the counter businesses are core  Papa said  He would not say if Valeant received interest in Bausch   We have to think about any alternative in front of us as we look to improve shareholder value   Papa said in the interview   We re going to take anything that we get  from an offer or unsolicited bid  very seriously   The Laval  Quebec based company still has  30 77 billion in long term debt  a legacy of Pearson s strategy of expanding through serial mergers and acquisitions  SECOND QUARTER FALLS SHORT On Tuesday  Valeant reported adjusted second quarter earnings and revenue that fell short of analyst expectations  but stuck by full year forecasts    I don t want to suggest for an instant that there  aren t  challenges  but we like our position for 2016   Papa said during a during a conference call  Valeant has previously missed deadlines for filing financial reports due to the sales and earnings restatements  triggering default notices  It has repaid  1 29 billion in debt this year and wants to renegotiate lender agreements to give itself a larger  cushion   Papa said  That action on debt lifted shares  according to Oliver Marti  a portfolio manager at Columbus Circle Investors    The stock is really driven by cash flow and covenants with the focus on stabilizing the business  and making progress on paying down debt  That is what they showed this quarter   Marti said  Valeant said it will break into three business segments around its Bausch   Lomb eyecare business  branded products including gastrointestinal drug Xifaxan and toenail treatment Jublia  and certain products including Obagi skin care treatments  It said its core geographies are the United States and Canada   Wells Fargo   NYSE WFC  analyst David Maris  a long time critic  questioned on the call whether the plan was just  new paint on the same old shed   Valeant is being investigated by the Securities and Exchange Commission as well as the U S  Attorney s offices in Massachusetts and New York  The government is looking at its pricing practices and its patient assistance programs  Valeant said it still expected full year revenue of  9 9 billion  10 1 billion and adjusted earnings of  6 60  7 00 per share   Second quarter revenue fell to  2 42 billion from  2 73 billion a year earlier  Analysts on average had expected revenue of  2 46 billion  according to Thomson Reuters I B E S  
Excluding items  Valeant earned  1 40 per share  missing analysts  average estimate of  1 48 ",2016-08-09,Reuters,"https://www.investing.com/news/stock-market-news/valeant-looks-to-sell-billions-in-assets-to-cut-debt,-stock-jumps-419367",419367
147980,369496,BHC,Valeant offers to increase lender interest payments in exchange for amendment,news,"NEW YORK  RLPC    Valeant Pharmaceuticals  NYSE VRX  International  TO VRX  is offering to pay lenders a higher interest rate in order to obtain an amendment to its debt agreement that would loosen one of its covenants  according to sources  The company previously obtained an amendment earlier this year to help stave off default  allowing it additional time to file its financial statements with securities regulators  Joe Papa  Valeant s chief executive officer  said on a conference call Tuesday that the company would seek to modify the interest financial maintenance coverage covenant on its bank debt   In addition to loosening its interest coverage ratio covenant  Valeant also wants to change some of the language around asset sales  sources said  There will be a lender call Wednesday at 3 pm to discuss the proposed amendment  In return for the amendment  the company is offering to increase the interest rate it pays lenders by 50 basis points  according to sources  It is also offering to pay a 25 basis points amendment fee  Valeant had a  1 35 billion revolving line of credit  a  1 424 billion A 3 tranche A term loan  an  835 6 million A 4 tranche A term loan  a  1 053 billion D 2 tranche B term loan  an  808 9 million C 2 tranche B term loan  a  2 45 billion E 1 tranche B term loan and a  3 88 billion F tranche B term loan as of June 30  according to an earnings release  The company also had  19 26 billion of senior notes  Lenders must decide if they will agree to the amendment by August 17  the sources said   Barclays   LON BARC  is arranging the amendment  A Barclays spokesperson and a spokesperson for Valeant did not immediately return e mails seeking comment   
The company  which reported earnings Tuesday  said it repaid  1 29 billion of debt in 2016  according to an earnings presentation  Valeant said it had a net loss of  302 million in the second quarter compared to a net loss of  53 million in the second quarter of 2015  according to the earnings release ",2016-08-09,Reuters,https://www.investing.com/news/stock-market-news/valeant-offers-to-increase-lender-interest-payments-in-exchange-for-amendment-419448,419448
147981,369497,BHC,Valeant under criminal investigation over Philidor ties  WSJ,news,"By Greg Roumeliotis and Alexandria Sage NEW YORK SAN FRANCISCO  Reuters    U S  prosecutors have opened a criminal investigation into Valeant Pharmaceuticals International Inc  N VRX  over whether it hid from insurers its relationship with a specialty pharmacy that helped boost its drug sales  the Wall Street Journal reported on Wednesday   Lawyers at the U S  Attorney s Manhattan office are trying to gauge whether concealing those ties may have amounted to defrauding insurers  the Journal report said  citing people familiar with the matter  A source familiar with the matter told Reuters later on Wednesday that investigators have been looking into what disclosures Valeant and the pharmacy  Philidor Rx Services  made to insurance companies about their relationship   U S  listed shares of Valeant  TO VRX   N VRX   which is headquartered in Canada  slid 12 5 percent to  23 90 in extended trading  The troubled company has seen its market value fall by some 90 percent in the last year as its drug pricing and other business practices prompted investigations by multiple U S  government agencies and by Congress   It first came under scrutiny from New York prosecutors last October over its drug pricing and distribution  Media also reported at the time that it used Philidor to overcome insurer rejections to reimbursing its medications  with Philidor resubmitting claims to insurers until they were approved   Valeant said in a statement on Wednesday that it was continuing to cooperate with the U S  Attorney s Office in New York regarding the investigation that was disclosed last October  The company did not provide further details on the subject of the probe    Valeant takes these matters seriously and intends to uphold the highest standards of ethical conduct as we move forward with our mission to improve people s lives with our healthcare products   the company said   The investigation by U S  prosecutors could lead to criminal charges against former Philidor executives and Valeant as a company  the Journal report said  citing one person familiar with the matter      Officials at the U S  Attorney s Office in Manhattan and representatives for Philidor  which closed its operations  were not immediately available for comment on the Journal report   SURPRISE DISCLOSURE  The October revelation of Valeant s ties to Philidor took investors by surprise  Following media reports of a relationship between the two  the drugmaker disclosed at the time that Philidor accounted for nearly 6 percent of its revenue and that it had an option to acquire the pharmacy  an unusual relationship in the pharmaceutical industry   Reuters and other media outlets reported on how Philidor helped secure insurer reimbursement for Valeant drugs  In some circumstances  the pharmacy would resubmit claims using the billing identification numbers of other affiliated pharmacies until an insurer approved payment  according to former employees   A small group of Valeant employees were deeply involved in directing Philidor s daily operations  raising questions about how much the drugmaker s executives knew of its practices  Reuters reported at the time   At least one payer  the pharmacy benefits manager OptumRx owned by UnitedHealth Group  N UNH   became aware of what appeared to be irregular billing practices and sought to shut out Philidor from its network  After Valeant s ties to Philidor became public  other payers cut off the pharmacy and it subsequently closed   Valeant has taken a series of steps to restore investor trust  including cutting off ties with Philidor last October  conducting an internal review of that relationship  replacing Chief Executive Michael  Pearson   LON PSON   overhauling its board of directors and appointing new leaders to run its main businesses   Billionaire investor William Ackman  whose Pershing Square  NYSE SQ  Capital Management is Valeant s largest shareholder  has taken a board seat to influence efforts to clean up the business  New management  led by CEO Joseph Papa  has sought to move beyond the questions over its Philidor ties  Ackman declined to comment  
Valeant is also under investigation by the U S  Securities and Exchange and U S  prosecutors in Massachusetts ",2016-08-11,Reuters,https://www.investing.com/news/stock-market-news/valeant-under-criminal-investigation:-wsj-419668,419668
148008,369524,BHC,Dollar Index Taking Another Leg Higher,opinion,"Top News Headlines
Obama sticks a fork in Keystone after company withdraws request 
Valeant  N VRX  troubles continue  CEO sells stock after margin call  Bill Ackman having a very bad month 
DOJ ratchets up scrutiny of drug pricing  Seeking information from Merck   Company Inc  N MRK   Eli Lilly and Company  N LLY  and  of course  VRX 
Berkshire Hathaway s  N BRKa  profit more than doubles  other earnings news last week was pretty poor 
Economic News
Jobs report much better than expected  avg  hourly earnings up too  Rate hike looking more certain 
Manufacturing data continues to be weak  ISM  Factory orders very weak 
Non Manufacturing survey much better than expected  Services still leading the economy 
Construction spending still showing strength 
Trade deficit improves but imports fall shows weak domestic economy 
Auto sales over 18 million annual rate 
Consumer credit surges most in history  up over  28 billion in September 
Random Thought Of The Week
You re probably hearing a lot of talk right now about how an overwhelming majority of earnings are beating estimates this season  We always do of course  Companies reduce expectations to a point where they are stepping over a low bar so they look good relative to the lowered expectations they created  I don t know why people still fall for it but you can be sure it will continue until it doesn t work and probably even after  Call it the Lake Woebegone effect 
What you probably haven t heard about is the quality of those earnings  When you hear the talking heads say that 70  of companies have beaten estimates they are referring to  operating earnings  or as I like to put it   earnings after the company strips out all the bad things that they claim are one time but probably aren t   The other type of earnings are  reported earnings  which are the earnings the companies are forced to report because they are in accordance with GAAP and because the SEC makes them  If you look at the current quarter  only 42  of companies are beating estimates on reported earnings  This is typical late cycle behavior we see every cycle  As you get closer to recession operating and reported earnings diverge with reported looking a lot worse than operating  What that means is the companies get increasingly creative with earnings as they become harder to come by 
Chart Of The Week
Good or bad  The dollar index appears to have completed its consolidation and is now taking another leg higher  There s good and bad in that  A higher dollar means lower commodity prices  earnings pressure for US multinationals and capital flowing to the US chasing dollar returns  It also puts pressure on companies and countries with dollar debts which become harder to repay  In the long run we are better off with a strong  stable dollar but a relentlessly rising dollar   just as a relentlessly falling one   is difficult to deal with 

Broad Market Top 10   3 Month Returns
Starting to see a bit of a shift after the big stock rally of the last month  Surprisingly though   considering the magnitude of the stock rally and the bond selloff   bonds still dominate the list and gold is hanging in there too 

MOMENTUM ASSET ALLOCATION MODEL SPDR Sector Returns   3 Month Returns

SPDR SECTOR ROTATION MODEL Country Returns Top 10   3 Month Returns

Commodity Returns Top 10   3 Month Returns

Bond Returns Top 10   3 Month Returns

Stock Valuation Update",2015-11-08,"Alhambra Investment Partners, LLC",https://www.investing.com/analysis/the-weekly-snapshot-270594,270594
148009,369525,BHC,Bull Market May Depend On This Stock,opinion,"When it comes to stocks that have been hit hard  Valeant Pharmaceuticals  N VRX  sure comes to mind  VRX has declined over 70  since July 
That decline has caused momentum to reach levels not seen since the 2009 lows at  1  
Volume skyrocketed at  2   Has panic selling taken place 
VRX after the huge decline finds itself testing a cluster of support at  3  
Valeant is part of the 4 year  white hot Bio tech sector  What VRX does at  3  above will have a big impact bio tech  which should also have an impact on the broad markets ",2015-11-13,Chris Kimble,https://www.investing.com/analysis/bull-market-may-depend-on-this-stock-271293,271293
148010,369526,BHC,Valeant Pharmaceuticals  Positive Divergences ,opinion,Friday s price bar was a possible reversal bar for Valeant Pharmaceuticals International Inc  N VRX   The stock made a new 52 week low during the session but closed the day with a nice gain of 2 22    despite the market sell off  This creates a bullish scenario for next week  Key daily technical indicators are displaying positive divergences and I think we could see a strong reversal over the coming sessions  Friday s high of  76 30 is resistance for the next upside move  If the stock can break through this level  we should see a strong follow through move ,2015-11-16,Antnio Costa,https://www.investing.com/analysis/valeant-pharmaceuticals-intl-inc-(nyse:vrx)---positive-divergences-271435,271435
148011,369527,BHC,Valeant Pharmaceuticals May Trade In  90 Area Soon,opinion,Valeant Pharmaceuticals International Inc  N VRX   The stock finished the day up 15 6  on solid volume of over 23 million of shares exchanging hands on the day  With no resistance between  87 and the 20 day EMA a break above the  87 level can see the stock trade in the  90 area pretty soon  Momentum indicators are slightly bullish now with RSI inching away above the 30  level  Have this on your watchlist ,2015-11-20,Antnio Costa,https://www.investing.com/analysis/valeant-pharmaceuticals-intl-inc---reversal-trend-271983,271983
148012,369528,BHC,The Week Ahead  What Are The Best Year End Investments ,opinion,"There is a lot of data to be reported in only three full trading days  but it does not rate to signal important economic changes  I expect plenty of participants to take the week off and even more will leave after the first hour on Wednesday  The punditry still has pages and air time to fill  despite the lack of fresh news  The punditry will be asking 
What are the best year end investments  
Prior Theme Recap
In my last WTWA  I predicted that the market story would focus on the message from falling commodity prices  This thesis lasted for one day  as the market continued the multi week trading pattern of following crude oil prices  That was all  The rest of the week included a rally that most found inexplicable  Gains occurred in the face of terrorist actions  falling commodity prices  and a strong signal of an imminent increase in interest rates  The strong rally left most participants shaking their heads and reaching to invent explanations  To get the full story  let us look at Doug Short s weekly chart  Doug s full post shows the various relevant moving averages in a very negative week for stocks   With the ever increasing effects from foreign markets  you should also add Doug s World Markets Weekend Update to your reading list  

Doug s update also provides multi year context  See his  for more excellent charts and analysis 
We would all like to know the direction of the market in advance  Good luck with that  Second best is planning what to look for and how to react  That is the purpose of considering possible themes for the week ahead  You can make your own predictions in the comments 
This Week s Theme
The economic calendar is normal  but all of the reports occur within three days  Friday s session is a half day  Many participants will be taking off and others will leave after Wednesday morning s data  TV producers will be reaching to find subjects  It may be the toughest week of the year to guess a theme  Volume will be low and surprise news could have a big effect  It is a bit too soon for the Santa Claus rally topic  but that is also possible 
My guess is that the discussion will focus on the surprising market resilience and what it means for investments 
People will be asking 
What are the best year end investments  
There will be a wide range of viewpoints  featuring the following 
Bonds  Stocks are over priced and dangerous 
Gold  Time to hedge against geopolitical and economic threats 
Safe stocks  emphasizing dividends 
Bets on an improving economy 
A shift to emerging markets 
Popular recent leaders 
There is an argument for each approach  Expect to see some new faces on TV and new sources featured in columns  As always  I have my own ideas  reported in today s conclusion  This week I have tried to give special emphasis to sources with specific stock ideas 
But first  let us do our regular update of the last week s news and data  Readers  especially those new to this series  will benefit from reading the  
Last Week s Data
Each week I break down events into good and bad  Often there is  ugly  and on rare occasion something really good  My working definition of  good  has two components 
The news is market friendly  Our personal policy preferences are not relevant for this test  And especially   no politics 
It is better than expectations 
The Good
There was a little good news  but most results were in line with expectations 
More dovish commentary from ECB head Draghi    
The Philly Fed beat expectations  While the index  1 9  did not show great expansion  the results have been getting wider attention   has the story and this chart showing the relationship with the more noted ISM index 

Bank lending strengthens   and a nice chart pack on credit 
Building permits rose 45K  in line with expectations  This continues a trend in this forward looking construction indicator  See  at Doug Short s site for more analysis and the expected great charts 
Builder confidence was reported as 62  a slight miss of expectations   that it is still a strong reading 


The Bad
Some of the economic data missed expectations  Feel free to add other suggestions in the comments 
Rail traffic is declining  Steven Hansen    gets beyond the noise of the weekly data and reveals the trend 

Housing starts missed forecasts   at Doug Short s site has a nice  detailed report 
Industrial production missed explanations  Steven Hansen    takes a deeper look at the data  explaining that it might be a little better than the headline indicates 
The Ugly 
Continuing terrorism  Just as those responsible for the Paris attacks were found  there was a new assault on a luxury hotel in Mali  As I write this  there is  to restaurants and cafes in Brussels 
This is  of course  a human story rather than one about markets  Many of us will be giving thanks this week for our own safety and that of friends and loved ones  Many will also support the victims and families in the way they best can 
I know that many are curious about why there was not a greater market impact   some explanations 
The Silver Bullet 
I occasionally give the Silver Bullet award to someone who takes up an unpopular or thankless cause  doing the real work to demonstrate the facts  Think of The Lone Ranger  No award this week  Nominations are always welcome 
Quant Corner
Whether a trader or an investor  you need to understand risk  I monitor many quantitative reports and highlight the best methods in this weekly update  This week I have made some changes in our regular table  separating three different ways of considering risk  For valuation I report the equity risk premium  This is the difference between what we expect stocks to earn in the next twelve months and the return from the ten year Treasury note  I have found this approach to be an effective method for measuring market perception of stock risk  This is now easier to monitor because of the excellent work of   whose analysis of the Thomson Reuters data is our principal source for forward earnings 
Our economic risk indicators have not changed 
In our monitoring of market technical risk  I am using our  new  Oscar model  I put  new  in quotes because Oscar is in the same tradition as Felix and the product of extensive testing  We have found that the overall market indication is more helpful for those investing or trading individual stocks  More about Oscar next week  The score ranges from 1 to 5  with 5 representing a high warning level  The 2 4 range is acceptable for stock trading  with various levels of caution 
I considered continuing to report the Felix updates  but I already have a distinction between long and short term methods  I want to minimize confusion  Those who want this information can subscribe to our weekly Felix updates 
For more information on each source   

Recent Expert Commentary on Recession Odds and Market Trends
Bob Dieli does a   subscription required  after the employment report and also a monthly overview analysis  He follows many concurrent indicators to supplement our featured  C Score  
  An array of interesting systems  Check out his site for the full story  We especially like his   confirming that there is no recession signal  He gets a similar result from the   updated this week 
This week Georg dropped the indicators emphasizing the ECRI WLI  which he has concluded add nothing to the forecasting power of his other approaches  He has written on this topic several times  but perhaps he will provide a summary of the factors behind his decision 
Doug Short  Provides an array of important economic updates including the best charts around  One of these is monitoring the ECRI s business cycle analysis  as his associate Jill Mislinski does in   The ECRI story is becoming repetitive and even more unhelpful  It seems too related to commodity prices  and only slightly changed from their failed recession forecast  It would be refreshing to see them do a complete reset and adopt a fresh approach 
  A variety of strong quantitative indicators for both economic and market analysis  While we feature the recession analysis  Dwaine also has a number of interesting systems  These include approaches helpful in both economic and market timing  He has been very accurate in helping people to stay on the right side of the market 
The Week Ahead
There is quite a bit of economic data for a 3   day week  Wednesday is the big day  While I highlight the most important items  you can get an excellent comprehensive listing at Investing com  You can filter for country  type of report  and other factors 
The  A List  includes the following 
New home sales  W   Good concurrent read on an important sector for economic growth
Michigan sentiment  W   Good concurrent indicator of job growth and spending
Personal income and spending  W   Can people afford holiday spending 
Consumer confidence  T  Conference Board version is similar to Michigan s  also showing recent strength 
Initial claims  Th   Fastest and most accurate update on job losses 
The  B List  includes the following 
Core PCE prices  W   The Fed s favorite inflation indicator  Will not have much significance until there are a few hot months 
Existing home sales  M   Not as important as new home sales  but shows the state of the market 
GDP 2nd estimate  T   Backward looking  but probably revised higher 
Durable goods   W   Improvement expected in this volatile series 
Crude oil inventories  W   Focus on oil prices keeps this report in the spotlight 
All quiet on the speaking front  but breaking news might have an exaggerated impact in the expected low volume environment 
How to Use the Weekly Data Updates 
In the WTWA series  I try to share what I am thinking as I prepare for the coming week  I write each post as if I were speaking directly to one of my clients  Each client is different  so I have five different programs ranging from very conservative bond ladders to very aggressive trading programs  It is not a  one size fits all  approach 
To get the maximum benefit from my updates  you need to have a self assessment of your objectives  Are you most interested in preserving wealth  Or like most of us  do you still need to create wealth  How much risk is right for your temperament and circumstances 
My weekly insights often suggest a different course of action depending upon your objectives and time frames  They also accurately describe what I am doing in the programs I manage 
Insight for Traders 
Oscar continues Felix s neutral market forecast  but he is fully invested  There are often plenty of good investments  even in an expected flat market  For more information  I have posted a further description     You can sign up for Felix and Oscar s weekly ratings updates via email to etf at newarc dot com  They appear almost every day at Scutify  follow   
The most dramatic lesson for traders comes from a rookie who did not accurately assess his risk  He held an overnight short position in a stock that was supposedly going bankrupt  The next morning he learned that his  37 000 account was wiped out and he owed his broker over  100 000  Shawn Langlois    has the story and this chart 

Insight for Investors 
I review the themes here each week and refresh when needed  For investors  as we would expect  the key ideas may stay on the list longer than the updates for traders  Major market declines occur after business cycle peaks  sparked by severely declining earnings  Our methods are focused on limiting this risk  Start with our  and follow the links 
We also have a page summarizing many of the   If you read something scary  this is a good place to do some fact checking 
Other Advice 
Here is our collection of great investor advice for this week 
If I had to pick a single most important article  it would be  from Rupert Hargreaves at Value Walk  He reports on advice from Michael Mauboussin  a leading expert on investor behavior  Read the entire piece and check out the great links  but here is a key segment 


Over the past decade  the S P 500 has gained 7 7  per annum  but the average investors has only been able to achieve a return of 5 3  per annum  According to Michael Mauboussin  these figures are similar across most of the world s markets and can be explained by one key factor  we often fail to keep a cool head and end up we buying high and selling low 


As Mauboussin puts it  a human phenomenon is the desire to be part of a group  which gives a sense of security but it s not always a good thing 

Many investors have the skill and tools to do well  but not the emotional stability or discipline 
 that this affects asset allocation as well  The  retail  funds  ETFs  and stocks have done worse than those favored by institutions 
 on the  enormous long term cost  of holding cash 
Stock Ideas 

Successfully bullish strategist Thomas Lee recommends a shift from consumer discretionary stocks to energy  James Picerno analyzes this call  comparing charts and data from both sectors and providing plenty of evidence via more links 

Morningstar reveals the top ten conviction buys of their  ultimate stock pickers   They also show the top ten new money purchases  Read the  for details of both lists and some underlying rationale 

Utility stocks    and it is not just a matter of rising rates 
  Valeant  N VRX   Oil prices to  70  There are many interesting ideas 
Warren Buffett is going against the crowd on IBM  N IBM   But what does he know    
13 Dividend Aristocrats with yields over 4     



Watch out for   
Obamacare effects   UnitedHealth Group  N UNH  downgraded earnings expectations  blaming the ACA  The health insurance group plummeted and the selling pressure rippled to hospitals and even to biotechs  The next day the other big insurers all stated that participation  fees  and revenues were on track  This has been a popular and important market sector  so the story deserves careful monitoring 
Tax scams  The IRS might lose your data  but they   You are probably already doing these seven things  but it only takes a moment to check 
Yield plays  MLPs  REITs  BDCs and others    
Personal Finance 
Professional investors and traders have been making Abnormal Returns a daily stop for ten year  The average investor should make time  even if not able to read every day as I do  for a weekly trip on Wednesday  Tadas always has first rate links for investors in this   There are several great links  but I especially liked this warning about non traded REITs from Micah Hauptman  financial services counsel for the Consumer Federation of America    

Nontraded REITs are rife with conflicts of interest both in how they are governed and how they are sold  Often  the entities that manage and sell nontraded REITS are closely affiliated and controlled by the same top executives who divvy up the high upfront costs investors pay  Further  the brokers who recommend these products are allowed to call themselves  trusted financial advisers  while they operate like salespeople seeking to earn a commission  These conflicted structures enable a systematic wealth transfer from retail investors  who need to make every dollar count  to the financial firms that create  manage  market and sell these products 

The article provides data on the huge impact of up front fees on eventual returns 
Josh Brown offers his typically  on the same topic   a familiar one for him 
China Outlook 
Another major mining company affirms Chinese economic growth rates    
Final Thoughts
For long term investors  the best sources of value require some confidence in economic growth  This is clearly a contrarian opinion  as you can see from the sources below 
One factor influencing stocks   especially those in the economically sensitive sectors   is the persistent belief that the economy is bad and getting worse  The results of Gallup polling show this effect  despite lower gas prices and an improved economy throughout 2015    

The article provides data showing the sharp contrast between this general poll and those that ask about individual circumstances 
 with a nice analysis on the factors behind the unhappiness of voters   an uneven recovery  misleading noise  and ignorance  each discussed nicely  The lesson he reaches for investors his one of my favorite themes  Be politically agnostic  Accept the reality of the policy environment and take advantage of whatever is offered  This advice will become more difficult to follow as election campaigns heat up 
By contrast   Davidson     explains as follows 
The most important knowledge of Value Investors  which lets them invest when others are racing to  high ground   is in understanding that throughout human history we have always recovered from self made disasters  Value Investors are primarily optimists and are virtually the only buyers at market recession lows  Geneticists  anthropologists  psychologists psychiatrists and neurologists have recently been coming to similar conclusions 
He elaborates nicely  showing how this applies to housing and shelter  Here is a key chart 

Investment Conclusion 
Key themes for a strengthening economy include financials  I especially like regional banks   technology  homebuilders  and mid to late stage cyclicals  While I cannot be sure that they are choices for the rest of 2015  the market seems to be swinging that way ",2015-11-22,Jeff Miller,https://www.investing.com/analysis/weighing-the-week-ahead:-what-are-the-best-year-end-investments-272095,272095
148017,369533,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 08 ,news,"Investing com   Canada stocks were higher after the close on Wednesday  as gains in the Healthcare  Materials and REITs sectors led shares higher 
At the close in Toronto  the S P TSX Composite rose 0 08  
The best performers of the session on the S P TSX Composite were Valeant Pharmaceuticals International Inc  TO VRX   which rose 14 74  or 3 83 points to trade at 29 82 at the close  Meanwhile   Kirkland Lake Gold Inc    TO KGI  added 9 64  or 1 08 points to end at 12 28 and  B2Gold Corp   TO BTO  was up 7 63  or 0 270 points to 3 810 in late trade 
The worst performers of the session were  Centerra Gold Inc   TO CG   which fell 8 02  or 0 65 points to trade at 7 45 at the close   Concordia Healthcare  Corp  TO CXR  declined 5 08  or 1 39 points to end at 25 95 and Linamar Corporation  TO LNR  was down 4 85  or 2 18 points to 42 81 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 637 to 527 and 120 ended unchanged 
Shares in Kirkland Lake Gold Inc   TO KGI  rose to 3 years highs  gaining 9 64  or 1 08 to 12 28  Shares in B2Gold Corp  TO BTO  rose to 3 years highs  up 7 63  or 0 270 to 3 810  Shares in Linamar Corporation  TO LNR  fell to 52 week lows  down 4 85  or 2 18 to 42 81  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 0 93  to 15 17 
Gold for August delivery was up 0 51  or 6 95 to  1365 65 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in August rose 1 74  or 0 81 to hit  47 41 a barrel  while the September Brent oil contract rose 1 75  or 0 84 to trade at  48 80 a barrel 
CAD USD was up 0 13  to 0 7714  while CAD EUR fell 0 09  to 0 6950 
The US Dollar Index was down 0 12  at 96 15 ",2016-07-06,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.08-412818,412818
148018,369534,BHC,Sequoia Fund exits Valeant position after losses,news," Reuters    Ruane  Cunniff   Goldfarb Inc  the investment firm that runs the Sequoia Fund and once the largest shareholder of Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX   said it exited its position in the embattled Canadian drugmaker by mid June  Valeant has been under intense scrutiny for its business and accounting practices  sending its shares plummeting 91 percent from the record high of  263 81 it touched last August   Valeant was our largest position to start the year and its 80 percent decline through June 30 badly penalized our results   Sequoia Fund said in a letter dated July 12  
Ruane  Cunniff   Goldfarb was sued earlier this year by shareholders  who claimed it recklessly took a huge stake in Valeant  causing more than  2 billion in losses ",2016-07-13,Reuters,https://www.investing.com/news/stock-market-news/sequoia-fund-exits-valeant-position-after-losses-414112,414112
148019,369535,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 11 ,news,"Investing com   Canada stocks were higher after the close on Wednesday  as gains in the Materials  Consumer Staples and Industrials sectors led shares higher 
At the close in Toronto  the S P TSX Composite rose 0 11  to hit a new 6 months high 
The best performers of the session on the S P TSX Composite were  First Majestic Silver  Corp   TO FR   which rose 9 46  or 1 90 points to trade at 21 98 at the close  Meanwhile   MAG Silver Corp    TO MAG  added 5 42  or 1 05 points to end at 20 42 and  Brookfield Business Partners  LP  TO BBU u  was up 4 60  or 1 14 points to 25 91 in late trade 
The worst performers of the session were  Corus Entertainment Inc   TO CJRb   which fell 7 52  or 1 03 points to trade at 12 66 at the close  Valeant Pharmaceuticals International Inc  TO VRX  declined 7 14  or 2 16 points to end at 28 11 and  Russel Metals Inc    TO RUS  was down 4 49  or 1 08 points to 23 00 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 647 to 533 and 125 ended unchanged 
Shares in First Majestic Silver Corp   TO FR  rose to 3 years highs  rising 9 46  or 1 90 to 21 98  Shares in MAG Silver Corp   TO MAG  rose to all time highs  up 5 42  or 1 05 to 20 42  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 5 54  to 14 66 
Gold for August delivery was up 0 61  or 8 20 to  1343 50 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in August fell 3 55  or 1 66 to hit  45 14 a barrel  while the September Brent oil contract fell 3 80  or 1 84 to trade at  46 63 a barrel 
CAD USD was up 0 52  to 0 7707  while CAD EUR rose 0 19  to 0 6946 
The US Dollar Index was down 0 24  at 96 32 ",2016-07-13,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.11-414213,414213
148020,369536,BHC,Valeant says ex CEO Pearson remains a significant shareholder,news," Reuters    Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX  said on Thursday its former CEO Michael  Pearson   LON PSON  remains a significant shareholder of the Canadian drugmaker   Valeant said Pearson exercised options to sell about 4 4 million shares apart from selling about 411 000 shares in June and July   Pearson  who was replaced by Joseph Papa in May  still holds more than 3 5 million shares and is required to hold 1 million shares for two years following employment termination  The company had 343 million shares outstanding as of June 2  according to a regulatory filing   Pearson s share sale were to satisfy tax obligations with respect to the 2015 margin sale conducted by Goldman Sachs  NYSE GS  and for additional liquidity  the company said   While I trimmed my ownership position for personal reasons  I plan on holding my remaining shares until the company recovers and returns to being traded on fundamentals   Pearson said in a statement  
Valeant has been under intense scrutiny for its business and accounting practices  sending its shares plummeting 92 percent from the record high of  263 81 it touched last August ",2016-07-14,Reuters,https://www.investing.com/news/stock-market-news/valeant-says-ex-ceo-pearson-remains-a-significant-shareholder-414393,414393
148021,369537,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 14 ,news,"Investing com   Canada stocks were higher after the close on Thursday  as gains in the Healthcare  Mining and Energy sectors led shares higher 
At the close in Toronto  the S P TSX Composite gained 0 14  to hit a new 6 months high 
The best performers of the session on the S P TSX Composite were  Birchcliff Energy Ltd    TO BIR   which rose 10 69  or 0 84 points to trade at 8 70 at the close  Meanwhile   Kelt Exploration Ltd    TO KEL  added 5 63  or 0 260 points to end at 4 880 and Valeant Pharmaceuticals International Inc  TO VRX  was up 5 62  or 1 58 points to 29 69 in late trade 
The worst performers of the session were  Alamos Gold Inc   TO AGI   which fell 3 86  or 0 50 points to trade at 12 45 at the close   Boardwalk REIT   TO BEI u  declined 3 59  or 2 13 points to end at 57 12 and  Guyana Goldfields Inc    TO GUY  was down 3 30  or 0 300 points to 8 790 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 652 to 504 and 156 ended unchanged 
Shares in Birchcliff Energy Ltd   TO BIR  rose to 52 week highs  up 10 69  or 0 84 to 8 70  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 13 77  to 12 59 a new 1 month low 
Gold for August delivery was down 0 70  or 9 45 to  1334 15 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in August rose 1 65  or 0 74 to hit  45 49 a barrel  while the September Brent oil contract rose 1 92  or 0 89 to trade at  47 15 a barrel 
CAD USD was up 0 61  to 0 7754  while CAD EUR rose 0 35  to 0 6974 
The US Dollar Index was down 0 26  at 96 11 ",2016-07-14,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.14-414471,414471
148022,369538,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 24 ,news,"Investing com   Canada stocks were higher after the close on Friday  as gains in the Telecoms  Clean Technology and Utilities sectors led shares higher 
At the close in Toronto  the S P TSX Composite gained 0 24  to hit a new 52 week high 
The best performers of the session on the S P TSX Composite were  Celestica  Inc   TO CLS   which rose 8 51  or 1 12 points to trade at 14 28 at the close  Meanwhile   Bonavista Energy Corp   TO BNP  added 4 84  or 0 180 points to end at 3 900 and  Crew Energy Inc   TO CR  was up 3 15  or 0 18 points to 5 90 in late trade 
The worst performers of the session were Valeant Pharmaceuticals International Inc  TO VRX   which fell 6 24  or 2 00 points to trade at 30 03 at the close   Concordia Healthcare  Corp  TO CXR  declined 4 45  or 1 19 points to end at 25 55 and  HudBay Minerals  Inc   TO HBM  was down 4 25  or 0 28 points to 6 31 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 659 to 439 and 155 ended unchanged 
Shares in Concordia Healthcare Corp  TO CXR  fell to 52 week lows  down 4 45  or 1 19 to 25 55  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 0 08  to 12 59 
Gold for August delivery was down 0 60  or 8 00 to  1323 00 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in September fell 1 16  or 0 52 to hit  44 23 a barrel  while the September Brent oil contract fell 1 02  or 0 47 to trade at  45 73 a barrel 
CAD USD was down 0 42  to 0 7609  while CAD EUR rose 0 04  to 0 6933 
The US Dollar Index was up 0 52  at 97 44 ",2016-07-22,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.24-416118,416118
148023,369539,BHC,Wall Street can t stop talking about this potential  baby Valeant ,news,Unarguably  the biggest disaster for Wall Street in the last year was Valeant Pharmaceuticals  NYSE VRX   the drug company whose stock has lost about 90  of its value since October  Of course not everybody lost  Valeant was targeted by short sellers who made a bundle on the stock s plunge  And they re looking everywhere in the market for companies that may share Valeant s losing business strategy of using debt funded acquisitions to grow their product line  rather than R D   and then jack up the price of those acquired drugs   Enter Concordia International  a  1 6 billion Canadian drugmaker that Wall Street s short sellers are circling  trying to decide if it s a  baby Valeant   The stock is down 78  since this time last year  Some of the symptoms of Valeant s disease seem to be there  The company hiked   14 fold back in May  And then there s Donnatal  an irritable bowel syndrome drug from the 1940s that the company acquired back in 2014  In 2010  Donnatal cost  87  When Concordia acquired it  Donnatal cost  353  Concordia immediately increased the price to  602  It now costs  782 and generates 10  of the company s revenue  We ll get back to that  First  recall that once upon a time Valeant s strategy made it the darling of the hedge fund community  So there was a time when being compared to the company was something to brag about   He said his company was  an M A company very similar to Valeant     Valeant  when Mike  Pearson   LON PSON  took over the company was in a very similar position to what we are in now  He s done a very good job in terms of acquisitions  We have a very full pipeline and the objective is just to keep going  The wind is at our back so to speak and the opportunities are there   We should also note that Thompson was an associate general counsel and vice president for business development at Biovail  which merged with Valeant in 2010  Bear raid Of course  none of this necessarily makes Concordia a mini Valeant  and no company wants to be called that  anymore   So Concordia has gone very much on the defensive  Last week Charley Grant at  that Concordia is suing a semi retired short seller named Marc Cohodes for libel  This is what set Thompson and Concordia off   The management of Concordia  their past gig was at something called Biovail  which I was short a long time ago  and  was a complete and utter fraud  So  Mr   Thompson has a history of nonsense when he was at Biovail   Mr  Cohodes said in an interview with BNN back in April  Biovail was charged with accounting fraud and material misstatements back in 2008  It settled for  10 million neither admitting nor denying its guilt  Cohodes responded to the suit saying Thompson  believes that he can silence his and Concordia s critics  by hitting them with lawsuits  He does not sound like he had any intention of backing down  Cohodes isn t the only short seller Concordia has taken issue with  Back in March it  denying media reports that its fourth quarter financial results might be under review by PricewaterhouseCoopers   We categorically deny the claims being made in the report and our independent auditors stand by our results   said Mark Thompson  founder  chairman and chief executive officer of Concordia   Concordia has been the subject of an unrelenting and unscrupulous attack by a group of short sellers for several months  We will continue to monitor this situation and will act accordingly  However  we are extremely excited about the business we have built and the opportunity to deliver long term shareholder value   Not like Valeant There are ways in which Concordia is very different from Valeant  though those differences aren t necessarily great either  The FDA is currently reviewing Donnatal to try to figure out whether or not it s actually effective at all  RBC explained the issue a recent note to clients  The product is under review by the FDA and has been since 1975 until a hearing to determine whether it is effective occurs  There are no timelines for when or if a hearing is to be held  but the product represents  10  of the company s total revenues and would impact the valuation if it were not allowed to stay on the market  Continued weakness in the GBP following the recent Brexit vote could further impact Concordia s international business  These risks could impact Concordia s ability to meet our price target  valuation  and rating expectations  Of course  when something has been under review since 1975 it s hard to see why now  all of the sudden  it s going to become a priority   unless it just is  In January the House Republicans on the Energy and Commerce Committee  checking in on its Drug Efficacy Study Implementation  DESI  program  In March  the FDA responded with a list of drugs that are currently on the docket  and Donnatal was first on the list   Fewer than a dozen DESI proceedings remain open or  pending   covering approximately 20 active ingredients   said the letter   FDA is actively working to close these proceedings  It has been FDA s policy to allow continued marketing of drugs that are subject to a pending DESI proceeding    about the DESI program as well  The presentation was given by the FDA s historian Suzanne Junod and Robert Temple  MD  Deputy Director of the Office of Drug Evaluation  In response to Business Insider s questions about the drug  a Concordia spokesperson said the following   There is no change to Donnatal s regulatory status  Our business is based on product launches  M A and product promotion     But even if Donnatal doesn t get completely taken off the market for being ineffective  it s facing intense competition  As RBC notes  since Allergan  NYSE AGN pa  put another IBS drug  Viberzi  on the market in December 2015 Donnatal prescription growth has slowed   not the healthiest news for a bouncing baby billion dollar company ,2016-08-02,Business Insider,https://www.investing.com/news/stock-market-news/wall-street-can-039;t-stop-talking-about-this-potential--039;baby-valeant-039;-417998,417998
148024,369540,BHC,U S  futures trade in tight range as investors eye oil,news,"Investing com   Wall Street futures traded flat to higher on Tuesday in a second day of muted trade with low volume and volatility as market participants kept their eyes on oil with U S  equities near record highs
The blue chip Dow futures gained 19 points  or 0 10   by 10 53AM GMT  or 6 53AM ET  the S P 500 futures edged forward 2 points  or 0 08   while the tech heavy Nasdaq 100 futures traded up 6 points  or 0 12  
Despite some early losses in European trade  oil prices managed to continue the upward drive as North American traders hit their desks on Tuesday  after rising sharply in the prior session amid renewed hopes for an agreement among OPEC producers to freeze output 
U S  crude futures advanced 0 51  to  43 24 by 10 55AM GMT  or 6 55AM ET  while Brent oil traded up 0 31  to  45 53 
Oil futures spiked 3  on Monday as fresh hopes for an agreement among exporters to freeze production underpinned the market 
On the data front  investors looked ahead to second quarter nonfarm productivity and unit labor costs to be released at 12 30GMT  or 8 30AM ET  to be followed by June wholesale inventories at 14 00GMT  or 10 00AM ET 
On the company front  second quarter earnings continued winding down this week 
In a notable pre market move  Valeant Pharmaceuticals  NYSE VRX  jumped almost 7  in pre market trade despite worse than expected earnings as the Canadian drugmaker backed its full year guidance 
 Coach  Inc  NYSE COH    Whitewave Foods  Company  NYSE WWAV  or  Red Robin Gourmet  Burgers Inc  NASDAQ RRGB  were among other companies scheduled to report before the opening bell  while all eyes would be on Walt Disney s numbers after the close 
Outside of earnings  Honeywell International  NYSE HON  was reported to be in talks to acquire JDA Software in a deal that could be worth  3 billion  according to sources cited by Reuters 
In other M A news   Randstad Holdings NV   OTC RANJY  plans to buy U S  rival  Monster Worldwide Inc   NYSE MWW  for approximately  429 million  The  3 40 per share offer represents a 23  premium to Monster s closing price on Monday 
Delta Air Lines  NYSE DAL  was also under watch  cancelling 250 flights on Tuesday  after a power outage the prior day had forced the airline to cancel around 1 000 flights 
Elsewhere  European stocks were up in mid morning trade Tuesday  with gains in telecommunication and oil shares helping keep the region s benchmark hovering around a two week high 
Particular attention was on the U K  as sterling and 10 year government bonds slid on hints for more easing 
Writing in an opinion piece for the Times on Tuesday  Bank of England policymaker Ian McCafferty said more quantitative easing was likely to be required if the U K  s economic decline worsens 
The pound dropped to  1 2968  a level not seen since July 11 in wake of the dovish comments  GBP USD was last at 1 2982  down 0 44  on the day 
Meanwhile  the yield on the U K  10 year Gilt hit a record low of 0 592  before pulling back to 0 610  ",2016-08-09,Investing.com,https://www.investing.com/news/stock-market-news/u.s.-futures-trade-in-tight-range-as-investors-eye-oil-419279,419279
148025,369541,BHC,Valeant is leaping after reporting mixed earnings,news,Shares of troubled drugmaker Valeant Pharmaceuticals  NYSE VRX  are taking off after the company reported mixed earnings on Tuesday morning  Valeant earned an adjusted  1 40 per share   1 47 expected  on revenue of  2 42 billion   2 46 billion expected  during the second quarter  The firm did  however  beat on GAAP earnings with a loss of  0 88    0 92 expected    We continue to make progress towards stabilizing the organization   CEO Joseph Papa said in  accompanying the earnings   We are also announcing a new strategic direction for Valeant today  which  at its heart  has a mission to improve patients  lives and will involve reorganizing our company and reporting segments   Valeant also reaffirmed its guidance for the year  revenue of  9 9 billion to  10 1 billion and adjusted full year earnings of  6 60 to  7 a share  The earnings come after a year in which Valeant saw its business practices come under fire from short sellers  the US Senate  and presidential candidates  Financial misstatements also led to the removal of top executives and a monumental stock price drop  Following the news  Valeant s stock jumped 6 64  in premarket trading  as of 8 15 a m  ET  to  23 94 a share ,2016-08-09,Business Insider,https://www.investing.com/news/stock-market-news/valeant-is-leaping-after-reporting-mixed-earnings-419328,419328
148040,369556,BHC,iFOREX Daily Analysis   October 23  2015,opinion,"The dollar moved slightly higher against most major currencies on Wednesday  following Tuesday s strong U S  housing sector data which continue to provide support  while trading was expected to remain quiet with no major data to be released throughout the day  Sterling eased further against the dollar after the U K  Office for National Statistics reported that public sector net borrowing fell to  8 63 billion in September from  10 79 billion in August  whose figure was revised from a previously estimated  11 31 billion  Analysts had expected public sector net borrowing to decline to  9 40 billion last month  Meanwhile  USD CAD rallied 0 92  to trade at two week highs of 1 3106 after the Bank of Canada decided to hold its benchmark interest rate at 0 50   in a widely expected move  and downgraded its economic outlook citing the  complex  aftershocks of lower oil prices  On Thursday  the ECB s governing council will conclude its two day meeting in Malta  one of two annual meetings its holds each year outside Frankfurt  Traders appear hesitant to make any major moves ahead of the ECB meeting  Other major releases for today are the Spanish unemployment rate  U K retail sales  U S  jobless claims and U S  existing home sales 
EUR USD
EUR USD ended Wednesday s session almost unchanged trading in a tight range between 1 1324 and 1 1386  still supported by Tuesday s positive housing data  The dollar continues to show little movement against the euro on Thursday  as investors remain on the side lines ahead of the ECB monetary policy meeting in Malta where an extension of the bank s current monetary policy program is anticipated  Later in the day  the focus will shift to the U S  and specifically on U S  jobless claims and existing home sales data for further indications on the strength of the economy  For next week  the Federal Reserve s policy meeting will be in the spotlight  Other major releases for today are the Spanish unemployment rate  U S  jobless claims and U S  existing home sales 
Pivot  1 1395Support  1 1305 1 1265 1 123Resistance  1 1395 1 145 1 1495Scenario 1  Short positions below 1 1395 with targets   1 1305   1 1265 in extension Scenario 2  Above 1 1395 look for further upside with 1 145   1 1495 as targets Comment  As long as 1 1395 is resistance  look for choppy price action with a bearish bias 
WTI Oil
Crude oil prices fell considerably on Wednesday dipping to near October lows  as U S  stockpiles shot up last week adding to long term concerns related to a record high supply on energy markets nationwide  Crude oil prices traded in a broad range between  44 88 and  46 08 a barrel  before settling at  45 20  down by more than 2  for the day  The U S  Energy Information Administration  EIA  said U S  crude stockpiles surged by 8 million for the week ending on Oct  16  At 476 6 million barrels  U S  crude oil inventories remain near levels not seen for this time of year in at least 80 years  On Wednesday  an OPEC meeting in Vienna with eight non OPEC members  including Russia  did not produce any meaningful headlines  Investors are now looking ahead to next week s Federal Reserve open market meeting on Oct  27 28 to see if there are any policy changes that could affect the dollar 
Pivot  45 8Support  44 85 44 45 43 95Resistance  45 8 46 4 46 95Scenario 1  Short positions below 45 8 with targets   44 85   44 45 in extension Scenario 2  Above 45 8 look for further upside with 46 4   46 95 as targets Comment  As long as 45 8 is resistance  likely decline to 44 85 
S P 500
U S  stocks fell slightly on Wednesday as a sell off among Health Care and Biotechnology stocks offset gains from a GM and Boeing inspired rally  Shares in Valeant Pharmaceuticals International Inc  N VRX  fell as much as 25  after a report from short seller Citron Research accused the  50 billion pharmaceutical giant of a wide range of improprieties  including creating fake invoices for deceiving auditors and booking artificially high revenues  The biotech sector managed to recover most of the day s losses by market close but bearish sentiment still remains  The S P 500 was down 0 58   the Dow Jones Industrial Average slid 0 28   and the Nasdaq fell 0 84   Markets focus remains on third quarter corporate earnings data  while iinvestors are also looking ahead to next week s Federal Reserve open market meeting on Oct  27 28 to see if there are any policy changes that could affect the dollar 
Pivot  2044Support  1867 1820 1798Resistance  2044 2135 2180Scenario 1  Short positions below 2044 with targets   1952   1867 in extension Scenario 2  Above 2044 look for further upside with 2135   2180 as targets Comment  As long as 2044 is resistance  look for choppy price action with a bearish bias 
Coca Cola
Coca Cola  KO  reported sales of  11 4 billion  slightly below forecasts  Revenue dipped from a year earlier as the effects of a stronger U S  dollar had a strong impact on sales being brought back to the U S  from overseas 
    Pivot  40 4  Support  36 55 35 55 34 9  Resistance  40 4 42 25 43 7    Scenario 1  Short positions below 40 4 with targets   36 55   35 55 in extension   Scenario 2  Above 40 4 look for further upside with 42 25   43 7 as targets   Comment  The RSI lacks upward momentum ",2015-10-23,iFOREX,"https://www.investing.com/analysis/iforex-daily-analysis-:-october-23,-2015-269025",269025
148041,369557,BHC,The Week Ahead  Will The Fed Put The Brakes On The Breakout ,opinion,"The week ahead is loaded with data reports and earnings news  The FOMC has another meeting and rate decision  It occurs in the context of a nice stock rebound  The punditry will be asking 
Will the Fed put the brakes on the breakout  
Prior Theme Recap
In my last WTWA I predicted that the market story would turn to housing  the subject of most of the week s data  That proved to be one of my worst predictions  My discussion of the theme is intended as preparation for the media focus  not just my own opinion  My personal conclusion was that the housing story was important  but others did not think so  It did get reasonable attention  but earnings stories dominated  with secondary attention to Europe and China news  By Thursday  it was all about the market breakout and getting back to break even on the year 
To get the full story  let us look at Doug Short s weekly chart  You can clearly see the mid week turnaround   With the ever increasing effects from foreign markets  you should also add Doug s World Markets Weekend Update to your reading list  

While I take a weekly focus  Doug s update provides multi year context  See his full post for more excellent charts and analysis 
We would all like to know the direction of the market in advance  Good luck with that  Second best is planning what to look for and how to react  That is the purpose of considering possible themes for the week ahead  You can make your own predictions in the comments 
This Week s Theme
We have a huge economic calendar  with more important reports than we have seen in many weeks  Whenever the week includes a Fed meeting  we expect that to command attention  While most do not expect a policy change  it remains possible and could dominate market discussion until Wednesday afternoon  Much of the most important data will not be known  even by the Fed  until later in the week  This is a perfect setup for pundit pontification 
I expect a weeklong Fed focus  with everyone asking 
Will the Fed put the brakes on the breakout  
The question implies two parts 
Will Fed policy change 
Will Fed policy change Yes  A rate increase would merely move toward normal 
No  There is no sign of inflation and economies are weak    at Bloomberg View and  of Norther Trust  
No  It would create too much dollar strength    
It is too late  The Fed should have acted when the economy was stronger 

Does it matter Yes  The market strength rests upon worldwide liquidity  Changing this could halt the rally 
No  It is all about technical analysis and which wave we are in    at MarketWatch  
No  Fed policy has done little to help the economy  so gradual cuts will make little difference 
No  The economy is strong enough to deal with higher rates     CNBC  

There are sources taking each of these positions  I expect all to be cited in the week ahead 
As always  I have my own ideas  reported in today s conclusion  But first  let us do our regular update of the last week s news and data  Readers  especially those new to this series  will benefit from reading the  
Last Week s Data
Each week I break down events into good and bad  Often there is  ugly  and on rare occasion something really good  My working definition of  good  has two components 
The news is market friendly  Our personal policy preferences are not relevant for this test  And especially   no politics 
It is better than expectations 
The Good
The news of the week was mostly good 
Government shutdown less likely  The apparent choice of Paul Ryan as House Speaker is a good signal on this front  Investors who join me as political agnostics should not care about the partisan issues  just the consequences  We know that the market hates the uncertainty brought on by a debate over raising the debt limit  so this is good news 
Jobless claims  The lowest four week moving average since 1973    
China GDP beats forecasts benefiting from stimulus    
Central bank policy  China took aggressive action  but ECB President Mario Draghi needed only words   captured the essence of the story in a few words 

First there was the Fed  which backed off a rate hike in September  and seems unlikely to implement one at all this year  Earlier this week  the ECB chimed in  with President  dropping tea leaves the size of tires that the bank could and would expand its stimulus program later this year  if needed  Lastly    The People s Bank made two powerful moves  it cut interest rates by 25 basis points  and cut the reserve requirement ratio for banks  The ratio dictates how much money banks need to keep on hand  Cutting it is viewed as a very blunt and powerful way to push money into the economy  They needed to do something  China s third quarter GDP report was its worst showing since 2009  and most people think the real growth picture is even worse 


Housing data were strong   reported updates and additional commentary on each report 
Existing home sales
Builder confidence
Mortgage applications

Earnings beat rate  77  of stocks are beating reduced expectations    
The Bad
There was some negative data  including some of the important earnings stories 
Earnings commentary  The data showed success versus the lowered expectations  but the accompanying messages suggested continuing economic weakness  The  is a helpful companion piece  They are using   which now includes over 100 000 earnings calls  This is a great service that I use on my stocks  You should  too 
Housing permits declined   has a good story  noting that the overall trend is intact  This is an important indicator 
Bearish sentiment is declining  a contrary indicator    and helpful charts 

Earnings are poised for a second consecutive quarterly decline  currently estimated at 3 8    

The Ugly 
Cheating in science and medicine  Faked data supporting academic articles with faked reviews and email addresses   The    Perhaps authors should not be counted upon to suggest the reviewers  Sheesh 
The Silver Bullet 
I occasionally give the Silver Bullet award to someone who takes up an unpopular or thankless cause  doing the real work to demonstrate the facts  Think of The Lone Ranger  No award this week  despite the abundance of really bad analysis  I am thinking of starting a nominee section  This would include items that have obvious errors but which have not attracted any replies or refutation  Almost any two variable chart these days is a candidate 
Quant Corner
Whether a trader or an investor  you need to understand risk  I monitor many quantitative reports and highlight the best methods in this weekly update  For more information on each source   

Recent Expert Commentary on Recession Odds and Market Trends
Bob Dieli does a   subscription required  after the employment report and also a monthly overview analysis  He follows many concurrent indicators to supplement our featured  C Score  
  An array of interesting systems  Check out his site for the full story  We especially like his   confirming that there is no recession signal  He gets a similar result from the   This week Georg   showing how to trade in gradations rather than all in or all out 
  Provides an array of important economic updates including the best charts around  One of these is monitoring the ECRI s business cycle analysis  as he does in   The ECRI story is becoming repetitive and even more unhelpful  It seems too related to commodity prices  and only slightly changed from their failed recession forecast  It would be refreshing to see them do a complete reset and adopt a fresh approach 
  A variety of strong quantitative indicators for both economic and market analysis  While we feature the recession analysis  Dwaine also has a number of interesting systems  These include approaches helpful in both economic and market timing  He has been very accurate in helping people to stay on the right side of the market 
This week  about the difficulty of rebounding through the 200 day moving average once it has been breached for a  protracted time   He calls this situation the kiss of death  and presents the following table of results  We shall see 

Bob Bryan at BI cites   Citing sources from Goldman Sachs and BMO  he concludes as follows 

While it s always good to be on guard  it seems that most of the evidence supports the argument that the economic expansion still has a ways to go 

There is a chart for each of the six signs  including this one on homebuilder sentiment 

The Week Ahead
It is a huge week for economic data  While I highlight the most important items  you can get an excellent comprehensive listing at Investing com  You can filter for country  type of report  and other factors 
The  A List  includes the following 
FOMC rate decision  W   A focal point for the week 
Q3 GDP  Th   The advance read is expected to be weak  and will be heavily revised  It remains an important headline story 
New home sales  M   Key indicator in a key sector 
Consumer confidence  T   The Conference Board version provides a good read on satisfaction with employment and also spending prospects 
Michigan sentiment  F   Important for the same reasons as the Conference Board version  but with methodology I regard as better 
Personal income and spending  F   Both are important for consumption as an economic driver 
Employment cost index  F   Will signal labor market tightening and possible pressure on the Fed to start rate increases 
PCE prices  F   The Fed s favorite inflation measure is expected to remain low 
Chicago PMI  F   Always more important at the end of the week as a signal of the upcoming ISM report  Weakness expected 
Initial jobless claims  Th   The best concurrent news on employment trends  with emphasis on job losses 
The  B List  includes the following 
Pending home sales  Th   A good advance look 
Durable goods  T  
Crude oil inventories  Th   Current interest in energy keeps this on the list of items to watch 
Earnings remain important with plenty of big names on the calendar  FedSpeak will occur only after the FOMC meeting  mainly on Friday 
How to Use the Weekly Data Updates 
In the WTWA series I try to share what I am thinking as I prepare for the coming week  I write each post as if I were speaking directly to one of my clients  Each client is different  so I have five different programs ranging from very conservative bond ladders to very aggressive trading programs  It is not a  one size fits all  approach 
To get the maximum benefit from my updates you need to have a self assessment of your objectives  Are you most interested in preserving wealth  Or like most of us  do you still need to create wealth  How much risk is right for your temperament and circumstances 
My weekly insights often suggest a different course of action depending upon your objectives and time frames  They also accurately describe what I am doing in the programs I manage 
Insight for Traders 
Felix has remained bullish  and we increased our commitment accordingly  The penalty box indicator dropped dramatically  increasing our confidence in the multi week bullish call  For more information  I have posted a further description     You can sign up for Felix s weekly ratings updates via email to etf at newarc dot com  Felix appears almost every day at Scutify  follow him   
 from professional gambler Cathy Hulbert  Many of the psychology and money management issues are similar for those who have a real edge in these activities  If you have no edge  you should simply move on 
An edge is not enough if you cannot manage your emotions  Here are some examples of amateur mistakes 
The reasons for unnecessary and avoidable losses of amateur traders can often be attributed to the following 5 points 
Revenge trading  you open a new position just after your stop is triggered  without seeing valid re entry signals 
Playing catch up  you want to make up for past losses  force trades and violate your rules 
You flip through your charts without really knowing what you re looking for and then take trades that don t meet your criteria 
You want to avoid losses and  therefore  widen your stop loss order or take it off completely 
You miss a trading setup and then jump in too late  although you should have stayed out by then 
It is always good to have positive suggestions as well as mistakes to avoid  Dr  Brett is a reliable source for such advice   he has three important points that you would not think of on your own  A careful read of this would be time well spent for any trader  I especially like this suggestion 

Spend as much time learning from your trading as you actually spend trading   The ratio of practice time to performance time is a great predictor of elite performance  whether among Olympic athletes or chess champions 

Insight for Investors 
I review the themes here each week and refresh when needed  For investors  as we would expect  the key ideas may stay on the list longer than the updates for traders  Major market declines occur after business cycle peaks  sparked by severely declining earnings  Our methods are focused on limiting this risk  Start with our  and follow the links 
We also have a page summarizing many of the   If you read something scary  this is a good place to do some fact checking 
Other Advice 
Here is our collection of great investor advice for this week 
If I had to pick a single most important article  it would be this thoughtful analysis from Chuck Carnevale     Chuck analyzes a problem that many investors currently share  You buy a stock based upon your methods  in which you have confidence  The stock declines  You feel like you made a mistake   buyer s remorse  That is when you are prone to making a bad decision  Chuck does a detailed description of his decision  Whether you agree about the stock or not  you will learn from the analysis  We have all been there 

My case supporting investing in IBM  N IBM  is totally predicated on its generous current yield and my view of the safety and sustainability of its business  There is no shortage of positive and negative articles or reports across numerous financial blogs on IBM  Some of them contain important facts  but in my judgment  most of them represent simply the opinions of others  Personally  I prefer facts over opinions 

By the way   those who cite Warren Buffett s rule about not losing money should definitely read this article  Mr  Buffett does not worry about paper losses when the market disagrees with his own valuation  Losing money happens when you sell  just as Chuck explains 
See also  on the difference between the methods used by traders and investors  using Valeant  N VRX  as an example 
Public Stock Picking is Difficult 
The problem is how to get paid for your work  Those who analyze and write about stocks are under constant pressure to generate  actionable investment advice   It is all about page views  Chief Pundit Cramer generates so many recommendations that he is a walking bulls eye for critics  One retired professor sought to achieve accountability when a Cramer article made some especially strong claims  While Cramer never accepted the friendly bet  the original challenge is a matter of public record  The picks did not fare well   and the accounting on the 49 stock picks in question 
Stock Ideas 
Hidden opportunities in small cap value stocks  Dana Lyons  and offers a qualified   yes 
Finding opportunities in energy stocks depends on your understanding of supply and demand  This fascinating interactive chart  cannot be appreciated in the static form below  but it does hint at what we should be watching   U S  and OPEC production 

Meanwhile   that the Saudi s need to change policy or risk running out of financial assets in five years   Am I the only one who senses that the IMF is offering a lot of advice where it might not be needed or wanted  
Personal Finance 
Professional investors and traders have been making Abnormal Returns a daily stop for ten year  The average investor should make time  even if not able to read every day as I do  for a weekly trip on Wednesday  Tadas always has first rate links for investors in this   As always  there are several great links  but I especially liked  to check out your broker or advisor on FINRA s free site 

The 20  of brokers with the highest ex ante predicted probability of investor harm are associated with more than 55  of the investor harm cases and the total dollar investor harm in our sample  Our findings suggest that investors have access to valuable information that allows them to discriminate between brokers with a high propensity for investor harm from other brokers 

Few are really prepared for retirement  but this is not a big change  There was never a  golden age  for retirement  People used to work longer   has a great survey of the historical data  including this chart 

Similarly  if millennials do not want to work until age 75  they need a plan    
Market Outlook and Portfolio Evaluation 
How should you analyze returns  What time period  interval  starting point   takes up these questions  Most intriguing is the observation that the long term average of 7 5  was rarely seen  Only 5  of the time was it even close  That is something to keep in mind 

The best six months for stocks are  finally  upon us     
Morgan Stanley s summary of the key macro questions    

Final Thoughts
Will the Fed alter policy  Will it matter 
On the first question there are conflicting signals from excellent sources   much better than the ill informed opinions that make up most of the news flow on this subject  It is interesting to note that both sources see a vibrant internal debate at the Fed  where the discussion is free and wide ranging  Both sources provide some  inside baseball  that you will not see elsewhere 
Dovish  A rate increase is not imminent  and is likely to be delayed until mid 2016  Tim Duy  a leading expert on Fed watching   from a speech to business economists by Fed Governor Lael Brainard  Prof  Duy raves about the implications of this    Only a true expert and policy wonk could reach that conclusion  but that is why we should pay attention   Brainard is a   with outstanding academic credentials  consulting experience  and award winning work for think tanks and government  His key takeaway  She may join with an important Fed coalition that is less committed to an early rate hike 
Hawkish  The Fed bank boards are more supportive of an increase in the discount rate  For some years this rate has been 50 basis points above the fed funds rate  so it is an indicator of opinion about a rate increase  The bank presidents are frequently more hawkish than the appointed Governors  and their voting rights on the FOMC go through a rotation  Even so  an excellent and experienced observer  Bob Eisenbeis     shows the dramatic shift in the positions of the bank boards 

My own guess is  no change  at this meeting  but I have not ruled out a December shift 
Turning to the question of whether a policy change will matter for your investments   it is not likely unless you are focused on short term returns  The stock market skeptics believe two things 
The entire rally has been based upon central bank policy and increased liquidity
Even a gradual withdrawal of policy accommodation constitutes  tightening  
This leaves us with the ongoing market dilemma   time frames  Are we trading or investing  The former is a matter of psychology  while the latter rests upon your determination of the actual value of each potential investment 
A change in Fed policy is unlikely  but if it happens  it is not really important for long term investors ",2015-10-25,Jeff Miller,https://www.investing.com/analysis/weighing-the-week-ahead:-will-the-fed-put-the-brakes-on-the-breakout-269122,269122
148042,369558,BHC,Markets Advance Despite Weak Reports From U S  And China,opinion,"US stocks advanced on Monday led by energy shares and healthcare stocks  The dollar didn t change much versus most major currencies  with the ICE US dollar index  a measure of the dollar s strength against a basket of six currencies  ending up 0 17   The S P 500 live data indicate S P 500 rose 1 2  closing at 2 104 05  It is the broad market index s first close above 2100 since August 17  All sectors recorded gains  Stock market advanced despite economic reports indicated manufacturing sector in October grew at slowest pace in two and a half years  Investors focused instead on the performance of energy industry and the rising merger and acquisition activity in healthcare industry  The gains in energy sector were driven by Exxon  N XOM  and Chevron  N CVX   which rose 4 5  and 3 1  respectively after posting better than expected quarterly results on Friday 
Pfizer Inc  N PFE  rose 3 7    and AbbVie Inc  N ABBV  rallied 6 4   providing the biggest boost to the healthcare sector  Dyax shot 28 4  on the news the British drugmaker Shire PLC  L SHP  would buy the company for about  5 9 billion  US listed shares of Canadian drugmaker Valeant  N VRX   which engaged in tactics of acquiring rights to treatments and boosting prices  jumped 7 1  after short seller Citron Research said it would not be releasing new allegations how the company inflated sales and engaged in accounting practices reminiscent of power trader Enron Corporation that collapsed in 2001   Investors are now looking forward to this Friday s employment report to determine whether the Federal Reserve will raise interest rates in December  Today at 15 45 CET the New York ISM index for October will be released  At 16 00 CET September Factory Orders will come out  The tentative outlook is negative for the dollar 
European stocks closed higher on Monday in a choppy trade after opening lower following the disappointing data on China s manufacturing activity  Caixin manufacturing purchasing managers index indicated the manufacturing activity contracted for an eighth straight month in October  Investor optimism was boosted later as PMIs for euro zone and Germany came in higher than expected  easing concerns about the negative impact on euro zone of slowing growth in China and emerging markets  The DAX 30 index recorded the biggest gain among the European indices as it rose 0 9   Markets were also supported by the comments of European Central Bank  ECB  president Mario Draghi over the weekend that ECB was ready to do what it takes to keep its medium term inflation target on course  Banks were among best performers after the Greek banks passed the ECB stress tests  indicating the 14  4 billion euros of collective capital shortfall of four major banks was less than the 25 billion maximum allocated for bank recapitalisation as part of the country s bailout agreement  French carmaker Renault  PA RENA  gained 4 2   on data indicating increasing market share as French car registrations rose 1  in October  No important economic data are expected today in euro zone  At 19 00 CET ECB president Draghi will speak in Frankfurt 
Japan s markets are closed today for a Culture Day holiday  As market participants expected the Reserve Bank of Australia kept its cash rate today unchanged at a record low of 2 0   but said further easing was possible 
Several commodity futures prices are rising today after yesterday s retreat following weak Chinese PMI data 
Brent oil prices are falling today on concerns over weak global demand and rising oil production in Russia ",2015-11-03,IFC Markets,https://www.investing.com/analysis/markets-advance-despite-weak-reports-from-us-and-china-270138,270138
148043,369559,BHC,Valeant  The Real Scandal,opinion,"The Valeant Pharmaceuticals  N VRX  saga is probably a long way from a resolution  Anyone that says they know how it will end is either delusional or looking to influence the stock  That said  there are a few lessons to be gleaned 

Organic growth is superior to growth by acquisitions    especially when growth by acquisitions is financed with large amounts of debt and even more especially when that debt is fueled by Wall Street bond offerings 
In industries that rely on intellectual property  research and development spending is critical for survival 
Accounting transparency is a big deal  I m not saying that Valeant is Enron Part II  but I will say that unscrupulous behavior is a lot harder to detect when its wrapped up in complicated financial arrangements 
The more a company works to highlight non GAAP  AKA crap  results  the more investors should focus on GAAP results instead  As Gretchen Morgenson pointed out last week in the New York Times  Valeant earned  912 million in 2014 GAAP profits  while its non GAAP reported cash earnings were  2 85 billion 

Who s In
None of these lessons is new  They re commonsense  investing 101  which leads one to wonder why so many successful money managers have risked huge amounts on such an inherently sketchy business  Sequoia Fund s stake in Valeant is a staggering 34 million shares  Bill Ackman s Pershing Square Capital owns 20 million  SF based ValueAct  15 million  NYC based Paulson   Co  9 million  NYC based Lone Pine  5 million  and Greenwich based Viking Capital  5 million  New York s Brave Warrior Advisors  managed by Glenn Greenberg  son of legendary baseball player Hank Greenberg  has reportedly tied up more than a third of its assets in Valeant  These are massive investments from some of the biggest  best known funds in the world    and that is exactly where the problem lies 
These outsized bets are a side effect of liquidity  As assets under management grow  liquidity constraints reduce the number of potential stocks and bonds where a manager might make a meaningful investment  Everybody in money management knows this  but few discuss or acknowledge it  The optimum asset size    if maximizing performance potential is a firm s primary goal as opposed to maximizing the amount it can earn in fees    is almost always less than  1 billion  But a sub billion fund usually doesn t bring its managers fame or notoriety    and it certainly won t earn them enough to pay for record breaking apartments overlooking Central Park    so a combination of ego  greed and amorality seduces fund managers to bring in as many investors as they can  It gets harder and harder to produce great risk adjusted returns  The only way to do so without engaging in insider trading or other illegal practices is to lever up or beta up  That increases the risk of a performance blowup  Years ago  a famous Bay Area money manager friend summed the issue up succinctly   Almost everyone who manages over  500M is someone who checks his ethics at the front door every morning  
Behind The Curtain
The Valeant story shouldn t just raise questions about the fund managers who placed giant wagers on the company  We should also examine the people who gave those managers the capital to do so  Why would any asset allocator trust a multi billion dollar fund that continues to solicit new investors  The sad truth is that many large endowments and pension funds are overseen by political hacks with a minimal understanding of the investment landscape  Some endowments invest in funds solely because the manager is an alum and or significant donor  and the investment comes with the unspoken understanding that the manager will keep his or her donations flowing  It s a corrupt system  so I guess we shouldn t be terribly surprised when it results in the funding of  allegedly  corrupt companies like Valeant
What really makes my blood boil is the fact that nobody questions why the realized gains from university endowments are tax exempt  Or why donations to those endowments are tax deductible  Or why  unlike every other tax exempt organization in the country  university endowments are not required to give away five percent or more of their assets each year  Or why tax exempt organizations supposedly devoted to education have been raising the costs of tuition at an astronomical rate often at schools that educate no more students than they educated 30 or 40 years ago  Forget one pharmaceutical company and its  allegedly  suspicious accounting practices  These are the real scandals that deserve our attention    and our outrage ",2015-11-06,Scott Fearon,https://www.investing.com/analysis/the-real-scandals-in-the-valeant-story-have-nothing-to-do-with-valeant-270448,270448
148047,369563,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 63 ,news,"Investing com   Canada stocks were higher after the close on Tuesday  as gains in the Energy  Consumer Discretionary and Financials sectors led shares higher 
At the close in Toronto  the S P TSX Composite rose 0 63  to hit a new 6 months high 
The best performers of the session on the S P TSX Composite were  Baytex Energy  Corp  TO BTE   which rose 13 95  or 1 01 points to trade at 8 25 at the close  Meanwhile   Penn West Petroleum  Ltd   TO PWT  added 13 21  or 0 140 points to end at 1 200 and  MEG Energy Corp   TO MEG  was up 12 58  or 0 80 points to 7 12 in late trade 
The worst performers of the session were Valeant Pharmaceuticals International Inc  TO VRX   which fell 14 95  or 5 53 points to trade at 31 47 at the close   Concordia Healthcare   TO CXR  declined 6 32  or 2 16 points to end at 32 03 and  Centerra Gold Inc   TO CG  was down 4 03  or 0 29 points to 6 90 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 728 to 456 and 139 ended unchanged 
Shares in Valeant Pharmaceuticals International Inc  TO VRX  fell to 5 year lows  losing 14 95  or 5 53 to 31 47  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 1 06  to 12 14 
Gold for August delivery was down 0 04  or 0 45 to  1246 95 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in July rose 1 49  or 0 74 to hit  50 43 a barrel  while the August Brent oil contract rose 1 80  or 0 91 to trade at  51 46 a barrel 
CAD USD was up 0 42  to 0 7835  while CAD EUR rose 0 41  to 0 6899 
The US Dollar Index was down 0 18  at 93 86 ",2016-06-07,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.63-407049,407049
148048,369564,BHC,Valeant CEO cuts outlook for  distracted  company  shares plunge,news,"By Amrutha Penumudi and Rod Nickel
Reuters    Valeant Pharmaceuticals International Inc  TO VRX  slashed its 2016 forecasts on Tuesday  as its new chief executive said he would focus on rebuilding the reputation of a  distracted organization  with a debt loaded balance sheet 
The maker of toenail fungus cream Jublia and anti depressant drug Wellbutrin  which has faced intense scrutiny for business and accounting practices  missed first quarter profit estimates on weakness in its dermatology business 
The Laval  Quebec based drugmaker expects full year adjusted earnings of  6 60  7 00 per share  compared with its previous forecast of  8 50  9 50  and revenue of  9 9 billion  10 1 billion  down from  11 0 billion  11 2 billion 
The Canadian drugmaker s U S  listed shares  N VRX  slumped to close down 14 6 percent to  24 64  paring earlier losses of as much as 22 percent 
 Negative external attention continues to adversely impact the business and our reputation with patients  physicians and all of you  our shareholders  as well as our distracted organization   Chief Executive Joe Papa  who took over in May  said during a conference call with analysts 
He did not directly answer a question on whether there had been takeover offers for Valeant 
Ruane  Cunniff   Goldfarb Inc  one of Valeant s biggest shareholders  cut its stake by more than half to 4 7 percent as of May 31  it said in a regulatory filing 
The investment firm that runs the Sequoia Fund  long known for its ties to Warren Buffett  was sued by shareholders who claim it recklessly took a huge stake in Valeant 
Papa said the results reflected  significant disruption  over the past nine months  It will take up to six months to stabilize the company  he said  including staff recruitment  improving relationships with doctors and drug payers  selling assets and repaying debt 
Papa did not specify which assets would be put up for sale  but said they do not include core businesses of dermatology  consumer products  Bausch   Lomb eyecare and Salix gastrointestinal drugs 
The company has repaid  730 million of its roughly  30 billion in debt this year  and is aiming for total repayment of  1 7 billion  Valeant racked up much of the debt through its aggressive pace of acquisitions under former CEO Mike  Pearson   LON PSON  
Papa called Valeant s problems  speed bumps   but doubts remain for others 
Valeant has  15 billion in debt due by 2020  and  if the business stays the way it is  or continues to deteriorate  we believe Valeant will be challenged in making those debt payments   wrote  Wells Fargo   NYSE WFC  analyst David Maris  During the analysts  call  he questioned executives about a lack of transparency in how the company offered guidance 
Up to Monday s close  the stock had fallen nearly 90 percent from its August 2015 high of  263 81 
Valeant filed its 2015 financial report in late April  after missing an original deadline of March 15 due to an in house review of its accounting practices  allaying concerns about a possible default on its debt  The probe found problems dating back to 2014 
The company  which will hold its 2016 annual meeting of shareholders on June 14  filed its quarterly report on Tuesday with the U S  regulators  ahead of a July 31 deadline 
Papa said there are still challenges  including with U S  dermatology sales  which are reliant on a pact with pharmacy Walgreens Boots Alliance Inc  O WBA   Dermatology sales dropped 43 percent during the first quarter compared with the same period in the previous year 
Valeant s net loss was  373 7 million  or  1 08 per share in the first quarter  compared with a profit of  97 7 million  or 28 cents per share  a year earlier 
On an adjusted basis  Valeant earned  1 27 per share  missing the average analyst estimate of  1 37  according to Thomson Reuters I B E S 
Total revenue rose 9 3 percent to  2 37 billion  missing the average analyst estimate of  2 38 billion ",2016-06-07,Reuters,"https://www.investing.com/news/stock-market-news/valeant-ceo-cuts-outlook-for-'distracted'-company,-shares-plunge-407059",407059
148049,369565,BHC,Valeant said to weigh sale of Egyptian drugmaker Amoun  Bloomberg,news, Reuters    Valeant Pharmaceuticals International Inc  N VRX   TO VRX  is considering the sale of Egyptian drugmaker Amoun Pharmaceutical Co to accelerate its debt reduction plan  Bloomberg reported  citing people with knowledge of the matter  Valeant is working with  Goldman Sachs Group   NYSE GS  on the sale  which is at a preliminary stage  according to the report  It is also weighing a sale of some of its Latin American operations  Bloomberg reported   Valeant bought Amoun for about  800 million last year  Valeant  which earlier in the week reported lower than expected first quarter profit  could not be immediately be reached for comment  The Canadian company has said that it is aiming to lower its almost  30 billion debt ,2016-06-09,Reuters,https://www.investing.com/news/stock-market-news/valeant-said-to-weigh-sale-of-egyptian-drugmaker-amoun:-bloomberg-407569,407569
148050,369566,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 51 ,news,"Investing com   Canada stocks were lower after the close on Thursday  as losses in the Mining  Energy and Consumer Staples sectors led shares lower 
At the close in Toronto  the S P TSX Composite declined 0 51  
The best performers of the session on the S P TSX Composite were  BRP Inc    TO DOO   which rose 7 42  or 1 48 points to trade at 21 43 at the close  Meanwhile  Valeant Pharmaceuticals International Inc  TO VRX  added 5 68  or 1 73 points to end at 32 19 and  Novagold Resources Inc    TO NG  was up 4 61  or 0 35 points to 7 94 in late trade 
The worst performers of the session were Performance Sports Group Ltd  TO PSG   which fell 8 84  or 0 39 points to trade at 4 02 at the close   First Quantum Minerals Ltd    TO FM  declined 7 74  or 0 77 points to end at 9 18 and  Penn West Petroleum  Ltd   TO PWT  was down 5 51  or 0 070 points to 1 200 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 590 to 578 and 143 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 4 99  to 13 89 
Gold for August delivery was up 0 76  or 9 65 to  1271 95 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in July fell 1 50  or 0 77 to hit  50 46 a barrel  while the August Brent oil contract fell 1 20  or 0 63 to trade at  51 88 a barrel 
CAD USD was down 0 20  to 0 7863  while CAD EUR rose 0 49  to 0 6949 
The US Dollar Index was up 0 51  at 94 07 ",2016-06-09,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-0.51-407575,407575
148051,369567,BHC,Valeant pays  54 million to settle U S  kickback  fraud claims,news,"By Jonathan Stempel NEW YORK  Reuters    Valeant Pharmaceuticals International Inc  NYSE VRX  will pay  54 million to settle civil charges that its Salix unit paid illegal kickbacks to induce doctors to prescribe seven of its products  causing the submission of thousands of fraudulent reimbursement claims to the U S  government  The accord announced on Thursday by the U S  Department of Justice covers alleged improper activity at the former Salix Pharmaceuticals Inc from 2009 to 2013  predating its April 2015 acquisition by Valeant for more than  11 billion  Salix admitted and accepted responsibility for routinely paying doctors hundreds or thousands of dollars  or offering perks including lavish meals at restaurants such as Le Bernardin and Nobu  to attend some of its roughly 10 000  speaker programs   including many with little or no educational value  One doctor from Rochester  New York allegedly received more than  200 000 for attending numerous events  including some where he was told not to do slide presentations and that dinner was the only gathering planned   Receipts from Salix s speaker programs   which were approved by managers   evidence the existence of speaker programs that were quite clearly happy hours   the government added  The Justice Department said the kickback scheme worked  as many attendees began prescribing Salix products more often  It said this led to thousands of false payment claims being submitted to Medicare and Medicaid  and two healthcare programs serving active and retired military personnel   Salix found a way to pay doctors money and treated them to fancy meals to push their drugs   U S  Attorney Preet Bharara in Manhattan said in a statement  The drugs and devices covered by the lawsuit are Apriso  Deflux  MoviPrep  OsmoPrep  Relistor  Solesta and Xifaxan  Valeant spokeswoman Laurie Little said the company is pleased to settle  and that the alleged misconduct  involved personnel who are no longer with the company   The payment marks an additional financial strain on Laval  Quebec based Valeant  whose stock price has fallen more than 90 percent since August amid scrutiny over its business and accounting practices and high debt load  Salix s settlement resolves claims originally brought under the federal False Claims Act in two lawsuits by the physician Steven Peikin and four former Salix employees  Such lawsuits let whistleblowers bring cases on behalf of the U S  government  and share in any recoveries  The government typically joins cases it considers stronger  
According to settlement papers  Salix will pay  46 53 million to the United States and  7 47 million to resolve civil fraud claims by various U S  states ",2016-06-09,Reuters,"https://www.investing.com/news/stock-market-news/u.s.-accuses-valeant's-salix-unit-of-kickbacks,-false-claims-407583",407583
148052,369568,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 29 ,news,"Investing com   Canada stocks were lower after the close on Thursday  as losses in the Materials  Healthcare and Energy sectors led shares lower 
At the close in Toronto  the S P TSX Composite fell 0 29  
The best performers of the session on the S P TSX Composite were Interfor Corp  TO IFP   which rose 2 38  or 0 26 points to trade at 11 18 at the close  Meanwhile   Avigilon Corp   TO AVO  added 2 16  or 0 28 points to end at 13 27 and  West Fraser Timber Co  Ltd    TO WFT  was up 2 14  or 0 83 points to 39 58 in late trade 
The worst performers of the session were  Surge Energy Inc    TO SGY   which fell 5 56  or 0 140 points to trade at 2 380 at the close   Baytex Energy  Corp  TO BTE  declined 5 53  or 0 40 points to end at 6 83 and Valeant Pharmaceuticals International Inc  TO VRX  was down 5 10  or 1 56 points to 29 05 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 818 to 372 and 131 ended unchanged 
Shares in Valeant Pharmaceuticals International Inc  TO VRX  fell to 5 year lows  falling 5 10  or 1 56 to 29 05  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 3 01  to 17 80 
Gold for August delivery was down 0 38  or 4 85 to  1283 45 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in July fell 3 87  or 1 86 to hit  46 15 a barrel  while the August Brent oil contract fell 3 61  or 1 77 to trade at  47 20 a barrel 
CAD USD was down 0 37  to 0 7716  while CAD EUR fell 0 15  to 0 6869 
The US Dollar Index was up 0 05  at 94 72 ",2016-06-16,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-0.29-408918,408918
148053,369569,BHC,Ackman s Pershing Square hedge fund cuts eight staffers,news,"BOSTON  Reuters    Billionaire investor William Ackman  whose hedge fund is having double digit losses this year  cut 10 percent of his staff this week when he laid off eight lower level employees  a person familiar with the matter said on Friday 
The people who were laid off worked largely in investor services and were cut as the firm has increasingly automated certain tasks like filling in paperwork for investors  the person said  No investment team members were let go 
New York based Pershing Square  NYSE SQ  managed  12 billion at the end of May  down from  20 billion a year ago  The activist firm makes roughly a dozen concentrated bets and has long had a smaller staff than many similarly sized hedge funds 
This year has been difficult for the firm with the Pershing Square International Fund losing 17 29 percent since January  making it one of the industry s worst performers this year 
Last year the fund dropped 16 6 percent  largely due to Ackman s bet on Valeant Pharmaceuticals  NYSE VRX   whose share price has tumbled 90 percent in the last 12 months 
News of the layoffs was first reported by the Wall Street Journal ",2016-07-01,Reuters,https://www.investing.com/news/stock-market-news/ackman's-pershing-square-hedge-fund-cuts-eight-staffers-412015,412015
148054,369570,BHC,Activist hedge funds dial it back in first half of 2016,news,"By Svea Herbst Bayliss
BOSTON  Reuters    Activist hedge funds were choosier in throwing their weight around corporate boardrooms during the first half of the year as they managed a smaller cash pile and struggled to beat benchmark returns 
Activist investors  including billionaires like Pershing Square s William Ackman and Trian Fund Management s Nelson Peltz  mounted 75 activist campaigns  a 7 percent drop from the first half of 2015 when they mounted 81  according to new data to be released on Tuesday by London based research group Activist Insight 
This year s figure is the lowest since the first half of 2013 when 72 campaigns were waged 
Campaigns can include high profile battles for board seats  public statements about strategy and critiques of senior management s performance 
 This is the first evidence that activists are slowing down   said Josh Black  an analyst at Activist Insight  which tracks activist fund managers and their activities 
Campaigns sharply increased between 2011 when funds mounted 53 in the first half and 2012 when there were 71 in the first six months  according to the data 
Headline making fights are still being mounted  including Barington Capital s contest for two board seats at Chico s FAS Inc  where the retailer said in its June 6 proxy statement that it plans to spend  5 9 million to stop the hedge fund s effort 
Overall activist investing has become slightly less noisy this year as returns are off and investors have taken home some cash as strong stock market returns  often helpful to activists  have ebbed 
While activists were once able to push companies into buying back stock or making other changes swiftly  they have recently focused more on operations  which can mean joining a board and having less time for other fights  Black said 
Starboard Value s Jeff Smith joined Yahoo  NASDAQ YHOO  Inc s board while Ackman joined Valeant Pharmaceuticals  NYSE VRX  International Inc s board this year 
The Valeant investment has hurt Ackman  and his Pershing Square  NYSE SQ  Holdings fund has lost 21 percent so far this year 
Peltz  Trian Partners is roughly flat 
On average  activist funds lost 0 38 percent in the first half  according to data from Chicago based Hedge Fund Research 
Activists  cash pile is also smaller  with assets at  112 5 billion at the end of the first quarter  down about 8 percent from  122 9 billion on Dec  31  2015  according to HFR data  In the first quarter investors pulled out  4 3 billion  a shift from the record  14 billion they added in 2014 ",2016-07-05,Reuters,https://www.investing.com/news/stock-market-news/activist-hedge-funds-dial-it-back-in-first-half-of-2016-412499,412499
148070,369586,BHC,Healthcare Sector Outperforms S P 500 For Last 3 Years,opinion,"In time we may all owe a debt of thanks to Martin Shkreli  CEO of Turing Pharmaceuticals and a former hedge fund manager  Their 5 456  increase in Daraprim brought attention to the importance of regular price hikes in driving revenue growth at major drug companies  The Wall Street Journal later noted that almost 80  of the increase in the top line for the manufacturers of 30 top selling drugs came from raising prices versus increasing volumes  It strikes me that this may just become a political issue in the U S   especially heading into an election year  High drug prices affect millions of Americans and it s easy for the media to find some poor individual whose needed medication has suddenly tripled in price  Hillary Clinton s infamous  price gouging  tweet shows that the issue easily lends itself to sound bites  a necessary condition to retain media interest  Big pharma represents a fairly easy target  Congressional hearings no doubt loom for companies such as Valeant  N VRX   whose business model relies on testing the limits of the market s acceptance for price hikes  They operate as a ruthless capitalist in a market where the laws of economics routinely fail  since customers  patients  are rarely informed buyers and typically incur the expense not directly through paying the asking price  but indirectly through consequently higher health insurance premiums or ultimately higher taxes  One friend told me he holds an investment in health care stocks as a hedge against rising medical expenses for him and his wife  an unusual yet insightful approach 
A common refrain from drug companies is that high drug prices  and the relatively unregulated U S  market has the highest  allow money to be reinvested back into R D  This is a weak argument  If research has a high enough IRR  it can be funded through capital from the public and private markets  it doesn t have to be through retained earnings  It s just as likely that the ability to charge whatever they can dramatically increases the IRR on R D  High drug prices themselves makes the R D more worthwhile than it would be otherwise 
We don t invest in healthcare stocks  as might be apparent  Therefore  to the extent we run investment strategies that are benchmarked against the S P 500  we are effectively short the health care sector  which has outperformed the S P 500 for the last three years and remains on pace to do so again in 2015  The issue of drug pricing isn t likely to recede soon though  and maybe health care stocks will start receiving some of the opprobrium so routinely heaped on banks and oil companies  The energy sector is due for a break as most out of favor 
Martin Shkreli used to work at a hedge fund  and he would probably like the economics of the General Partner  GP  in the MLP sector too  Targa Resources Partners  N NGLS  is an MLP whose business is divided between the midstream activities of Gathering and Processing  G P  of crude oil and natural gas across the central U S   and downstream activities of Marketing and Distribution  NGLS recently provided guidance for 2016 that included flat distribution growth  reflecting the more challenging environment for some energy infrastructure businesses  However  as the hedge fund is to the hedge fund manager  so is NGLS to Targa Resource Corp  N TRGP   the GP of NGLS  The same guidance projected 15  dividend growth at TRGP  Flat returns for hedge fund clients rarely hurt the hedge fund manager  and so it is at TRGP whose Incentive Distribution Rights  IDRs  are at the 50  level  entitling it to half the Distributable Cash Flow from NGLS  the MLP it controls through its ownership of the GP and IDRs  TRGP currently yields 6 3  on its forecast  4 12 2016 dividend  and with a market cap of  3 7BN is of sufficiently modest size to be of interest to many potential acquirers 
We are invested in TRGP ",2015-10-12,Simon Lack,https://www.investing.com/analysis/hedge-fund-manager-runs-drug-company-267770,267770
148071,369587,BHC,Valeant s Decline Reveals Dirty Secret Of Fund Management ,opinion,"How would you feel if your equity fund manager lagged the index by 5  in a year  Supposing that you hired the manager  or bought his fund  as part of the diversified equity part of your portfolio and he missed by 5  in a year  Let s say that you ve been patient  and then he underperforms by another 5  in the next six months  Would you fire someone who lags the market by 10  in 18 months 
Returns vs  business risk
I have met people who say that they love managers who hit the home run and loathe benchmark huggers  but investors get very nervous when their managers lag the market by as little as 5 10  in a relatively short  1 3 years  time frame  From the perspective of the manager  this level of risk tolerance brings up the issue of business risk  How do you maximize performance using your process  or  secret sauce   without taking on excessive business risk that sinks the entire firm 
Risk comes in all shapes and sizes  For an equity portfolio  common sources of risk are sector and industry risk  market cap risk and stock specific risk  To illustrate my example  consider the lowly issue of stock specific risk  which should be diversifiable  at least according to theory  
The recent case of price volatility in Valeant Pharmaceuticals  N VRX  TO VRX   is an instructive example in risk control  In the past few weeks  I have spoken to a number of Canadian portfolio managers whose performance was blindsided by specific risk from that one single stock  The outlook for VRX is highly divisive and talking about it is the equivalent of bringing up touchy topics like religion or gun control in polite company   Incidentally  I have no opinion on the stock  
The chart below depicts the price of VRX in the top panel and the TSX VRX ratio in the bottom panel  which shows what would have happened to relative performance had a manager had no position in VRX for the past few years 
  Despite the fact that the stock got hit yesterday  VRX has shown remarkable returns in the past few years  In the space of about 5 years  the stock has become a 10 bagger and anyone who didn t own it would have underperformed the index  bottom panel   Consider the following effects for a manager who did not hold VRX 
If he didn t own it at the end of 2013  the relative return shortfall would be over 8  when VRX hit its peak this year  For some investment organizations  that kind of shortfall could be a near death experience 
Even with the pullback  the relative performance shortfall would only be back to 2013 levels and would have not made up for the shortfalls in the previous years 
The art of business risk management
The analysis brings up a key question for the business risk for investment management operations  Yes  we would all like to have the courage to bet our investment convictions  but how much business risk is the practice willing to take  Supposing that an operation were to lose half its clients because of a single decision on a stock  what does that do to the bottom line  Revenues would go down by about 50   but there are fixed costs such as rent  salaries  systems  legals  etc  Profitability would plunge in such an instance  Is the investment management business willing to take that kind of risk 
If not  then there are a couple of steps a manager can do  First  he has to decide the appropriate level of stock specific risk he is willing to take against the benchmark  Supposing a stock has a 3 5  weight in the benchmark  would you hold a 0  if you ranked it a  sell    3 5  bet   a non zero weight  such as 2 5       1  vs  benchmark  or 1 5       2  vs  benchmark  
On the other hand  if you ve ranked it a  buy   would a 5 5  weight      2  vs  benchmark  be appropriate  What about 8 5       5  vs  benchmark  
Another way of approaching the problem would be to try and determine the median competitor weight in the stock  with techniques that I have written about before   Then set benchmark weight to be the median competitor weight instead of the index weight 
I show this example as just how a simple decision on a single stock can crash an entire investment management practice  I haven t even gone into all the other ways that risk can rear its ugly head  such as macro factor  sector  size and so on 
Asking too much of managers 
This post also illustrates the dirty little secret of fund management  Investors are asking too much of managers and managers are consequently reacting rationally by closet indexing 
Investors have to ask themselves  How much rope are you willing to give a manager to succeed  Is John Hussman flaming out  or is he a brilliant thinker going through a bad patch  Other well known managers like Bill Miller and Ken Heebner have had their ups and downs  how patient are you willing to be  If you have a low level of patience  then you are forcing managers to become benchmark huggers because you are not giving them enough room to win 
For managers  Given the realities of the market  how much risk are you willing to take so you don t crash your firm 
Disclosure  Cam Hui is a portfolio manager at Qwest Investment Fund Management Ltd     Qwest     This article is prepared by Mr  Hui as an outside business activity  As such  Qwest does not review or approve materials presented herein  The opinions and any recommendations expressed in this blog are those of the author and do not reflect the opinions or recommendations of Qwest 
None of the information or opinions expressed in this blog constitutes a solicitation for the purchase or sale of any security or other instrument  Nothing in this article constitutes investment advice and any recommendations that may be contained herein have not been based upon a consideration of the investment objectives  financial situation or particular needs of any specific recipient  Any purchase or sale activity in any securities or other instrument should be based upon your own analysis and conclusions  Past performance is not indicative of future results  Either Qwest or Mr  Hui may hold or control long or short positions in the securities or instruments mentioned ",2015-10-22,Cam Hui,https://www.investing.com/analysis/how-valeant-revealed-the-dirty-little-secret-of-fund-management-268863,268863
148072,369588,BHC,iFOREX Daily Analysis   October 22  2015,opinion,"The dollar moved slightly higher against most major currencies on Wednesday  following Tuesday s strong U S  housing sector data which continue to provide support  while trading was expected to remain quiet with no major data to be released throughout the day  Sterling eased further against the dollar after the U K  Office for National Statistics reported that public sector net borrowing fell to  8 63 billion in September from  10 79 billion in August  whose figure was revised from a previously estimated  11 31 billion  Analysts had expected public sector net borrowing to decline to  9 40 billion last month  Meanwhile  USD CAD rallied 0 92  to trade at two week highs of 1 3106 after the Bank of Canada decided to hold its benchmark interest rate at 0 50   in a widely expected move  and downgraded its economic outlook citing the  complex  aftershocks of lower oil prices  On Thursday  the ECB s governing council will conclude its two day meeting in Malta  one of two annual meetings its holds each year outside Frankfurt  Traders appear hesitant to make any major moves ahead of the ECB meeting  Other major releases for today are the Spanish unemployment rate  U K retail sales  U S  jobless claims and U S  existing home sales 
EUR USD
EUR USD ended Wednesday s session almost unchanged trading in a tight range between 1 1324 and 1 1386  still supported by Tuesday s positive housing data  The dollar continues to show little movement against the euro on Thursday  as investors remain on the side lines ahead of the ECB monetary policy meeting in Malta where an extension of the bank s current monetary policy program is anticipated  Later in the day  the focus will shift to the U S  and specifically on U S  jobless claims and existing home sales data for further indications on the strength of the economy  For next week  the Federal Reserve s policy meeting will be in the spotlight  Other major releases for today are the Spanish unemployment rate  U S  jobless claims and U S  existing home sales 
Pivot  1 1395Support  1 1305 1 1265 1 123Resistance  1 1395 1 145 1 1495Scenario 1  Short positions below 1 1395 with targets   1 1305   1 1265 in extension Scenario 2  Above 1 1395 look for further upside with 1 145   1 1495 as targets Comment  As long as 1 1395 is resistance  look for choppy price action with a bearish bias 
WTI Oil
Crude oil prices fell considerably on Wednesday dipping to near October lows  as U S  stockpiles shot up last week adding to long term concerns related to a record high supply on energy markets nationwide  Crude oil prices traded in a broad range between  44 88 and  46 08 a barrel  before settling at  45 20  down by more than 2  for the day  The U S  Energy Information Administration  EIA  said U S  crude stockpiles surged by 8 million for the week ending on Oct  16  At 476 6 million barrels  U S  crude oil inventories remain near levels not seen for this time of year in at least 80 years  On Wednesday  an OPEC meeting in Vienna with eight non OPEC members  including Russia  did not produce any meaningful headlines  Investors are now looking ahead to next week s Federal Reserve open market meeting on Oct  27 28 to see if there are any policy changes that could affect the dollar 
Pivot  45 8Support  44 85 44 45 43 95Resistance  45 8 46 4 46 95Scenario 1  Short positions below 45 8 with targets   44 85   44 45 in extension Scenario 2  Above 45 8 look for further upside with 46 4   46 95 as targets Comment  As long as 45 8 is resistance  likely decline to 44 85 
S P 500
U S  stocks fell slightly on Wednesday as a sell off among Health Care and Biotechnology stocks offset gains from a GM and Boeing inspired rally  Shares in Valeant Pharmaceuticals International Inc  N VRX  fell as much as 25  after a report from short seller Citron Research accused the  50 billion pharmaceutical giant of a wide range of improprieties  including creating fake invoices for deceiving auditors and booking artificially high revenues  The biotech sector managed to recover most of the day s losses by market close but bearish sentiment still remains  The S P 500 was down 0 58   the Dow Jones Industrial Average slid 0 28   and the Nasdaq fell 0 84   Markets focus remains on third quarter corporate earnings data  while iinvestors are also looking ahead to next week s Federal Reserve open market meeting on Oct  27 28 to see if there are any policy changes that could affect the dollar 
Pivot  2044Support  1867 1820 1798Resistance  2044 2135 2180Scenario 1  Short positions below 2044 with targets   1952   1867 in extension Scenario 2  Above 2044 look for further upside with 2135   2180 as targets Comment  As long as 2044 is resistance  look for choppy price action with a bearish bias 
Coca Cola
Coca Cola  KO  reported sales of  11 4 billion  slightly below forecasts  Revenue dipped from a year earlier as the effects of a stronger U S  dollar had a strong impact on sales being brought back to the U S  from overseas 
    Pivot  40 4  Support  36 55 35 55 34 9  Resistance  40 4 42 25 43 7    Scenario 1  Short positions below 40 4 with targets   36 55   35 55 in extension   Scenario 2  Above 40 4 look for further upside with 42 25   43 7 as targets   Comment  The RSI lacks upward momentum ",2015-10-22,iFOREX,"https://www.investing.com/analysis/iforex-daily-analysis-:-october-22,-2015-268918",268918
148073,369589,BHC,Stocks Move Lower Ahead Of ECB Meeting ,opinion,"U S  benchmarks extended their losses on Wednesday as the health care sector weighed down in the market  erasing gains from earlier in the session to end lower for the second consecutive day  Valeant Pharmaceuticals International Inc  N VRX   one of the key components in health care sector  had been accused of falsely claiming revenues  pulling the company s shares as much as 40  lower  despite attempts by the company to refute the claims  As a result  the S P s health care sector was dragged 0 9  lower  Other companies also suffered declines  as UnitedHealth Group Inc  N UNH  was pulled down nearly 2  as Valeant concerns spilled over to other parts of the sector  The Standard   Poor s 500 index fell 11 83 points  or 0 6   to close the trading day at 2 018 94  with only one of its 10 main sectors finishing higher  The Dow Jones Industrial Average declined 48 50 points  or 0 3   to finish at 17 168 61  and the Nasdaq Composite shed 40 85 points to trade at 4 840 12  According to Katie Stockton  chief technical strategist at BTIG  the S P is likely to be supported around a level of 2 000  while the 200 day moving average of 2 060 likely acting as a resistance level  According to Stockton  the 200 day moving average is widely followed  making it self fulfilling in a sense  She went on to add the market is in a state of confusion 
European shares remained flat on Wednesday ahead of the European Central Bank s meeting scheduled to release its minutes later today  Investors likely avoided substantial investment ahead of what is currently perceived to be further expansion of the quantitative easing program currently employed in the Eurozone  The Stoxx Europe 600 finished 0 01  lower after moving in and out of positive territory during the session  This marks the index s second day of declines after moving away from a two month high on Tuesday due to declines in the commodities sector  The French CAC 40 finished 0 46  higher to trade at 4 695 10  The UK s FTSE 100 rose 0 05  to trade at 6 348 42  and the German DAX 30 added 0 89  to trade at 10 238 10 
The U S  dollar moved lower from a nine day high against the yen on Wednesday  ahead of the ECB s highly anticipated meeting on Thursday  The dollar traded at 119 90 yen late on Wednesday after touching as high as 120 10  the highest since October 12  The dollar remained little changed against the euro  trading at  1 1342 on the euro 
The European Central Bank will hold a meeting on Thursday  announcing any changes to interest rates  However  judging by the central bank s recent remarks  changes in policy are not likely ",2015-10-22,OptionsClick,https://www.investing.com/analysis/stocks-move-lower-ahead-of-ecb-meeting-268921,268921
148080,369596,BHC,Valeant rejected joint takeover bid from Takeda  TPG in spring  source,news,"By Michael Flaherty  Reuters    Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX  received a joint takeover offer from Japan s Takeda Pharmaceutical Co Ltd  T 4502  and TPG Capital Management LP  TPG UL  this spring that the Canadian drugmaker rejected  according to a source familiar with the matter  The offer was made a few weeks before Joseph Papa took over as Valeant s new chief executive in April last week  the source told Reuters   The board wants to give Papa time to focus on running the company before thinking about a sale offer  the source said  Takeda and private equity firm TPG were ready to offer a substantial premium to Valeant  whose stock had fallen about 65 percent this year up to the close of trade on April 22 as the drugmaker was not just seeking a new head but was also hit by an accounting scandal  the source added  However  analysts from Mizuho Securities USA said that large shareholders and board members are so far  underwater  on their positions and would not want to part with the stock even at a premium to current levels   It would require a hostile offer and protracted battle to dislodge the current board  which most activists may find unattractive   Irina Koffler  an analyst from Mizuho  said in a note late Thursday  The brokerage  which reiterated its  underperform  rating on Valeant  also said the company s assets do not warrant a premium bid at this time  TPG and Valeant declined to comment  Takeda did not immediately respond to a request for comment   There are currently no talks between the three companies following the bid s rejection  according to the Wall Street Journal  which first reported the news late Thursday and also added that as part of the approach Takeda would take the business of Salix Pharmaceuticals and TPG would take much of the rest   
Valeant s shares were up 6 percent at  28 55 on the New York Stock Exchange in extended trading on Thursday ",2016-05-26,Reuters,"https://www.investing.com/news/stock-market-news/valeant-rejected-joint-takeover-bid-from-takeda,-tpg-in-spring:-source-404885",404885
148081,369597,BHC,Valeant s former CEO to receive  9 million severance payment  other fees,news,"NEW YORK  Reuters    Michael  Pearson   LON PSON   the former chief executive officer of Valeant Pharmaceuticals  NYSE VRX  International  TO VRX   will receive a  9 million severance payment and agreed to a consulting agreement worth hundreds of thousands of dollars  according to a document filed with regulators  Pearson  who left Valeant on May 2 after a year in which it had drawn scrutiny for its sharp drug price increases  financial relationship with a specialty pharmacy and accounting practices  is also eligible for a pro rated performance bonus for 2016  the separation agreement document said   He can earn  83 333 a month this year as a consultant and next year  the company agreed to pay him  15 000 per month for consulting services  plus expenses  If Valeant severs the consulting services  Pearson will still receive the payments that would have been due  the document said  After that time  Pearson could be paid  3 750 per day for any consulting services  He also promised to cooperate with the company on providing information related to government inquiries  Pearson  who was replaced by former Perrigo CEO Joseph Papa  had led Valeant since 2008  driving its growth through serial acquisitions  Under his watch  the company s stock hit a high of  263 70 in August of 2015 and fell as low as  25 27 in April of 2016 due to doubts that the company could recover from its hefty debt load  It hit a year low of  23 55 on May 12  after he left  
Valeant announced Pearson s departure in March as activist investor William Ackman took a position on the company s board of directors ",2016-05-31,Reuters,"https://www.investing.com/news/stock-market-news/valeant's-former-ceo-to-receive-$9-million-severance-payment,-other-fees-405539",405539
148082,369598,BHC,Valeant to report first quarter results on June 7,news," Reuters    Valeant Pharmaceuticals Inc  TO VRX   N VRX   which has come under scrutiny for its business and accounting practices  said on Tuesday it would host a conference call on June 7 to discuss first quarter results  The Beleaguered Canadian drugmaker reiterated that it expects to file its quarterly report with U S  and Canadian regulators on or before June 10  ahead of a July 31 deadline  The troubled drugmaker filed its 2015 financial report in late April  allaying concerns about a possible default on its debt of more than  30 billion  
The company missed an original March 15 deadline  citing an in house review of its accounting practices  The probe found problems dating back to 2014 ",2016-05-31,Reuters,https://www.investing.com/news/stock-market-news/valeant-to-report-first-quarter-results-on-june-7-405641,405641
148083,369599,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 01 ,news,"Investing com   Canada stocks were lower after the close on Wednesday  as losses in the Energy  Consumer Discretionary and Consumer Staples sectors led shares lower 
At the close in Toronto  the S P TSX Composite lost 0 01  
The best performers of the session on the S P TSX Composite were Valeant Pharmaceuticals International Inc  TO VRX   which rose 3 98  or 1 49 points to trade at 38 91 at the close  Meanwhile   Dorel Industries Inc   TO DIIb  added 3 18  or 1 08 points to end at 35 04 and  Torex Gold Resources Inc    TO TXG  was up 3 17  or 0 060 points to 1 950 in late trade 
The worst performers of the session were  Surge Energy Inc    TO SGY   which fell 4 76  or 0 120 points to trade at 2 400 at the close   Precision Drilling  Corporation  TO PD  declined 4 54  or 0 28 points to end at 5 89 and  Secure Energy Services Inc    TO SES  was down 3 98  or 0 37 points to 8 92 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 637 to 511 and 141 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 2 19  to 13 41 
Gold for August delivery was down 0 23  or 2 75 to  1214 75 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in July rose 0 20  or 0 10 to hit  49 20 a barrel  while the August Brent oil contract rose 0 06  or 0 03 to trade at  49 92 a barrel 
CAD USD was up 0 17  to 0 7650  while CAD EUR fell 0 35  to 0 6838 
The US Dollar Index was down 0 44  at 95 41 ",2016-06-01,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-0.01-405927,405927
148084,369600,BHC,Valeant gets another default notice from bondholders,news," Reuters    Troubled Canadian drugmaker Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX  said it received another notice of default from bondholders for the delay in filing its first quarter report   However  the company reiterated that it would file the report with U S  and Canadian regulators on or before June 10  ahead of a July 31 deadline  Valeant has lost more than half its value since mid March  after it said a delay in the filing of its annual report could put it at risk of a default on its borrowings  
The Laval  Quebec based company is also facing mounting scrutiny from the U S  Congress  prosecutors and regulators over its drug pricing  business practices and accounting  issues that have pushed its shares down nearly 89 percent since August ",2016-06-03,Reuters,https://www.investing.com/news/stock-market-news/valeant-gets-another-default-notice-from-bondholders-406352,406352
148085,369601,BHC,Wall Street points to higher open  Valeant shares plunge 10 ,news,"Investing com   U S  stock futures pointed to a higher open on Tuesday  tracking strong gains in European and Asian equities  after dovish comments from Federal Reserve Chair Janet Yellen cooled near term U S  rate hike bets and as oil prices firmed above the  50 level 
The blue chip Dow futures rose 55 points  or 0 31   by 10 55GMT  or 6 55AM ET  the S P 500 futures tacked on 6 points  or 0 27   while the tech heavy Nasdaq 100 futures advanced 17 points  or 0 37  
Wall Street ended higher on Tuesday  with the S P 500 rising to a seven month peak  after Fed Chair Yellen gave a largely upbeat assessment of the U S  economic outlook  but declined to set a specific timetable for the U S  central bank s next interest rate hike 
Yellen s comments all but ruled out a chance for a June rate hike  with traders pricing in just a 4  probability based on Fed funds futures  Odds for a July rate hike dropped to 27  from 33  before Yellen spoke  Those odds were at nearly 60  before the disappointing May jobs report late last week 
Meanwhile  oil prices firmed above the  50 level as investors continued to weigh supply disruptions in Nigeria and amid expectations for a decline in U S  crude inventories 
The American Petroleum Institute will release its inventories report later in the day  while Wednesday s government report could show crude stockpiles fell by 3 5 million barrels in the week ended June 3 
In a light day for U S  economic data  productivity and unit labor costs for the first quarter are due at 12 30GMT  or 8 30AM ET  A reading on consumer credit for April is expected at 19 00GMT  or 3 00PM ET 
Among active pre market movers  Valeant Pharmaceuticals  NYSE VRX  shares plunged 11  ahead of the opening bell after the troubled pharmaceutical group announced disappointing first quarter profit and revenue  prompting it to slash its guidance for the year 
Yahoo  NASDAQ YHOO  shares inched up amid reports that  Verizon Communications   NYSE VZ  plans to submit a second round bid of around  3 billion for the tech firm s core internet business 
Elsewhere  European and Asian stock markets posted sharp gains Tuesday  as investors digested the latest comments from Federal Reserve Chair Janet Yellen 
In the currency market  the U S  dollar index  which measures the greenback s strength against a trade weighted basket of six major currencies  was down 0 2  at 93 84  close to the previous session s three week lows of 93 74
The dollar slumped more than 1  against the pound as two new polls on the June 23 referendum on the U K  s membership in the European Union showed the  remain  camp with a slight lead  reducing jitters that the vote could lead to a Brexit 
Meanwhile  the Australian dollar jumped 1  against its U S  counterpart after the country s central bank left rates on hold on Tuesday and held off from indicating that more monetary easing is on the cards ",2016-06-07,Investing.com,https://www.investing.com/news/stock-market-news/wall-street-points-to-higher-open;-valeant-shares-plunge-10-406927,406927
148086,369602,BHC,Valeant Pharmaceuticals plunges 16  after cutting guidance,news,"Investing com   Valeant Pharmaceuticals International Inc  NYSE VRX   TO VRX  plummeted 16  in pre market trade on Tuesday after reporting disappointing first quarter earnings and cutting its forward guidance 
The troubled pharmaceutical reported adjusted earnings per share  EPS  of  1 27  falling below expectations for  1 37 
Revenue in the first three months of the year settled at  2 37 billion  compared to the consensus forecast of  2 39 billion 
Furthermore  the Canadian firm once again cut its full year guidance to  6 60  7 00 per share  from the prior estimate of  8 50  9 50 
Analysts had penciled in  8 47 for 2016 
The pharmaceutical had been struggling to turn around the company after facing scrutiny from the U S  Congress  prosecutors  and regulators over its drug pricing  business practices and accounting practices 
Just last year  the agreement with the distributor of its drugs Philidor RX Services was terminated  hurting sales 
 The first quarter s results reflect  in part  the impact of significant disruption this organization has faced over the past nine months   chairman and chief executive officer Joseph Papa said 
 This has been a difficult period for Valeant and its stakeholders  and while there are some challenges to work through in certain business operations in 2016  such as our U S  dermatology unit  the majority of our businesses are performing according to expectations   he added ",2016-06-07,Investing.com,https://www.investing.com/news/stock-market-news/valeant-pharmaceuticals-plunges-16-after-cutting-guidance-406958,406958
148111,369627,BHC,Rolling Out Decisions  Evaluating A VRX Trade,opinion,"Rolling options is an important exit strategy choice when selling covered call and put options  Options can be rolled up and down in the same contract month or a future contract month  For the most part  we roll down in the same contract month and roll out or out and up in the next contract month  I recently wrote an article evaluating a trade executed by one of our members where an option was rolled up in the same contract month  an approach I rarely subscribe to  In this article we will evaluate another real life trade by one of our members  we have a great group   where an option was rolled out  The two month results were positive but could they have been better 


The initial trade with VRX  Month 1 

5 26 2015  Buy 100 NYSE VRX at  234 60
5 26 2015  Sell 1 x June  240 00 call at  4 50
6 17 15  Early on expiration Friday the stock was still trading near  234 60

Let s feed this preliminary information into the multiple tab of the Ellman Calculator 


VRX  Initial Calculations


We see a respectable 1 9  initial return with the possibility of an additional 2 3  from share appreciation  Because share price remained stagnant  the actual one month return was 1 9  or 23  annualized  Very nice so far 


The second trade with VRX  Month 2 

The option was rolled out to the next month  240 strike  This involved closing the June  240 00 contract  BTC  and opening the July  240 00 contract  STO   The option credit for these trades netted  0 20  Then  mid contract  the option was rolled down to the  235 00 strike  Here are the trades in month 2 

6 17 2015  Rollout to the July  240 00 strike for a net credit of  20 00 for the contract
7 8 2015  BTC  buy to close  the July  240 00 call at  2 35
7 9 2015  STO  sell to open  the July  235 00 call at  4 50
7 17 2015  VRX was trading at  240 00 level and shares were sold at  235 00


Calculating 2 month returns

The shares were purchased at  234 60 and sold for  235 00  a net credit of  40 00 for the 100 shares  less small trading commissions   There were option credits of  450 00    20 00  includes rolling option debit     450 00    920 00  There was an option debit of  235 00  The net option credit was  685 00  The total position credit was  685 00    40 00    725 00 which calculates to a 2 month return of 3 1  on a cost basis of  23 460 00  This annualizes to 18 5   On the surface  this looks pretty good  especially when we compare it to other investment choices we have these days 


Could the trade have been improved 

As Blue Collar Investors  we are always looking for ways to elevate our returns  even good ones  to higher levels  A 3 1  2 month return appears reasonable on the surface  but of that total  1 9  was generated in month 1  The remaining 1  was generated in month 2  so therein lies the weakness of this 2 month trade  It seems that the option from month 1 was rolled when there was no need to do so  The share price was much less than the strike   240 00   and so allowing the option to expire worthless was the prudent thing to do  take no action   That would eliminate any time value spent to close the near month option plus eliminate one commission  Since the shares would not be sold  the next month option could be sold on Monday  Let s make the reasonable assumption that the time value remaining on the near month option was  0 10 and so the next month  240 00 strike sold for  0 30  leaving a net credit of  0 20  Even if the option wasn t rolled  the initial return of the next month option   0 30 is our educated assumption  only generated 0 12  initial profit  far too little 


How to improve this 2 month trade

First  don t roll the option
Sell a lower strike if VRX was still maintained as an underlying security  probably the  235 00 strike  which was used late in the contract
Using the  235 00 strike would have generated a significantly higher time value return  especially if it was used early in the contract  It is reasonable to assume the return would be greater than the  4 50 originally generated in the near month trade  which had a higher strike of  240 00  
If the calculations for VRX did not meet our goals  sell the stock and use a different security

Discussion

Exit strategies like rolling options are absolutely critical to maximizing covered call returns  There are times when these strategies should and should not be used  Setting goals for initial monthly returns is one way we are guided to proper decisions  For example  if a trader sets a goals range for monthly returns of 2 4  as I do  a rolling return of 0 12  would never be given consideration  That said  the trade was an overall success and I commend our member for the way it was managed  Now  lets take that 18  annualized return and bump it up even higher 



Market tone

Financial markets took a breather from recent volatility  and global stocks generally rebounded after a run of daily losses ended Monday  US data releases were mixed  This week s economic reports 

US GDP grew at an annualized pace of 2 3  in the second quarter  below the median economist forecast of 2 6   First quarter GDP was revised up to 0 6  growth from the 0 2  contraction reported previously  Growth was the result of an increase consumer spending and strengthening labor and housing markets
The Fed s two day July meeting ended Wednesday with no policy action and only minor changes in the post meeting statement
The employment cost index rose a seasonally adjusted 0 2  in the second quarter  the smallest quarterly gain since record keeping began in 1982  Sluggish wage growth could cause the Fed to wait longer before raising interest rates
US home prices continued to rise  but pending home sales fell and the home ownership rate sank to a 48 year low
The S P Case Shiller Home Price Index rose 4 4  in the 12 months ended in May  up from 4 3  in April
Pending home sales declined 1 8  in June after five straight monthly increases
The home ownership rate dropped to 63 5  in the second quarter  the lowest since 1967
US nondefense capital goods excluding aircraft  a key proxy for business spending plans  increased 0 9  in June after falling 0 4  in May
Overall durable goods orders rose 3 4   driven by an 8 9  jump in orders for transportation equipment
The University of Michigan consumer sentiment index fell to 93 1 for the final July reading down from 96 1 in June and below the median economist forecast of 94 0
The Conference Board s index of consumer confidence dropped to 90 9 in July from a downwardly revised 99 8 in June  The current reading is the lowest since September 2014  and the monthly decline was the steepest since August 2011
Initial US jobless claims rose 12 000 to 267 000 for the week ended July 25th
Continuing claims climbed 46 000 to 2 26 million for the week ended July 18th

For the week  the S P 500 rose by 1 16  for a year to date return of 2 18  

Summary

IBD  Uptrend under pressure

GMI  5 6  Buy signal

BCI  Cautiously bullish using an equal number of in the money and out of the money strikes The Fed watch continues with a probable rate hike of 25 basis points in September or December  When it occurs  it may temporarily spook the market ",2015-08-02,Dr. Alan Ellman,https://www.investing.com/analysis/rolling-out-decisions:-evaluating-a-real-life-trade-260206,260206
148112,369628,BHC,Clinton Takes Down Biotechnology ETF  Buy The News ,opinion,"The shot was heard around the world of biotech yesterday 

The reaction was immediate and sharp for iShares NASDAQ Biotechnology Fund  NASDAQ IBB  as it lost 4 6  on the day on trading volume nearly 3x the 3 month average 
Hillary Clinton s tweet was enough to take down iShares Nasdaq Biotechnology  IBB   However  IBB has proven very resilient in the face of earlier strong selling pressures 
I doubt many of the quick trigger fingers bothered to read the NY Times article that was the source of Clinton s outrage  Here are some of the key paragraphs from the beginning of  

 Specialists in infectious disease are protesting a gigantic overnight increase in the price of a 62 year old drug that is the standard of care for treating a life threatening parasitic infection 
The drug  called Daraprim  was acquired in August by Turing Pharmaceuticals  a start up run by a former hedge fund manager  Turing immediately raised the price to  750 a tablet from  13 50  bringing the annual cost of treatment for some patients to hundreds of thousands of dollars 
Turing s price increase is not an isolated example  While most of the attention on pharmaceutical prices has been on new drugs for diseases like cancer  hepatitis C and high cholesterol  there is also growing concern about huge price increases on older drugs  some of them generic  that have long been mainstays of treatment 
Although some price increases have been caused by shortages  others have resulted from a business strategy of buying old neglected drugs and turning them into high priced  specialty drugs  

Missing from the article was a specific quantification of the scale of the problem  the cost to the health care system  and or an estimate of excess profits made by the industry  The article was mainly focused on specific cases of egregious price hikes and a fascinating examination of the background of Martin Shkreli  the founder and chief executive of Turing  Ironically  the article also note that two members of Congress wrote a letter in August to Valeant Pharmaceuticals  NYSE VRX  to investigate sharp price hikes on two recently acquired heart medications  One of those Congressmen  independent Vermont Senator Bernie Sanders  is fiercely competing with Clinton for nomination from the Democratic party for President  Is it possible that Clinton is moving quickly to prevent Sanders from getting all the credit for going after evil drug companies 
None of these gaps and intricacies matter for now as sellers seek to get out first and ask questions later  If I traded this special situation  I would stand ready to buy as soon as Clinton announced released her plan  hopefully her plan at least fills in some of the gaps left by the article   The buy the news strategy gets more tempting the deeper the selling going into Clinton s announcement 
Certainly  risks to IBB have increased some unknown amount and perhaps IBB deserves to lose some of its premium  However  given the main business model of IBB constituent companies is NOT price gouging  Clinton s sabre rattling could very well end up tangential to IBB s prospects 
Moreover  there are multiple layers of uncertainty ahead  Clinton wins the Democratic nomination  maybe a Sanders nomination has the same impact for drug companies  but theoretically the market already got a chance to panic about the odds of a Sanders victory   Clinton wins the Presidency  Clinton gets Congress to pass a related bill  said bill survives a battery of legal challenges  In other words  there are many  many years between now and the time that we could even have a hope of knowing whether any kind of related regulation descends upon IBB  The present value of this uncertainty is probably just about zero  Thus  buying IBB on a bet that Clinton related losses will eventually reverse seems like a good risk reward bet 
Note also the past resiliency of IBB to past selling  From a technical perspective  IBB SHOULD have topped out already  Monday s high volume selling  September 21  2015  confirmed the 50 day moving average  DMA  as resistance and cracked the even more important 200DMA  The current close is just the third lowest close since the flash crash  In other words  the technical stakes are VERY high here 
Full disclosure  no positions",2015-09-22,Dr. Duru,https://www.investing.com/analysis/hillary-clinton-takes-down-the-ishares-nasdaq-biotechnology-265801,265801
148113,369629,BHC, 1 Reason Stocks Are Declining  Is Hillary To Blame For Biotech Smash ,opinion,"In the wake of yet another big market selloff  biotechs down over 6  today   the Nasdaq 100 index down 2 87   and the S P 500 down 2 56   mainstream media parrots floated numerous reasons behind the selloff 
All of the parrots are wrong 
Lack of Inflation 
Bloomberg interviewed Jeff Korzenik  Fifth Third Bank s chief strategist in its piece  
In the accompanying video  Korzenik blamed the Fed and a  lack of visible inflation  
In the same video segment  Jamie Dimon bragged about the strength of the US economy and the health of the US consumer  As long as a bubble is expanding  things always look good 
Of course the idea that inflation is a benefit to stocks and the economy is preposterous  but that s what puppets have been trained to believe  and say 
China to Blame 
Reuters writer Noel Randewich says  

 U S  stocks finished sharply lower on Monday and were on track for their worst quarter in four years as investors worried about the health of China s economy and its potential impact on the timing of a U S  interest rate increase  

Is Hillary to Blame for Biotech Smash 
Reuters writers Ransdell Pierson and Bill Berkrot say  

Democratic lawmakers on Monday attacked  massive  price increases of two heart drugs from Canada s Valeant Pharmaceuticals International Inc  NYSE VRX   fueling a rout in drugmaker shares on worries of a government and insurer clampdown on U S  drug prices 
The Democratic House members also urged panel Chairman Jason Chaffetz  a Republican  to invite Valeant Chief Executive Michael Pearson  LONDON PSON  to testify at a hearing next week  That would put him in the same hot seat as Martin Shkreli  chief executive officer of privately held Turing Pharmaceuticals  who had already been called to testify 
Tiny Turing has been widely criticized for a price hike of more than 5 000 percent for its Daraprim treatment for a dangerous parasitic infection 
Clinton on Monday called on Turing to roll back the  750 price to its original  13 50 
Clinton last week unveiled a plan that includes a  250 monthly cap on out of pocket costs for prescription drugs  it would allow the Medicare plan for the elderly to negotiate drug pricing  and permit Americans to buy drugs more cheaply from other countries 
  Stock  selling hasn t really stopped since Hillary Clinton made her comments last week on Monday   said Jeff Jonas  a portfolio manager with Gabelli funds   The Democratic committee members would certainly continue that trend that Hillary started  

Biotech Sector Daily

That looks pretty ominous  But let s put a proper perspective on things 
Biotech Sector Weekly


History suggests the recent selloff is just a start of a correction  Charts like those above smack of bubbles  and bubbles typically do not deflate in an orderly manner 
 1 Reason Stocks are Declining
To paraphrase Bill  It s the economy  stupid  Clinton  I suggest  It s the valuations  stupid  
Valuations are well beyond absurd  Many biotechs won t ever make a dime  And it s not just biotechs  Most market segments have absurd valuations 
The market is starting to care  a reflection of a change in sentiment  Hillary s statements may have been a catalyst for a sentiment change  but most likely she merely goosed sentiment that had already changed 
Not to Blame 
China is not to blame 
Hillary is not to blame 
Fed hikes are not to blame 
To Blame
Rate hike discussion is not to blame 
However  the Fed itself is to blame for creating the loosey goosey conditions that fostered a bubble in equities and junk bonds 
The Fed will now have to deal with yet another asset bubble crash  they don t even see coming   Price deflation the Fed foolishly attempted to defeat  is now more likely than ever 
Price deflation never was  nor ever will be  an economic problem  Asset bubbles are always a problem  The Fed still has not figured this out  Thanks to group think  the Fed never will figure this out 
Bubble Debate
For more on bubble valuations and why I expect negative real returns for 7 10 years  please see Bubble Debate  Equity Allocations vs  Shiller PE  Simple World ",2015-09-29,Mike (Mish) Shedlock,https://www.investing.com/analysis/1-reason-stocks-are-declining;-is-hillary-to-blame-for-biotech-smash-266457,266457
148114,369630,BHC,iFOREX Daily Analysis   September 29  2015,opinion,"The dollar erased gains against the other major currencies on Monday  after data showed that U S  pending home sales dropped unexpectedly last month  although comments by Federal Reserve official William Dudley added to expectations for a near term U S  rate hike 
The U S  National Association of Realtors said that pending home sales dropped 1 4  in August  confounding expectations for a 0 4  uptick after a 0 5  rise the previous month  Earlier on Monday  the U S  Bureau of Economic Analysis reported that personal spending rose 0 4  in August  beating expectations for an increase of 0 3   The report also showed that personal income increased by 0 3  last month  compared to expectations for a 0 4  gain  Meanwhile  New York Federal Reserve Bank President William Dudley said the Fed remains on track for a rate hike this year and could move as soon as the upcoming meeting in October 
Today in the euro zone Germany and Spain are to release preliminary data on consumer price inflation  while the U K  is to report on net private lending  Later on Canada is to publish data on raw material price inflation  the U S  is to report on the trade balance and consumer sentiment  and Bank of England Governor Mark Carney is due to speak at an event in London 
But more than everything else investors await the release of September inflation data in the euro zone on Wednesday and the non farm payrolls data on Friday  for further indications on the strength of the global economy 
EUR USD
The euro rose sharply on Monday  as a sell off among commodities and U S  equities weighed heavily on the dollar  Following a four day losing streak last week  the euro has now closed higher against the dollar in four of the last five sessions 
Investors now await the release of September inflation data in the euro zone on Wednesday  for further indications on the strength of the global economy  Analysts expect to see a 0 1  gain for the month  following a 0 1  increase in August 
Pivot 1 121
Support 1 1211 11851 1145
Resistance 1 12951 1331 1355
Scenario 1 Long positions above 1 121 with targets   1 1295   1 133 in extension 
Scenario 2 Below 1 121 look for further downside with 1 1185   1 1145 as targets 
Comment The RSI is bullish and calls for further upside 
Gold
Gold futures fell sharply on Monday amid a wavering dollar  as relatively optimistic personal income data reinforced the argument for an imminent interest rate hike by the Federal Reserve 
But gold prices held mostly steady on Tuesday in Asia  as demand for the safe haven strengthened after International Monetary Fund head Christine Lagarde said in an interview on Monday that the IMF is likely to revise downwards its estimates for global economic growth due to slower expansion in emerging economies 
Today investors  focus will be on the U S  report on trade balance and consumer sentiment  to gain more informations on the strength of the economy 
Pivot 1139
Support 112811211116
Resistance 113911481157
Scenario 1 Short positions below 1139 with targets   1128   1121 in extension 
Scenario 2 Above 1139 look for further upside with 1148   1157 as targets 
Comment As long as 1139 is resistance  likely decline to 1128 
WTI Oil
Crude oil prices fell more than 2  on Monday  reversing gains from late last week  amid mounting concerns that an interest rate hike by the Federal Reserve will weigh on energy prices worldwide 
Meanwhile  at the 70th session of the United Nation s General Assembly in New York  both U S  president Barack Obama and Iran president Hasan Rouhani devoted significant portions of their speeches to the ramifications of an implementing Iranian Nuclear Deal 
Iran is reportedly hoarding 30 million barrels of crude ready for export shortly after a deal is implemented  It has been estimated that Iran could increase oil exports by as much as one million barrels per day within a year of the final approval of the agreement  So the deal is widely considered bearish for crude 
But crude oil prices rebounded in Asia on Tuesday  ahead of today s American Petroleum Institute release on U S  crude stockpiles  and before Wednesday data from the U S  Department of Energy 
Pivot 45 3
Support 43 743 242 35
Resistance 45 345 7546 4
Scenario 1 Short positions below 45 3 with targets   43 7   43 2 in extension 
Scenario 2 Above 45 3 look for further upside with 45 75   46 4 as targets 
Comment As long as 45 3 is resistance  likely decline to 43 7 
NASDAQ 100
U S  stocks finished sharply lower on Monday and were on track for their worst quarter in four years  as investors worried about the health of China s economy and its potential impact on the timing of a U S  interest rate increase 
The Nasdaq lost 3   the S P 500 dropped more than 2  and the Dow Jones industrial average fell 1 92  Much of the damage came from pharmaceutical and biotech stocks  after Democratic lawmakers on Monday attacked  massive  price increases of two heart drugs from Canada s Valeant Pharmaceuticals International Inc  NYSE VRX   The broad healthcare sector and China are hurting the market 
Investors will now scrutinize non farm payrolls data on Friday  for further indications on the strength of the global economy 
 Pivot  4437
Support  1926 1907 1895
Resistance  4017 3788 3700
Scenario 1  Short positions below 4437 with targets   4017   3788 in extension 
Scenario 2  Above 4437 look for further upside with 4690   4816 as targets 
Comment  The RSI is bearish and calls for further decline ",2015-09-29,iFOREX,"https://www.investing.com/analysis/iforex-daily-analysis-:-september-29,-2015-266492",266492
148115,369631,BHC,Biotechs Making A Comeback  NVAX  HZNP  OPXA  GILD  VRX,opinion,"The US stock market has taken a beating recently  with biotechs taking the brunt of the punishment after comments made by Hillary Clinton  However  today is a relatively green day across the board  and there are several biotech stocks that are making a comeback  Here are 5 biotechs that are making a comeback that s well worth paying attention to   
Novavax Finally Sees The Gains It Deserves
Novavax Inc  NASDAQ NVAX  
Novavax is having an incredible day in the market today  and it s well deserved  Yesterday  NVAX announced top line data from the Phase 2 study of its RSV F Vaccine candidate  The results showed improved antibodies  prompting the soon to come launch of two Phase 3 studies  Also  NVAX announced that it has been awarded a grant of up to  82 million from the Bill   Melinda Gates Foundation for the further development of the vaccine  All in all  the news the company produced yesterday was incredibly popular  However  the stock continued to fall  Nonetheless  we re seeing a strong reversal today  giving NVAX the gains it deserves  Currently  12 03   NVAX is trading at  7 10 per share after a gain of 10 76  so far today 
Horizon Pharma Starts To Recover
Horizon Pharma PLC  NASDAQ HZNP 
Horizon Pharma has had a rough time in the market recently  However  it seems as though the stock is finally starting to reach support  Currently  12 24   HZNP is trading at  18 37 per share after a gain of 9 28  so far today on high volume  On an average day  3 55 million shares of HZNP trade hands  However  so far today  that number is 4 81  about double the normal trading volume on the stock  Today s gains come amid a hostile takeover attempt of Depomed Inc  NASDAQ DEPO   Horizon believes that Depomed is misleading shareholders about a recommendation report from an independent shareholder advisory firm and is planning a continuation of its takeover attempt  This is definitely going to be one to watch 
Opexa Therapeutics Gains On Heavy Volume
Opexa Therapeutics Inc  NASDAQ OPXA 
Over the past couple of days  Opexa Therapeutics has been having a rough time in the market  This was the result of the board s approval of a one for eight reverse stock split  However  today  the stock is starting to recover in strong volume  Currently  12 32   OPXA is trading at  3 02 per share after a gain of 24 20   On an average day over the past 50 days  48 970 share of the stock trade hands  However  today so far 833 284 shares have traded hands  OPXA is an incredibly strong company that has been receiving bullish ratings from several analysts lately  So  if this one s not on your watch list at the moment  you may want to reconsider 
Gilead Sciences  NASDAQ GILD  Starts Heading In The Positive Direction
Gilead Sciences  Inc 
Gilead Sciences has had a tough year  In the beginning of the year  the stock declined as investors proved to be concerned about ABBV stepping into the HCV market  However  GILD has maintained it s control over the market and continued to produce positive earnings reports  Then  more recently  Hillary Clinton made comments about the price of prescription drugs for chronically ill patients  driving GILD down further  At this point  GILD is an incredible stock that is oversold and going for a very low price  So  if you re looking for a strong opportunity in the biotech space  look no further than Gilead Sciences  Currently  12 37   GILD is trading at  97 66 per share after a gain of 1 73  so far today 
Valeant Pharmaceuticals  NYSE VRX  Begins To Recover 
Valeant Pharmaceuticals Intl INC 
Valeant Pharmaceuticals tanked on both Monday and Tuesday after House Democrats requested a subpoena on the company over the decision to raise the prices of two of its heart health drugs  House Democrats want the company to explain the reason the pricing of Isuprel and Nitropress have increased 212  and 525  respectively since the company purchased the rights to the drugs in February  However  today  the stock is starting to recover  Currently  12 42   VRX is trading at  168 90 per share after a gain of 6 84  so far today  However  I don t think we ve come anywhere close to the end of the battle between VRX and House Democrats  So  keep a close eye on this one ",2015-10-01,Joshua Rodriguez,"https://www.investing.com/analysis/biotechs-making-a-comeback:-novavax-(nvax),-horizon-pharma-(hznp),-opexa-266701",266701
148120,369636,BHC,Regulatory filings show which Valeant investors exited in first quarter,news,"By Svea Herbst Bayliss BOSTON  Reuters    Some of Valeant Pharmaceuticals International Inc  NYSE VRX   s most loyal supporters lost hope during the first quarter and either exited the embattled company or significantly cut back their stakes  regulatory filings released on Monday show  Brahman Capital  which had been invested in Valeant for more than five years and committed roughly one quarter of its capital to the company  liquidated its position by selling 8 2 million shares  its filing shows  Senzar Asset Management  which had put nearly 15 percent of its assets in Valeant  said in a filing that it also exited its position  having sold 1 3 million shares  Brave Warrior  a Valeant investor for more than four years with roughly one quarter of its capital invested in the company  slashed its stake by 67 percent  The fund sold 4 2 million shares during the quarter  its filing shows  Even hedge funds that had not put as much money to work in Valeant exited the stock  filings show   Viking Global Investors exited  selling 7 8 million shares  Iridian Asset Management liquidated its entire holding of 4 3 million shares while Coatue Management sold its entire holding of 1 7 million shares and Jana Partners got rid of its 1 6 million shares  Valeant s troubles in the first quarter are well documented and came to a head on March 15  The share price skidded 50 percent when former Chief Executive officer Michael  Pearson   LON PSON   back after a long medical leave  said the company would not meet its earnings goals and might default on its debt  But which investors had made big moves in Valeant became clear only on Monday  when hedge funds were required to submit quarterly filings to the Securities and Exchange Commission  While so called 13 F filings  showing which stocks investment managers owned at the end of the previous quarter  are backward  looking  they are still watched closely for possible trends  Valeant had been one of the pharmaceutical industry s most widely owned stocks as its steady stream of acquisitions fueled strong stock gains  But questions about its accounting and business practices  coupled with lawmakers  concerns about sharp price hikes  clouded its prospects last summer  In the last 52 weeks  its stock tumbled 87 percent  Still  the company had its supporters and filings show that a few hedge funds added to their bets during the first quarter  Okumus Fund Management nearly doubled its holding to 3 7 million shares  while Farley Capital raised its stake by 38 percent to 378 458 shares  It also bought call options on 17 000 shares  Farallon Capital bought 219 700 shares to own 269 700 shares at the end of the quarter  
Most notably  Pershing Square  NYSE SQ  Capital Management  the company s biggest public supporter with a 9 percent stake  put its founder and vice chairman on Valeant s board during the first quarter ",2016-05-16,Reuters,https://www.investing.com/news/stock-market-news/regulatory-filings-show-which-valeant-investors-exited-in-first-quarter-402346,402346
148121,369637,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 17 ,news,"Investing com   Canada stocks were higher after the close on Tuesday  as gains in the Mining  Materials and Energy sectors led shares higher 
At the close in Toronto  the S P TSX Composite added 0 17  
The best performers of the session on the S P TSX Composite were  Penn West Petroleum  Ltd   TO PWT   which rose 14 63  or 0 12 points to trade at 0 94 at the close  Meanwhile  Amaya Inc  TO AYA  added 7 83  or 1 31 points to end at 18 04 and Valeant Pharmaceuticals International Inc  TO VRX  was up 7 80  or 2 72 points to 37 57 in late trade 
The worst performers of the session were Premium Brands Holdings Corporation  TO PBH   which fell 4 59  or 2 60 points to trade at 54 03 at the close   First Capital Realty Inc    TO FCR  declined 4 03  or 0 87 points to end at 20 71 and  New Flyer Industries Inc   TO NFI  was down 3 60  or 1 53 points to 41 00 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 410 to 401 and 104 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 4 05  to 15 63 
Gold for June delivery was up 0 45  or 5 75 to  1279 95 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in June rose 1 68  or 0 80 to hit  48 52 a barrel  while the July Brent oil contract rose 1 04  or 0 51 to trade at  49 48 a barrel 
CAD USD was down 0 08  to 0 7749  while CAD EUR fell 0 04  to 0 6848 
The US Dollar Index was unchanged 0 00  at 94 53 ",2016-05-17,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.17-402640,402640
148122,369638,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 06 ,news,"Investing com   Canada stocks were lower after the close on Thursday  as losses in the Industrials  REITs and Real Estate sectors led shares lower 
At the close in Toronto  the S P TSX Composite declined 0 06  
The best performers of the session on the S P TSX Composite were  Concordia Healthcare   TO CXR   which rose 6 38  or 2 47 points to trade at 41 18 at the close  Meanwhile   Precision Drilling  Corporation  TO PD  added 5 27  or 0 30 points to end at 5 99 and  Alacer Gold  Corp  TO ASR  was up 5 14  or 0 16 points to 3 27 in late trade 
The worst performers of the session were  Russel Metals Inc    TO RUS   which fell 6 46  or 1 51 points to trade at 21 86 at the close  Valeant Pharmaceuticals International Inc  TO VRX  declined 5 23  or 1 89 points to end at 34 27 and  DHX Media Ltd   TO DHXb  was down 4 71  or 0 33 points to 6 67 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 453 to 355 and 96 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 0 65  to 15 28 
Gold for June delivery was down 1 49  or 19 05 to  1255 35 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in June fell 0 17  or 0 08 to hit  48 11 a barrel  while the July Brent oil contract fell 0 43  or 0 21 to trade at  48 72 a barrel 
CAD USD was down 0 47  to 0 7636  while CAD EUR fell 0 37  to 0 6816 
The US Dollar Index was up 0 13  at 95 32 ",2016-05-19,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-0.06-403239,403239
148123,369639,BHC,Valeant gets notice of default from bondholders,news," Reuters    Beleaguered Canadian drugmaker Valeant Pharmaceuticals International Inc  TO VRX   N VRX  said it received a notice of default from bondholders for the delay in filing its first quarter report  The company said it can avert default by filing the report by July 18   Last week  Valeant had said it expected to file the report with U S  and Canadian regulators on or before June 10  ahead of a July 31 deadline  Valeant had been one of the pharmaceutical industry s most widely owned stocks as its steady stream of acquisitions fueled strong gains in its shares   However  questions about its accounting and business practices  coupled with lawmakers  concerns about sharp price hikes  clouded its prospects last summer  Valeant also filed its 2015 financial report last month  after missing the original March 15 deadline  citing an in house review of its accounting practices  The probe found problems dating back to 2014  
The Laval  Quebec based company s U S  listed stock was down about 1 percent after the bell on Thursday ",2016-05-19,Reuters,https://www.investing.com/news/stock-market-news/valeant-gets-notice-of-default-from-bondholders-403284,403284
148124,369640,BHC,Valeant CEO   I don t need to sell anything  ,news,"Joseph Papa has been on the job for just three weeks  but the new CEO of Valeant Pharmaceuticals  NYSE VRX  has some big questions to answer about the embattled company 
Like  will Valeant start to sell assets to pay down a massive debt pile 
Papa addressed the issue at the UBS Global Healthcare Conference on Monday  making sure to both remind everyone that he isn t in desperate need of cash  and also leave open the opportunity that sales or spin offs could happen 
 I don t need to sell anything   he said  Last week   was considering selling some of its cancer and dermatology products to pay down its debt 
Shareholder Bill Ackman has also suggested that the company spin off a stake in Bausch   Lomb in order to force investors to recognize its real value  which is Ackman s eyes is much higher than Valeant is currently worth  
Still  Papas clearly isn t ruling anything out either 
 There will be some places where we ll have to make some decisions on what s core   he said
Last week  Valeant also announced that it  the discount it gave to hospitals for certain heart medications   Nitropress and Isuprel   to up to 40   When asked about the discounts and the price increases that provoked them  Papa owned up to it  calling the price increases a mistake 
 Did we do that  Yes  Was it a mistake  Yes  ",2016-05-23,Business Insider,https://www.investing.com/news/stock-market-news/valeant-ceo:-'i-don't-need-to-sell-anything'-403829,403829
148125,369641,BHC,Valeant CEO Papa plans to lower debt by more than  1 5 billion in 2016,news,"By Caroline Humer NEW YORK  Reuters    Valeant Pharmaceuticals Inc  TO VRX  plans to lower its debt by at least  1 5 billion this year  Chief Executive Officer Joseph Papa said on Monday during his first large meeting with investors since taking the top job three weeks ago  Valeant has about  30 billion in debt and has had to appease creditors  who had the option of forcing early payment of some loans and bonds after Valeant missed deadlines for filing financial records with regulators and triggering default notices  Papa told investors at the UBS Global Healthcare Conference that the company would fund the payoffs in part through the sale of non core assets outside of its main franchises if it can get attractive prices for the assets  Papa said core assets include the dermatology business  Bausch   Lomb eyecare  and its gastroenterology products  many of which were acquired in its purchase of Salix Pharmaceuticals last year  The company has been working on trying to regain its footing after sharp drug price increases last year drew criticism and investigations from U S  lawmakers  The states of Massachusetts and New York are also conducting inquiries into its patient assistance programs and pricing  When distribution for its dermatology products with Philidor RX Services fell apart last year  the company replaced it with a deal with Walgreens Boots Alliance  N WBA   which Papa said has had some  speed bumps   Papa said the company will launch a second phase of the program this summer   Valeant last week announced plans for a new discount program on the price of two heart drugs  Isuprel and Nitropress  and is now working on potential changes in the price of other drugs that have come under scrutiny in Congress  Those include Cuprimine and Syprine  two drugs that are used to treat a genetic disorder that causes copper to build up in the body s organs  
 I have a couple more of those products that I still need to work on   Papa said   And I told Congress I would work on those  ",2016-05-23,Reuters,https://www.investing.com/news/stock-market-news/valeant's-new-ceo-papa-says-there-is-a-lot-to-work-on-403804,403804
148126,369642,BHC,SEC raises concerns about Valeant s use of  Non GAAP  measures,news," Reuters    The Securities and Exchange Commission is concerned about the way Canadian drugmaker Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX  has been disclosing its  non GAAP  financial measures  regulatory filings showed on Tuesday  The SEC has questioned Valeant s practice of stripping away acquisition related expenses from its  non GAAP  or adjusted metrics  given that the drugmaker had been fueling growth through frenzied deal making  The company is facing mounting scrutiny by members of Congress  prosecutors and regulators over its drug pricing  business practices and accounting  issues that have led to its share plummeting nearly 90 percent since August  In multiple letters  the SEC said Valeant s management is in possession of all the facts and urged for adequate and accurate financial disclosures   We are concerned with your overall format and presentation of the non GAAP measures and believe revisions to your future earnings releases and investor materials are appropriate   the SEC said in a letter to the company in February   In response  the Laval  Quebec based company defended its use of non GAAP measures but agreed to make changes in its disclosures  The SEC also questioned Valeant s disclosure of the tax effects of the costs it stripped out of its non GAAP measures  calling the strategy  potentially misleading    Non GAAP measures are metrics that don t comply with generally accepted accounting principles  or GAAP  the standard set of accounting rules in the United States   Typically  they exclude non cash and non recurring items from a company s results and are designed to present a truer reflection of performance  This correspondence  which demonstrates the SEC s lack of comfort with Valeant s reporting  could add gravity to the multiple investigations the company is currently embroiled in  Wells Fargo s David Maris said  cutting his target price to a range of  25  30 from  27  31   The troubled drugmaker filed its 2015 financial report last month  allaying concerns about a possible default on its debt of more than  30 billion  The company missed an original March 15 deadline  citing an in house review of its accounting practices  The probe found problems dating back to 2014   Valeant s U S  listed shares closed down marginally at  26 11  while the stock ended down nearly 5 percent at C 34 29 on the Toronto Stock Exchange   The company said late on Tuesday it was reviewing its compensation policies to reflect the current environment   
Among the amendments that may be considered include adding qualitative performance measures to incentives  as well as introducing relative total shareholder return measures to long term incentives for top executives  Valeant said ",2016-05-24,Reuters,https://www.investing.com/news/stock-market-news/sec-raises-concerns-about-valeant's-use-of-'non-gaap'-measures-404213,404213
148127,369643,BHC,Valeant appoints Tyco s Sam Eldessouky corporate controller,news," Reuters    Embattled drugmaker Valeant Pharmaceuticals International Inc  N VRX  appointed Sam Eldessouky senior vice president and corporate controller  effective May 31  Eldessouky joins from security systems maker Tyco International Plc  N TYC   where he has worked since 2004  most recently as senior vice president  controller and chief accounting officer  
Valeant said in March that  improper conduct  by former Chief Financial Officer Howard Schiller and former Corporate Controller Tanya Carro had contributed to a misstatement of financial results ",2016-05-26,Reuters,https://www.investing.com/news/stock-market-news/valeant-appoints-tyco's-sam-eldessouky-corporate-controller-404677,404677
148145,369661,BHC,Stocks Break Out Again But May Be Running On Fumes,opinion,"Despite low trading volume  a strong dollar  mixed economic and earnings reports  paralyzing weather conditions throughout much of the U S   and ominous global news events  stocks continue to march ever higher  The world remains on edge about potential Black Swan events from the likes of Russia  Greece  or ISIS  or lone wolf extremists   Moreover  the economic recovery of the U S  may be feeling the pull of the proverbial ball and chain from the rest of the world s economies  Nevertheless  awash in investable cash  global investors see few choices better than U S  equities 

In this weekly update  I give my view of the current market environment  offer a technical analysis of the S P 500 chart  review our weekly fundamentals based SectorCast rankings of the ten U S  business sectors  and then offer up some actionable trading ideas  including a sector rotation strategy using ETFs and an enhanced version using top ranked stocks from the top ranked sectors 

Market overview 

Happy days are here again  or so the U S  stock market would have us believe  as all major indices are hitting or challenging new highs  The S P 500 long ago eclipsed the 2000 mark and is now holding above 2100  The Dow Jones Industrials is solidly above 18 000  Even small caps and mid caps have joined the new high party  The NASDAQ  which hasn t challenged its Internet bubble high of 5 048 in 15 years  managed to close Monday above 5 000 and seems determined to make its own new high    perhaps this week  As a reminder  next Monday  the bull market will reach its 6 year anniversary 

Stock buybacks and M A continue at a robust pace  even though these aren t the most popular uses of cash reserves among activist investors  who tend to prefer capital expenditures  hiring  and increased dividends  Nevertheless  the market has applauded some recent M A that involved some of our top stock picks  Last week  Valeant Pharmaceuticals  NYSE VRX   which is in Sabrient s annual Baker s Dozen top picks list this year  spiked  14  after announcing it would acquire former Sabrient favorite Salix Pharmaceuticals  SLXP   which 16 months ago bought another of our former favorites Santarus  Then today  NXP Semiconductor  NXPI   which has been in three consecutive Baker s Dozen top picks lists  announced it will acquire Freescale Semiconductor  FSL   which is also highly ranked in our system  NXPI was up over  17  for the day 

Earnings season is winding down  and FactSet reported Q4 earnings growth to be  3 7  overall  which is pretty good  although revenue growth has been much more muted  Q4 GDP was revised downward to  2 2  and the ISM manufacturing index fell to 52 9  due in part to the West Coast port slowdown   but both are still pretty good  So  economic growth continues to slog ahead  and the Fed is expected to continue on its path toward normalizing monetary policy  Although there might be some short term hits to stocks when rates start bumping up  the consensus is that it would take a fed funds rate of over 3  before there would be any meaningfully negative impact on the economy  With inflation nowhere in sight  it is unlikely we will see fed funds rate that high anytime soon 

Overseas  China has again cut rates by 25 bps as its economy sputters  relatively speaking   inflation remains low  and credit continues to expand  And in Europe  Greece seems to be more willing to work out a deal than the new government s bluster initially suggested  Nevertheless  global demand for U S  Treasury bonds remains strong  and much of that demand is from Europe  Indeed  the U S  10 Year Treasury yield closed Monday at 2 08  as it consolidates after its February spike  and Bloomberg reported last week that institutions are piling into bond ETFs at the fastest pace on record  taking in  32 billion globally this year 

Given that the Fed is likely to start tightening later this year  does that necessarily suggest poor stock performance and widening credit spreads  Apparently not  Scott Minerd of Guggenheim points out that during the nine months leading up to first rate increase over the past six tightening periods since 1980  the S P 500 has returned an average of  23 5  while high yield bonds have outperformed investment grade bonds by 4 0  

The CBOE Market Volatility Index  VIX   a k a  fear gauge  closed Monday at 13 04 and remains below the 15 threshold  reflecting investor complacency 

SPY chart review 

The SPDR S P 500 Trust  ARCA SPY  closed Friday at 210 66 and continues to make new highs on modest volume  It is in a minor uptrend that appears to be setting up as a bullish ascending triangle  with higher lows  However  oscillators RSI  MACD  and Slow Stochastic are all somewhat overbought and look overdue for a more significant pullback    which would be healthy by testing support levels and recharging bullish conviction  Support resides at the 20 day simple moving average currently near 208  the 50 day SMA around 206  the 100 day SMA and the lower uptrend line  which are both near 203  and then the critical 200 day SMA that is now approaching 200  With blue skies overhead  a further rally could make it up to the upper trend line of the long standing bullish channel  which is approaching 215  Even with the overbought conditions and the need for a corrective pullback  the chart remains bullish in the mid and longer term 



Latest sector rankings  

Relative sector rankings are based on our proprietary SectorCast model  which builds a composite profile of each equity ETF based on bottom up aggregate scoring of the constituent stocks  The Outlook Score employs a forward looking  fundamentals based multifactor algorithm considering forward valuation  historical and projected earnings growth  the dynamics of Wall Street analysts  consensus earnings estimates and recent revisions  up or down   quality and sustainability of reported earnings  forensic accounting   and various return ratios  It helps us predict relative performance over the next 1 3 months 

In addition  SectorCast computes a Bull Score and Bear Score for each ETF based on recent price behavior of the constituent stocks on particularly strong and weak market days  High Bull score indicates that stocks within the ETF recently have tended toward relative outperformance when the market is strong  while a high Bear score indicates that stocks within the ETF have tended to hold up relatively well  i e   safe havens  when the market is weak 

Outlook score is forward looking while Bull and Bear are backward looking  As a group  these three scores can be helpful for positioning a portfolio for a given set of anticipated market conditions  Of course  each ETF holds a unique portfolio of stocks and position weights  so the sectors represented will score differently depending upon which set of ETFs is used  We use the iShares that represent the ten major U S  business sectors  Financial  iShares US Financials  NYSE IYF    Technology  iShares Dow Jones US Technology  NYSE IYW    Industrial  iShares US Industrials  NYSE IYJ    Healthcare  iShares US Healthcare  NYSE IYH    Consumer Goods  iShares US Consumer Goods  NYSE IYK    Consumer Services  iShares US Consumer Services  NYSE IYC    Energy  iShares DJ US Energy Sector Fund  NYSE IYE    Basic Materials  iShares US Basic Materials  NYSE IYM    Telecommunications  iShares US Telecommunications  NYSE IYZ    and Utilities  iShares US Utilities  NYSE IDU    Whereas the Select Sector SPDRs only contain stocks from the S P 500  I prefer the iShares for their larger universe and broader diversity  Fidelity also offers a group of sector ETFs with an even larger number of constituents in each 

 Here are some of my observations on this week s scores 

1  Technology has moved back into first place with an Outlook score of 78  followed closely by Financial at 77  Technology displays the best return ratios  a good forward long term growth rate and forward P E  and among the best sell side analyst sentiment  i e   only minor net downward revisions to earnings estimates   Financial displays by far the lowest forward P E  reasonably good forward long term growth rate  and reasonably good sentiment among both insiders  buying activity  and sell side analysts  Consumer Goods Staples  Industrial  and Healthcare round out the top five  Notably  Utilities took the brunt of the net downward earnings revisions and fell pretty far down the rankings  while Industrial and Basic Materials have seen a solid improvement in their scores  which is bullish 

2  Once again  Energy continues to hold the bottom spot given the persistent weakness in oil prices and the ongoing downward earnings revisions  although the Wall Street onslaught has greatly diminished  Energy is among the worst in all factors in the model  with the exception of return ratios  Joining Energy in the bottom two is Telecom 

3  Looking at the Bull scores  Energy and Basic Materials display the top score of 59  followed by Financial and Technology at 58  Utilities scores the lowest at 46  The top bottom spread is 13 points  which is still somewhat on the low side but better than the tight spreads we were seeing several weeks ago  It is generally desirable in a healthy market to see low correlations reflected in a top bottom spread of at least 20 points  which indicates that investors have clear preferences in the stocks they want to hold 

4  Looking at the Bear scores  Utilities displays the highest score of 63 this week  which means that stocks within this sector have been the preferred safe havens on weak market days  Financial has the lowest score of 41  followed closely by Energy  The top bottom spread has widened to 22 points  which indicates low sector correlations on particularly weak market days  Ideally  certain sectors will hold up relatively well while others are selling off  Again  it is generally desirable in a healthy market to see low correlations and a top bottom spread of at least 20 points 

5  Technology displays the best all around combination of Outlook Bull Bear scores  while Energy is the worst  Looking at just the Bull Bear combination  Utilities is the strongest  followed closely by Healthcare  indicating superior relative performance  on average  in extreme market conditions  whether bullish or bearish   while Financial is the worst due to its low Bear score  Healthcare displays the most balanced performance overall 

6  Overall  this week s fundamentals based Outlook rankings look a lot more bullish to me  with economically sensitive sectors Tech  Financial  Industrial  and all weather Healthcare in the top five and the emergence of Basic Materials  Pushed back down near the bottom are defensive sectors Utilities and Telecom  which also have some of the higher Bear scores  What would further enhance the bullishness of the rankings would be if Technology had a score above 90 and if Consumer Services Discretionary switched place with Consumer Goods  But overall  I would call this a bullish ranking for stocks  However  keep in mind  the Outlook Rank does not include timing or momentum factors  but rather is a reflection of the fundamental expectations of individual stocks aggregated by sector 

Stock and ETF Ideas 

Our Sector Rotation model  which appropriately weights Outlook  Bull  and Bear scores in accordance with the overall market s prevailing trend  bullish  neutral  or defensive   retains its bullish bias  and the model suggests holding Technology  Financial  and Industrial  in that order   Note  In this model  we consider the bias to be bullish from a rules based trend following standpoint when SPY is above both its 50 day and 200 day simple moving averages  

Other highly ranked ETFs from the Technology  Financial  and Industrial sectors include iShares Goldman Sachs Network  NYSE IGN   iShares DJSU Financial Services  NYSE IYG   and iShares DJ Transport Average Index  ARCA IYT  

For an enhanced sector portfolio that enlists some top ranked stocks  instead of ETFs  from within the top ranked sectors  some long ideas from Technology  Financial  and Industrial sectors include CommScope  COMM   Brocade Communications Systems  BRCD   Intercontinental Exchange  ICE   Affiliated Managers Group  NYSE AMG   Union Pacific  NYSE UNP   and JetBlue Airways  JBLU   All are highly ranked in the  

However  if you prefer to maintain a neutral bias  the Sector Rotation model suggests holding Technology  Financial  and Consumer Goods Staples  in that order  And if you prefer a defensive stance on the market  the model suggests holding Utilities  Healthcare  and Consumer Goods Staples  in that order 

IMPORTANT NOTE  I post this information each week as a free look inside some of our institutional research and as a source of some trading ideas for your own further investigation  It is not intended to be traded directly as a rules based strategy in a real money portfolio  I am simply showing what a sector rotation model might suggest if a given portfolio was due for a rebalance  and I may or may not update the information each week  There are many ways for a client to trade such a strategy  including monthly or quarterly rebalancing  perhaps with interim adjustments to the bullish neutral defensive bias when warranted    but not necessarily on the days that I happen to post this weekly article  The enhanced strategy seeks higher returns by employing individual stocks  or stock options  that are also highly ranked  but this introduces greater risks and volatility  I do not track performance of the ETF and stock ideas mentioned here as a managed portfolio 
Disclosure  Author has no positions in stocks or ETFs mentioned Disclaimer  This newsletter is published solely for informational purposes and is not to be construed as advice or a recommendation to specific individuals  Individuals should take into account their personal financial circumstances in acting on any rankings or stock selections provided by Sabrient  Sabrient makes no representations that the techniques used in its rankings or selections will result in or guarantee profits in trading  Trading involves risk  including possible loss of principal and other losses  and past performance is no indication of future results ",2015-03-02,Scott Martindale,https://www.investing.com/analysis/stocks-break-out-again-but-may-be-running-on-fumes-243600,243600
148146,369662,BHC,Valeant Pharma Acquires Salix For  11 1 Billion,opinion,Valeant Pharmaceuticals  NYSE VRX  beat out Endo International in a battle to take over Salix Pharmaceuticals Ltd  NASDAQ SLXP  in a deal valued at  11 1 billion  Valeant had originally agreed to pay  158 per share of Salix but increased the offer to  178 per share  Valeant offered an all cash offer while Endo s offer was cash and stock valued at about  172 per share  though Endo later withdrew this deal Valeant CEO J  Michael Pearson  LONDON PSON  commented   We continue to be very excited about the combination of our two companies and we are committed to getting this deal done  This revised offer provides Salix shareholders with all cash at a significant premium and the certainty to close by April 1  Valeant develops a broad range of medication to treat dermatological needs  eye health  and infectious diseases while Salix specializes in gastrointestinal disorders  This deal comes a year after Valeant failed to acquire Allergen  most known for Botox treatment Aside from the failed Allergen buyout  Valeant has been growing by steadily acquiring other pharmaceutical and cosmeceutical companies  Since 2012  Valeant has acquired more than one dozen companies  Some speculate that Valeant may have trouble paying for the latest acquisition because they did not make a payment scheme immediately clear  Aside from financial speculations  analysts were bullish on Valeant Pharma before they had secured the deal On March 16  Canaccord Genuity analyst  maintained a Buy rating on Valeant Pharma with a price target of  230  Maruoka was confident that Valeant Pharma would seal the deal with Salix because the  all cash offer provides more certainty for Salix shareholders and a faster close  as it is not dependent on additional due diligence   The analyst continued   We doubt Endo will be inclined to raise its bid at this point  so we have even higher conviction level that Valeant will emerge the winner  Neil Maruoka has rated Valeant 8 times since April 2014  earning a 100  success rate recommending the pharmaceutical company with an average return of  31 5  per VRX recommendation  Overall  Maruoka has an 81  success rate recommending stocks with a  15 8 average return per recommendation Separately on March 16  analyst  of Cantor Fitzgerald reiterated a Buy rating on Valeant with a price target of  222  The analyst also voiced confidence that Salix would accept Valeant s offer and did not foresee  a bidding war  with Endo s  less significant  offer Irina Rivkind Koffler has rated Valeant Pharma 9 times since March 2014  earning an 89  success rate recommending the company with a  41 6  average return per VRX rating  Overall  Rivkind Koffler has a 78  overall success rate recommending stocks with a  39  average return per recommendation On average  the top analyst recommendation for Valeant Pharma on is Strong Buy ,2015-03-18,Sarah Roden,https://www.investing.com/analysis/valeant-pharma-acquires-salix-245368,245368
148147,369663,BHC,Earnings  GDP Take Spotlight Off The fed,opinion,"As we get into the heart of earnings season and anticipate the GDP report for Q1  the investor spotlight has been taken off the Federal Reserve and timing of its first interest rate hike  at least temporarily  Even though Q1 economic growth will undoubtedly look weak  the future remains bright for the U S economy   even though many multinationals will struggle with top line growth due to the strong dollar   and any near term selloff resulting from weak economic or earnings news should be bought yet again in expectation of better results for the balance of the year  High sector correlations remain a concern  reflecting herd like risk on risk off behavior rather than thoughtful stock picking 
In this weekly update  I give my view of the current market environment  offer a technical analysis of the S P 500 chart  review our weekly fundamentals based SectorCast rankings of the ten U S  business sectors  and then offer up some actionable trading ideas  including a sector rotation strategy using ETFs and an enhanced version using top ranked stocks from the top ranked sectors 
Market Overview
Similar to Q1 2014  it appears that severe winter weather in the US is going to reveal its harsh impact on Q1 economic activity  which is likely to show economic growth near zero or even negative  GDP is scheduled to be released on April 29  Other negative factors include cutbacks in Energy sector spending  the West Coast port slowdown  and the strong dollar  Already  we have seen consumer spending flat or declining in December  January  and February  jobs growth has slowed  and U S  retail sales had its worst 3 month performance since 2009  Nevertheless  most economists are still forecasting positive growth  so investors might decide to sell first and let the dust settle if when bad numbers are actually released 
With the reduced expectation for corporate earnings  the S P 500 has a forward valuation that has reached about 17x  Moreover  the CAPE  cyclically adjusted P E  has reach about 28x  which is the highest since the pre meltdown years of 1928 and 2007 
Of course  the U S  10 Year Treasury was yielding around 4 5  in July 2007  whereas it closed last week at 1 95   so the equity markets can justify higher valuation multiples  Nevertheless  a poor GDP report could send equity investors scurrying for cover while the 10 year yield would likely retreat to its January low near 1 7   But I would take such circumstances as yet another buying opportunity in anticipation of better economic news going forward  given the milder weather  There is still underlying US economic strength and a cautious optimism of continued recovery  despite the strong dollar  With their general focus on the domestic market  small caps in particular should continue to thrive 
The Fed has had it ZIRP  zero interest rate policy  in place since December 16  2008  Today  given the tight credit spreads  which indicates optimism about continued recovery   low unemployment  near the Fed s target   and a strong equities market  that is still somewhat undervalued relative to bonds   some are predicting the first fed funds rate hike will finally arrive in June  However  given the absence of inflation and a strong  and strengthening  dollar  I think the Fed might choose to hold off until September  particularly if the Q1 GDP growth is weak 
The VIX  a k a  the  fear gauge   closed Friday at 12 58  which is now well below the 15 threshold between investor fear and complacency  Notably  ConvergEx reports that the average price correlation among the 10 S P 500 business sectors continued to be quite high at 82   although Energy stocks were 53  correlated   Moreover  EAFE stocks  in US dollars  also showed 82  correlation to the S P 500  while emerging market stocks showed 77  correlation  As for high yield bonds  they showed only a 57  correlation to the S P 500  Of course  it s much more preferable for there to be low correlations reflecting investor selectivity in their choices  rather than herd like risk on risk off behavior 
SPY Chart Review
The SPDR S P 500  ARCA SPY  closed Friday at 210 05 after a strong week  Once again  it found reliable support at the lower uptrend line of the long standing bullish rising channel  bolstered by the 100 day simple moving average  Each test of support led to a successively smaller bull flag continuation pattern  and only time will tell as to whether the latest bounce will lead to a challenge of the February highs near 212  Oscillators RSI  MACD  and Slow Stochastic are all on a bullish trajectory  In last week s article  I predicted a strong move one direction or the other but with an expectation that it would be to the upside  We ll see whether the bulls can keep it going given the anticipation of market moving earnings and economic reports that will come out over the next few weeks  and of course the historically weak month of May lurking on the horizon  Below the 100 day SMA and the uptrend line resides the critical 200 day SMA  around 202  followed by round number support at the 200 price level 

Latest Sector Rankings 
Relative sector rankings are based on our proprietary SectorCast model  which builds a composite profile of each equity ETF based on bottom up aggregate scoring of the constituent stocks  The Outlook Score employs a forward looking  fundamentals based multifactor algorithm considering forward valuation  historical and projected earnings growth  the dynamics of Wall Street analysts  consensus earnings estimates and recent revisions  up or down   quality and sustainability of reported earnings  forensic accounting   and various return ratios  It helps us predict relative performance over the next 1 3 months 
In addition  SectorCast computes a Bull Score and Bear Score for each ETF based on recent price behavior of the constituent stocks on particularly strong and weak market days  High Bull score indicates that stocks within the ETF recently have tended toward relative outperformance when the market is strong  while a high Bear score indicates that stocks within the ETF have tended to hold up relatively well  i e   safe havens  when the market is weak 
Outlook score is forward looking while Bull and Bear are backward looking  As a group  these three scores can be helpful for positioning a portfolio for a given set of anticipated market conditions  Of course  each ETF holds a unique portfolio of stocks and position weights  so the sectors represented will score differently depending upon which set of ETFs is used  We use the iShares that represent the ten major U S  business sectors  Financial  NYSE IYF   Technology  NYSE IYW   Industrial  NYSE IYJ   Healthcare  NYSE IYH   Consumer Goods  NYSE IYK   Consumer Services  NYSE IYC   Energy  NYSE IYE   Basic Materials  NYSE IYM   Telecommunications  NYSE IYZ  and Utilities  NYSE IDU   Whereas the Select Sector SPDRs only contain stocks from the S P 500  I prefer the iShares for their larger universe and broader diversity  Fidelity also offers a group of sector ETFs with an even larger number of constituents in each 
 Here are some of my observations on this week s scores 
Healthcare remains in first place with a solid Outlook score of 86  Healthcare displays good sell side analyst sentiment  net revisions to earnings estimates  and above average scores in most factors in the model  including return ratios  forward long term growth rate  and insider sentiment  buying activity   Financial takes second with a score of 81  with reasonably good analyst and insider sentiment and the lowest forward P E  Technology falls to third this week at 80 and still displays good factor scores across the board  including the highest return ratios 
The rankings have returned to their 3 tier bunching of Outlook scores  After Healthcare  Financial  Tech  and Utilities at the top  the middle tier has Consumer Goods  Staples Noncyclical   Consumer Services  Discretionary Cyclical   Industrial  and Basic Materials  and at the bottom remains Energy and Telecom  Energy continues to hold the bottom spot with an Outlook score of 2 given the persistent weakness in oil prices and the ongoing downward earnings revisions from Wall Street  Energy is among the worst in all factors in the model  including a forward long term growth rate near zero and by far the highest forward P E 
Looking at the Bull scores  Industrial displays the top score of 62  followed by Healthcare  Notably  Energy saw its score rise quite a bit this week all the way up to 60  Telecom sports the lowest Bull score of 51  Once again  all scores are above 50  and the top bottom spread remains relatively narrow at only 11 points  which reflects elevated sector correlations  i e   broad risk on buying   It is generally desirable in a healthy market to see low correlations reflected in a top bottom spread of at least 20 points  which indicates that investors have clear preferences in the stocks they want to hold 
Looking at the Bear scores  Energy displays the highest  i e   best  score of 49  which means that stocks within this sector have been the preferred safe havens  relatively speaking  on weak market days  Industrial is the lowest at 39  The top bottom spread remains a narrow 10 points  which reflects elevated sector correlations on particularly weak market days  i e   broad risk off selling   Ideally  certain sectors will hold up relatively well while others are selling off  so it is generally desirable in a healthy market to see low correlations reflected in a top bottom spread of at least 20 points 
Healthcare displays the best all around combination of Outlook Bull Bear scores  while Energy is the worst  Looking at just the Bull Bear combination  Energy has surged to the top  followed by Utilities and Healthcare  indicating superior relative performance  on average  in extreme market conditions  whether bullish or bearish   while Telecom scores the worst 
Overall  this week s fundamentals based Outlook rankings have taken a slightly more defensive tone  given the move in Utilities and Consumer Goods  Staples Noncyclical   and the fall in Industrial  Thus  I would characterize the rankings as neutral  Keep in mind  the Outlook Rank does not include timing or momentum factors  but rather is a reflection of the fundamental expectations of individual stocks aggregated by sector 
Stock And ETF Ideas
Our Sector Rotation model  which appropriately weights Outlook  Bull  and Bear scores in accordance with the overall market s prevailing trend  bullish  neutral  or defensive   has returned to a bullish bias and suggests holding Healthcare  Financial  and Technology in that order   Note  In this model  we consider the bias to be bullish from a rules based trend following standpoint when  ARCA SPY  is above both its 50 day and 200 day simple moving averages  
Other highly ranked ETFs from the Healthcare  Financial  and Technology sectors include First Trust NYSE Arca Biotechnology Index Fund  NYSE FBT    First Trust NASDAQ ABA Community Bank Index Fund  NASDAQ QABA  and First Trust NASDAQ Technology Dividend Index Fund  NASDAQ TDIV   
For an enhanced sector portfolio that enlists some top ranked stocks  instead of ETFs  from within the top ranked sectors  some long ideas from Healthcare  Financial  and Technology sectors include Valeant Pharmaceuticals  NYSE VRX    Regeneron Pharmaceuticals  NASDAQ REGN    FirstMerit Corp  NASDAQ FMER    PacWest Bancorp  NASDAQ PACW    Ambarella  NASDAQ AMBA   and Skyworks Solutions  NASDAQ SWKS    All are highly ranked in the  
If you prefer to maintain a neutral bias  the Sector Rotation model still suggests holding Healthcare  Financial  and Technology  in that order  But if you prefer a defensive stance on the market  the model suggests holding Healthcare  Utilities  and Energy  in that order 
IMPORTANT NOTE  I post this information each week as a free look inside some of our institutional research and as a source of some trading ideas for your own further investigation  It is not intended to be traded directly as a rules based strategy in a real money portfolio  I am simply showing what a sector rotation model might suggest if a given portfolio was due for a rebalance  and I may or may not update the information each week  There are many ways for a client to trade such a strategy  including monthly or quarterly rebalancing  perhaps with interim adjustments to the bullish neutral defensive bias when warranted    but not necessarily on the days that I happen to post this weekly article  The enhanced strategy seeks higher returns by employing individual stocks  or stock options  that are also highly ranked  but this introduces greater risks and volatility  I do not track performance of the ETF and stock ideas mentioned here as a managed portfolio 
Disclosure  Author has no positions in stocks or ETFs mentioned ",2015-04-13,Scott Martindale,"https://www.investing.com/analysis/earnings,-gdp-take-spotlight-off-the-fed-248244",248244
148148,369664,BHC,Thursday s Pre Market Insights  GPRO  NBS VRX  CTRP,opinion,"GoPro Inc  NASDAQ GPRO  shares increased  2 63  in pre market trading to  54 68 after CEO Nick Woodman unveiled GoPro s virtual reality system at the Code tech conference yesterday in California  The product will be comprised of six cameras and will be available in the second half of the year  though prices have yet to be announced  According to   there are ten analysts who recommend to Buy GoPro  five recommending Hold  and zero recommending Sell 
Neostem Inc  NASDAQ NBS  shares fell more than  22  in pre market trading to  2 05 after the biopharmaceutical company announced an underwritten public offering of 12 5 million shares of common stock at  2 00 per share  NeoStem will use capital for research and development  strategic transactions  and other relevant corporate purposes  According to TipRanks  there are three analysts with Buy ratings on the stock and zero with Sell or Hold ratings 
Valeant Pharmaceuticals  NYSE VRX  shares increased more than 2  to  244 26 after they received FDA approval for Xifaxan  a drug for irritable bowel syndrome in adults  The Canadian biopharmaceutical company acquired the drug after it purchased Salix Pharmaceuticals  According to Tipranks  there are five analysts with Buy ratings on VRX and one with a Sell 
Ctripcom International Ltd  NASDAQ CTRP  shares fell 2 86  to  79 18 in pre market trading after the Chinese online travel company was hacked  The hack disturbed the website and mobile services but customer reservation data has not been harmed  According to TipRanks  eight analysts have a Buy rating on the stock and none have a Hold or Sell rating ",2015-05-28,Sarah Roden,"https://www.investing.com/analysis/thursdays-pre-market-insights:-gopro-inc-(gpro),-neostem-inc-(nbs),-val-253265",253265
148153,369669,BHC,The new Valeant CEO s pay package is putting the company in serious danger,news,"If you blinked  you may have missed it   a lot of politicians did 
It s the part of incoming Valeant Pharmaceuticals  NYSE VRX  CEO Joe Papa s pay package that makes it a dangerous deal 
 Wednesday that Papa agreed to a  67 million pay package 
But that s not the most important part here 
If Valeant s shares reach a price of  270  Papa will get stock equaling  500 million 
That s right  If Papa manages to get the embattled company s stock up by eight times its current level  he ll take home a staggering amount of money 
This news broke at the end of Wednesday s Senate hearing for Valeant  the former Wall Street darling under fire for buying up drugs and then jacking up their prices by  sometimes  triple digit percentages 
Claire McCaskill  D MO  had things to say about the package Thursday morning too 
 In terms of Mr  Papa s compensation package  it strikes me as tone deaf to incentivize the exact kind of raise the stock price at all costs mentality that drove Valeant s immoral and disastrous business strategy to this point   she said in a statement 
 I certainly hope I m wrong and that he has success in moving this company in a new direction  but the onus will be on him and Valeant to prove that  as they long ago lost the benefit of the doubt with the American public  
This is really a story about how a company incentivizes its CEO to care about stock price more than anything else   more than customers  employees  or products   and this is also a story about how that incentivization goes totally over Washington s head 
See no evil
See  McCaskill s colleague  Sen  Susan Collins  R Maine   also had a reaction to this news on Wednesday  She heard about the news just as she was closing the hearing  Collins  mic was still on  and it picked up her dismay just before cameras cut out on the hearing 
 Did you see this last thing  the pay   67 million  This is outrageous   she said 
Afterward  though  when reporters asked her about the issue  she said that billionaire hedge fund manager and Valeant board member Bill Ackman  who had been testifying  talked her off the ledge 
Here s what she said  emphasis ours  
Well  I just asked Mr  Ackman about that and he says that that is not accurate  My staff gave me a heart attack at the end of the hearing by handing me an email saying that the new CEO was being paid  67 4 million  That is not what was explained to us by Mr  Ackman  He explained a very complicated process where there is a base salary and then over a four year period  if the stock goes up  there are bonuses that would be given  But the stock has to go up considerably in order for those bonuses to be paid  There was nothing that added up to  67 4 million in one year  I would encourage you to ask him because he negotiated the deal  This was the first question I asked him when I learned of this 
It s a good question  Sen  Collins  but it s not at all the right one  The real prize here is the  500 million Papa would get for bringing Valeant s stock price back up  So the question isn t how much he s getting  but how he s getting it 
And given the setup in place  who do you think that  270 a share threshold will incentivize Papa to put first  his customers or the shareholders 
Hear no evil
During the hearing  outgoing Valeant CEO Michael  Pearson   LON PSON  said that he regretted making statements that made it seem like he only cared about shareholder interests 
 I have come to realize that because many of my public statements have occurred in the context of talking with shareholders   and those remarks naturally focused on shareholders  interests   my cumulative public comments have left the misimpression that shareholder interests were my only focus as CEO of Valeant   he said 
But it was never just Pearson s public statements that gave the impression that he cared about shareholders first  It was his actions   the company s aggressive business model  which he pioneered  It was Valeant s low budget for research and development and the high margins that came from buying drugs and then jacking up their prices  It was the growth model was made it attractive shareholders and dangerous for patients 
Now that this model isn t available anymore  Valeant has said it will have to rely on selling a large volume of drugs in order to make the profits it used to enjoy  That hasn t happened yet  and analysts don t think it will happen this year at all  In fact  the company has dampened expectations for 2016 
Plus  if the company stands by its commitment to lower prices    it could be a long time before it does  At the hearing  board member and billionaire hedge fund manager Bill Ackman said he would bring down prices 30   That isn t much for some drugs that have seen their prices increase by triple digits  but it s likely enough to keep Valeant s glory days out of reach 
Speak no evil
So what is incoming CEO Joe Papa  whose compensation is tied to the company s stock price  to do  Is he to try his best to make something out of a lower growth  lower margin business model and be happy with that 
Or should he go back to being aggressive about bringing up the stock price by any means necessary 
Papa is being brought over to Valeant from Perrigo  an over the counter drug maker  While he was there  Papa engaged in some of the same behavior as Valeant  For two examples  Perrigo  to avoid US taxes  like Valeant left for Canada   and Perrigo   like Valeant  even as it was fending off a hostile bid from Mylan  NASDAQ MYL  
Again  this is part of a model Valeant pioneered when it was profitable    even with all the lip service  and so far it s just that  lip service  that top brass have given to lowering prices  it will be hard for a new CEO not to go back to the basics that drove the stock price up to the triple digits 
McCaskill  for her part  does not seem convinced 
 Only time will tell if this amounts to meaningful  substantive change or if it s simply rearranging deck chairs on the Titanic in a desperate attempt to fool the business community into believing the company is headed in a different direction   she said in her statement 
The market shares her skepticism  After all the promises Valeant leadership made during the hearing  the stock hasn t moved at all  There s tons of uncertainty here except for the fact that there s  500 million on the line for Papa if he can boost the company s stock price  That s all we know for sure ",2016-05-02,Business Insider,https://www.investing.com/news/economy-news/the-new-valeant-ceo-039;s-pay-package-is-putting-the-company-in-serious-danger-399295,399295
148154,369670,BHC,Ackman defends Valeant  hints at more changes,news,"By Svea Herbst Bayliss and Caroline Humer BOSTON NEW YORK  Reuters    Billionaire investor William Ackman on Monday mounted a vigorous defense of Valeant Pharmaceuticals  TO VRX   ruling out any sale of the drug company s  crown jewel  assets but saying price cuts and even a new name may be in its future  Ackman  whose Pershing Square  NYSE SQ  Capital Management owns 9 percent of Valeant  predicted the company would turn around with the help of its new chief executive officer and by selling greater volumes of products instead of just raising the price of its drugs  He also took aim at Berkshire Hathaway  N BRKa  Vice Chairman Charlie Munger  who criticized Valeant at Berkshire s annual shareholder meeting over the weekend   The company is not a sewer   Ackman said on CNBC television s  Halftime Report   echoing the words Munger used to describe Valeant   It is not fair to indict an entire company based on the actions of a few   Ackman said   Valeant has become Ackman s biggest headache in the last year as the stock price tumbled some 85 percent  One year ago he touted the Canadian company as one of his best ideas at the Sohn Investment conference  This year he will not be speaking at the conference  where he has been a regular for years  Ackman told CNBC  he is sticking with Valeant because he feels he can  fix  the company   The time to invest is pretty much when everyone thinks this is a bad idea   Ackman said  calling Valeant  the cheapest large company I ve seen in my career   In the roughly six weeks that Ackman and his firm s Vice Chairman Steve Fraidin have been directors on Valeant s board  the board has hired Joseph Papa to replace Michael  Pearson   LON PSON  as chief executive and ensured that the company released its long delayed annual report on Friday  On Monday  Ackman said that Valeant does not have to sell any assets to meet obligations and added that it will have a  an investment grade balance sheet sometime within the next two to three years without selling one asset   At some point the Valeant name may be jettisoned  Ackman said  acknowledging that company employees are now embarrassed to say they work for the company  Valeant s aggressive accounting tactics and practice of pushing up prices on newly acquired drugs has hurt the company  putting it into the crosshairs of other prominent investors  including Munger and Buffett at Berkshire  who called Valeant s business model  enormously flawed   Munger acknowledged Ackman s investing acumen in an interview with Fox Business  saying  he s certainly made a brilliant investment in  General Growth Properties   N GGP  and he s totally right about  Herbalife   N HLF   where Ackman has a  1 billion short position   Ackman said Valeant s management and the board understand the anger shown toward the company by lawmakers and investors  
As Ackman spoke  Valeant s stock cut its losses by nearly half to trade at  32 52 per share ",2016-05-02,Reuters,https://www.investing.com/news/stock-market-news/ackman:-valeant-has-no-plans-to-sell-'crown-jewel'-assets---cnbc-399341,399341
148155,369671,BHC,Canada stocks lower at close of trade  S P TSX Composite down 1 14 ,news,"Investing com   Canada stocks were lower after the close on Tuesday  as losses in the Mining  Energy and Materials sectors led shares lower 
At the close in Toronto  the S P TSX Composite fell 1 14  
The best performers of the session on the S P TSX Composite were Valeant Pharmaceuticals International Inc  TO VRX   which rose 11 51  or 4 70 points to trade at 45 55 at the close  Meanwhile   Kinaxis Inc   TO KXS  added 6 55  or 2 64 points to end at 42 92 and Performance Sports Group Ltd  TO PSG  was up 4 34  or 0 20 points to 4 81 in late trade 
The worst performers of the session were  Encana  Corporation  TO ECA   which fell 10 43  or 0 97 points to trade at 8 33 at the close   HudBay Minerals  Inc   TO HBM  declined 8 07  or 0 49 points to end at 5 58 and  Penn West Petroleum  Ltd   TO PWT  was down 7 69  or 0 10 points to 1 20 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 594 to 233 and 70 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 14 64  to 18 72 
Gold for June delivery was down 0 57  or 7 40 to  1288 40 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in June fell 2 66  or 1 19 to hit  43 59 a barrel  while the July Brent oil contract fell 1 88  or 0 86 to trade at  44 97 a barrel 
CAD USD was down 1 50  to 0 7861  while CAD EUR fell 1 26  to 0 6833 
The US Dollar Index was up 0 46  at 92 96 ",2016-05-03,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-1.14-399627,399627
148156,369672,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 51 ,news,"Investing com   Canada stocks were higher after the close on Friday  as gains in the Materials  Mining and Industrials sectors led shares higher 
At the close in Toronto  the S P TSX Composite added 0 51  
The best performers of the session on the S P TSX Composite were  Sierra Wireless Inc    TO SW   which rose 22 09  or 4 16 points to trade at 22 99 at the close  Meanwhile   Alacer Gold  Corp  TO ASR  added 11 69  or 0 36 points to end at 3 44 and  IAMGold  Corporation  TO IMG  was up 9 72  or 0 42 points to 4 74 in late trade 
The worst performers of the session were Valeant Pharmaceuticals International Inc  TO VRX   which fell 13 28  or 5 91 points to trade at 38 58 at the close   Concordia Healthcare   TO CXR  declined 7 82  or 2 69 points to end at 31 69 and  Great West Lifeco Inc    TO GWO  was down 3 91  or 1 39 points to 34 14 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 500 to 312 and 99 ended unchanged 
Shares in Alacer Gold Corp  TO ASR  rose to 52 week highs  rising 11 69  or 0 36 to 3 44  Shares in IAMGold Corporation  TO IMG  rose to 52 week highs  gaining 9 72  or 0 42 to 4 74  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 5 07  to 16 84 
Gold for June delivery was up 1 46  or 18 60 to  1290 90 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in June rose 0 72  or 0 32 to hit  44 64 a barrel  while the July Brent oil contract rose 0 73  or 0 33 to trade at  45 34 a barrel 
CAD USD was down 0 44  to 0 7746  while CAD EUR fell 0 43  to 0 6793 
The US Dollar Index was up 0 12  at 93 84 ",2016-05-06,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.51-400503,400503
148157,369673,BHC,New Mexico public employees to exit Ackman s Pershing Square,news,"By Svea Herbst Bayliss
NEW YORK  Reuters    New Mexico s public employees are taking their final chunk of money out of billionaire investor William Ackman s hedge fund Pershing Square  NYSE SQ  Capital Management  the pension fund s chief investment officer said on Friday 
The  14 billion pension is asking the  12 billion hedge fund to return  13 million  the last remaining bit of a once larger investment  Jonathan Grabel  chief investment officer for the Public Employees Retirement Association of New Mexico told Reuters in a telephone interview 
Pershing Square was a top industry performer in 2014  when it delivered a 40 percent return  But more recently it has been close to the bottom  losing 20 percent last year 
Through April its Pershing Square International fund has lost nearly 15 percent while the average hedge fund is up 0 8 percent  according to eVestment  As one of the industry s biggest activist hedge funds with bets on Canadian Pacific Railway Ltd   Mondelez International Inc   NASDAQ MDLZ  and Valeant Pharmaceuticals International Inc  NYSE VRX   it features prominently in many pension funds 
But Pershing Square locks its investors  money up for a long time    it takes them two full years to exit completely    and so Grabel said his pension fund had to move now or risk being stuck for a while longer 
 We didn t have a meaningful allocation anymore and so the redemption is more related to our asset allocation not their performance   Grabel said  The pension is overhauling its manager lineup and cutting its allocation to global stocks  which make up the bulk of Pershing Square s portfolio 
 I have to give Bill Ackman and his team credit  They are true to their mandate and they believe in it with conviction   he said  adding that the pension fund realized a profit of roughly  10 million from its investment with Ackman 
A Pershing Square spokesman was not immediately available to comment 
Over the last year  Pershing Square s fortunes have come under pressure as a bet on Valeant Pharmaceuticals tumbled 85 percent amid greater scrutiny of the company s accounting and business practices  including sharp drug price hikes 
A new CEO started at Valeant on Monday  Ackman and Pershing Square s vice chairman are now directors on its board  which is expected to be significantly reshaped at the next annual meeting 
Despite the heavy losses in his portfolio late last year and early this year  investors have been largely loyal to Ackman  taking out only about 2 percent of the fund s assets in the first quarter ",2016-05-06,Reuters,https://www.investing.com/news/stock-market-news/new-mexico-public-employees-to-exit-ackman's-pershing-square-400522,400522
148158,369674,BHC,Valeant to file quarterly report by June 10  reiterates forecast,news,"By Ankur Banerjee and Allison Lampert  Reuters    Valeant Pharmaceuticals International Inc  TO VRX   N VRX  said on Monday it expected to file its first quarter report with U S  and Canadian regulators on or before June 10  ahead of a July 31 deadline  and reiterated its first quarter forecasts  Embattled Valeant filed its 2015 financial report last month  allaying concerns about a possible default on the company s debt of more than  30 billion  The company missed an original March 15 deadline to file its annual report  citing an in house review of its accounting practices  The probe found problems dating back to 2014  Valeant  whose U S  shares were down 3 percent in afternoon trading  also said on Monday it expected filings for the second quarter ending June 30 and thereafter to be filed on time  The Laval  Quebec based company  which also reiterated its first quarter revenue and adjusted earnings forecasts  is under scrutiny from the U S  Congress  prosecutors and regulators over its drug pricing  business practices and accounting  Valeant said in March that it expected first quarter adjusted earnings of  1 30  1 55 per share and revenue to be in the range of  2 3 billion  2 4 billion  Analysts on average expect earnings of  1 36 per share and revenue of  2 36 billion  according to Thomson Reuters I B E S   The drugmaker said last month that Joseph Papa  former chief executive of  Perrigo Co  Plc  N PRGO   would replace Michael  Pearson   LON PSON  as CEO  Pearson s frenzied dealmaking fueled double digit profit growth at Valeant until the disclosure last fall of its controversial relationship with a specialty drug distributor  and its strategy of sharply increasing drug prices drew criticism  Michael Sabia  chief executive of Canada s second largest pension fund manager on Monday called Valeant  a business built to satisfy the short term impulses of equity managers in the public markets   Sabia  CEO of Caisse de d p t et placement du Qu bec  said the fund which oversees C 248 billion in assets  owned a small amount of Valeant stock which they sold  at the right time  before the price collapsed   It is the poster child of what can happen when the focus of capital markets is on the short term   Sabia said at the CFA Institute s annual conference  Valeant s U S  shares were trading at  28 99  a far cry from their August high of  263 70  The company s shares sank earlier this year after it said it would delay filing its 2015 financial report  opening the door to possible default on its debt  
The company s Toronto listed shares were down 2 4 percent at C 37 65 ",2016-05-09,Reuters,"https://www.investing.com/news/stock-market-news/valeant-to-file-quarterly-report-by-june-10,-reiterates-forecast-400816",400816
148159,369675,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 09 ,news,"Investing com   Canada stocks were higher after the close on Wednesday  as gains in the Mining  Materials and Energy sectors led shares higher 
At the close in Toronto  the S P TSX Composite gained 0 09  
The best performers of the session on the S P TSX Composite were  Encana  Corporation  TO ECA   which rose 13 40  or 1 06 points to trade at 8 97 at the close  Meanwhile   Intertain Group   TO IT  added 10 65  or 1 13 points to end at 11 74 and  First Quantum Minerals Ltd    TO FM  was up 8 21  or 0 70 points to 9 23 in late trade 
The worst performers of the session were Enerplus Corporation  TO ERF   which fell 7 86  or 0 58 points to trade at 6 80 at the close   Avigilon Corp   TO AVO  declined 6 61  or 1 02 points to end at 14 41 and Valeant Pharmaceuticals International Inc  TO VRX  was down 5 82  or 2 09 points to 33 84 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 459 to 350 and 99 ended unchanged 
Shares in Valeant Pharmaceuticals International Inc  TO VRX  fell to 5 year lows  losing 5 82  or 2 09 to 33 84  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 1 55  to 16 53 
Gold for June delivery was up 1 11  or 14 00 to  1278 80 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in June rose 3 20  or 1 43 to hit  46 09 a barrel  while the July Brent oil contract rose 4 22  or 1 92 to trade at  47 44 a barrel 
CAD USD was up 0 49  to 0 7783  while CAD EUR unchanged 0 00  to 0 6811 
The US Dollar Index was down 0 44  at 93 81 ",2016-05-11,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.09-401421,401421
148160,369676,BHC,Key player in Pershing Square s Valeant bet leaving firm,news,By Svea Herbst Bayliss LAS VEGAS  Reuters    William Doyle  a key figure in Pershing Square  NYSE SQ  Capital Management s controversial investment in battered drug company Valeant Pharmaceuticals  NYSE VRX   is leaving the hedge fund  its founder  William Ackman  told investors on Wednesday   Doyle joined Pershing Square s investment team in October 2014  but had also been involved in other projects including advising cancer therapy company Novocure  which listed its stock last year   The demands of overseeing Novocure and managing its relationship with shareholders and other stakeholders have made it infeasible for Bill to continue as a member of the investment team   Ackman wrote in a letter to investors that was seen by Reuters  Novocure said on Wednesday that Doyle will be the company s executive chairman after having already been a board member  Ackman said Doyle will also spend time at Table Management  an entity that oversees private investments for Ackman s family  Ackman wrote in his letter  Doyle introduced Michael  Pearson   LON PSON   the former CEO of Valeant  and Ackman  the billionaire activist investor  in early 2014 and a year later Ackman s Pershing Square invested in the Canadian drugmaker  In 2015  Ackman called Valeant his best idea but it has become the firm s biggest ever loser  Valeant s stock has tumbled 85 percent amid scrutiny over its accounting and pricing practices  ultimately prompting Ackman to join Valeant s board and forcing Pearson to leave his position as CEO  Doyle was friends with Pearson from their days as consultants at McKinsey and Doyle knew Ackman through Harvard Business School  Doyle joined Pershing Square s investment team shortly after brokering the initial meeting and helped oversee science oriented investments  Last month  Pershing Square said Doyle would not stand for reelection as a board member at animal health company  Zoetis Inc   NYSE ZTS   Earlier this week the fund sold a chunk of its investment in the company  Doyle s exit marks the second departure of a Pershing Square investment team member in five months  In January  Paul Hilal  who has been friends with Ackman since college  left the firm ,2016-05-11,Reuters,https://www.investing.com/news/stock-market-news/key-player-in-pershing-square's-valeant-bet-leaving-firm-401425,401425
148162,369678,BHC,David Tepper s Appaloosa bought and sold Valeant shares in first quarter,news,"NEW YORK  Reuters    David Tepper s hedge fund firm Appaloosa bought nearly 1 million shares in Valeant Pharmaceuticals International Inc  NYSE VRX  in the first three months of 2016  according to regulatory filings  but sold them during the first quarter   Shares of Valeant jumped 2 percent after filings revealed Appaloosa s 945 000 share stake  but CNBC reported that the firm has already sold out of the position  citing a person familiar with the situation  A spokesman for Appaloosa declined to comment  Despite a 10 percent reduction in its exposure  Appaloosa s largest stake continued to be placed in SPDR S P 500 ETF  NYSE SPY  Trust call options  Its 2 7 million SPY calls were valued at more than  555 million by the end of the quarter  and accounted for roughly 9 8 percent of its portfolio  Hedge fund SEC disclosures are backward looking and come out 45 days after the end of each quarter  Still  the filings offer a glimpse into what hedge fund managers saw as investment opportunities  
The filings do not disclose short positions  or bets that a stock will fall  As a result  they do not always present a complete picture of a management firm s stock holdings ",2016-05-13,Reuters,https://www.investing.com/news/stock-market-news/david-tepper's-appaloosa-bought-and-sold-valeant-shares-in-first-quarter-401995,401995
148172,369688,BHC,Top 5 Trade Ideas  Week Of October 8  2012,opinion,American Capital  ACAS American Capital  ACAS  is moving higher after a retest at the 20 day Simple Moving Average  SMA  toward the previous high at 12  It has support for a continued move higher from a rising and bullish Relative Strength Index  RSI  and a Moving Average Convergence Divergence indicator  MACD  that is about to cross to positive  The Measured move higher takes it to 12 30 but the 3 box reversal Point and Figure chart  PnF  has a price objective much higher at 22 75  Asiainfo Linkage  ASIA Asiainfo Linkage  ASIA  has been moving in a symmetrical triangle since May  The latest hold of support on the base and move higher comes with a RSI that is moving from an extreme oversold condition on the RSI higher  The MACD is also starting to improve  Allscripts Healthcare Solutions  MDRX Allscripts Healthcare Solutions  MDRX  moved out of consolidation and into the gap on Friday  The gap fill higher comes at 15 81  but the PnF price objective is even higher at 21 50  The RSI is technically overbought so long positions need to be cautious  but it remains bullish and the MACD is supportive for more upside  too  Southwestern Energy  SWN Southwestern Energy  SWN  is working within two nested Inverse Head and Shoulders patterns  After breaking the dotted neckline and now moving back higher it is about to break the larger neckline  The price objectives of the two are 43 65 and 47 15 and the PnF sees it potentially higher at 51  The bullish RSI and the positive MACD support more upside for a push higher  Valeant Pharmaceuticals  VRX Valeant Pharmaceuticals  VRX  did not give a chance to enter when it jumped higher from a Cup and Handle after Labor Day  But after the recent pullback it presents an interesting trading opportunity with the bearish engulfing candle Friday  A continued move higher over Friday s high could continue the run to the previous high at 61 11 while a confirmation of the bearish engulfing candle would see look for a gap fill lower  The RSI is bullish and trending higher while the negative MACD is is improving  both supporting the upside After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Saturday which  heading into next week suggest keeping an eye on volatility as a signal for a turn  with the expectation that it will remain subdued  Gold looks to be set up to move lower short term but remain bullish longer term while Crude Oil looks lower  and may be seeking a bottom nearby  US Treasurys are set up to continue lower while the Dollar Index may continue to consolidate but is also biased lower  The Shanghai Composite starts trading again with a bias to continue the bounce within the downtrend from before the holiday while Emerging Markets consolidate at resistance  These all set up for the US Equity Index ETF s  SPY  IWM and QQQ to continue higher  The charts of the Indexes themselves agree with the bias but show signs of consolidation or a short pullback  Use this information as you prepare for the coming week and trade m well Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ,2012-10-08,Gregory W. Harmon,"https://www.investing.com/analysis/top-5-trade-ideas:-week-of-october-8,-2012-139000",139000
148173,369689,BHC,Valeant Pharmaceuticals Receives CRL  Share Price Remains Stable,opinion,It was just announced that Valeant Pharmaceuticals  VRX  received a complete response letter for the NDA that was submitted for IDP 108  efinaconazole  for the treatment of toenail Onychomycosis  fungus growth   This really puts a dent in the company s rally after the acqusition of Bausch   Lomb for  8 7 B  investors seemed to like the price that Valeant paid   as well as its recent acqusition of Obagi Medical Products one month ago  According to the company  the CRL was issued due to questions that the FDA brought up about Chemistry  Manufacturing and Controls  CMC  related areas part of the NDA  The drug itself seemed to be fine and primed for FDA approval since the FDA brought up no concerns with the safety and efficacy profile of IDP 108  although this CRL will delay the process a bit  Here is a  Investors  who seem to view this as more a  minor annoyance  than anything worth worrying about  did not drop the share price significantly despite today s 7 6  rally  at time of writing   Valeant Pharmaceuticals is now up 21  in the last 5 days and 35  in the last 30 days  and is poised to be the biggest winner in the big pharma space today ,2013-05-29,Myriad Equity,"https://www.investing.com/analysis/valeant-pharmaceuticals-receives-crl,-share-price-remains-stable-168790",168790
148174,369690,BHC,Volcano Corp To Be Acquired Soon ,opinion,"Summary
In the area of acquisitions  we ve had a solid history of very accurate behavior based predictions 
Although many companies do an excellent job of hiding the progress of a potential acquisition  some clues can still give observant investors an indication that an acquisition is close 
However  it can be difficult to make accurate conclusions is that company officers are obligated to keep quiet about these details to obviously avoid insider trading and other SEC violations 
We believe we have identified one such company we believe is close to be acquired 
Written by Michael Kovar and Scott Matusow  The company we believe is close to being acquired for a nice premium is Volcano Corp   NASDAQ VOLC   Volcano Corp  designs  develops  manufactures and commercializes a broad suite of precision guided therapy tools including intravascular ultrasound and fractional flow reserve products  The company s intravascular ultrasound  IVUS  offerings are used by clinicians to measure the stage and severity of disease present in cardiac and peripheral vessels  IVUS is also used in post stent placement procedures to confirm adequate expansion of the stent and full apposition to the vessel wall  Volcano also provides functional measurement  FM  consoles and single use pressure and flow guide wires  which are used to gauge the impact of arterial plaque on blood flow and pressure  Currently  more than 3 900 Volcano s5 s5i IVUS and FM systems are installed worldwide  with approximately half of its revenues coming from outside the United States  The company is located in San Diego  CA and had sales in 2013 approaching  400 million  Volcano has been the focus of an activist investor who has had success in encouraging takeovers in the past  We will look at some of the clues that indicate a takeover may be close as well as comparing with other takeovers  mainly ones we have closely followed and written on  Toward the end of last year  a fund named Engaged Capital  LLC became vocal as well as announcing a 5 1  stake in Volcano  Glenn Welling  founder of Engaged Capital  said at the time  Volcano is a very attractive acquisition candidate for the large medical device players within the cardiac space  We don t believe they should sell themselves today  Once the stock is more fairly valued  and once they ve achieved some of the targets  Engaged pursues  constructive  activism  working with management to make changes that boost shareholder value  according to its website  Engaged Capital requested at the time that Volcano use some of its  500 million in cash to buy back its own undervalued stock  then priced around  20 share   In December of last year  Volcano announced that they are authorizing a  200 million share buyback program  Along with this measure  Volcano also restructured its business toward the end of 2013  spending about  20 million in one time costs  The market seems to have simply looked at the bottom line quarterly miss versus the details of why the company missed on earnings  To us  this  cleanup  or restructuring seems to be to preparation to be acquired  Another reason the stock has dipped perhaps  is management s less than attractive guidance in the recent earnings call  This prompted us to think back on the acquisition of both Solta and Obagi Medical  as their stock prices dropping to lower levels prior to their respective take over s    both on lowered guidance  We covered both Obagi and Solta  accurately predicting the acquisition of both companies  We believe the case for an acquisition to occur soon with Volcano is as strong  if not stronger than the prior acquisitions of Obagi and Solta  In Obagi s case  the management said they had no plans to hire an investment banker  which went against the activist s position of wanting a takeover  However  when looking back  it clearly seems Obagi was working on a deal quietly when we consider that there was a sale approximately six months after  Solta also appeared to become entrenched by stating it would be fine on its own and subsequently announced drastic cost reduction and restructuring plans in a quarterly earnings call soon before being acquired  The difference shown so far in the case of Volcano  is that the company appears to have taken most of the steps that the activist requested  Both Solta and Obagi were purchased by Valeant Pharmaceuticals  NYSE VRX  in 2013  Valeant is a huge player which is evident by its most recent bid to buy Allergan  NYSE AGN  for  52 7 billion in cash and stock  This deal was rejected accompanied by some jabs from Allergan CEO claiming the bid doesn t offer sufficient value  Since the acquisitions of Solta and Obagi  Valeant stock has gone up considerably as it appears to be making good use of the companies along with typical great performance in other areas  What is also interesting to note  is that Volcano recently acquired AtheroMed for  115M  with an upfront cash price of  100M  and  15M reserved for future milestone payments  However  with no comments from Engaged Capital yet  it s possible this was by design and not against its wishes  So  this deal is likely to add value to Volcano without taking on debt along with making the company more attractive and a more complete asset to potential suitors  Volcano seems to have acquired AtheroMed mainly for its Phoenix device  which received 510 k  clearance last January  In addition  the device also has CE Mark designation in Europe  The Phoenix device is a peripheral atherectomy system which is designed to provide physicians with a safe  versatile  and user friendly primary therapy medium for treating PAD to restore blood flow to the ankle and foot  Volcano believes that this acquisition could place its company in position to grab a decent share of the global atherectomy market  which is valued in the range of  350  400 million with an annualized growth rate of 7   Additional comments by Welling concerning Volcano late last year included such remarks as  Constructive talks continue   so it remains to be seen if any negative feedback comes from the recent AtheroMed acquisition  However  we believe that Welling is receptive of this acquisition and believe the company is in the beginning process of being acquired  Of the  500 million in cash the company once had  spending  200 million for a buyback and about  100 million for the acquisition still leaves them with an abundance of cash  Lately  activists have been quiet  just as was the case with both Solta and Obagi Medical where soon thereafter their acquisitions occurred 
Change of Control Filings
One thing that seems common among other imminent buyouts such as Valeant s purchase of Obagi Medical is when SEC filings start to demonstrate change in ownership compensation clauses  Obviously  if directors and company executives start to suspect that a takeover may take place  they want to protect themselves or make it beneficial for them to stick around  Conversely  it is potentially in the company s best interest to provide these types of arrangements  sometimes referred to as golden parachutes  so that everyone doesn t just quit or start looking for other positions  If a potential deal fell apart or until a potential deal closed  the company would have a big problem if many employees fled  Also  even if the deal consummated  it s important to have people around who know the most about the operations of the company and how to access financial and other valuable information  In February of this year  an 8k SEC filing referred to compensation plans and included  for high level executives if change of control  occurred  A noteworthy section of this 8k is below with some areas in bold  Amended and Restated Executive Employment Agreements with President and Chief Executive Officer and Chief Financial Officer The Amended Employment Agreements also provide that in the event of a qualifying termination  Messrs  Huennekens and Dahldorf will also receive 24 months accelerated vesting of any equity awards with time based vesting  Additionally  the Amended Employment Agreements provide Messrs  Huennekens and Dahldorf with100  accelerated vesting of all of their equity awards in the event of a qualifying termination that occurs within the period commencing 90 days prior to or ending 12 months following a change in control  The Amended Employment Agreements also provide that in the event of a termination of employment for any reason other than for cause  Messrs  Huennekens and Dahldorf will generally have a period of up to 12 months to exercise any vested options following the date of termination  Officer Change in Control Severance Benefit Plan On February 11  2014  the Compensation Committee approved our Officer Change of Control Severance Plan  the  Severance Plan    The Severance Plan provides for severance benefits to eligible officers whose employment is terminated within 90 days prior to and 12 months following a Change of Control  either due to a termination without Cause or a resignation for Good Reason  each  a  Covered Termination    The Severance Plan provides that upon a Covered Termination  and provided the eligible officer timely provides us with an effective release of claims  he or she will be entitled to receive as severance benefits    I   a lump sum cash payment equal to 100  of such officer s annual base salary and target annual cash incentive bonus   ii  payment for premiums for continued group health insurance coverage for a period of 12 months following termination  and   III   immediate full vesting of all then outstanding equity awards  The Severance Plan does not override any severance benefits provided under any individual employment agreement or severance agreement  but the benefits under the Severance Plan will be reduced by benefits under any such individual arrangement  The Compensation Committee will designate our officers  at or above the level of senior vice president  who are eligible to participate in the Severance Plan  Currently  each of our named executive officers is eligible to participate  Obviously  the high level executives at Volcano are doing what they can to gain protection and profit nicely if an acquisition does occur  This filing does not necessarily means that an acquisition of Volcano is imminent  but it does signal that upper management has added the correct corporate governance  in case an acceptable offer comes to fruition  One of the main issues with Obagi Medical was the fact that it failed in corporate governance    one of the main issues that activist firm Voce Capital complained about publicly  Volcano seem to have its  corporate governance squarely in line here with its  severence package 
Unusual Options Activity
A couple of weeks ago  there was one single options trade of approximately 3000 contracts purchased for the June  17 50 call when the stock was out of the money  The call price was half of what it is now  yet the trader has not yet closed out their position  This tells us that this trader wants to be assigned a position in the stock  rather than to take the massive profit they have now  The open interest stands at a little over 3200 call contracts for the month  which will expire on June 21    at the moment  these contracts are in the money 
Potential Suitors
Many large medical device companies would be very interested in Volcano Corporation  Three below are companies that would make sense to us  Boston Scientific  NYSE BSX  has a valuation close to  17 billion and develops  manufactures  and markets medical devices for use in various interventional medical specialties worldwide  One of its segments focuses entirely on cardiovascular devices  In this area  the company provides many products including stents  balloon catheters  wires  peripheral embolization devices  and vena cava filters to treat patients with peripheral disease  Additionally  it provides biliary stents  drainage catheters  and micro puncture sets to treat patients with non vascular disease  Volcano s product line would be a nice fit for Boston Scientific  Medtronic  NYSE MDT  is beginning to dwarf Boston Scientific a bit with a valuation around  61 billion  Its Cardiac and Vascular group s products include pacemakers  electrophysiology catheters  coronary and peripheral stents  heart valve replacement technologies  and open heart and coronary bypass grafting surgical products  Medtronic is another industry giant that has a lot of leverage and looking to consolidate  and Volcano s assets would make for a nice integration here  Abbott Laboratories  NYSE ABT  has a similar valuation to Medtronic coming in at about  60 billion  One of Abbott s segments specializes in vascular products and provides coronary  endovascular  vessel closure  and structural heart devices  However  the company has a very wide scope of products and segments  Abbott should have interest in a company like Volcano  but likely a bit less than the prior companies we mention above  Nevertheless  Abbott is another big company with plenty of leverage at its  disposal  It should be mentioned that Valeant might have an interest in Volcano  but is not a likely suitor due to the fact that its  management is looking to merge with larger companies this year  as it  numerous times last year  Volcano s product line would fit nicely into these three in particular as the companies are the leaders in the segment that Volcano does business in  All of the above companies have the necessary sale forces  leverage  and experience to get the most value out of Volcano  and could potentially increase sales by 30  or more  Additionally  while interest rates are at record lows and likely to increase next year per Fed guidance  we are seeing a large amount of merger and acquisition interest throughout the market  Larger companies are snatching up these smaller ones at record rates  Because of Medtronic and Boston Scientific s focus heavily on medical devices  we lean toward those two as the top candidates to pursue a deal with Volcano  Volcano s product line would fit nicely into these companies in particular  Because of Medtronic and Boston Scientific s focus heavily on medical devices  we lean toward those two as the top candidates to pursue a deal with Volcano  While Volcano is certainly taking the correct steps to bring itself a higher value and to make itself more attractive to potential suitors  as Engaged Capital asked for  we believe after its  recent acquisition of AtheroMed using 100  cash brings its  company value to what Engaged Capital is looking for  Also  as we mention  with interest rates being so low at the current time  a great window of opportunity is in the near term for Volcano  Therefore  we think an acquisition will take place here before the end of this year    before interest rates are likely to rise    in the hands of a company like Abbott Laboratories or Medtronic  Volcano s devices could be marketed as cost cutting products for cash strapped hospitals   If you look at where healthcare is headed in the United States and really around the world in terms of trying to improve outcomes and reducing the cost of therapy  this is right in that sweet spot   Denhoy said 
Conclusion and Price Opinion
With regards to the Valeant takeover of Solta Medical  we wrote in November of 2013 how the hiring of an investment banker indicated an imminent takeover  This ended up being about a month prior to the takeover taking place  On May 21st and 22nd  it was reported that Volcano   However  to date there has not been any admission by Volcano with regards to hiring an investment banker  and the company does not have to disclose if it has hired one  In both the Obagi and Solta cases  it was extremely quiet prior to deal as most would expect  Activists who were very vocal in the past were all of a sudden quiet  We haven t heard any further updates from Engaged Capital in months and feel this is hopefully a good thing for Volcano shareholders  With the worldwide scope of Volcano  it would be a good opportunity for any multinational company to immediately start generating a lot of additional revenue  The assets of Volcano would be used much more effectively with a strong sales and management team having access to more resources and large healthcare facility relationships  The company has generated pretty consistent and slightly increasing sales for several years which should give any buyer confidence that this would continue  With the growth stagnant compared to the industry however  companies such as Boston Scientific and Medtronic would seem like natural front runners that could benefit from Volcano s product line   23  25 share would seem like a good bargain while providing a fair premium  If a bidding war was occurring behind the scenes  it would be possible to escalate from there   23 share being on the low end of our price range would be approximately  1 2 billion for a company generating around  400 million in sales per year along with a potentially significant amount more with its recent acquisition of AtheroMed  which falls in line with that Engaged Capital has asked for  With companies such as Valeant and many others growing via mergers and acquisitions  we should see this trend continue  Additionally  we are seeing along of merger and acquisition activity this year throughout the broader market  This is likely occurring because of record low interest rates that are likely to be coming to an end sometime next year  Since the cost to lever an acquisition is tied to the low interest rate  it makes sense for companies that have their eyes on growing to take advantage of these rates now  rather than wait until next year where these deals would cost them substantially more capital  There is no question in our minds that Volcano is likely to be acquired before the end of this year  The ultra quietness here is actually is very  loud  to us  It would not surprise us that if behind the scenes  an actual deal is being worked on as we speak ",2014-06-13,Scott Matusow,https://www.investing.com/analysis/volcano-corp-to-be-acquired-soon-215881,215881
148175,369691,BHC,Wall Street Up Despite Fed Jitters  Geopolitics,opinion,"Wall Street squeezed out slim gains Tuesday to close higher for the third consecutive day despite unfriendly data on housing and inflation plus continued tensions in the Middle East  After digesting a big jump in consumer prices and weaker than expected housing starts and permits  Wall Street climbed out of the red amid positioning before tomorrow s conclusion to the Federal Open Market Committee meeting  As the U S  economy continues to show more consistent growth  the FOMC is expected to retain its bond buying tapering schedule by shaving another  10 billion off its Quantitative Easing program  The market also expects policy makers to remain optimistic on the outlook for both inflation and employment 
Stocks began the day under water following release of a report that showed a 0 4  increase in consumer prices  twice what the Street was expecting  Excluding food and fuel prices  CPI rose 0 3   beating estimates for a modest 0 2  increase  Also reported Tuesday  May housing starts tumbled 6 5  to a seasonally adjusted annual pace of 1 million  more than the expected decline to 1 04 million from 1 07 million in April  Permits were also weaker than expected  falling to 991 000 from a downwardly revised 1 06 million in April  In corporate news  Valeant Pharmaceuticals  NYSE VRX  is taking its  53 billion offer for Allergan  NYSE AGN  directly to shareholders and soliciting proxies in an attempt to replace the current Allergan board  Shares of both VRX and AGN closed more than 1  higher  Retail equity brokers got a shot in the arm from Senate hearings taking a hard look at the proliferation of  high frequency trading   which allows certain firms to capitalize on their ability to execute faster trades  Shares of TD Ameritrade  NYSE AMTD   Charles Schwab  NYSE SCHW  and E TRADE  NASDAQ ETFC  closed with significant gains 
Here s Where The Markets Stood At The Close
US MARKETS
Dow Jones Industrial Index was up 27 points   0 2   at 16 808
S P 500 was up 4 points   0 2   at 1 941
NASDAQ Composite Index was up 16 points   0 4   at 4 337
GLOBAL SENTIMENT
FTSE 100 was up 0 18 
Nikkei 225 was up 0 29 
Hang Seng Index was down 0 42 
Shanghai Composite Index was down 0 92 
UPSIDE MOVERS
    BIOL Oracle Partners prevails in board  legal fight  forcing CEO s outster
    GWPH Preliminary data from a trial into its Epidiolex treatment for drug resistant epilepsy showed positive results 
    GIGA  2 4 mln order from U S  Navy for Model 8003 Precision Scalar Analyzers
    BTUI Raises Q2 revenue guidance
    ANFI Reported better than expected Q4 earnings and revenue
DOWNSIDE MOVERS
    PGEM Goldman downgraded the stock to sell from neutral
    STRM Risks Nasdaq delisting after failing to file 10 Q quarterly report on time
    ACOR  Planning  300 mln public offering of convertible senior notes due 2021 
After Hours Stock News From  
Copyright   2014 MT Newswires  a Division of MidnightTrader  Inc ",2014-06-17,Midnight Trader,"https://www.investing.com/analysis/wall-street-up-despite-fed-jitters,-geopolitics-216423",216423
148176,369692,BHC, Cutting Through Valeant s Story,opinion,"Allergan  NYSE AGN   maker of Botox  continued its fight against the hostile takeover attempt by Valeant Pharmaceuticals  NYSE VRX  recently in a press release reiterating its belief that VRX s acquisition driven business model is unsustainable  The release contains quotes from notable hedge fund managers such as Jim Chanos and John Hempton that call VRX a roll up 
The most interesting quotes  however  come from e mails between Allergan and executives at Morgan Stanley  NYSE MS   which was aiming to get hired to advise Allergan  In one e mail  an executive at Morgan Stanley wrote that one of his colleagues could  use his significant relationships with media and analysts to provide a clear and detailed articulation of why Valeant is a house of cards and your investors should not want to take the stock  
Want to take a guess at which prominent investment bank has since been retained by that  house of cards   Morgan Stanley reportedly is now advising Valeant on the acquisition despite the earlier misgivings of its executives 
Now  no one should be surprised that Morgan Stanley has switched sides on this deal  It s their business to make money off an acquisition like this one  and it doesn t matter which side pays them  Investors should view these e mails from Morgan Stanley as a reminder that lots of people stand to make money of an acquisition of this size  and executives have many reasons to stretch the truth 
In particular  Valeant has been guilty of some dubious assertions in its attempts to defend itself from claims that its business model is nothing more than a rollup scheme and that its stock is overvalued 
Dubious Claim  1  VRX is fairly valued
One example of Valeant s dubious storytelling comes from their Investor Relations page  On the  Advanced Fundamentals  tab  VRX compares its P E ratio to its industry  sector  and the S P 500  The table shows VRX s P E of 18 as comparable to the market as a whole and superior to its industry and sector 
What the table fails to mention is that VRX s P E is based off its adjusted  non GAAP earnings  which removes billions of dollars in what it classifies as  one time costs  related to its acquisitions  The P E for the S P 500  on the other hand  is based off of GAAP earnings that include these one time costs  and the sector and industry P E s appear to be based the non GAAP measures of each company in the sector or industry  Some of these non GAAP metrics remove the same items as VRX  others don t 
VRX is essentially lumping several different measurements under one label and pretending that these different metrics are comparable when they really are not  In addition to the fact that VRX excludes costs that other companies are including  its P E also neglects the significant amount of debt that the company has taken on in order to finance its acquisition spree 
Figure 1 compares VRX to its sector  industry  and the S P 500 on the basis of both price to economic book value  PEBV  and enterprise value net operating profit after tax  NOPAT   Both of these metrics use comparable measurements of profit and incorporate the impact of debt on a company s valuation 
Figure 1   True Valuation Comparison

Sources    New Constructs  LLC and company filings 
We can see that from an Enterprise Value NOPAT perspective VRX is significantly more expensive than its sector and nearly three times as expensive as the S P 500  Even more strikingly  we see that VRX has a negative economic book value  which means that the perpetuity value of its current cash flow is worth less than its debt  VRX looks very expensive on this basis 
Dubious Claim  2  VRX s past acquisitions are value creating 
More importantly  some of VRX s claims about the value creation of its acquisitions are dubious  Its track record over the past couple years at least don t support this claim  Since 2009  VRX has increased its invested capital from  2 3 billion  26 8 billion  a nearly 13 fold increase  Over that same time  after tax profit  NOPAT  has only tripled  As a result  return on invested capital  ROIC  has declined from 15  to 4   That trend shows value destruction not creation  Companies often use earnings growth to paper over value destroying acquisitions 
The situation may be even worse than it appears  as our calculations assume that VRX is putting one time expenses from its acquisitions in items such as  Restructuring  integration  and other costs   which we exclude  John Hempton of Bronte Capital has argued that the company may be misclassifying recurring items as one time charges in an attempt to boost its non GAAP earnings 
Dubious Claim  3  Allergan bid is about long term value  not short term revenue growth
Valeant CEO J  Michael Pearson has referred to the proposed merger as  strategically compelling and enormously value creating   Perhaps Pearson has a different definition of  value creating  than I do  as it s hard for me to see a way that this acquisition can create value for VRX shareholders 
In order to create value for shareholders  a company must earn an ROIC greater than its weighted average cost of capital  WACC   At the proposed  53 billion price  AGN would need to earn a NOPAT of just over  4 billion in order for the ROIC on the deal to exceed VRX s WACC of 7 6  
Even if we take VRX s optimistic assumption of  2 7 billion in cost savings as realistic  AGN would still come up just short of that  4 billion target  Any value creation from this deal would rest upon the assumption that VRX can strip AGN s research budget to the core  as it has done with other acquisitions  and still achieve long term profit growth  a questionable claim at the very least  If this acquisition works out as optimistically as VRX anticipates  it might just barely break even on an economic earnings basis 
If we look at the ramifications of this deal in comparison to VRX s valuation  a similar picture emerges  With the increase in shares and debt from this deal  VRX would need to grow NOPAT by 27  compounded annually for 12 years in order to justify its  118 share valuation  This would include a 218  increase in NOPAT in year 1 of the acquisition  These outcomes are not likely and reflect the value at risk here 
VRX s market value prices in a significant amount of growth for a company that is slashing R D budgets left and right  VRX may be correct in its assertions that R D spending in the U S  is inefficient  though some of their claims on that point are questionable as well   but eliminating research spending altogether is not a good solution  VRX s strategy of buying up companies to acquire new products is even less efficient per the trend in ROIC  and it can t last forever  as the company eventually will run out of cash for these acquisitions because they cost more money than they make 
Unlike VRX  AGN has a strong business  It currently earns an ROIC of 20  and its economic earnings are positive and growing  The price VRX proposes to pay for AGN is very generous  but the fact that much of that price would be paid in the form of risky  overvalued VRX stock should give investors pause  AGN is a strong company  and it should resist being pulled into the unsustainable business model of VRX 
Sam McBride contributed to this report 
Disclosure  David Trainer and Sam McBride receive no compensation to write about any specific stock  sector  or theme ",2014-07-01,David Trainer,https://www.investing.com/analysis/cutting-through-valeants-story-217936,217936
148190,369706,BHC,Valeant in talks to hire Perrigo s Papa as CEO  source,news,"By Carl O Donnell  Reuters    Drugmaker Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX  is seeking to appoint  Perrigo Co  Plc s  N PRGO  boss Joseph Papa as its new chief executive  a source familiar with the matter said  The Canadian drugmaker is negotiating a contract with the Perrigo CEO and it aims to announce his appointment as soon as next week  the source told Reuters   However  Perrigo board has not said whether it would allow Papa to void a non compete clause in his contract  the source said   Valeant declined to comment on the  rumors   A call to Perrigo s media contact was not immediately returned  The Wall Street Journal earlier reported that Valeant was looking to name Papa as next CEO  Valeant said in March CEO Michael  Pearson   LON PSON  was leaving the company  just three weeks after returning from a two month medical leave  The company said at that time Pearson would remain in his post until it finds his successor   Debt laden Valeant has recently settled with some of its lenders after a missed deadline for filing its annual report put the company at risk of a default  It secured an extension until May 31  but has pledged to file its statements toward the end of April   Reuters reported last week Valeant had brought in investment banks to review its options amid interest from buyout firms and other companies in its businesses  
Pearson and activist investor William Ackman  who joined Valeant s board last month  have said Valeant was considering selling non core assets to help cut its  30 billion debt pile ",2016-04-22,Reuters,"https://www.investing.com/news/stock-market-news/valeant-wants-perrigo's-papa-as-its-new-ceo:-cnbc,-citing-dow-jones-397188",397188
148191,369707,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 05 ,news,"Investing com   Canada stocks were lower after the close on Friday  as losses in the Materials  IT and Consumer Staples sectors led shares lower 
At the close in Toronto  the S P TSX Composite declined 0 05  
The best performers of the session on the S P TSX Composite were  Freehold Royalties Ltd    TO FRU   which rose 7 90  or 0 92 points to trade at 12 57 at the close  Meanwhile   Baytex Energy  Corp  TO BTE  added 7 67  or 0 47 points to end at 6 60 and Valeant Pharmaceuticals International Inc  TO VRX  was up 7 30  or 3 10 points to 45 57 in late trade 
The worst performers of the session were  First Majestic Silver  Corp   TO FR   which fell 7 69  or 0 94 points to trade at 11 29 at the close   Labrador Iron Ore Royalty Corp   TO LIF  declined 4 96  or 0 77 points to end at 14 74 and  TransAlta  Corp  TO TA  was down 4 84  or 0 32 points to 6 29 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 415 to 406 and 96 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 0 98  to 14 18 
Gold for June delivery was down 1 22  or 15 20 to  1235 10 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in June rose 1 27  or 0 55 to hit  43 73 a barrel  while the June Brent oil contract rose 1 35  or 0 60 to trade at  45 13 a barrel 
CAD USD was up 0 53  to 0 7894  while CAD EUR rose 1 05  to 0 7031 
The US Dollar Index was up 0 47  at 95 06 ",2016-04-22,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-0.05-397407,397407
148192,369708,BHC,Valeant names Papa CEO after he resigns from Perrigo,news,"By Carl O Donnell and Greg Roumeliotis  Reuters    Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX  named Joseph Papa as its chief executive officer on Monday  the day after he resigned from the top spot at drugmaker  Perrigo Co  Plc  N PRGO   The move is a boon for Valeant  which is in need of a turnaround after controversy about its relationship with a specialty pharmacy and doubts over its acquisitive business model had driven its shares down 86 percent since August  Shares of Perrigo  which replaced Papa with President John Hendrickson and also reported lower than expected preliminary earnings  sank 12 percent in premarket trading  while Valeant rose 2 4 percent  Papa  60  is expected to join Valeant by early May  Valeant said  He will also be on its board  Laval  Quebec based Valeant grew quickly under current CEO Michael  Pearson   LON PSON  as it embarked on an acquisition spree  snapping up other drugmakers and in many cases sharply raising prices of their products   But the company lost favor with investors last year as its strategy came under scrutiny from regulators  the public and politicians  Pearson returned to Valeant at the end of February  after two months of medical leave while he was being treated for pneumonia  and agreed in March to step down as soon as his replacement is appointed  He will stay until Papa is in place  Valeant said  Papa joined Perrigo in 2006 and was previously president and chief operating officer of Watson Pharmaceuticals Inc  Perrigo is scheduled to hold its annual general meeting of shareholders on Tuesday  Reuters reported earlier this month that Valeant had brought in investment banks to review its options amid interest from buyout firms and other companies in a number of its businesses   The change in Perrigo s leadership comes just months after the Dublin based generic drugmaker rebuffed a  26 billion takeover by Mylan NV  O MYL   the largest ever hostile bid decided by a shareholder vote   Papa resigned on Sunday  Hendrickson  who has been with Perrigo for 27 years and previously led several of its operations  including its U S  consumer healthcare business  was named CEO effective immediately  Perrigo s board also will separate the roles of CEO and chairman  A director  Laurie Brlas  was named chairman  
The company reported preliminary first quarter earnings of  1 71 to  1 77 per share and said it expected a full year profit of  8 20 to  8 60 per share  excluding special items  Both are below analysts  expectations  according to Thomson Reuters I B E S ",2016-04-25,Reuters,https://www.investing.com/news/stock-market-news/exclusive:-perrigo-to-name-hendrickson-ceo-as-papa-joins-valeant---sources-397665,397665
148193,369709,BHC,Washington s  unprecedented overreach  causing losses  asset manager Visium,news,"NEW YORK  Reuters    Visium Asset Management  the approximately  7 billion investment firm led by Jacob Gottlieb  is blaming the U S  government for some of its losses this year 
The Visium Balanced hedge fund  which focuses on healthcare stocks  lost money in March on  Allergan Inc   NYSE AGN pa  when a planned merger with  Pfizer  Inc  NYSE PFE  collapsed because of concern the U S  Department of the Treasury would block the deal  along with other so called tax inversions 
 We did not expect the unprecedented overreach of the Treasury s authority and we incorrectly interpreted the Treasury as recognizing the limitations of its own powers   Visium wrote this month in a private letter to clients that was reviewed by Reuters  The letter said Visium had sold its Allergan shares following the news 
The fund also cited government concerns for losses on pharmaceutical company Endo International PLC  In its letter  Visium blamed the decline on concern that companies such as Valeant Pharmaceuticals International Inc  NYSE VRX   which acquire drugs and then raise their prices  could face increased regulation 
 Investors have been wary of buying into companies that are exposed to this pricing reform   the Visium letter said   We believe ENDP is purely collateral damage from the VRX decline  
It said Endo s lower stock price  presents an opportunity  as it is well positioned to recover from its recent price weakness  
The Balanced fund is down nearly 8 percent this year through April 15  according to a report by HSBC s Alternative Investment Group 
Visium also suffered losses in its largest hedge fund  Visium Global  which bets on a variety of industries  The fund is down about 5 6 percent for the year as of April 15  according to the HSBC report 
Among the fund s losing bets was one against energy stocks as oil prices rallied  according to a separate letter to investors  The losses erased gains from its holdings of Swiss telecommunications company Sunrise Communications Group AG and hotel groups  Starwood Hotels    Resorts Worldwide  NYSE HOT  Inc and Marriott International Inc 
A smaller fund called Visium Institutional Partners is also down nearly 13 percent for the year through April 15  An industry benchmark called the Hedge Fund Intelligence Americas Global Equity Index fell about 3 5 percent through March 
New York based Visium disclosed to clients in March that it is being investigated by the U S  Justice Department and the Securities and Exchange Commission over trading and valuation issues 
A spokesman for Visium did not immediately respond to a request for comment ",2016-04-27,Reuters,https://www.investing.com/news/stock-market-news/washington's-'unprecedented-overreach'-causing-losses:-asset-manager-visium-398314,398314
148194,369710,BHC,Ackman  Valeant pledge reforms after spiking drug prices,news,"By Sarah N  Lynch and Bill Berkrot WASHINGTON NEW YORK  Reuters    Activist investor William Ackman promised U S  lawmakers on Wednesday that he will urge the board of Valeant Pharmaceuticals  TO VRX  to reduce the high prices of four life saving drugs that are now at the heart of two congressional probes  Speaking before the Senate Special Committee on Aging  Ackman revealed that Valeant s board will hold a conference call on Thursday to discuss the costs of heart medications Isuprel and Nitropress  as well as Cuprimine and Syprine  two drugs that are used to treat a genetic disorder that causes copper to build up in the body s organs  Valeant raised the price of Isuprel by about 720 percent and Nitropress by 310 percent  after acquiring them in 2015  The other two were raised by 5 878 percent and 3 162 percent  respectively   My recommendation is going to be to reduce the prices   Ackman testified  The Senate Special Committee on Aging is one of two U S  congressional panels investigating sky rocketing price increases of certain decades old drugs acquired by companies including Valeant and Turing Pharmaceuticals  a company founded by Martin Shkreli  Ackman  a major Valeant shareholder  appeared Wednesday alongside the company s outgoing Chief Executive Michael  Pearson   LON PSON  and Howard Schiller  a board member and former chief financial officer  Ackman joined the board last month as Valeant faced mounting scrutiny by members of Congress  prosecutors and regulators over its drug pricing  business practices and accounting   issues that have caused its share price to plummet almost 90 percent since August  Valeant has about  30 billion of debt and has been negotiating with creditors  some of whom issued notices of default after it missed a deadline for the filing of its financial results  Ackman said Wednesday that one of his top priorities is to protect the company from bankruptcy  Later  in response to a question from Reuters  he expressed confidence that the company will recover   There is not going to be any bankruptcy of Valeant   he said   We were in a death spiral  and we have taken steps to deal with the banks  We are going to file our 10K on time  We brought in a new CEO   Pearson  Ackman and Schiller all told lawmakers on Wednesday they regretted Valeant s pricing decisions   The company was too aggressive and I  as its leader  was too aggressive in pursuing price increases on certain drugs   he said  But many lawmakers on the panel appeared skeptical  They questioned Valeant s business model of investing little in research and development  and the company s practice of acquiring decades old drugs and raising the prices  Senator Claire McCaskill  the panel s top Democrat  angrily asked each of the panelists at one point if they could recall one drug that Valeant didn t raise the price on    Not in the United States   Pearson responded  while Schiller was only able to come up with the name of one drug Valeant acquired after its purchase of Salix   That is not social good  that is social bad   McCaskill said   Lawmakers also questioned whether Valeant s patient assistance and rebate programs are truly helping patients and hospitals afford the medications  Senator Susan Collins  the panel s chairman  said her committee s investigation has thus far been unable to find a single hospital that has received a discount   I can assure you that many of the large hospital systems are getting discounts on the heart drugs   Pearson said   Pearson is expected to step down in the coming weeks to make way for the incoming CEO  Joseph Papa  previously of Perrigo Company  N PRGO   Wednesday s hearing also featured testimony from doctors and a patient with Wilson s Disease who was forced to stop using Syprine because of the price spike   Dr  Frederick Askari of the University of Michigan told the panel that the cost of Syprine is now so high that it has become less expensive to get a liver transplant and a life time supply of anti rejection medications  The patient  Berna Heyman  testified that Valeant refused to help her when she called to complain about the prices  Later  after speaking with the media  the company changed its tune  offered to help  and even sent flowers  
 I refused the flowers   she said ",2016-04-27,Reuters,"https://www.investing.com/news/stock-market-news/ackman,-valeant-pledge-reforms-after-spiking-drug-prices-398448",398448
148195,369711,BHC,Valeant to name four new directors as soon as Friday  WSJ,news," Reuters    Drugmaker Valeant Pharmaceuticals International Inc  NYSE VRX  is expected to name four new directors as soon as Friday  the Wall Street Journal reported  Five of its long standing directors have agreed to step down to make room for the new nominees  the Journal reported  citing people familiar with the matter   Valeant chairman Robert Ingram is also considering leaving  the report said  citing a source  
New Chief Executive Joseph Papa  former  Perrigo Co   NYSE PRGO  Plc head  will also join the board and take on the role of chairman  the report said ",2016-04-27,Reuters,https://www.investing.com/news/stock-market-news/valeant-to-name-four-new-directors-as-soon-as-friday:-wsj-398463,398463
148196,369712,BHC,Valeant annual report reveals new issues  company overhauls board,news,"By Caroline Humer  Reuters    Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX  on Friday issued a 2015 financial report that met an important deadline for creditors but also revealed new details on a broad range of financial and legal issues as well as changes to its board  Shares in Valeant fell 4 0 percent to  33 81 in midday trading in New York on Friday and are well down from their all time high of  263 70 in August  The company has been facing scrutiny from the U S  Congress  prosecutors  and regulators over its drug pricing  business practices and accounting practices   Valeant s relationship with Philidor RX Services  which has been distributing its drugs  was terminated last year  hurting Valeant sales   The publication of the report satisfies demands from Valeant s creditors  but also shows the difficult road ahead for the drugmaker  Wall Street analysts and investors said   We think investors should sell on this catalyst since the business is quite weak and faces a number of headwinds   Mizuho Securities analyst Irina Koffler said in a research note  The annual report does not answer some more basic questions about what strategy Valeant will adopt  said David Neuhauser  managing director of Livermore Partners  which is short Valeant   They continue to dig out of a very troubled situation that will take time   Neuhauser said  In the report  Valeant restated its 2015 financial loss and 2014 earnings as it had forecast   The report also revealed new details about the poor sales of its Addyi sexual dysfunction drug  financial details about its Xifaxin gastroenterology treatment  and also disclosed possible inventory issues on its pharmaceuticals in Poland and Russia  The company also revealed it is being investigated by the U S  Department of Justice in North Carolina  The regulators have requested material relating to the production  marketing  distribution  sale and pricing of three of its life saving drugs  Valeant said  Massachussetts and New York are also investigating similar issues   In a separate statement  Valeant said that seven current board members would not be standing for re election at its June 14 shareholder meeting  including Howard Schiller  the company s former Chief Financial Officer and G  Mason Morfit  who represents ValueAct  Robert Ingram will remain  along with ValueAct representative Robert Hale and several others including activist investor Bill Ackman   Ackman  one of Valeant s largest shareholders  had signaled the board changes at a Congressional hearing earlier this week where he spoke on Valeant s behalf  He vowed that the company would change its business model and revisit certain price increases  including on two heart treatments  Valeant had said it would file its report by April 29  although it had an extension agreement with its creditors to delay the filing until June 11 to stave off a possible default on its  30 billion debt  
Valeant had also said in February that it would restate results for 2014 and 2015  and on Friday  the Laval  Quebec based company said no further restatements were required ",2016-04-29,Reuters,"https://www.investing.com/news/stock-market-news/valeant-files-annual-report,-says-in-compliance-with-covenants-398873",398873
148197,369713,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 47 ,news,"Investing com   Canada stocks were higher after the close on Friday  as gains in the Mining  Materials and Telecoms sectors led shares higher 
At the close in Toronto  the S P TSX Composite gained 0 47  to hit a new 6 months high 
The best performers of the session on the S P TSX Composite were  First Quantum Minerals Ltd    TO FM   which rose 16 70  or 1 53 points to trade at 10 69 at the close  Meanwhile   Air Canada   TO AC  added 12 68  or 1 050 points to end at 9 330 and  Torex Gold Resources Inc    TO TXG  was up 11 50  or 0 230 points to 2 230 in late trade 
The worst performers of the session were  Bombardier Inc   TO BBDb   which fell 7 35  or 0 15 points to trade at 1 89 at the close  Valeant Pharmaceuticals International Inc  TO VRX  declined 5 45  or 2 41 points to end at 41 83 and  Concordia Healthcare   TO CXR  was down 5 02  or 1 93 points to 36 48 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 473 to 369 and 88 ended unchanged 
Shares in Torex Gold Resources Inc   TO TXG  rose to 3 years highs  gaining 11 50  or 0 230 to 2 230  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 1 41  to 15 79 
Gold for June delivery was up 2 39  or 30 25 to  1296 65 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in June fell 0 11  or 0 05 to hit  45 98 a barrel  while the July Brent oil contract fell 0 82  or 0 39 to trade at  47 38 a barrel 
CAD USD was up 0 09  to 0 7973  while CAD EUR fell 0 76  to 0 6966 
The US Dollar Index was down 0 76  at 93 02 ",2016-04-29,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.47-399009,399009
148219,369735,BHC,Valeant s getting a little mercy,news,"What a difference a day   or two   makes 
Valeant has been talking to its lenders to try and amend the terms of some loans it has taken out 
The company had failed to file its 10 K by March 15  and a failure to file it before April 29 would have triggered a technical default on those loans 
On Monday  Valeant Pharmaceuticals  NYSE VRX   creditors  to showing the company mercy by allowing Valeant to amend the terms of its debt 
Now  according to The  it looks like they will 
According to the 
Valeant agreed to pay a fee of  50 000 per  10 million of loans to lenders for the amendment and to boost interest rates on the debt by 1 percentage point  though the rate could decline if Valeant achieves certain financial metrics  the person said 
The company needed more than half of the creditors of its  11 billion in secured loans to agree 
Valeant s share price was up 18  during regular trading on Wednesday  and jumped another 4  in after hours trading after the WSJ reported the loan agreement 
This all started when Valeant announced that it would delay the findings of its annual report because of a discrepancy found by its internal ad hoc committee 
The committee was created to find any issues surrounding Valeant s involvement with a once secret distributor called Philidor  The committee found a  58 million error   a blip  really  for a company Valeant s size   and then concluded its investigation into Philidor on Tuesday 
Philidor s existence was disclosed in October  when scrutiny over Valeant s pricing practices  combined with accusations of malfeasance from a short seller  forced the company to acknowledge Philidor 
It looks like everyone wants to put that behind them  though  We ll see how that works ",2016-04-07,Business Insider,https://www.investing.com/news/stock-market-news/valeant's-getting-a-little-mercy-394088,394088
148220,369736,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 98 ,news,"Investing com   Canada stocks were higher after the close on Friday  as gains in the Mining  Energy and Materials sectors led shares higher 
At the close in Toronto  the S P TSX Composite added 0 98  
The best performers of the session on the S P TSX Composite were  First Quantum Minerals Ltd    TO FM   which rose 13 36  or 0 74 points to trade at 6 28 at the close  Meanwhile   Yamana Gold Inc   TO YRI  added 8 35  or 0 36 points to end at 4 67 and  MEG Energy Corp   TO MEG  was up 7 88  or 0 49 points to 6 71 in late trade 
The worst performers of the session were Valeant Pharmaceuticals International Inc  TO VRX   which fell 6 08  or 2 84 points to trade at 43 86 at the close  Interfor Corp  TO IFP  declined 5 50  or 0 75 points to end at 12 89 and  West Fraser Timber Co  Ltd    TO WFT  was down 5 22  or 2 49 points to 45 23 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 806 to 476 and 341 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 6 14  to 17 90 a new 3 months low 
Gold for June delivery was up 0 36  or 4 50 to  1242 00 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in May rose 6 12  or 2 28 to hit  39 54 a barrel  while the June Brent oil contract rose 5 93  or 2 34 to trade at  41 77 a barrel 
CAD USD was up 1 17  to 0 7695  while CAD EUR rose 0 96  to 0 6750 
The US Dollar Index was down 0 29  at 94 23 ",2016-04-08,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.98-394366,394366
148221,369737,BHC,Top Democrat  in letter  blasts Valeant CEO for lack of cooperation,news,"WASHINGTON  Reuters    A top Democrat in the U S  House of Representatives on Tuesday called on Valeant Pharmaceuticals International Inc  NYSE VRX  for more details on its relationship with Philidor RX services and chided the company for not providing Congress any documents or other requested information  
 Your refusal to cooperate fully with Congress is extremely troubling and reflects a pattern of obstruction that impairs our ability to protect the American people against your company s exorbitant price increases   U S  Representative Elijah Cummings wrote in a letter to Valeant Chief Executive Michael  Pearson   LON PSON  ",2016-04-12,Reuters,"https://www.investing.com/news/politics-news/top-democrat,-in-letter,-blasts-valeant-ceo-for-lack-of-cooperation-394950",394950
148222,369738,BHC,Drugmaker Valeant s bond holders intend to call default,news," Reuters    Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX  said on Tuesday that it received a notice of default from its bond holders as a result of a delay filing its annual report  Centerbridge Partners LP issued the notice  but it is not expected to lead to a default  according to people familiar with the matter   Centerbridge declined to comment  Valeant said in a statement that it now has until June 11 to make the filing  under its bond agreements  but repeated its intention to file it on or before April 29  The company said the notice of default does not mean it must pay back the bonds faster  Last week  Valeant said its lenders had given it an extra month to file the annual report  providing breathing room for the embattled drugmaker as it tries to win back investor confidence   
Valeant shares were down 0 7 percent after normal trading hours in New York  They had closed up 2 0 percent at  31 99 ",2016-04-12,Reuters,https://www.investing.com/news/stock-market-news/drugmaker-valeant's-bond-holders-intend-to-call-default-395020,395020
148224,369740,BHC,Hedge funds  billion dollar club loses members in 2015,news,"By Svea Herbst Bayliss BOSTON  Reuters    The exclusive club of Americas based hedge funds managing more than  1 billion in assets shrunk a bit in 2015 after market gyrations in the second half of the year took a bite out of returns and prompted some investors to pull money  data released on Wednesday show  Numbers compiled by industry news and data provider Hedge Fund Intelligence show that 312 North and South American based hedge funds   mostly in the United States   ranked in the Billion Dollar Club at the start of 2016  down from 316 at the start of 2015 and 314 in July 2015  J P  Morgan Asset Management topped the list of firms that slimmed down the most  managing  49 2 billion in assets at the start of 2016  down from  59 30 billion at the start of 2015  the data showed  Despite shrinking in size  J P  Morgan still ranks as the second biggest player  after Ray Dalio s Bridgewater Associates  which oversees  104 billion in assets  Claren Road Asset Management  which is majority owned by  Carlyle Group   NASDAQ CG   suffered the second biggest drop in size  with assets down by nearly  4 billion to  1 23 billion in January 2016  The credit oriented fund  which had been popular with pension funds  had posted poor returns for more than a year  prompting many investors to exit  Assets declined at 43 percent of the firms last year  with an average decline in assets of 16 percent  the data showed  John Paulson and William Ackman  two of the industry s best known billionaire investors  were also among the biggest losers in assets  stung by holdings of shares of drugmaker Valeant Pharmaceuticals  NYSE VRX  Inc  which crashed 60 percent in the second half of the year  shrinking assets of the funds of both Paulson and Ackman by roughly  3 5 billion  Paulson   Co   whose assets peaked at  38 billion several years ago  oversaw  14 21 billion on Jan  1  2016 while Ackman s Pershing Square  NYSE SQ  Capital Management had  14 41 billion in assets  the data show  But there were winners as well  Dalio s Bridgewater posted a  14 60 billion gain in assets followed by AQR Capital Management s  12 billion gain  putting AQR s total assets at  47 20 billion  making it the third biggest U S  hedge fund firm  
The next largest firm  Daniel Och s Och Ziff Capital Management  had  44 6 billion in assets in January  A bribery scandal and tough market conditions have cut Och Ziff assets to  42 billion now ",2016-04-13,Reuters,https://www.investing.com/news/stock-market-news/hedge-funds'-billion-dollar-club-loses-members-in-2015-395292,395292
148225,369741,BHC,Debt laden Valeant faces tough choices in asset sales ,news,"By Carl O Donnell NEW YORK  Reuters    As Valeant Pharmaceuticals  NYSE VRX  considers a multibillion dollar auction to pare down  30 billion in debt  its challenge will be choosing which assets to sell without compromising any of its key businesses  analysts and investment bankers said  Investors have lost confidence in the drugmaker s ability to grow profits after its pricing and distribution practices came under investigation by Congress and by federal prosecutors  Its market capitalization has plunged to  11 billion from nearly  90 billion  raising questions about how it can shoulder its substantial debt  Key shareholders  including activist investor William Ackman  who joined Valeant s board last month  are trying to shore up its finances  The drugmaker is working with investment banks Goldman Sachs  NYSE GS  and Centerview to assist with potential divestitures  and provide other strategic guidance  Reuters reported on Thursday  In the process  Valeant will need to ensure that it doesn t forfeit too much cash flow in selling key assets  which could leave its existing debt burden harder to bear       As a result  the company is more likely to part with a handful of coveted drugs  possibly including gastrointestinal antibiotic Xifaxan  than carve out a major division for sale  according to analysts and investment bankers interviewed by Reuters  Other assets that could go on the block include skin care products under its Obagi  Cerave and Solta brand lines  as well as toe fungus treatment Jublia  they said   The company wants to stop short of selling off core divisions  such as Bausch   Lomb  Salix  and Medicis  that are fundamental to Valeant s strategy  they said   Valeant did not immediately respond to requests for comment   In December  Valeant s outgoing Chief Executive  Michael  Pearson   LON PSON   said the company s debt was about was  6 billion higher than desirable for the long term  based on earnings figures at the time  Last month  the company sharply cut its 2016 earnings forecasts  It also pared back its ambitions for near term debt reduction   Meanwhile  Valeant has set an April 29 deadline to file its financial statements after missing a March deadline and satisfy the terms of its loans  It is also searching for a new CEO to replace Pearson  TROPHY ASSETS A sale of eye care division Bausch   Lomb  one of Valeant s trophy assets  could fetch as much as  20 billion and go a long way toward paying off debt  according to an analysis by Annabel Samimy  an equity analyst at Stifel   But B L remains one of the company s most profitable businesses  potentially delivering earnings before interest  tax  depreciation and amortization  EBITDA  of  1 6 billion in 2016  according to Umer Raffat  an analyst at Evercore ISI  Valeant s overall EBITDA guidance for 2016 the next four quarters is  6 billion   Giving up cash flow to retire debt  is kind of circular   said one Valeant investor  and could ultimately force the drugmaker to sell significantly more than  6 billion to reach its long term debt goals  The investor spoke on condition of anonymity because he was not authorized to speak to media  Several other assets have strong potential for cash flow growth  allowing them to command a high valuation relative to their earnings  according to several investment bankers who spoke on condition of anonymity because they were not authorized to discuss individual companies       Antibiotic drug Xifaxan is expected to see revenues grow to as much as  1 billion in 2016  a substantial uptick based on fourth quarter sales of  210 million  The treatment accounts for about half of the revenues of Valeant s Salix division  and could be worth upwards of  4 5 billion in a sale  according to some analyst estimates      Other assets  like Jublia  could fare better under different ownership that has better ties to payers    These products are more likely to perform better if they were in the hands of other companies   said David Amsellem  an analyst at Piper Jaffray who had downgraded Valeant to an  underweight  rating in March   Although tempting  Valeant would probably do best to avoid unloading its worst performers  like female libido drug Addyi  which could force it to suffer a writedown on its balance sheet and further depress its stock  according to one of the investment bankers   Valeant bought Addyi for  1 billion shortly after it was approved for the U S  market in 2015  but it has since struggled to gain traction among doctors and patients   In recent weeks  the task of curbing Valeant s debt has become increasingly urgent as downgrades in its credit rating and ongoing negotiations with creditors threaten to raise the company s cost of capital  Last week  Standard   Poor s cut its corporate credit rating on Valeant to  B  from  B   and its secured debt rating to  BB   from  BB   
Valeant has recently settled with some of its lenders after a missed deadline for filing its 10 K annual report put the company at risk of a default  It has secured an extension until May 31  but has pledged to file its statements toward the end of this month ",2016-04-19,Reuters,https://www.investing.com/news/stock-market-news/debt-laden-valeant-faces-tough-choices-in-asset-sales-396321,396321
148237,369753,BHC,Ackman s fund falls 7 percent in March  hurt by Valeant,news,"BOSTON  Reuters    Billionaire investor William Ackman s Pershing Square  NYSE SQ  Holdings  Ltd fund lost 7 1 percent last month  hurt largely by Valeant Pharmaceuticals   TO VRX  roughly 60 percent tumble in March  March s poor performance leaves Ackman s fund with a 25 6 percent loss for the year  a person familiar with its returns said on Friday  This marks a dramatic turnaround from Pershing Square s 40 percent gain in 2014  
Pershing Square owns a 9 percent stake in Valeant and the company s stock tumbled last month when it cut its financial forecasts and said it could face default if it fails to file its annual report by the end of April  Last week the company s chief executive officer agreed to step down and Ackman formally joined the board ",2016-04-01,Reuters,"https://www.investing.com/news/stock-market-news/ackman's-fund-falls-7-percent-in-march,-hurt-by-valeant-393142",393142
148239,369755,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 24 ,news,"Investing com   Canada stocks were lower after the close on Tuesday  as losses in the Consumer Staples  Telecoms and Utilities sectors led shares lower 
At the close in Toronto  the S P TSX Composite fell 0 24  
The best performers of the session on the S P TSX Composite were Valeant Pharmaceuticals International Inc  TO VRX   which rose 10 02  or 3 44 points to trade at 37 77 at the close  Meanwhile   Torex Gold Resources Inc    TO TXG  added 6 63  or 0 110 points to end at 1 770 and OceanaGold Corporation  TO OGC  was up 5 95  or 0 210 points to 3 740 in late trade 
The worst performers of the session were  Semafo Inc    TO SMF   which fell 7 43  or 0 35 points to trade at 4 36 at the close   Air Canada   TO AC  declined 2 95  or 0 250 points to end at 8 220 and Hudson s Bay Company  TO HBC  was down 2 91  or 0 54 points to 18 01 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 700 to 553 and 350 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 3 28  to 18 91 
Gold for June delivery was up 1 02  or 12 40 to  1231 70 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in May rose 0 87  or 0 31 to hit  36 01 a barrel  while the June Brent oil contract rose 0 82  or 0 31 to trade at  38 00 a barrel 
CAD USD was down 0 52  to 0 7601  while CAD EUR fell 0 49  to 0 6676 
The US Dollar Index was up 0 01  at 94 60 ",2016-04-05,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-0.24-393685,393685
148240,369756,BHC,Ackman to face investor grilling after record quarterly loss,news,"By Svea Herbst Bayliss BOSTON  Reuters    Billionaire investor William Ackman is set to face close questioning on Wednesday when he details his hedge fund s biggest ever quarterly loss and explains how he plans to handle the investment that led to the fall   Valeant Pharmaceuticals  NYSE VRX  International  Ackman s Pershing Square  NYSE SQ  Capital Management has blocked off one hour on Wednesday morning for him and his analysts to walk investors through exactly how one of its funds lost 25 percent in the first three months of 2016  including bets on Platform Specialty Products   Herbalife   NYSE HLF  and Valeant  The losses are a severe blow for one of the hedge fund industry s most closely followed investors and come on top of a record 20 5 percent drop in 2015  He has already told investors that he plans to take a far more active role in Valeant and last month joined the company s board  cementing his commitment to the company for some time  The board is looking for a new chief executive and is committed to filing a long delayed annual report by the end of April  Ackman is sure to be pressed for details on all those issues in the call  which is a regular quarterly update with investors  A spokesman for Ackman declined to comment   Five months ago Ackman held a call that lasted nearly four hours as he tried convince investors that Valeant was still a good buy  That message seemed to fall on deaf ears as the stock price has tumbled nearly 70 percent since then  Ackman lost roughly  1 billion on his Valeant investment in one day last month when its stock fell 50 percent on fears it could default  That prompted even long time Valeant supporters such as Brave Warrior Advisors  Glenn Greenberg to liquidate half of his stake  Overall  Ackman s investors appear to be sticking with him  Redemption requests for the first quarter totaled roughly 2 percent of the firm s roughly  12 billion in assets   This is going to be a badly scraped knee that may even require stitches but it is not life threatening   one Ackman investor said about the losses and Valeant situation  The structure of Pershing Square shields it from a sudden sharp loss of capital   investors can only withdraw their money gradually and some of them can only exit by selling shares to another investor   
In a rare piece of good news  Valeant said on Tuesday that it has finished an internal review and found no additional problems that would require further restatements of its financial statements  Its shares climbed 10 percent ",2016-04-06,Reuters,https://www.investing.com/news/stock-market-news/ackman-to-face-investor-grilling-after-record-quarterly-loss-393770,393770
148246,369762,BHC,Ackman says Valeant may find new CEO in weeks  not months,news,"By Svea Herbst Bayliss BOSTON  Reuters    Billionaire activist investor William Ackman on Wednesday offered a more optimistic outlook for Valeant Pharmaceuticals  NYSE VRX  Inc   saying the embattled drug maker s annual report will be filed soon and that its search for a new CEO is moving forward  Valeant shares surged some 20 percent after Ackman s remarks  adding to a roughly 10 percent gain on Tuesday after an internal committee did not find additional problems requiring restatements of the Canadian company s financial results  In a conference call with investors of his firm s Pershing Square  NYSE SQ  Holdings fund  Ackman said Valeant is on track to deliver its delayed 10 K annual report by the end of April  He said that financial filing would eliminate fears the company might default on its debt  possibly rekindling interest among investors   This will be a significant milestone and make the stock investable again   he said  Ackman also said progress is being made in the search to replace Valeant Chief Executive Officer Michael  Pearson   LON PSON   who was forced to step down after the stock fell about 50 percent on March 15 in the wake of disappointing fourth quarter results and guidance as well as mistakes in presenting the numbers   We are cautiously optimistic that it is a matter of weeks not months to identify a new CEO   said Ackman  who joined Valeant s board last month  The call on Wednesday was the first time Ackman and his team had walked investors through the portfolio since reporting that the Pershing Square Holdings fund dropped 25 percent in the first three months of the year  its worst ever result  While Ackman discussed other losing bets including Platform Specialty Products and  Herbalife   NYSE HLF   he spent the bulk of the call answering questions about Valeant  
While acknowledging mistakes  Ackman said he still liked Valeant s stock and told investors he can make back the bulk of the money that had been lost   There is more upside for us in Valeant in the short term than in any other company in the portfolio   he said ",2016-04-06,Reuters,"https://www.investing.com/news/stock-market-news/ackman-says-valeant-board-may-find-new-ceo-in-weeks,-not-months-393822",393822
148247,369763,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 32 ,news,"Investing com   Canada stocks were higher after the close on Wednesday  as gains in the Healthcare  Energy and Clean Technology sectors led shares higher 
At the close in Toronto  the S P TSX Composite rose 0 32  
The best performers of the session on the S P TSX Composite were Valeant Pharmaceuticals International Inc  TO VRX   which rose 18 53  or 7 00 points to trade at 44 77 at the close  Meanwhile   Surge Energy Inc    TO SGY  added 13 40  or 0 260 points to end at 2 200 and Enerplus Corporation  TO ERF  was up 9 34  or 0 44 points to 5 15 in late trade 
The worst performers of the session were  Metro Inc    TO MRU   which fell 4 15  or 1 82 points to trade at 42 08 at the close   B2Gold Corp   TO BTO  declined 3 26  or 0 070 points to end at 2 080 and Cogeco Communications Inc  TO CCA  was down 3 24  or 2 23 points to 66 62 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 709 to 531 and 331 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 3 36  to 18 39 
Gold for June delivery was down 0 37  or 4 50 to  1225 10 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in May rose 5 21  or 1 87 to hit  37 76 a barrel  while the June Brent oil contract rose 5 02  or 1 90 to trade at  39 77 a barrel 
CAD USD was up 0 29  to 0 7633  while CAD EUR rose 0 19  to 0 6699 
The US Dollar Index was down 0 10  at 94 52 ",2016-04-06,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.32-393903,393903
148251,369767,BHC,Valeant gets extra month from lenders to file annual report,news," Reuters    Valeant Pharmaceuticals International Inc  TO VRX  said on Thursday its lenders had agreed to give it an extra month to file its annual report  providing further reassurance to investors as the company attempts to win back their confidence  The extensions provide relief if Valeant is unable to file its annual report by April 29   a deadline the company reiterated that it intended to meet  The Canadian company said last week that it had asked its lenders for another month to file the report  seeking to reduce the risk of a default on its  30 billion debt if it missed the April 29 deadline  Valeant  whose U S  shares  N VRX  were up about 8 percent in premarket trading  said its lenders had agreed to a May 31 deadline to lodge the report   The company is comfortable with its current liquidity position and cash flow generation for the rest of the year  and remains well positioned to meet its obligations   Valeant said  repeating a statement it made last week  The amendment to the company s credit agreement also allows it to extend the filing deadline for its first quarter report to July 31 from June 14  The deal with its lenders requires Valeant to apply substantially all net asset sale proceeds to prepay its term loans  The agreement also waives the cross default to indentures that arose when the annual report was not filed on the original due date of March 15  The Laval  Quebec based company said in February it would not meet the March 15 deadline because of a review of its accounting practices by a board committee  Valeant said on Tuesday that the committee  which was probing the company s ties to specialty drug distributor Philidor  had completed its review and had not found anything that would require additional restatements  Up to Wednesday s U S  close  Valeant s stock had risen almost 30 percent in two days  helped by that news as well as a comment by key shareholder and board member William Ackman that a new chief executive could be appointed within weeks  The company said last month that CEO Michael  Pearson   LON PSON  would step down as soon as a replacement was found  Fueled by acquisitions  Valeant grew at a frantic pace under Pearson and became a Wall Street favorite as it delivered double digit profit growth  However  the Valeant story began to unravel late last year as its aggressive acquisition strategy and practice of sharply raising drug prices come under intense public  political and regulatory scrutiny  
The company s shares  which hit a record high of  263 81 in August  were trading at  36 90 before the opening bell ",2016-04-07,Reuters,https://www.investing.com/news/stock-market-news/valeant-gets-extra-month-from-lenders-to-file-annual-report-394037,394037
148276,369792,BHC,Janus  Gross says Valeant based on leverage  financial engineering,news,"By Jennifer Ablan NEW YORK  Reuters    The business model of Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX   target of a securities investigation and under scrutiny for its pricing and accounting practices   was based on leverage and financial engineering   fund manager Bill Gross of  Janus Capital  Group Inc  N JNS  said Tuesday  In a tweet on the Janus Capital stream  Gross said   Valeant biz model was based on leverage and fincl  engineering  At the extreme it mirrors global monetary policy and their economies   Valeant was not immediately available for comment   Gross said last week on Bloomberg TV that he sold the Valeant bonds that were inherited in a Janus client account he was overseeing    We sold the bonds the first day that the problems arrived   and that was three months ago   Gross said   Gross  manager of the  1 3 billion Janus Global Unconstrained Bond Fund  said in a Janus video on Tuesday that Federal Reserve officials appear to be focused on keeping the stock market up and hoping that generates a  wealth effect    I think central banks have gone too far   certainly the ECB  European Central Bank  and the BoJ  Bank of Japan  have gone into negative territory and I think there are long term consequences for that   Gross said   
 The closeness to the zero bound  interest rates  basically robs savers of their ability to earn money and threatens business models  such as insurance companies and banks in terms of their margin   and certainly  pension funds in terms of their ability to earn money  ",2016-03-22,Reuters,"https://www.investing.com/news/economy-news/janus'-gross-says-valeant-based-on-leverage,-financial-engineering-391376",391376
148277,369793,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 50 ,news,"Investing com   Canada stocks were lower after the close on Tuesday  as losses in the Industrials  Materials and REITs sectors led shares lower 
At the close in Toronto  the S P TSX Composite declined 0 50  
The best performers of the session on the S P TSX Composite were Valeant Pharmaceuticals International Inc  TO VRX   which rose 9 37  or 3 55 points to trade at 41 45 at the close  Meanwhile   Veresen Inc    TO VSN  added 7 17  or 0 62 points to end at 9 27 and  Celestica  Inc   TO CLS  was up 5 90  or 0 78 points to 14 00 in late trade 
The worst performers of the session were  ProMetic Life Sciences Inc    TO PLI   which fell 7 85  or 0 27 points to trade at 3 17 at the close  Potash Corporation of Saskatchewan  TO POT  declined 4 56  or 1 13 points to end at 23 64 and  Badger Daylighting Ltd    TO BAD  was down 4 15  or 0 95 points to 21 93 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 641 to 620 and 351 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 4 07  to 19 42 
Gold for April delivery was up 0 27  or 3 40 to  1247 60 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in May fell 0 41  or 0 17 to hit  41 35 a barrel  while the May Brent oil contract rose 0 48  or 0 20 to trade at  41 74 a barrel 
CAD USD was up 0 43  to 0 7666  while CAD EUR rose 0 41  to 0 6831 
The US Dollar Index was up 0 26  at 95 65 ",2016-03-22,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-0.50-391403,391403
148278,369794,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 84 ,news,"Investing com   Canada stocks were lower after the close on Wednesday  as losses in the Mining  Materials and Energy sectors led shares lower 
At the close in Toronto  the S P TSX Composite fell 0 84  
The best performers of the session on the S P TSX Composite were  Boyd Group Income Fund   TO BYD u   which rose 11 52  or 7 23 points to trade at 70 00 at the close  Meanwhile  Valeant Pharmaceuticals International Inc  TO VRX  added 6 54  or 2 71 points to end at 44 16 and  CCL Industries Inc   TO CCLb  was up 4 37  or 9 98 points to 238 19 in late trade 
The worst performers of the session were Amaya Inc  TO AYA   which fell 20 57  or 3 82 points to trade at 14 75 at the close   First Quantum Minerals Ltd    TO FM  declined 16 32  or 1 35 points to end at 6 92 and  Teck Resources Ltd   TO TCKb  was down 13 38  or 1 49 points to 9 65 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 807 to 470 and 300 ended unchanged 
Shares in Boyd Group Income Fund  TO BYD u  rose to all time highs  rising 11 52  or 7 23 to 70 00  Shares in CCL Industries Inc  TO CCLb  rose to all time highs  rising 4 37  or 9 98 to 238 19  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 2 81  to 18 71 
Gold for April delivery was down 2 18  or 27 20 to  1221 40 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in May fell 4 05  or 1 68 to hit  39 77 a barrel  while the May Brent oil contract fell 3 06  or 1 28 to trade at  40 51 a barrel 
CAD USD was down 1 24  to 0 7569  while CAD EUR fell 0 97  to 0 6769 
The US Dollar Index was up 0 42  at 96 07 ",2016-03-23,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-0.84-391638,391638
148279,369795,BHC,Senate s request for info from Ackman related to Valeant  source,news,"BOSTON  Reuters    U S  legislators investigating price hikes in the pharmaceutical industry have asked William Ackman s hedge fund for information on Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX   according to a person familiar with the matter  Ackman s  12 billion Pershing Square  NYSE SQ  Capital Management owns a 9 percent stake in Valeant and is the Canadian drug company s third largest investor  On Thursday  Ackman told his investors that Pershing Square received a request for information a week ago from the U S  Senate Special Committee on Aging  Ackman said his fund was cooperating with the probe  but he did not give details on what was being sought by lawmakers in his letter to clients   The request is directly related to Valeant   the person familiar with the matter told Reuters on Friday  Valeant has sparked public outrage and been criticized by U S  lawmakers for dramatically hiking the price of older drugs  The Canadian company has disclosed several investigations  including the one from Congress and probes by the Securities and Exchange Commission and U S  Attorney s offices in Massachusetts and New York  Pershing Square has lost billion of dollars  on paper  as Valeant s stock price tumbled some 85 percent in the last year amid questions about its pricing strategy plus its business and accounting practices  
Ackman formally joined Valeant s board on Monday ",2016-03-25,Reuters,https://www.investing.com/news/economy-news/senate's-request-for-info-from-ackman-related-to-valeant:-source-391943,391943
148280,369796,BHC,Valeant CEO subpoenaed to testify before U S  Senate panel,news,"By Sarah N  Lynch WASHINGTON  Reuters    The chief executive of Valeant Pharmaceuticals International Inc  NYSE VRX   which is under scrutiny for dramatically hiking the price of older drugs  has been summoned to testify at a U S  congressional hearing on April 27  the panel said on Monday  The Senate Special Committee on Aging hearing comes as the Canadian based company is coping with a variety of federal investigations into its accounting practices that led to a restatement and delays in the filing of its annual report  Valeant said last week CEO Michael  Pearson   LON PSON  would step down  after a board committee probing the company s ties to specialty pharmacy Philidor Rx Services had found accounting problems dating back to December 2014  Billionaire William Ackman  whose Pershing Square  NYSE SQ  Capital Management owns a 9 percent stake in Valeant  has joined the company s board  A spokesperson for Valeant did not immediately respond to an email seeking comment  U S  prosecutors in Massachusetts and Manhattan are probing Valeant s pricing and distribution channels  while the Securities and Exchange Commission is investigating its accounting and disclosure issues  The Senate committee is one of two congressional bodies that are looking into aggressive prescription drug pricing  Both committees are particularly focused on Valeant and Turing Pharmaceuticals  a private company founded by Martin Shkreli  a 32 year old entrepreneur who has come under fire for raising the price of the drug Daraprim by more than 5 000 percent to  750 a pill  In February  the U S  House Committee on Oversight and Government Reform held a long and contentious hearing on drug pricing  At that hearing  Shkreli  who is facing unrelated securities fraud charges  asserted his Fifth Amendment right against self incrimination  Pearson did not testify at the hearing in the U S  House of Representatives because he was on medical leave  Howard Schiller  Valeant s then interim CEO and former chief financial officer  testified in Pearson s place  Since then  however  Valeant has publicly accused Schiller and the company s corporate controller with  improper conduct  which helped contribute to a misstatement of its financial results  
Schiller  through his attorneys  has denied any wrongdoing ",2016-03-28,Reuters,https://www.investing.com/news/stock-market-news/valeant-ceo-subpoenaed-to-testify-before-u.s.-senate-panel-392153,392153
148281,369797,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 24 ,news,"Investing com   Canada stocks were higher after the close on Monday  as gains in the Financials  Utilities and Consumer Discretionary sectors led shares higher 
At the close in Toronto  the S P TSX Composite gained 0 24  
The best performers of the session on the S P TSX Composite were Great Canadian Gaming Corporation  TO GC   which rose 3 64  or 0 64 points to trade at 18 24 at the close  Meanwhile   Intertain Group   TO IT  added 3 63  or 0 35 points to end at 10 00 and  West Fraser Timber Co  Ltd    TO WFT  was up 3 37  or 1 60 points to 49 12 in late trade 
The worst performers of the session were Valeant Pharmaceuticals International Inc  TO VRX   which fell 7 62  or 3 14 points to trade at 38 07 at the close  Performance Sports Group Ltd  TO PSG  declined 7 03  or 0 31 points to end at 4 10 and  Surge Energy Inc    TO SGY  was down 5 78  or 0 130 points to 2 120 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 602 to 599 and 314 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 7 21  to 19 34 
Gold for June delivery was down 0 16  or 2 00 to  1221 50 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in May fell 0 05  or 0 02 to hit  39 44 a barrel  while the June Brent oil contract fell 0 37  or 0 15 to trade at  40 88 a barrel 
CAD USD was up 0 64  to 0 7584  while CAD EUR rose 0 37  to 0 6773 
The US Dollar Index was down 0 20  at 95 98 ",2016-03-28,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.24-392176,392176
148282,369798,BHC,Valeant seeks lender approval to extend deadline for annual report,news,"By Ankur Banerjee  Reuters    Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX  said it was asking its lenders to extend until May 31 the deadline for it to file its annual report  lessening the chance of a default on its  30 billion debt if it misses the current deadline of April 29  Valeant  whose U S  listed shares were down 4 9 percent at 27 56 at midday  said on Wednesday it still intended to meet the end April deadline  Valeant said last week that a board committee probing the company s ties to specialty drug distributor Philidor Rx had found accounting problems dating back to December 2014  On Wednesday  the Canadian drugmaker said the committee had not found any additional items affecting its financial statements  but had not finished its review   The company is comfortable with its current liquidity position and cash flow generation for the rest of the year  and remains well positioned to meet its obligations   Valeant said  An extension to May 31 would give creditors some additional comfort in the near term  Mizuho Securities analyst Irina Koffler said in a client note  The longer term worry  she said  was that Valeant s revenue base would erode over time while the company allocated all available cash to debt repayment  Valeant said the proposed waiver must be approved by lenders holding more than 50 percent of the company s loans in principal amount   Even if they are confident they are going to file by April 29  they still want to give themselves an extra month of runway   said Justin Forlenza  an analyst at Covenant Review  Valeant also said it was seeking to extend the deadline for filing its report for the first quarter to July 31 from June 24  The Laval  Quebec based drugmaker said the amendment to its credit agreement would restrict its ability to make certain acquisitions  pay dividends and make other payments until its financial statements were filed  The company would also be required to apply substantially all of its net asset sale proceeds to prepay its term loans  Valeant  under Chief Executive Michael  Pearson   LON PSON   was an investor darling for years as it went on an acquisition spree and delivered double digit profit growth  But its shares have dropped nearly 90 percent since August when the company s strategy of buying companies and sharply raising prices of their drugs started to come under scrutiny  Valeant is also under investigation by the U S  Congress and various U S  government agencies over to its business strategy and links to links to Philidor  which has since shut down  
Valeant said earlier in March that Pearson would step down after a successor was found  The company also added activist investor William Ackman  whose Pershing Square  NYSE SQ  Capital Management holds 9 percent of Valeant  to its board ",2016-03-30,Reuters,https://www.investing.com/news/stock-market-news/valeant-seeks-waiver-from-lenders-related-to-filing-annual-report-392479,392479
148283,369799,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 58 ,news,"Investing com   Canada stocks were higher after the close on Wednesday  as gains in the Consumer Staples  Industrials and REITs sectors led shares higher 
At the close in Toronto  the S P TSX Composite rose 0 58  
The best performers of the session on the S P TSX Composite were  Dollarama Inc   TO DOL   which rose 7 46  or 6 17 points to trade at 88 91 at the close  Meanwhile   Corus Entertainment Inc   TO CJRb  added 7 29  or 0 80 points to end at 11 78 and  Mitel Networks Corporation   TO MNW  was up 7 19  or 0 71 points to 10 58 in late trade 
The worst performers of the session were Valeant Pharmaceuticals International Inc  TO VRX   which fell 7 17  or 2 71 points to trade at 35 10 at the close   Tahoe Resources Inc   TO THO  declined 4 99  or 0 71 points to end at 13 51 and  Turquoise Hill Resources  Ltd   TO TRQ  was down 3 77  or 0 13 points to 3 32 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 644 to 604 and 338 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 3 55  to 18 46 
Gold for June delivery was down 0 82  or 10 10 to  1227 40 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in May fell 0 03  or 0 01 to hit  38 27 a barrel  while the June Brent oil contract rose 0 33  or 0 13 to trade at  39 98 a barrel 
CAD USD was up 0 89  to 0 7715  while CAD EUR rose 0 52  to 0 6808 
The US Dollar Index was down 0 37  at 94 82 ",2016-03-30,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.58-392605,392605
148285,369801,BHC,Regulator orders drugmaker Valeant management to cease trading,news,"By Rod Nickel  Reuters    Valeant Pharmaceuticals  NYSE VRX  International Inc s  TO VRX  directors and key officers have received a cease trade order by the securities regulator in the Canadian province of Quebec  on the company s request  Valeant said on Thursday  In a separate statement  the Autorit  Des Marches Financiers  AMF  said the order against trading shares takes effect Thursday and is in place for 15 days  Included in the order are Chief Executive Mike  Pearson   LON PSON   Chief Financial Officer Robert Rosiello and board member Bill Ackman  The order states that AMF intends to issue a new order if Valeant does not make filings by April 15  The delay in Valeant filing its annual report poses a risk of debt default  Valeant said March 15  generating new scrutiny of the much criticized company  Defaulting on debt could prompt lenders to demand faster repayment and place restrictions on Valeant s ability to borrow  The company is largely run out of the United States  but it is headquartered in Laval  a suburb of Montreal  Quebec  The company is also incorporated in the western Canadian province of British Columbia  A spokesman for the British Columbia Securities Commission did not immediately respond to a request for comment  In a statement  Valeant said it asked AMF for the cease trade order  pending the filing of its 2015 audited financial statements    The company is working diligently and intends to make the required filings on or before April 29  2016   Valeant said  The cease trade order technically applies only to Quebec  but the practical effect of such orders in Canada  which does not have a national securities regulator  is to stop trading across the country  said Sylvain Theberge  spokesman for AMF  in an email to Reuters   The persons affected have undertaken not to trade anywhere  including the United States  he said   Theberge said Valeant is not under active investigation by AMF  but has been under  verification   since October  He declined to elaborate  Valeant shares rose 0 2 percent in Toronto and New York after earlier losses  The company s stock has plummeted since August over a string of controversies  including U S  government scrutiny of its drug price hikes and former ties to a specialty pharmacy  
The cease trade order was first reported by the Wall Street Journal ",2016-03-31,Reuters,https://www.investing.com/news/stock-market-news/regulator-orders-drugmaker-valeant-management-to-cease-trading-392810,392810
148289,369805,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 40 ,news,"Investing com   Canada stocks were lower after the close on Friday  as losses in the Energy  Clean Technology and Consumer Staples sectors led shares lower 
At the close in Toronto  the S P TSX Composite fell 0 40  
The best performers of the session on the S P TSX Composite were Valeant Pharmaceuticals International Inc  TO VRX   which rose 7 34  or 2 50 points to trade at 36 55 at the close  Meanwhile   Alacer Gold  Corp  TO ASR  added 5 53  or 0 13 points to end at 2 48 and  BRP Inc    TO DOO  was up 5 51  or 1 07 points to 20 50 in late trade 
The worst performers of the session were  Birchcliff Energy Ltd    TO BIR   which fell 8 70  or 0 46 points to trade at 4 83 at the close  BlackBerry Ltd  TO BB  declined 7 59  or 0 80 points to end at 9 74 and  ARC Resources Ltd    TO ARX  was down 6 41  or 1 21 points to 17 68 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 607 to 604 and 353 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 0 27  to 18 50 
Gold for June delivery was down 0 91  or 11 30 to  1224 30 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in May fell 4 25  or 1 63 to hit  36 71 a barrel  while the June Brent oil contract fell 4 14  or 1 67 to trade at  38 66 a barrel 
CAD USD was down 0 05  to 0 7686  while CAD EUR fell 0 19  to 0 6745 
The US Dollar Index was down 0 10  at 94 56 ",2016-04-01,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-0.40-393118,393118
148310,369826,BHC,Ackman sells part of Mondelez stake  has no plans for other sales,news,By Svea Herbst Bayliss BOSTON  Reuters    Billionaire investor William Ackman adjusted his battered hedge fund portfolio on Wednesday when he sold 20 million shares of snack maker Mondelez International  one day after another key holding  Valeant Pharmaceuticals  NYSE VRX   lost half of its value  In a three paragraph letter sent to investors after the close of trading on Wednesday and seen by Reuters  Ackman said his firm  Pershing Square  NYSE SQ   has no plans to sell other investments right now and has  substantial uninvested cash    The letter came one day after Pershing Square lost about  800 million when Valeant was pummeled after raising the possibility that it may default on its debt and posting a worse than expected financial outlook  Ackman s Pershing Square Holdings has now lost 26 4 percent since January  marking one of the worst performances in the hedge fund industry this year  Before today s sale  Pershing Square owned 43 million shares  or 7 5 percent  of Mondelez  which makes Oreo cookies  Trident gum and Milka chocolate  It now owns 5 6 percent of the company  The hedge fund unveiled its position in Mondelez in August 2015 and has since been pushing for a sale   We continue to believe in the potential for operating improvements and margin expansion that we expect will lead to substantial further increases in value   Ackman wrote in the letter   On Tuesday  Ackman barely contained his frustration with Valeant in an earlier note  warning the company and assuring his investors that Pershing Square was  going to take a more proactive role at the company to protect and maximize the value of our investment    Last week  Pershing Square s vice chairman  Steve Fraidin  a veteran mergers and acquisitions lawyer  joined Valeant s board  It was roughly a year ago that Ackman unveiled his investment in Valeant  coming not quite a year after working with the fast growing company on a deal in 2014 to buy Allergan  NYSE AGN pa   in which Pershing Square owned shares  The bet on Allergan helped Pershing Square earn a 40 percent gain in 2014  The size of Ackman s fund has shrunk dramatically to roughly  12 billion at the end of February from about  19 billion in early 2015  But because he listed shares on the Amsterdam stock exchange in 2014  he has a cushion of permanent capital  Still  investors have expressed concern about the fund s performance and Ackman urged them in Tuesday s and Wednesday s letters to call the investor relations team or him personally with any questions ,2016-03-16,Reuters,"https://www.investing.com/news/stock-market-news/ackman-sells-part-of-mondelez-stake,-has-no-plans-for-other-sales-390364",390364
148311,369827,BHC,Canada stocks higher at close of trade  S P TSX Composite up 1 06 ,news,"Investing com   Canada stocks were higher after the close on Thursday  as gains in the Mining  Industrials and Energy sectors led shares higher 
At the close in Toronto  the S P TSX Composite rose 1 06  to hit a new 3 months high 
The best performers of the session on the S P TSX Composite were  Teck Resources Ltd   TO TCKb   which rose 17 44  or 1 72 points to trade at 11 58 at the close  Meanwhile  Canaccord Genuity Group Inc  TO CF  added 15 56  or 0 61 points to end at 4 53 and  HudBay Minerals  Inc   TO HBM  was up 11 42  or 0 54 points to 5 27 in late trade 
The worst performers of the session were Valeant Pharmaceuticals International Inc  TO VRX   which fell 11 82  or 5 18 points to trade at 38 66 at the close   Concordia Healthcare   TO CXR  declined 8 34  or 3 45 points to end at 37 93 and OceanaGold Corporation  TO OGC  was down 6 81  or 0 260 points to 3 560 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 802 to 508 and 329 ended unchanged 
Shares in Valeant Pharmaceuticals International Inc  TO VRX  fell to 3 years lows  losing 11 82  or 5 18 to 38 66  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 2 35  to 18 69 
Gold for April delivery was up 2 27  or 27 90 to  1257 70 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in April rose 4 60  or 1 77 to hit  40 23 a barrel  while the May Brent oil contract rose 2 70  or 1 09 to trade at  41 42 a barrel 
CAD USD was up 0 92  to 0 7705  while CAD EUR rose 0 07  to 0 6807 
The US Dollar Index was down 0 96  at 94 78 ",2016-03-17,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-1.06-390627,390627
148312,369828,BHC,S P says it may cut Ackman hedge fund s rating ,news,By Svea Herbst Bayliss NEW YORK  Reuters    Billionaire investor William Ackman s already very bad week got worse on Thursday  Rating agency Standard   Poor s said it may cut its BBB rating of Ackman s publicly traded Pershing Square  NYSE SQ  Holdings  AS PSH  vehicle in the wake of weak investment returns and a sharp drop in its net asset value   The fund s performance since we initiated the rating on PSH in May 2015 has been weaker than peers  in contrast to its stellar track record in previous years   S P analysts wrote  noting that the fund lost money on 11 of 12 positions since October 2015  A spokesman for the firm declined to comment  Ackman s Pershing Square oversees roughly  11 billion for wealthy clients  including state pension funds  The fund s net asset value tumbled to  3 8 billion this week from  5 3 billion in October 2015  the S P analysts wrote  That pushed the fund s debt to total assets ratio to more than 20 percent from 15 percent at the end of October 2015  The most immediate cause for Ackman s woes is the sharp decline in drug company Valeant Pharmaceuticals   TO VRX  stock price  which crashed more than 50 percent this week and cause Ackman s firm to lose roughly  1 billion on paper  The company delivered worse than expected financial guidance and raised the chance of defaulting on its debt if it breaches agreements with creditors by not filing its annual report on time  This year alone  the Pershing Square Holdings fund  which has been trading publicly since 2014  lost 26 4 percent  That followed on a 20 percent drop in 2015  The year it was listed in Amsterdam  it scored a 40 percent gain  As one of the hedge fund industry s most widely followed investors  Ackman is now being vilified just as much as he was celebrated two years ago when he worked with Valeant to try to buy rival drug company Allergan  NYSE AGN pa   in which he owned shares  Investors are privately saying they are concerned about Pershing Square s big bet on Valeant  Ackman has scrambled this week to soothe that concern by sending back to back memos urging clients to call him personally with questions  S P underscored his high profile stature by writing  Bill Ackman s prominent role exposes the fund to key man risk   But the analysts noted that Ackman has taken  proactive steps to respond to the turmoil   On Wednesday the fund sold 20 million shares of snack food maker Mondelez  O MDLZ   increasing its free cash  Last week Pershing Square Vice Chairman Steve Fraidin  a veteran mergers and acquisitions lawyer  joined Valeant s board ,2016-03-17,Reuters,https://www.investing.com/news/economy-news/s-amp;p-says-it-may-cut-ackman-hedge-fund's-rating-390632,390632
148313,369829,BHC,In U turn  investors pull money from U S  stock funds in week  Lipper,news,By Trevor Hunnicutt NEW YORK  Reuters    Investors turned on U S  based stock funds in the latest week  pulling  2 1 billion from the funds just one week after the funds posted their first inflows of the year  Lipper data showed on Thursday   Retail investors have been leery about equity for some time   said Jeff Tjornehoj  head of Americas research for Lipper   They want to see a sustained rally   While mutual fund investors pulled nearly  4 billion from stock funds during the last week  exchange traded fund investors added money to those funds for a third straight week  ETF flows are seen as representing institutional trading behavior more so than mutual funds  Overall  the outflows in the week to March 16 hit U S  based international stock funds hardest  Those funds posted  2 9 billion in outflows during the week  Lipper said  European stock funds posted nearly  1 billion in outflows  while Japanese stock funds posted  597 million in outflows  Lipper said  a seventh straight week of outflows for both categories as easy monetary policy in both regions has failed to lift U S  investors  spirits  Emerging market stock funds posted  408 million in outflows after taking in  1 6 billion the week before  Precious metals commodity funds attracted  173 million during the week  for a 10th straight week of new cash  according to Lipper  Funds focused on healthcare and biotechnology shares posted  850 million in outflows during a week that saw the value of shares of troubled drugmaker Valeant Pharmaceuticals International Inc  NYSE VRX  halved in one day alone  Financial sector funds posted  709 million in outflows  Lipper said  Overall  though  on a net basis domestic focused stock funds in the United States took in  755 million  Lipper data showed  U S  based taxable bond funds attracted  4 1 billion during the same period measured by Lipper  for an eighth straight week of inflows  High yield bond funds added a fifth week to their streak of inflows  adding  1 7 billion in new cash  Higher grade bond funds took in  2 billion  Treasury funds posted  135 million in outflows  a third straight week of outflows  the data showed  Emerging market debt funds took in  190 million  Lipper said  as the U S  Federal Reserve said it would hold interest rates steady  Relatively low risk money market funds posted  36 billion in outflows during the week  the category s largest outflows since February 2014  the fund research service said  Tjornehoj said the outflows were driven by institutional investors  but it was unclear whether those investors are deploying the cash to buy riskier assets ,2016-03-17,Reuters,"https://www.investing.com/news/economy-news/in-u-turn,-investors-pull-money-from-u.s.-stock-funds-in-week:-lipper-390642",390642
148315,369831,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 91 ,news,"Investing com   Canada stocks were lower after the close on Friday  as losses in the Healthcare  Consumer Staples and Energy sectors led shares lower 
At the close in Toronto  the S P TSX Composite lost 0 91  
The best performers of the session on the S P TSX Composite were  BRP Inc    TO DOO   which rose 17 92  or 2 88 points to trade at 18 95 at the close  Meanwhile  Canadian Energy Services   Technology Corp  TO CEU  added 8 54  or 0 27 points to end at 3 43 and Pengrowth Energy Corporation  TO PGF  was up 8 46  or 0 11 points to 1 41 in late trade 
The worst performers of the session were  Paramount Resources Ltd    TO POU   which fell 14 63  or 1 40 points to trade at 8 17 at the close  Valeant Pharmaceuticals International Inc  TO VRX  declined 9 65  or 3 73 points to end at 34 93 and  Penn West Petroleum  Ltd   TO PWT  was down 8 53  or 0 11 points to 1 18 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 639 to 621 and 353 ended unchanged 
Shares in Valeant Pharmaceuticals International Inc  TO VRX  fell to 5 year lows  down 9 65  or 3 73 to 34 93  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 2 30  to 19 12 
Gold for April delivery was down 0 70  or 8 90 to  1256 10 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in April unchanged 0 00  or 0 00 to hit  40 20 a barrel  while the May Brent oil contract fell 0 17  or 0 07 to trade at  41 47 a barrel 
CAD USD was down 0 39  to 0 7677  while CAD EUR unchanged 0 00  to 0 6809 
The US Dollar Index was up 0 33  at 95 08 ",2016-03-18,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-0.91-390847,390847
148316,369832,BHC,Activist hedge funds wounded by market turmoil,news,"By Michael Flaherty and Svea Herbst Bayliss
 Reuters    Hedge funds wounded by recent stock market gyrations may struggle to pressure companies and reap the benefits of their activist campaigns  lawyers and bankers at Tulane Law School s corporate law conference in New Orleans said this week 
William Ackman  one of the world s biggest activists  sold a chunk of U S  snack maker  Mondelez International Inc   NASDAQ MDLZ  to make up for a hole in his Pershing Square  NYSE SQ  portfolio after Valeant Pharmaceuticals International Inc  NYSE VRX  lost half its value 
More hedge fund managers feel the need to de risk their portfolios  Avinash Mehrotra  co head of Goldman Sachs  NYSE GS   M A shareholder advisory group  said at the conference  Funds facing the most pressure may be those that allow clients to get money out fastest 
 If you re running an activist strategy  you generally need two  three  four quarters to prosecute that strategy  If you have got a quarterly call     you have a mismatch on the asset side of your equation  which is your holdings  and the liability side  which is the call on your capital   Mehrotra said 
As a group  activists have already lost 6 52 percent in the first two months of 2016  far more than the average hedge fund s 2 percent drop  according to data from Hedge Fund Research 
Ackman s Pershing Square  battered by Valeant  is off 22 percent through the middle of March  while Nelson Peltz  Trian Fund Management lost 7 percent and Barry Rosenstein s Jana Partners fell 7 3 percent in the first two months of the year 
But the biggest fallout may be among the smaller funds that seized on the wave of assets that flowed into the sector  attracted by the outsized returns of brand name agitators such as Ackman and Carl Icahn 
For example  Jerome Lande folded his Coppersmith Capital Management into a bigger firm  Scopia Capital  where he is now in charge of special situations  people familiar with the matter said  speaking on condition of anonymity  Scopia  which had roughly  10 billion in assets last year according to the most recent available regulatory filing  did not respond to a request for comment 
Willem Mesdag s Red Mountain is locking up its investors  capital for longer after losses  essentially turning the activist hedge fund into more of a private equity type vehicle  the sources said  Red Mountain  which had around  500 million in assets in 2015  did not respond to a request for comment 
Daniel Lewis shuttered his Orange Capital this year  and the founders of LionEye Capital shut that hedge fund down last year 
 There will be a shake out among some of the ankle biters and some of the others   David Katz  a partner at Wachtell  Lipton  Rosen   Katz  said at the conference  referring to smaller activists 
However  the activism model is hardly in danger of extinction  bankers and lawyers said  Year to date  activists have launched 96 U S  campaigns  a high historical figure  though 34 percent below the pace set in the same period in 2015  
Even top activists  however  acknowledge that the old play book of pushing for stock buybacks or quick sales is outdated  Starboard Value s Jeffrey Smith said recently that simply calling for a company to buy back shares  is not a plan   adding   That does not create value  
The stock gains from such moves have already been squeezed  The S P 500 buyback index  which measures the performance of the top 100 stocks with the highest buyback ratios  currently shows an 8 8 percent one year loss  
 This version of the story corrects the spelling of the name in fourth paragraph  ",2016-03-18,Reuters,https://www.investing.com/news/stock-market-news/activist-hedge-funds-wounded-by-market-turmoil-390863,390863
148320,369836,BHC,Drugmaker Valeant CEO leaving as investor Ackman joins board,news,"By Caroline Humer  Reuters    Drugmaker Valeant Pharmaceuticals International Inc  TO VRX   N VRX  said on Monday its chief executive officer is leaving and billionaire investor William Ackman would join the board as it tries to clean up accounting problems and save its business  The Canadian company  whose operations include prescription drugs  consumer products  and Bausch   Lomb eye care  has lost nearly 90 percent of its value as it came under public scrutiny for its pricing and distribution practices  including investigations by Congress and various government agencies   Valeant blamed accounting issues on  improper conduct  by top finance executives  On Monday  shares rose as much as 17 percent in New York trading   Just three weeks after CEO Michael  Pearson   LON PSON  returned from a two month medical leave  the company said he will leave  Also  Ackman of Pershing Square  NYSE SQ  Capital Management will join the board  the second seat given to the activist investment firm in as many weeks  The firm held a 6 3 percent stake as of March 8  In addition  a board committee said its five month investigation into Valeant s dealings with pharmacy Philidor Rx Services found broad accounting problems dating back to December 2014  The committee s work is ongoing and more restatements may be needed  Valeant said   The committee traced the issues in part to the former chief financial officer  Howard Schiller  who had been interim CEO while Pearson was on leave  and is still on the board  The company said Schiller s and the corporate controller s  improper conduct  contributed to a misstatement of financial results because they provided incorrect information related to revenue recognition to auditors and the board committee  Valeant pledged on Monday to file its annual report on or before April 29 after missing a deadline last week  which opened the door to a default on part of its  30 billion debt load  Last week  the company s stock  hovering around  60  lost one half of its value as investors wondered if it could manage the debt  built up from a stream of acquisitions  Since August  it has lost  80 billion in market value  BTIG analyst Timothy Chiang said the moves announced on Monday looked to be the start of a clean up process that will take time  but the sooner the company can submit its 10K filing  the better   There s not much visibility   Chiang said  ACCOUNTING  CAREFUL AND REASONED  Valeant s prescription drug sales began to unravel last year as its history of large price increases drew sharp criticism and the attention of lawmakers as well as New York and Massachusetts attorneys general  which opened investigations   On Monday  Elijah Cummings  a U S  representative from Maryland who has investigated Valeant  said  It is clear that there are more than just  accounting problems  at Valeant  and company executives need more than new faces to fix them   The company s profitable dermatology franchise faltered as it stopped distribution through pharmacy Philidor due to investor and media scrutiny   In January  while Pearson was still on leave  the company said it would need to restate earnings from 2014 and 2015 due to revenue recognition issues   Valeant said on Monday it has started a search for a successor to Pearson  who joined the company in 2008 and built it on acquisitions and drug price increases  His first big stumble came when its hostile takeover attempt of  Allergan Inc   NYSE AGN pa   done with Ackman  failed  Investors had debated the merits of Pearson s return to the top job in recent weeks  but Valeant Chairman Robert Ingram said in the company statement that he would be missed and thanked him for staying until a new CEO is found  After the Philidor problems surfaced  Valeant s board began an investigation  which has identified revenue recognition and other accounting problems  the company said  The probe and the dismissal of its corporate controller led to the delay of the regulatory filing  Valeant said  The company said Schiller had been asked to leave the board and refused to do so  requiring another board member to step down to make room for Ackman  Schiller said in a statement he had not engaged in improper conduct  adding that accounting decisions were  careful and reasoned   BOARD RESHUFFLE Valeant had already begun making changes before Monday  It added a Pershing Square representative in a reshuffling two weeks ago that named three new members to the board   The company said last week it would not hit its 2016 earnings targets and would need to negotiate with lenders because of the delay in filing its annual report with the Securities and Exchange Commission   At the time  shares fell sharply  leading Ackman to lose more than  700 million in one day   Institutional investors  including TIAA CREF and CalPERS  filed securities fraud lawsuits against the company in New Jersey last year  accusing Valeant of inflating its share price by not disclosing the use of specialty pharmacies to prop up sales of high priced drugs  John Hempton of Bronte Capital  who has been shorting shares of Valeant  said on Monday he still believes Valeant shares will be worthless   Hempton said Valeant is currently forecasting  6 billion in earnings before interest  taxes  depreciation and amortization from just over  10 billion in revenue for 2016   If you believe a bunch of non patent protected drugs can do this in the face of a payer revolt against rigged prices  I will sell you some stock and the Brooklyn Bridge   Hempton said   
Shares rose 6 2 percent to  28 65 in New York trading after rising as high as  31 59 ",2016-03-21,Reuters,"https://www.investing.com/news/stock-market-news/valeant-says-ceo-pearson-to-step-down,-names-ackman-to-board-391091",391091
148323,369839,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 47 ,news,"Investing com   Canada stocks were higher after the close on Monday  as gains in the Healthcare  Utilities and IT sectors led shares higher 
At the close in Toronto  the S P TSX Composite gained 0 47  
The best performers of the session on the S P TSX Composite were  Concordia Healthcare   TO CXR   which rose 9 97  or 3 50 points to trade at 38 61 at the close  Meanwhile  Performance Sports Group Ltd  TO PSG  added 9 56  or 0 41 points to end at 4 70 and Valeant Pharmaceuticals International Inc  TO VRX  was up 8 50  or 2 97 points to 37 90 in late trade 
The worst performers of the session were  Badger Daylighting Ltd    TO BAD   which fell 6 88  or 1 69 points to trade at 22 88 at the close   Autocanada Inc   TO ACQ  declined 5 56  or 1 00 points to end at 17 00 and  Celestica  Inc   TO CLS  was down 4 82  or 0 67 points to 13 22 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 707 to 568 and 331 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 2 20  to 18 64 
Gold for April delivery was down 0 78  or 9 80 to  1244 50 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in May rose 1 26  or 0 52 to hit  41 66 a barrel  while the May Brent oil contract rose 1 02  or 0 42 to trade at  41 62 a barrel 
CAD USD was down 0 61  to 0 7642  while CAD EUR fell 0 31  to 0 6798 
The US Dollar Index was up 0 33  at 95 38 ",2016-03-21,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.47-391160,391160
148339,369855,BHC,Valeant gives Pershing Square one board seat  adds two other directors,news," Reuters    Embattled Valeant Pharmaceuticals International Inc  N VRX   TO VRX  said on Wednesday it has added a representative from shareholder Pershing Square  NYSE SQ  Capital Management to its board of directors as well as two other new directors  Pershing Square  run by activist investor Bill Ackman  bought a stake in Valeant last year when the drugmaker s shares were on the rise  They have fallen 68 percent since  Last fall  the company became the target of two U S  state investigations into its drug pricing practices  and its relationship with Philidor RX Services  a pharmacy selling its dermatology products  came under scrutiny and was dissolved   During the last two weeks  the company delayed its annual financial filing with regulators  postponed a preliminary earnings announcement  and said it would restate financials  Chief Executive Officer Michael  Pearson   LON PSON  returned from a two month medical leave and a top dermatology executive left  It also disclosed an investigation by the U S  Securities and Exchange Commission  Stephen Fraidin  a veteran Wall Street lawyer who is vice chairman at Pershing Square  joined the board  Valeant said  He previously worked at the Kirkland   Ellis law firm before joining Pershing last year  Fred Eshelman  a drug executive who founded Furiex Pharmaceuticals Inc  and Thomas Ross  an academic who is a fellow at Duke University and president emeritus of the University of North Carolina  also joined the board  Anders Lonner  former CEO of Swedish specialty drug company  Meda AB   ST MEDAa   stepped down from the board  Valeant said  The board now has 14 members   Wells Fargo   NYSE WFC  analyst David Maris  who has an  underperform  rating on the stock  said in a research note that Pershing Square had proposed Eshelman for the board at Allergan  NYSE AGN pa  during its and Valeant s failed hostile bid for the company  Maris said investors will likely have reservations about Ross as well  given his ties to Duke University  to which CEO Pearson has donated  45 million   Valeant plans to report preliminary fourth quarter earnings and hold a conference call on March 15  On Tuesday  Ackman said the company will reveal  messy  fourth  and first quarter results  and said Valeant needed to stabilize soon  If not  new management will be brought in or the company will be sold  he said  Valeant s board set up a committee last year to look into the relationship between Valeant and Philidor  As a result of that ongoing investigation  it is restating financials  The committee is advised by Mark Filip  a partner at Kirkland   Ellis  
On Wednesday  its shares rose 6 6 percent to  67 20 ",2016-03-09,Reuters,"https://www.investing.com/news/stock-market-news/valeant-gives-pershing-square-one-board-seat,-adds-two-other-directors-388887",388887
148340,369856,BHC,U S  panel asks Valeant to justify withholding documents,news," Reuters    A U S  congressional committee stepped up the pressure on Valeant Pharmaceuticals International Inc  TO VRX   N VRX  on Thursday  urging the company to explain why it was withholding documents related to an investigation into drug pricing  The House Oversight Committee had sent a letter to Valeant Chief Executive Michael  Pearson   LON PSON  last August  seeking documents about steep hikes in prices of two of the company s heart drugs  The drugmaker rejected the request in September  saying the information was  highly proprietary and confidential   the committee said in a statement on Thursday  The committee said it had sent another letter to Pearson last week  seeking descriptions of each undisclosed document  the total number of pages of each document withheld  and the rationale behind the withholding    We are surprised and puzzled by the committee s statement given that we have produced more than 78 000 pages of documents   Robert Kelner  partner at Covington   Burling  who is representing Valeant said       we have declined to produce documents covered by the attorney client privilege  and we are preparing a log for the committee detailing what documents are being withheld under that privilege   Kelner said  Valeant s business and accounting practices came under regulatory scrutiny late last year  The company s shares have tumbled around 75 percent since their record high of  263 81 in August  
They were trading down 1 8 percent at  65 68 on Thursday ",2016-03-10,Reuters,https://www.investing.com/news/stock-market-news/u.s.-panel-asks-valeant-to-justify-withholding-documents-389198,389198
148341,369857,BHC,U S  futures slide as Fed meeting kicks off  data takes backburner,news,"Investing com   U S  futures pointed to a lower open on Tuesday after Monday s session saw a flat  mixed close as investors kept an eye on crude and geared up for the Federal Reserve s policy announcement on Wednesday 
The blue chip Dow futures dropped 70 points  or 0 41   by 10 54GMT  or 6 54AM ET  the S P 500 futures fell 10 points  or 0 49   while the tech heavy Nasdaq 100 futures traded down 17 points  or 0 39  
Tuesday s session will kick off the Fed s two meeting with traders digging in ahead of the release of not only the U S  central bank s decision on monetary policy  but also the updated economic projections of its members and the following press conference with Fed chair Janet Yellen 
Markets do not expect changes to the federal funds rate at this meeting with most experts suggesting that June could be the first opportunity for a hike 
However  close attention will be paid to the economic forecasts and  especially  the dot plot that shows Fed members  forecasts for the future path of interest rates 
The FOMC statement will center attention as investors scour the document for language changes  only to be replaced in the headlines by remarks from the Fed chief herself who will further clarify the central bank s position on the economy  unemployment and the path of interest rates 
In this context  data released on Tuesday could take a backseat to this focus on the Fed  but the highlight will be the publication of retail sales for February at 12 30 GMT or 8 30AM ET 
At the same time  the U S  will also publish data on February producer price inflation as well as the March Empire State Manufacturing index 
In economic data of lesser impact  January business inventories and the NAHB housing market index will be released at 14 00GMT or 10 00AM ET 
Meanwhile  crude continued to be unable to regain its footing  tumbling to a one week low on Tuesday after Iran dashed hopes that there would be a coordinated production freeze any time soon 
Traders looked ahead to fresh weekly information on U S  stockpiles of crude and refined products  The American Petroleum Institute will release its inventories report later in the day  while Wednesday s government report could show crude stockpiles rose by 3 4 million barrels in the week ended March 11 
U S  crude futures fell 2 37  to  36 30 by 10 56AM GMT or 6 56AM ET  while Brent oil traded down 2 30  to  38 62 
In business news  Valeant Pharmaceuticals International Inc  NYSE VRX  slumped 10  in the pre market after its earnings per share missed consensus by  0 11 
Oracle Corporation  NYSE ORCL  will be reporting earnings after the market close ",2016-03-15,Investing.com,"https://www.investing.com/news/stock-market-news/u.s.-futures-slide-as-fed-meeting-kicks-off,-data-takes-backburner-389957",389957
148343,369859,BHC,Valeant cuts 2016 forecasts  says report delay poses default risk,news," Reuters    Valeant Pharmaceuticals International Inc  NYSE VRX   The Canadian drugmaker  the target of U S  investigations into its business and accounting practices  reiterated that it would delay filing its annual report with U S  regulators but for the first time raised the specter of a default as a result  Valeant  whose U S  listed shares were down 18 3 percent in premarket trading  said failure to file the report by Tuesday s deadline would mean it would be in breach of a covenant and that holders of at least 25 percent of any series of notes may deliver a notice of default  As of Sept  30  Valeant had about  30 billion of long term debt  However  Chief Executive Michael  Pearson   LON PSON  expressed optimism about the company s finances   We are comfortable with our current liquidity position and cash flow generation for the rest of the year  and remain well positioned to meet our obligations   he said in a statement  The company said last month it would delay filing its annual report while a board committee looked into its accounting practices  The company also said it would restate 2014  2015 financial statements  Valeant s troubles began late last year when questions were raised about its drug pricing strategy and allegations emerged that it was using drug distributor Philidor RX Services to inflate revenue in its dermatology business  Laval  Quebec based Valeant has since cut ties with Philidor  which has now gone out of business  Valeant is being investigated by the U S  Securities and Exchange Commission over its relationship with Philidor  Reuters has reported  The company also the subject of U S  state investigations for steep price increases on some of is drugs  The company said on Tuesday that revenue in 2016 is now expected to be  11 0 billion to  11 2 billion  compared with its previous estimate of  12 5 billion to  12 7 billion  The  1 5 billion cut reflected slower growth in the company s U S  dermatology  gastrointestinal and women s health businesses  Valeant said  Valeant originally provided a 2016 forecast in December  but withdrew it on Feb  29 when Pearson returned from two months medical leave  Valeant reported fourth quarter adjusted earnings of  2 50 per share  compared with the average analyst estimate of  2 61  The company said it expected adjusted earnings of  9 50  10 50 per share for 2016  compared with its previous estimate of  13 25  13 75  Analysts on average were expecting earnings of  13 24 per share on revenue of  12 41 billion  according to the Thomson Reuters I B E S  
Up to Monday s close of  69 04  Valeant s U S  listed shares had fallen about 74 percent since their August high of  263 81  The company s Toronto listed stock closed at C 91 58 on Monday ",2016-03-15,Reuters,https://www.investing.com/news/stock-market-news/valeant-cuts-2016-revenue-forecast-389946,389946
148345,369861,BHC,Valeant cuts 2016 revenue forecast  warns of default risk ,news,Investing com   Canadian drugmaker Valeant Pharmaceuticals  NYSE VRX  cut its revenue forecast for the year on Tuesday and warned it may be facing a default risk  Valeant said 2016 revenue is now expected to be  11 0 billion to  11 2 bn  compared with its previous estimate of  12 5 bn to  12 7 bn  The company reported fourth quarter earnings of  2 50 per share  compared with the average analyst estimate of  2 61  Valeant said it would delay filing its final annual report with U S  regulators  but warned it could face a default if doesn t file by April 29  The drugmaker is the target of U S  investigations into its business and accounting practices ,2016-03-15,Investing.com,"https://www.investing.com/news/stock-market-news/valeant-cuts-2016-revenue-forecast,-warns-of-default-risk-390017",390017
148349,369865,BHC,Wall Street trades down on jitters ahead of the Fed,news,"Investing com   U S  stocks gave up ground on Tuesday while investors digested a string of last round data showing weak consumption and recovering inflation prior to the Federal Reserve s policy decision on Wednesday and oil remained unable to recover from global supply worries ahead of key U S  inventory data 
At 16 37GMT or 12 37 ET  the Dow 30 lost 26 points or 0 15   while the S P 500 gave up 9 points or 0 45  and the tech heavy NASDAQ Composite traded down 25 points or 0 52  
Tuesday s session accompanied the kick off of the Fed s two meeting with traders digging in ahead of the release of not only the U S  central bank s decision on monetary policy  but also the updated economic projections of its members and the following press conference with Fed chair Janet Yellen 
Markets do not expect changes to the federal funds rate at this meeting with most experts suggesting that June could be the first opportunity for a hike 
However  close attention will be paid to the economic forecasts and  especially  the dot plot that shows Fed members  forecasts for the future path of interest rates 
The FOMC statement will center attention as investors scour the document for language changes  only to be replaced in the headlines by remarks from the Fed chief herself who will further clarify the central bank s position on the economy  unemployment and the path of interest rates 
In this context  the data released on Tuesday gave markets food for thought with consumption indicators showing weakness and price data showing a recovery in inflation as it crept closer to the Fed s 2  target 
The focus was on February retail sales  which  although they dropped less than expected  still registered their largest two month decline in a year  underlining concerns over the economic outlook 
Business inventories also rose unexpectedly with the total business inventories to sales ratio hitting a seven year high  another indicator of a soft consumer demand in the economy 
Not all the data was worrisome as the March Empire State Manufacturing index made a surprising recovery and showed the first expansion in eight months thanks to growth in new orders and shipments 
But price side data continued to show a recovery  with the February producer price inflation  PPI  unchanged from a year ago  suggesting that the downward trend could be reaching its end 
The data point is relevant for inflation as producers tend to try and pass price increases onto consumers  so PPI could be considered a leading indicator 
With all this in mind  the Atlanta Fed cut its forecast for growth in the U S  economy for the first quarter of 2016 on Friday from 2 2  to 1 9  precisely due to Friday s retail sales report 
Additionally   Barclays   LON BARC  too became the latest of a string of experts to cut growth forecasts for the U S  economy in the first quarter as these experts dropped their estimate by half a percent to 1 9  
Individual Fed officials are expected to cut their own forecasts in the update to economic projections that will accompany the statement tomorrow and  along with the February CPI released on Wednesday  the data will probably center the debate on future policy moves at the heart of the U S  central banks 
Fed doves will be concerned about the need for maintain accommodative measures in order to protect the still fragile economy  while the hawks will point towards the recovery in inflation as they express worries over falling behind the curve 
Outside jitters over the next Fed move  crude continued to be a major market focus on Tuesday as it tumbled to more than a one week low on Tuesday after Iran dashed hopes that there would be a coordinated production freeze any time soon 
With that in mind  investors looked ahead to fresh weekly information on U S  stockpiles of crude and refined products  The American Petroleum Institute will release its inventories report later in the day  while Wednesday s government report could show crude stockpiles rose by 3 4 million barrels in the week ended March 11 
U S  crude futures fell 2 96  to  36 08 by 16 41GMT or 12 41ET  while Brent oil traded down 2 50  to  38 54 
In company news  Valeant Pharmaceuticals International Inc  NYSE VRX  grabbed headlines on Tuesday  losing more than 40   after reporting earnings far below consensus  and cutting forecasts for 2016  all while admitting that the delay in submitting its annual report could pose default risk and the CEO of the Canadian drugmaker  Michael  Pearson   LON PSON   admitted that the company wasn t  running on all cylinders  
 FactSet Research Systems Inc   NYSE FDS  also fell close to 4  after disappointing with its own quarterly earnings report and guidance 
Oracle Corporation  NYSE ORCL  will be reporting earnings after the market close ",2016-03-15,Investing.com,https://www.investing.com/news/stock-market-news/wall-street-trades-down-on-jitters-ahead-of-the-fed-390044,390044
148350,369866,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 57 ,news,"Investing com   Canada stocks were lower after the close on Tuesday  as losses in the Healthcare  Mining and IT sectors led shares lower 
At the close in Toronto  the S P TSX Composite fell 0 57  
The best performers of the session on the S P TSX Composite were  B2Gold Corp   TO BTO   which rose 8 57  or 0 150 points to trade at 1 900 at the close  Meanwhile  Pengrowth Energy Corporation  TO PGF  added 4 96  or 0 06 points to end at 1 27 and  Cameco  Corp  TO CCO  was up 4 73  or 0 75 points to 16 60 in late trade 
The worst performers of the session were Valeant Pharmaceuticals International Inc  TO VRX   which fell 50 71  or 46 44 points to trade at 45 14 at the close  Performance Sports Group Ltd  TO PSG  declined 9 71  or 0 51 points to end at 4 74 and  HudBay Minerals  Inc   TO HBM  was down 9 35  or 0 46 points to 4 46 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 780 to 481 and 328 ended unchanged 
Shares in Valeant Pharmaceuticals International Inc  TO VRX  fell to 3 years lows  falling 50 71  or 46 44 to 45 14  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 0 75  to 21 42 
Gold for April delivery was down 0 90  or 11 20 to  1233 90 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in April fell 2 15  or 0 80 to hit  36 38 a barrel  while the May Brent oil contract fell 2 05  or 0 81 to trade at  38 72 a barrel 
CAD USD was down 0 74  to 0 7485  while CAD EUR fell 0 80  to 0 6738 
The US Dollar Index was up 0 06  at 96 66 ",2016-03-15,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-0.57-390095,390095
148353,369869,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 58 ,news,"Investing com   Canada stocks were higher after the close on Wednesday  as gains in the Mining  Materials and Energy sectors led shares higher 
At the close in Toronto  the S P TSX Composite added 0 58  
The best performers of the session on the S P TSX Composite were  First Quantum Minerals Ltd    TO FM   which rose 10 72  or 0 82 points to trade at 8 47 at the close  Meanwhile   B2Gold Corp   TO BTO  added 10 53  or 0 200 points to end at 2 100 and  Primero Mining  Corp  TO P  was up 9 35  or 0 230 points to 2 690 in late trade 
The worst performers of the session were Valeant Pharmaceuticals International Inc  TO VRX   which fell 2 88  or 1 30 points to trade at 43 84 at the close   TransAlta  Corp  TO TA  declined 2 66  or 0 16 points to end at 5 85 and  North West Company Inc    TO NWC  was down 2 25  or 0 67 points to 29 10 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 779 to 497 and 309 ended unchanged 
Shares in Valeant Pharmaceuticals International Inc  TO VRX  fell to 3 years lows  losing 2 88  or 1 30 to 43 84  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 9 48  to 19 19 
Gold for April delivery was up 2 59  or 31 90 to  1262 90 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in April rose 5 94  or 2 16 to hit  38 50 a barrel  while the May Brent oil contract rose 3 98  or 1 54 to trade at  40 28 a barrel 
CAD USD was up 1 86  to 0 7627  while CAD EUR rose 0 74  to 0 6793 
The US Dollar Index was down 1 02  at 95 67 ",2016-03-16,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.58-390349,390349
148377,369893,BHC,Exclusive  SEC probe of Valeant began with review of short seller   sources ,news,"By Carl O Donnell and Sarah N  Lynch NEW YORK  Reuters    A U S  regulatory probe of Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX   disclosed by the company on Monday  is focused on the drugmaker s relationship with specialty pharmacy Philidor RX Services and was triggered by Valeant s own request that regulators investigate a short seller s allegations  people familiar with the matter said  The Monday disclosure of the Securities and Exchange Commission investigation put new pressure on Valeant  contributing to a nearly 20 percent drop in its shares  The company on Monday confirmed the probe but did not provide any details on it  Valeant did not immediately respond to a request for comment on Tuesday  The Wall Street Journal reported that the probe was focused on Valeant s relationship with Philidor   Some of the people interview by Reuters said that Valeant Chief Executive Michael  Pearson   LON PSON  described the Philidor link to some brokerage analysts during one on one conversations on Monday and Tuesday  Pearson said the SEC review was a continuation of an investigation  requested by Valeant  of a short seller that raised questions about Valeant s business model and ethics  the people said  In October  Valeant invited the regulator to investigate what it called  completely untrue  allegations from Andrew Left  a short seller and founder of Citron Research  that Valeant used its relationship with Philidor as part of an effort to book false revenues   The SEC probe that resulted has placed focus on Philidor but has also looked into other areas of Valeant s operations  the people said  It is separate from an existing investigation into Salix Pharmaceuticals  which was purchased by Valeant last year  according to a person familiar with the matter  In that matter  the SEC is primarily focused on whether the former executives misled investors about inventory levels for certain key drugs  News of the investigation on Monday added to investor uncertainty after Canada based Valeant withdrew 2016 earnings guidance and announced the return of Pearson  who had been on extended medical leave after a bout of pneumonia   Valeant shares fell about half a percent on Tuesday  closing at  65 45 per share on the New York Stock Exchange  Investors in the drugmaker still face significant uncertainty  including the outcome of the investigation by an ad hoc board committee into Valeant s relationship with Philidor  its upcoming earnings report and annual report and its 2016 earnings guidance  Valeant told analysts it planned on revealing the SEC investigation in its 2015 annual 10 K report  which has not yet been filed after being delayed by the company  the people said  
The company s stock has dropped nearly  200  or about 75 percent  from its peak last year ",2016-03-01,Reuters,https://www.investing.com/news/stock-market-news/exclusive:-sec-probe-of-valeant-began-with-review-of-short-seller---sources-387403,387403
148378,369894,BHC,Valeant appoints Ari Kellen executive vice president,news," Reuters    Valeant Pharmaceuticals International Inc  N VRX   TO VRX  said it appointed Ari Kellen executive vice president  succeeding Deb Jorn who has resigned  effective immediately  Eric Abramson  vice president of dermatology and immunology marketing  has been appointed general manager of the U S dermatology business  the Canadian drugmaker said in a statement on Wednesday  Valeant disclosed on Monday that the U S  Securities and Exchange Commission is investigating the company s relationship with Philidor RX Services and also said it would delay filing its annual report beyond the 15 day extension period  
Valeant Chief Executive Michael  Pearson   LON PSON  returned from a prolonged medical leave  and the company has canceled the release of its fourth quarter earnings and withdrew its 2016 financial guidance ",2016-03-02,Reuters,https://www.investing.com/news/stock-market-news/valeant-appoints-ari-kellen-executive-vice-president-387646,387646
148379,369895,BHC,Valeant reiterates key executive resigned  was not asked to go,news,"By Natalie Grover  Reuters    Valeant Pharmaceuticals International Inc  TO VRX   N VRX   responding to investors  queries  said on Thursday that Executive Vice President Deb Jorn had not been asked to leave  reiterating that she had resigned for personal reasons  Jorn oversaw the Canadian drugmaker s U S  dermatology business  which had ties with Philidor Rx Services  a specialty pharmacy that came under fire for using aggressive tactics to increase insurer reimbursement  mostly for dermatology drugs  Valeant in October severed its ties with Philidor  which has since shut shop  The company s relationship with Philidor is the focus of an investigation by the U S  Securities and Exchange Commission  Reuters reported  A Valeant board committee is also investigating the company s ties with Philidor  and the drugmaker on Thursday said Jorn s departure  is not the result of an action taken by the Ad Hoc Committee of the Board of Directors    This unexpected change is yet another setback and comes at an especially inopportune time  as Valeant is dealing with a number of issues on several fronts   said  Wells Fargo   NYSE WFC  analyst David Maris  who has an  underperform  rating on the stock  Valeant s woes began last year when it attracted staunch criticism for its pricing strategy and accounting practices   The company on Sunday said it would delay releasing its fourth quarter results and withdrew its financial forecast for the year  adding to investors  uncertainty  CEO Michael  Pearson   LON PSON  returned from medical leave on the same day  Late on Wednesday Valeant announced the resignation of Jorn  who was in charge of the company s U S  dermatology and gastrointestinal businesses  It named Eric Abramson  vice president of dermatology and immunology marketing  general manager of the dermatology business and Ari Kellen  executive vice president and company group chairman  as head of the gastrointestinal business  The two divisions accounted for roughly a third of the company s third quarter revenue of about  2 8 billion  Wells Fargo s Maris estimated  Laval  Quebec based Valeant s shares were down about 3 percent at  65 47 in afternoon trading on Thursday on the New York Stock Exchange  
They have plummeted from a high of  263 81 in early August to a more than three year low of  59 87 on Tuesday  a day after Valeant said it was being investigated by the SEC ",2016-03-03,Reuters,"https://www.investing.com/news/stock-market-news/valeant-reiterates-key-executive-resigned,-was-not-asked-to-go-387747",387747
148380,369896,BHC,Valeant sets earnings date  shares jump on hope for positive news,news," Reuters    Valeant Pharmaceuticals International Inc  TO VRX   N VRX   the subject of intense scrutiny over its business practices and pricing policies  said it would release preliminary quarterly results and guidance on March 15  raising hopes the company will serve up some positive news after months of uncertainty  Valeant s stock   which had plunged 24 percent since the company said last week that it would delay its results  withdrew 2016 guidance and was the target of an SEC probe   rose as much as 8 5 percent in morning trading on Monday  The stock has shed about 77 percent of its value since August  when it hit a record high of  263 81  The Laval  Quebec based company had originally been scheduled to release its fourth quarter results on Feb  29   This stock has been so volatile     it is possible the company s announcement it will report Q4 earnings and update guidance on the 15th has some investors more optimistic that some recent fears about accounting restatements and withdrawn guidance won t be as bad as perceived   Morningstar analyst Michael Waterhouse said in an email to Reuters  Reuters reported on Tuesday that a probe by the U S  Securities and Exchange Commission was focused on the drugmaker s relationship with Philidor RX Services  a specialty drug distributor that came under fire for its aggressive tactics to increase insurer reimbursements   Valeant has since cut ties with Philador and reached a deal to distribute its drugs through Walgreens Boots Alliance Inc  O WBA   The company said the delay in releasing the results was related to the return of Chief Executive Michael  Pearson   LON PSON  two months after he was hospitalized for pneumonia   Now that I have returned  I have been working diligently to review the business so that I can share our latest performance and outlook with shareholders   Pearson said in a statement on Monday  Valeant said it would hold a conference call after releasing its results  The company said this month it would restate results for 2014 and 2015 after identifying some sales to Philidor that should have been recognized when products were dispensed to patients  not when they were delivered to the distributor  
Valeant s Toronto listed shares were up 8 percent at C 88 15 at midday  while its U S  listed shares trading at  66 43 ",2016-03-07,Reuters,"https://www.investing.com/news/stock-market-news/valeant-sets-earnings-date,-shares-jump-on-hope-for-positive-news-388430",388430
148381,369897,BHC,Valeant mulls three new directors  including one from Pershing Square  sources,news,"By Svea Herbst Bayliss and Carl O Donnell NEW YORK  Reuters    Embattled drug company Valeant Pharmaceuticals  NYSE VRX   whose stock price has tumbled 38 percent this year  is mulling giving board seats to activist hedge fund Pershing Square  NYSE SQ  Capital Management  one of its biggest investors  two people familiar with the matter said  Stephen Fraidin  a veteran Wall Street lawyer who is vice chairman at William Ackman s Pershing Square  is expected to join Valeant s 12 member board  the sources said  The company is also expected to give a seat to Fredric Eshelman  a long time pharmaceutical industry executive  as well as one other person  adding a total of three new directors  the sources said  The company was not immediately available to comment  The move comes after a particularly rocky few weeks in which Valeant said it would restate its earnings  its chief executive returned from a lengthy sick leave  it postponed a scheduled earnings statement and acknowledged that the country s top securities regulator is investigating the company   It also marks a dramatic shift for Pershing Square  which made the investment as a rare passive bet  saying a year ago that it believed in Valeant s management and policy of favoring acquisitions over in house research  By putting a representative on the board  the  12 billion New York based hedge fund  which owns 16 5 million shares  is demanding a louder voice in running the company  It has taken a similar approach with some of its best performing investments  including railroad Canadian Pacific  The board already has two investor representatives  Mason Morfit and Robert Hale  They work for San Francisco based hedge fund ValueAct  which owns 14 9 million shares and ranks as the fourth biggest owner after Pershing Square  Fraidin joined Pershing Square in early 2015  around the time Ackman began investing in Valeant  A year earlier Ackman  with advice from Fraidin s law firm  created an unusual structure in which he bought shares in drug firm Allergan  NYSE AGN pa  but was working with Valeant  whose shares he owned  in a bid to buy Allergan  While no merger ensued  Allergan s gains in 2014 helped deliver one of Ackman s most profitable years ever   Pershing Square Holdings gained 40 percent  Last year and this year Valeant has weighed on returns  due to an attack by short sellers who questioned the firm s sales and accounting practices  
Valeant is a favorite stock among hedge funds  with John Paulson s Paulson   Co   Brahman Capital and Viking Global Investors ranking as other big investors ",2016-03-08,Reuters,"https://www.investing.com/news/stock-market-news/valeant-mulls-three-new-directors,-including-one-from-pershing-square:-sources-388732",388732
148382,369898,BHC,Valeant gives Pershing Square a seat on its board ,news," Reuters    Valeant Pharmaceuticals International Inc  N VRX   TO VRX   under scrutiny for its accounting and business practices  said it had given shareholder Pershing Square  NYSE SQ  Capital Management a seat on its board and added two additional directors 
Stephen Fraidin  a veteran Wall Street lawyer who is vice chairman at William Ackman s Pershing Square  has joined the board  along with Fred Eshelman and Thomas Ross  Valeant said 
Anders Lonner has stepped down as a director  the company said on Wednesday ",2016-03-09,Reuters,https://www.investing.com/news/stock-market-news/valeant-gives-pershing-square-a-seat-on-its-board-388879,388879
148407,369923,BHC,Smirking Shkreli refuses lawmakers  questions  calls them  imbeciles ,news,"By Sarah N  Lynch and David Ingram WASHINGTON NEW YORK  Reuters    Former drug executive Martin Shkreli smirked and brushed off questions about drug prices then tweeted that lawmakers were imbeciles on Thursday  when he appeared at a U S  congressional hearing against his will  Shkreli  32  sparked outrage last year among patients  medical societies and Democratic presidential front runner Hillary Clinton after his company  Turing Pharmaceuticals  raised the price of the drug Daraprim by more than 5 000 percent to  750 a pill  The lifesaving medicine  used to treat a parasitic infection  once sold for  1 a pill and has been on the market for more than 60 years  At a hearing of the U S  House Committee on Oversight and Government Reform  Shkreli repeatedly invoked the Fifth Amendment of the U S  Constitution  which says no person shall be compelled in any criminal case  to be a witness against himself   Wearing a sport jacket and collared shirt rather than his usual T shirt  he responded to questions by laughing  twirling a pencil and yawning  Committee Chairman Jason Chaffetz  a Utah Republican  asked Shkreli what he would tell a single  pregnant woman with AIDS who needed Daraprim to survive  and whether he thought he had done anything wrong  Shkreli declined to answer   I intend to follow the advice of my counsel  not yours   said Shkreli after South Carolina Republican Representative Trey Gowdy suggested he could answer questions that were unrelated to pending fraud charges against him   After the hearing  Shkreli s lawyer  Benjamin Brafman  attributed his client s behavior to  nervous energy    Later  though  Shkreli wrote on Twitter   Hard to accept that these imbeciles represent the people in our government   U S  Representative Elijah Cummings  who learned about the tweet while Turing Chief Commercial Officer Nancy Retzlaff was testifying  pounded his fist on the dais  The Maryland Democrat then shouted about an internal Turing document in which a staffer joked about the price increase   You all spent all of your time strategizing about how to hide your price increase     and coming up with stupid jokes while other people were sitting there trying to figure out how they were going to survive   Cummings said  Shkreli was arrested in December and charged with running his investment funds and companies almost like a Ponzi scheme  He has pleaded not guilty to the fraud charges  which are not related to the pricing of Daraprim  He also stepped down from Turing and was fired from  KaloBios Pharmaceuticals Inc   PK KBIOQ   Cummings pleaded with Shkreli to reconsider his views about drug pricing   You can go down as the poster boy for greedy drug company executives  or you can change the system   At one point  Brafman asked to address the committee  but Chaffetz said no  Shkreli was even asked about his purchase of a limited edition Wu Tang Clan hip hop album for  2 million    Is that the name of the album  The name of the group   Gowdy asked  After Shkreli again invoked the Fifth Amendment  Gowdy added   I am stunned that a conversation about an album he purchased could possibly subject him to incrimination    Shkreli was allowed to leave early after he repeated he would not answer questions   SUCH CONTEMPT  Representative John Mica  a Florida Republican  said he would consider asking fellow lawmakers to hold Shkreli in contempt for his behavior    I don t think I ve ever seen the committee treated with such contempt   Mica said  Brafman said Shkreli would have liked to discuss drug pricing but had no choice  given the criminal charges against him  Shkreli s tweet did not amount to waiving his right against self incrimination  experts said   The First Amendment protects Mr  Shkreli s right to post his opinion on Twitter  N TWTR  that the Congress is populated by  imbeciles   This is classic political free speech   said lawyer Paul Callan  Also at the hearing  Valeant Pharmaceuticals Inc  TO VRX  interim CEO Howard Schiller put forward a conciliatory face  testifying that his company had changed its business and pricing tactics   Where we have made mistakes  we are listening and changing   Schiller said during opening remarks   In a number of cases  we have been too aggressive  about price increases   Valeant shares rose more than 5 percent during the hearing  Retzlaff testified that Turing acquired Daraprim because it was  priced far below its market value  and is committed to investing revenue into new treatments  
The Federal Trade Commission and the New York attorney general are investigating Turing for possible antitrust violations ",2016-02-04,Reuters,https://www.investing.com/news/stock-market-news/ex-drug-executive-shkreli-invokes-fifth-amendment-before-congress-383309,383309
148408,369924,BHC,CVS says 2015 drug spending grew 5 percent  far less than in 2014,news,By Caroline Humer NEW YORK  Reuters    CVS Health Corp  N CVS  said on Tuesday its pharmacy benefit customers spent about 5 percent more on prescription drugs in 2015 than in 2014  a year when drug spending jumped nearly 12 percent  The No  2 U S  drugstore chain attributed the lower increase to careful management of its coverage plans  saying it negotiated with pharmaceutical makers for rebates and discounts and had more selective coverage that excluded pricey drugs  It also said fewer new high priced specialty drugs hit the market in 2015 and that inflation in branded drugs for high volume disorders like diabetes had one of the biggest impacts on spending  Drug spending in 2014 was boosted in part by a pricey new hepatitis C treatment from Gilead Sciences  O GILD   CVS said  In 2015  AbbVie Inc s  O ABBV  competing product hit the market and is estimated to have nearly halved the price of Gilead s treatment  CVS competes against Express Scripts Holding Corp  O ESRX  and Optum  a unit of UnitedHealth Group Inc  N UNH   Express Scripts also is expected to release a detailed drug spending report for 2015   CVS Chief Medical Officer Troyen Brennan said that the 2015 overall drug price trend would have been nearly the same as in 2014 if it had not made changes to its main coverage plan  called a formulary  or negotiated such steep discounts  Drug companies have a list price but typically provide discounts and rebates to large buyers  One drug Brennan called out as particularly pricey was Valeant Pharmaceuticals   N VRX  Jublia  a toenail fungus treatment whose price rose 950 percent during the year  A cheaper oral medication that has better clinical results is preferred  he said  Valeant has been criticized for raising prices of its treatments sharply and for using a pharmacy that used aggressive tactics to push sales of its drugs ,2016-02-23,Reuters,"https://www.investing.com/news/stock-market-news/cvs-says-2015-drug-spending-grew-5-percent,-far-less-than-in-2014-385944",385944
148409,369925,BHC,J J must pay  72 million for cancer death linked to talcum powder  lawyers,news,"By Jonathan Stempel  Reuters    Johnson   Johnson  N JNJ  was ordered by a Missouri state jury to pay  72 million of damages to the family of a woman whose death from ovarian cancer was linked to her use of the company s talc based Baby Powder and Shower to Shower for several decades  In a verdict announced late Monday night  jurors in the circuit court of St  Louis awarded the family of Jacqueline Fox  10 million of actual damages and  62 million of punitive damages  according to the family s lawyers and court records  The verdict is the first by a U S  jury to award damages over the claims  the lawyers said  Johnson   Johnson faces claims that it  in an effort to boost sales  failed for decades to warn consumers that its talc based products could cause cancer  About 1 000 cases have been filed in Missouri state court  and another 200 in New Jersey   Fox  who lived in Birmingham  Alabama  claimed she used Baby Powder and Shower to Shower for feminine hygiene for more than 35 years before being diagnosed three years ago with ovarian cancer  She died in October at age 62  Jurors found Johnson   Johnson liable for fraud  negligence and conspiracy  the family s lawyers said  Deliberations lasted four hours  following a three week trial  Jere Beasley  a lawyer for Fox s family  said Johnson   Johnson  knew as far back as the 1980s of the risk   and yet resorted to  lying to the public  lying to the regulatory agencies   He spoke on a conference call with journalists  Carol Goodrich  a Johnson   Johnson spokeswoman  said   We have no higher responsibility than the health and safety of consumers  and we are disappointed with the outcome of the trial  We sympathize with the plaintiff s family but firmly believe the safety of cosmetic talc is supported by decades of scientific evidence   Trials in several other talc lawsuits have been set for later this year  according to Danielle Mason  who also represented Fox s family at trial  In October 2013  a federal jury in Sioux Falls  South Dakota found that plaintiff Deane Berg s use of Johnson   Johnson s body powder products was a factor in her developing ovarian cancer  Nevertheless  it awarded no damages  court records show  Valeant Pharmaceuticals International Inc  TO VRX  now owns the Shower to Shower brand but was not a defendant in the Fox case  
The case is Hogans et al v  Johnson   Johnson et al  Circuit Court of the City of St  Louis  Missouri  No  1422 CC09012 ",2016-02-23,Reuters,https://www.investing.com/news/stock-market-news/j-amp;j-must-pay-$72-million-for-cancer-death-linked-to-talcum-powder:-lawyers-386143,386143
148410,369926,BHC,Valeant board debating Pearson s return as health improves  CNBC,news," Reuters    The health of Valeant Pharmaceuticals International Inc s  TO VRX  Michael  Pearson   L PSON  is improving  the company said on Thursday  but CNBC reported that there was debate within the board over whether he was ready to return to work  Pearson  who joined Valeant  N VRX  as chief executive in 2010  was hospitalized with severe pneumonia in late December  The company named former Chief Financial Officer Howard Schiller as interim CEO in January   
CNBC  citing a source  said Pearson was ready to return but the board was debating whether he should ",2016-02-25,Reuters,https://www.investing.com/news/stock-market-news/valeant-board-debating-pearson's-return-as-health-improves:-cnbc-386498,386498
148411,369927,BHC,Valeant CEO Pearson to return effective immediately  results delayed,news,"By Caroline Humer NEW YORK  Reuters    Valeant Pharmaceuticals  N VRX  International  TO VRX  said on Sunday that Chief Executive Officer Michael  Pearson   L PSON  would return from medical leave effective immediately  and it postponed the release of fourth quarter results planned for Monday  Valeant was under pressure for its drug price increases when it said in late December that Pearson had been hospitalized for severe pneumonia  Weeks later  the company appointed board member and former Chief Financial Officer Howard Schiller as interim CEO  saying Pearson remained unwell  Investors have been divided on Pearson s return  and shares fell last week  reflecting concern about the company s future  On Feb  22  Valeant said it would delay filing its audited 2015 annual report with the U S  Securities and Exchange Commission and planned to restate some revenues and earnings from 2014 and 2015 as a result of the preliminary results of that review  It set Feb  29 as a date to announce unaudited fourth quarter earnings   On Friday  CNBC reported that Valeant s board of directors was mulling whether Pearson would return  The company said that because of Pearson s return  it would delay the Monday release of financials and its conference call  Valeant also withdrew its prior financial outlook and said it would release preliminary 2015 results and a 2016 outlook  in the near term    I realize that recent events are disappointing to everyone and it is my responsibility to set the appropriate tone for the organization   Pearson said in the statement  He said among his immediate priorities would be  improving Valeant s reporting procedures  internal controls and transparency   Valeant s shares fell from a high of  263 70 in August to a low of  69 34 in November as it came under pressure over its dealings with Philidor RX Services  a pharmacy with which it had a close relationship and which sources said used aggressive tactics to increase sales of its dermatology products  A board committee began an investigation into those ties  Valeant is also being investigated by the New York and Massachusetts attorneys general  The board committee is continuing to review the accounting matters and to assess the impact on financial reporting and internal controls  Valeant said   ISI Evercore analyst Umer Raffat said in a research note that Pearson s return was a positive development that should calm investors  But he said that rescheduling Monday s earnings call and withdrawing 2016 guidance was a negative  
On Friday  shares closed at  80 65 in New York trading ",2016-02-28,Reuters,"https://www.investing.com/news/stock-market-news/valeant-ceo-pearson-to-return-effective-immediately,-results-delayed-386884",386884
148412,369928,BHC,U S  stock futures trim losses after China easing move,news,"Investing com   U S  stock futures trimmed losses on Monday  coming off the lowest levels of the session after the People s Bank of China lowered the amount of cash banks are required to hold in a surprise move 
The blue chip Dow futures shed 39 points  or 0 23   by 11 50GMT  or 6 50AM ET  after being down by more than 100 points earlier  Meanwhile  the S P 500 futures dipped 5 points  or 0 22   while the tech heavy Nasdaq 100 futures declined 18 points  or 0 41  
The People s Bank of China reduced its reserve requirement ratio by 0 5  to 17 0   effective March 1  as Beijing steps up efforts to support the economy 
The Shanghai Composite tumbled nearly 3  on Monday to hit levels not seen since late 2014  after the country s central bank guided the yuan lower  prompting fresh concerns over the world s number two economy 
At a weekend G20 meeting in Shanghai  PBOC head Zhou Xiaochuan tried to ease concerns that China s economic strategy hinges on a weaker yuan  saying there is no basis for a persistent depreciation in the currency 
The moves by Beijing to weaken the yuan have prompted concerns over a China led slowdown in global growth 
Meanwhile  oil price movements remained in focus  U S  crude was down just 5 cents  or 0 15   at  32 73 a barrel during early morning hours in New York  while Brent added 8 cents  or 0 23   to  35 52  as hopes that major oil producers will work together to cap output provided support 
Market players looked ahead to key U S  economic data later in the day to gauge if the world s largest economy is strong enough to withstand further rate hikes in 2016 
The U S  is to publish reports on business activity in the Chicago region for the month of February at 14 45GMT or 11 45AM ET and pending home sales for January at 15 00GMT or 12 00PM ET 
Among active pre market movers  shares of Valeant Pharmaceuticals  N VRX  International lost more than 4  after the struggling drug maker said it would reschedule its planned call to discuss fourth quarter results  which had been slated to happen Monday 
In earnings news   Lumber Liquidators Holdings Inc   N LL  dropped 2  after posting a much bigger quarterly loss than analysts expected as the retailer s sales took a hit from allegations surrounding the safety of laminates in its hardwood flooring 
Elsewhere  European and Asian stocks dropped Monday as sentiment took a hit after a weekend meeting of G20 finance chiefs ended without a plan to spur global growth  while investors worried over renewed expectations for another Fed rate hike ",2016-02-29,Investing.com,https://www.investing.com/news/stock-market-news/u.s.-stock-futures-trim-losses-after-china-easing-move-386972,386972
148414,369930,BHC,Valeant shares slide on news of probe by U S  SEC,news,"By Ankur Banerjee and Carl O Donnell  Reuters    Shares in Valeant Pharmaceuticals International Inc  N VRX  fell as much as 21 percent on Monday after the drugmaker revealed that it was under investigation by the U S  Securities and Exchange Commission   Valeant confirms that it has several ongoing investigations  including investigations by the U S  Attorney s Offices for Massachusetts and the Southern District of New York  the SEC  and Congress   said Laurie Little  a Valeant spokeswoman  She said the company confirmed that it  received a subpoena from the SEC in the fourth quarter of 2015 and  in the normal course  would have included this disclosure in its 2015 10 K  We do not have further detail to provide at this time   The company s U S  traded shares fell 18 4 percent to close at  65 80 per share  The SEC probe is separate from an existing investigation into a company purchased last year by Valeant  Salix Pharmaceuticals Ltd  according to a person familiar with the matter   News of the probe came a day after the Canadian company canceled the release of fourth quarter earnings  withdrew 2016 financial guidance and said its chief executive had returned from medical leave  Valeant then attempted to hold a conference call with sell side analysts but later backed out after news of the call was leaked to members of the press  according to people familiar with the matter  News that the call had been scheduled was first reported by Bloomberg  The cancellation was first reported by CNBC   Valeant is still holding one on one conversations with sell side analysts and major investors  the people said   The company has told a number of large investors that it is optimistic about its 2016 financial guidance  according to people familiar with the matter  It said that it withdrew guidance as a precautionary measure and that investors should not assume that the updated guidance will be significantly lower than what was previously announced  the people said  Valeant does not expect to file the annual report on its 10 K within the 15 day extension period since it has not yet determined if any restatements are required  the company said in a filing     In December  Valeant provided 2016 adjusted earnings guidance of between  13 25 and  13 75 per share    At this point  investor anxiety is primarily focused on the upcoming earnings report and 10 K   said Umer Raffat  an equity analyst at Evercore   They just want to be absolutely sure that it won t contain any more major bad news    The stock has been see sawing for the past month  often gaining or losing 5 percent or more as speculation has swirled about its future  The timing of CEO Pearson s return from severe pneumonia had been unknown  and there was speculation on Wall Street on whether he would return at all  The full outcome of its board investigation into the relationship with pharmacy Philidor RX Services  now terminated  remained unknown  Investors have questioned how the company will regain sales of many dermatological products that Philidor sold  and do not know the terms of a new distribution agreement with Walgreens Boots Alliance  O WBA  Inc   Last week  the company said it would restate earnings to reflect preliminary findings from the board review  adding that it should have accounted for  58 million of revenue later than it did   
Moody s Investors Service placed the ratings of Valeant under review for downgrade  reflecting concerns that the company s operating performance is weaker than its expectations ",2016-03-01,Reuters,https://www.investing.com/news/stock-market-news/valeant-shares-slide-on-news-of-probe-by-u.s.-sec-387032,387032
148418,369934,BHC,Clinton campaign says TV spot shows commitment to fight predatory drug pricing,news,"WASHINGTON  Reuters    A television advertisement set to air on Tuesday from the presidential campaign of Hillary Clinton underscores the Democratic front runner s willingness to take on predatory drug pricing  according to a campaign statement  The ad  set to run in nominating contests following Super Tuesday voting and titled  Predatory   shows Clinton criticizing Valeant Pharmaceuticals  N VRX  International Inc  TO VRX  for its pricing practices and making clear that she is willing to take steps to end them  according to Hillary for America     Valeant shares fell as much as 21 percent on Monday after the Canadian drugmaker revealed it was under investigation by the U S  Securities and Exchange Commission  
It is also being investigated by U S  attorneys in New York and Massachusetts ",2016-03-01,Reuters,https://www.investing.com/news/politics-news/clinton-campaign-says-tv-spot-shows-commitment-to-fight-predatory-drug-pricing-387201,387201
148419,369935,BHC,Ackman s Pershing Square Holdings fund down 19 9 percent in 2016,news,"By Svea Herbst Bayliss BOSTON  Reuters    Billionaire investor William Ackman s Pershing Square  NYSE SQ  Holdings has lost 19 9 percent in the first two months of 2016 as two of the hedge fund s most prominent bets moved in the wrong direction in recent days  a person familiar with the returns said on Tuesday  Ackman  one of the industry s most widely watched investors  told clients that his Pershing Square Holdings dropped 9 8 percent in February  Losses for the first eight weeks of 2016 are now nearly as high as they were for all of 2015  when the fund lost 20 5 percent  While the fund had a string of strong days earlier in the month  it suffered blows in recent days  Late last week  Herbalife   NYSE HLF  Ltd   in which Ackman has a  1 billion bet that its shares will fall  said in a filing that it was discussing a  potential resolution  of an investigation by the Federal Trade Commission  That sent the shares surging about 27 percent on Friday  Ackman first accused Herbalife of running a pyramid scheme in 2012  an allegation the company denies  and he has asked regulators  including the FTC  to investigate  He has said that he would make money on the bet if the share price drops to the mid  30 range  It closed at  56 41 on Tuesday  having climbed some 17 percent in the last month  The second blow came when Valeant Pharmaceuticals  NYSE VRX   in which Ackman has been invested for roughly a year  disclosed that the Securities and Exchange Commission is investigating the company  sending its shares tumbling on Monday  The company also canceled a planned earnings call and said its chief executive  Michael  Pearson   LON PSON   who had been on an extended medical leave  had returned over the weekend  The stock price has fallen 22 9 percent in the last five days  The moves were particularly painful because Ackman runs a very concentrated portfolio and invests in only a few companies at a time  
Most fund managers are still tallying their returns and some have indicated they benefited as the stock market rebounded last month ",2016-03-01,Reuters,https://www.investing.com/news/stock-market-news/ackman's-pershing-square-holdings-fund-down-19.9-percent-in-2016-388361,388361
148437,369953,BHC,Ackman s Pershing Square Holdings ends 2015 down 20 5 percent,news,"BOSTON  Reuters    Billionaire investor William Ackman s Pershing Square  N SQ  Holdings hedge fund ended 2015 with a 20 5 percent loss after Valeant Pharmaceuticals  N VRX   a top holding  has battered in the second half of the year  The fund  one of several portfolios run by the firm  ended December nearly flat with a 0 3 percent gain for the month  Pershing Square  one of the industry s most closely watched hedge funds  told investors in an update  
News of the sharp drop wasn t a surprise since Ackman told investors two weeks ago that the year would likely end up being the worst in the firm s 11 year history  But it illustrates just how volatile the activist investor s returns can be after he scored a 40 percent gain in 2014 when he ranked among the industry s best performers ",2016-01-05,Reuters,https://www.investing.com/news/stock-market-news/ackman's-pershing-square-holdings-ends-2015-down-20.5-percent-378734,378734
148438,369954,BHC,Valeant names interim CEO  timing of Pearson s return unknown,news," Reuters    Drugmaker Valeant Pharmaceuticals International Inc  N VRX  on Wednesday named Howard Schiller as interim chief executive officer to replace Michael  Pearson   L PSON   who has been on medical leave due to pneumonia 
 J  Michael Pearson remains in the hospital where he is being treated for severe pneumonia  and as the timing of his expected return is uncertain  he will be on a medical leave of absence until further notice   Valeant said in a statement 
Schiller was Valeant s chief financial officer from December 2011 to June 2015 and is now on the company s board  Before Valeant  he worked in investment banking at Goldman Sachs  N GS  for 24 years 
Robert Ingram  a Valeant director since December 2010  will be chairman  the Canadian company said 

Valeant shares were down 3 percent at  97 19 in premarket New York trading  Reports broke on Tuesday evening of the appointment of a CEO to replace the management team that had been running Valeant since Pearson was hospitalized in late December ",2016-01-06,Reuters,https://www.investing.com/news/stock-market-news/valeant-names-interim-ceo;-timing-of-pearson's-return-unknown-378903,378903
148439,369955,BHC,Valeant s Pearson says timing of return uncertain,news," Reuters    Valeant Pharmaceuticals  N VRX  International Inc s  TO VRX  ailing chief executive  Michael  Pearson   L PSON   said he was on the road to recovery but was uncertain about when he would return from medical leave    I m glad to say that I m on the road to recovery and although the timing of my return remains uncertain  I look forward to being back at work when able   Pearson said in a memo to employees  Pearson  who joined Valeant as CEO in 2010 after a 23 year career at consultancy McKinsey   Co  was hospitalized with severe pneumonia in late December  Valeant in January named its former chief financial officer and Pearson s long time lieutenant  Howard Schiller  as interim chief executive   During most of the years Pearson led the Laval  Quebec based company  Schiller worked alongside him  The two employed a rapid growth strategy based on a constant stream of acquisitions and drug price increases  
But last year Valeant s surging growth stalled amid questions about its pricing  accounting practices  and for close ties to a specialty pharmacy ",2016-01-25,Reuters,https://www.investing.com/news/stock-market-news/valeant's-pearson-says-timing-of-return-uncertain-381550,381550
148440,369956,BHC,Ackman acknowledges mistakes in 2015  details changes in portfolio,news,"By Svea Herbst Bayliss
BOSTON  Reuters    Sitting on a double digit loss that is the deepest in his firm s history  billionaire investor Bill Ackman on Tuesday told investors that he made mistakes last year in not cutting two big positions but said he sees plenty of new investment opportunities 
Ackman  whose Pershing Square  N SQ  Capital Management lost between 16 percent and 20 percent in its funds in 2015  said it was a  very costly  mistake that he did not sell drug maker Valeant Pharmaceuticals International Inc  N VRX  when the stock price rose to  200 over the summer 
He also said that right along with Valeant s tumble  the rest of our portfolio went into free fall which continued up until the present   His Pershing Square Holdings portfolio has lost roughly 14 percent this year alone 
But Ackman said he could not sell when he became aware of a large potential transaction that the Canadian drug maker Valeant was working on  Valeant s stock price tumbled some 70 percent amid questions about its business and accounting practices  Now with hindsight  Ackman said  We should have avoided becoming restricted to preserve trading flexibility  
Pershing Square ended up selling some Valeant shares at year s end to take a loss for tax purposes 
Similarly  he feels the firm should have cut its stake in Canadian Pacific when it reached Canadian  240 per share and he said it was a mistake to buy more shares in Platform Specialty Products at  25 a share to help the company finance an acquisition 
Ackman said last year s sharp drop reminded investors that stocks can  trade at any price in the short term  which underscores why his firm shies away from using margin leverage   We expect that there have been many margin loan liquidations in recent weeks which have contributed to dramatic stock price declines  
Late last year  Ackman cut the firm s position in candy maker Mondelez by selling forward contracts representing 15 million shares at an average price of  44 a share  During the summer the firm built a large notional short position in the Chinese yuan to guard against weakness in the Chinese economy  But so far  he has made only a modest profit 
Ackman also said that Paul Hilal  a partner at the firm and Ackman s college roommate  is leaving the firm to pursue his own venture  which Ackman said he expects to participate in at some point  As for himself  Ackman is sticking with his firm  noting that he has no plans to step down ",2016-01-26,Reuters,"https://www.investing.com/news/stock-market-news/ackman-acknowledges-mistakes-in-2015,-details-changes-in-portfolio-381851",381851
148441,369957,BHC,Valeant defends price hikes after Clinton remarks  shares jump,news, Reuters    Shares of Valeant Pharmaceuticals International Inc  TO VRX   N VRX  jumped 6 percent on Friday  after the company responded to criticism by Democratic presidential contender Hillary Clinton over price hikes for its migraine drug  The stock had tumbled Thursday  pressured by a blog post by Clinton s campaign that detailed exorbitant price increases for the drug  D H E  45   At an Iowa town hall over the weekend  Clinton had said the list price for 10 vials of D H E  45 had increased to more than  14 000 in December  from just over  3 000 in June 2014  Valeant said Friday in a statement that a generic version of the drug  made by Perrigo Company PLC  N PRGO   was widely available and outsold the branded product  Valeant said it has less than 1 percent market share for the drug    Whenever the sales volume of a drug declines  manufacturers must consider pricing adjustments to keep production of the drug viable   Valeant said on its website   Patients are able to choose generic versions of the drug  however  at significantly lower prices   Valeant shares jumped 6 percent in New York and Toronto in morning trading  after falling about 9 percent on Thursday  Perrigo stock was up slightly  D H E  45  or dihydroergotamine  is an injectable analgesic  Valeant  based in Laval  Quebec  has been under pressure since last year as cracks appeared in its business model of acquiring older drugs  steeply increasing their U S  price  and using aggressive methods to overcome insurer barriers to reimbursing its medicines ,2016-01-29,Reuters,https://www.investing.com/news/stock-market-news/valeant-defends-price-hikes-after-clinton-remarks;-shares-jump-382396,382396
148445,369961,BHC,Documents show profit seeking behind price hikes at Turing  Valeant,news,"By Sarah N  Lynch and Caroline Humer WASHINGTON NEW YORK  Reuters    A decision by Turing Pharmaceuticals to increase profits by raising the price of a lifesaving drug by 5 000 percent drove some patient co pays up to  16 000  according to excerpts of documents that congressional committee members made public on Tuesday  The excerpts  highlighted in memos released by Democrats on the powerful U S  House of Representatives Committee in Oversight and Government Reform  give a rare behind the scenes glimpse into the business decisions behind drastic price increases at Turing and Canada based Valeant Pharmaceuticals International Inc  N VRX   The increases sparked a major public outcry  Both companies now face federal investigations over drug pricing   The document excerpts show how Valeant bought two heart medicines for their  material pricing potential   The company increased the price of Isuprel by 525 percent and Nitropress  by 212 percent  The documents also suggest Valeant hiked the prices of another 20 drugs by more than 200 percent between 2014 and 2015  In a statement  Valeant said it had responded to complaints about pricing by offering volume based discounts of up to 30 percent  Turing said in a statement it cut the price of Daraprim by up to 50 percent for hospitals  It said it used the funds from the price increase for research and development and patient access programs  A lawyer for Martin Shkreli  Turing s former chief executive officer  did not respond to a request for comment  Shkreli  who also faces securities fraud charges  is slated to appear on Thursday before the House Oversight Committee with Valeant interim CEO Howard Schiller  Elijah Cummings  the panel s top Democrat  called for the probe   Tuesday s excerpts show how Shkreli and Turing tried to maximize profits from Daraprim  while warding off potential public relations backlash from HIV patients who rely on the drug  The drug treats toxoplasmosis  a parasitic infection   Very good  Nice work as usual   1bn here we come   Shkreli wrote in a May email to the board  Not long after Turing acquired the drug  reports began to pour in about patients with skyrocketing co pays   In one August email  a Walgreens Boots Alliance  O WBA  executive wrote to ask if the company would grant exceptions for  those patients with a co pay over the approved amount of  10 000   In another case  the company received a plea from Walgreens to reduce the price for a dog  who was  obviously not covered by insurance   
A Turing executive turned down the request and directed the pharmacy to a  vet meds website  ",2016-02-02,Reuters,"https://www.investing.com/news/stock-market-news/documents-show-profit-seeking-behind-price-hikes-at-turing,-valeant-382905",382905
148447,369963,BHC,U S  lawmakers unlikely to get answers from ex drug executive Shkreli,news,By David Ingram and Sarah N  Lynch NEW YORK WASHINGTON  Reuters    Martin Shkreli  the former drug executive who raised the price of a lifesaving medicine by 5 000 percent  is set to appear as a witness at a congressional hearing on Thursday but is unlikely to answer lawmakers  questions about price spikes  Shkreli  32  sparked outrage last year among patients  medical societies and Democratic presidential front runner Hillary Clinton after his company Turing Pharmaceuticals raised the price of 62 year old Daraprim to  750 a pill from  13 50  The medicine  used to treat a parasitic infection  once sold for  1 a pill  The U S  House Committee on Oversight and Government Reform is scheduled to hold a hearing on drug prices at 9 a m  EST  1400 GMT   with Shkreli and others from the pharmaceutical industry as witnesses  For weeks  Shkreli battled with lawmakers  He insisted that if called to appear  he would invoke the Fifth Amendment right against self incrimination and remain silent  Lawmakers said his testimony was essential to investigating why drug prices had risen and that if he chose not to answer questions  he must do so in person  Shkreli s lawyer  Benjamin Brafman  repeated on Wednesday that Shkreli would not answer questions  Speaking to reporters after a court hearing  Brafman said the reason was the unrelated criminal charges that Shkreli defrauded investors  In December  Shkreli was arrested and charged with running his investment funds and companies almost like a Ponzi scheme  He has pleaded not guilty  stepped down from Turing and was fired from  KaloBios Pharmaceuticals Inc   PK KBIOQ   He is also a former head of Retrophin Inc  O RTRX   which sued him  alleging mismanagement  The Federal Trade Commission and the New York attorney general are investigating Turing for possible antitrust violations  Other expected witnesses on Thursday include Turing Chief Commercial Officer Nancy Retzlaff and Valeant Pharmaceuticals  TO VRX  interim Chief Executive Howard Schiller  Retzlaff said in written testimony released by the committee that Turing discounted the price of Daraprim to hospitals by 50 percent in November after consulting with patient groups  She added that Turing reinvests much of its income in research and had 13 projects in its pipeline as of December   Schiller said in written testimony that Valeant has tried to keep drugs affordable through volume based rebates and a partnership with Walgreens  O WBA    He also wrote that patients were best served when prices reflected the market   When these drugs are priced to reflect more closely their true clinical value  the more accurate price signals incentivize generic competition and innovation  ,2016-02-04,Reuters,https://www.investing.com/news/stock-market-news/u.s.-lawmakers-unlikely-to-get-answers-from-ex-drug-executive-shkreli-383228,383228
148458,369974,BHC,Valeant hires attorney  crisis management firm as U S  scrutiny mounts,news,"By Sarah N  Lynch and David Ingram WASHINGTON NEW YORK  Reuters    U S  pharmaceuticals firm Valeant  under mounting pressure from Congress and prosecutors over its drug pricing  has hired an attorney in Washington  DC and crisis public relations experts with political connections  according to sources familiar with the matter  The move  confirmed by sources and through documents viewed by Reuters  signals a shift for Valeant Pharmaceuticals  N VRX   which does not maintain a large presence on Capitol Hill  In recent months the company has attracted scrutiny over steep price hikes on some of its drugs  potentially anti competitive behavior in its contact lens business and close ties to a specialty pharmacy with aggressive billing practices   Valeant shares have lost nearly 75 percent of their value following the disclosures  Billionaire Bill Ackman  one of Valeant s largest shareholders  has said the company made a  meaningful mistake  of underinvesting in public relations as it dealt with questions about its business practices   Valeant recently retained attorney Robert Kelner  a partner at the law firm Covington   Burling  to help respond to congressional inquiries  including an investigation led by an oversight committee in the U S  House of Representatives  according to a November 20 letter seen by Reuters that was sent to Democratic Congressman Elijah Cummings of Maryland  Covington s attorney roster includes former Attorney General Eric Holder  and it has represented major drugmakers such as Johnson   Johnson  N JNJ  and Pfizer   Valeant has separately tapped Vianovo  a boutique crisis public affairs firm run by former political campaign and government aides that specializes in  high stakes brand  policy and crisis issues  and counts Wal Mart  N WMT  and  IBM   N IBM  among its clientele  according to a person familiar with the matter   Vianovo has also lobbied on behalf of companies including  Apache Corp   N APA   as well as health care networks such as Adventist Healthcare  according to government records   Valeant s lobbying efforts are far more modest than that of industry peers  and the company has spent less than  250 000 for the first half of 2015  according to reports filed by its lobbyists  Pharmaceutical giant Pfizer  by contrast  spent  4 9 million during the first half of 2015   The Senate Special Committee on Aging last week kicked off the first of a series of hearings to investigate rising costs in off patent drugs  with a focus on two heart drugs manufactured by Valeant   Valeant was asked to provide documentation to the panel by December 2   The panel s Republican Chairwoman  Susan Collins of Maine  told reporters on Wednesday she plans to ask Valeant Chief Executive Michael  Pearson   L PSON  to testify at a future hearing  The House Oversight Committee is also investigating drug pricing and plans to hold a hearing sometime in the new year    Valeant uses a variety of firms for legal and public relations work  Covington recently was retained to assist the company in responding to congressional inquiries   Laurie Little  the senior vice president of investor relations  said in a statement   According to a July 2015 survey sponsored by the Public Affairs Council  64 percent of Americans say a company s honesty and responsiveness in dealing with a crisis is the most important factor when deciding whether to buy from that company in the future   
The survey also found that the pharmaceutical industry was deemed the least trustworthy sector ",2015-12-13,Reuters,"https://www.investing.com/news/stock-market-news/valeant-hires-attorney,-crisis-management-firm-as-u.s.-scrutiny-mounts-375827",375827
148461,369977,BHC,U S  House Democrats to seek testimony from Valeant in coming weeks,news,"By Sarah N  Lynch WASHINGTON  Reuters    Democrats on a U S  House of Representatives panel are planning to call Valeant Pharmaceuticals  TO VRX  Chief Executive Michael  Pearson   L PSON  to testify in early 2016 about steep price hikes for some of the company s drugs  a Democratic aide said  The hearing before the House Oversight Committee could be held as early as late January as part of an ongoing probe into sky rocketing drug prices  a Republican committee aide said  The Republican majority sets the agenda for the committee and gets to decide which witnesses to call  but the Democratic minority is typically allowed to select at least one witness of their choice  On Tuesday  Republican Chairman Jason Chaffetz and other lawmakers sent the FDA a letter inquiring about the process for reviewing generic drugs as part of the ongoing investigation  The letter specifically references the biotechnology firm KaloBios  which was recently acquired by Turing CEO Martin Shkreli  A Republican committee aide told Reuters that the panel has been talking to a number of pharmaceutical companies as part of the probe  but Republicans have not yet decided which they will summon to testify  Valeant and Turing Pharmaceuticals have been under mounting U S  government scrutiny over their practice of acquiring off patent drugs and drastically hiking the prices  Last week  the U S  Senate Special Committee on Aging kicked off a series of hearings designed to investigate the causes behind drastic drug price increases   The panel s chairwoman  Republican Senator Susan Collins  expects to call both Pearson and Shkreli to testify at a hearing in 2016  Valeant is under the microscope not only for its drug prices but also for its previously close ties to Philidor  a specialty pharmacy with aggressive billing tactics  The company s shares have lost nearly 75 percent of their value after it disclosed it had received subpoenas from federal prosecutors  Valeant recently hired Covington   Burling attorney Robert Kelner to manage the congressional inquiries  as well as a crisis public relations firm  Turing is under investigation for possible antitrust violations by the New York Attorney General   In addition  federal prosecutors and securities regulators are also probing Shkreli s relationship with pharmaceutical company Retrophin  O RTRX   which he used to head  and hedge funds he managed  according to Retrophin s corporate filings  Maryland Congressman Elijiah Cummings  the ranking Democrat on the House Oversight panel  has been among the most vocal critics of Valeant and Turing s pricing practices  He has repeatedly asked Valeant to turn over documents to the committee and to make some of the company s employees available for interviews to discuss Valeant s business relationship with Philidor  In a Dec  15 letter from Cummings to Pearson seen by Reuters  Cummings complained that the company has failed to turn over all of the information requested   Your refusal to provide any documents or witnesses is obstructing this congressional investigation and preventing a full understanding of your company s suspect actions   Cummings wrote  Cummings said he wants the company to produce records and interviews by Jan  8   A Valeant spokeswoman said the company disagrees with many of his statements  and that it has provided information to the committee and will cooperate  
A Turing spokesperson did not have any immediate comment ",2015-12-16,Reuters,https://www.investing.com/news/stock-market-news/u.s.-house-democrats-to-seek-testimony-from-valeant-in-coming-weeks-376264,376264
148465,369981,BHC,Valeant says can contain hit to dermatology  projects 2016 growth,news,"By Caroline Humer and Carl O Donnell  Reuters    Drugmaker Valeant Pharmaceuticals International Inc  TO VRX   N VRX  on Wednesday said that fourth quarter profit was hit when it cut ties with pharmacy Philidor Rx Services  but that it could contain the damage next year and grow profit  The company said it would rebuild lost business through a distribution agreement with Walgreens pharmacies announced on Tuesday  and said the arrangement would also help sales of products like Xifaxin for irritable bowel syndrome and Addyi  a new sexual dysfunction treatment for women  The Canadian drugmaker forecast 2016 earnings would grow 30 percent to  13 25 to  13 75 per share off a lowered 2015 outlook  just below Wall Street s highest expectations  Valeant shares rose 8 percent to  118 75 in New York trading  gaining ground as Chief Executive Michael  Pearson   L PSON  led investors through a four hour meeting in which he defended the company s plan to rebuild its dermatology business  In October  shortseller Citron Research accused Valeant of having inflated revenue  and several news outlets including Reuters reported on how Philidor used aggressive tactics to try to increase insurer reimbursement  mostly for dermatology drugs  Valeant has denied the shortseller accusations and a board committee is investigating the Philidor situation  The news had knocked shares from an August high of  263 70 to a low of  69 34 on Nov  18  They have since recovered  helped in part as its largest investor  Bill Ackman s Pershing Square  N SQ  Capital Management  increased its stake  Pearson declined to give an update on the investigation  or comment on investigations by U S  prosecutors in New York and Massachusetts and by Congress over the company s history of price increases and its patient access programs   He denied that the company was considering a break up  a possibility raised by large investors as a way to recover value  and told investors that the Philidor situation was behind them  The company stopped using Philidor in October  losing 20 percent of its dermatology prescriptions and  250 million in sales in the fourth quarter  Pearson said  Valeant also rolled back all price increases it had planned during the quarter    We ve moved on from Philidor  We ended our relationship and now we have Walgreens  Walgreens is about as reputable as you can get   Pearson said  Valeant s announcement on Tuesday of the distribution deal with Walgreens Boots Alliance Inc  O WBA  boosted shares  but investors questioned how Walgreens could drive sales if pharmacy benefit managers still refuse to cover Valeant drugs  The two largest U S  drug benefit managers  Express Scripts Holdings Corp  O ESRX  and CVS Health  N CVS   do not pay for many drugs Valeant sells because they prefer patients use typically less costly generic versions   CVS Health CEO Larry Merlo told investors at its own investor meeting on Wednesday that the agreement between Valeant and Walgreens appeared to be an attempt to circumvent its policies meant to drive down costs for insurers and employers  He noted the government does not approve of these programs or allow them in healthcare plans like Medicare  2016 PROFIT OUTLOOK Valeant  which has been criticized for a business model that depends on growth through purchasing companies and making large price increases on their older drugs  said 2016 sales would be driven by volume and pledged to cut prices  Political pressure on price hikes  and a heavy debt load from buying Salix Pharmaceuticals as well as its stock decline  has forced Valeant to change strategy  It predicted no major deals next year but said it hoped to do some small purchases   That is a shift in strategy but it is one that is consistent with the way the world is going right now   Pearson said  The new Walgreens agreement  which starts in January  will be similar to the one with Philidor  he said  Valeant will allow customers to receive the prescription immediately and take the risk that it may not receive reimbursement from pharmacy benefit managers down the road  Pearson said that such payers would benefit from price cuts on more than 30 branded products to match generic prices  Customers would benefit from the patient access program  in which it offers coupons or zero co pays to cut the patient price   A poll of more than 200 investors by ISI Evercore recently found about 25 percent expected 2016 earnings of about  14 per share and 23 percent expected  13 per share  Valeant forecast that another closely watched metric  cash earnings  would be  6 9 billion to  7 1 billion in 2016  It said that was about  500 million lower than previously forecast because of the costs of setting up the Walgreens deal  about  75 million in retention payments it has planned for 700 employees  planned price cuts and restructuring charges  About 22 percent in the ISI Evercore poll expected cash earnings of  6 5 billion and 18 percent expected  6 75 billion  Valeant also said it will cut its debt by about  2 25 billion in 2016 and book revenues of  12 5 billion to  12 7 billion  compared with 2015 sales it estimated at  10 4 billion to  10 5 billion   
The company cut its 2015 profit forecast to  10 23  10 33 per share from  11 67  11 87 ",2015-12-16,Reuters,"https://www.investing.com/news/stock-market-news/valeant-projects-30-percent-growth-in-2016-profit,-shares-jump-376382",376382
148466,369982,BHC,Big U S  pharmacies square off on Daraprim supplies,news,"By Deena Beasley  Reuters    As Turing Pharmaceuticals Chief Executive Officer Martin Shkreli contends with charges of securities fraud  major U S  pharmacies are moving to assure patients of continued access to the company s key drug  Daraprim  Shkreli was arrested on Thursday for engaging in what U S  prosecutors said was a Ponzi like scheme at his former hedge fund and a pharmaceutical company he previously headed  Turing officials did not respond to multiple requests for comment on the company s future plans regarding Shkreli or its drug distribution   Leading pharmacy chain Walgreens Boots Alliance Inc  O WBA   currently the exclusive U S  supplier of Daraprim  said it has inventory of the drug  which has a list price of  750 per dose  But growing public backlash against that price has resulted in the entry of new competitors   compounding pharmacies able to produce similar versions for a fraction of the cost   CVS Health Corp  N CVS   the No  2 U S  drug benefit manager  told Reuters on Thursday it can provide an alternative to Daraprim that is compounded by Avella Specialty Pharmacy  at a price of  30 per 30 pills  The 62 year old treatment is used to fight parasitic infections in AIDS patients  pregnant women and others   The CVS arrangement is similar to one between  Imprimis Pharmaceuticals Inc   O IMMY   a compounding pharmacy based in San Diego  and Express Scripts Holdings Inc  O ESRX   the largest U S  manager of prescription drug plans  to offer lower cost pyrimethamine  the generic version of Daraprim   Compounding pharmacies operate differently from drug manufacturers whose treatments must be approved by the U S  Food and Drug Administration for mass sale  Instead  such pharmacies can prepare medications only for individual patients once they have a prescription  and must comply with state and federal regulations   Meanwhile  several major medical groups have started to urge doctors to seek out such lower cost alternatives to Daraprim  providing detailed instructions on how to do so  Walgreens said in an emailed statement that it has  urged Turing to expand the number of specialty pharmacies to promote greater access  and it is our understanding that they will be doing so in the near future   Turing officials could not be reached for comment  Turing  founded by Shkreli early this year  has made front page headlines since it bought the rights to Daraprim in August for  55 million from Impax Laboratories Inc   With no rival manufacturers making the drug  Turing quickly raised the price for a tablet of Daraprim to  750 from  13 50   The move sparked widespread criticism   first by medical groups such as the Infectious Diseases Society of America and the HIV Medicine Association  followed by presidential candidates Hillary Clinton  Bernie Sanders  and Donald Trump   Overnight  the tiny company was vilified as an example of pharmaceutical industry greed  an accusation also leveled at much bigger players like  Gilead Sciences Inc   O GILD  and Valeant Pharmaceuticals International Inc  N VRX   Turing said last month that it would not change the list price of Daraprim  but would offer the drug to hospitals at a discount of up to 50 percent    We don t have any reason to believe that the allegations of an investment Ponzi scheme by Turing s CEO will encumber production of Daraprim   a spokesman for Kaiser Foundation Health Plan said in an emailed statement   However  we are still waiting to see proof of Mr  Shkreli s promise to reduce the price of this needed generic drug   Shkreli  who began his career working for various hedge funds  in 2008 formed a partnership to launch MSMB Capital Management  which became known for filing requests to the Food and Drug Administration to reject products developed by  Navidea Biopharmaceuticals   A NAVB  and  MannKind Corp   O MNKD   MSMB profited by selling short the stock of both companies   Retrophin Inc  O RTRX   initially a portfolio company operated from the MSMB offices  was created in 2011 with an emphasis on biotechnology  Shkreli was president and CEO at Retrophin  which says it focuses on treatments for serious  catastrophic  or rare diseases  until October 2014  when he was fired by the company s board   Retrophin s board earlier this year accused Shkreli in a lawsuit of using  65 million in company funds to repay MSMB investors who had lost money  Shkreli also sits on Turing s board along with Chairman Ron Tilles  who formerly worked at Retrophin  and one other member  Walter C  Blum  according to the company s website   Imprimis CEO Mark Baum said that even if Turing s other investors decided to remove Shkreli  that alone would not be enough to change the fortunes of Daraprim  While at Retrophin  Shkreli hiked the price of its key drug  Thiola for kidney stones  to  30 a pill from  1 50  That price has not changed since Shkreli left   
 Once Turing went and paid what it did to buy that drug  they were locked into raising the price   Baum said ",2015-12-18,Reuters,https://www.investing.com/news/stock-market-news/big-u.s.-pharmacies-square-off-on-daraprim-supplies-376706,376706
148467,369983,BHC,Valeant CEO J  Michael Pearson hospitalized with severe pneumonia  NYT,news,NEW YORK  Reuters    Valeant Pharmaceuticals  TO VRX  Chief Executive J  Michael  Pearson   L PSON  was hospitalized with severe pneumonia on Friday  the New York Times reported  citing a company spokeswoman ,2015-12-25,Reuters,https://www.investing.com/news/stock-market-news/valeant-ceo-j.-michael-pearson-hospitalized-with-severe-pneumonia:-nyt-377539,377539
148471,369987,BHC,Valeant CEO Pearson remains hospitalized for pneumonia  Bloomberg,news,"NEW YORK  Reuters    Valeant Pharmaceuticals  N VRX  International Inc  TO VRX  Chief Executive J  Michael  Pearson   L PSON  has been moved to another hospital where he is being treated for a severe case of pneumonia  a company spokeswoman told Bloomberg on Sunday  Elaine Andrecovich  a public relations manager at Morristown Medical Center  where Pearson initially was admitted for treatment on Friday  confirmed that Pearson is not at the hospital but declined to provide more details   Laurie Little  a Valeant spokeswoman  told Bloomberg that Pearson is still in a hospital but declined to say where  Little did not immediately respond to a Reuters email requesting comment on Pearson s condition  Pearson  56  joined Valeant as CEO in September 2010 after a 23 year career at McKinsey   Company and became chairman of the board in 2010  Pearson s illness comes as investors are turning up pressure on the Canadian drugmaker to provide a more detailed plan on how it will grow profits in 2016  Under Pearson s leadership  the company has come under U S  government scrutiny for acquiring off patent drugs and drastically hiking the prices  
Valeant s U S  listed shares  down about 20 percent this year  closed at  114 11 on Thursday ",2015-12-27,Reuters,https://www.investing.com/news/stock-market-news/valeant-ceo-pearson-remains-hospitalized-for-pneumonia:-bloomberg-377680,377680
148477,369993,BHC,Valeant selects trio to fill in for ailing CEO  shares dive,news,"By Ransdell Pierson NEW YORK  Reuters    Valeant Pharmaceuticals International Inc  TO VRX   N VRX  on Monday said a group of company executives will immediately take over for its chief executive officer until he returns from medical leave  news that sent its shares tumbling 10 percent  The Canadian company said CEO Michael  Pearson   L PSON   56  was being treated for severe pneumonia  The decision to put leadership in the hands of three executives was unusual  experts said  and suggested a lack of confidence in any one company executive to temporarily fill Pearson s shoes   A spokeswoman for Valeant  based in Laval  Quebec  declined to comment on the decision to appoint a trio to take over for Pearson  Valeant and Pearson have come under pressure for steep price increases on some drugs and for close ties to a specialty pharmacy that used aggressive methods to overcome insurer barriers to reimbursing its medicines  Pearson was hospitalized with the lung condition on Friday  The company spokeswoman on Monday declined to say whether he had experienced any complications or when he might return  adding it was honoring a family request for privacy  The spokeswoman also declined to comment on Pearson s medical history    It is an inopportune time for their leader to take sick leave after the company has faced credibility issues in recent months   said Morningstar analyst Damien Conover   If the company was on solid footing  it wouldn t be as much of an issue   Valeant said its board has created an  office of the Chief Executive Officer   which will include General Counsel Robert Chai Onn  Group Chairman Ari Kellen and Chief Financial Officer Robert Rosiello  The board also created a committee to oversee and support the office of the CEO  including lead independent director Robert Ingram  president of ValueAct Capital Mason Morfit and former Valeant CFO Howard Schiller  Jerome Reisman  a partner in the law firm Reisman Peirez Reisman and Capobianco of Garden City  New York  said Valeant s three member CEO committee will likely prove too cumbersome   With all these kings they re appointing to the troika  nobody will be able to make decisions   said Reisman  a financial legal consultant to numerous drugmakers   A committee on a committee just won t work  You need a strong CEO   Dr  Bruce Hirsch  an infectious disease specialist at North Shore University Hospital in Manhasset  New York  said the vast majority of patients with pneumonia fully recover thanks to effective antibiotics  But others are slow to recover and can be tired for months afterward  he said  particularly if they have pre existing structural lung disease  including damage from emphysema  bronchitis  asthma and smoking  He noted pneumonia can be caused by a range of bacteria  viruses  fungi  as well as inflammation  and in very severe cases can cause heart attacks or heart failure  Pearson  who joined Valeant as CEO in 2010 after a 23 year career at consultancy McKinsey   Co  has made rapid fire acquisitions that greatly increased Valeant s size and share price  But Valeant s stock has plunged more than 60 percent since August  due largely to questions about the company s marketing practices and the sustainability of its business model  Investors have been turning up pressure on the Laval  Quebec based company to provide a more detailed plan on how it will boost profits in 2016   Under a deal announced this month  Walgreens Boots Alliance Inc  O WBA  will take over many functions previously handled by specialty pharmacy Philidor Rx Services  Valeant cut ties with the Philidor in response to allegations of aggressive billing practices  
Valeant shares fell 10 5 percent to  102 14 on the New York Stock Exchange ",2015-12-28,Reuters,https://www.investing.com/news/stock-market-news/valeant-selects-trio-to-fill-in-for-ailing-ceo;-shares-dive-377814,377814
148487,370003,BHC,Closing controversial pharmacy to hurt drugmaker Valeant  CEO,news,"By Euan Rocha and Rod Nickel  Reuters    Cutting ties with a controversial specialty pharmacy will hurt Valeant Pharmaceuticals International Inc  TO VRX   N VRX  in the short term  the company s chief executive said on Tuesday  As of last week  Philidor Rx Services has stopped adjudicating insurance claims for drugs and it will cease operations by the end of January  Valeant Chief Executive Officer Mike  Pearson   L PSON  said in a conference call with investors and analysts  Valeant shares fell 2 4 percent during the call before normal trading hours in New York  Pearson said Valeant would give details when it updates financial guidance in December   The past few weeks have been a painful learning experience for me personally   said Pearson  who sounded tired and at times stumbled over prepared remarks about the company s missteps  Pearson said short term disruption in Valeant s dermatology business would be significant  affecting both average prices and sales volume for drugs in the fourth quarter as Philidor winds down  The company will aim to put a new program in place within 90 days for selling its dermatology products  Valeant s priority for the near term will be paying down debt  Pearson said  The company s long term debt was more than  30 billion as of Sept  30  nearly double its level a year earlier  The CEO has come under increasing pressure as the company s stock plunged from  263 70 on Aug  5 to close below  86 on Monday on scrutiny over high price mark ups for its drugs and accusations it used Philidor to inflate revenue   Valeant has denied the allegations  but has not allayed investor concerns as new reports surface of questionable billing practices at Philidor  Pearson  who said he remains committed to Valeant  said he feels  very good  about the company s controls  in response to a question about whether scrutiny of Valeant could turn up other concerns  
Activist investor Bill Ackman  whose Pershing Square owns a large position in Valeant  said on Monday that Valeant s stock was now an  extraordinary bargain  ",2015-11-10,Reuters,"https://www.investing.com/news/stock-market-news/controversial-pharmacy-to-close,-drugmaker-valeant-says-370558",370558
148488,370004,BHC,U S  investigative panel to look into drug pricing next year,news,"By Sarah N  Lynch WASHINGTON  Reuters    A U S  House of Representatives investigative panel said it plans to hold a 2016 hearing on skyrocketing drug costs  a move that comes at a time when Valeant Pharmaceuticals International is facing increased scrutiny into its pricing practices  A spokeswoman for the U S  House Committee on Oversight   Government Reform said on Monday the panel is conducting a thorough investigation into drug pricing and has reached out to drug companies to gather information  Earlier this month  the U S  Senate Special Committee on Aging launched a new probe into drug pricing at Valeant  TO VRX   N VRX  and Turing  signaling growing bipartisan agreement on the need to review the rising cost of prescription drugs in the United States   Democratic members have pressed House Oversight Chairman Jason Chaffetz  a Republican  for months to invite Valeant Chief Executive J  Michael  Pearson   L PSON  to testify at a hearing over his company s massive price increases of two heart medicines  The top Democrat on the investigative panel  Elijah Cummings  had previously urged the panel to subpoena Valeant  On Monday  Cummings also sent a letter to Pearson requesting interviews with a handful of Valeant executives who were directly involved in the operations of specialty pharmacy Philidor Rx Services  According to a letter seen by Reuters  Cummings asked Pearson to make employees Gary Tanner  Bijal Patel and Alison Pritchett available for  transcribed  interviews   Troubling new allegations suggest that a group of Valeant employees helped launch Philidor s business in 2013 and have remained involved in its daily operations   Cummings wrote    These allegations suggest that Valeant employees may have been personally involved in questionable billing practices that led Valeant to cut ties with Philidor last month   Valeant is reviewing the letter and will respond  Valeant spokeswoman Laurie Little said in an e mailed statement    As we have said previously  Valeant s board of directors has formed an ad hoc committee to review allegations related to the company s business relationship with Philidor and related matters   Cummings  letter came just a few days after Reuters reported about how several top Valeant employees worked closely with the founders of Philidor to set up the business and expand its operations  Two Valeant employees  for instance  were copied on a November 2014 email which contained an attachment explaining how Philidor employees could bill the highest amount an insurance company was willing to pay by resubmitting rejected claims at different price points   The email  reviewed by Reuters  was sent to Tanner and Patel  who both used pseudonyms for their communications within Philidor  Reuters also reported that Pritchett was involved in building relationships with specialty pharmacies  Valeant first disclosed its ties to Philidor late last month  amid concerns over the pharmacy s tactics to get insurers to pay for Valeant medications  It has since severed ties with the pharmacy  saying it has  lost confidence  in Philidor after questions about its business practices  Committee spokeswoman MJ Henshaw said the panel is still in fact finding mode and  at this point we don t feel that a subpoena is a necessary step that needs to be taken   
Valeant is also facing investigations by prosecutors in New York and Massachusetts over its drug pricing and programs that provide financial assistance to help patients cover out of pocket expenses for their medications ",2015-11-16,Reuters,https://www.investing.com/news/stock-market-news/u.s.-investigative-panel-to-look-into-drug-pricing-next-year-371485,371485
148489,370005,BHC,Obama nominee to lead FDA defends drug industry ties,news,"By Toni Clarke  Reuters    President Barack Obama s nominee to head the U S  Food and Drug Administration defended his ties to the pharmaceutical industry on Tuesday during a Senate committee hearing that included questions on soaring drug prices  Presidential candidate Bernie Sanders was among the Democrats who grilled Dr  Robert Califf  64  who joined the FDA in January as a deputy commissioner  If confirmed  Califf would oversee an agency whose regulatory reach covers 20 cents of every dollar spent by U S  consumers and includes food  drugs  tobacco  dietary supplements and cosmetics  Califf previously held senior positions at Duke University  where he founded a large academic clinical research center that received more than half of its funding from the drug industry  Over the years  Califf has led multiple large scale company funded clinical trials and published more than 1 200 papers  Responding to questions from Senator Elizabeth Warren of Massachusetts  a Democrat  Califf told the committee that the clinical trials he conducted at Duke  if funded by a drug company  had  ironclad  contracts giving the investigators the final rights to publication  Sanders  a Democratic senator from Vermont  said that the FDA needs a candidate who can stand up to an industry that has been  ripping off  the American people by charging  outrageous  prices for medicines   I have to say to you with regret that you are not that person   Sanders told the nominee during the hearing called by the Senate Health  Education  Labor   Pensions committee  Sanders and other critics say Califf s financial ties to the industry will prevent him from impartially regulating it  Politicians are scrutinizing the cost of prescription drugs following revelations of extreme price increases for some old or mediocre drugs charged by privately held Turing Pharmaceuticals  Valeant Pharmaceuticals  N VRX  International and others   While all of us agree that clearly we want great new products out on the market to save lives  for millions of people it doesn t matter what the products are  they just cannot afford them   Sanders said   The committee will vote on whether to approve the nomination  which must eventually be approved by the full Senate  Patient groups and medical associations expect Califf to help speed new drugs to market and have publicly backed him  making his confirmation widely expected   The FDA faces pressure from lawmakers and patient groups to make it easier for drug companies to bring new products to market  The U S  House of Representatives has passed a bill known as the 21st Century Cures Act that would require the FDA to consider more flexible forms of clinical trials and incorporate patient experience into its review process  A similar bill is being considered in the Sentate  Critics say the bills risk weakening the FDA s ability to ensure drugs are safe and effective   Califf said it is possible to develop a clinical trial system that could be used to deliver better clinical trial results with larger  more representative patient populations  at lower cost  by using existing electronic health records   We ve got to overcome some interoperability problems   he said   but we can do this   Speaking after the hearing at an event organized by the patient advocacy group Friends of Cancer Research  Califf said achieving a balance between fostering drug innovation and protecting patient safety is difficult  
 You ve got to have an internal compass and dedication to the mission   he said ",2015-11-17,Reuters,https://www.investing.com/news/politics-news/obama-nominee-to-lead-fda-defends-drug-industry-ties-371727,371727
148491,370007,BHC,Valeant to offer cash  stock to keep staff after turmoil,news,"By Rod Nickel  Reuters    Valeant Pharmaceuticals  N VRX  International Inc  TO VRX  will likely offer cash and stock incentives to more key U S  staff as it aims to avoid mass departures from the heavily scrutinized company  a spokeswoman said on Wednesday  Laval  Quebec based Valeant partially uses stock to compensate employees  but shares have fallen more than 70 percent since early August over concerns about its use of a U S  specialty pharmacy and price spikes for some of its drugs  About 70 Valeant employees in key positions below the executive level are receiving cash and stock to stay with the company  and Valeant will likely offer the incentives to more U S  staff in coming weeks  said Laurie Little  head of investor relations  She did not give details   In the U S   definitely there has been some anxiety   Little said at a Jefferies investor conference in London   Through this turmoil  we definitely don t want to see an exodus   Little said employees outside the United States are feeling less pressure because Valeant is known by other names in some countries  Valeant s previously undisclosed use of a specialty pharmacy  Philidor Rx Services  drew allegations from short seller Citron Research last month that it was inflating revenues  The company has denied the allegations  but said it would sever ties with Philidor   
Valeant shares on Wednesday climbed 1 5 percent to  71 35 in New York morning trading ",2015-11-18,Reuters,"https://www.investing.com/news/stock-market-news/valeant-to-offer-cash,-stock-to-keep-staff-after-turmoil-371863",371863
148495,370011,BHC,Norfolk Southern hostile to Canadian Pacific s  28 4 billion bid,news,"By Greg Roumeliotis  Reuters    U S  railroad operator  Norfolk Southern  Corp  N NSC  all but rejected a  28 4 billion acquisition offer by  Canadian Pacific Railway  Ltd  TO CP  on Tuesday  calling it  low premium  and warning it would face significant regulatory hurdles  While Norfolk Southern said it would carefully evaluate the offer  its sour response represents a setback to Canadian Pacific as well as its largest shareholder  William Ackman s activist hedge fund Pershing Square Capital Management LP   Ackman  a big advocate of consolidation in the North American railway sector  recruited Hunter Harrison  who had previously been chief executive officer of Canadian National Railway Co  TO CNR   as CEO of Canadian Pacific in 2012  In a statement earlier on Tuesday announcing its offer to Norfolk Southern  Canadian Pacific argued that the combined railroad would offer unparalleled customer service and competitive rates for shippers  and that it would satisfy the U S  Surface Transportation Board  STB  and Canadian regulators  The STB has a public interest test when considering whether to approve mergers  so a deal would not only have to address antitrust concerns but also result in improved service  economic efficiencies and public safety for those using the railways  Yet not only has Canadian Pacific failed to convince Norfolk Southern that the merger could receive regulatory clearance  it has offered no protection for Norfolk Southern shareholders in the event the deal would be blocked  according to a source who asked not to be identified because details of the discussions are not public  The first time Canadian Pacific contacted Norfolk Southern about the deal was after a Bloomberg News report on Nov  9 that cited people familiar with the matter who said the two companies had held early stage merger talks  the Reuters source added  Norfolk Southern Chief Executive James Squires subsequently met with Harrison in Florida last week to discuss the potential merger  according the source  Squires told Harrison he viewed the regulatory obstacles as insurmountable and that Norfolk Southern had a plan of its own to drive shareholder value  the source added   Canadian Pacific is offering Norfolk Southern shareholders  46 72 in cash and 0 348 Canadian Pacific shares for every Norfolk Southern share they own  Norfolk Southern said in its statement  That works out to about  94 94  a 9 percent premium to Norfolk Southern  based on both stocks  Tuesday close   REGULATORY RISK Regulators have been skeptical of North American railway mergers for years  Canadian National Railway Co s  TO CNR  bid to buy Warren Buffett owned Burlington Northern Santa Fe was blocked by U S  antitrust authorities in 1999 2000  More recently  Canadian Pacific s merger talks with CSX Corp  N CSX   which also owns a large network across the eastern United States  also failed last year  Norfolk Southern operates 20 000 route miles in 22 states  mostly in Eastern United States  while Canadian Pacific transports to eight major ports in the United States and Canada  including Vancouver and Montreal  East  and west based North American railways meet in Chicago and hand off cargo  a process that can take days  A deal with Norfolk Southern would improve congestion around Chicago  Canadian Pacific said in its statement  U S  railroad stocks have dropped sharply this year  hurt by a fall in high margin coal shipments and weak oil prices  Up to Tuesday s close  Canadian Pacific s shares had fallen nearly 33 percent this year  while Norfolk Southern s stock had lost about 24 percent  Canadian Pacific has a market value of  21 15 billion   15 89 billion   
Ackman is currently under pressure because of heavy losses in another Canadian company  Valeant Pharmaceuticals  N VRX  International Inc  TO VRX   whose shares have plunged more than two thirds since early August over concerns about its financial practices and drug pricing ",2015-11-18,Reuters,https://www.investing.com/news/stock-market-news/norfolk-southern-hostile-to-canadian-pacific's-$28.4-billion-bid-371756,371756
148496,370012,BHC,Canada stocks higher at close of trade  S P TSX Composite up 0 55 ,news,"Investing com   Canada stocks were higher after the close on Thursday  as gains in the Healthcare  Materials and IT sectors led shares higher 
At the close in Toronto  the S P TSX Composite gained 0 55  
The best performers of the session on the S P TSX Composite were Valeant Pharmaceuticals International Inc  TO VRX   which rose 15 34  or 14 87 points to trade at 111 79 at the close  Meanwhile   First Majestic Silver  Corp   TO FR  added 8 86  or 0 35 points to end at 4 30 and  Concordia Healthcare   TO CXR  was up 7 15  or 3 38 points to 50 66 in late trade 
The worst performers of the session were  Penn West Petroleum  Ltd   TO PWT   which fell 9 40  or 0 14 points to trade at 1 35 at the close   Ensign Energy Services Inc    TO ESI  declined 8 13  or 0 58 points to end at 6 55 and  Paramount Resources Ltd    TO POU  was down 8 04  or 0 81 points to 9 26 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 745 to 674 and 190 ended unchanged 
Shares in Ensign Energy Services Inc   TO ESI  fell to 5 year lows  falling 8 13  or 0 58 to 6 55  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 1 27  to 18 69 
Gold for December delivery was up 1 20  or 12 80 to  1081 50 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in January fell 0 27  or 0 12 to hit  41 84 a barrel  while the January Brent oil contract rose 0 14  or 0 06 to trade at  44 20 a barrel 
CAD USD was up 0 04  to 0 7521  while CAD EUR fell 0 64  to 0 7008 
The US Dollar Index was down 0 59  at 99 07 ",2015-11-19,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-0.55-372170,372170
148497,370013,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 30 ,news,"Investing com   Canada stocks were lower after the close on Friday  as losses in the Materials  Mining and Energy sectors led shares lower 
At the close in Toronto  the S P TSX Composite lost 0 30  
The best performers of the session on the S P TSX Composite were Valeant Pharmaceuticals International Inc  TO VRX   which rose 8 29  or 9 27 points to trade at 121 06 at the close  Meanwhile   Intertain Group   TO IT  added 4 91  or 0 67 points to end at 14 32 and  DHX Media Ltd   TO DHXb  was up 4 28  or 0 36 points to 8 78 in late trade 
The worst performers of the session were  Bankers Petroleum Ltd    TO BNK   which fell 21 43  or 0 450 points to trade at 1 650 at the close   New Gold Inc    TO NGD  declined 8 72  or 0 26 points to end at 2 72 and  First Quantum Minerals Ltd    TO FM  was down 8 54  or 0 45 points to 4 82 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 755 to 615 and 183 ended unchanged 
Shares in Bankers Petroleum Ltd   TO BNK  fell to 3 years lows  falling 21 43  or 0 450 to 1 650  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 3 16  to 18 08 
Gold for December delivery was down 0 05  or 0 50 to  1077 40 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in January fell 0 35  or 0 14 to hit  41 58 a barrel  while the January Brent oil contract rose 0 67  or 0 29 to trade at  44 48 a barrel 
CAD USD was down 0 50  to 0 7490  while CAD EUR rose 0 33  to 0 7037 
The US Dollar Index was up 0 61  at 99 69 ",2015-11-20,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-0.30-372329,372329
148499,370015,BHC,Ackman boosts stake in drugmaker Valeant,news," Reuters    Activist investor Bill Ackman s hedge fund has significantly increased its investment in Valeant Pharmaceuticals International  N VRX   and signaled it may play a greater role in the beleaguered drugmaker s strategy  according to a regulatory filing   Ackman s Pershing Square  N SQ  Capital Management raised its stake in Valeant to 9 9 percent from 5 7 percent reported in March  according to a filing on Monday with the U S  Securities and Exchange Commission  Shares in the company rose 3 1 percent in after hours trading  Pershing noted in its filing that it may conduct discussions with Valeant management  other shareholders and relevant parties  including other companies in  Valeant s  industry  about the drugmaker s strategic plans and other matters  The language about contacting other drugmakers did not appear in its first ownership filing in March  The disclosure comes at a time of heightened speculation about the future of Valeant  which is under scrutiny for steep price hikes on its drugs to boost profits and for its close ties to a specialty pharmacy that used aggressive tactics to get insurers to reimburse the cost of its medicines   Some key Valeant investors have questioned whether Chief Executive Michael  Pearson   L PSON  should step down  Ackman earlier this month expressed confidence in Pearson s leadership  People familiar with Ackman s thinking have said the billionaire is open to considering alternatives for Valeant s future  including a sale    You are one of the most shareholder oriented CEOs I know   Ackman wrote to Pearson in an email seen by Reuters   You have assured me that you and the rest of the board are considering any and all alternatives that would benefit shareholders and other stakeholders   For the past few months  Valeant shares have seen steep losses  declining in value from more than  260 per share in August to a low of  69 34 last week  The losses were initially triggered by a critique of rising drug prices from presidential candidate Hillary Clinton in late September  and then accelerated when short sellers raised questions about Valeant s relationship with specialty pharmacy Philidor Rx Services last month   
Ackman last year teamed up with Valeant in a failed attempt to acquire rival drugmaker Allergan  N AGN pa  ",2015-11-23,Reuters,https://www.investing.com/news/stock-market-news/ackman-boosts-stake-in-drugmaker-valeant-372643,372643
148541,370057,BHC,Valeant s crisis fuels feud between Ackman and Australian fund manager Hempton,news,"By Jennifer Ablan NEW YORK  Reuters    Just before Bill Ackman gave a presentation on Friday to defend one of his biggest investments  Valeant Pharmaceuticals  N VRX   from allegations of accounting and insurance fraud  he was taunted by John Hempton  who runs a small hedge fund from Australia  It was the latest act in a long running feud  In an email he sent Ackman  who is one of the world s best known hedge fund managers  was a link to Hempton s latest critique of the Canadian drug maker s potential problems  one of the most detailed produced by anyone yet   It concluded that while Valeant  TO VRX  had probably not been artificially inflating its sales numbers  its relationship with the specialty pharmacy firm Philidor RX Services  may well cause Valeant to collapse   taking its share price to zero   For Ackman s Pershing Square Capital Management hedge fund that is a scary thought  Pershing s Valeant investment was worth as much as  5 1 billion at its peak in August  though it has now lost more than half of that  As of Oct  31  the fund has lost 19 percent this year  largely because of Valeant  though it did gain 40 4 percent in 2014   Hempton said in the email that he should have given Ackman an advance copy as  it would have helped you prepare for your call today    He signed off with  Love as always  John  It isn t the first time in recent weeks that Hempton has needled Ackman   Indeed  Hempton has been attacking Ackman since soon after Ackman launched a billion dollar short bet against nutritional supplement company  Herbalife  Ltd  N HLF  in 2012  While Ackman has a long position in Valeant and Hempton says his fund  Bronte Capital  is betting against it  the opposite has been the case on Herbalife  with Ackman short and Hempton long  In the world of finance  the contrast between the two almost couldn t be greater  The Adelaide University educated Hempton  48  runs less than  200 million of funds from a tiny office he sometimes sleeps in near Sydney s Bondi Beach  He looks more like the Australian public servant he once was   with large round spectacles  while sweaters and jeans are as often part of his garb as collared shirts and ties  The 6 ft 3 inch tall Ackman has distinguished silvery locks  He runs  16 5 billion at Pershing Square with its expensive mid town Manhattan offices  He has an MBA from Harvard  is big on New York s philanthropy circuit  and is impeccably groomed with perfectly knotted ties and expensive suits One investor who has knowledge of both said Ackman can be a  Master Of The Universe type  while Hempton behaves like an underdog who wants to get even  Both are  wound way too tight   the investor said  Ackman  who declined to comment for this story  has had major battles with other investors before  He got involved in a very public spat with fellow activist investor Carl Icahn over Herbalife in January 2013   On his call on Friday  Ackman did praise Hempton for good some good research on Valeant  before adding that he has  gotten a lot of things wrong   THE GRADUATE  Certainly  the tensions between the two have worsened in recent weeks   On Oct  15  only a few days before a story from an investigative journalist  Roddy Boyd of the Southern Investigative Reporting Foundation  and a report from short seller Andrew Left of Citron Research  exposed Valeant s ties with Philidor and questioned the company s accounting and its behavior towards insurers  Hempton had teased Ackman in an email  In a riff off the famous exchange from the movie  The Graduate  Hempton wrote to Ackman  I just want to say one word to you  Just one word   Philidor    Ackman  who has never met the Australian  replied   Not sure I understand  Perhaps you could explicate further   according to an email released by Hempton  Philidor s relationship with Valeant had hardly ever been referred to publicly by either Valeant or its critics until then  Ackman conceded on Friday s call that Valeant may have made missteps but ultimately was a fundamentally sound company that would pay fines for any wrongdoing if necessary  He said he didn t see anything revealed so far that would result in its collapse   Hempton  who helped to reveal a number of accounting frauds among Chinese stocks listed in North America in 2010 2012 and writes a blog at brontecapital blogspot com  is very open about his distaste for Ackman  When asked last week if he had ever met Ackman he said he would prefer to  hang out with drug dealers and prostitutes   He says he felt fooled back in 2012 by Ackman s arguments that Herbalife was a  pyramid scheme  that caused  enormous harm  to  vulnerable communities around the world   Hempton s own research discovered a Hispanic community in New York and other cities that said the supplements had helped them lose weight and improved their lives   Ackman has firmly stood by his contention that many of the people who sign up as distributors of Herbalife products are exploited by the company and end up losing money  He argues that eventually this structure will implode   Hempton s recent campaign against Ackman has included questioning the way Pershing reports its performance and asking regulators to release documents about a probe it may have carried out into Pershing over Herbalife  A request that was declined  The struggles over Valeant and Herbalife may have taken a toll on Hempton s results  He says after some very strong years  Bronte has been generally flat  with some periods of gains and losses  since 2013   
But he contends it is a viable investment strategy to deliberately take the opposite path to Ackman   You can goad him and he makes his positions bigger   Hempton said   That is even better to trade against  It s not a personal obsession   it s a way of making money  ",2015-11-03,Reuters,https://www.investing.com/news/stock-market-news/valeant's-crisis-fuels-feud-between-ackman-and-australian-fund-manager-hempton-369439,369439
148542,370058,BHC,Icahn nods at Valeant interest  pushes for cash repatriation law,news,"By Michael Flaherty NEW YORK  Reuters    Billionaire investor Carl Icahn made a cryptic reference suggesting he has an interest in embattled drug maker Valeant on Tuesday  and said he was speaking to U S  politicians about a corporate cash repatriation law that would deter so called tax inversion deals    I m not in Valeant  well  I don t want to say I m not completely in it but I m not going to tell you where I am with it   Icahn said  when asked about the company at the New York Times DealBook conference  He did not explain further  Valeant Pharmaceuticals  N VRX  International Inc  TO VRX  shares have plunged almost 40 percent since a scathing report last month by a short seller alleged accounting improprieties in a network of specialty pharmacies  Icahn said he was speaking to Wisconsin Republican Congressman Paul Ryan and New York Democratic Senator Chuck Schumer about a law that would encourage U S  companies to repatriate cash from overseas  and would discourage the controversial practice of inversion  where a company strikes a merger deal to re incorporate overseas and lower its tax rate  Icahn said he supports Republican presidential candidate Donald Trump  but said he would not be Treasury Secretary under him  as Trump has suggested  The activist investor said he never goes to Washington  but added that some of the politicians he speaks to are brighter than some of the chief executives he deals with  Speaking on his latest corporate campaign  Icahn said he had been in touch with American International Group Inc  N AIG  Chief Executive Peter Hancock and confirmed that the two would soon meet  In a letter sent to AIG last week  Icahn said he wanted Hancock to spin off AIG s life and mortgage units into public companies  cut costs more aggressively and give back more cash to shareholders  Hancock said on Tuesday that a split would drive up certain expenses and distract the company from cost cutting  adding the amount AIG spent on U S  regulatory compliance was a fraction of its total regulatory compliance costs around the world  AIG is also taxed as a life and non life insurer  which allows it foreign tax credits  Hancock had said in a letter to shareholders in 2014 that changes to this structure would mean forfeiting  significant economic benefit   
Icahn said on Tuesday he has agreed to hear what Hancock has to say  in a meeting that Hancock said will happen on Thursday ",2015-11-03,Reuters,https://www.investing.com/news/politics-news/icahn-speaking-to-u.s.-politicans-about-repatriation-laws-369525,369525
148543,370059,BHC,Exclusive  U S  insurer caught on to odd billing at Valeant linked pharmacy,news,"By Carl O Donnell  Tim Reid and Caroline Humer NEW YORK LOS ANGELES  Reuters    OptumRx  a leading U S  pharmacy benefits manager  began to stop payments to a pharmacy closely linked to Valeant Pharmaceuticals International  N VRX  more than a year ago after recognizing billing irregularities  former employees at the pharmacy and sources familiar with the matter told Reuters  Hatboro  Pennsylvania based Philidor Rx Services persisted in efforts to secure reimbursement for Valeant drug sales even after receiving a cease and desist order from OptumRx  one of its largest revenue sources  in September 2014  two sources familiar with the matter said  OptumRx is owned by UnitedHealth Group  N UNH   In response  Philidor submitted claims to OptumRx for Valeant drugs using the identification numbers of at least four other affiliated pharmacies  these sources said   Philidor s business practices are at the heart of fraud allegations posed in late October by Citron Research s Andrew Left  an influential short seller in Valeant stock  Valeant had already come under scrutiny for charging high mark ups on drugs made by companies it has acquired   Its ties to Philidor  which surfaced two weeks ago  have led investors to question Valeant s legal liabilities and future prospects  sending its shares down 45 percent  Valeant has denied Left s accusation that it used Philidor to inflate its revenue  But it prompted the drugmaker to disclose that it paid Philidor  100 million for an option to acquire the company in December  raising questions of what it knew of Philidor s practices  OptumRx s September cease and desist letter cited a breach of its contract with Philidor  the sources familiar with the matter said  It isn t clear what billing irregularities caused OptumRx to send the letter  the sources said  In the months that followed  OptumRx recognized that drug reimbursement claims filed with the identification numbers of four other pharmacies could be traced to Philidor  the sources said  Starting in January  OptumRx sent cease and desist letters to the pharmacies  which worked in a network run by Philidor  the sources said  Spokespeople for both Valeant and Philidor declined to comment   OptumRx works every day to protect the interests of our customers and members   said OptumRx spokesman Matt Stearns   That is why we began terminating Philidor from our networks months ago  and why we monitor closely the practices of all the pharmacies with whom we do business   OPTION TO BUY  Philidor primarily dispenses Valeant drugs directly to patients  and then presses payers like OptumRx to cover the cost  contributing nearly 6 percent of Valeant s total revenue so far this year  The company said last week it will sever ties to Philidor and set up an internal committee to review the allegations regarding Valeant s business relationships with Philidor  The Wall Street Journal reported that a Philidor training manual from a year ago instructed employees to use another pharmacy s identification number to file claims with insurers who don t have a contract with the pharmacy  In interviews with Reuters  former employees and sources familiar with the matter said that the practice was also applied to OptumRx  which had a contract on reimbursement to Philidor  It continued at least into early 2015  after Valeant had purchased the option to buy Philidor  giving it the right to name certain employees and be on a joint steering committee with its distribution partner   One former Philidor employee said he was informed by his manager in the fall of 2014 that OptumRx was not taking Philidor claims  The employee was told to bill the benefits manager using the National Provider Identification number   unique identifiers issued by the government   of West Wilshire Pharmacy in Los Angeles  By early 2015  Philidor was also using the NPIs of R O Pharmacy LLC in Camarillo  California  and of SafeRx in South Plainfield  New Jersey  to bill OptumRx    Our main approach was to use West Wilshire s NPI   said a second former employee   We would sometimes still try to do it with Philidor s NPI  but we were pretty much always turned down  at which point we would use West Wilshire s    Philidor asked its employees not to discuss its dealings with OptumRx in emails  and devoted special training sessions to how to successfully bill OptumRx after it began rejecting Philidor claims  the former employees said  A fourth pharmacy whose NPI was used to bill OptumRx was Orbit Pharmacy in Houston   Orbit referred questions to Philidor s general counsel  Gretchen Wisehart  Wisehart did not respond to requests for comment  Calls to West Wilshire and SafeRx went unanswered  West Wilshire was the first pharmacy to receive a cease and desist letter  in January  the sources familiar with the matter said  Shortly afterward  OptumRx conducted an unannounced inspection of R O Pharmacy in California where it determined that R O was working with Philidor and was in the process of being acquired by a Philidor affiliate  the sources said   OptumRx issued a cease and desist letter barring R O from doing business with the benefits manager  the sources said  R O has accused Philidor of fraudulently using its NPI to dispense drugs that R O doesn t stock  
According to California pharmacy law  a state licensed pharmacy can fill prescriptions on behalf of another pharmacy  but it must be clearly documented to patients that the state licensed pharmacy is the one providing the medication ",2015-11-04,Reuters,https://www.investing.com/news/stock-market-news/exclusive:-u.s.-insurer-caught-on-to-odd-billing-at-valeant-linked-pharmacy-369713,369713
148544,370060,BHC,Senate panel probing Valeant  Turing over drug costs,news,"By Caroline Humer  Sarah N  Lynch and Toni Clarke  Reuters    A U S  Senate panel on Wednesday launched a bipartisan probe into pharmaceutical pricing  seeking documents from four drugmakers including Valeant Pharmaceuticals  N VRX  and Turing Pharmaceuticals  companies embroiled in controversy over price hikes on lifesaving drugs  The Senate s Special Committee on Aging also requested information from Retrophin Inc and Rodelis Therapeutics  according to a statement from the panel s Republican Chairwoman Susan Collins and Claire McCaskill  its top Democrat  Also on Wednesday  Democratic members of a U S  House of Representatives investigative committee asked Republicans to call a vote to subpoena Valeant and Turing  These Democratic leaders called for an investigation of drug prices in September  emboldened by press reports of a more than 5000 percent overnight increase in a toxoplasmosis drug made by Turing and a more than 600 percent increase in a blood pressure treatment from Valeant  That investigation  along with news that Democratic Presidential candidate Hillary Clinton found the increases  outrageous  and the release of her plan to restrict drugmaker profits  has hurt their stock prices  Drugmakers and their defenders say drugs are priced to help enable discovery and development of innovative new treatments   The effort has not yet been taken up broadly by Republicans  Investors and analysts have said it would take a wider bipartisan push to possibly change how drugmakers price their medicines   House investigative committee Republican Chairman Jason Chaffetz  who could authorize an investigation  so far has blocked it  His spokesperson did not immediately respond to request for comment  Retrophin shares fell 14 percent to  18 67 on Nasdaq  Valeant shares fell over 2 percent to  95 50 on the New York Stock Exchange   In a letter to Valeant Chief Executive Mike  Pearson   L PSON   the Senate committee chairs requested information on sodium drug Nitropress  which is used to treat high blood pressure  Its price rose by 625 percent to  1 346 62 per vial on the day Valeant acquired the drug  the letter said  It also cited an 820 percent increase to  36 811 for 25 pills of heart drug Isuprel and a 2 949 percent increase to  26 189 for 100 capsules of Cuprimine for rheumatoid arthritis  Valeant said it planned to cooperate with the committee on the inquiry  Drug prices fluctuate due to factors  including the cost of development and acquisition and complexities in the health care cost reimbursement system   spokeswoman Laurie Little said in an emailed statement  Valeant is already the subject of a probe by federal prosecutors in New York and Massachusetts into drug pricing and patient assistance programs  and is also under scrutiny over separate allegations that it used specialty pharmacies to pad its revenue  The Senate committee also sent a letter to Retrophin requesting information about Thiola  a drug that treats kidney disease  and whose price rose to  30 per tablet from  1 50 after Retrophin acquired licensing rights    Pharmaceutical pricing that strikes the right balance between affordability and enabling innovation is an issue of legitimate concern for patients and the industry   Retrophin director of investor relations Chris Cline said in an emailed statement  The company said it was focused on developing its pipeline of drugs rather than acquiring and re marketing old therapies   
The Senate committee also said it wanted to hear more about Turing s Daraprim  an anti infective drug used to treat toxoplasmosis among other diseases  Earlier this year Turing raised the price on the drug overnight to  750 per pill from  13 50  Turing did not immediately comment on Wednesday s probe  In September Turing said it would cut the price of Daraprim  but has not yet done so  The New York state attorney general s office is also investigating Turing over whether its Daraprim price increases violated antitrust rules   The sudden  aggressive price hikes for a variety of drugs used widely for decades affect patients and health care providers and the overall cost of health care   Collins said in a statement  adding that the Senate committee is probing the increases given the potential harm to patients ",2015-11-04,Reuters,https://www.investing.com/news/politics-news/senators-probe-pharmaceutical-drug-pricing-369640,369640
148545,370061,BHC,Valeant CEO feels heat as shares tumble to 2 1 2 year lows,news,"By Caroline Humer and Svea Herbst Bayliss NEW YORK BOSTON  Reuters    Valeant Pharmaceuticals International Inc  TO VRX   N VRX  shares fell as much as 20 percent on Thursday to a level not seen since 2013  heaping new pressure on Chief Executive Officer Michael  Pearson   L PSON  after weeks of steep losses due to concerns about the drugmaker s business practices  The stock has plunged from  263 70 on Aug  5 to below  80 on Thursday on scrutiny over high price markups for its drugs and accusations it used a specialty pharmacy  Philidor Rx Services  to inflate revenue  Valeant has denied the allegations  but has not allayed investor concerns as new reports surface of questionable billing practices at Philidor  One new trigger for selling  said BMO analyst Alex Arfaei  may be a Wall Street Journal article on Thursday in which major Valeant investor Bill Ackman  of hedge fund Pershing Square Capital Management  told a Valeant board member that Pearson may have to go  Ackman s firm and its investors have lost roughly  2 3 billion from their 6 percent stake in Valeant since the bet was made early in the year  The size of Ackman s fund has shrunk to roughly  14 5 billion from  20 billion earlier in the year as Valeant  his biggest bet  has soured   Later Thursday  Ackman in an email to Pearson  seen by Reuters  expressed confidence in the CEO s leadership and willingness to take steps in the best interest of investors   You are one of the most shareholder oriented CEOs I know   Ackman wrote to Pearson   You have assured me that you and the rest of the board are considering any and all alternatives that would benefit shareholders and other stakeholders    A Valeant spokeswoman said Pearson retained the full confidence of the company s board of directors   Mike remains focused on running the business and has been meeting with physicians  partners and other stakeholders   Laurie Little said   The comments did not halt the slide in U S  traded shares  off 15 percent to  78 27 on Thursday after hitting a bottom of  73 37 earlier in the session  the lowest since May 2013  The latest selloff is pushing longer term investors who bought stock more than two years ago into the red  Tiger Ratan Capital Management  a smaller hedge fund  invested in Valeant 2 1 2 years ago and had 22 percent of its assets in the stock at the end of the second quarter  One large investor in Valeant who declined to be identified said Pearson is still the right man to be CEO   Why would you force out the guy who knows this operation better than anyone else in the middle of this crisis   he said  STEEP LOSSES Pearson  who grew up in Canada  took over at Valeant in 2008 after working as a pharmaceutical industry consultant at McKinsey   Co  He drove up Valeant s revenue sevenfold  mainly through a quick succession of acquisitions  including Salix Pharmaceuticals and Bausch   Lomb  Pearson has been widely criticized for eliminating jobs and cutting research and development for quick returns at companies that Valeant buys  The company is being investigated by prosecutors in New York and Massachusetts and been summoned to testify to Congress over its steep drug prices increases  But the steepest stock slide was precipitated by a report from influential short seller Citron Research on Oct  21  claiming the company was using an undisclosed relationship with Philidor to inflate revenue  Valeant has since cut off ties with the firm and said it was investigating its practices   They really possess very little in redeeming qualities in the eyes of the public   said Peter Mann  portfolio manager at Gluskin Sheff   Associates  which sold its small Valeant position in September   The market overall has probably reached its saturation point  with Valeant  Mutual fund managers  in particular  are feeling the pressure to tell clients and their own management they have steered clear of Valeant  something that is exacerbating the selling pressure   Weitz Investment Management said on Nov  2 on its website that it had exited its Valeant positions  Hedge fund Blue Mountain said it got out of the position in October but did not rule out getting back in  While Blue Mountain did not name Valeant in its letter  a source confirmed it was the drugmaker  Hedge fund Jana Partners has also exited Valeant  Other Valeant investors who bought the stock in 2013  including hedge funds Arrow Capital Management  Antipodean Advisors  Meru Capital and Hoplite Capital  would be feeling pain if they still hold the stock  Other big investors  including ValueAct and Viking Global Investors  have been with Valeant for longer and may still be sitting on gains   Valeant short sellers  however  are benefiting for now  John Hempton of Bronte Capital told Reuters he has increased the firm s short position  many times on the way down  all at prices over  100   Hempton was among the first investors to raise red flags on Valeant s business relationship with Philidor   Activity in puts betting on the shares dropping as low as  45 in the coming months suggested some investors were loading up on disaster insurance  On Thursday  options volume on Valeant surged to 237 000 contracts  or 3 4 times the daily average  with heavy trading in puts that protect against declines in the shares  Even so  bond traders have not written off Valeant  Valeant bonds dropped by as much as 4 points in early trading on Thursday before paring back nearly half of those losses  
 There is a view that Valeant has a core group of businesses that should provide support relative to their existing debt obligations   said Jon Duensing  deputy chief investment officer at Amundi Smith Breeden ",2015-11-05,Reuters,"https://www.investing.com/news/stock-market-news/valeant-shares-tumble-20-percent,-retrace-ground-to-2013-levels-369905",369905
148546,370062,BHC,Valeant says Goldman Sachs sold 1 3 million shares backing loan to CEO,news,"NEW YORK  Reuters    Valeant Pharmaceuticals  N VRX  International said on Friday that Goldman Sachs  N GS  sold 1 3 million shares of Valeant on Nov 5 that were securing loans made to its CEO Michael  Pearson   L PSON   Valeant shares on Thursday closed at  78 77 after having fallen as much as 20 percent during the session  The company has been under pressure over scrutiny of its high price markups and accusations it used a pharmacy Philidor Rx Services  to inflate revenue  Valeant said that Pearson had pledged about 2 million shares as collateral for loans of about  100 million that he used for  among other things  financing charitable contributions  purchasing Valeant shares  and meeting tax obligations related to vesting and payment of Valeant equity awards  Goldman Sachs required repayment of the loans and sold the shares in order to be able to repay them in full  the company said   
 It was not my desire that shares be sold now   Pearson said   I have the complete confidence in Valeant s ability to move forward  ",2015-11-06,Reuters,https://www.investing.com/news/stock-market-news/valeant-says-goldman-sachs-sold-1.3-million-shares-backing-loan-to-ceo-370073,370073
148547,370063,BHC,Valeant investors divided on fate of CEO Pearson,news,"By Michael Flaherty and Svea Herbst Bayliss  Reuters    Large investors holding stock in Valeant Pharmaceuticals International Inc  TO VRX   N VRX  are split over whether to support the embattled drug company s chief executive or to advocate for new leadership  as the company struggles to recover from a stock plunge sparked by allegations of faulty accounting      Interviews with fund managers invested in the company suggest that while Valeant CEO Michael  Pearson   L PSON  still enjoys solid support from some key investors  the backing may be waning  with other investors saying they think new leadership is needed to stabilize the company        Still  shareholders worry that if Pearson leaves  the stock will fall further  having already lost more than half of its value since coming under siege this fall  Scrutiny over pricing policies from U S  politicians  federal investigations into its operations and a short seller note aimed at its accounting practices have sent shares into a tailspin   I think the jury is still out as far as the big investors and his future goes   said one shareholder  who like others interviewed for this story  requested anonymity   There are people who would like to see a fresh start    Investor criticism of the former McKinsey consultant  who transformed Valeant from a small drug company into a behemoth through acquisitions  included questioning of both his overall leadership and his handling of the present crisis  especially with regard to investor relations   In an email to Pearson reported by the Wall Street Journal on Thursday  hedge fund billionaire Bill Ackman  Valeant s third largest shareholder  expressed support for Pearson  even while questioning some aspects of his handling of the crisis   While I have strong views on Valeant s communication strategy and would have taken a different approach   Ackman wrote   you and the board should not interpret this as a negative reflection on my view of you as the CEO of the company     Another large Valeant shareholder told Reuters that Pearson should stay  and that the stock plunge has been exaggerated  given that the accounting questions have been raised about only a small number of Valeant drugs  which together are responsible for about 10 percent of the company s revenue  Valeant has denied accusations of accounting discrepancies      But the investor acknowledged that Pearson s future is far from clear    I think the company is more valuable with Mike  Pearson  as CEO   the investor said   There are those who don t           Several funds in the past few weeks have disclosed that they sold off their shares of Valeant  including respected value investor Wally Weitz and hedge fund Jana Partners  though none expressed a loss of confidence in Pearson       As for large institutional investors invested in the stock  the lingering concern is whether Pearson can get his arms around the damage and contain it       One shareholder said that Pearson should have spent more money building up the investor relations arm of the company  which could have helped him better manage the  just in case scenario that just hit him   
A spokeswoman for Valeant said Friday that Pearson had the  full confidence  of the board of directors ",2015-11-06,Reuters,https://www.investing.com/news/stock-market-news/valeant-investors-divided-on-fate-of-ceo-pearson-370177,370177
148548,370064,BHC,Ackman says Valeant likely to pay down debt in the next 18 months,news," Reuters    Bill Ackman  Valeant Pharmaceuticals International Inc s  N VRX   TO VRX  third largest shareholder  said the Canadian drugmaker will likely use its free cash flow to pay down debt in the next 18 months   Ackman said on Monday that Valeant was still his hedge fund Pershing Square s biggest holding  calling the stock an  extraordinary bargain    Valeant  which had total long term debt of  30 18 billion as of Sept  30  is under scrutiny for drug pricing and allegations of inflating revenue  The company s stock has plunged about 45 percent through Friday s close of  78 77  after short seller Citron research alleged on Oct  21 that the company had used a specialty pharmacy to inflate revenue  Ackman called the sell off in Valeant shares a result of unwarranted  fear  and  panic   The billionaire investor has backed Valeant and its under pressure Chief Executive Michael  Pearson   L PSON  through the crisis  but has faulted the company for a weak response to fraud allegations  Valeant will hold a conference call on Tuesday to allay investor concerns after a tumultuous few weeks for the embattled drugmaker   Ackman was not briefed on Valeant s Tuesday call  a person familiar with the matter told Reuters   What s important is reassuring the investors about the durability of the business   Mizuho analyst Irina Koffler said  The Canadian drugmaker is being investigated by federal prosecutors in New York and Massachusetts   Valeant Chief Executive Michael Pearson  Chief Financial Officer Robert Rosiello  Chairmen Ari Kellen and Deb Jorn  along with Corporate Controller Tanya Carro  will be on the call  which will begin at 8 00 a m ET on Tuesday  Valeant also said it intends to host an investor day and update its annual and quarterly financial outlook before the end of the year   
Shares of the company  which has a market value of  28 3 billion  were up 3 3 percent at  84 47 in afternoon trading ",2015-11-09,Reuters,https://www.investing.com/news/stock-market-news/valeant-to-give-an-update-on-operations-in-conference-call-on-tuesday-370374,370374
148582,370098,BHC,Ackman faults Valeant s reaction to short seller allegations,news,"BOSTON  Reuters    Hedge fund mogul William Ackman told his investors on Friday that he was confident in his bet on Valeant Pharmaceuticals  N VRX   but faulted the company for a weak response to a short seller s allegations it is improperly inflating revenues  He said during a teleconference that Valeant had made a  meaningful mistake  of underinvesting in its public relations  offering only a curt denial of short seller Citron s claims this month it used phantom sales to boost its bottom line  
Ackman s Pershing Square Capital Management hedge fund is one of Valeant s top investors  and has taken a big hit due to Valeant s falling share price ",2015-10-30,Reuters,https://www.investing.com/news/stock-market-news/ackman-faults-valeant's-reaction-to-short-seller-allegations-368920,368920
148583,370099,BHC,Hedge Funder Ackman Strongly Defends Valeant,news,"By   

On the same morning that Valeant Pharmaceuticals  N VRX   stock opened down 6 5 percent on news that it had cut ties with a specialty pharmacy partner  hedge fund manager Bill Ackman mounted a lengthy defense of the embattled drugmaker  Though critical of the company s laissez faire approach to public relations  Ackman expressed confidence in Valeant s business and growth prospects 
 We don t think the business model is broken   Ackman said on the hours long call Friday morning  one week after he increased his stake in Valeant by 2 million shares as scrutiny intensified over Valeant s specialty pharmacy partners  In March  Ackman s hedge fund  Pershing Square Capital Management  disclosed a 5 percent stake in Valeant  when the stock was trading at around  200 per share  Valeant shares opened at  103 Friday 
Investors have grown increasingly wary of the Canadian drug manufacturer after its relationship with a little known specialty pharmacy  Philidor RX  was revealed  Former Philidor employees have told the press that they were trained to use questionable means to push insurers into accepting Valeant s drugs for treatments that could otherwise have been covered by cheaper generics 
It was only hours before the scheduled call that Valeant announced it had severed ties with Philidor  which together with related pharmacies represented 7 percent of Valeant s earnings for 2015   We understand that patients  doctors and business partners have been disturbed by the reports of improper behavior at Philidor  just as we have been   Michael  Pearson   L PSON   Valeant s chief executive  said in a statement 
Ackman defended the use of specialty pharmacies  but said Valeant s underinvestment in public relations and government outreach was a  meaningful mistake  
 I don t think Michael Pearson has walked the halls of Congress  maybe ever   Ackman said  Valeant is facing multiple federal investigations over issues surrounding patient assistance  drug pricing and market fairness 
The hedge fund manager also downplayed the cost to Valeant of the Philidor debacle  saying that the estimated  500 million in revenue that flow through Philidor s distribution channels represented just a small part of Valeant s business  The drugmaker has distinguished itself with decade long string of major acquisitions  including Pepcid maker Salix and eye care giant Bausch and Lomb 
Given the stock s current value    which has plunged more than 50 percent since its August highs    Ackman estimated that by 2019  Valeant s shares could be worth roughly double Friday s  100 price  An explosive short seller s report last week sent the stock plunging nearly 30 percent  where it has remained 
Since redoubling his investment  shareholders have grown dubious of the specialty pharmacy model  in which mail order operations like Philidor offer to discount patients  prescriptions and maneuver insurers into covering pricey drug costs  Critical reports in the New York Times and elsewhere have connected the model to eye popping price hikes in niche pharmaceuticals 
Ackman said that Valeant might be more careful moving forward with practices that  while legal  raise hackles in the public  citing what he called the New York Times rule   It might be a legit business practice  but it doesn t look good on the front page of the New York Times  
Still  Valeant s forays into the specialty pharmacy world still won Ackman s approval on the call   Specialty pharmacy is the future of the industry   he said 
Ackman and other Pershing Square partners were midway through the hundred plus questions submitted by investors when short seller Citron Research    whose somewhat unsubstantiated report last week helped tank Valeant s stock    tweeted that a story  dirtier than anyone has reported  was due Monday  Valeant stock immediately fell 3 percent on the announcement 
Valeant Pharmaceuticals International  VRX  Stock Price   Current Day   FindTheCompany",2015-10-30,International Business Times,https://www.investing.com/news/stock-market-news/hedge-funder-ackman-strongly-defends-valeant-368940,368940
148584,370100,BHC,Valeant says Philidor pharmacy shutting down as it cuts ties,news,"By Caroline Humer and Svea Herbst Bayliss  Reuters    Valeant Pharmaceuticals International Inc  N VRX   TO VRX   seeking to allay investor concerns about its business practices  said Friday it is cutting ties with a specialty pharmacy called Philidor Rx Services accused of helping it inflate revenue  The news failed to stem Valeant s sliding share price  which lost another 12 percent on Friday even after Bill Ackman  whose hedge fund owns a 6 3 percent stake in Valeant  told investors the shares were  tremendously undervalued   Valeant said it would bolster its internal investigation into the matter by adding to the team an outside lawyer who once worked in the U S  Department of Justice  The drugmaker s move comes amid growing pressure from investors after Valeant disclosed two weeks ago that it was under investigation by the U S  government over its patients  assistance program and drug pricing and distribution  Influential short seller Citron Research was one of the first critics to call the company out on Philidor in an Oct  20 report  saying Valeant was using the pharmacy set up to inflate revenue  Valeant has denied any wrongdoing   Citron tweeted Friday that Valeant shares have a better chance of going to zero than  Herbalife  Ltd  N HLF   Citron said    VRX has a better chance of going to 0 than  HLF EVER will  Citron to update full story on Monday  Dirtier than anyone has reported    Valeant disclosed this week that it had paid  100 million for an option to buy Philidor  Bloomberg on Thursday detailed wrongdoing in its processing of medical claims  building on earlier reports about business practices   Later Thursday  three top U S  drug benefit managers  who administer prescription medicine benefits for health plans  said they would no longer work with the pharmacy  Express Scripts  O ESRX   CVS Health  N CVS  and OptumRx  part of UnitedHealth Group Inc  N UNH   said they made the decision after conducting audits of the pharmacy  Philidor will be shutting down operations as soon as possible  Valeant said  Bill Ackman  whose Pershing Square Capital Management has a 6 3 percent stake in Valeant  told investors on Friday that  life will go on  for the company as it continues to sell high demand products like Bausch   Lomb contact lenses    We think the Valeant business is quite robust   Ackman said on a widely attended conference call  He said shares are undervalued  The hedge fund swept up 2 1 million additional Valeant shares last week as the stock plummeted  making Pershing Square the company s second largest shareholder  leapfrogging asset manager T  Rowe Price   Valeant shares fell 12 4 percent Friday to  97 61  their lowest in about two years and well below their Aug  5 high of  263 70  They have given up almost half their value since the company disclosed the Philidor pharmacy distributed drugs making up 6 percent of Valeant revenue this year  Bloomberg reported on Thursday that Philidor has altered doctors  orders to wring more payment out of insurers  according to former employees and an internal document  which details how to proceed with a prescription for certain Valeant drugs after they have been rejected   LOST CONFIDENCE IN PHILIDOR  Valeant first disclosed less than two weeks ago that it was using a pharmacy called Philidor  which works with a network of pharmacies including one called R O Pharmacy that is also involved in lawsuits with Valeant over nonpayment and other issues   We have lost confidence in Philidor s ability to continue to operate in a manner that is acceptable to Valeant   Valeant Chief Executive Michael  Pearson   L PSON  said in a statement   Operating honestly and ethically is our first priority  and you have my absolute commitment that we will make it right   Valeant said that former U S  Deputy Attorney General Mark Filip had been appointed to advise a committee that it formed earlier this week to look into the allegations related to the company s association with Philidor  Filip works for Kirkland   Ellis  Philidor accounted for 6 8 percent of Valeant s total revenue in the third quarter and 5 9 percent so far this year  The drugmaker said it intended to develop a plan to ensure minimal disruption to patients  access to drugs  Valeant shares have lost more than half their value since September as the company has come under attack on several fronts  U S  prosecutors are also investigating the company over drug pricing  a hot issue in the U S  presidential campaign  
Valeant was until recently one of the most popular healthcare stocks among investors  with its model of rapid acquisition driven growth  Its abrupt slide from market darling to a company under fire has weighed heavily on ValueAct Partners and Pershing Square  two well known U S  activist funds ",2015-10-30,Reuters,https://www.investing.com/news/stock-market-news/valeant-severs-ties-with-controversial-pharmacy-distributor-368865,368865
148585,370101,BHC,Canada stocks lower at close of trade  S P TSX Composite down 1 90 ,news,"Investing com   Canada stocks were lower after the close on Friday  as losses in the Healthcare  Financials and Utilities sectors led shares lower 
At the close in Toronto  the S P TSX Composite lost 1 90  
The best performers of the session on the S P TSX Composite were  MEG Energy Corp   TO MEG   which rose 8 15  or 0 82 points to trade at 10 88 at the close  Meanwhile   Bombardier Inc   TO BBDb  added 6 77  or 0 09 points to end at 1 42 and  Progressive Waste Solutions  Ltd   TO BIN  was up 6 22  or 1 84 points to 31 44 in late trade 
The worst performers of the session were Valeant Pharmaceuticals International Inc  TO VRX   which fell 17 67  or 26 19 points to trade at 122 04 at the close   Husky Energy Inc    TO HSE  declined 12 83  or 2 60 points to end at 17 67 and  Concordia Healthcare   TO CXR  was down 7 88  or 3 42 points to 40 00 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 744 to 617 and 191 ended unchanged 
Shares in Valeant Pharmaceuticals International Inc  TO VRX  fell to 52 week lows  losing 17 67  or 26 19 to 122 04  Shares in Husky Energy Inc   TO HSE  fell to 5 year lows  down 12 83  or 2 60 to 17 67  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 7 43  to 19 52 
Gold for December delivery was down 0 47  or 5 40 to  1141 90 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in December rose 0 80  or 0 37 to hit  46 43 a barrel  while the December Brent oil contract rose 1 40  or 0 69 to trade at  49 48 a barrel 
CAD USD was up 0 74  to 0 7648  while CAD EUR rose 0 58  to 0 6955 
The US Dollar Index was down 0 32  at 97 05 ",2015-10-30,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-1.90-368976,368976
148586,370102,BHC,Exclusive  Beyond Valeant  U S  payers scrutinize other drugmaker ties to pharmacies,news,"By Deena Beasley
LOS ANGELES  Reuters    Express Scripts Holding Co  the largest U S  pharmacy benefit manager  is reviewing pharmacy programs run by  AbbVie Inc   N ABBV  and Teva Pharmaceuticals Industries Ltd after finding questionable practices at Valeant Pharmaceuticals  N VRX  International Inc s partner pharmacy  Philidor Rx Services 
Express Scripts and other big managers of prescription medicine benefits for health plans said on Thursday they would no longer work with Philidor as concerns mount that Philidor was improperly directing drugs made by Valeant to patients 
Valeant  which has headquarters in Quebec  has since said it was cutting ties with Pennsylvania based Philidor  and that the pharmacy was suspending operations 
A handful of other drugmakers operate their own pharmacies and ship drugs directly to patients  Many of the rest employ independent specialty pharmacies that can haggle with insurers and link patients to programs under which drugmakers cover their out of pocket costs 
Such tactics can allow drugmakers to work around reimbursement restrictions from Express Scripts and other insurers  which are directing patients to cheaper generic versions of widely used medicines to save costs 
Health insurers  faced with sharply rising drug costs  are increasing their oversight of prescription drug pricing  which has also become a key issue in the 2016 presidential election 
 We are reviewing and evaluating all similar captive pharmacy arrangements that we know of and will work to identify others   said Brian Henry  a spokesman for Express Scripts  He defined a captive pharmacy as one that derives the vast majority of prescription volume from one manufacturer or one product 
AbbVie said its wholly owned Pharmacy Solutions business aims to help patients and doctors verify insurance coverage in certain instances for drugs such as its widely used rheumatoid arthritis treatment Humira  The company said the program accounts for less than 0 2 percent of its U S  sales 
 We believe that Pharmacy Solutions does provide a level of service  We don t see any change at this time   said AbbVie spokesman Greg Miley 
Teva s Shared Solutions program helps multiple sclerosis patients access its Copaxone treatment  which has recently begun to face competition from generics  The company said in a statement that approximately 0 5 percent of its sales flow through the company s pharmacy 
Both AbbVie and Teva did not respond to requests for further comment 
CVS Health  N CVS   the second largest pharmacy benefit manager  also said it is continuing to investigate other pharmacies to uncover inappropriate billing and dispensing activities 
Erik Gordon  a professor at the University of Michigan s Ross School of Business  noted that independent specialty pharmacies provide an important service by dispensing expensive and complex products that require special handling  such as cancer treatments 
That is different from examples like Philidor  he said 
 Captive specialty pharmacies often are a vehicle for drug company parents to push their own products  especially products that are off patent and face cheaper competitors   Gordon said 
Shares of Valeant have lost more than half their value since mid September as the company came under fire on several fronts  such as evidence of extreme price hikes for several of its drugs and allegations that it used Philidor to inflate revenue and circumvent insurer controls on high cost prescriptions  Valeant has denied the accusations 

Valeant said sales of its drugs through Philidor  including acne medicines and a treatment for toenail fungus  accounted for about 7 percent of its total third quarter revenue ",2015-10-30,Reuters,"https://www.investing.com/news/stock-market-news/exclusive:-beyond-valeant,-u.s.-payers-scrutinize-other-drugmaker-ties-to-pharmacies-368997",368997
148587,370103,BHC,Goldman Sachs says Valeant has long road ahead  cuts rating,news,By Ankur Banerjee  Reuters    Goldman Sachs  N GS  on Monday downgraded Valeant Pharmaceuticals International Inc s  TO VRX   N VRX  stock  nearly two weeks after an influential short seller accused the Canadian drug maker of cooking its books  While investors have fled the company s stock  which has lost a third of its value since Citron Research published its report on Oct  21  sell side analysts have remained stubbornly positive on the stock  BTIG and BMO Capital Markets have lowered their ratings to  hold  in the past two weeks  Including Goldman  seven of the 22 brokerages covering the stock now have a  hold  rating  versus three a month earlier  Only one brokerage   Veritas Investment Research   has an  underperform  or  sell  rating  while fourteen have  buy  or higher ratings   We expect a much longer road than we previously thought for the dust to settle   Goldman Sachs analyst Gary Nachman said in a note  He cut his price target to  122 from  180   the lowest on the stock  Nachman  however  said he continued to believe that Valeant s strong fundamentals could justify a much higher valuation in the longer term  None of the 10 analysts contacted by Reuters responded to emails requesting comment   Valeant s shares rose as much as 10 percent on Monday after Citron said it would not be releasing new allegations against Valeant  but would continue to investigate and report  the vast spectrum of claims now piling up  against the company  The shares gave up most of their gains to trade up 4 percent at  97 978 in afternoon trading  Jefferies and Canaccord Genuity also cut their price targets on Monday  The median price target on the stock has fallen to  196 50 from  287 50 in a month  according to Thomson Reuters data  Citron had accused Valeant of using specialty pharmacy Philidor to create  phantom accounts  to inflate sales  Valeant denied any wrongdoing and on Oct  30 said it ended its ties with Philidor  Philidor accounted for 6 8 percent of Valeant s total revenue in the latest quarter  Bill Ackman  the company s second largest shareholder  told investors on Friday that  life will go on  for the company and blamed bad public relations and naive investors for Valeant s predicament  To be sure  Valeant s problems started well before the Citron brouhaha  Once a Wall Street darling  driving sales through acquisitions  Valeant said on Oct  14 that it had been subpoenaed by U S  prosecutors investigating its drug prices  Standard   Poor s Ratings Services  which on Friday lowered its credit rating on the company to  B   from  BB    said Valeant s ability to grow organically will be constrained after Philidor s loss and because of the company s pledge to restrain price increases ,2015-11-02,Reuters,"https://www.investing.com/news/stock-market-news/goldman-sachs-says-valeant-has-long-road-ahead,-cuts-rating-369279",369279
148588,370104,BHC,Citron publishes no new allegations against Valeant  shares rise,news,"NEW YORK  Reuters    Influential short selling firm Citron Research did not publish new allegations against Valeant Pharmaceuticals  N VRX  International Inc  TO VRX  on Monday as many investors had anticipated  giving the beleaguered shares of the Canadian drugmaker a boost  Citron had promised in a tweet on Friday to  update  the story on Monday  following on from its scathing report in October that alleged accounting improprieties in a network of specialty pharmacies  including Philidor Rx  that Valeant used to distribute its drugs      Valeant s operation is far  dirtier  than just Philidor   Citron said in Monday s report  but did not make any further allegations  saying instead that  our work is done here     We are passing all new information on to the mainstream media investigative reports  whose legal teams are far deeper than those at Citron   the report said  Shares of Valeant jumped in early New York trading  and were up 8 percent by mid afternoon  at  101 24  Valeant shares have fallen from a peak of  260 in August  Citron s initial Oct  21 report had sent the stock down as much as 40 percent in one session  and Friday s tweet took another 10 percent off Valeant shares   The firm initially tweeted that it was going to release another explosive report on the embattled drug giant during a four hour conference call by billionaire investor William Ackman on Friday  where he defended his position in Valeant  Citron is overseen by Andrew Left  who is among a small group of short sellers who publish free reports on firms they claim are overvalued or engaged in fraud   During a CNBC interview on Monday  Left said his decision not to make further allegations stemmed from a desire to move investor focus to Valeant from Citron   He declined to provide details of his financial position in Valeant and laughed at suggestions that he had made  150 million on Valeant options  He said that he had not closed out his Valeant positions  and predicted more details would come out   In Monday s note  he said Valeant was looking at insurance fraud  accounting fraud  mail fraud  health information privacy violations and perjury  among other issues   We do not know the whole nature of what we are going to see in Valeant   Left said  In his October report  he likened Valeant to energy giant Enron Corp  which collapsed after an accounting scandal  and focused on information that Valeant had never disclosed to investors about its use of Philidor and other related pharmacies   Valeant has denied the fraud allegations and said last week that it would contact the U S  Securities and Exchange Commission about investigating Citron  Left told CNBC on Monday he was not contacted by the SEC over the weekend  Valeant spokeswoman Laurie Little said in an emailed statement on Monday that  Citron admits in its latest report that it has no substantiation for further allegations against Valeant    Given that its last report was filled with demonstrably false statements about our business  we are not surprised  even as Citron continues to mislead investors in an attempt to profit by driving down our stock   the statement added  
On Friday  Valeant said it had severed ties with Philidor after losing confidence in the division s operating practices  The announcement came after the two largest U S  pharmacy benefit managers said they were excluding Philidor from their pharmacy network ",2015-11-02,Reuters,https://www.investing.com/news/stock-market-news/citron-does-not-release-new-allegations-on-valeant-369224,369224
148589,370105,BHC,Wall St  climbs  led by energy  healthcare  Nasdaq 100 hits 15 year high,news,"By Lewis Krauskopf  Reuters    U S  stocks added to their recent run with gains across all sectors on Monday  led by increases in the beaten down energy group and the acquisition driven healthcare industry  The gains on the first trading day of the month followed the best monthly performance of the major indexes in four years in October  The Nasdaq 100  NDX  on Monday closed at its highest level in more than 15 years  Data on Monday showed U S  manufacturing activity in October sank to a 2 1 2 year low  but a rise in new orders offered encouragement  Elsewhere  factory activity in Germany beat economists  estimates  and manufacturing in Central and Eastern Europe kept up a robust pace in October   The fact that we have got sturdy numbers from outside the U S  accompanied by a relatively decent      U S  manufacturing  report  I think that cocktail was supportive of risk assets getting a boost   said Mark Luschini  chief investment strategist at Janney Montgomery Scott in Philadelphia  The Dow Jones industrial average  DJI  rose 165 22 points  or 0 94 percent  to 17 828 76  the S P 500  SPX  gained 24 69 points  or 1 19 percent  to 2 104 05 and the Nasdaq Composite  IXIC  added 73 40 points  or 1 45 percent  to 5 127 15  The S P  which is up nearly 13 percent since hitting its lowest level for the year in August  broke through the 2 100 barrier  bringing it nearer to its all time closing high of 2 130 82 in May   The upward trend that was put in place last week has continued to gain steam   said Michael James  managing director of equity trading at Wedbush Securities in Los Angeles   I don t necessarily think there s a specific catalyst for it today  Risk appetite has clearly increased   As the U S  earnings seasons winds down  investors are looking to economic data  including this Friday s employment report  for clues as to whether the Federal Reserve will raise interest rates when it meets in December  The S P energy index  rose 2 4 percent  Oil majors Exxon  N XOM  and  Chevron   N CVX  were two of the three biggest drivers of positive performance for the Dow after both companies posted better than expected results on Friday  Chevron gained 4 5 percent to  94 96 and Exxon finished up 3 1 percent at  85 28  The S P healthcare index  increased 2 percent   Pfizer   N PFE  rose 3 7 percent  and AbbVie  N ABBV  jumped 6 4 percent  providing the biggest boost to the sector  Dyax  O DYAX  soared 28 4 percent to  35 35 after British drugmaker  Shire   L SHP  said it would buy the company for about  5 9 billion  The Nasdaq biotechnology index  NBI  closed up 3 8 percent   U S  listed shares of Valeant  N VRX  rose 7 1 percent at  100 47 after short seller Citron Research said it would not be releasing new allegations against the Canadian drugmaker  The S P financial sector  SPSY  gained 1 6 percent  led by increases from the big banks  Visa  N V  fell 3 percent to  75 22 after offering to buy its former subsidiary Visa Europe Ltd for as much as  23 3 billion  The stock was the biggest drag on the Dow and the S P 500  Hewlett Packard started trading after its split  HP Inc  N HPQ  jumped 13 percent to  13 83  while Hewlett Packard Enterprise  slipped 1 6 percent to  14 49  Advancing issues outnumbered declining ones on the NYSE by 2 525 to 569  for a 4 44 to 1 ratio on the upside  on the Nasdaq  2 217 issues rose and 628 fell for a 3 53 to 1 ratio favoring advancers  
The S P 500 posted 25 new 52 week highs and four new lows  the Nasdaq recorded 76 new highs and 44 new lows ",2015-11-02,Reuters,https://www.investing.com/news/stock-market-news/stock-futures-up-slightly-as-factory-data-awaited-369188,369188
148590,370106,BHC,Ackman s fund lost 7 3 percent in October  off 19 percent for year,news,BOSTON  Reuters    Billionaire investor William Ackman s Pershing Square Holdings portfolio has lost 19 percent this year after his bet on Valeant Pharmaceuticals  N VRX  International soured  turning one of last year s biggest winners into one of this year s most prominent losers  Pershing Square Holdings lost 7 3 percent in October  the firm  which invests roughly  16 billion for state pension funds  endowments and wealthy investors said on a Web site  The trouble was largely related to a 47 percent tumble in the stock of Valeant  a drug company Ackman added to his concentrated portfolio earlier this year  But another one of Ackman s big bets on Platform Specialty Products also soured when it lost roughly 20 percent in the last month   Last year Pershing Square Holdings gained 40 percent ,2015-11-03,Reuters,"https://www.investing.com/news/stock-market-news/ackman's-fund-lost-7.3-percent-in-october,-off-19-percent-for-year-369419",369419
148629,370145,BHC,Valeant stock rebounds  but allegations shrink CEO s fortune,news,"By Rod Nickel  Reuters    Valeant Pharmaceuticals Inc  TO VRX   N VRX  shares rebounded on Friday from four days of steep losses over allegations of fraud  which it denied  but this week s stock selloff has already cost the company s chief executive well over  1 billion  The value of Chief Executive Mike Pearson s stake in the company had stood at  2 66 billion when Valeant shares peaked at  263 70 on Aug  5 on the New York Stock Exchange  according to filings  The value of that stake sunk to about  1 11 billion as of close of markets on Thursday  Laval  Quebec based Valeant on Thursday moved to reassure investors  saying it would address the allegations in detail on a conference call on Monday  The stock began to recover after that announcement  although it still closed lower on Thursday  On Friday  shares climbed about 10 percent in Toronto and 9 percent in New York trading  to C 157 89 and  119 81 respectively  They had lost 25 percent in the previous two trading days   I m hoping the modest bounce today is the market collecting themselves again and trying to inject some rationality into this whole thing   said Annabel Samimy  analyst at Stifel Nicolaus   Company  Concerns about Valeant are overblown and based on a misunderstanding of how the U S  drug supply chain works  she said   A law firm announced a lawsuit against Valeant and seeks class action status on behalf of buyers of the company s stock between Feb  23 to Oct  20 after influential short seller Citron Research alleged the Canadian drugmaker used specialty pharmacies to create  phantom sales   The company has already issued statements denying the claims  Valeant did not immediately respond to multiple requests for comment on Friday  BMO analyst Alex Arfaei said in a note on Friday that he was concerned about Valeant s lack of disclosure until recently about its relationship with a pharmacy called Philidor   Not disclosing these types of financial relationships left Valeant vulnerable to the types of weak allegations raised by Citron   Arfaei said  
Citron s allegations have heaped pressure on Valeant  which is already under scrutiny for price hikes on drugs that it has acquired  including investigations by federal prosecutors in New York and Massachusetts ",2015-10-23,Reuters,https://www.investing.com/news/stock-market-news/valeant-rebounds-ahead-of-monday-call-to-address-allegations-367721,367721
148630,370146,BHC,Legal tangle in California may shed light on specialty pharmacies,news,"By David Ingram NEW YORK  Reuters    As Valeant Pharmaceuticals  N VRX  prepares to defend its drug sales practices to Wall Street on Monday  new details are emerging about the tangled relationships   and litigation   among Valeant s specialty pharmacy partners   The court cases  which have drawn media attention in recent days  are expected to be addressed during Monday morning s investor call  a person familiar with the matter said   Valeant lost more than 30 percent of its market value this past week as the company disclosed details of its relationship to a Pennsylvania based pharmacy called Philidor Rx Services    Specialty pharmacies are designed to handle medicines that require complex storage or administration  often for serious conditions such as cancer or rheumatoid arthritis  Valeant has used Philidor to dispense a range of its medications  including conventional treatments for acne and toenail fungus    Influential short seller Citron Research accused the drugmaker of using Philidor to create  phantom sales  of its products or push more product through distribution channels than sales would warrant  an allegation that Valeant has denied outright    Although the two companies are separate legal entities  Valeant said last week that it holds a right to purchase Philidor  which in turn said that it holds the right to acquire control of other affiliated pharmacies    Philidor has not addressed questions of its sales practices  It said last week that it works with a network of pharmacies and provides them with call center functions  help with insurance claims  technical support and  certain management services      One of those affiliates is R O Pharmacy based in California  which has been in a heated dispute with Valeant  Philidor and a related holding company for more than three months   R O sued Valeant in federal court in California on Oct  6  after receiving a demand letter from Valeant for more than  69 million  money that R O said it didn t owe  R O said in court documents that it informed Valeant after receiving the payment demand that either Valeant was conspiring to perpetrate a fraud on R O  or both companies were the victims of fraud by a third party     Even earlier  beginning in July  R O owner Russell Reitz demanded that Philidor end certain practices that Reitz said were illegal  including use of R O S pharmacy identification numbers to bill health insurers  according to court documents   The correspondence went on through the summer  culminating in a separate lawsuit in California state court brought against R O by a Delaware holding company named Isolani  The lawsuit  filed on Sept  8  stated that Isolani had purchased a stake in R O and an agreement to acquire full ownership  and that R O subsequently breached a management services agreement entered into at the same time  The suit alleged that R O was unlawfully withholding more than  15 million in payments it had received from health insurers and others that belonged to Isolani  R O alleges that Isolani is a front for Philidor  the court documents show   Lawyers for Isolani  a lawyer for R O  multiple officials at Philidor and spokespeople for Valeant did not respond to repeated requests for comment   The state lawsuit brought by Isolani and the federal lawsuit brought by R O are both at early stages  and there have been no rulings in either case   Investment banking advisory firm Evercore drew attention to the state court case in a note to clients on Thursday  Evercore said it was hard to have a definitive view on whether what Philidor was doing was  kosher or not   and it asked whether Valeant could be on the hook for any potential fine against Philidor  Philidor itself is not a party to either of the two lawsuits  But R O s attorney  Gary Kaufman  filed copies of correspondence in the state court suit  in which his client raised concerns about Philidor s actions and called for terminating R O s agreements with Isolani  On Aug  31  Kaufman sent a letter to a lawyer for Isolani alleging that Isolani and Philidor were engaging in a  massive fraud    He said Philidor had targeted R O for acquisition in 2014 because Philidor needed access to valuable multi state pharmacy licenses and payer contracts  and had subsequently used R O s provider numbers  to bill payers for prescriptions dispensed by Philidor    Philidor last week said it has a contractual right to acquire R O  subject to regulatory approval   
Shares of Valeant rebounded somewhat on Friday after four days of steep losses  Shares closed up 5 7 percent for the day at  116 16 in trading in New York  still far short of the nearly  170 per share at which it began the week ",2015-10-25,Reuters,https://www.investing.com/news/stock-market-news/legal-tangle-in-california-may-shed-light-on-specialty-pharmacies-367844,367844
148631,370147,BHC,Global shares cool as easing expectations fade,news,"By Lionel Laurent LONDON  Reuters    Stock markets cooled on Monday as euphoria about the prospect of further central bank policy easing faded  with investors warning against over confidence ahead of another week of interest rate decisions  Comments on Monday from a key economic adviser to Prime Minister Shinzo Abe  who said the Bank of Japan did not need to boost its monetary stimulus as early as this week  have tempered expectations that Friday s policy review will see new action  The monthly Ifo survey of German business morale dipped in October but beat forecasts  suggesting Europe s largest economy remains resilient in the face of a slowdown in emerging markets and the emissions scandal at carmaker Volkswagen  DE VOWG p   Corporate expectations over a half year horizon hit a seven month high  suggesting many firms believe they can cope with the economic headwinds   We have had a pretty good rally in risk assets since the beginning of October     Clients have only really got two or three more weeks to do anything before year end and they are not going to take big positions going into December   said Sean Darby  a strategist at Jefferies   On Japan  people also may have read too much into the possible crossover from the ECB   Bets that Japan s already massive stimulus would be increased had risen after China cut interest rates last week and the European Central Bank indicated it may add to its asset purchase program in December  The U S  Federal Reserve  which also meets this week  is also increasingly seen delaying its first rate increase for nearly a decade until next year  Global equities  which have rebounded 10 percent from the depths of September s sell off  were broadly flat on Monday  with the pan European FTSEurofirst 300  FTEU3  index down 0 2 percent  MSCI s index of Asia Pacific shares outside Japan edged up 0 2 percent  U S  shares were also set to open lower  with futures down around 0 1 percent  Valeant Pharmaceuticals  N VRX  sank nearly 14 percent in pre market trading after the company said it would set up a panel to probe allegations about its associations with specialty pharmacy distributor Philador  Poland s benchmark equity index  WIG20  reversed early falls and rose 0 3 percent after the main opposition party Law and Justice won weekend parliamentary elections  The party confirmed its plan to introduce a banking tax as of January 2016  which hit bank stocks like PKO BP  WA PKO  and mBank  WA MBK   There were some mixed updates from earnings season  French carmaker  Peugeot   PA PEUP  fell 2 1 percent after a trading update and Philips  AS PHG  fell 0 7 percent after warning that the sale of its Lumileds division was in doubt  The prospect of more central bank cash was seen supporting bond markets  with Italian and Spanish bond yields at nearly their lowest levels in half a year on expectations additional ECB stimulus will lift lower rated euro zone bonds  German Bund yields hovered just above 0 50 percent  Portuguese yields bucked the trend  rising after opposition Socialists pledged to topple the government in a no confidence vote  with political instability seen as a potential setback in Lisbon s path to recovery  Crude oil prices edged higher but remained range bound on indications that global storage is nearing capacity  
Iron ore futures in China and Singapore ticked lower amid pressure from a weak steel market  though copper prices edged higher ",2015-10-26,Reuters,https://www.investing.com/news/stock-market-news/global-shares-cool-as-easing-expectations-fade-367846,367846
148632,370148,BHC,Drugmaker Valeant raises detailed defense but doubts remain,news,"By Caroline Humer and Euan Rocha  Reuters    Drugmaker Valeant Pharmaceuticals International Inc  TO VRX   N VRX  laid out a detailed defense on Monday of its relationship with a little known specialty pharmacy  but its arguments failed to calm all investor concerns  Valeant shares have lost more than half their value in recent weeks as the company came under attack on several fronts   U S  prosecutors are investigating Valeant over drug pricing  an issue emerging in the U S  presidential campaign  The falling stock price  in turn  complicates Valeant s acquisition driven strategy  And those stock losses accelerated last week when short seller Citron Research  run by Andrew Left  published a sharply critical report on the company   The stock dropped another 2 percent in volatile afternoon trading in New York and Toronto  Laval  Quebec based Valeant said it has asked U S  securities regulators to investigate Citron s  completely untrue  allegation that the company used its ties with a specialty pharmacy to inflate revenue  and said it would conduct a review of its pharmacy network   About a dozen executives  directors  and a former chief financial officer   some of whom Chief Executive Mike  Pearson   L PSON  said were operating on little sleep   made up Valeant s defense team on a conference call with investors and analysts  The call included an unequivocal endorsement of Pearson by lead director Robert Ingram    Left s  motivation is the same as one who runs into a crowded theater and falsely yells fire  He wanted people to run   Pearson said   He intentionally designed the report to frighten our shareholders to drive down the price of our stock so he could make money for his short selling    Left disputed Pearson s comment in a statement   Yelling fire in a crowded theater is a lot different than walking into a theater  smelling smoke and yelling   Hey everyone  there could be a fire    Now the information is out  people have had an opportunity to inspect the theater and they have chosen to leave     maybe there is fire   Left said on Bloomberg TV that he had not been contacted by the U S  Securities and Exchange Commission  He refused to discuss his trading of Valeant  Valeant said it would set up an ad hoc committee to look into allegations related to the company s association with specialty pharmacy Philidor  The committee includes Mason Morfit  president of one of Valeant s largest shareholders ValueAct Capital  who is rejoining the board  Philidor said it welcomed formation of the committee and would cooperate with it  Peter Andersen  chief investment officer at Boston based Congress Wealth Management  a long time Valeant investor  said he was impressed with the directors and senior management  but sold his stake Monday because of uncertainty facing the company   They are an excellent example of modern corporate governance in terms of being open and available  I feel they discredited the short seller s allegations   he said  but added   The stock is going to be stuck in limbo   REBUILDING CONFIDENCE Valeant cleared the air somewhat  but not enough  said BMO analyst Alex Arfaei  in a note    There is still much more that needs to be done to rebuild investor confidence  which we argue has been significantly weakened   Arfaei said he wondered what other undisclosed business practices Valeant might be involved in that could undermine the stock   Valeant said in a filing Monday it received a subpoena in a U S  government probe of payments between its Bausch   Lomb division and medical professionals  Valeant should sever its relationship with Philidor so it can focus on its core business  said BTIG analyst Tim Chiang   But J P  Morgan analyst Chris Schott said in a note that concerns about Valeant s connection with Philidor were  overblown    Valeant said it paid  100 million in December 2014 for its option to buy Pennsylvania based Philidor Rx Services Llc  which also included contractual rights  such as influence over certain personnel hirings and a place on a joint steering committee  Philidor accounted for about 7 percent of its total revenue and EBITDA in the third quarter  and 44 percent of sales of Jublia  Valeant s toenail fungus treatment  Valeant said  but added it is not material for reporting purposes   Valeant described Philidor as independent  and said Valeant does not have legal liability for it   The company said a board review had found the company in compliance with the law on revenue recognition from drugs sold through Philidor   Valeant s link to Philidor came under scrutiny after a New York Times report said that Valeant and other drugmakers were using specialty drug distributors to circumvent barriers to raising prices   Valeant has said it properly accounts for sales through its pharmacy partners and only books revenue once one of its medicines reaches a patient   FOCUS ON SPECIALTY PHARMACIES Specialty pharmacies are designed to handle complex medications that have unique requirements for storage or administration  But Valeant has also used such pharmacies to sell more conventional medicines directly to patients  and work out reimbursement from insurers afterward  That may allow them to get past limits on a drug s use imposed by insurers or a retail pharmacy  In Valeant s case  the company has been under scrutiny for its ties to Philidor  which has been accused by one of its affiliates of improper billing practices  The Wall Street Journal reported that Valeant and Philidor are more interconnected than previously disclosed  and highlighted business practices that included a few Valeant workers who used alternative names  sometimes fictional ones  while working in Philidor s office  Valeant chief compliance officer Seana Carson said the company s ad hoc committee will also review that report   Pearson said Valeant will consider all options  including buying Philidor or severing ties with it  as well as using other specialty pharmacies  
The acquisitive company has been considering a sale or other options for its neurological business  but such a move is now on the back burner  Pearson said ",2015-10-26,Reuters,https://www.investing.com/news/stock-market-news/valeant-calls-for-sec-investigation-into-short-seller's-actions-367911,367911
148633,370149,BHC,Top U S  drugmakers ride new products to strong results,news,"By Bill Berkrot and Ransdell Pierson NEW YORK  Reuters    Growing sales of expensive new cancer drugs and other newer medicines propelled top U S  drugmakers  Pfizer  Inc  N PFE   Merck   Co  N MRK  and Bristol Myers Squibb Co  N BMY  to stronger than expected third quarter profits  The results  announced on Tuesday  demonstrate that the  patent cliff  that had been hurting earnings as huge selling drugs like Pfizer s Lipitor and Bristol s Plavix went generic is now well behind these companies  Shares of all three rose as they also modestly raised their full year forecasts  Merck s Keytruda and Bristol Myers  Opdivo  both immunotherapies for advanced melanoma and lung cancer  and Pfizer s Ibrance for breast cancer are off to strong starts  with Wall Street forecasting eventual multibillion dollar sales  Keytruda and Opdivo list for about  150 000 for a year of treatment  and Ibrance goes for about  118 000  In addition  blood clot and stroke preventer Eliquis  which Pfizer and Bristol share  has begun to take off and is on track for annual sales of nearly  2 billion   This is the best innovation based new product cycle in these companies  storied histories   said Suntrust Robinson Humphrey analyst John Boris   Eliquis is just knocking the cover off the ball   Merck and Bristol are testing their new immuno oncology drugs in numerous combinations and in dozens of different types of cancer   Pfizer said it expected to introduce a drug from the same PD 1 class as Opdivo and Keytruda in 2017  with one or more additional launches each year through 2022  It plans to have 10 new immuno oncology drugs in clinical testing by next year  The largest U S  drugmaker said 50 000 U S  patients had used Ibrance  which is awaiting European approval  It had sales of  230 million for the quarter   A whole slew of  future  blockbuster drugs are getting traction today   said Tony Scherrer  director of research at Smead Capital Management   The pipelines look great   The three drugmakers all invest heavily in research and development  which led to the new medicines   That stands in stark contrast to the business model of Valeant Pharmaceuticals  N VRX  International  TO VRX   which is known for buying companies and slashing R D  The Canadian company has come under fire for its business practices  which include sharply raising prices of the drugs it acquires  The high cost of prescription drugs has become a major topic of the current U S  presidential campaign  with calls by candidates and others to rein in prices and out of pocket expenses to patients   Merck Chief Executive Officer Ken Frazier called the pricing discussions  a lot of noise  that he does not believe will tarnish the industry s reputation  Pfizer CEO Ian Read said he believed that higher co pays demanded by insurers were more of a problem for patients than prices charged by drugmakers   We must preserve the market based system in the U S  that enables us to develop breakthrough treatments and cures for patients   Read said  
Bristol Myers shares were up 2 5 percent at midday  while Pfizer rose 2 2 percent  and Merck gained 1 4 percent ",2015-10-27,Reuters,https://www.investing.com/news/stock-market-news/pfizer-revenue-falls-about-2-percent-on-strong-dollar-368161,368161
148634,370150,BHC,Valeant s ambitious plan for its contact lens business,news,"By Carl O Donnell NEW YORK  Reuters    Valeant Pharmaceuticals International  VRX  has pursued a plan in recent months to dominate the market for specialty contact lenses  according to two people familiar with the company s approach and some of the company s communications with its customers  The Canadian drugmaker s goal  spelled out to key employees and demonstrated through its actions  has been to acquire other manufacturers  take on competitors and raise prices for unfinished lens components  Valeant entered the contact lens business with its purchase of Bausch and Lomb in 2013 for  8 7 billion  At the time of the acquisition  Bausch and Lomb manufactured about 75  of the basic components of rigid gas permeable lenses  known as   buttons   said Kurtis Brown  who worked for Bausch and Lomb prior to Valeant s purchase  After manufacture  buttons are customized for individual patients  typically by laboratories specializing in that process   With the acquisition of Paragon Vision Sciences in May for an undisclosed sum  Valeant and Bausch and Lomb further consolidated their grip on the market  gaining control of more than 80  percent of the gas permeable button market  according to one of the sources familiar with Valeant s operations and the representative of an industry group  Rigid lenses comprise only about 10  of the contact lens market  and are popular among people who cannot wear soft lenses   The acquisition of Paragon also gave Valeant and Bausch and Lomb full control of the small market for Ortho K buttons  which are used to create one type of gas permeable lens  said Brown  now a marketing manager for lens manufacturer Menicon America Inc  Sales of Ortho K buttons and finished Ortho K lenses comprise only about  5 million in annual sales for Valeant companies   The U S  Federal Trade Commission is investigating the Paragon purchase as part of an anti trust probe  a source interviewed by the FTC told Reuters  Valeant disclosed on Monday that it had received a letter from the FTC on or about Oct  16 seeking more information about its acquisition of Paragon   On Tuesday  Valeant declined to comment on specifics of its strategy in the specialty contact lens market but defended its purchase of Paragon       Our acquisition of Paragon Holdings supports our mission to improve consumers  lives by bringing to market innovative  specialty eye care solutions  and we are cooperating with the FTC on its inquiry   the company said in a statement emailed to Reuters    Bausch   Lomb is now operated as a division of Valeant  and Paragon has been rolled into Bausch   Lomb  In recent months  Bausch and Lomb also has moved to acquire laboratories that turn the raw components   buttons   into finished lenses   The plan has encountered challenges  however  with at least four laboratories   including Alden Optics  Art Optical and Tru Form Optics   holding out  at least for now  against Bausch and Lomb s purchase overtures  according to one of the sources familiar with Valeant s contact lens operations and some of the labs themselves    In the months after it began trying to acquire laboratories  Bausch and Lomb increased button prices for its customers  which included more than 30 laboratories that customize lenses  according to Jan Svochak  president of the contact lens manufacturers association  an industry trade group  The price increases for buttons ranged from 15 percent to more than 120 percent  a source with direct knowledge of the price hikes said  Keith Parker  owner and president of Advanced Vision Technology  said that his lab was hit with a first price increase from Bausch and Lomb in mid September and a second one on October 1  all on overnight wear lenses    They were substantial   he said of the price increases   Some of them 100 percent  some of them more than 100 percent    The company also did away with volume discounts  he said  In response to the price increases  some labs have begun switching to other button suppliers  such as Contamac  according to at least three laboratories interviewed by Reuters  Contamac has not responded to a request for comment   Last week  Bausch and Lomb sent a letter to the optometrist community promising to  adjust down  some of the increased prices after complaints from laboratories    In the long run  Bausch and Lomb hopes to do more manufacturing and distribution of finished lenses directly to optometrists  This would enable Bausch and Lomb to bypass some of the laboratories now filling that role and thereby buttress its profits  according to one of the people familiar with Valeant s operations and several laboratories   According to the two sources familiar with Valeant s contact lens operations  Bausch and Lomb hopes a newly created division  to be called Advanced Vision Products  will bring in more than  100 million in revenue by the end of 2016 from sales of specialty contact lens products  including customized gas permeable contact lenses   Bausch and Lomb currently earns about  30 million annually from manufacturing gas permeable lenses and their basic components  the sources said    Valeant was already the subject of a U S  probe into price increases for its heart medications  and its stock price was battered last week after short seller Andrew Left accused it of using mail order pharmacies to fraudulently book revenues  
Valeant denied Left s assertions and laid out a detailed defense on Monday of its relationship with specialty pharmacy Philidor  the firm at the center of Left s accusations ",2015-10-29,Reuters,https://www.investing.com/news/stock-market-news/valeant's-ambitious-plan-for-its-contact-lens-business-368585,368585
148635,370151,BHC,CVS  Express Scripts drop Valeant s Philidor  stock dives,news,By Michael Flaherty and Caroline Humer  Reuters    Valeant Pharmaceuticals  N VRX  Inc  sustained hits on several fronts on Thursday after CVS Health Corp  N CVS  and Express Scripts dropped Philidor from their networks in a sign the fallout from the drugmaker s connection with the specialty pharmacy is spreading  The moves by the nation s two largest pharmacy benefit managers whacked Valeant shares before the market close  and pushed them 10 percent lower to  99 after hours  After coming under pressure this summer  Valeant s stock plunged last week after short seller Citron Research said that the company was using its drug distributor  Philidor Rx  to inflate revenue numbers  About a dozen Valeant officials held a conference call on Monday to address the accusations  which helped ease pressure on the company s stock  Valeant said it properly accounts for sales through its pharmacy partners and only books revenue once one of its medicines reaches a patient  Valeant s stock recovered throughout the week than sank on the CVS and Express Scripts news  CVS  late on Thursday  said its Caremark program was dropping Philidor  CVS took the step following an audit of Philidor  citing  noncompliance  with its provider agreement  the company said  Shortly after the market close  Express Scripts said it too was ending its ties to Philidor   CVS did not explain the  noncompliance  further when contacted by Reuters  Bloomberg on Thursday said Philidor has altered doctors  orders to wring more payment out of insurers  according to former employees and an internal document  which details how to proceed with a prescription for certain Valeant drugs after they have been rejected   Valeant s drugs are provided to patients through many channels  including traditional retail pharmacies  specialty pharmacies  and directly from health care providers   said Valeant Spokeswoman Laurie Little in an emailed statement   Philidor declined to comment on Thursday   CVS and Express Scripts Holdings manage most of the prescriptions filled under health plans run by the nation s largest insurers  Express Scripts manages prescription benefits for 85 million people   The move by CVS and Express Scripts will have a direct impact on Valeant  though Philidor accounts for a small portion of the Canadian company s revenues  In Valeant s detailed presentation on Monday that spelled out its dealings with Philidor  the company said that the pharmacy accounted for about 5 9 percent of its total sales so far this year  The stock was trading as high as  260 per share in August  The next month  U S  Democratic politicians singled out Valeant for hiking drug prices on consumers  and a federal subpoena followed  With the stock under pressure  the Citron report last Wednesday sent it into a tailspin  TOP SHAREHOLDER SPEAKS The CVS announcement came after mutual fund manager Ruane  Cunniff   Goldfarb Inc   sent a letter to its own investors about the Valeant saga  The Sequoia Fund  which the mutual fund manages  owns 9 93 percent of Valeant and is the company s largest shareholder  While the letter is largely a defense of Valeant s practices  it says that the company needs to move faster with paying down its debt  It also points out that Valeant s aggressive business practices have  pushed boundaries   and that the company needs to better manage its image   We would stress the importance of taking a more systemic approach to managing business practices with an eye on the company s long term corporate reputation   said the letter dated Oct  28 and signed by Ruane  Cunniff   Goldfarb President Robert Goldfarb and Executive Vice President David Poppe  Separately  two of the five independent directors of the Sequoia Fund resigned over the weekend  the Wall Street Journal reported on Thursday  citing the board s chairman  A person who answered the phone at Ruane  Cunniff   Goldfarb said the chairman  Roger Lowenstein  could not be reached  ACTIVISTS HIT Valeant s abrupt slide from a hedge fund darling to a drug company under fire has weighed heavily on two of the best known U S  activist funds  ValueAct Partners and Pershing Square  ValueAct has been an investor in Valeant since 2006  and played a significant role in instituting the company s strategy and its current CEO  Michael  Pearson   L PSON   Pearson took over in 2008 and built Valeant into a more than  40 billion company with over 100 transactions  ValueAct  with  19 billion under management  now has two directors on the company s board  and was the fourth largest shareholder as of June 30  William Ackman s Pershing Square  Valeant s third largest shareholder  has scheduled a call on Friday at 9 am EDT to address the drug company s issues  Pershing owned 5 7 percent of Valeant as of June 30  and faced a paper loss of more than  800 million at one point last week ,2015-10-29,Reuters,"https://www.investing.com/news/stock-market-news/cvs,-express-scripts-drop-valeant's-philidor;-stock-dives-368804",368804
148669,370185,BHC,Shares in Asia mixed with Shanghai rebounding after break,news,"Investing com   Shares in Asia were mixed on Thursday with China recovering slightly after a downbeat start to the day 
The Shanghai Composite dropped at the start only to recover after the break  up 0 24  
The Nikkei 225 fell 0 54   while the S P ASX 200 gained 0 11  
In Australia  the NAB quarterly business confidence survey fell to flat from plus 4 in the previous quarter  while conditions gained to plus 11 from plus 5 
The quarterly business outlook is always a little out of date but is a good sector indicator  It covers more than 900 companies compared with between 300 and 600 in the monthly survey  The outcome is usually consistent with monthly surveys 
Overnight  U S  stocks fell slightly on Wednesday as a sell off among Health Care and Biotechnology stocks offset gains from a GM and Boeing inspired rally 
Shares in Valeant Pharmaceuticals International Inc  N N VRX  fell as much as 25  after a report from short seller Citron Research accused the  50 billion pharmaceutical giant of a wide range of improprieties  including creating fake invoices for deceiving auditors and booking artificially high revenues 
Separately  the company disclosed on Wednesday that it has recently been served subpoenas by the U S  Attorney s Office in Massachusetts and the Southern District of New York stemming from investigations into the pricing information it provided to the Centers for Medicare and Medicaid Services 
The Dow Jones Industrial Average reversed territory late in Wednesday s session to close lower  while weakness in the Health Care sector weighed heavily on both the NASDAQ Composite index and the S P 500 Composite index  The Dow lost 48 50 or 0 28  on Wednesday to close at 17 168 61  while the NASDAQ fell by 40 85 or 0 84  to end the session at 4 840 12 
On the S P 500  all 10 sectors closed in the red  as it fell 11 83 or 0 58  to 2 018 94  Stocks in the Energy  Basic Materials and Health Care industries lagged  All three major indices still remain on track to end the month with their strongest October in four years ",2015-10-22,Investing.com,https://www.investing.com/news/stock-market-news/shares-in-asia-mixed-with-shanghai-rebounding-after-break-367373,367373
148670,370186,BHC,Valeant vows to refute  phantom sales  allegations,news,"By Euan Rocha and Ransdell Pierson TORONTO NEW YORK  Reuters    Valeant Pharmaceuticals  N VRX  International Inc  TO VRX  moved to reassure investors on Thursday after being accused of using specialty pharmacies to inflate revenue  and said it would refute them in detail on a conference call with investors  Valeant shares have lost more than 25 percent of their value since influential short seller Citron Research made the allegations on Wednesday  The company had already issued statements denying the claims   Valeant said at least 10 of its executives and board members would participate in a call on Monday  including Chief Executive Michael  Pearson   L PSON   its current and former chief financial officers  and board member Robert Hale  who represents key shareholder ValueAct Capital    We look forward to our call on Monday where we will address and refute recent allegations   Pearson said  Citron s allegations have heaped pressure on Valeant  which is already under scrutiny for extreme price hikes on drugs that it has acquired over the years  including investigations launched by federal prosecutors in New York and Massachusetts  Valeant has built a reputation for rapidly acquiring drugmakers and scaling up sales of their medicines  in some cases through steep price increases  The company has said a growing amount of its revenue comes through its specialty pharmacy partners  which will fill patient prescriptions even before they have secured reimbursement from their health insurers  Citron alleged that the pharmacies allow Valeant to create phantom accounts that boost its revenue  Valeant maintains it only books revenue once a drug is received by a patient  On Thursday  some of the company s greatest champions on Wall Street began to express doubt about its prospects  and a securities regulator in Quebec said it was keeping a close eye on developments regarding its pharmacy ties   Alex Arfaei  an analyst with BMO Capital Markets who had long held a  buy  rating on Valeant  downgraded the company on Thursday to  market perform   He questioned disclosures that suggest Valeant had operational control of one of its specialty pharmacies  whereas other drugmakers consider their affiliated specialty pharmacies fully independent   Valeant s structure may not be illegal  but we find it aggressive and questionable   Arfaei said in a research note  He added that concerns over Valeant s handling of the business would linger unless resolved by an investigation  Valeant s swoon this week has hurt major shareholders  including billionaire William Ackman whose Pershing Square Capital Management hedge fund lost about  500 million alone in Wednesday s rout  Rival specialty drugmakers including  Horizon Pharma  Plc  O HZNP  and Endo International  O ENDP  also fell sharply  Valeant s secondary loan price fell for a second day on Thursday in volatile trading  pulling down trading levels for a range of other drugmaker loans  according to Thomson Reuters Loan Pricing Corp   Valeant s five year credit default swaps have blown out 44 percent  or 195 basis points  to 637 5 basis points  according to Markit data  That means the cost of insuring  10 million of Valeant bonds against default has become  195 000 more expensive  The company s swaps are relatively new  however  and therefore not very liquid   But the company has also seen signs of support  Ackman bought additional Valeant shares during Wednesday s rout  Standard   Poor s also said it is sticking by its ratings on Valeant  saying speculation about potential fraud was unfounded  SPECIALTY PHARMACY CHANNEL Specialty pharmacies typically are used to deliver drugs that require special handling  or for patients with complex medical conditions like multiple sclerosis or rheumatoid arthritis  A New York Times story early this week said Valeant was using its ties with a pharmacy called Philidor to sell more conventional medications to get past health insurer barriers to reimbursement  Citron wrote that Valeant was also using Philidor accounts to inflate its revenue  Valeant has categorically denied the allegations  saying it only books revenue once its drugs reach patients  But Pearson surprised investors earlier in the week by disclosing the company had an option to acquire Philidor   On Thursday  the Autorit  Des March s Financiers  AMF   which regulates companies based in Quebec including Valeant  said it does not have an active probe into the drugmaker  The regulator is  watching very seriously the evolution of the situation   said Sylvain Th berge a spokesman for the AMF in an email  adding that the AMF is in communication with the U S  Securities and Exchange Commission about the matter   Regardless of the accuracy of allegations  we don t see a quick end to unquantifiable headline risk   Susquehanna analyst Andrew Finkelstein said in a note   The brokerage firm suspended its ratings and estimates on the company  noting that a battle with short sellers means Valeant s shares are not likely to trade on fundamentals in the near term  Yet Pearson also had some social media backing from Martin Shkreli  the CEO of Turing Pharmaceuticals  a start up drug firm  which sparked outrage by raising the price on a decades old drug by 5 000 percent   
Valeant  is not overreporting revenue  Give me a break   Shkreli posted on Twitter  N TWTR   noting that the company s sales are in line with prescription drug data from independent research firm IMS Health  Shkreli said he has bought shares of Valeant ",2015-10-22,Reuters,https://www.investing.com/news/stock-market-news/valeant-vows-to-refute-'phantom-sales'-allegations-367562,367562
148671,370187,BHC,Shares in Asia up smartly on overnight Wall St lift,news,"Investing com   Asian shares rose on Friday following overnight sharp Wall Street gains 
The Nikkei 225 was up 2 35   while the Shanghai Composite rose 0 41  and the S P ASX 200 jumped 1 78  
Overnight  U S  stocks surged on Thursday  enjoying one of their strongest performances of the month  amid robust earnings from several prominent companies and indications from the European Central Bank that it will introduce further stimulus measures before the end of the year 
Shares in McDonald s Corporation  N MCD  jumped more than 8  to a record high of 111 00  after the world s largest fast food chain reported better than expected results during its third quarter of fiscal year 2015 on Thursday  McDonald s  N N MCD  global sales among established restaurants soared 4  on the quarter  amid resurgent demand in China and the company s decision to swap margarine for butter on its Egg McMuffin sandwiches  McDonald s is in the midst of completing wholesale changes in its corporate structure since Steve Easterbrook took over as CEO earlier this year 
The Dow Jones Industrial Average and the S P 500 Composite index each rose by more than 1 5  during Thursday s session to reach nine week highs  The Dow gained 320 55 or 1 87  to close at 17 489 16  while the S P 500 added 33 57 or 1 66  to 2 052 51  as nine of 10 sectors closed in the green  Stocks in the Basic Materials  Industrials and Technology industries led  each gaining more than 2 25  on the day 
The NASDAQ Composite index also closed dramatically higher  despite being limited by continued weakness among health care and hospital stocks  Shares in Valeant Pharmaceuticals International Inc  N N VRX  fell sharply again on Thursday  after nearly plunging 20  one session earlier amid a report from a short seller accusing the company of falsifying records in an effort to bolster revenues  The NASDAQ still added 79 93 or 1 65  to end Thursday s session at 4 920 05 
All three major indices received a boost on Thursday morning after ECB president Mario Draghi offered strong hints that the central bank is prepared to cut interest rates in the euro zone from their current record low of 0 5  and extend the scope of its  1 1 trillion bond buying program  Draghi s comments sent the dollar soaring more than 1 4  and pushed EUR USD to its lowest level in three weeks ",2015-10-22,Investing.com,https://www.investing.com/news/stock-market-news/shares-in-asia-up-smartly-on-overnight-wall-st-lift-367578,367578
148694,370210,BHC,Canada stocks higher at close of trade  S P TSX Composite up 2 07 ,news,"Investing com   Canada stocks were higher after the close on Wednesday  as gains in the Healthcare  Utilities and Mining sectors led shares higher 
At the close in Toronto  the S P TSX Composite rose 2 07  
The best performers of the session on the S P TSX Composite were  Concordia Healthcare   TO CXR   which rose 17 94  or 8 66 points to trade at 56 94 at the close  Meanwhile  Valeant Pharmaceuticals International Inc  TO VRX  added 12 33  or 26 14 points to end at 238 20 and Hudson s Bay Company  TO HBC  was up 8 92  or 1 85 points to 22 58 in late trade 
The worst performers of the session were Performance Sports Group Ltd  TO PSG   which fell 3 92  or 0 73 points to trade at 17 88 at the close   Mitel Networks Corporation   TO MNW  declined 3 70  or 0 33 points to end at 8 60 and  Gran Tierra Energy Inc    TO GTE  was down 3 38  or 0 100 points to 2 860 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 833 to 551 and 173 ended unchanged 
Shares in Mitel Networks Corporation  TO MNW  fell to 52 week lows  losing 3 70  or 0 33 to 8 60  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 8 38  to 24 27 
Gold for December delivery was down 1 12  or 12 60 to  1114 20 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in November rose 0 38  or 0 17 to hit  45 40 a barrel  while the November Brent oil contract rose 0 65  or 0 32 to trade at  48 55 a barrel 
CAD USD was up 0 54  to 0 7490  while CAD EUR rose 1 19  to 0 6701 
The US Dollar Index was up 0 36  at 96 41 ",2015-09-30,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-higher-at-close-of-trade;-s-p-tsx-composite-up-2.07-364062,364062
148695,370211,BHC,Valeant subpoenaed by U S  prosecutors  shares slump,news,"By Ransdell Pierson and Bill Berkrot  Reuters    Valeant Pharmaceuticals International Inc  already under fire over steep price hikes for two heart drugs  said it had been subpoenaed by U S  prosecutors seeking details on its patient assistance programs  drug pricing and distribution practices  U S  listed shares of Valeant  N VRX   which said it would cooperate with the investigations  slumped 6 7 percent to  165 33 in afternoon trading on Thursday  The Canadian company  which was rapped by Democratic lawmakers in late September over those price increases  said late Wednesday it was reviewing subpoenas from the offices of attorneys for the District of Massachusetts and the Southern District of New York  Valeant tripled the price of its drug Isuprel and raised the price six fold for another heart drug  Nitropress  after buying them in February  While the magnitude of the price hikes has put Valeant in the political crosshairs  raising drug prices is not illegal in the United States  The company said it had hired a consultant to review the drugs  pricing and reimbursement  The consultant found that  there was considerable room to increase the price of both drugs   Chief Executive Michael  Pearson   L PSON  said in a letter on Wednesday in response to concerns expressed by Democratic Senator Claire McCaskill  Pearson has built Valeant into one of the world s largest drugmakers through numerous acquisitions  His business model has featured price hikes on medicines  while slashing research spending of acquired companies   PROFITEERING   Many companies charge high prices for drugs  but not many duplicate the Valeant business model   said Erik Gordon  a professor at University of Michigan s Ross school of business  In the letter to McCaskill  Pearson said Valeant has made substantial investments in manufacturing in the United States  Shares of many drugmakers have slumped since Democratic presidential hopeful Hillary Clinton last month proposed ways to prevent industry  profiteering   Clinton s comments followed reports that startup drugmaker Turing Pharmaceuticals had hiked the price of a 62 year old drug it had acquired by more than 5 000 percent to  750 a tablet   The same medicine  used to treat a parasitic infection  is sold in Britain by GlaxoSmithKline  L GSK  for 43 pence  66 cents  a pill   The United States has no price controls on medicines  though such curbs are common in Europe  Piper Jaffray analyst Richard Purkiss does not see the Valeant subpoenas as a precursor to a larger industry investigation because of the significant investment in high risk research made by most large drugmakers and biotechs   There is an unwritten social contract where you can have a degree of pricing power  but only if you engage in substantial funding of research as a percentage of your sales  Companies that extract high prices without spending on R D are in a different space   Purkiss said  Gordon said drugmakers  patient assistance programs  which are aimed at helping patients pay for their medicines  can sometimes be deemed improper inducement to drive up sales   Guggenheim analyst Louise Chen said she believed the federal prosecutors  inquiries to be politically motivated  with a financial settlement within two to three years as a likely outcome    Typically  companies agree to a fine and admit no guilt   she said  Valeant officials declined to comment beyond the content of the company s statement  Officials at both prosecutors  offices declined to comment   
Officials with PhRMA  the nation s largest trade group for pharmaceutical companies  said it could not comment as Valeant was not a member of the organization ",2015-10-15,Reuters,https://www.investing.com/news/stock-market-news/valeant-subpoenaed-by-u.s.-prosecutors-over-drug-pricing-concerns-366257,366257
148696,370212,BHC,Canada stocks lower at close of trade  S P TSX Composite down 0 33 ,news,"Investing com   Canada stocks were lower after the close on Thursday  as losses in the Healthcare  Energy and Consumer Discretionary sectors led shares lower 
At the close in Toronto  the S P TSX Composite declined 0 33  
The best performers of the session on the S P TSX Composite were  Mitel Networks Corporation   TO MNW   which rose 5 52  or 0 54 points to trade at 10 33 at the close  Meanwhile   Aecon Group Inc    TO ARE  added 4 12  or 0 58 points to end at 14 66 and  First Quantum Minerals Ltd    TO FM  was up 3 99  or 0 30 points to 7 81 in late trade 
The worst performers of the session were  Concordia Healthcare   TO CXR   which fell 7 40  or 3 25 points to trade at 40 67 at the close  Valeant Pharmaceuticals International Inc  TO VRX  declined 5 39  or 12 35 points to end at 216 73 and  Tourmaline Oil Corp    TO TOU  was down 5 08  or 1 75 points to 32 71 
Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 703 to 645 and 191 ended unchanged 
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was down 2 79  to 19 88 
Gold for December delivery was up 0 26  or 3 10 to  1182 90 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in November rose 0 75  or 0 35 to hit  46 99 a barrel  while the December Brent oil contract rose 1 09  or 0 54 to trade at  50 23 a barrel 
CAD USD was up 0 69  to 0 7783  while CAD EUR rose 1 47  to 0 6838 
The US Dollar Index was up 0 49  at 94 45 ",2015-10-15,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-0.33-366408,366408
148697,370213,BHC,Why You ll See No Ads For  Female Viagra ,news,"By   

American women who have lost their desire for sex can now walk into a doctor s office and ask for a pink pill called Addyi to resurrect it  But despite all the hype around the drug s market introduction  women won t be bombarded with television  radio  print or digital advertising from the drug s maker for at least 18 months  The company  Sprout Pharmaceuticals  has pledged to postpone all paid advertising for more than a year to temper the U S  Food and Drug Administration s concerns about the drug s safety 
Sales of Addyi launched nationwide on Saturday  and the Raleigh  N C  based company says the highly anticipated medicine is meant to help the estimated 16 million American women who suffer from a form of low sexual desire known as hypoactive sexual desire disorder  HSDD   Supporters have applauded the drug s arrival as the dawn of a new era for women s sexual health  and executives at Canadian pharmaceutical giant Valeant Pharmaceuticals  N VRX  found it intriguing enough to pay  1 billion for Sprout  in August 
The company s promise to regulators does not prohibit it from getting the word out about Addyi through other popular channels  however  and Sprout s willingness to engage potential customers through social media  interviews with media outlets and key influencers signals the upending of traditional pharmaceutical marketing strategy 
 I think what they re doing is pretty clever  actually   Dan Leinweber  president at a boutique PR firm called Leinweber Associates  says   This is a much less costly way to get their word out in a much more credible way  
Sprout won FDA approval of Addyi in August after a hard and long fight following two previous rejections  Selling a drug it cannot advertise in a brand new market is the company s next big challenge  Addyi is meant for women who struggle with HSDD  characterized by a sudden loss of sexual desire that cannot be explained by other factors such as anxiety or relationship problems  The drug is similar to an antidepressant in that it adjusts brain chemicals including serotonin that are thought to be associated with sexual drive 
Since Addyi is the first pill to treat any form of low sexual desire  most women don t know that such treatment is available  Viagra was also a brand new drug in a new class of sexual medicine when it debuted in 1998  Since then  Viagra has been one of the most heavily advertised drugs in the world and earned handsome profits for Pfizer  The company spent  232 million on advertising Viagra in 2014 alone  At its peak  Viagra brought in  2 billion in revenue in 2012 
Other pharmaceutical companies are spending more and more on consumer advertising as Sprout holds back  The U S  and New Zealand remain the only two countries in the Organization for Economic Cooperation and Development  OECD   a coalition of 34 advanced and emerging nations  to permit pharmaceutical companies to advertise medicine to consumers  Globally  drug companies spent  4 53 billion on such advertising efforts in 2014  up 18 percent from the year before 

A New Age Of Marketing
Sprout can still find creative ways to spread the word about Addyi without relying on traditional media buys  The company has already demonstrated its skill at drumming up grassroots support among potential customers  It sponsors a nonprofit called Even the Score that sent women to testify before the FDA and accuse the agency of sexism for failing to give Addyi a green light after approving drugs to treat common sexual problems in men such as erectile dysfunction 
Sprout will continue to promote Addyi through partnerships with groups such as Even the Score  though the group is careful to say that it does not support one single treatment over another  A day before the drug s first sales  Even the Score posted a flashback photo of women who spoke out in support of the drug to their Facebook  O FB  page  It also published a YouTube video that does not mention Addyi by name but mimics a Viagra advertisement soon after the new drug s approval 
Leinweber also says granting interviews to major media outlets over the course of the next 18 months could help the company spread the message about Addyi without spending a penny on radio or television ads 
 It ll get people talking about the brand  not just consumers but key influencers like physicians and people who would prescribe it   he says   In effect  this sort of online word of mouth will effectively function as non paid advertising and drive traffic to their website and then stimulate customer engagement and sentiment with Addyi  
CEO Cindy Whitehead appeared on many morning shows and news broadcasts in the days after Addyi s approval in August  Sprout also maintains a website for the drug and runs several social media accounts  though there was no mention of Addyi s launch on the company s Facebook page or sparsely used Twitter  N TWTR  account 

News of the new drug can also effectively spread by word of mouth   particularly with the help of outspoken supporters  of which Sprout has plenty  Amanda Parrish  a 52 year old woman from Nashville  Tennessee  participated in a clinical trial for Addyi and was so satisfied with her results that she began speaking widely about her experience with help from Sprout s media team  On Saturday  she posted an update titled  ADDYI is AVAILABLE  to her personal blog  which read  I ve got mine   do you have yours   
However  word of mouth could also backfire if those who try the drug find it to be underwhelming  In clinical trials  the daily pill boosted the number of sexually satisfying experiences that women had by 1 6 to 2 5 per month  There was a strong placebo effect detected in the trial  and only 9 to 15 percent of women experienced improvement in three outcomes above and beyond what could be explained by a placebo 
 I think a lot of people will maybe try it once and be like   Ok    I don t feel anything    Max Jacobs  a biotech analyst at Edison Investment Research  says   That s bad word of mouth  
Physician Outreach
Since women can also learn about the medicine through their doctors  Sprout has hired and trained around 150 sales representatives which is common practice within the pharmaceutical industry  This group will visit doctors  offices nationwide and walk prescribers through a brief online course about Addy s risks that the FDA requires as an extra measure of caution for this medicine  Monday was the first day that the sales force hit the road  Representatives will initially reach out to obstetrician gynecologists before expanding to psychiatrists 
Still  Jacobs says he wouldn t count on Addyi generating more than  50 million in annual sales  which is far below some early projections that reached over  1 billion  He says Sprout faces an uphill battle in not only spreading the word to potential patients  but also in persuading doctors that the drug is safe and effective  The FDA issued a black box warning for the drug which prohibits patients from consuming alcohol while on it because some patients who drank alcohol and took the drug during clinical trials experienced a drop in blood pressure and fainted 
 I think it s going to be very difficult for a physician to say   Hey  I think you should try this  because there are all the safety risks and it s probably not going to work and the data just aren t very impressive   he says ",2015-10-19,International Business Times,https://www.investing.com/news/stock-market-news/why-you'll-see-no-ads-for-'female-viagra'-366898,366898
148698,370214,BHC,Exclusive  Clinton urges U S  regulators to examine Daraprim price hike,news,"By Amanda Becker WASHINGTON  Reuters    Democratic presidential candidate Hillary Clinton on Monday urged U S  regulators to determine how to bring lower cost generic drugs to market more swiftly and combat anticompetitive practices in the pharmaceutical industry   Clinton s requests to the Food and Drug Administration and the Federal Trade Commission were prompted by what she called the  egregious actions of Turing Pharmaceuticals   according to letters reviewed by Reuters  The company drew fire from Clinton last month after news reports that it had raised the price of Daraprim  a 62 year old treatment for a dangerous parasitic infection  to  750 a tablet from  13 50 after acquiring it  Clinton s criticism sent drug industry stock prices tumbling  Turing Chief Executive Officer Martin Shkreli promised to lower Daraprim s cost to an unspecified price  and Turing is in the midst of a rebranding effort after being mocked on  Saturday Night Live   In her letter to the FDA  which regulates food and drug safety  Clinton said that Turing has still not  meaningfully lowered the price   The company s decision to  artificially increase the price  exploited vulnerable patients dependent on the drug  which is often used by those with compromised immune systems  Clinton said      The FDA should expedite any pending reviews  and encourage applications for review  of other generic alternatives to Daraprim   Clinton wrote  The FDA told Reuters it will review the letter and respond directly to the sender  but noted that the agency s review of medicines are a matter of public record  In her letter to the FTC  a consumer protection agency  Clinton acknowledged it has only  limited authority to address price gouging when it is the result of unilateral action in a market with no competition   but urged it to examine both the industry overall and Turing specifically      I believe it would be a great service to the Congress and the Administration if the FTC would study and make recommendations on whether and how our laws might be amended to address this problem   Clinton wrote  offering an indication of how she might attempt to overhaul pharmaceutical practices if elected president in November 2016  Clinton also asked the FTC to investigate whether Turing s decision to increase Daraprim s cost amounts to the type of anticompetitive behavior the agency can regulate  The FTC did not immediately respond to a request for comment  Drug prices are also being scrutinized by Democrats in Congress and U S  prosecutors  Most pharmaceutical companies regularly raise prices  saying it reflects the drugs  value in the market  The head of Valeant Pharmaceuticals International Inc  N VRX   which has also come under fire for raising drug prices and is being investigated by the government  said Monday he predicts lower price increases are ahead for the whole industry   The pharmaceutical industry is being aggressively sort of attacked for past pricing actions   CEO J  Michael  Pearson   L PSON  told investors   I do think  given that environment  the pricing that pharmaceutical companies will take in the future will be more modest   The Daraprim price increase was unusual because it was so large  In interviews  Shkreli has defended the steep hike  and Turing last week announced it was making  improvements  to Daraprim s affordability and accessibility to  clarify any misunderstandings about Turing s pricing and distribution   according to a release  A Turing spokesman on Monday did not respond to requests to comment on Clinton s letters to the FDA and FTC  Clinton last month unveiled a plan for a  250 monthly cap on out of pocket prescription drug costs and other measures to stop what she calls  price gouging  by pharmaceutical companies  Turing s Daraprim and Shkreli were featured in a television advertisement run by Clinton s campaign about how she plans to take on  skyrocketing out of pocket costs   
 Nobody in America should have to choose between buying the medicine they need and paying their rent   Clinton says in the ad ",2015-10-19,Reuters,https://www.investing.com/news/politics-news/exclusive:-clinton-urges-u.s.-regulators-to-examine-daraprim-price-hike-366849,366849
148699,370215,BHC,Valeant CEO sees new drug pricing environment ahead,news,"By Caroline Humer  Reuters    Valeant Pharmaceuticals  N VRX  International Inc  TO VRX   which has been criticized for raising drug prices and is being investigated by the U S  government  predicted on Monday that lower price increases are ahead for the whole industry  Valeant CEO J  Michael  Pearson   L PSON  told investors the company s 2016 outlook is based on expectations for a new pricing environment where none of its drugs have an actual price increase of more than 10 percent  Valeant shares fell 7 7 percent  or  13 73  to close at  163 83 on the New York Stock Exchange  Concerns about drug pricing have loomed over pharmaceutical stocks since last year and the sector s shares have fallen sharply in the past few weeks since Democratic presidential candidate Hillary Clinton criticized the price rises on the campaign trail   The pharmaceutical industry is being aggressively sort of attacked for past pricing actions   Pearson said   I do think  given that environment  the pricing that pharmaceutical companies will take in the future will be more modest   Valeant  which has become one of the world s largest drug companies through a steady stream of acquisitions  and others have been criticized for acquiring companies and raising the prices of drugs in order to boost profits  Federal prosecutors in New York and Massachusetts opened investigations into the company  asking for information about price increases as well as the workings of its patient assistance programs for poor people to access its drugs  Pearson said Valeant was unlikely to look for acquisitions based on what he called mispriced assets  or drugs with prices that can be significantly increased because of their value to health care   Given the evolution of our product mix  coupled with the recent events  it is likely that we will pursue fewer  if any  transactions that are focused on mispriced products   he said  Valeant is also considering selling  spinning off or taking private its neurological and other pharmaceutical business  a move one Wall Street analyst described as paving the way for Valeant s business model to be less controversial   The neurological business accounts for most of Valeant s price actions and realized price increases on average of more than 30 percent  JP Morgan analyst Chris Schott wrote in a research note  He estimated it to make up about 10 percent of the company s revenues   The move would fit into a strategy that Pearson said has already been underway  Valeant has begun during the past two years to increase sales volumes as a percentage of growth compared with price increases   We ll just be pragmatic and why focus on areas of the business that is just going to create a lot of media stir   he added  referring to the recent wave of negative publicity over steep price increases for older medicines  Pearson said the company would begin to focus more on research and development  on which it historically has spent little  Last year the company spent  100 million on R D and it sees that growing to  400 million to  500 million in 2016  with a focus on dermatology  contact lenses and surgical sectors  Pearson indicated Valeant is scaling back on acquisitions  saying that while it continues to look at them  buying back shares may make more sense with the company s stock at its current price  
Valeant reported unexpectedly better quarterly profits earlier on Monday ",2015-10-19,Reuters,https://www.investing.com/news/stock-market-news/valeant-pharma-revenue-rises-36-percent-366780,366780
148729,370245,BHC,Canada stocks lower at close of trade  S P TSX Composite down 1 30 ,news,"Investing com   Canada stocks were lower after the close on Monday  as losses in the Mining  Materials and Energy sectors led shares lower 
At the close in Toronto  the S P TSX Composite declined 1 30  to hit a new 6 months low 
The best performers of the session on the S P TSX Composite were  Restaurant Brands Intl   TO QSR   which rose 3 85  or 2 01 points to trade at 54 21 at the close  Meanwhile  Valeant Pharmaceuticals Inc  TO VRX  added 3 30  or 10 79 points to end at 337 49 and ONEX Corporation  TO OCX  was up 2 91  or 2 05 points to 72 56 in late trade 
The worst performers of the session were  First Majestic Silver  Corp   TO FR   which fell 14 10  or 0 66 points to trade at 4 02 at the close  Sherritt International Corporation  TO S  declined 11 76  or 0 18 points to end at 1 35 and Enerplus Corporation  TO ERF  was down 10 59  or 0 94 points to 7 94 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 1016 to 384 and 174 ended unchanged 
Shares in First Majestic Silver Corp   TO FR  fell to 3 years lows  falling 14 10  or 0 66 to 4 02  Shares in Sherritt International Corporation  TO S  fell to all time lows  losing 11 76  or 0 18 to 1 35  Shares in Enerplus Corporation  TO ERF  fell to all time lows  falling 10 59  or 0 94 to 7 94  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 8 69  to 14 01 
Gold for December delivery was up 0 53  or 5 80 to  1091 80 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in September fell 2 40  or 1 16 to hit  46 98 a barrel  while the September Brent oil contract fell 3 23  or 1 76 to trade at  52 85 a barrel 
CAD USD was up 0 10  to 0 7673  while CAD EUR fell 0 90  to 0 6916 
The US Dollar Index was down 0 74  at 96 62 ",2015-07-27,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-1.30-353157,353157
148730,370246,BHC,Valeant to buy  female Viagra  maker Sprout Pharma,news,"By Natalie Grover and Ankur Banerjee  Reuters    Canada s Valeant Pharmaceuticals International Inc  TO VRX   N VRX  said on Thursday it would buy Sprout Pharmaceuticals  maker of the first approved treatment for low sexual desire in women  for about  1 billion plus milestone payments  Sprout s controversial pink libido pill  Addyi  won approval from the U S  Food and Drug Administration on Tuesday after being rejected twice over concerns about its effectiveness and side effects  Addyi  popularly called the  female Viagra   carries a strong warning about potentially dangerous low blood pressure and fainting  especially when taken with alcohol  raising some doubts about its commercial prospects  There are also concerns that the FDA was pressured into approving Addyi  given that Viagra   the first treatment for male sexual dysfunction   was approved more than a decade ago  Unlike Viagra  which affects blood flow to the genitals  Addyi is meant to activate sexual impulses in the brain  Raghuram Selvaraju  managing director of brokerage H C  Wainwright   Co  has estimated peak sales of  100 million a year for Addyi  while Len Yaffe  managing director of hedge fund Kessef Capital Management  expects sales of  300 million  Viagra   a  blockbuster  in drug industry parlance   generated sales of about  1 7 billion in 2014   The fact is we don t know how big the market is for this condition   Selvaraju said  adding that  there is still a perception that this is not a real medical condition   Valeant s U S  shares fell 4 percent to  235 in morning trading  while its Toronto listed shares dropped 3 9 percent to C 307 81  Valeant had been in talks with Sprout for about three weeks  Chief Executive Michael  Pearson   LONDON PSON  said on CNBC  Montreal area based Valeant  Canada s biggest drug company  has grown rapidly through acquisitions  In its biggest deal  it bought Salix Pharmaceuticals earlier this year for about  11 billion  Sprout  based in Raleigh  North Carolina  was co founded in 2011 by husband and wife Cindy and Robert Whitehead  after they sold Slate Pharmaceuticals  another small drugmaker they had founded  Sprout has 34 employees  Valeant said it would pay  500 million upfront and make another installment next year for privately owned Sprout  The drugmaker said it expected the deal to close in the third quarter of 2015 and Addyi to be available in the United States by the end of the year  
Skadden  Arps  Slate  Meagher   Flom served as Valeant s legal counsel  Sullivan   Cromwell was Sprout s legal adviser and Perella Weinberg Partners was its financial adviser ",2015-08-20,Reuters,https://www.investing.com/news/stock-market-news/valeant-nears-deal-for-'female-viagra'-maker-sprout-pharmaceuticals:-wsj-356792,356792
148731,370247,BHC,Ackman s hedge fund down 13 1 percent for August,news,"BOSTON  Reuters    Hedge fund mogul William Ackman s Pershing Square Holdings portfolio fell 13 1 percent this month  leaving the fund down 4 3 percent for the year  the firm said on Thursday  The performance numbers cover returns through Tuesday  Aug  25  On Wednesday  Ackman told investors that his firm s roughly 10 percent gain through July had turned into a loss amid the market rout  He did not say exactly how much the fund had lost  
On Thursday  when stocks rose steeply for a second day in a row  several of Ackman s holdings saw strong gains including Valeant  TO VRX  and Canadian Pacific  TO CP   suggesting to some investors that his portfolio s performance may still improve before month end numbers are finalized next week ",2015-08-27,Reuters,https://www.investing.com/news/stock-market-news/ackman's-hedge-fund-down-13.1-percent-for-august-358077,358077
148732,370248,BHC,Valeant gets right to develop AstraZeneca s psoriasis drug,news," Reuters    Canada s Valeant Pharmaceuticals International Inc  NYSE VRX  said it has been granted an exclusive license by AstraZeneca Plc to develop and commercialize its late stage experimental psoriasis drug brodalumab  The arrangement excludes Japan and certain other Asian countries where rights are held by Kyowa Hakko Kirin Co  Valeant said on Tuesday  Valeant said it will make an up front payment of  100 million to AstraZeneca  and additional pre launch milestone payments of up to  170 million and sales related milestone payments of up to  175 million following launch  
Brodalumab belongs to a class of drugs called IL 17 inhibitors that work by blocking a signaling pathway that plays a key role in inducing and promoting inflammatory diseases  Psoriasis is a chronic autoimmune disease in which the growth cycle of skin cells is accelerated ",2015-09-01,Reuters,https://www.investing.com/news/stock-market-news/valeant-gets-right-to-develop-astrazeneca's-psoriasis-drug-359435,359435
148733,370249,BHC,Democrat Clinton to unveil plan to fight drug  price gouging ,news,"By Emily Stephenson WASHINGTON  Reuters    Democratic presidential candidate Hillary Clinton will unveil a plan this week to cap out of pocket costs for specialty drugs  she said on Monday  after her tweet accusing companies of  price gouging  sent biotech stocks tumbling   I m announcing a detailed plan to crack down on these abuses   Clinton said during a campaign stop in Little Rock  Arkansas   There s no excuse   she added  Clinton is expected to discuss the specifics in Iowa on Tuesday  While Clinton has maintained her front runner status among Democrats seeking their party s nomination for the November 2016 election  she has been under pressure to take more populist stances to widen her lead over the current second place Democratic candidate  U S  Senator Bernie Sanders   She could face more hurdles if Vice President Joe Biden enters the race  Clinton led a recent Reuters Ipsos opinion poll with 48 percent support  Sanders already has introduced legislation in the Senate to crack down on what he called  skyrocketing  increases in prescription drug prices  On Monday  shares of biotech companies such as Immunogen and Gilead Sciences  NASDAQ GILD  dropped after Clinton tweeted that steep prices for specialty drugs were  outrageous   Clinton pointed to a New York Times story about a 62 year old drug to treat a deadly parasitic infection that soared in price to  750 a tablet from  13 50 after the drug was bought in August by a start up pharmaceutical company   It s disgraceful   Clinton said in Arkansas  referencing the drug prices in the story   Big Pharma  companies have long been criticized for steadily raising prices of prescription medicines in the United States  unrestrained by price controls that are common in other countries   Also controversial has been a strategy by some companies to raise prices for older drugs that they acquire  Examples include the heart medications Nitropress and Isuprel  which were bought by Valeant Pharmaceuticals  NYSE VRX  Inc this year  Specialty drugs are typically defined as high cost prescription medications used to treat chronic or life threatening conditions such as cancer  Clinton s comments on Monday were her first about how to tackle high drug prices  but she has talked about the problems facing consumers before   In June  Clinton said drug companies that benefit from a Pacific trade pact should offer bulk discounts on products to U S  government programs such as Medicare  The iShares Nasdaq Biotech ETF  which tracks an index of biotechnology and pharmaceutical stocks  was down about 4 3 percent at 341 48 on Monday afternoon  The Nasdaq biotech index skidded 4 3 percent  
For more on the 2016 presidential race  see the Reuters blog   Tales from the Trail     ",2015-09-21,Reuters,https://www.investing.com/news/politics-news/clinton-to-unveil-plan-to-fight-drug-'price-gouging'-362654,362654
148734,370250,BHC,Canada stocks lower at close of trade  S P TSX Composite down 2 80 ,news,"Investing com   Canada stocks were lower after the close on Monday  as losses in the Healthcare  Mining and Materials sectors led shares lower 
At the close in Toronto  the S P TSX Composite fell 2 80  to hit a new 52 week low 
The best performers of the session on the S P TSX Composite were  Penn West Petroleum  Ltd   TO PWT   which rose 3 03  or 0 02 points to trade at 0 68 at the close  Meanwhile   Pacific Rubiales Energy Corp   TO PRE  added 1 63  or 0 05 points to end at 3 12 and  Avigilon Corp   TO AVO  was up 1 60  or 0 18 points to 11 43 in late trade 
The worst performers of the session were  Concordia Healthcare   TO CXR   which fell 25 43  or 19 46 points to trade at 57 05 at the close  Valeant Pharmaceuticals International Inc  TO VRX  declined 16 30  or 43 20 points to end at 221 81 and  First Quantum Minerals Ltd    TO FM  was down 14 99  or 0 82 points to 4 65 
Falling stocks outnumbered advancing ones on the Toronto Stock Exchange by 1068 to 294 and 176 ended unchanged 
Shares in First Quantum Minerals Ltd   TO FM  fell to 5 year lows  down 14 99  or 0 82 to 4 65  
The S P TSX 60 VIX  which measures the implied volatility of S P TSX Composite options  was up 17 79  to 27 54 a new 1 month high 
Gold for December delivery was down 1 22  or 14 00 to  1131 60 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in November fell 2 71  or 1 24 to hit  44 46 a barrel  while the November Brent oil contract fell 2 57  or 1 25 to trade at  47 35 a barrel 
CAD USD was down 0 44  to 0 7468  while CAD EUR fell 0 84  to 0 6644 
The US Dollar Index was down 0 24  at 96 13 ",2015-09-28,Investing.com,https://www.investing.com/news/stock-market-news/canada-stocks-lower-at-close-of-trade;-s-p-tsx-composite-down-2.80-363600,363600
148764,370280,BHC,AbbVie boosts cancer drug pipeline with  21 billion Pharmacyclics deal,news,"By Supriya Kurane and Ben Hirschler  Reuters     AbbVie Inc   N ABBV  is to buy  Pharmacyclics  Inc  O PCYC  for about  21 billion  giving it access to what is expected to be one of the world s top selling cancer drugs and expanding its reach in the profitable oncology field  The deal    the latest example of a big drugmaker swooping on a biotech firm to refill its medicine pipeline    confounds expectations that Pharmacyclics would sell out to Johnson   Johnson  N JNJ   AbbVie will pay  261 25 per share in cash and stock  a 13 percent premium to Pharmacyclics stock s closing price on Wednesday  Back in 2008 and 2009  the shares dipped below  1  The acquisition lessens Chicago based AbbVie s dependence on its blockbuster rheumatoid arthritis drug Humira that accounts for most of its revenue but is expected to start to see sales decline from 2017 or 2018  AbbVie failed last October to buy Dublin based  Shire  Plc  L SHP  for  55 billion after the United States took steps to deter such tax lowering deals   Deutsche Bank   XETRA DBKGn  analyst Robyn Karnauskas said the deal was positive for AbbVie as Pharmacyclics  blood cancer treatment Imbruvica would diversify the business beyond Humira   Imbruvica is not only complementary to AbbVie s oncology pipeline  it has demonstrated strong clinical efficacy across a broad range of hematologic malignancies   AbbVie Chief Executive Richard Gonzalez said in a statement  Pharmacyclics expects U S  sales of Imbruvica to hit  1 billion this year and by 2020 worldwide sales are forecast to reach  5 8 billion  according to consensus analyst estimates compiled by Thomson Reuters Cortellis  AbbVie  which was spun out of  Abbott Laboratories   NYSE ABT  in 2013  said the deal would be  highly accretive  to its revenue and earnings by 2017  Sunnyvale  California based Pharmacyclics co markets Imbruvica with Johnson   Johnson  Besides Imbruvica  it has three product candidates in development  In a statement  J J said   We re looking forward to continuing our collaboration with the team at AbbVie to further develop and commercialize this important therapy for patients and their health care teams   Media reports had said J J was close to buying Pharmacyclics   Novartis  AG  VX NOVN  was also interested in the company  a report said  The acquisition is the latest in a spate of big pharma deals this year as many companies are strengthening their portfolios as old drugs go generic  Last month   Pfizer  Inc  N PFE  agreed to buy  Hospira  Inc  N HSP  for about  15 billion  and Canada s Valeant Pharmaceuticals International Inc  TO VRX   N VRX  agreed to buy  Salix Pharmaceuticals  Ltd  O SLXP  for about  10 billion  The deal  expected to close in the middle of the year  comprises about 58 percent cash and 42 percent AbbVie common stock  Pharmacyclics shareholders can opt for cash  AbbVie stock or a combination  AbbVie said  
Morgan Stanley advised AbbVie  while Centerview and J P  Morgan worked for Pharmacyclics ",2015-03-05,Reuters,https://www.investing.com/news/stock-market-news/abbvie-to-buy-pharmacyclics-in-$21-billion-deal-330929,330929
148765,370281,BHC,Wall St  bounces as dollar drops  Fed worries ease,news,By Caroline Valetkevitch  Reuters    U S  stocks rallied on Monday as the U S  dollar eased back from its recent peak and worries eased about the timing of a Federal Reserve interest rate hike  Recent dollar strength has increased expectations the Fed could be more cautious about raising rates this year  The day s gains gave the S P 500 its biggest percentage gain since Feb  3  with the S P utilities   which tend to do well in a low interest rate environment  among the day s best performing sectors  The utilities sector rose 1 7 percent  The S P healthcare sector  led gains in the S P 500  It jumped 2 2 percent  helped by a 5 7 percent price increase in shares of Amgen  O AMGN  to  163 03  following promising data in studies of a new class of cholesterol reducing drugs  All eyes will be on the Fed s statement Wednesday  when investors hope the central bank will give a clearer signal on the timing of its first interest rate hike in almost a decade   It seems to me that interest rate expectations are driving the market right now   said Uri Landesman  president at Platinum Partners in New York   Every day when they think it s going to start  they get nervous and sell them off  And every day they think it may be slower or not begin  then they take them up   The day s decline in the dollar helped ease some worries over how a robust greenback might erode the earnings of multinationals  The Dow Jones industrial average  DJI  rose 228 11 points  or 1 29 percent  to 17 977 42  the S P 500  SPX  gained 27 79 points  or 1 35 percent  to 2 081 19 and the Nasdaq Composite  IXIC  added 57 75 points  or 1 19 percent  to 4 929 51  The Dow and S P 500 had registered their third week of losses last week  Energy shares also bounced  adding to gains late in the session despite further losses in oil prices  The S P energy index  was up 1 4 percent  while U S  crude oil  settled down 96 cents at  43 88 a barrel and earlier hit its lowest since March 2009  Shares of  Exxon Mobil   N XOM  were up 1 1 percent at  84 76   Salix Pharmaceuticals   O SLXP  shares rose 2 percent to  172 75 after it agreed to an increased  173 per share offer from Valeant Pharmaceuticals  TO VRX   N VRX   Valeant shares were up 2 5 percent at  202 34  The biggest percentage decliner in the S P 500 was  Avon Products   N AVP   which was down 5 7 percent at  7 28 after S P Dow Jones Indices announced late Friday the stock would be moved out of the S P 500 this month   About 6 2 billion shares changed hands on U S  exchanges  below the 6 6 billion average for the month to date  according to BATS Global Markets   Advancing issues outnumbered declining ones on the NYSE by 1 980 to 1 083  for a 1 83 to 1 ratio  on the Nasdaq  1 549 issues rose and 1 202 fell  for a 1 29 to 1 ratio favoring advancers  The S P 500 posted 56 new 52 week highs and 10 new lows  the Nasdaq Composite recorded 168 new highs and 64 new lows ,2015-03-16,Reuters,https://www.investing.com/news/stock-market-news/wall-street-futures-rise-ahead-of-manufacturing-data-332565,332565
148766,370282,BHC,Valeant trumps Endo with  10 96 billion bid for Salix Pharma,news,"By Ankur Banerjee and Rod Nickel  Reuters    Valeant Pharmaceuticals International Inc  TO VRX   N VRX  increased its offer for  Salix Pharmaceuticals  Inc  O SLXP  to  10 96 billion in cash on Monday  eclipsing Endo International Plc  O ENDP   the only other bidder  The maker of gastrointestinal drugs has agreed to Valeant s new offer of  173 a share  up from a bid of  158 per share in cash made late last month  the two companies said in a joint statement  Salix would be the largest purchase ever made by Canada based Valeant  whose growth has been fueled by acquisitions and cost cutting  The acquisition would offer solace for dealmaking Valeant Chief Executive Michael  Pearson   LONDON PSON   whose hostile bid for  Allergan Inc   N AGN  failed last year  It would also boost investor Bill Ackman  who announced last week he had bought a more than  3 billion stake in Valeant after having worked with the company on the Allergan bid  Still  the deal would sharply raise Valeant s debt  and it is buying a company that last year was forced to slash its full year earnings forecast  The short bidding war for Salix pitted Valeant s Pearson against his former protege  Endo Chief Executive Rajiv De Silva  Salix shares rose 2 percent to  172 75 on the Nasdaq on Monday  while Valeant s U S  listed shares gained 2 5 percent to  202 34  Endo shares climbed 2 7 percent on the Nasdaq to  89 65  Endo said in a statement it was withdrawing its bid and has other potential deals and research and development on which to focus  Endo offered last Wednesday to buy Salix in a deal worth about  175 per share in cash and stock  As of Friday s close  Endo s offer was worth  172 56 per share  Valeant s new offer provides Salix stockholders with about  1 billion more in cash  Valeant said  The deal was expected to close on April 1  Valeant also announced a  1 45 billion share offering and said it would use the net proceeds  along with borrowed funds and cash on hand to fund the purchase  A source close to the matter said Valeant would not issue more debt to fund the acquisition  according to IFR  a Thomson Reuters publication  Ackman plans to buy 3 million shares in the offering for about  600 million  the Financial Times reported  citing a person familiar with the situation  Ackman s stake in the company would rise to 6 percent from about 5 percent  the paper said   
Valeant said its bid gives Salix an enterprise value of about  15 8 billion ",2015-03-16,Reuters,https://www.investing.com/news/stock-market-news/valeant-raises-offer-for-salix-pharma-to-$173-per-share-332568,332568
148767,370283,BHC,Big name investors take sides on Ackman bet on Valeant  filings,news,"By Svea Herbst Bayliss BOSTON  Reuters    Wall Street s savviest investors are picking sides on Bill Ackman s new bet on Valeant Pharmaceuticals  NYSE VRX  International Inc  TO VRX   with BlueMountain Capital and T  Rowe Price adding money  while Viking Global Investors and Jana Partners cut stakes  With its stock up 56 percent since January  the Canadian company is giving new and existing investors plenty to cheer about  In the last 52 weeks  it has risen 80 percent  outperforming both the S P 500 Index and the Pharmaceuticals sub index  The shares closed at C 270 02   224 63  on the Toronto stock exchange on Friday  When the serial acquirer bought Salix Pharmaceuticals Ltd earlier this year  some investors were tempted to get in on the mergers and acquisitions boom now sweeping the drug industry  T  Rowe Price bought an additional 2 3 million Valeant shares  raising its stake 12 percent to 20 1 million shares at the end of the first quarter  according to filings made on Friday with the Securities and Exchange Commission  Hound Partners increased its stake by 22 percent and reported holding 2 6 million shares on March 31   BlueMountain Capital Management raised its bet 356 percent during the first quarter  buying 723 682 shares to boost its stake to 926 919 shares  Adage Capital Management listed a new position of 50 000 shares  according to SEC documents  Big backers ValueAct Capital and Ruane Cunniff   Goldfarb largely kept their positions unchanged at 19 3 million and 34 3 million shares  respectively  The biggest new backer was  Ackman s Pershing Square Capital Management  which bought 19 5 million shares during the quarter  according to a filing made in March  Speaking publicly about his bet for the first time earlier this month  Ackman called Valeant an early stage  Berkshire Hathaway Inc   N BRKa   Valeant Chief Executive Officer Michael  Pearson   LONDON PSON  has engineered roughly 100 deals  the most recent being earlier this year when the company outbid a rival to win Salix Pharmaceuticals  The win helped wipe away some memories of last year s bruising loss in its bid to buy  Allergan Inc   NYSE AGN   Ackman acknowledged  however  that Valeant is hard to value  and clearly some investors were worried enough to cut back  Viking Global Investors reduced its stake by more than half  to 4 million shares at the end of the quarter  while Jana Partners slashed its holdings 63 percent to 1 57 million shares  Iridian Asset Management owned 3 million shares after cutting its holding by 22 percent  Brave Warrior trimmed its holding by 4 percent to 5 9 million shares  and Lone Pine Capital cut its stake 32 percent and owned 5 6 million shares at the end of the quarter  
Meanwhile  Sachem Head  run by former Ackman protege Scott Ferguson  opened a new position in Salix  buying 725 000 shares ",2015-05-15,Reuters,https://www.investing.com/news/stock-market-news/big-name-investors-take-sides-on-ackman-bet-on-valeant:-filings-342113,342113
148794,370310,BHC,Valeant says may raise Allergan bid  beats on profit,news,"By Rod Nickel and Ashutosh Pandey  Reuters    Valeant Pharmaceuticals International Inc VRX TO VRX N said on Monday that it may raise its bid for Botox maker Allergan Inc AGN N after the Canadian company posted a better than expected quarterly profit 
Valeant CEO Michael Pearson said a possible revised stock and cash bid would be worth more than  200 per share  assuming that Valeant s stock rises  and would include more cash  The current bid is worth about  52 7 billion or  176 per share 
Shares of Laval  Quebec based Valeant were up 3 percent at C 139 51 in Toronto on Monday  Allergan stock was up 1 7 percent at  180 45 
Valeant s third quarter results were keenly anticipated for their potential impact on Valeant s bid for Allergan  maker of anti wrinkle injection Botox  Unlike most quarters in which  according to critics  one time charges related to acquisitions obscure Valeant s performance  the company made few deals as it stalked Allergan 
 When people have time to reflect on our performance this quarter  it hopefully goes a long way of convincing the Allergan shareholders that our currency is actually a great stock to own   Pearson told Reuters 
He said Valeant is considering adding more cash to its bid  and could make a decision on it at any time 
 We have some money in our pocket   he said 
Pearson expects that once it becomes clear Valeant will win Allergan  Valeant s stock will rise  adding further value to the bid 
Valeant teamed up with activist investor Bill Ackman in April to make a hostile offer for Allergan  which rejected Valeant s offer  Allergan did not immediately respond to Pearson s comments 
Allergan will hold a special shareholder meeting on Dec  18  when Ackman hopes to remove most directors  possibly leading to negotiations with Valeant 
Valeant s relationship with Ackman and his Pershing Square Capital Management hedge fund is not strained as some have speculated  Pearson said 
 We re completely aligned   he said on an earlier call with analysts 
The company raised its full year adjusted earnings forecast to  8 22  8 32 per share from  7 90  8 10 per share 
The company raised its fourth quarter adjusted profit forecast to  2 45  2 55 per share on expectations of double digit same store organic growth 
Analysts on average were expecting the company to earn  8 03 per share for the full year and  2 38 per share for the fourth quarter  according to Thomson Reuters I B E S 
Valeant also raised its 2015 adjusted profit forecast to  10 per share from  9 65 per share  Analysts were expecting  9 58 per share 
Valeant posted a profit attributable to the company of  275 4 million  or 81 cents per share  in the third quarter  compared with a loss of  973 2 million  or  2 92 per share  a year earlier 
Cash earnings  or profit adjusted for one time items  was  2 11 per share  above the average analyst estimate of  1 99 per share 

Revenue jumped 33 percent to  2 06 billion  matching analysts  expectations 
 Reporting by Rod Nickel in Winnipeg  Manitoba  and Ashutosh Pandey in Bangalore  editing by Saumyadeb Chakrabarty  Don Sebastian and Matthew Lewis ",2014-10-20,Reuters,https://www.investing.com/news/stock-market-news/valeant-says-may-raise-allergan-bid;-beats-on-profit-313593,313593
148795,370311,BHC,Valeant secures financing for potential Salix bid   Bloomberg,news," Reuters    Canada s Valeant Pharmaceuticals International Inc  TO VRX   N VRX  has arranged financing for a potential takeover bid for bowel drug maker Salix Pharmaceuticals Ltd  O SLXP   Bloomberg reported  citing people familiar with the matter   Valeant will likely bid more than  150 per share for the company  Bloomberg said  quoting one of those people     A bid of  150 per share would value Salix at about  9 6 billion  Salix s stock was up 4 6 percent at  149 82 in afternoon trading on the Nasdaq on Thursday  Salix  based in Raleigh  North Carolina  was not immediately available for comment  A Valeant spokeswoman said the company does not respond to market rumors or speculation  Bloomberg  citing sources  reported earlier this month that British drugmaker Shire Plc  L SHP   O SLXP  was also interested in Salix     
Valeant s U S  listed shares were up about 1 9 percent at  167 45 on the New York Stock Exchange  The company s Canadian shares were up about 0 6 percent at C 209 ",2015-02-12,Reuters,https://www.investing.com/news/stock-market-news/valeant-secures-financing-for-potential-salix-bid:--bloomberg-327874,327874
148796,370312,BHC,Exclusive  Shire Plc moves to prepare Salix bid   sources,news," Reuters    British pharmaceutical company Shire Plc  L SHP  has taken initial steps towards a bid for U S  bowel drugmaker Salix Pharmaceuticals Inc  O SLXP  and is working with advisers on a potential offer  according to people familiar with the matter       Shire is evaluating how to secure financing for a Salix bid  one of the sources said  The sources cautioned that Shire may still decide against a bid given the deal s complexity  Salix is considering its options in the midst of a management shakeup and inventory issues  sources previously told Reuters      Valeant Pharmaceuticals International Inc  TO VRX  has also been exploring an offer for Salix  the people added  It is not clear whether other companies are also preparing bids for Salix  
    The sources asked not to be identified because the deliberations are confidential  Salix  Shire and Valeant declined to comment ",2015-02-12,Reuters,https://www.investing.com/news/stock-market-news/exclusive:-shire-plc-moves-to-prepare-salix-bid---sources-327911,327911
148797,370313,BHC,Drugmaker Valeant close to buying Salix   source,news,"By Nadia Damouni NEW YORK  Reuters    Valeant Pharmaceuticals International Inc is close to a  10 2 billion deal to acquire gastrointestinal drugmaker Salix Pharmaceuticals Ltd  according to a person directly familiar with the matter   The agreement with Salix  known for its irritable bowel syndrome drug Xifaxan  for around  160 per share could come as early as next week  the source said on Friday  requesting not to be identified as the matter is confidential  Spokespersons for Raleigh  North Carolina based Salix and Laval  Quebec based Valeant declined to comment  Salix s stock jumped 4 1 percent to  156 97 in afternoon trading on the Nasdaq  A deal of that size would be the largest ever for Valeant  which lost a takeover contest for Allergan Inc  NYSE AGN  last year  The usually acquisitive Valeant slowed its buying pace dramatically while it pursued Allergan  and Chief Executive Michael Pearson  LONDON PSON  said last month that it would focus in 2015 on buying smaller  private companies  He did not rule out bigger deals  however  Valeant s New York and Toronto shares rose more than 2 percent  CNBC first reported on Friday that Valeant was close to a deal with Salix  Salix is working with advisers to consider its options in the midst of a management shakeup and inventory issues  Last November  Salix announced that supply levels for Xifaxan and other drugs were higher than it had previously indicated  forcing it to slash its full year earnings forecast  British drugmaker Shire Plc  LONDON SHP  as of last week had taken initial steps towards a bid for Salix and was working with advisers on a potential offer  according to people familiar with the matter  Endo International Plc has expressed interest but was rebuffed by Salix  according to a source  
Valeant is buying assets from bankrupt cancer vaccine maker Dendreon Corp for  495 million  although Valeant also gets  80 million in cash ",2015-02-20,Reuters,https://www.investing.com/news/stock-market-news/drugmaker-valeant-close-to-buying-salix---source-328953,328953
148798,370314,BHC,Valeant nears deal to buy Salix for about  10 billion  WSJ,news, Reuters    Valeant Pharmaceuticals International  TO VRX  is near a deal to buy Salix Pharmaceuticals Ltd  O SLXP  for about  10 billion  the Wall Street Journal reported on Saturday ,2015-02-21,Reuters,https://www.investing.com/news/stock-market-news/valeant-nears-deal-to-buy-salix-for-about-$10-billion:-wsj-329051,329051
148825,370341,BHC,Ackman  other shareholders ask Allergan to call special meeting,news,"By Svea Herbst Bayliss and Caroline Humer
BOSTON NEW YORK  Reuters    Investors owning 31 percent of shares of Allergan Inc have asked the company to call a special shareholder meeting  activist shareholder William Ackman said on Friday  giving the hedge fund manager a victory in his fight to acquire the Botox maker 
Ackman  whose Pershing Square Capital Management is Allergan s largest shareholder  said 35 shareholders including some of Allergan s  longest standing  and  largest  investors handed in paperwork on Friday to compel Allergan to call the meeting 
Pershing Square and Valeant Pharmaceutical International Inc made a  52 billion hostile offer for Allergan in April  Since then Allergan has been fighting for investor support for its own stand alone plan that includes cost cuts and making an acquisition of its own 
Meanwhile  Ackman has been working to sign up enough shareholders and said that Allergan  under its bylaws  is required now to call the meeting no later than Dec  20 
Pershing Square also said on Friday that it filed a lawsuit in Delaware to require Allergan to schedule the meeting  anticipating that the company would likely fight doing so  Ackman and Valeant s cash and stock offer is now worth  49 billion 
Allergan said in a press release that it would review the requests from shareholders in connection with Pershing Square s meeting request and expects to report the results promptly after its review 
Allergan also said that Ackman and Valeant s offer undervalues the company
At the meeting  Ackman hopes to replace the bulk of Allergan board members with his own slate of directors who might agree to the takeover deal and to force Allergan to open discussions 
Ackman s lawsuit is the latest legal tussle for the companies and follows Allergan s insider trading suit against Valeant and Ackman filed in federal court in California on Aug  1 
DELIVERING THE PAPERWORK
Friday s move  in which Valeant and Ackman delivered the shareholder paperwork to Allergan s headquarters in Irvine  California  satisfies Allergan s bylaws that at least one quarter of its shareholders request the meeting  Ackman said 
The hedge fund manager  who called the task of filling out the paperwork  burdensome   said one shareholder  whose paperwork totals 174 pages  had to deliver 85 signatures 
T  Rowe Price Associates  The Vanguard Group  State Street Global Advisors and BlackRock Institutional Trust Company are the next largest shareholders after Pershing Square 
While some Allergan shareholders have sold holdings since the deal was announced  Ackman said many of the shareholders who back the meeting have owned Allergan stock since before he and Valeant Pharmaceuticals unveiled their takeover deal on April 22  More investors may still fill out the paperwork  he said 

Analysts had expected Ackman to gather more than 25 percent of the votes after two large proxy advisory firms urged investors to join Ackman in calling for the meeting 
 Reporting by Svea Herbst Bayliss and Caroline Humer  Editing by Chris Reese and Leslie Adler ",2014-08-22,Reuters,"https://www.investing.com/news/stock-market-news/ackman,-other-allergan-shareholders-submit-paperwork-for-meeting-305112",305112
148826,370342,BHC,Allergan  facing shareholder demands  calls special meeting for December 18 ,news," Reuters    Allergan Inc said on Tuesday that it has scheduled a special shareholders meeting for Dec  18  when activist investor Bill Ackman  who supports a hostile bid for the company by Valeant Pharmaceuticals Inc  will attempt to oust most of its board 
Although Allergan set a date for the meeting  it said in a Delaware court filing that it will review the validity of the shareholder requests for the meeting on Sept  4 
California based Allergan  the maker of Botox anti wrinkle skin injections  is trying to fend off a  49 billion hostile takeover by Canada s Valeant  Ackman s Pershing Square Capital Management  Allergan s biggest shareholder  hopes to see a revamped Allergan board that would be willing to negotiate with Valeant 
Ackman said on Friday that investors holding 31 percent of Allergan shares had asked for the meeting  Pershing Square said it also filed a lawsuit in Delaware to require Allergan to schedule the meeting  anticipating that the company would likely fight doing so 

At least 25 percent of shareholder support is necessary under Allergan s bylaws to call the meeting 
 Reporting by Rod Nickel in Winnipeg  Manitoba  Editing by Leslie Adler ",2014-08-26,Reuters,"https://www.investing.com/news/stock-market-news/allergan,-facing-shareholder-demands,-calls-special-meeting-for-december-18-305741",305741
148827,370343,BHC,Valeant  Ackman get October 6 trial over Allergan special meeting,news,"By Tom Hals
WILMINGTON Del   Reuters    Valeant Pharmaceuticals International Inc and activist investor William Ackman got their request for an expedited trial on Wednesday over the timing of a special meeting of Allergan Inc shareholders  a key to their  50 billion hostile takeover fight 
Delaware Court of Chancery Chancellor Andre Bouchard ordered a three day trial to begin on Oct  6  That start date is in line with their request for the court to order Allergan   after the trial ends   to call a special meeting by mid November 
That is about a month earlier than the Dec  18 date when Allergan has said it will hold the meeting at which Ackman and Valeant hope to elect new board members and open discussions on a deal 
The court order comes after Ackman s Pershing Square Capital Management hedge fund and Canada s Valeant sued the maker of Botox anti wrinkle treatment on Friday  saying the company did not intend to call a meeting at all  Allergan subsequently set the meeting date 
In the lawsuit  Pershing Square  Allergan s biggest shareholder  alleged that Allergan was trying to avoid a special meeting to give it time to find an alternative deal 
In setting the expedited trial date  Bouchard said it was pretty apparent to him that  Allergan may not want a special meeting at all  
Since Valeant and Pershing Square offered to buy Allergan on April 22  Allergan has consistently rejected the offer  saying it undervalues the company  It has also announced a series of cost cuts and said it was looking for acquisitions as it seeks to persuade shareholders they are better off if it stands alone 
Allergan s lawyer told Bouchard on Wednesday that it needed time to avoid a  bum rush  by Pershing Square and to determine if Pershing Square had violated federal securities laws in obtaining its 9 7 percent stake 
Ackman began accumulating his stake in February when it and Valeant started talking about buying Allergan together  He disclosed his stake on April 21  and the companies announced the offer on April 22  which instantly pushed Allergan shares higher and created  1 billion in paper gains for Ackman 
Allergan has sued both Ackman and Valeant for insider trading in federal court in California  saying that aspects of their unusual arrangement violated securities regulations 

Valeant shares fell  1 12  or less than 1 percent  to  115 98 and Allergan fell  1 59  or less than 1 percent  to  162 38 
 Reporting by Tom Hals  additional reporting by Caroline Humer in New York  Editing by Lisa Von Ahn and Jonathan Oatis ",2014-08-27,Reuters,"https://www.investing.com/news/stock-market-news/valeant,-ackman-get-october-6-trial-over-allergan-special-meeting-305971",305971
148828,370344,BHC,Ackman s Pershing Square plans  2 billion Amsterdam fund listing,news,"AMSTERDAM LONDON  Reuters    Pershing Square Holdings  a fund managed by activist investor Bill Ackman  hopes to raise  2 billion from a listing on the Euronext Amsterdam stock exchange  the company said in a statement on Monday 
The company expects the fund to have a market capitalization of at least  5 billion after the share offering  which will be priced at  25 a share 
New York hedge fund manager Ackman  famed for aggressive moves including a  1 billion bet against US nutrition firm Herbalife  is currently engaged in a battle to broker a sale of Botox maker Allergan  N AGN  to Valeant Pharmaceuticals  TO VRX  
Pershing Square Holdings said it had already received commitments worth  1 5 billion from 30 cornerstone investors  It currently has more than 300 investors 
The fund is run by Pershing Square Capital Management  a North America focused equities investment manager founded by Ackman in 2003 which had  14 1 billion in assets under management at the end of June 
Reuters reported earlier this month that UBS  VX UBSN  and Deutsche Bank  DE DBKGn  were to run the listing  Credit Suisse  VX CSGN  is acting as joint bookrunner  the firm said 
Pershing Square Holdings gained 31 2 percent during the first eight months of 2014  according to an investor with the fund  making it one of the industry s best performing funds of the year  It expects to be admitted for trading on Oct  13 

 Reporting by Thomas Escritt and Freya Berry  editing by Jason Neely and Susan Thomas ",2014-09-15,Reuters,https://www.investing.com/news/stock-market-news/ackman's-pershing-square-plans-$2-billion-amsterdam-fund-listing-309453,309453
148829,370345,BHC,Allergan reaches truce with suitors on special shareholder meeting,news," Reuters    Allergan Inc  N AGN  and its suitors Pershing Square Capital Management and Valeant Pharmaceuticals Inc  TO VRX  settled their pending litigation before the Delaware Court of Chancery and agreed to hold a special shareholder meeting on the originally scheduled date  Dec  18 
Billionaire William Ackman s Pershing Square and Canada s Valeant sued the maker of Botox anti wrinkle treatment last month  alleging that Allergan was trying to avoid a special meeting to give it time to find an alternative deal  Allergan subsequently set the meeting for Dec  18 
Pershing Square  Allergan s largest shareholder with a 9 72 percent stake  and Valeant made a hostile offer for Allergan in April  Since then  Allergan has been fighting for investor support for its own stand alone plan that includes cost cuts and making an acquisition of its own 
To force the company to the table  Ackman has been pushing for a special meeting where he hopes to replace most board members with his own nominees  who he expects will be more receptive to Valeant s bid 
Allergan said late Monday it continues to believe that Valeant s unsolicited exchange offer is  grossly inadequate  and urged shareholders to reject the offer 
Allergan s shareholders of record Oct  30 will be entitled to receive notice of and vote at the Dec  18 meeting 
Allergan is pursuing an existing litigation in California but will no longer seek the invalidation of any special meeting requests or seek to postpone or cancel the meeting  Pershing Square said early Tuesday 
In August  Allergan filed a civil lawsuit in California  accusing Valeant Pharmaceuticals and Ackman of violating securities laws by using insider information as they prepared a takeover bid for the drug company 

 Valeant and Pershing Square believe that Allergan s claims and request for relief in the California litigation are entirely without merit and will ultimately be rejected   Pershing Square said in a statement 
 Reporting by Supriya Kurane in Bangalore  Editing by Gopakumar Warrier ",2014-09-16,Reuters,https://www.investing.com/news/stock-market-news/allergan-reaches-truce-with-suitors-on-special-shareholder-meeting-309610,309610
148830,370346,BHC,Valeant may raise Allergan bid  says it won t walk away,news," Reuters    Valeant Pharmaceuticals Inc  TO VRX  may raise its hostile takeover bid for Allergan Inc  N AGN  and will not walk away from its pursuit ahead of Allergan s Dec  18 special shareholder meeting  Chief Executive Michael Pearson said on Monday 

Pearson also said speculation that Valeant s relationship was strained with Pershing Square Capital Management  Allergan s biggest shareholder  is false 
 Reporting by Rod Nickel in Winnipeg  Manitoba Editing by W Simon ",2014-10-20,Reuters,"https://www.investing.com/news/stock-market-news/valeant-may-raise-allergan-bid,-says-it-won't-walk-away-313579",313579
148860,370376,BHC,Allergan readies defense as it fights Valeant for votes,news,"By Caroline Humer and Deena Beasley NEW YORK and LOS ANGELES  Reuters    Allergan Inc  N AGN  may take on debt to buy back its own shares as part of a multi faceted plan to thwart a  53 billion takeover bid by Valeant Pharmaceuticals International Inc  TO VRX   N VRX  and activist investor William Ackman 
The company is also considering making acquisitions of its own and more spending cuts to increase shareholder value  Chief Executive David Pyott said in an interview  outlining steps to build support for Allergan  best known for its Botox anti wrinkle injections  to remain a standalone company 
But Allergan  which is expected to unveil the plan when it releases second quarter results sometime in July  faces an uphill battle 
Valeant says it already has enough shareholders on its side to call a special meeting to replace Allergan board members with nominees who support its takeover proposal  To call a meeting  the acquisitive Canadian company needs support of the holders of at least 25 percent of the shares 
It is possible that Allergan can turn the tide  but it won t be easy  said Ronny Gal  an analyst at Sanford C  Bernstein 
 When I run my numbers  a buyback alone doesn t quite cut it   Gal said   A buyback plus another round of costs cuts  or the acceleration of the discussed cost savings  does  
An Allergan acquisition could help as well if it increases the company s profits  Gal said  In order to get near term investors on its side  Allergan needs to deliver another  10 per share of value in 2015 or  11 per share in 2016  he said 
 The question is  how big of a buyback and how big are the cost cuts   he said 
LEVERAGED BUYBACK
Allergan announced an initial round of spending cuts in May when it first rejected Valeant s offer  When it rejected Valeant s offer again on June 10  it said that it would unveil more cuts and capital measures when it releases its second quarter results 
In the interview   Allergan CEO Pyott was more specific   Pyott has met with investors to talk about the company s defense  which he said could include issuing new debt to buy back shares  He said Allergan could borrow up to  10 billion without affecting its investment grade rating  but he did not say how much the company might spend on the buybacks 
 Our goal now is to give them most of what they want   Pyott said  referring to Allergan shareholders 
A leveraged buyback would increase the amount of Allergan s debt  making its balance sheet less attractive to a would be acquirer  Allergan currently has little debt  one of the company features that appeals to debt laden Valeant 
A buyback would also reduce the number of shares outstanding  which would raise its earnings per share and increase shareholder value  An acquisition by Allergan could also increase earnings  he said 
THE VALEANT PLAN
Valeant Chief Executive Michael Pearson said in an interview last week that he believes Valeant and Ackman  who owns nearly 10 percent of Allergan through Pershing Square Capital Management  have the backing of enough Allergan shareholders to support the deal 
According to sources  Valeant and Ackman have won over a prominent hedge fund  Paulson   Co   which has bought more than 6 million Allergan shares 
The company has said it will cut about  2 7 billion in spending at Allergan and that it would rely less on internal research and development in the future  Allergan says that such cuts would limit the company s growth potential 
Valeant also might pay more to get a deal done  Pearson said  Valeant has already raised its offer twice but has held firm now for about a month 

 We have a walk away price for Allergan  I can t tell you what our walk away price is  but right now we don t have any reason to raise because we would be bidding against ourselves   Pearson said 
The offer  which includes  72 in cash plus 0 83 of a Valeant share  is currently worth about  177 per share  or  53 billion  The deal value is calculated based on 303 5 million diluted shares outstanding as of March 31  and Ackman s holding of 28 878 638 shares 
 Additional reporting by Rod Nickel in Winnipeg  Manitoba and Olivia Oran in New York ",2014-07-01,Reuters,https://www.investing.com/news/stock-market-news/allergan-readies-defense-as-it-fights-valeant-for-votes-292591,292591
148861,370377,BHC,Ackman urges Allergan talks with Valeant  no delay to special meeting,news,"By Rod Nickel   Reuters    Activist investor Bill Ackman urged Botox maker Allergan Inc  N AGN  to negotiate a possible takeover by Valeant Pharmaceuticals Inc  TO VRX  and not delay a special shareholder meeting that could overturn most of Allergan s board   Ackman s Pershing Square Capital Management hedge fund  Allergan s largest shareholder with a 9 7 percent stake  is attempting to gain support of shareholders owning 25 percent of Allergan to call a special meeting  during which it would seek to remove six directors   Allergan can delay the meeting until as late as November    We  on behalf of Allergan s other shareholders  ask that you do not delay the inevitable any further   Ackman wrote in a letter to Allergan s board  released on Wednesday   What legitimate board of directors attempts to silence or otherwise delay hearing what its own shareholders have to say    Ackman also called Allergan s criticism of Valeant a  scorched earth response  and said spreading false information to drive down Valeant s stock would be market manipulation   Allergan  known for its Botox anti wrinkle injections  said that Ackman s economic interests were aligned with Valeant s and he was trying to distract Allergan shareholders from the fact that Valeant s offer is too low    Pershing Square s letter to the Allergan Board is not based on facts  and is rooted purely in self interest and innuendo   said an Allergan spokesperson   Laval  Quebec based Valeant  made an unsolicited cash and stock bid for California based Allergan in April and has since raised its  51 billion offer   
Allergan shares edged up 0 1 percent at  164 51 in midday trading in New York  while Valeant stock added 1 percent to  120 60     Reporting by Rod Nickel in Winnipeg  Manitoba and Ransdell Pierson in New York  Editing by Bernadette Baum ",2014-07-16,Reuters,"https://www.investing.com/news/stock-market-news/ackman-urges-allergan-talks-with-valeant,-no-delay-to-special-meeting-295463",295463
148862,370378,BHC,Ackman  Allergan rules on shareholder meetings onerous,news,"By Rod Nickel   Reuters    Allergan Inc  N AGN   trying to fend off a hostile takeover bid from Valeant Pharmaceuticals International Inc  TO VRX   has thrown up obstacles to a special shareholders meeting  its biggest investor said on Thursday   Pershing Square Capital Management  which is led by Bill Ackman  is attempting to muster at least 25 percent support of Allergan shares to hold a special meeting that could replace most of the Botox anti wrinkle injection maker s board  which has refused to negotiate with Valeant   In a webcast for investors  Ackman said Allergan s rules for special meetings were designed to stop them from occurring   The company limits special meetings to a small window during a given year and requires a high percentage of stockholders to call one  Ackman said  Shareholders must hold their stock through the date of the special meeting for them to count  he added   The rules are  the most onerous special meeting provisions of any public company in the United States   Ackman said   Laval  Quebec based Valeant made an unsolicited cash and stock bid in April for Allergan and has since raised its offer  which is currently worth about  51 billion  Allergan has rejected the offer   An Allergan spokesperson dismissed criticism by Pershing  which supports the takeover bid    Today s presentation by Mr  Ackman is more of the same   baseless accusations and mischaracterizations designed to distract stockholders so Valeant can acquire Allergan at the lowest possible price    Allergan is  stockholder friendly  and focused on delivering value to investors  the spokesperson said   Ackman said Pershing hoped to gather enough shareholder support by mid August to call a special meeting  but probably needed as much as 40 percent for a  big cushion  to offset possible stock sales before the meeting occurs  He said the hedge fund met on Wednesday with shareholder advisory firm Institutional Shareholder Services  which could make a recommendation on Valeant s offer in early August   Ackman estimated that a merged Valeant and Allergan would trade at  223 per share  slightly higher than the view of fellow activist investor John Paulson  who estimated  222 on Wednesday   Allergan shares were up 0 7 percent at  166 92 in afternoon trading in New York  while Valeant had tacked on nearly 4 percent at C 131 31 in Toronto   Valeant officials did not respond to a request for comment   Ackman used much of the nearly three hour webcast to criticize Allergan s corporate governance and its business  including the approaching expiry of patents on some products and the return on its research and development spending   He also said the longer Allergan delays negotiating with Valeant  the greater the risk that a potential deal will fall apart due to a sudden change in equity or debt markets   
 I would say the financing markets cannot get better than where they are   Ackman said   You can t ask for a better market than this  but that can change overnight      Reporting by Rod Nickel in Winnipeg  Manitoba  Editing by Lisa Von Ahn and Andre Grenon ",2014-07-17,Reuters,https://www.investing.com/news/stock-market-news/ackman:-allergan-rules-for-shareholder-meetings-too-onerous-295868,295868
148863,370379,BHC,Republican lawmaker to grill U S  SEC over Ackman tactics ,news,"By Sarah N  Lynch WASHINGTON  Reuters    A U S  lawmaker will pressure the U S  Securities and Exchange Commission on Thursday to consider a raft of reforms  after William Ackman s aggressive efforts to take over Allergan Inc raised concerns about loose rules governing disclosure and shareholder voting 
Republican Representative Edward Royce of California plans to grill SEC Corporation Finance Director Keith Higgins at a House Financial Services hearing 
Among his top concerns is a rule that lets investors such as Ackman delay publicly reporting when they have amassed a large stake in a company for days 
 I am especially interested in the SEC s process when looking at novel or creative deals like the announced joint bid by Valeant Pharmaceuticals and Pershing Square for Allergan   Royce said in a statement 
 Mr  Higgins  appearance before the committee is an opportunity to make sure that the Commission is making robust reviews of these sorts of deals to ensure strong investor protections and market transparency  
Saat Alety  Royce s spokesman  said that Royce is prepared to take legislative action if the SEC fails to fix the problem on its own 
UNUSUAL TACTICS
In recent months  Royce has been writing letters to the SEC to express concerns about some unusual maneuvers that Ackman s company Pershing Square Capital Management has used in its joint effort with Valeant Pharmaceuticals International Inc to win a  53 billion hostile takeover of Allergan  which is headquartered near Royce s California district 
In one May letter  Royce said he was concerned about early efforts by Ackman to call a non binding shareholder vote outside of Allergan s typical election procedures as a way to pressure Allergan to negotiate a deal 
Royce said he feared this  shadow  election would make it tough for shareholders to  truly understand what is going on  
Pershing Square dropped plans for a shareholder referendum in May and has since pursued a more traditional proxy battle 
In a July 2 letter to Royce  SEC Chair Mary Jo White said that the Corporation Finance division will  continue to consider issues raised by the filing related to the abandoned shareholder referendum  and  issues raised by any future filings of a similar nature  
Ackman s tactics have raised a number of regulatory questions  both about his actions and about hostile takeover bids generally 
It has renewed calls to fix a SEC rule that affords large investors a 10 day delay before they must report when they have amassed more than a 5 percent stake in a company 
The 2010 Dodd Frank law authorized the SEC to shorten the reporting period  but so far the SEC has not taken up the measure 

Higgins  division is in charge of reviewing financial statements of public companies and corporate governance matters 
In that role  his division would oversee a rule writing on the reporting period and also review proxy filings and related regulatory matters 
Royce s questions on Thursday will touch on just one of what is expected to be a wide ranging list of topics at the hearing 
Lawmakers also plan to ask Higgins about other matters  from rulemakings required by the Dodd Frank and JOBS Act laws  to how the SEC oversees proxy advisory firms 
 Reporting by Sarah N  Lynch  Editing by Lisa Shumaker ",2014-07-24,Reuters,https://www.investing.com/news/stock-market-news/republican-lawmaker-to-grill-u.s.-sec-over-ackman-tactics-297447,297447
148864,370380,BHC,Shareholder adviser ISS backs Ackman call for Allergan meeting,news," Reuters    Institutional Shareholder Services  ISS  is backing activist investor Bill Ackman s call for a special meeting of Allergan Inc  N AGN  investors that could topple the company s board and increase the chances of a takeover by Valeant Pharmaceuticals International  TO VRX  
ISS  recommendation on Wednesday follows a similar view from shareholder advisory firm Glass Lewis on Monday  giving Ackman s Pershing Square Capital Management momentum as the hedge fund tries to muster support for the meeting  ISS is the largest proxy adviser for institutional investors 
Pershing  Allergan s biggest investor with a 9 7 percent stake  needs to garner shareholder support representing 25 percent of the California company  best known for its Botox anti wrinkle injections  Pershing wants to replace most of Allergan s board  which has refused to negotiate with Valeant  which is based in Laval  Quebec 
In a report  ISS said  there appear to be significant governance issues which could be addressed  in a special meeting 
Ackman and Valeant said they are pleased with the ISS and Glass Lewis reports 
 The ISS Report should cause Allergan shareholders to question the credibility of a Board that is pursuing frivolous litigation tactics and baseless attacks to delay or stop the right for shareholders to fix anti shareholder bylaws  elect shareholder friendly directors and to voice their concerns about Allergan s poor corporate governance   Ackman said in a statement 
Allergan said the advisory firms were merely stating that shareholders should have the right to call a special meeting 
 These recommendations do not change the fact that Valeant s offer is grossly inadequate  substantially undervalues Allergan  creates significant risks and uncertainties for Allergan stockholders and is not in the best interests of the company and its stockholders   Allergan said in a statement 
Allergan has been fighting the takeover bid since it was announced on April 22 
Valeant s cash and stock offer is currently worth about  49 billion  after its shares fell 12 percent since reporting disappointing second quarter earnings on July 31 
Pershing Square and Valeant officials could not be reached immediately for comment 
Allergan shares lost 1 2 percent in afternoon trading in New York to  156 56  while Valeant s U S  listed stock dipped 0 4 percent to  110 20 

 Reporting by Rod Nickel in Winnipeg  Manitoba  Editing by Tom Brown and Leslie Adler ",2014-08-06,Reuters,https://www.investing.com/news/stock-market-news/shareholder-adviser-iss-backs-ackman-call-for-allergan-meeting-301620,301620
148865,370381,BHC,California judge sets August 20 hearing in Allergan vs  Valeant case ,news," Reuters    The federal judge in California overseeing Allergan Inc s  N AGN  insider trading lawsuit against Valeant Pharmaceuticals  TO VRX  and activist investor William Ackman has set an Aug  20 hearing date to decide on a fast track schedule for the case  according to court documents 
Allergan  fighting a hostile takeover by Valeant and Ackman s Pershing Square Capital Management hedge fund  filed the lawsuit on Aug  1  The Botox maker said in the complaint that Valeant and Ackman violated securities laws on tender offers when they teamed up on a  48 billion cash and stock offer 
The case could have implications for efforts by Pershing Square  which owns nearly 10 percent of Allergan s shares  and Valeant to call and hold a meeting of Allergan shareholders to vote in new board members 
Under Allergan s bylaws  Ackman needs 25 percent of shareholders to ask the company to call a meeting  Pershing Square has been gathering investor support and has said that it plans to submit the request in mid August 
Those bylaws also say that Allergan cannot accept a special meeting request if there is a violation of securities rules  such as insider trading 
Ackman and Valeant offered to buy Allergan on April 22 and laid out a plan for spending cuts at the company  It later launched a hostile tender offer for its shares 
Allergan has mounted a defense that includes its own cost cutting plans  and has urged shareholders not to support the meeting or the deal 

Judge David Carter in U S  District Court  Central District of California  said in the documents that he would consider Allergan s request for an expedited schedule at a hearing rather than outside of  normal procedures   as requested 
 Reporting by Caroline Humer  Editing by Jonathan Oatis ",2014-08-08,Reuters,https://www.investing.com/news/stock-market-news/california-judge-sets-aug.-20-hearing-in-allergan-vs.-valeant-case-302259,302259
148866,370382,BHC,Exclusive  ValueAct CEO says Valeant does not need to buy Allergan,news,"By Nadia Damouni NEW YORK  Reuters    ValueAct Capital  a top shareholder in Valeant Pharmaceuticals International Inc  TO VRX   N VRX   supports the company s independent business plan and does not believe the Canadian drugmaker has to buy Allergan Inc  N AGN   the investor told Reuters on Monday 
ValueAct likes a potential combination between Valeant and its takeover target Allergan  but said a drawn out bidding war for the Botox maker might be too distracting 
 A year on the sidelines waiting for  Allergan  to do a scorched earth sort of defense is a huge cost to Valeant   ValueAct Chief Executive Jeff Ubben told Reuters in an interview 
ValueAct has a stake of roughly 5 7 percent in Valeant  making it the company s third largest investor  according to Thomson Reuters data as of early May 
 Mike has other targets and other things to do with his low tax rate   Ubben said  referring to Valeant Chief Executive Mike Pearson 
In an emailed statement to Reuters on Monday  a Valeant spokesman said   We agree that Valeant has very attractive stand alone prospects  
Although Valeant still believes an Allergan combination would  create extraordinary value for both sets of shareholders   the spokesman said  Valeant also  has a rich pipeline of other business development opportunities  
Allergan is fighting a hostile  52 billion bid from Valeant teamed up with billionaire investor William Ackman  The company has accused Valeant and Ackman of violating securities laws by using insider information as they prepared a takeover bid for the drugmaker 
 We really believe in the stand alone plan  We do not need to do the Allergan deal   Ubben said  adding that he saw Valeant stock rising to  130 to  140 within a year s time 
Shares of Valeant were down 1 5 percent at  107 51 on Monday afternoon on the New York Stock Exchange  The shares ended New York trading at around  126 on April 21  just before the takeover bid for Allergan was unveiled 

Representatives Allergan did not immediately respond to requests for comment 
 Additional reporting by Olivia Oran  Writing by Soyoung Kim  Editing by Chizu Nomiyama and Matthew Lewis ",2014-08-11,Reuters,https://www.investing.com/news/stock-market-news/exclusive:-valueact-ceo-says-valeant-does-not-need-to-buy-allergan-302581,302581
148867,370383,BHC,Pershing Square sues U S  over Fannie Mae  Freddie Mac,news,"By Jonathan Stempel and Svea Herbst Bayliss  Reuters    Pershing Square Capital Management LP  the hedge fund firm run by William Ackman  has sued the U S  government  claiming that its stripping of Fannie Mae s and Freddie Mac s profit illegally short changes investors in the mortgage companies  common stock 
In a complaint filed on Thursday with the U S  Court of Federal Claims in Washington  D C   Pershing is challenging the government s  brazen  practice since 2012 of funneling virtually all profit from Fannie  OB FNMA  and Freddie  OB FMCC  into the U S  Treasury Department s coffers 
It said this will have by next month created a  130 billion  windfall  through the  confiscation of the entire net worth  of both companies  with an eye to winding them down 
 The net worth sweeps make plaintiffs   and all of the other common shareholders    shareholders  in name only   according to the complaint  which three retirees who own Fannie Mae stock have joined as plaintiffs 
Pershing accused the government of violating the Fifth Amendment of the U S  Constitution by taking private property for public use without just compensation  It seeks damages and other remedies 
The Treasury Department declined to comment  The Federal Housing Finance Agency  which is Fannie s and Freddie s conservator  did not immediately respond to a similar request 
Pershing s lawsuit adds to public battles being waged by Ackman  including a bid with Valeant Pharmaceuticals International Inc  TO VRX  for Botox maker Allergan Inc  N AGN   and a campaign against nutrition company Herbalife Ltd  N HLF   which he calls a pyramid scheme  a characterization the company denies 
Other investors  including hedge fund firm Perry Capital LLC and Bruce Berkowitz s Fairholme Capital Management LLC  have also sued the government over Fannie and Freddie  which were bailed out in September 2008 amid mounting mortgage losses 
But those lawsuits have often focused on the companies  preferred stock  which threw off 10 percent dividends before they were eliminated in 2012 
In contrast  Ackman s lawsuit focuses on common shareholders 
Pershing disclosed last November it had invested close to a half billion dollars for common share stakes of 9 98 percent in Fannie Mae and 9 77 percent in Freddie Mac 
Both companies  shares have risen by roughly one half since the week that Ackman revealed his stakes  and Berkowitz proposed that Fairholme and other investors recapitalize both companies 
In Thursday trading  Fannie rose 14 cents to  3 99  and Freddie rose 15 cents to  3 97 
The Court of Federal Claims handles lawsuits seeking money from the government 
It is also where former American International Group Inc  N AIG  Chairman Maurice  Hank  Greenberg is suing the United States over the insurer s  182 3 billion bailout  which he said illegally diluted the AIG stake of his Starr International Co 

The case is Rafter et al v  U S  et al  U S  Court of Federal Claims 
 Reporting by Jonathan Stempel in New York  Svea Herbst Bayliss in Boston and Jason Lange in Washington  D C   Editing by Lisa Shumaker and Ken Wills ",2014-08-14,Reuters,"https://www.investing.com/news/stock-market-news/pershing-square-sues-u.s.-over-fannie-mae,-freddie-mac-303615",303615
148868,370384,BHC,Top hedge funds flocked to Allergan amid bid backed by Ackman,news,"By Svea Herbst Bayliss BOSTON  Reuters    Billionaire investor William Ackman  who often says he is flattered when others follow him into a stock he likes  was joined by several prominent hedge funds that made new bets on takeover target Allergan Inc  N AGN  during the second quarter 
Regulatory filings released on Thursday give the first comprehensive look at Allergan s redrawn shareholder map since Ackman and deal partner Valeant Pharmaceuticals Inc  TO VRX  made public their pursuit of the Botox maker in late April  And while the data  released in so called 13 F filings  is backward looking and could have changed in the 45 days since the end of the quarter  investors say that it gives at least a strong flavor for what savvy investors are thinking 
Ackman s Pershing Square Capital Management disclosed a 9 7 percent stake in Allergan at the time  By the end of June  John Paulson s Paulson   Co  Jamie Dinan s York Capital Management and Andreas Halvorsen s Viking Global Investors had also bought in  according to the documents released by the U S  Securities and Exchange Commission 
The filings show that several large mutual fund firms that already owned Allergan made even bigger bets during the quarter  T  Rowe Price  for example  more than doubled its position  although it did not say exactly which funds owned the shares 
Paulson s moves have been tracked closely by investors since his winning bet against the overheated U S  housing market  He has publicly supported Valeant s bid for Allergan  now worth about  49 billion  But many other shareholders have been silent and it was not clear who else had gotten in or gotten out 
In the last weeks  the fight for Allergan has become even more bitter  Proxy advisory firms are urging its shareholders to support Ackman s call for a special meeting to consider a deal 
Yet one of Valeant s top shareholders  hedge fund ValueAct Capital Management  suggested that Valeant may not be able to afford a drawn out  damaging fight 
Allergan charged in a lawsuit filed earlier this month in California that Pershing Square broke insider trading laws when setting up its partnership with Valeant  Now U S  securities regulators are asking questions about the planned takeover  a person familiar with the matter said on Thursday 
Thursday s filings show that York Capital Management bought 2 4 million shares of Allergan during the quarter  York also bought put options on Allergan  Eric Mindich s Eton Park Capital Management said it owned 901 000 shares while Viking Global Investors reported owning 803 369 shares  Viking also raised its bet on Valeant by buying an additional 2 5 million shares 
Other new owners include Farallon Capital Management  founded by Tom Steyer and now run by Andrew Spokes  which said it owned 612 500 shares  Hoplite Capital Management also opened a new position and owned 625 850 shares 
Sachem Head Capital  run by Scott Ferguson who left Ackman s firm in 2012 to open his own shop  also bought in  opening a new position with 490 000 shares  Ferguson also opened a new position in Valeant with 419 500 shares 
Investors who exited or cut their positions include Capital Research Global Investors  which ranked as Allergan s second largest shareholder at the end of the first quarter but sold out its holdings during the second quarter  Hedge fund Jennison Associates cuts its position by more than half  selling 6 2 million shares while Montag   Caldwell sold 1 3 million shares  cutting its stake by 36 percent 
The decision to buy in at that time paid off big as Allergan s stock price surged 38 percent in the second quarter 
Since then the share price has come under some pressure  The spread on the deal   or the difference between the value of the two companies  shares and the ratio implied by the deal s terms   has widened slightly to about 5 2 percent from less than 3 percent earlier this week after a key Valeant shareholder questioned the deal s logic 
Some investors have said that Allergan s share price suggests the deal may have less of a chance of getting done now  But several investors told Reuters this week they expect that Ackman will succeed in attracting enough support to call the special shareholder meeting where shareholders will get their first chance to say what they think about the deal 
 Additional reporting by Caroline Humer  Olivia Oran and Soyoung Kim in New York  Editing by Michele Gershberg and Lisa Shumaker ",2014-08-14,Reuters,https://www.investing.com/news/stock-market-news/top-hedge-funds-flocked-to-allergan-amid-bid-backed-by-ackman-303618,303618
148899,370415,BHC,Allergan Rejects Valeant s  45 7B Takeover Bid,news,"By    Allergan Inc s  NYSE AGN  board Monday rejected an unsolicited takeover proposal by Valeant Pharmaceuticals  TO VRX  worth  45 7 billion  stating that the deal undervalued the Botox maker 
Allergan said in a statement Tuesday that Canada based Valeant s proposal not only undervalued the Irvine  Calif  based company  but also created significant risks and uncertainties for the company and its stockholders  Valeant had offered to acquire Allergan on April 22 for  48 30 a share in cash and a stock swap of 0 83 of its common share for each Allergan share  which added up to a valuation of  152 88 a share  which was at a premium of over 7 percent to Allergan s stock price at the time 
 After careful review and consideration  our Board of Directors has unanimously determined that Valeant s unsolicited proposal substantially undervalues Allergan and does not reflect the value of the Company s leading market positions  sales and marketing foundation  industry leading research and development efforts  as well as future revenue and earnings growth   David E I  Pyott  Allergan s chairman and CEO  said in the statement 
Pyott also wrote a letter to Valeant s Chairman and CEO Michael Pearson  according to the statement  where he asked for more clarity on Valeant s plans to cut costs  without harming the long term viability and growth trajectory of our business   adding that the strategy that Valeant follows counters Allergan s approach 
 We are disappointed that Allergan has rejected our value creating offer without engaging in any substantive discussions with Valeant or Allergan s largest stockholder  Pershing Square  and we remain committed to pursuing this transaction   Laurie Little  Valeant s spokesperson  said according to Fox News 

The bid was handled by New York based Pershing Square Capital Management  which is headed by William Ackman 
 We believe Allergan is in a great spot   David Maris  an industry analyst at BMO Capital Markets Corp  in New York  said in a note  according to Bloomberg  adding   Valeant s prospects of completing this deal are less than 50 percent   ",2014-05-13,International Business Times,https://www.investing.com/news/stock-market-news/allergan-rejects-valeant's-$45.7b-takeover-bid-283782,283782
148900,370416,BHC,US Drug Companies Take Merger Route To Ease Headaches,news,"By    U S  drug companies have a headache 
Pressed by expiring patents on Lipitor  Viagra and other recent wonder drugs that made companies like Pfizer Inc   NYSE PFE  billions of dollars and challenged by foreign competitors facing smaller tax bills  several large U S  pharmaceutical companies are eyeing non U S  acquisitions  The search for foreign acquisitions is also reflects the fact that global healthcare spending is falling as consumers and nations balk at out of control costs  

Amid those factors Pfizer last month sweetened its bid for British rival Astrazeneca  LONDON AZN  to 58 8 billion pounds   98 9 billion  following earlier rejected offers for the company  Add to that the Novartis AG  SIX NOVN  plan to swap assets with GlaxoSmithKline PLC  LONDON GSK  and a recent buying spree by Canada s Valeant Pharmaceuticals International Inc   NYSE VRX  and you have  175 billion of proposed deals  according to CMS Pharma CEO Andrew Bardot 
And U S  drug maker Abbott Laboratories  NYSE ABT  said Friday it s buying Chile s CFR Pharmaceuticals to double its Latin American branded generics business for just shy of  3 billion 
Speaking last month to TerrapinBriefings com  Bardot said   Pfizer is chasing the next big acquisition  Military tacticians would refer to it as  carpet bombing  as opposed to a  precise strike  
He said the purchase would bolster Pfizer s drug development pipeline and cut costs  He added that that it would also   benefit from a tax inversion  and the cherry on the cake  
Obviously Pfizer aims to cut costs in the current environment and the Financial Times calculated last month that combined tax savings and synergies with AstraZeneca could be  38 billion 
The Pfizer deal epitomizes the high cost of deals these days  and that s one caveat Bardot says may cool activity   Valuations are too high  rendering many acquisitions unpalatable  Many will have to wait until the  biotech bubble  deflates   Bardot said 
Valeant made news earlier this year when it teamed up with activist investor Bill Ackman to bid for Botox maker Allergan Inc   NYSE AGN   Their cash and stock offer  which includes a nearly  15 billion cash component  an SEC filing stated  values Allergan shares at  165 to  170 a share  according to reports  Ackman s Pershing Square  a New Jersey based hedge fund with assets of about  13 billion  spent about  4 billion to acquire a 9 7 percent stake in the Irvine  Ca  based Allergan and believes the company is undervalued 
 There is a logical thread in terms of combining a product portfolio for both companies by focusing on strong brands  such as Botox  in markets where patients or doctors themselves are making the buying decision rather than cost conscious healthcare payers   Bardot told TerrapinBriefings com 
He added that Valeant and Acman know how to cut costs  He said Valeant plans to cut research and development spending at Allergan to  200 million from  1 1 billion 
Swiss company Novartis last month unveiled maybe the most interesting recent big pharma deal when it agreed to acquire GlaxoSmithKline s cancer drug business for  14 5 billion and at the same time sell Glaxo most of its vaccine business for  7 1 billion plus royalties  The Swiss company also said it was selling its animal health division to Eli Lilly and Company  NYSE LLY  for nearly  5 4 billion 
Echoing the other dealmakers Novartis CEO Joseph Jimenez said when he announced the deal that    The transactions  improve our financial strength  and are expected to add to our growth rates and margins immediately   
The deal impressed Bardot  who was prompted last month to say of the company   Novartis is the ballerina in the Bolshoi  An insightfully crafted series of transactions  each in itself worth of a Harvard Case Study as to how it addresses a weakness  a strength or just factor market realities  This would be the ultimate precision strike  taking home what you need and nothing more  minimizing collateral damage  i e  transactional risks and any subsequent integration risks   limiting cash outflow  maximizing cash inflows  Masterful in every way  ",2014-05-16,International Business Times,https://www.investing.com/news/stock-market-news/us-drug-companies-take-merger-route-to-ease-headaches-284825,284825
148901,370417,BHC,European stocks fall despite easing expectations  Dax down 0 06 ,news,"Investing com   European stocks fell on Wednesday  even as comments by European Central Bank President Mario Draghi on Tuesday fuelled expectations for further easing measures by the central bank 
During European morning trade  the DJ Euro Stoxx 50 fell 0 29   France s CAC 40 edged down 0 18   while Germany s DAX eased 0 06  
On Tuesday  ECB President Mario Draghi said the bank was aware of the risks of persistently low inflation and was prepared to take steps to get euro zone inflation back to its target  the latest indication that the bank could ease monetary policy at its upcoming meeting next week 
The comments came a day after Draghi said the ECB is weighing a wide range of policy options  including interest rate cuts  and liquidity injections or broad based asset purchases to help shore up the fragile recovery in the euro area 
Financial stocks were mixed  as BNP Paribas  PARIS BNPP  slipped 0 13  and Societe Generale  PARIS SOGN  rose 0 20  in France  while Germany s Deutsche Bank  XETRA DBKGn  edged up 0 25  
Among peripheral lenders  Italy s Unicredit  MILAN CRDI  and Intesa Sanpaolo  MILAN ISP  gained 0 20  and 0 70  respectively  while Spain s Banco Santander  MADRID SAN  declined 0 40  
Elsewhere  Nestle  SIX NESN  saw shares gain 0 43  after the food company said it will expand its skincare unit in North America by paying  1 4 billion in cash for commercial rights to sell Valeant Pharmaceuticals  NYSE VRX  products 
Hugo Boss  XETRA BOSSn  slid lower on the other hand  down 0 39   after its majority shareholder Permira Advisers LLP said it is selling 3 95 million shares in the German company at  101 25 
In London  FTSE 100 slipped 0 11   weighed by losses in Glaxosmithkline  LONDON GSK   down 1 35   amid reports the drugmaker s  commercial practice  is under investigation by the U K  Serious Fraud Office  The company has been accused in a number of countries of bribing government and hospital officials 
Mining stocks added to losses  as Glencore Xstrata  LONDON GLEN  inched down 0 02  and Fresnillo  LONDON FRES  edged 0 14  lower  while rivals Bhp Billiton  LONDON BLT  and Rio Tinto  LONDON RIO  slid 0 56  and 0 71  respectively 
Weir Group  LONDON WEIR  was also on the downside  slipping 0 15   after it abandoned its pursuit of Metso Oyj  HEL MEO1V   The Finnish company s management turned down an all share offer valuing the maker of mining and construction equipment at  4 6 billion euros 
Meanwhile  financial stocks were mixed  Shares in Lloyds Banking  LONDON LLOY  dipped 0 01  and Barclays  LONDON BARC  tumbled 1 10   while the Royal Bank of Scotland  LONDON RBS  gained 0 47  and HSBC Holdings  LONDON HSBA  climbed 0 80  
In the U S   equity markets pointed to a steady open  The Dow 30 futures pointed to a 0 08  gain  S P 500 futures signaled a 0 05  uptick  while the Nasdaq 100 futures indicated a 0 07  rise ",2014-05-28,Investing.com,https://www.investing.com/news/stock-market-news/european-stocks-fall-despite-easing-expectations;-dax-down-0.06-286531,286531
148902,370418,BHC,European stocks turn moderately higher amid easing talk  Dax up 0 10 ,news,"Investing com   European stocks turned moderately higher on Wednesday  as comments by European Central Bank President Mario Draghi on Tuesday continued to fuel expectations for further easing measures by the central bank 
During European afternoon trade  the DJ Euro Stoxx 50 inched 0 05  higher  France s CAC 40 edged up 0 13   while Germany s DAX added 0 10  
On Tuesday  ECB President Mario Draghi said the bank was aware of the risks of persistently low inflation and was prepared to take steps to get euro zone inflation back to its target  the latest indication that the bank could ease monetary policy at its upcoming meeting next week 
The comments came a day after Draghi said the ECB is weighing a wide range of policy options  including interest rate cuts  and liquidity injections or broad based asset purchases to help shore up the fragile recovery in the euro area 
Financial stocks turned broadly higher  as French lenders BNP Paribas  PARIS BNPP  and Societe Generale  PARIS SOGN  gained 0 46  and 0 85   while Germany s Deutsche Bank  XETRA DBKGn  edged up 0 18  
Among peripheral lenders  Italy s Unicredit  MILAN CRDI  and Intesa Sanpaolo  MILAN ISP  jumped 1 23  and 1 84  respectively  while Spain s Banco Santander  MADRID SAN  and BBVA  MADRID BBVA  rose 0 03  and 0 54  
Elsewhere  Nestle  SIX NESN  saw shares edge up 0 14  after the food company said it will expand its skincare unit in North America by paying  1 4 billion in cash for commercial rights to sell Valeant Pharmaceuticals  TO VRX  products 
Hugo Boss  XETRA BOSSn  rallied 1 01   erasing earlier losses  after its majority shareholder Permira Advisers LLP said it is selling 3 95 million shares in the German company at  101 25 
In London  FTSE 100 edged up 0 08   as U K  lenders tracked their European counterparts higher 
Shares in Barclays  LONDON BARC  added 0 09  and Lloyds Banking  LONDON LLOY  climbed 0 45   while HSBC Holdings  LONDON HSBA  and the Royal Bank of Scotland  LONDON RBS  jumped 1 10  and 1 42  respectively 
Meanwhile  Glaxosmithkline  LONDON GSK  remained sharply lower  down 1 44   amid reports the drugmaker s  commercial practice  is under investigation by the U K  Serious Fraud Office  The company has been accused in a number of countries of bribing government and hospital officials 
Mining stocks still added to losses  as Glencore Xstrata  LONDON GLEN  slipped 0 13  and Bhp Billiton  LONDON BLT  tumbled 0 98   while rival company Rio Tinto  LONDON RIO  declined 0 76  
Weir Group  LONDON WEIR  also remained on the downside  dropping 0 94   after it abandoned its pursuit of Metso Oyj  HEL MEO1V   The Finnish company s management turned down an all share offer valuing the maker of mining and construction equipment at  4 6 billion euros 
In the U S   equity markets pointed to a higher open  The Dow 30 futures pointed to a 0 17  gain  S P 500 futures signaled a 0 17  rise  while the Nasdaq 100 futures indicated a 0 17  increase 
Also Wednesday  data showed that the number of people unemployed in Germany rose by the largest amount in five years in May  The seasonally adjusted jobless total rose by 24 000 this month to 2 905 million  compared to expectations for a fall of 15 000 
The German unemployment rate remained unchanged at 6 7   well below the euro zone average of 11 8  ",2014-05-28,Investing.com,https://www.investing.com/news/stock-market-news/european-stocks-turn-moderately-higher-amid-easing-talk;-dax-up-0.10-286569,286569
148930,370446,BHC,Valeant Pharma And Pershing Square Pursue Botox Maker Allergan,news,"By    Hedge fund manager William Ackman s Pershing Square  which picked up a nearly 10 percent stake in Botox maker Allergan Inc  NYSE AGN on Monday  is working with Valeant Pharmaceuticals International Inc  NYSE VRX  to acquire Allergan 
The cash and stock offer  which includes a nearly  15 billion cash component according to an SEC filing  is expected to value the deal between  165 a share to  170 a share  Bloomberg reported Monday  citing a source  Ackman s Pershing Square  a New Jersey based hedge fund with assets of about  13 billion  which spent about  4 billion to acquire a 9 7 percent stake in the Irvine  Ca  based Allergan and believes the Botox treatment maker is undervalued  is pursuing the acquisition in partnership with Canadian firm Valeant  according to Bloomberg 
 We firmly believe that combining Valeant and Allergan would create an unrivaled platform for growth and value creation in health care  and we look forward to finalizing and announcing the terms of our proposal shortly   Valeant reportedly said via e mail  according to Bloomberg 
Valeant  which acquired Bausch   Lomb for  8 7 billion in August and is expanding from the generic drugs segment into the specialty drugs category by building a presence in ophthalmology  dermatology and dentistry  generated   5 76 billion in revenues in 2013  Allergan s revenues for 2013 stood at  6 2 billion  registering a 12 4 percent growth  helped by leading product Botox  revenues for which grew 12 percent to  2 billion 
 I don t think it s any secret that a combination of Valeant and Allergan would make a lot of sense   Timothy Chiang  an analyst at CRT Capital Group LLC said  according to Bloomberg  adding   The question has always been  it s not whether Valeant would be interested in buying Allergan  it s a question of would Allergan sell to Valeant  

On Monday  Allergan acknowledged the reports of an acquisition but said in a statement   Allergan has had no discussions with either Valeant or Pershing Square with respect to this matter  The Company notes that neither Valeant nor Pershing Square has put forward an offer or proposal with respect to any type of merger transaction involving the Company  and the public disclosure materials filed by those entities suggest that they have expressly reserved the right to terminate their business relationship should no such offer be forthcoming  
Valeant said in its filing that Barclays PLC NYSE BCS and Royal Bank of Canada NYSE RY have agreed to assist in the transaction  While Allergan s stock jumped more than 20 percent in after hours trading on Monday  Valeant s stock soared 10 31 percent on the New York Stock Exchange ",2014-04-22,International Business Times,https://www.investing.com/news/stock-market-news/valeant-pharma-and-pershing-square-pursue-botox-maker-allergan-278584,278584
